[{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Part A:", "Subjects with documented type 2 diabetes mellitus diagnosis whose HbA1c levels are >7 and at or less than 9.5%; at screening, who are either controlled by diet alone, or are on monotherapy with oral sulfonylureas, DPP-IV inhibitors (e.g. sitagliptin), or metformin.", "Men and women 30", "65 years of age, inclusive, at screening.", "Women: post-menopausal or surgically sterile, i.e. women of non-childbearing potential.", "Male subjects must agree to use a contraception method", "Body weight 50kg for men and 45kg for women and BMI within the range 22 35kg/m2, inclusive.", "Subjects taking stable regimens of aspirin, ACE inhibitors, beta-blockers, calcium channel blockers, thyroid replacement hormone, and HMG-CoA reductase inhibitors (statins) will be allowed if their dose regimen(s) remain constant throughout the study period.", "Signed and dated written informed consent prior to enrollment into the study, including performance of any screening procedures.", "The subject is able to understand and comply with protocol requirements", "In France, a subject will be eligible for inclusion in this study if he or she is affiliated with or a beneficiary of a social security category."], "exclusion": ["Part A:", "Requiring insulin therapy or use of combination oral antidiabetic medications or use of monotherapy other than oral sulfonylureas, DPP-IV inhibitors (e.g. sitagliptin), or metformin within the 3 months prior to screening.", "Medically unable or unwilling to discontinue current anti-diabetic therapy for 72 hours prior to admission to the research facility and remain off medication until the follow-up visit.", "Past or present disease (other than type 2 diabetes mellitus) including, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease and endocrine disease.", "Past or present history of irritable bowel syndrome, gastrointestinal surgeries, or any other gastrointestinal complaints, history of GI intolerance to sitagliptin, lactose intolerance or hepatobiliary conditions that may interfere with the absorption of GSK1614235 or interfere with the objectives and endpoints of the study.", "As a result of the medical interview and/or the physical examination, Investigator considers the subject inappropriate for inclusion in the study.", "History or presence of sensitivity or allergy to the study drug or drugs, GSK 1614235 or sitagliptin, their components, or drugs of these classes or a history of drug or other allergy that contraindicates participation.", "Subjects with laboratory results that are not clinically significant may be included in the study", "Significant renal disease as manifested by one of the following: Creatinine clearance <60mL/min Urine albumin concentration at or >300ug/mg of creatinine. Known loss of a kidney, either by surgical ablation, injury, or disease.", "Positive test results for hepatitis C antibodies, hepatitis B surface antigen, and HIV at screening.", "Abuse of alcohol", "A positive pre-study urine drug screen", "No significant concomitant health problems other than type 2 diabetes mellitus and otherwise healthy. Subjects with the following clinical laboratory values are excluded: ALT or AST > 2 times the upper limit of normal at screening. Bilirubin > 1.5 times the upper limit of normal at screening (total; subjects above this limit may only be included if direct bilirubin is within normal limits). Fasting triglycerides > 400mg/dL (22.2mmol/L) at screening. Fasting LDL cholesterol > 160mg/dL (3.3mmol/L). Participation in a study trial with any investigational new drug (new chemical entity) within 90 days prior to the start of the study. For ECG rates and intervals, the average of 3 ECG assessments, separated by 5 minutes is used. Significant ECG abnormalities include but are not limited to: Males Females Heart Rate < 45 and >100 bpm < 45 and >100 bpm PR Interval <120 and > 220 ms <120 and > 220 ms QRS duration < 70 and >120 ms < 70 and >120 ms QTC Interval (Bazett) > 450 ms > 450 ms", "Blood pressure must be at or >80/60mmHg and at or <150/95mmHg at screening and at admission to the study facility.", "Participation in the study will result in the subject having donated more than 1,500mL blood (males) or 1,000mL (females) in the previous 12 months and where participation in study would result in donation of blood in excess of 580mL within a 56-day period.", "Participation in a study trial with any investigational new drug (new chemical entity) within 90 days prior to the start of the study.", "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless it is in the opinion of the investigator and sponsor that the medication will not interfere with 17. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.", "Lactating females.", "Unwillingness or inability to follow the procedures outlined in the protocol.", "Subject is mentally or legally incapacitated.", "History of sensitivity to heparin or heparin-induced thrombocytopenia.", "otinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.", "Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. Inclusion Criteria Part B:", "Healthy as determined by medical evaluation: medical history, physical examination, ECG, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the finding is unlikely to introduce additional risk and will not interfere with the study procedures.", "Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.", "Body weight at or >50 kg for men, at or >45kg for women, and BMI within the range 19 - 30 kg/m2 (inclusive).", "A female subject is eligible to participate if she is of non-childbearing potential", "Male subjects must agree to use a contraception method", "Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Part B Exclusion Criteria A subject will not be eligible for inclusion in this study if any of the following criteria apply:", "Past or present disease that may affect the outcome of this study, including, but not limited to: cardiovascular, renal, hepatic, malignancy, hematological, neurological, and/or endocrine. Clinically significant abnormalities are noted for ECG assessments. For rates and intervals, the average of 3 ECG assessments, separated by 5 minutes is used. Significant ECG abnormalities include but are not limited to: Males Females Heart Rate < 45 and >100 bpm < 45 and >100 bpm PR Interval <120 and > 220 ms <120 and > 220 ms QRS duration < 70 and >120 ms < 70 and >120 ms QTC Interval (Bazett) > 450 ms > 450 ms", "Past or present history of irritable bowel syndrome, gastrointestinal surgeries, or any other gastrointestinal complaints, history of GI intolerance to sitaglitpin, lactose intolerance or hepatobiliary conditions that may interfere with the absorption of GSK1614235 or interfere with the objectives and endpoints of the study.", "AST, ALT, alkaline phosphatase or bilirubin > 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)", "A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening", "Fasting triglycerides > 400mg/dL at screening", "Fasting LDL cholesterol > 160mg/dL", "Clinically significant abnormalities of TSH or known thyroid disease.", "A positive pre-study drug/alcohol screen.", "A positive test for HIV antibody.", "History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.", "Participation in a clinical trial and received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).", "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.", "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that contraindicates participation.", "Participation in the study will result in the subject having donated more than 1,500mL blood (males) or 1,000mL (females) in the previous 12 months and where participation in study would result in donation of blood in excess of 580mL within a 56-day period.", "Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing", "Lactating females.", "Unwillingness or inability to follow the procedures outlined in the protocol.", "Subject is mentally or legally incapacitated.", "History of sensitivity to heparin or heparin-induced thrombocytopenia.", "Cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.", "Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication."], "nct_id": "NCT00976261"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Subjects with Type 1 or Type 2 Diabetes Mellitus who participated in previous Phase 2 extension protocols"], "exclusion": ["Smoking", "Pregnancy"], "nct_id": "NCT00143247"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["High risk population", "Age 40 to 70 yrs.", "BMI > 25 and < 40; FPG >5.5 mmol/l and < 7.8 mmol/l; IGT in OGGT"], "exclusion": ["Known type 2 diabetes", "Drug intake affecting glucose tolerance", "Any cardiovascular events within the last 6 months"], "nct_id": "NCT00629213"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["The subject has a clinical diagnosis of type 1 diabetes mellitus requiring treatment with insulin for a minimum of 6 months at Screening; -OR- The subject has a clinical diagnosis of type 2 diabetes requiring treatment with insulin with or without oral antidiabetic agents for a minimum of 6 months at Screening.", "The subject has a HbA1c of 7.0% to 11.0% at Screening."], "exclusion": [], "nct_id": "NCT00108004"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["The study will enroll subjects, both men and women with type 2 diabetes of at least six months duration. The age of enrolled subjects will range from 21-60 years old. An HbA1c blood test must show that the person's diabetes is under control. Eligible subjects must have normal electrocardiogram tracings and normal hematological, electrolyte and liver laboratory results at screening. Females of childbearing age must agree to use an effective form of birth control throughout the study period."], "exclusion": ["Subjects will be excluded if they have known vascular disease, uncontrolled hypertension (>140/90 mmHg), marked hyperlipidemia (serum low density lipoprotein > 4.1 mmol/L or serum triglycerides > 7.8 mmol/L), and a body mass index greater than 40 kg/m2 (range 27-40). Other important exclusion criteria are cigarette smoking, volunteers taking Coumadin, and recent use of antioxidant supplements or aspirin. Females who are pregnant or breastfeeding will be excluded. People cannot participate in this study if they are taking medications (other than antidiabetic medications) which may affect blood sugar."], "nct_id": "NCT00362518"},{"minimum_age": 19.0, "maximum_age": 38.0, "gender": "F", "inclusion": ["Woman (European Caucasian)", "PCOS", "BMI = or > 35"], "exclusion": ["Cushing syndrome", "Adrenal hyperplasia", "Androgen-producing tumors", "Anovulation caused by hyperprolactinemia", "Pregnancy, breast feeding", "Use of oral contraceptives/hormone treatment/insulin-sensitizing agents"], "nct_id": "NCT00779571"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Each consecutive subject referred to a diabetes clinic for a diagnostic OGTT meeting the above criteria will be assessed as a potential candidate for the study till a total recruitment of 75 individuals will be reached.", "The OGTT will be performed after an overnight fast as described below.", "Individuals with IGT (FPG value of < 7.0 mmol/l, and 2-h PG > 7.8 and < 11.1 mmol/l), IFG (FPG > 6.1 and < 7.0 mmol/l, and 2-h PG value of < 11.1 mmol/l).", "Subjects who had both IFG and IGT will included as well.", "Subjects with normal glucose tolerance (FPG <6.1 and 2-h PG <7.8 mmol/l) will be also recruited as controls"], "exclusion": ["Use of drugs known to interfere with glucose metabolism (corticosteroids, beta-blockers, etc)", "Pregnant women, women who are breast feeding", "Active arterial disease (unstable angina, myocardial infarction, cerebrovascular accident, etc) within 3 months of trial entry", "History of malignancy", "Uncontrolled hypertension or hypothyroidism; history of alcohol, or drug abuse, or both", "Active liver disease", "Subjects tacking cyclic hormone replacement therapy"], "nct_id": "NCT00879801"},{"minimum_age": 65.0, "maximum_age": null, "gender": "A", "inclusion": ["type 2 diabetes managed by diet or metformin only", "A1c < 8.5%"], "exclusion": ["treated with insulin or oral agents other than metformin in the past 6 months", "evidence of diabetic complications including coronary artery disease, stroke, transient ischemic attacks, peripheral vascular disease, nephropathy, retinopathy, or neuropathy", "type 1 diabetes or a history suggestive of a secondary causes of diabetes", "A1c \u2265 8.5%", "participated in another clinical trial within the past 30 days"], "nct_id": "NCT00451113"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Are male or female outpatients", "No self-reported history of diabetes", "No self-reported history of prior genetic testing for diabetes", "Not pregnant (self report)", "Are \u226518 and <81 years of age", "Scheduled to receive serum glucose test in participating clinic", "Fasting at time of blood draw (no food or drink", "except water", "previous 8 hours: self report)", "Able and willing to give legally effective consent", "Able and willing to participate in patient questionnaires", "Ambulatory"], "exclusion": ["Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening", "Self-report of current or prior diabetes diagnosis", "Self-reported prior history of genetic testing for diabetes", "Baseline serum glucose test result >125"], "nct_id": "NCT00849563"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes type II"], "exclusion": ["Non-English speaking"], "nct_id": "NCT00965510"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Enrolling subjects must have Type 1 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite intensive insulin management efforts. (Intensive management is defined as monitoring of glucose values at home no less than three times each day and by the administration of three or more insulin injections each day. Such management must be monitored in close cooperation with an endocrinologist or primary care physician, as defined by at least three contacts during the previous 12 months. If an endocrinologist did not participate in the ongoing management effort during the past year, then an independent endocrinologist must assess the adequacy of the management efforts prior to enrollment.) The complicating situations are: a. Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels of < 54 mg/dL, b. Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia and which is associated with a blood glucose below 54 mg/dl OR two or more hospital visits for diabetic ketoacidosis over the last year, c. Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by: i) Retinopathy-a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system 44,or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy, or ii) Nephropathy-a confirmed rise of 50 \u00b5g/min (72 mg/24h) of microalbuminuria or greater over at least three months (beginning anytime within the past two years) despite the use of an ACE inhibitor, or iii) Neuropathy-persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine)."], "exclusion": ["Severe co-existing cardiac disease, characterized by any one of these conditions:", "Recent myocardial infarction (within past six months), or", "Angiographic evidence of non-correctable coronary artery disease, or", "Evidence of ischemia on functional cardiac exam (functional testing is required for all subjects, with a stress echo test recommended for subjects with a history of ischemic disease). Patients unable to perform an exercise stress echocardiogram test will undergo adenosine vasodilator stress test, and if there is a history of bronchospasm, will undergo dobutamine stress test.", "Active alcohol or substance abuse-includes cigarette smoking (must be abstinent for six months). Active alcohol abuse should be considered using the current NIAAA definitions, whereby alcohol abuse is defined by a pattern of drinking that is accompanied by one or more of the following situations within a 12-month period:", "Failure to fulfill major work, school, or home responsibilities;", "Drinking in situations that are physically dangerous, such as while driving a car or operating machinery;", "Recurring alcohol-related legal problems, such as being arrested for driving under the influence of alcohol or for physically hurting someone while drunk;", "Continued drinking despite having ongoing relationship problems that are caused or worsened by the effects of alcohol.", "Psychiatric disorder making the subject not a suitable candidate for transplantation, e.g., schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled on current medication. (A psychological or psychiatric consultation is required only if considered necessary by some current indication or history.)", "History of non-adherence to prescribed regimens", "Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB)", "Any history of or current malignancies except squamous or basal skin cancer", "BMI > 26 kg/m2", "C-peptide response to arginine stimulation (5 gm I.V.) (any C-peptide \u2265 0.3 ng/mL at 2, 3, 4, 5, 7 and 10 min post-infusion)", "Inability to provide informed consent 10. Age less than 18 or greater than 65 years 11. Creatinine clearance <80 mL/min/1.73 m2 12. Serum creatinine >1.6 mg/dL 13. Macroalbuminuria (urinary albumin excretion rate >300 mg/24h) 14. Baseline Hb <10.5 gm/dL in women, or <13 gm/dL in men 15. Baseline LFT's outside of normal range with the exception of Gilberts Syndrome. (An initial LFT test panel with any values >1.5 times upper limits of normal will exclude a patient; a re-test for any values between normal and 1.5 times normal should be made, and if the values remain elevated above normal limits, the patient will be excluded.) 16. Presence of gallstones (subjects may be eligible two weeks after a laparoscopic cholecystectomy) 17. Portal hypertension, detected by baseline duplex ultrasonography (assessment of direction of flow in right, left and main portal vein [antegrade (normal) or retrograde (abnormal indicative of portal hypertension)]; hemangioma in liver on baseline ultrasonography 18. Untreated proliferative retinopathy 19. Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast-feeding 20. Evidence of sensitization on PRA (determined by demonstration of positive results for anti-HLA antibodies using solid phase immunoassay with soluble HLA Class I molecules as a target, or a general PRA panel with reactivity >20%) 21. Insulin requirement >0.7 IU/kg/day 22. HbA1C >12% 23. Inability to reach the study hospital for transplantation within 24 hrs of notification 24. Untreated hyperlipidemia (fasting LDL cholesterol >130 mg/dL and/or fasting triglycerides >200 mg/dL) 25. Treated hyperlipidemia that is uncontrolled (fasting LDL cholesterol >130 mg/dL; and/or fasting triglycerides >200 mg/dL) 26. Under treatment for a medical condition requiring chronic use of steroids aa. Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT/INR >1.5 27. Addison's disease. All subjects should be screened with a basal 8:00 a.m. cortisol test. Results less than the lower limit of normal indicate further testing (e.g., a Cortrosyn stimulation test) to rule out adrenal insufficiency. Abnormal ACTH stimulation test will be an exclusion criterion."], "nct_id": "NCT00303134"},{"minimum_age": 20.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["impaired fasting glucose and/or", "impaired glucose tolerance", "overweight (BMI > 26 kg/m\u00b2)"], "exclusion": ["type 2 diabetes", "severe illness (cancer diagnosis, stroke or myocardial infarction in the last 12 months)", "diagnosis of a current mental disease"], "nct_id": "NCT00707447"},{"minimum_age": 6.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Informed consent obtained prior to any trial-related activities", "Any patient with diabetes type 1 is eligible for the study, including newly", "The selection of the patients will be at the discretion of the individual physician"], "exclusion": ["Type 2 diabetes", "Currently treated with Levemir\u00ae"], "nct_id": "NCT00704574"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": [": Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents"], "exclusion": [": Patients that did not participate in the VADT."], "nct_id": "NCT00256646"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetics in accordance with WHO.", "Male and female patients, between 18 and 75 years of age.", "Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.", "Normal blood creatine clearance and normal liver function test results.", "BMI less than or equal to 45 kg/m2"], "exclusion": ["Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.", "Therapy with beta-blockers or thiazide diuretics within the prior 3 months", "Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.", "Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.", "Receiving any investigational drug within 30 days of the baseline visit."], "nct_id": "NCT00961662"},{"minimum_age": 18.0, "maximum_age": 99.0, "gender": "F", "inclusion": ["Gestational diabetes diagnosis within past three years", "Access to computer with internet, USB port and Windows XP or Vista", "Regular email user (weekly or more)", "Can walk a block on her own", "Sedentary (less than 150 minutes purposeful physical activity per week)"], "exclusion": ["Pregnancy", "Unable to consent legally"], "nct_id": "NCT00862602"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Fasting blood glucose < 126mg/dL"], "exclusion": ["Fasting blood glucose > 126mg/dL"], "nct_id": "NCT00707616"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Males and females >40 years old;", "High-risk subjects with type 2 diabetes (WHO criteria);", "History of diabetes not exceeding 25 years;", "High blood pressure (systolic and/or diastolic blood pressure >135/85 mmHg or concomitant treatment with blood pressure lowering medications);", "Serum creatinine concentration <1.5 mg/dl;", "Overnight urinary albumin excretion (in at least 2 of 3 consecutive overnight urine collections) \u2265 7 and <20 \u00b5g/min;", "Legal capacity;", "Written informed consent."], "exclusion": ["Uncontrolled diabetes (glycated hemoglobin >11%);", "Specific contraindications or history of hypersensitivity to the study drugs;", "Serum potassium \u2265 5.5 mEq/L despite diuretic therapy, and optimized metabolic and acid/base control;", "Bilateral renal artery stenosis;", "Previous history of allergy or intolerance, or evidence of immunologically-mediated renal disease, systemic diseases, cancer;", "Drug or alcohol abuse;", "Any chronic clinical conditions that may affect completion of the trial or confound data interpretation;", "Pregnancy or lactating;", "Women of childbearing potential without following a scientifically accepted form of contraception;", "Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;", "Evidence of an uncooperative attitude;", "Any evidence that patient will not be able to complete the trial follow-up."], "nct_id": "NCT00503152"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00029848"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes", "35-75 years", "BMI 25-30, HbA1c (Swedish standard)", "Oral antidiabetic treatment"], "exclusion": ["Heart failure", "Renal failure", "Insufficient knowledge in Swedish"], "nct_id": "NCT00960674"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": [": Subjects with a known diagnosis of type 2 diabetes -"], "exclusion": [": None, except known intolerance to n-acetylcysteine -"], "nct_id": "NCT00609102"},{"minimum_age": 55.0, "maximum_age": null, "gender": "A", "inclusion": ["Age greater or equal to 55", "Type 2 diabetes", "English speaking", "Ability to use glucose meter"], "exclusion": ["Unable to give informed consent", "Unwilling to allow SMBG levels to be shard with primary care physician"], "nct_id": "NCT00700908"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": For Patients With Type 1 Diabetes", "Aged 18-65", "Presence of type 1 diabetes mellitus.", "2-25 year duration. For Patients With Type 2 Diabetes", "Aged 25-65 years", "presence of type 2 diabetes mellitus.", "2 years since initial diagnosis."], "exclusion": ["Renal disease, microalbumin >300 ug/mg)", "Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease", "Symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels.", "Women who are currently pregnant", "proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included.", "HbA1c levels less than 7.0% (normal range 4.0", "6.0%).", "HbA1c levels greater than 14.0%", "patients who underwent intensive insulin treatment within one year", "a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or diastolic 90 mmHg) who may be at risk when mildly increasing physical activity", "a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission.", "Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse", "Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2."], "nct_id": "NCT00142922"},{"minimum_age": null, "maximum_age": 0.019178082191780823, "gender": "A", "inclusion": ["Biological parent and/or full (not half) sibling of the newborn infant had type 1 diabetes as defined by the World Health Organization", "The infant's parent or legal guardians gave signed consent to participate"], "exclusion": ["An older sibling of the newborn infant had been included in the TRIGR intervention", "Multiple gestation", "The parents were unwilling or unable to feed the infant cow's milk based products for any reason (e.g., religious, cultural).", "The newborn infant had a recognizable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc.", "The gestational age of the newborn infant was less than 35 weeks.", "The infant was older than 7 days at randomization.", "Inability of the family to take part in the study (e.g. the family has no access to any of the Study Centers, the family has no telephone).", "The infant had received any infant formula other than Nutramigen prior to randomization.", "No HLA sample drawn before the age of 8 days."], "nct_id": "NCT00179777"},{"minimum_age": 18.0, "maximum_age": 99.0, "gender": "A", "inclusion": ["Diabetes type 1, 2 or LADA: 18-75 years of age.", "Group A: 150 Type 1 Diabetes, duration 15 years (+/-2 years) and 150 Type 2", "Diabetes 2 years (+/-2 years) (50% F/M)", "Group B: 150 Type 1 Diabetes, duration 20 years (+/-2 years) and 150 Type 2", "Diabetes 7 years (+/-2 years) (50% F/M)", "Group C: 150 Type 1 Diabetes, duration 25 years (+/-2 years) and 150 Type 2", "Diabetes 12 years (+/-2 years) (50% F/M)", "Group D: 50 LADA, onset after 35 years of age, duration of 5-10 years (50% F/M)", "Type 1 Diabetes: Positive ICA antibodies and/or GAD-antibodies and/or neg C-peptide. Debut <30 years of age.", "Type 2 Diabetes: Negative ICA-antibodies and GAD-antibodies and pos C-peptide (>0.35 mmol/l).", "LADA: Positive ICA-antibodies and/or GAD-antibodies. Debut >35 years of age."], "exclusion": [], "nct_id": "NCT00969956"},{"minimum_age": 35.0, "maximum_age": 65.0, "gender": "M", "inclusion": ["Type 2 diabetes patients and with partial edentulism."], "exclusion": ["Active periodontal disease,", "Uncontrolled diabetes,", "Smokers,", "Any metabolic bone diseases or other systemic disorders."], "nct_id": "NCT00971516"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["aged 18 to 70 years", "normal glycated hemoglobin (<6% healthy, <7.5% diabetic)", "absence of chronic conditions (except Type 2 diabetes)", "must be able to read and sign consent", "must be able to comply with protocol requirements"], "exclusion": ["allergies to eggs, buckwheat, rice flour, or sugar substitutes (Splenda)", "acute or chronic conditions (except Type 2 diabetes)", "blood glucose >10mmol/L at beginning of test session", "medications that affect glycemic control"], "nct_id": "NCT00841503"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["- Male and female between 18 and 65 years.", "BMI 25.1", "34.9.", "Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a minimum of 12 months prior the enrollment.", "Diagnosis of T2DM for at least 3 years.", "Patient has been under routine care of hte study physician or another physician that can supply a reliable medical record for at least 3 years.", "HbA1c >/ 7.5 documented for at least 3 months.", "Stable weight (nor significant weight change (>3%) over the 3 months prior to enrollment.", "Stable medication for at least one month prior to enrollment except for diabetes medications which should be stable for at least 3 months prior to enrollment.", "Ability and willingness to return for all scheduled visits and participate in recommended parameter setting and physician recommended medical/laboratory assessments."], "exclusion": ["Prior abdominal surgery, except laparoscopic cholecystectomy.", "Taking appetite suppressant.", "Severe eating disorders.", "Severe pulmonary, renal or cardiac disease.", "Obese due to a clinically diagnosed endocrine disorder.", "Subjects with impaired liver function.", "History of peptic ulcer disease.", "History of malignant disease.", "Use of prescription, over the counter or herbal weight loss products. 10. Pregnant or planning on pregnancy while enrolled in study."], "nct_id": "NCT00450710"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes treated with diet/exercise or metformin", "HbA1c less than or equal to 7%", "Men and women aged 45-80 years old", "If female, must be post-menopausal (natural or surgical)"], "exclusion": ["Endocrine disorders (acromegaly, anorexia, Cushings, type 2 diabetes, hyperparathyroidism, hyperthyroidism, hypercalcemia)", "GI conditions (celiac sprue, gastric bypass/gastrectomy, active inflammatory bowel disease, cirrhosis)", "Cancer (including multiple myeloma) within 3 years of the study (except local non-melanoma skin cancers and cervical carcinoma in situ)", "Active alcoholism or drug abuse", "Chronic kidney disease with a GFR < 60", "HIV/AIDS", "History of hypersensitivity reaction to sitagliptin or other DPP-4 inhibitors", "Hemoglobin < 12 mg/dL for men and < 10 for women", "Taking medications that could affect bone turnover (estrogen, progesterone, testosterone, bisphosphonates, SERMS, calcitonin, teriparatide cyclosporine glucocorticoids, methotrexate or phenothiazines), thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 inhibitors, exenatide, insulin, weight loss drugs"], "nct_id": "NCT00732121"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes on glibenclamide with or without", "Glycated hemoglobin \u2264 7.5%", "Stable dosage for three weeks"], "exclusion": ["HbA1c > 7.5%", "Fasting C-peptide below normal", "Concurrent infectious disease", "Pregnancy", "Malignant disease", "Inability to give informed consent"], "nct_id": "NCT00734669"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["patients with acute ST-segment elevation infarction (defined from ECG), treated with primary percutaneous coronary intervention PCI)were prospectively included.", "Stable patients"], "exclusion": ["known DM", "unstable patient", "signs of heart failure", "renal failure defined as creatinine >200 umol/l"], "nct_id": "NCT00926133"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus", "BMI more than 25"], "exclusion": ["Type 1 diabetes", "pancreatic diabetes", "presence of concomitant endocrinal disorder", "non-overweight type 2 diabetes", "type 2 diabetes with secondary failure to sulfonylurea and taking insulin", "presence of proliferative retinopathy or chronic renal failure", "known cirrhosis of liver", "heavy alcoholic", "presence of active tuberculosis", "known HIV disease or any active infection", "major mental illness", "failure to comply with the exercise advice due to physical incapacity (e.g., severe osteoarthritis, hemiparesis or any other disabling neurological disease)", "present pregnancy (or planning pregnancy)", "lactating mothers", "using any kind of hormones including oral contraceptives, systemic corticosteroids, nicotinic acid", "use of anti-obesity drug within the past 3 months", "chronic gastroparesis or chronic severe gastrointestinal symptoms", "a history of gastric or duodenal ulcers", "abdominal surgery within 1 year will not be included in the study", "patients with congestive heart failure or overt nephropathy will also not be included, due to unreliability of anthropometric measurements in such subjects and the relative risk of lactic acidosis"], "nct_id": "NCT00922194"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": Subjects meeting all of the following criteria will be considered for enrollment into the study:", "Type 2 diabetes mellitus, as defined by the American Diabetes Association for at least five years, treated with insulin for at least 6 months (no history of ketoacidosis).", "HbA1c between 7.5% and 11.0%, inclusive at both pre-screening and pre-randomization (week -2).", "For at least 3 months prior to week -8 visit, subjects must have been on a stable insulin regimen with two daily s.c. injections of premixed insulin: NPH plus regular insulin or NPH plus rapid acting insulin (insulin lispro or insulin aspart) in a mixture of 70/30 or 75/25. \"Stable\" means no change in regimen and no more than 30 % change in dose. Optionally, the subject can have been treated in addition with metformin according to its current official product information leaflet, treatment with other oral blood glucose lowering drugs is not allowed.", "Documentation of a full ophthalmologic exam (incl. fundoscopy)during the 6 months prior to randomization.", "Women are either not of childbearing potential (surgically sterile, or postmenopausal for more than 2 years). Women of childbearing potential must not be pregnant and agree to use a reliable contraceptive measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device or condom with spermicide.", "Willing and able to perform specified home blood glucose monitoring and to otherwise comply with study protocol requirements.", "Willing to change from a twice daily insulin regimen to a regimen requiring four daily insulin injections.", "Provision of signed and dated informed consent prior to any study procedures.\"Prescreening\" informed consent, obtained in writing for all subjects, may be used during screening, but full study-specific informed consent must be obtained in writing for all subjects after any post-screening procedures."], "exclusion": [": Subjects presenting with any of the following will not be included in the study:", "Two or more severe hypoglycemic episodes within the past 3 months, or any hospitalization or emergency room visit due to poor diabetic control within the past 3 months prior to randomization.", "History of hypoglycemia unawareness.", "Impaired hepatic function, as shown by, but not limited to, ALAT (SGPT) or ASAT (SGOT) above 2x the upper limit of normal as measured at visit 1.", "Impaired renal function, as shown by, but not limited to, serum creatinine > 177 mmol/l (> 2 mg/dl) as measured at visit 1 (if no lower values due to individual metformin intake are required) or current renal dialysis.", "Body mass index (BMI) > 38 kg/m2.", "Any other clinically significant abnormalities on screening laboratory evaluation (unless discussed with the monitor and approved by the study management).", "Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation) during the study.", "History of hypersensitivity to insulin or insulin analogues or any of the excipients in the HMR 1964 formulation.", "Donation of blood or transfusion during the 2 months prior to the screening visit.", "Pregnant or lactating women, or women planning to become pregnant during the study.", "Treatment with any investigational drug in the last month before visit 1 (screening).", "Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.", "Any clinically significant major organ system disease such as relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, hematologic or other major systemic diseases making implementation of the protocol or interpretation of the study results difficult.", "Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.", "History of drug or alcohol abuse within the last 2 years or current addiction to substances of abuse.", "Night shift workers.", "Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.", "Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00174668"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "M", "inclusion": ["statin and fibrate Wash out for one week", "HbA1c>7% and <12% (Arms 1 and 3)", "HbA1c<6% (Arms 2 and 4)", "Metabolic sd according NCEP III (3 out 4 criteria) (Arms 1 and 2)"], "exclusion": ["secondary CV prevention"], "nct_id": "NCT00932087"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": [": 54-Week Base Study:", "Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes) 50-Week Extension Study:", "Patients who complete the 54-week base study are eligible to enter the 50-week extension study"], "exclusion": ["Patients who do not have Type 2 Diabetes Mellitus (a specific type of diabetes)"], "nct_id": "NCT00103857"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["Dx of gestational diabetes treated with insulin", "To be in post-partum", "Delivery of a baby of at least 37 weeks of gestation", "Have signed the consent form"], "exclusion": ["History of glucose intolerance of diabetes before the pregnancy", "Obstetrical pathology during pregnancy"], "nct_id": "NCT00921882"},{"minimum_age": 10.0, "maximum_age": 23.0, "gender": "A", "inclusion": ["Diabetes, type 2", "Obese"], "exclusion": ["Diabetes, type 1"], "nct_id": "NCT00114998"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Diabetic patients registered in the particular centre for more than 12 months.", "Patients should have visited the centre at least once in the last 3-6 months apart from the initial visit.", "Patients willing to sign informed consent form."], "exclusion": ["Repetition of any patient as patients should not be included twice for any reason.", "Unwilling to participate or unable to comply with protocol requirements."], "nct_id": "NCT00877526"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["For All Subjects:", "Nonsmoking", "Body mass index <42 kg/m2", "FEV1 greater than or equal to 70% of predicted , DLco and TLC greater than or equal to 80% of predicted at screening,", "No abnormalities in screening pulmonary radiology", "For Subjects with diabetes mellitus:", "Type 1 or type 2 diabetes for at least 2 years", "HbA1c greater than or equal to 6.6 % and less than or equal to 12.0 %", "For Subjects without abnormalities in glucose control:", "No history of diabetes", "Normal results from a formal glucose tolerance test"], "exclusion": ["History of chronic obstructive pulmonary disease, asthma, or other significant pulmonary disease", "Significant renal, hepatic, or cardiac disease", "Women who are pregnant, lactating, or planning on becoming pregnant", "Subjects who have participated in studies of other investigational drugs within the previous 3 months", "Evidence of severe complications of diabetes"], "nct_id": "NCT00308737"},{"minimum_age": 10.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Subject with Type 1 diabetes (> 1year since diagnosis)", "CSII or MDI", "HbA1c at inclusion < 7.5 %", "No concomitant diseases that influence metabolic control", "No current use of CGM"], "exclusion": ["Subject has known allergy to medical grade adhesives", "Subject has a medical condition, which in the Investigator's opinion, may compromise patient safety", "Subject is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management", "Subject is currently using another CGM device or has used real-time continuous glucose monitoring in the previous 4 weeks", "Subject is receiving peritoneal dialysis solutions containing icodextrin", "Female subject who is pregnant or planning to become pregnant within the planned study duration"], "nct_id": "NCT00843609"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00308373"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes by ADA criteria (laboratory determinations of fasting glucose \u2265 126 mg/dL, random glucose \u2265 200 mg/dL, or two-hour oral glucose tolerance test (OGTT) glucose \u2265 200 mg/dL) documented and confirmed in medical record or a laboratory determination of HbA1c \u2265 7%. For asymptomatic patients diagnosed with diabetes with a normal fasting glucose but an elevated two-hour glucose during an OGTT, the HbA1c must be \u2265 6%.", "BMI \u2265 85th percentile documented at time of diagnosis or at screening.", "Age < 18 at time of diagnosis.", "Signed informed consent and assent forms as appropriate."], "exclusion": ["Genetic syndrome or disorder known to affect glucose tolerance other than diabetes.", "Patient on medication known to affect glucose tolerance, insulin sensitivity or secretion within 60 days of the time of diagnosis. If diagnosis is confirmed after the patient has been off the medication for 60 days, the patient may be included. Exclusionary medications include but are not limited to", "inhaled steroids at dose above 1000 mcg daily fluticasone equivalent,", "oral glucocorticoids,", "antirejection or chemotherapy agents (e.g., tacrolimus, L-asparaginase),", "atypical antipsychotics."], "nct_id": "NCT00722397"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Age >35 and < 70", "Age of diabetes diagnosis >35 and <70", "White European", "Pre-SU HbA1c <=10%", "HbA1c (on treatment) <= 9%", "No myocardial infarction or Acute coronary syndrome in previous year", "No stroke or transient ischaemic attack in previous year", "No or stable (background) retinopathy (no unscheduled laser treatment in the last 6 months)", "eGFR > 60mls/min", "No Proteinuria >30mg/dl on multistix 10SG", "No active foot ulceration or infection", "Liver ALT \u2264 twice the upper limit of the reference range", "Contactable by telephone"], "exclusion": ["Type 1 diabetes", "HbA1c >10% prior to commencing SU", "HbA1c>9% on SU treatment", "Recent MI or Stroke within last 12 months", "Pre-proliferative or proliferative retinopathy", "eGFR<60 ml/min", "Proteinuria >30mg/dl on multistix 10SG", "Active foot ulceration or infection", "Liver ALT > twice the upper limit of the reference range", "Female planning to conceive within the study period", "Any other significant medical reason for exclusion as determined by the investigator"], "nct_id": "NCT00738088"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Rural Primary Care Physicians"], "exclusion": ["Non-rural non-primary care physicians"], "nct_id": "NCT00403091"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": [": Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents."], "exclusion": [": Patients not registered in the VADT."], "nct_id": "NCT00256633"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Age >20", "Diabetes mellitus Type 2 (American Diabetes Association criteria) of at least 3 months duration", "HbA1c >7.5%", "Body-mass index (BMI) > 27"], "exclusion": ["Positive GAD 65 or IA-2 antibodies at inclusion.", "HbA1c >12%, polyuria and thirst (exclusion of severely decompensated patients)", "C-peptide < 400pmol/l (basal )", "Established anti-inflammatory therapy (includiung cortisone, NSAID, Cox-2-inhibitor). Low dose aspirin (\u00a3 100mg) will be tolerated.", "CRP >30 mg/dl, fever, current treatment with antibiotics, or chronic granulomatous infections (e.g. tuberculosis) in the history or on a screening chest X-ray.", "Neutropenia or anemia (leucocyte count < 2.0x109 /l, hemoglobin <11g/dl for ma les or <10g/dl for females)", "Pregnancy or breast-feeding. When appropriate (fertile women),anticonception for at last 3 month prior inclusion will be required.", "Severe liver or renal disease ( AST or ALT>3 times the upper limit of normal laboratory range, serum creatinine >130mM)", "Ongoing malignant neoplasm", "Use of any investigational drug within 30 days of enrollment into the study or within 5 half-lives of the investigational drug (whichever is longer)", "Immunosuppressive treatment or immunodeficient diseases."], "nct_id": "NCT00303394"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Non-obese patients (BMI < 27 kg/m2)", "Type 2 diabetes", "Age 40 years or older", "HbA1c = 6.5% or higher at baseline."], "exclusion": ["No known contraindications for either of the study-drugs (known allergy to the study-drugs; heart-, liver- or kidney-failure)", "Pregnancy", "Other serious physical or mental illnesses with a life-shortening prognosis.", "Drug or alcohol abuse.", "Weight-loss of more than 5 kg during the last 6 month prior to enrollment."], "nct_id": "NCT00118963"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["type 2 diabetes with haemoglobin A1c level between 7 and 8.5% at the last visit", "treated with oral blood glucose lowering therapy, which has not been changed for the last three months."], "exclusion": ["pregnant women; women trying to become pregnant", "patients with a serum creatinine concentration over 150 micromol/l in men and 120 micromol/l in women, Cockcroft < 50 ml/min", "hepatic enzyme levels (ALAT) over 90 U/l (2 x upper limit)", "patients known with allergy or intolerance for yeast", "patients currently taking chromium supplements", "patients treated with insulin."], "nct_id": "NCT00145093"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Pre-Diabetes"], "exclusion": ["Insulin therapy", "Treatment with any beta-blocker in the 30 days before study entry", "Asthma", "Chronic obstructive pulmonary disease (COPD)", "Greater than first degree heart block", "Heart rate less than 60 bpm", "Systolic blood pressure less than 90 mm Hg", "Raynaud's phenomenon", "Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators", "Pregnant", "Creatinine clearance less than 35 ml/min", "Hematologic dysfunction (white blood cell [WBC] count less than 3000 or hematocrit less than 28%)", "Allergy to amide anesthetics"], "nct_id": "NCT00925119"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Body mass index (BMI) 25-42kg/m^2", "Type 2 diabetes or prediabetes"], "exclusion": ["Currently smokes", "History or evidence of cardiovascular disease or other major chronic illness", "Currently exercising regularly or following a weight loss diet", "Uncontrolled high blood pressure", "Any illness that would prevent participation in a moderate-intense exercise program", "Pregnant", "Substance abuse", "Use of insulin"], "nct_id": "NCT00928005"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["type 2 diabetes mellitus,", ">18 years old,", "with a documented HbA1c more than 7.0%,", "an LDL cholesterol >100 mg/dl AND a blood pressure >130/80 mm Hg documented at least once in the medical records within the last 6 months, and", "willing to comply with the study interventions will be eligible for the study."], "exclusion": ["pregnancy,", "unable to attend the group sessions,", "disease conditions such as psychiatric instability (acutely suicidal, psychotic) or organic brain injury that preclude them from performing diabetes self-care,", "enrolled in the Providence VAMC's Telehealth program"], "nct_id": "NCT00409240"},{"minimum_age": 21.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes for at least 1 year", "age 21-75 years", "long-acting insulin at bedtime", "metformin during the day", "for women of child bearing age use of reliable method of birth control"], "exclusion": ["serum creatinine above 130 umol/l for men and above 110 for women", "systolic blood pressure > 175 or diastolic > 104 mmHg", "heart disease", "serum calcium > 2.54 mmol/l", "history of renal stones"], "nct_id": "NCT00400491"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy", "Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy"], "exclusion": ["Systemic hipertension", "Cardic disease", "Lupus", "Any kind of artritis", "Allergies", "Optic Neuritis", "VKH", "Cancer", "Inmunological diseases"], "nct_id": "NCT00600236"},{"minimum_age": 20.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients aged from 20 to 80 years", "Admitted for CABG", "Type 2 diabetes", "Type 1 diabetes", "Type 2 diabetes discovered during surgical or anaesthetic pre-operative consultation (plasmatic glycemia > 1.26 g/l) needing only dietary guidelines", "Informed consent signed", "Patients affiliated to the french social security"], "exclusion": ["Other types of cardiac surgery than CABG", "Patients admitted in emergency", "Pregnancy or breastfeeding", "Patients included in an other clinical trial with an exclusion period still running", "Patients under safeguard of justice"], "nct_id": "NCT00878891"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 or type 2 diabetes mellitus"], "exclusion": ["Subjects who are unlikely to comply with the protocol", "Subjects who are currently being treated with Levemir\u00ae", "Subjects who previously were enrolled into the study", "Subjects with hypersensitivity to Levemir\u00ae or any of its excipients"], "nct_id": "NCT00700765"},{"minimum_age": 40.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Diet treatment only for at least two weeks", "Body mass index (BMI) between 22-34 kg/m2 inclusive", "HbA1C between 6.5-12.0% inclusive", "Fasting blood glucose (FBG) between 7.0-18.0 mmol/L inclusive", "Patients should be negative (lesser than 70 kU/l) for antibodies against glutamic acid decarboxylase (GAD)"], "exclusion": ["Pharmacological treatment with medication or pancreatitis that the Investigator expected to interfere with blood glucose levels", "History of cancer or any clinically significant cardiovascular respiratory, hepatic, haematological, gastrointestinal, dermatological, venereal, neurological or psychiatric disorder as judged by the Investigator", "Impaired renal function, serum creatinine greater than 150\u00b5mol/L", "Patients, who were known to have serum hepatitis or who were carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies, or had a positive result to the test for HIV 1/2 antibodies", "Patients, who had received an investigational drug in the four months new chemical entity or licensed product preceding the start of dosing", "Patients, who had donated plasma or blood in the past month, or in excess of 500 mL in the past 12 weeks", "Patients who had a significant history of alcoholism or drug/chemical abuse"], "nct_id": "NCT00400283"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["well-controlled diabetes", "no history of myocardial infarction", "stable post CABG for at least 3 months"], "exclusion": ["heart failure", "valvular disease", "abnormal kidney or liver function", "cerebrovascular disease", "primary pulmonary disease", "other systemic or acute illness that may impede the testing or training"], "nct_id": "NCT00172536"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Has type 2 diabetes treated with either: *A stable regimen of metformin for a minimum of 3 months, and/or *Diet modification and exercise for a minimum of 3 months.", "Has HbA1c of 7.1% to 11.0%, inclusive.", "Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive."], "exclusion": ["Received any investigational drug within 3 months prior to screening.", "Is currently treated with any of the following excluded medications: *Thiazolidinediones within 3 months of screening; * Sulfonylureas within 3 months of screening; * Insulin within 1 year of screening.", "Participated previously in an exenatide clinical study."], "nct_id": "NCT00103935"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Male or female, 18 to 75 years of age.", "Diagnosis of Type 2 diabetes mellitus", "Stable coronary artery disease (CAD) documented or suspected, not requiring adjustment for \u22652 months, as determined by: a. A history of myocardial infarction verified by Q-wave electrocardiogram and/or medical records, occurring greater than 6 months before the screening Visit; OR b. A coronary angiogram and/or stress test; OR c. A ankle brachial pressure index less than 0.9; OR d. Age greater than 60 years of age", "Hp 2-2 genotype.", "Ability to communicate and comply with all study requirements. -"], "exclusion": [], "nct_id": "NCT00491543"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Male, non-fertile female (i.e., post menopausal, post hysterectomy, or sterilized by tubal ligation) or female of childbearing potential using a medically approved birth control method.", "The patient has a diagnosis of diabetes mellitus according to WHO classification.", "The patient has a positive GAD antibody test of 101 WHO units or more on two separate occasions.", "Age 18 +", "The patient did not start on insulin within 1 month of diagnosis", "Written informed consent to participate in the study.", "Ability to comply with all study requirements."], "exclusion": ["Pregnant or breast-feeding females and females who plan pregnancy or breast-feeding during the course of the study.", "A history of: Diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months", "Acute infections, which may affect blood glucose control within 4 weeks prior to visit 1.", "Malignancy including leukaemia and lymphoma (not including basal cell skin cancer) within the last 5 years.", "The patient has a known immune deficiency from any disease, or a condition associated with an immune deficiency.", "The patient is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy, or any medication that, in the opinion of the site investigator, might interfere with the study.", "Any of the following significant laboratory abnormalities:", "Patients with severe renal failure as defined previous renal transplant or currently having renal dialysis or GFR <30.", "Clinically significant laboratory abnormalities, confirmed by repeat measurement, that may interfere with the assessment of safety and/or efficacy of the study drug, other than hyperglycemia and glycosuria at visit 1.", "Severe ketonuria (+++ on urine sticks testing; ++ on repeated urine sticks testing).", "The patient is a known or suspected drug abuser.", "The patient has chronic hepatitis or liver cirrhosis, or any other chronic liver disease. 10. The patient is known to test positive for hepatitis B antigens or hepatitis C antibodies 11. The patient is known to test positive for HIV antibodies. 12. The patient has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the site investigator, are likely to affect the patient's response to treatment or their ability to complete the study. 13. The patient has chronic haematological disease. 14. The patient has had a severe blood loss (>400 mL, e.g., blood donation) within 2 months before the first dosing of the study medication. 15. The patient has known proliferative retinopathy. 16. Patient has had stage 3-4 heart failure. 17. The patient is participating in another research study which may affect the results of this trial."], "nct_id": "NCT00776607"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": [": Of diabetic subjects:", "Type 2 diabetes", "Age: 30-65 years", "BMI: 27-35 Of nondiabetic subjects:", "Age: 30-65 years", "BMI: 27-35"], "exclusion": [": Of diabetic subjects:", "Medication, which have any influence on glucose metabolism and gene expression in adipose tissue and skeletal muscle at the time of sampling of biopsies.", "Disease in liver, heart, vessels or endocrine organs Of nondiabetic subjects:", "Type 2 diabetes", "Relatives with type 2 diabetes", "Hyperglycemia", "Medication, which have any influence on glucose metabolism and gene expression in adipose tissue and skeletal muscle at the time of sampling of biopsies.", "Disease in liver, heart, vessels or endocrine organs"], "nct_id": "NCT00143013"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 DM:", "Age > 18 years", "Subjects diagnosed with type 1 DM (diagnosed based upon history of ketoacidosis, proven insulin dependence, absent C-peptide and or positive autoantibody profile (such as anti-GAD etc.)", "Stable A1C < 8.5%", "BMI < 31", "Type 2 DM:", "Age > 18 years", "Subjects diagnosed with type II DM (diagnosed as adult onset, not-insulin dependent and not on insulin)", "Stable A1C < 8.5%", "BMI < 31"], "exclusion": ["History of active, unstable cardiovascular disease (including MI, CHF, Stroke, Angina, CABG, stenting/PTCA, peripheral vascular disease, intermittent claudication)", "Pregnancy, nursing or likely to get pregnant during the course of the study (not on oral contraceptives and premenopausal)", "Chronic Kidney Disease (creatinine > 2.0)", "Liver function test abnormalities, not previously worked up (AST or ALT >4x upper limit of normal)", "Active substance abuse including alcohol", "History of severe Hypertriglyceridemia (untreated TG > 500) and on therapy", "Use of agents that interfere with cholesterol absorption (such as fiber, resins etc.) which can not be discontinued for the duration of the study", "Actively enrolled in a weight loss program or following a special diet ( e.g.: Atkins diet)", "History of malignancy <5y", "History of Rhabdomyolysis and Myopathy", "Use of on-going oral corticosteroids", "History of HIV infection", "Use of following drugs/compounds: cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, niacin, amiodarone, verapamil or large quantities of grape fruit juice (> 1 quart per day)", "Proteinuria: more than or equal to 300mg/24 hours calculated from random urine specimen.", "BMI >31", "Anyone with hypersensitivity to either one of the study medications", "Allergy to Soy bean products", "Unable to consume milk products with or without Lactaid\u00ae"], "nct_id": "NCT00879710"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 or 2 diabetes", "Including newly diagnosed not on insulin or insulin analogue treatment", "Selection at the discretion of the physician", "Adult patients with type 1 and 2 diabetes mellitus, and type 1 patients 6 years and older"], "exclusion": ["Current treatment with Levemir\u00ae", "Previously enrolled in the study", "Hypersensitivity to Levemir\u00ae"], "nct_id": "NCT00706017"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Is 18 to 75 years of age, inclusive;", "Has a clinical diagnosis of type 2 diabetes mellitus;", "Is anti-glutamic acid decarboxylase (GAD) antibody negative;", "Has an A1C \u2265 7.0% and \u2264 10.5%;", "Has a body mass index (BMI) \u2265 25 kg/m2 and \u2264 40 kg/m2;", "Is treated with either \u2265 2 oral antidiabetic agents (OA) or basal insulin \u00b1 OA(s) or basal-bolus insulin \u00b1 OA(s) for at least 3 months (Subjects may also be treated with exenatide [Byetta] or pramlintide [Symlin].", "If on concomitant metformin, has serum creatinine < 1.5 mg/dL (male) or <1.4 mg/dL (female);", "If female, has a negative urine pregnancy test"], "exclusion": ["Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months;", "Has clinical cardiovascular disease (CVD) as evidenced by prior myocardial infarction, stroke, arterial revascularization and/or angina with ischemic changes on ECG at rest, changes on graded exercise test, or positive cardiac imaging test results;", "Has abnormalities on the screening (Visit 1) 12-lead ECG that are deemed by the investigator to be clinically significant;", "Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route or potent inhaled,intrapulmonary, intranasal, or topical steroids that are known to have a high rate of systemic absorption;", "Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be non-compliant;", "Has any significant medical condition, laboratory findings, or medical history that in the investigator's opinion may affect successful completion of the study and/or personal well-being;"], "nct_id": "NCT00922649"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type II diabetes mellitus", "Poor glycemic control"], "exclusion": ["Heart failure", "Renal disease", "Liver disease", "Cardiovascular event"], "nct_id": "NCT00306176"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 or type 2 diabetes", "asthma or COPD"], "exclusion": ["Current smoking habit"], "nct_id": "NCT00157339"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Subjects must have been diagnosed with type 2 diabetes, with HbA1c level >=7.0% and <=11.0% and a fasting glucose level <=280 mg/dL.", "Men or women of nonchildbearing potential (WONCBP), aged 18 to 65 years inclusive on study day 1.", "Body mass index in the range of 27 to 40kg/m\u00b2 (inclusive) and body weight >=50 kg.", "Subjects must be otherwise generally healthy, but may be enrolled with a stable chronic illness, if it is well controlled and does not interfere with the primary objective of the study.", "Subjects must currently be treated for diabetes with metformin alone at a total daily dose of >=1gm (administered QD or BID) and that dose must have been stable for at least 4 weeks before study day 1.", "Nonsmoker."], "exclusion": ["Any significant disease with the exception of diabetes mellitus.", "Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the investigational product.", "Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.", "Any clinically important problems in physical examination results, vitals sign measurements, ECGs, or clinical laboratory test results.", "Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.", "Positive findings of urine drug screen", "Use of any investigational or non-permitted prescription drug within 30 days before investigational product administration."], "nct_id": "NCT00970593"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["A clinical diagnosis type 2 diabetes mellitus.", "Women must not be pregnant or breastfeeding during the study and 30 days after the study.", "Must sign an informed consent form at the study clinic."], "exclusion": ["Severe chronic diseases that would prevent from participating and completing the study by investigator's judgement.", "Use of an investigational drug within 30 days or 5 half lives before first dose of study medication.", "Insulin use for > 1 week in past 3 months."], "nct_id": "NCT00256867"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Males and females >40 years old;", "High-risk subjects with type 2 diabetes (WHO criteria);", "Serum creatinine concentration of 1.8 mg/dl or more (but less than 3.5 mg/dl);", "Urinary albumin to creatinine ratio >1000mg/g for the patients without previous ACE inhibitor and ARB therapy and >500mg/g for the patients with previous ACE inhibitor or ARB therapy (in spot morning urine)", "Legal capacity;", "Written informed consent."], "exclusion": ["Specific contraindications or history of hypersensitivity to the study drugs or other;", "Serum potassium \u2265 6 mEq/L despite diuretic therapy, and optimized metabolic and acid/base control;", "Bilateral renal artery stenosis;", "Previous history of allergy or intolerance, or evidence of immunologically-mediated renal disease, systemic diseases, cancer;", "Drug or alcohol abuse;", "Any chronic clinical conditions that may affect completion of the trial or confound data interpretation;", "Pregnancy or lactating;", "Women of childbearing potential without following a scientifically accepted form of contraception;", "Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;", "Evidence of an uncooperative attitude;", "Any evidence that patient will not be able to complete the trial follow-up;", "Dual RAS blockade with an ACE inhibitor and an ARB."], "nct_id": "NCT00494715"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus for at least 6 months", "One or more oral antihyperglycemic medications for at least 12 weeks", "HbA1c equal to or greater than 7.0%, and equal to or less than 10.5%", "Nonsmokers, have not smoked for at least 6 months and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the duration of the study", "Satisfactory lung function results to meet the requirement of the study"], "exclusion": ["Previously received any form of inhaled insulin", "Have a current diagnosis or past history of asthma, chronic obstructive pulmonary disease or other clinically relevant lung disease", "History or presence of liver disease", "History or presence of kidney disease"], "nct_id": "NCT00490854"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00871572"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes > 3month duration", "Age 18", "Hb A1C <12%", "On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment", "Normal creatine", "Negative for GAD antibodies", "SMBG >4/d and willing/able to comply with study requirements", "Demonstrated adherence to visits and instructions."], "exclusion": ["Severe hypoglycemic during the last month", "Severe cardiac, pulmonary or cerebral disease", "Demonstrated non compliance with clinical recommendations", "Pregnancy, nursing or women who could potentially become pregnant", "Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump"], "nct_id": "NCT00874809"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 Diabetes", "HbA1c > = 8.0% and < = 12.0%", "Serum triglyceride concentration < = 600 mg/dL", "Fasting c-peptide > = 1.0 ng/ml", "Body mass index < = 41 kg/m2", "Drug naive patients"], "exclusion": ["History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular accidents, accelerated/malignant hypertension, or hypertension related CHF (congestive heart failure) within six months prior to screening and during the Lead-In Phase.", "Women of child Bearing Potential", "Uncontrolled hypertension, CHF defined as New York Heart Association (NYHA) Class II, III and IV, exacerbation of previously stable CHF (any NYHA class) or uncontrolled cardiac arrhythmia in the 30 days prior to screening and during the Lead-In Phase.", "History of renal disease, bladder cancer, pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease."], "nct_id": "NCT00106808"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["type 2 diabetes", "BMI 20-45kg/m2"], "exclusion": ["NYHA Class II to IV heart failure", "females who are pregnant, lactating, or less than 6 weeks post-partum"], "nct_id": "NCT00849056"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Subjects may be males or non-pregnant, non-lactating females age 18-80 years.", "Subjects must have been diagnosed with type 2 diabetes mellitus according to the current ADA criteria.", "Triglyceride levels above 149 mg/dL", "Minimum of 2 years after diagnosis of type 2 diabetes", "Prior to participation in this study, each subject must sign an informed consent document."], "exclusion": ["Presence of type 1 diabetes mellitus (defined as C-peptide < 1 ng/ml or diabetes onset at < 35 years of age in a non-obese patient).", "Presence of diabetic retinopathy that is more severe than \"background\" level.", "Presence of diabetic nephropathy, defined by urine dipstick results greater than 300 mg/100 mL for protein (proteinuria).", "Presence of clinically significant neuropathy that is clearly of non-diabetic origin, e.g. alcoholic or autoimmune.", "Bilateral amputation of lower extremities or foot ulcers involving the great toes. Presence of neuroarthropathy (Charcot deformity) is allowable.", "History of major macrovascular events such as myocardial infarction or stroke.", "Participation in another clinical trial concurrently or within 30 days prior to entry into this study.", "The use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB) is allowed but must have been stable for at least 30 days prior to study entry and may not change during the course of the study. This is prudent due to their potential effects on blood flow.", "Patients with moderate or severe hepatic insufficiency or abnormalities of liver function defined as any liver enzymes (aspartate aminotransferase,alanine transaminase, alkaline phosphatase) greater than 3 times the upper limit of normal. 10. Presence of pedal edema. 11. Presence or history of heart failure New York Heart Association Class II or greater. 12. Other serious medical conditions that in the opinion of the investigator, would compromise the subject's participation in the study. 13. Concomitant use of medications known to exacerbate triglyceride levels, such as estrogens."], "nct_id": "NCT00931879"},{"minimum_age": 10.0, "maximum_age": 15.0, "gender": "A", "inclusion": ["Children in 6th-8th grade"], "exclusion": ["Diabetes", "Exercise induced asthma", "Pregnancy", "Any chronic medication that interferes with glucose homeostasis"], "nct_id": "NCT00954577"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Type 1 or type 2 diabetes mellitus", "age > 18 years"], "exclusion": ["Profound vision loss", "Severe hearing impairment"], "nct_id": "NCT00629434"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["are male or female outpatients at least 18 years of age", "provide written consent to the release of their data after being informed of the study", "diagnosed with type 2 diabetes mellitus and are taking metformin, or a sulfonylurea or both", "are reliable, and agree to keep all appointments for clinic visits, complete tests and procedures as may be required by the attending physician in the course of routine clinical care", "are treated with exenatide according to the approved Product Insert, as prescribed by the investigator in the routine care of the patient"], "exclusion": ["are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug.", "are currently taking insulin.", "are pregnant or have intentions of becoming pregnant within the duration of the study.", "are the investigators or their immediate families. Immediate family is defined as the investigator's spouse, parents, natural or legally adopted child (including stepchild living in the investigator's household), grandparents, or grandchild. Employees of investigators are also not eligible."], "nct_id": "NCT00622323"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 30-75 years", "type 2 diabetes determined by self-report with verification", "6.5% < HbA1C < 11%", "sedentary lifestyle", "not being physically active greater than or equal to 3 days per week for 20 minutes each time for the previous 6 months, and not performing regular resistance exercise"], "exclusion": ["inadequate control of co-morbid conditions", "resting blood pressure greater than or equal to 160/100 mm Hg", "Triglycerides greater than or equal to 500 mg/dL", "BMI is greater than or equal to 48", "current use of an insulin pump or insulin injections other than Lantus", "metal object in the body that may interfere with MRI/MRS scans", "factors that may limit adherence to intervention or affect conduct of the trial", "unable or unwilling to communicate with staff, to provide written informed consent, or accept the randomized assignment", "failure to complete behavioral run-in and baseline testing", "hospitalization for depression in the last 6 months", "not physically capable of performing the exercise required for the study protocols", "consuming > 14 alcoholic beverages per week", "plans to be away > 4 weeks in the next 9 months", "lack of support from primary health care provider or family members", "significant weight loss in the past year (>20 lbs) or current use of weight loss medications", "current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder 10. another member of household is a participant or staff member of HART-D 11. bariatric surgery 12. other temporary intervening event, such as sick spouse, bereavement, or recent move 13. other medical, psychiatric, or behavioral limitations that, in the view of the principal investigator, may interfere with study participation or the ability to follow the intervention protocol", "underlying diseases or conditions likely to limit lifespan and/or affect the safety of the intervention", "pregnant or plan on becoming pregnant in the next 9 months", "cancers requiring treatment in the past 5 years, unless prognosis is excellent", "self-reported HIV or tuberculosis", "history or evidence of serious arrythmias, cardiomyopathy, congestive heart failure, aortic aneurysm, or heart transplantation", "renal disease: urine dipstick 4+ protein, serum creatinine is greater than or equal to 1.4 mg/dL (women) or is greater than or equal to 1.5 mg/dL (men) or currently receiving dialysis", "any other medical condition or disease that is life threatening or that can interfere with or be aggravated by exercise", "advanced neuropathy or retinopathy"], "nct_id": "NCT00458133"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["history of gestational diabetes or overweight (>25 kg/m2) with family history of type 2 diabetes", "sedentary"], "exclusion": ["history of diagnosis of diabetes, hypertension, heart disease or chronic renal disease", "current medications which adversely influence glucose tolerance", "not planning to continue the pregnancy to term", ">16 weeks gestation", "contraindications to participating in moderate physical activity", "inability to read English at a 6th grade level", "self-reported participation in >30 min of moderate or vigorous-intensity exercise on >3 days/wk", "prior participation in the study", "non-singleton pregnancy"], "nct_id": "NCT00728377"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 and type 2 diabetes patients", "Insulin requiring patients", "Sufficiently fluent in english", "HbA1c > 7.5", "Last visit with Diabetes Specialist Nurse (DSN) < 12 months"], "exclusion": ["Psychiatric disorders", "Poor vision or/and lack of manual dexterity", "Prior use of T+", "Participation in another ongoing trial", "Patients with antenatal/gestational", "Patients who are in transition between the children services and adult services Insulin pump users"], "nct_id": "NCT00922376"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Blood glucose criteria must be met", "Not currently on drug therapy for type 2 diabetes", "Body mass index (BMI) in the range 22-45", "Diagnosis of type 2 diabetes for at least 8 weeks"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of serious diabetic complications", "Evidence of serious cardiovascular complications", "Significant laboratory abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00101712"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 Diabetes"], "exclusion": [], "nct_id": "NCT00101751"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Individuals >18 years old with type 1 or type 2 diabetes mellitus."], "exclusion": ["Individuals currently taking the maximum dose of an ACE inhibitor or an ARB.", "Individuals with a history of a MI, percutaneous coronary interventions, coronary artery bypass graft (CABG) surgery, acute coronary syndromes, recent/on going atrial fibrillation, frequent atrial arrhythmias, frequent ventricular arrhythmias, or acute myocardial ischemia changes.", "Individuals whose treatment dosage changes 2 months prior to the study for antihypertensive and antidiabetes medications, and the following medications that may affect the ANS: anti-tuberculosis drugs, nitrofurantoin, metronidazole, chloramphenicol, perhexiline maleate, amiodarone, clofibrate, tricyclic antidepressants, phenytoin, barbiturates, neuroleptic, antiparkinsonism drugs, and nitrated drugs.", "Pregnant or lactating females.", "Individuals with impaired renal function (i.e., creatinine >1.5 mg/dl), a history of dialysis, nephritic syndrome or renovascular hypertension.", "Individuals with potassium levels within 0.5 mmol/L of the upper limit of normal (i.e., hyperkalemia)."], "nct_id": "NCT00935064"},{"minimum_age": 18.0, "maximum_age": null, "gender": "M", "inclusion": ["Type 2 diabetes mellitus.", "Serum testosterone 12 nmol/L or less on two consecutive samples taken on different days and symptoms compatible with hypogonadism.", "Peripheral vascular disease as defined by", "previous diagnosis by a specialist vascular surgeon OR", "ABPI less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene).", "Agreement to maintain antihypertensive and antilipid treatments at prior doses during 3 month duration of study.", "Ability to give written informed consent after verbal and written explanation in the English language.", "Ability to comply with all study requirements."], "exclusion": ["Current or previous breast cancer.", "Current or previous prostate cancer.", "Raised prostate specific antigen (PSA) or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion.", "Severe symptoms of benign prostatic hypertrophy ('prostatism')", "Treatment with testosterone in the 3 months prior to the trial.", "Investigational drug treatment in the 3 months prior to the trial."], "nct_id": "NCT00504712"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["patient undergoing non-cardiac surgery (inpatient only)"], "exclusion": ["outpatient procedures, cardiac surgery"], "nct_id": "NCT00738114"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients between the ages of 18", "75, inclusive", "Diagnosed with type 2 diabetes", "Hemoglobin A1c value greater than or equal to 8.0%", "Antidiabetic treatments may include sulfonylurea agents (non-sulfonylurea agents must be withdrawn)", "Overweight, obese (body mass index 25-45 kg/m2)"], "exclusion": ["Change of dose of lipid or blood pressure lowering therapy within past three months", "Previous treatment with colesevelam for hyperlipidemia", "Serum triglyceride greater than 500 mg/dL", "Serum low density lipoprotein-cholesterol less than 60 mg/dL"], "nct_id": "NCT00147745"},{"minimum_age": 17.0, "maximum_age": 66.0, "gender": "A", "inclusion": [": Patients who have had diabetes and/or dyslipidemia prior to gastric by-pass. -"], "exclusion": [":Patients who have had type 2 diabetes that was diet controlled at time of surgery; and debilitated patients who are unable to come in for a physical exam. -"], "nct_id": "NCT00879125"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes mellitus", "HbA1c \u2264 9%", "Overweight or obese (BMI \u2265 25 kg/m2 and \u2264 45 kg/m2)", "Age \u2265 30 and \u2264 70 years (postmenopausal if female)", "Stable medical therapy for past 3 months", "Stable body weight (within \u00b1 2 kg) for past 3 months", "Plans to remain in the Columbus, OH metropolitan area for at least 1 year"], "exclusion": ["Substance abuse", "Current use of prescription or over-the-counter medications or supplements known to affect body composition", "Current use of prescription or over-the-counter medications or supplements known to interact with thiazolidinediones(TZDs)", "Current or previous diagnosis of congestive heart failure", "Self-report of claustrophobia", "Abnormal liver function", "Impaired cognitive function", "Current or previous diagnosis of renal disease", "Gastrointestinal diseases or disorders", "Current use of hormone therapies, or use within the past 3 months", "Discontinuation of diabetes medication"], "nct_id": "NCT00607945"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Ethnicity: all ethnic groups", "Gender: men and women", "Age", "Lower age limit: 40 years inclusive", "Upper age limit: NONE", "BMI", "Lower BMI limit: 25 inclusive", "Upper BMI limit: 40 inclusive", "Glucose Intolerance / Mild Diabetes defined as", "Fasting glucose \u2265100 mg/dl OR", "2-hr glucose after OGTT \u2265140 mg/dl OR", "5.8 \u2264 Hemoglobin A1c \u2264 7 Major"], "exclusion": ["Diabetes requiring pharmacotherapy", "Smoking", "Hyperparathyroidism", "Hypercalcemia (Calcium > 10.5 mg/dl)", "Kidney stone", "Pregnancy"], "nct_id": "NCT00436475"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes mellitus", "Is receiving monotherapy or combination antidiabetic therapy with a glycosylated hemoglobin level between 6.5% and 11.0%, inclusive, at Screening (between 7.0 and 11.0%, inclusive, if the participant's antidiabetic regimen includes insulin)", "Diagnosis of acute coronary syndrome within 15 to 90 days prior to randomization."], "exclusion": ["Signs of type 1 diabetes mellitus", "Currently receiving a glucagon-like peptide-1 analogue for glycemic control of type 2 diabetes mellitus at Screening", "Received a dipeptidyl peptidase-4 inhibitor for either more than 14 days total or within the 3 months prior to Screening."], "nct_id": "NCT00968708"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus Type 2"], "exclusion": ["Severe Asthma, severe COPD", "Smoking"], "nct_id": "NCT00367445"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus"], "exclusion": ["Known or suspected allergy to study product or related products.", "Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months."], "nct_id": "NCT00775736"},{"minimum_age": 25.0, "maximum_age": 80.0, "gender": "M", "inclusion": ["Healthy", "Type 2 diabetes"], "exclusion": ["Heart failure", "Lung disease", "Anti-coagulation treatment"], "nct_id": "NCT00412906"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Diabetic patients with proven presence of the disease who complained of insomnia."], "exclusion": ["Patients with liver or renal problems (serum creatinine above 1.5 mg/dL)."], "nct_id": "NCT00869128"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 diabetes for at least 3 months", "Type 2 diabetics on oral antidiabetic medicines and/or insulin therapies"], "exclusion": ["Patients taking intermediate acting insulin such as NPH", "Recurrent severe hypoglycemia", "Patients with late diabetic complications"], "nct_id": "NCT00624767"},{"minimum_age": 18.0, "maximum_age": 73.0, "gender": "A", "inclusion": ["On a stable dose of metformin as defined by the protocol", "Body mass index (BMI) in the range 22-45", "Blood glucose criteria must be met"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of significant diabetic complications", "Evidence of serious cardiovascular complications", "Laboratory value abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00106340"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Not previously treated with oral antidiabetic agents as defined by the protocol", "Blood glucose criteria must be met", "Body mass index (BMI) in the range 22-45"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of serious diabetic complications", "Evidence of serious cardiovascular complications", "Laboratory value abnormalities as defined by the protocol", "Known sensitivity to pioglitazone", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00101803"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Recent onset type 1 diabetes as defined by clinical diagnosis within the last 6 months and age less than 30 or at least one islet autoantibody marker (GAD, IAA, or IA-2). or", "High risk of pre-type 1 diabetes as defined by first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2). or", "Individuals with established type 1 diabetes of greater than 6 months duration who were under age 30 or at least one islet autoantibody marker positive (GAD, IAA, or IA-2) at time of diagnosis or who currently are GAD or IA-2 autoantibody marker positive. or", "Normal control as defined by no family history of type 1 diabetes and normal tolerance test (tolerance testing to be performed as part of protocol)."], "exclusion": ["Individuals under 18 years of age", "Individuals unable or unwilling to give informed consent/HIPAA authorization", "Individuals who are clinically unstable", "Individuals with any contraindications to MRI examination, for example, individuals with pacemakers", "Pregnant or lactating women", "Individuals with allergies to iron or dextran", "Individuals with a history of cirrhosis"], "nct_id": "NCT00585936"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Adults with capacity to perform study", "Diabetes Mellitus Type 2", "C-peptide > 0", "HbA1C >5.5", "Unchanged diabetes treatment during last 3 months", "Weight and HbA1C varied less than 5% during last 3 months", "No acute heart disease during last 6 months", "Unchanged treatment with betablocker last 6 months", "Unchanged treatment with thyroid hormone substitution last 6 months"], "exclusion": ["Treatment with insulin", "Chronic treatment with steroids (not inhaled)", "Treatment with Waran (anticoagulant cumarin type)", "Creatinin > 130 micromol/L", "Elevated liver enzymes (ALAT,ASAT,ALP or GT > 4 X upper reference value)", "Acute heart disease", "Changed treatment with betablocker or thyroid hormone substitution"], "nct_id": "NCT00435240"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["type 2 diabetes", "Between 18 and 75 years of age", "Male or non-pregnant, non-lactating female, at least 6 weeks postpartum", "If of childbearing potential, is practicing birth control", "BMI is more than or equal to 18kg/m2 and less than or equal to 35kg/m2", "If on anti-hyperglycemic, anti-hypertensive, lipid-lowering, or thyroid medications or hormone therapy, has been on constant dosage for at least 3 months prior to screening visit"], "exclusion": ["Uses insulin for glucose control or has type 1 diabetes", "History of diabetic ketoacidosis.", "Current infection; surgery or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks.", "Active malignancy", "Significant cardiovascular event less than or equal to 6 months prior to screening visit or history of congestive heart failure", "End state organ failure or status post organ transplant", "History of renal disease", "Current hepatic disease", "History of severe gastroparesis", "Has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV", "Currently taking herbals, dietary supplements, or medications, other than anti-hyperglycemic medications, during the past 4 weeks that could profoundly affect blood glucose", "Clotting or bleeding disorders", "Allergic or intolerant to any ingredient found in the study products"], "nct_id": "NCT00499148"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["type 2 diabetes", "A1c 0.700-0.099", "ability to read and write English", "signed ICF"], "exclusion": ["participation in previous 6 months in exercise > 2 times per week for at least 20 min per session", "insulin therapy changes in medication for diabetes, BP or Lipids"], "nct_id": "NCT00877864"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["type 2 diabetes", "elevated blood pressure and pulse pressure", "albuminuria"], "exclusion": ["Severe hypertension", "History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm", "Liver, kidney (not caused by diabetes), or pancreas disease", "Type 1 diabetes or uncontrolled type 2 diabetes", "Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/exclusion criteria may apply."], "nct_id": "NCT00171561"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["type 2 diabetes", "inadequately controlled on 50% of maximal-dose of an insulin secretagogue and metformin"], "exclusion": ["heart failure (NYHA II-IV)"], "nct_id": "NCT00609856"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["type 2 diabetes", "BMI 20-45kg/m2 inclusive"], "exclusion": ["females who are pregnant, lactating, or <6 weeks post-partum", "CHF NYHA class III-IV"], "nct_id": "NCT00849017"},{"minimum_age": 19.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["type 2 diabetes", "dietary therapy"], "exclusion": ["lipid-lowering therapy", "anti-hyperglycemic drug therapy"], "nct_id": "NCT00939939"},{"minimum_age": 10.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with Type 1, Type 2, or Gestational Diabetes", "Above the age of 10"], "exclusion": ["Does not meet inclusion criteria", "Patients requiring dialysis", "Participation in other clinical investigations within the previous month.", "Pregnancy(excluding patients that intend to participate in the gestational group)"], "nct_id": "NCT00433758"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["Patients 18-78 years old inclusive at Visit 1", "T2DM patients treated with metformin for at least 3 months and a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to Visit 1", "Patient agreement to maintain same dose of metformin throughout study", "HbA1c of \u2265 7.0 and \u2264 9.5 % at Visit 1", "Body Mass Index (BMI) in the range of 22-45 kg/m2 at visit 1"], "exclusion": ["Pregnant or nursing (lactating) women", "FPG \u2265 270 mg/dL ( \u2265 15.0 mmol/L)"], "nct_id": "NCT00860288"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Prior diagnosis of Type 2 Diabetes for at least 1 year based on one of the following:", "Fasting blood glucose >126 on two separate occasions", "Random blood glucose >200 with symptoms", "Abnormal 75 or 100 gram Oral Glucose Tolerance Test (OGTT) defined as: fasting blood glucose >100, 2hour post prandial blood sugar of >140", "On medications for diabetes (oral or insulin)", "Age >/=18", "Stable but uncontrolled blood glucose (Hemoglobin A1C >7%, </= 12%)", "Ingestion of at least three eight ounce servings of sugar sweetened beverage daily.", "Stable solid diet and exercise pattern and agreement not to change these during the study", "Able and willing to maintain a complete diet diary for three days each week of the study (total of 12 days of recording)", "Able to attend regular study visits", "Able to give informed consent", "Working phone number in order to contact patient 10. Able and willing to understand and comply with the intervention"], "exclusion": ["Women who are known to be pregnant at enrollment based on a positive pregnancy test. Pregnancy test will be given to all female subjects of child bearing age prior to enrollment in the study. Pregnant women will be excluded on the basis that blood glucose data are significantly affected by the physiology of pregnancy. This exclusion is not based on any potential risk to the pregnant women or fetus.", "Individuals <18 years of age", "Diagnosis of Type 1 Diabetes", "Malabsorbtive syndrome of any type (will be determined based on medical history from patient and/or medical chart)", "On Acarbose prior to start of study", "On a weight loss diet within one month of enrollment"], "nct_id": "NCT00585897"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["type 2 diabetes mellitus", "age: 35-70 years"], "exclusion": ["Heart failure corresponding to NYHA- class III and IV", "history of stroke", "history of myocardial infarction", "unstable angina pectoris", "peripheral artery disease stadium IIb and more", "kidney disease (Creatinine > 1,8 mg/dl and/or creatinine clearance <50 ml/min calculated according to the Cockroft formula and/or macroalbuminuria >200 mg/l)", "malignant diseases", "chronical alcohol consumption (more than 50 ml of highly concentrated alcohol or equivalents / day)", "pregnancy or lactation", "potentially child- bearing women without sufficient contraception (sufficient contraception is defined as the use of a contraceptive method that has an efficiency of over 99% (according to CHMP/EWP/225/02)). A pregnancy test will be performed before the commencement of the study.", "arterial hypotonia (blood pressure<90/50 mmHg) or arterial hypertonia with systolic blood pressure >159 mmHg and/or diastolic blood pressure >99 mmHg", "arterial hypertonia requiring more than three antihypertensive agents", "advanced diabetes complications (subjects must have been investigated with regard to these complications maximum 6 months previously by a specialized physician) such as:", "proliferative diabetic retinopathy", "diabetic neuropathy requiring morphium derivatives", "patients with an acute foot syndrome", "HbA1c >10 %", "participation to other studies within the previous 3 months"], "nct_id": "NCT00437008"},{"minimum_age": 10.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Males or females who are 10", "17 years of age", "History of type 2 diabetes", "Nonsmoker", "No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes"], "exclusion": ["History of diabetic ketoacidosis", "History of stroke, chronic seizures or major neurological disorder", "Consumes alcohol", "Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola or other beverages containing caffeine per day", "Unable to swallow tablets", "Has had surgery, donated or lost 1 unit of blood, or participated in another investigational study within a minimum of 4 weeks prior to starting the study", "History of multiple and/or severe allergies or has had an allergic reaction to or significant intolerability to prescription or non-prescription drugs or food", "Currently a regular user of any illicit drugs or has a history of drug or alcohol abuse", "History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases", "Has an estimated creatinine clearance of less than or equal to 80 mL/min"], "nct_id": "NCT00730275"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["essential hypertension,", "diabetes type 2"], "exclusion": ["severe cardiovascular disease,", "grade 3 hypertension,", "secondary hypertension,", "abnormal liver enzymes"], "nct_id": "NCT00160160"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 Diabetes", "Non diabetic"], "exclusion": ["Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin", "Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)", "Anemia"], "nct_id": "NCT00609154"},{"minimum_age": 30.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus (WHO)"], "exclusion": ["Terminal disease (renal, cancer, heart failure)"], "nct_id": "NCT00935805"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["presence of type 2 diabetes (at least 1 year) as defined by A1c between \u22656.5% and \u22648.1%, at recruitment,", "treatment with diet or oral hypoglycemic medication be unchanged starting at least 2 months prior to the beginning of the study (at recruitment, week -8)", "between the age of 40 and 75 years", "systolic blood pressure <140 and diastolic blood pressure <90", "clinically euthyroid (measuring T3 and T4)", "normal renal and liver functions", "post-menopausal or non-pregnant women (Post-menopausal includes: those females with more than a year of cessation of menstruation)", "a negative result on a pregnancy test administered at screening", "subjects taking an effective form of birth control (example: condom, abstinence, etc.)", "willing to comply with the study protocol and sign a consent form"], "exclusion": ["individuals with bleeding disorders", "individuals with allergies to nitroglycerin", "planned surgery, pregnancy or breastfeeding", "taking insulin; clinically significant diabetes complications (retinopathy, nephropathy, or neuropathy); serum triglycerides \u2265 4.5 mmol/L", "increased A1c level of more than 2% from baseline during the study", "history of angina or heart attack", "use of ginseng or any natural health products with glucose modulating and/or anti-platelet activity within 2 months", "BMI > 35 kg/m2 including a weight fluctuation of + 2kg during treatment periods", "smoke cigarettes; alcohol intake > 2 drinks/day", "the presence of any conditions which, in the opinion of the investigator, might jeopardize the health and safety of the subject or study personnel or adversely affect the study results, if the subject participated in the study", "Subjects taking Warfarin or Coumadin, prescription NSAIDs, chronic use of high-dose (>81mg) non-prescription NSAIDs, or selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, or sympathomimetics or medications affecting nitric oxide levels, or any known or suspected sensitivity to any of the ingredients in the test product or placebo cannot participate in the study."], "nct_id": "NCT00728403"},{"minimum_age": 18.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs."], "exclusion": ["Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus that is poorly controlled"], "nct_id": "NCT00110435"},{"minimum_age": 18.0, "maximum_age": 66.0, "gender": "A", "inclusion": ["have type 2 diabetes mellitus that has been diagnosed for at least three months", "must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea", "must be willing to wash-out of these medications for 14 days prior to the start of the study", "must have bloodwork that meets certain criteria (for example, total cholesterol < 240 mg/dL)"], "exclusion": ["must not have any other major illness other than diabetes"], "nct_id": "NCT00259896"},{"minimum_age": 10.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Middle school student body is at least 50% minority (defined as African American, Hispanic/Latino, and/or Native American) and/or greater than 50% eligible for free or reduced lunch.", "Middle school annual school-wide attrition from all causes is <= 25% (estimate determined from data provided by the school).", "Middle school expected cohort size at end of study is at least 50 per school determined by applying 50% anticipated enrollment rate and annual school-wide attrition rate over 3 years.", "Student able to participate in the school's standard PE program.", "Student's parent/guardian has provided informed consent for the child to participate in data collection and evaluation procedures.", "Student has provided informed assent to participate in data collection and evaluation procedures."], "exclusion": [": (none specified)"], "nct_id": "NCT00458029"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Males and females (non-childbearing potential), aged 18-65 years", "Diagnosis of Type 2 diabetes mellitus for at least 6 months prior to screening", "Fasting plasma glucose \u2264 240 mg/dL prior to metformin washout", "Body mass index < 42 kg/m^2", "HbA1c value of 7 to 11%", "C-peptide \u2265 1.0 ng/mL", "Ability to provide written informed consent"], "exclusion": ["History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, incontinence, or nocturia", "Use of any blood glucose lowering agent other than metformin", "Prior exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening", "Laboratory or electrocardiogram abnormalities deemed significant by the Sponsor or the Investigator", "Positive test result for glutamic acid decarboxylase (GAD) antibody", "Surgery within 6 months of screening", "Exposure to any investigational agent or participation in any investigational trial within 30 days prior to Day 1", "Hypersensitivity to an SGLT2 inhibitor", "History of drug or alcohol abuse within the last 12 months"], "nct_id": "NCT00962065"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetic patients who are aged 35 to 80 year-old"], "exclusion": ["Insulin use", "Patients who receive any dyslipidaemia under medications (including statins) in recent one year", "Women of child-bearing potential are excluded (i.e. menopausal women or post-hysterectomy women are included in this study) due to radiation exposure in this study", "Active inflammatory diseases", "Vasculitis, symptomatic coronary artery disease, symptomatic cerebrovascular diseases", "Significant concomitant disease such as active infection, malignancy, hepatic or renal dysfunction at the time of enrollment (i.e. T-Bil > 3 mg/dl\uff0cALT > 2.5 times the upper limit of normal range and Creatinine > 2 mg/dl in our hospital)"], "nct_id": "NCT00932048"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose.", "Has a documented history of dyslipidemia with or without cardiovascular risk factors but without type 1 or 2 diabetes.", "Is on a stable antidiabetic regimen, which may have included oral antidiabetic medication and/or insulin, for at least 3 months prior to Screening.", "Prior to Randomization, the participant has a mean low density lipoprotein cholesterol level greater than or equal to 100 mg/dL and less than or equal to 190 mg/dL for 2 consecutive samples.", "Prior to Randomization, the subject has mean triglyceride level greater than or equal to 400 mg/dL for 2 consecutive samples.", "Is willing and able to comply with the recommended, standardized diet."], "exclusion": ["Has annine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, identified during screening.", "Has a serum creatinine greater than 133 mmol/L, identified during screening.", "Has a creatine kinase greater than 3 times the upper limit of normal, identified during screening.", "Has active liver disease or jaundice.", "Has taken any bile acid sequestrants [eg, cholestyramine], and intestinal cholesterol uptake inhibitors [eg, ezetimibe]) from 30 days before Screening until study completion or any fibrates for 6 weeks before Visit 1.", "Has a previous history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.", "Has an endocrine disorder, such as Cushing's syndrome, hyperthyroidism, or inappropriately treated hypothyroidism affecting lipid metabolism.", "Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary angioplasty, coronary or peripheral arterial surgery, or multiple risk factors that confer a 10-year risk for cardiovascular heart disease greater than 20% based on Framingham risk scoring.", "Has a positive hepatitis B surface antigen or hepatitis C virus antibody test, as determined by medical history.", "Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.", "Has received any investigational medication 30 days prior to screening, or is participating in an investigational study.", "Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.", "Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.", "Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).", "Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.", "Has uncontrolled hypertension", "Has had inflammatory bowel disease or any other malabsorption syndrome, or has had gastric bypass or any other surgical procedure for weight loss.", "Has a history of drug abuse or a history of high alcohol intake within the previous 2 years.", "Has type 1 or 2 diabetes mellitus.", "Subject had a history of photoallergic or phototoxic reaction during treatment with a fibrate or ketoprofen."], "nct_id": "NCT00251680"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Completion of all required visits of a qualifying Phase 3 core protocol (e.g., Visit 8/Day 196 of PHX1149-PROT301)", "Current treatment of Type 2 diabetes mellitus as in PHX1149-PROT301"], "exclusion": ["Except for Type 2 diabetes, any other uncontrolled, serious pulmonary, cardiovascular, hematologic, renal, gastrointestinal, endocrine, neurological, proliferative, immunosuppressive, psychiatric, or urogenital disorder; or diseases of skin and its appendages, the eyes, ears, nose, or throat", "Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment"], "nct_id": "NCT00865592"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Chronic heart failure"], "exclusion": ["For patients with type 2 diabetes: * Vascular complications.", "For patients with chronic heart failure:", "Severe uncontrolled heart failure.", "Untreated severe hypertension, hypotension.", "Bradycardia.", "Known intolerance to beta blocker treatment.", "Pregnancy,"], "nct_id": "NCT00497003"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female European out-patients", "Greater than or equal to 30 years of age", "Type 2 diabetes first diagnosed at greater than or equal to 30 years of age", "Urinary protein excretion between 200-4000 mg/day exclusive", "Mean sitting dBP less than or equal to 110 mgHg", "Medically justifiable to withdraw antihypertensive treatment due to poor tolerability or inefficacy of previous treatment, or verification that treatment is still necessary"], "exclusion": ["Females pregnant, nursing or planning to become pregnant or were of childbearing potential and not using acceptable methods of contraception", "Secondary forms of hypertension other than diabetic nephropathy, malignant hypertension or patients with sitting dBP exceeding 110 mmHg or sitting sBP exceeding 200 mmHg", "ECG evidence of 2nd or 3rd degree AV-block, atrial fibrillation, cardiac arrhythmia (requiring therapy) or bradycardia", "Presence of significant cardiovascular disease", "Significant cerebrovascular disease, gastrointestinal, haematological or hepatic disease or myocardial infarction in last 12 months or a previous history of any serious underlying disease", "Concurrent renal disease, nephrectomy and/or renal transplant, serum creatinine level greater than or equal to 2.0 mg/dL or creatinine clearance CLCR less than or equal to 50 mL/min", "Clinically significant lab abnormalities (ASAT/SGOT, ALAT/SGPT and \u03b3-GT )", "Serum potassium level < 2.5 mmol/L or > 5.5 mmol/L", "Treatment of concurrent indications with drugs or medication which could have influenced BP", "History of hypersensitivity, lack of response or contraindication to Ang II-antagonists, HCTZ or atenolol, or hypersensitivity to related drugs (cross-allergy)"], "nct_id": "NCT00362960"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Medical diagnosis of Type 2 diabetes in the past 2 years", "Have access to a computer on a regular basis"], "exclusion": ["Pregnant or lactating", "Other medical conditions where changes in diet or physical activity would be contraindicated"], "nct_id": "NCT00877851"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in the Eye."], "exclusion": ["Proliferative Diabetic Retinopathy in the Study Eye.", "Subjects Receiving Concomitant Intravitreal Anti-VEGF Therapy."], "nct_id": "NCT00701181"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients, 18-75 years of age;", "type 2 diabetes;", "normal hepatic function, or mild or moderate hepatic impairment."], "exclusion": ["type 1 diabetes, or latent autoimmune diabetes in adults;", "diabetic neuropathy, retinopathy or nephropathy;", "treatment with insulin or PPAR gamma agonist within 6 weeks of screening;", "clinically significant cardiovascular disease."], "nct_id": "NCT00437606"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["type 2 diabetes mellitus (as defined by the National Diabetes Data Group)", "normal cardiovascular exam", "non smoker (for 1 year prior to entry)", "Healthy volunteers", "no known medical problems", "normal cardiovascular exam", "fasting glucose < 110 mg/dL", "non-smoker (for 1 year prior to entry)"], "exclusion": [": Type 2 Diabetics", "untreated hypertension (>140/90 mmHg)", "untreated hypercholesterolemia (LDL > 75th percentile for age)", "cigarette smoking within 1 year", "neuropathy requiring medication", "nephropathy (> 300mg/24 hour urinary albumin, or serum creatinine > 1.4 mg/dL", "abnormal cardiovascular exam", "treatment with thiazolidinedione within 1 year", "post-menopausal women taking hormone replacement therapy (Note: subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must stop these medications for 2 weeks prior to taking study drug. If blood pressure rises to >140/90, subjects will be prescribed an alternative medication or be withdrawn from the study. Healthy Volunteers", "abnormal cardiovascular exam", "use of prescription medications", "fasting glucose > 110mg/dL", "cigarette smoking within 1 year"], "nct_id": "NCT00153179"},{"minimum_age": 65.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes > 3 months duration", "Male or female", "Over 65 years of age", "Diet controlled only", "HgbA1C < 8.5%"], "exclusion": ["Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring treatment with these during the study.", "Anemia", "hgb below 130 g/L (males) and below 120 g/L (females).", "Taking medications that known to interfere with glucose metabolism eg systemic corticosteriods, non-selective beta blockers.", "Known or suspected allergy to glyburide, sulfa drugs or GlucoNorm impaired liver function, as shown by but not limited to AST and/or ALT > 2x the upper limit of normal.", "Impaired renal function, as shown by but not limited to serum creatinine > 133 \u00b5mol/L (males) or 124 \u00b5mol/L (females).", "Participated in another clinical trial within the past 30 days."], "nct_id": "NCT00451620"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents."], "exclusion": ["Not a part of the VADT."], "nct_id": "NCT00252525"},{"minimum_age": 30.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus", "Normal lung function"], "exclusion": ["Smokers"], "nct_id": "NCT00143338"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Type 2 diabetes", "HbA1c \u2265 7%", "Age \u2265 18"], "exclusion": ["Contraindication to sitagliptin or metformin", "Pregnant or breast feeding women", "Reproductive-age women who refuse contraception", "Type 1 diabetes, gestational diabetes, or diabetes with secondary cause", "Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT > 3-fold the upper limit of normal)", "Renal failure (Cr > 2.0)", "Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment)", "Not appropriate for oral antidiabetic agent", "Medication which affect glycemic control", "Disease which affect efficacy and safety of drugs", "Other clinical trial within 30 days"], "nct_id": "NCT00969566"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["insulin resistant syndrome or Type 2 Diabetes."], "exclusion": ["Use of >= 2 concomitant oral antihyperglycaemic agents within 3 months of study start.", "Initiation of anti-hypertensive or lipid lowering therapy <= 6 months prior to study start or who increased the dose 3 months prior to study start.", "Unstable or severe angina or congestive heart failure NYHA class i-iv, history of acute myocardial infarction or stroke within last 6 months.", "Any history of surgical intervention in the right carotid artery.", "Clinically significant hepatic disease.", "Creatinine clearance <40ml/min."], "nct_id": "NCT00306644"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes ,stable dose of Metformin,HbA1c >= 7%, but < 9%"], "exclusion": ["Type 1 diabetes mellitus, Body Mass Index (BMI) >40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT > 1.5 times UNL, creatinine clearance <60 mL/min"], "nct_id": "NCT00924534"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "M", "inclusion": [": Patients with type 2 diabetes", "Non-smokers", "Free of overt coronary disease (stress ECG)", "Body mass index < 35 kg.m-2", "Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1", "Unmedicated (diet controlled) Healthy controls", "Non-smokers", "Free of overt coronary disease (ECG)", "Body mass index < 30 kg.m-2", "Fasting plasma glucose < 6.1 mmol.L-1", "Unmedicated"], "exclusion": [], "nct_id": "NCT00168519"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Males or females between the ages of 18 and 70 years.", "Subjects must have a BMI of \u2265 30 kg/m2.", "Subjects must have a BP < 130/80 mm Hg and no prior history of hypertension.", "A known history of type 2 diabetes mellitus < 3 years (now 5 years).", "Subjects must have an HbA1c of < 9%.", "Diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months.", "Subjects must be able to understand and willing to adhere to the study protocol."], "exclusion": ["Subjects with history of hypertension (BP > 140/90 mm HG) or who have received antihypertensive drug therapy prior to the study.", "Obese nondiabetic controls with impaired glucose tolerance (2-hour glucose between 140", "199 mg/dl) during a 75-g OGTT.", "Diabetic subjects who require insulin therapy or have received an insulin sensitizer agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering the study (at SV1, week-2).", "Subjects with fasting triglyceride levels > 250 mg/dL prior to the study (at SV1, week-2).", "Clinically relevant hepatic disease (ALT 2.5x > upper limit of normal), or other significant medical or surgical illness.", "Renal failure, as shown by a serum creatinine \u22651.5 mg/dL for males, or \u2265 1.4 mg/dL for females.", "Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.", "Female subjects are pregnant or breast feeding at time of enrollment into the study."], "nct_id": "NCT00738023"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy", "Diet treated subjects: 7.5% < HbA1c < 10%", "Single oral drug therapy subjects: 7.0% < HbA1c < 9.5%", "Body Mass Index (BMI): max 40 kg/m^2"], "exclusion": ["Subjects treated with thiazolidinediones or insulin", "Subjects with any serious medical conditions"], "nct_id": "NCT00154401"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": [": Type 2 diabetic patients with hypertension, with all 5 of the criteria listed below:", "Age 20 years and above", "Blood pressure >125/75 mmHg", "Urinary protein creatinine ratio 1g/g\u30fbcr or Urinary protein >1 g/day", "Presence of diabetic retinopathy", "Already performing dietary management", "There were no limitations on serum creatinine.", "BP was recorded 3 times while the patient was seated and averaged.", "The subjects in this study were outpatients with written informed consent."], "exclusion": ["Another definable renal disease other than DN", "Collagenosis", "Malignant hypertension with emergent treatment", "Severe hypertension (diastolic BP >120 mmHg)", "Severe chronic heart failure or acute myocardial infarction in the past 6 months", "Atrial fibrillation or severe arrhythmia", "Anamnesis of cerebrovascular disease with neuropathy", "Anamnesis of anaphylaxis or chronic dermatopathy", "Severe hepatic disease 10. Pregnancy 11. Anamnesis of anaphylaxis from angiotensin II receptor blocker 12. Patients are judged to be inapposite by the attending physician"], "nct_id": "NCT00407680"},{"minimum_age": 10.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Obese adolescents defined as BMI greater than the 95th percentile for age and gender", "Metformin naive subjects"], "exclusion": ["Elevated fasting plasma glucose \u2265 6.0 mmol/L", "2 hour plasma glucose \u2265 11.1 mmol/L after a standard glucose load", "A1C > 6.0%", "Medication other than \"over the counter\" drugs, oral contraceptive pill or thyroid hormone replacement", "Smoking", "Pregnancy", "Renal insufficiency (serum creatinine > the upper limit of normal)", "Hepatic dysfunction (> 1.5 times the upper limit of normal for AST and ALT)", "Latex Allergy", "Hypersensitivity to metformin or its ingredients", "Breast feeding", "Subjects with a history of lactic acidosis", "Abnormal creatinine clearance", "HIV, HBV, and HCV infections", "Drug and alcohol abuse", "Severe mental disorders", "Subjects who are planning radiologic exams involving in i.v. injection of iodinated contract materials", "Participation in another clinical trial", "Significant history or presence of cardiovascular, pulmonary, gastrointestinal, immunologic, endocrine, neurologic disorders", "Malignant diseases", "Previous exposure to any pharmaceutical antidiabetic agent"], "nct_id": "NCT00934570"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients have type 2 diabetes mellitus on diet/exercise therapy"], "exclusion": ["Patients have type 1 diabetes mellitus"], "nct_id": "NCT00411554"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Recent control obtain (HbA1c<8%) after diabetes improvement program", "Receives care in primary care clinic"], "exclusion": ["pregnant"], "nct_id": "NCT00362193"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with type 2 diabetes", "Speaks and understands Spanish language", "Able to attend community based diabetes education workshops"], "exclusion": ["Pregnant", "Undergoing active cancer treatment", "Diagnosed with insulin dependant diabetes (type 1)", "Pre or borderline diabetes", "Prior or concurrent participation in other diabetes self-management program", "Clinical diagnosis of Alzheimer's Disease", "Mental health condition preventing group participation or cognitive ability"], "nct_id": "NCT00496145"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Newly diagnosed type 2 diabetic patients.", "Hospitalization due to hyperglycemia hyperosmolality syndrome.", "Those who age between 30 and 80 years old and can inject insulin by themselves."], "exclusion": ["Pregnant women.", "Impaired liver function (ALT > 120 U/L)", "Impaired renal function (Serum creatinine >3.0 mg/dL)", "Recently suffered from MI or CVA.", "Patients are acute intercurrent illness.", "2-hour C-peptide level < 1.8 ng/mL."], "nct_id": "NCT00506194"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients, 18-75 years of age;", "type 2 diabetes mellitus treated with one oral antihyperglycemic agent for >=3 months prior to screening."], "exclusion": ["type 1 diabetes mellitus;", "treatment with insulin, PPAR agonists or systemic corticosteroids during the 3 months prior to screening;", "women who are pregnant, breast-feeding or not using adequate contraceptive methods."], "nct_id": "NCT00366379"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Historical diagnosis of type 2 diabetes mellitus without the chronic use of antidiabetic therapy and an 8 week history of diet and exercise.", "Historical diagnosis of type 2 diabetes mellitus on a stable dose of metformin as mono-therapy for at least 3 months prior to screening.", "Glycosylated hemoglobin between 7.5% and 10.0%, inclusive.", "Fasting C-peptide concentration is greater than or equal to 0.8 ng per mL.", "Any other chronic medications which have been stable for at least 4 weeks prior to Screening.", "Body mass index at Screening is greater than or equal to 23 kg/m2 and less than 45 kg/m2.", "Able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.", "Compliance with single-blinded study medication during the run-in phase is at least 75% and does not exceed 125% based on tablet counts performed by the study staff."], "exclusion": ["Systolic blood pressure is greater than 160 mm Hg, or diastolic pressure is greater than 100 mm Hg at repeat measurements.", "Any history of bladder cancer or has a history of cancer that has been in remission for less than 5 years prior to Screening (a history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed).", "Glycosylated hemoglobin is less than 7.5% and greater than 10.0%.", "Creatine phosphokinase is greater than or equal to 5 times the upper limit of normal at screening.", "Hemoglobin is less than or equal to 12 g per dL for males and less than or equal to 10 g per dL for females.", "Alanine aminotransferase and aspartate aminotransferase are greater than or equal to 2.5 upper limit of normal.", "Total bilirubin is greater than or equal to 1.5 times the upper limit of normal at screening.", "Serum triglyceride concentration is greater than or equal to 400 mg per dL.", "Estimated glomerular filtration rate is less than or equal to 60 mL per min using the Modification of Diet in Renal Disease equation or the Cockroft-Gault equation.", "Abnormal thyroid-stimulating hormone as defined by central laboratory normals.", "Positive test result for hepatitis B surface antigen or hepatitis C antibody.", "Urine albumin to creatinine ratio is greater than or equal to 1000 \u03bcg per mg at screening.", "History of microscopic or macroscopic hematuria.", "Two consecutive unexplained positive urinalysis dip-stick and greater than or equal to 3 red blood cells per high-powered field on two consecutive measurements.", "History of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.", "Diabetic gastroparesis that in the investigator's opinion is moderate or severe and hence may impair absorption of study medication.", "The subject has New York Heart Association Class III or IV heart failure.", "Has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram, cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening.", "History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.", "Received treatment with probucol within 1 year of randomization.", "Donated or received any blood products within 12 weeks prior to Screening.", "Received treatment for greater than 7 days within 8 weeks prior to randomization or is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "oral or systemically injected glucocorticoids", "Prescription or over the counter weight-loss drugs", "Peroxisome proliferator-activated receptor agonists, including fibric acid derivatives", "Niacin", "Ezetemibe", "Bile-acid binding agents", "warfarin", "phenytoin", "any alteration in lipid-lowering medication (change in dosage or drug)", "Chronically treated with insulin.", "Received any investigation drug within 4 weeks prior to Screening.", "History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.", "Hypersensitive to TAK-379 or its excipients.", "History of drug abuse or a history of alcohol abuse within 2 years prior to Screening.", "Any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the subject according to the protocol."], "nct_id": "NCT00722917"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": -English speaking people with newly diagnosed Type 2 diabetes (within 3-12 months of diagnosis) who are attending the Alfred Hospital, Diabetes Education Outpatient Clinic."], "exclusion": ["age <30 years or > 75 years;", "body mass index (BMI) < 25 kg/m2 or >37 kg/m2;", "on corticosteroid or insulin therapy;", "presence of established renal and/or liver disease (serum creatinine more than 0.12 mmol/L/albumin excretion rate greater than 300 \u00b5g per minute or ALT more than twice the upper limit of normal respectively)."], "nct_id": "NCT00163683"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male or female, age 18 to 70", "Females are non-lactating and using adequate contraception, in the opinion of the Principal Investigator and negative serum pregnancy test if of child bearing potential (intact uterus and pre-menopausal)", "Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months. Type 2 diabetes may be untreated or may be treated with diet and exercise only and/or pharmacologic therapy as in Inclusion Criterion 4", "Pharmacologic treatment for type 2 DM may include the following and must be stable for > 3 months Glucophage (Metformin) (< maximum dose of 2550 mg) or Glucophage XR (< maximum dose of 2000 mg)", "HbA1C level of 6.5 to 10.9%", "Fasting C-peptide level of greater than or equal to 0.8 nmol/L (2.4 ng/mL)", "ACTH stimulation test results with any cortisol level (baseline, 30 or 60 minutes) of >18 \u00b5g/dL", "Normal thyroid stimulating hormone 9.12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality 10.BMI of 26 to 40 kg/m2 11.Subjects with a history of hypertension may be on a stable anti-hypertensive regimen (except those drugs stated under Exclusion Criterion 7) for > 2 months 12.Ability to comprehend and a willingness to provide informed consent"], "exclusion": ["History of any atherosclerotic disorder (myocardial infarction, angina, cerebrovascular accident, peripheral vascular disease or congestive heart failure secondary to ischemic myocardial injury) that would, in the estimation of the Investigator, make it unsafe to stop all lipid lowering drugs during the course of the study", "Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other imidazole compounds", "History of malignancy (except basal cell carcinoma) within the 3 years before the initial dose of the study medication", "Excessive alcohol intake or drug abuse using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), criteria", "Any other clinically significant medical condition, as determined by the Investigator. These clinically significant medical conditions include proliferative diabetic retinopathy and neuropathic symptoms that limit activities of daily living", "Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication", "Concomitant therapy with the following: any antacid or ulcer medication, weight loss medications, oral or injected hypoglycemics (metformin is allowed) or insulin, steroids, cyclosporine, tacrolimus, midazolam, digoxin, coumarin derivatives, phenytoin, rifampin, loratadine, HIV protease inhibitors, spironolactone, thiazide diuretics, calcium channel blockers and erythromycin. Subjects taking lipid lowering medications may be enrolled if Investigator determines that subject does not have any conditions that preclude this cessation and subject is willing to stop such medications 21 days prior to Study Visit 1 through Study Visit 3 (Day 16)", "History of HIV", "Positive hepatitis B (HBsAg) or positive hepatitis C (Hepatitis C antibody) test during Screening 10. WBC count <4000/\u00b5L or >14,000/\u00b5L 11. Hemoglobin <12.0 gm/dL in females and <14.0 gm/dL in males 12. Any single hepatic enzyme (ALT, AST, AP and total bilirubin) is greater than the upper limit of the normal reference range used by the central laboratory 13. Creatinine > 1.5 times the upper limit of normal 14. Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation (mannitol or sodium chloride)"], "nct_id": "NCT00302224"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["pregnant women with gestational diabetes (Freinkle\u00b4s classification: type A2 and B1) or pregestational type 2 diabetes.", "less than 30 weeks of gestation", "women who plan to attend their pregnancy at the institution (INPerIER)"], "exclusion": ["women with type 1 pregestational diabetes or gestational diabetes type A1.", "women with multiple pregnancies", "women with renal or hepatic disease", "women who could not follow the dietary recommendations within the study"], "nct_id": "NCT00860613"},{"minimum_age": 20.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["BMI > 35 Kg/m2", "Metabolic syndrome diagnosed"], "exclusion": ["Type 1 diabetes", "Uncontrolled type 2 diabetes", "Cirrhosis or active hepatitis", "Pregnancy", "Recent MI or stroke"], "nct_id": "NCT00923260"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subjects with a diagnosis of both hyperlipidemia and hypertension."], "exclusion": ["Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus.", "Subjects with other atherosclerotic disease."], "nct_id": "NCT00174330"},{"minimum_age": 25.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Normal control: fasting plasma glucose (FPG) less than 126 mg/dl.", "T2DM: FPG >\uff1d126 mg/dl.", "Group 1 (good glycemic control): HbA1c<\uff1d7% in the past 6 months", "Group 2 (poor glycemic control): HbA1c>\uff1d8% in the past 6 months"], "exclusion": ["Acute systemic diseases"], "nct_id": "NCT00155922"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["On a stable dose of metformin as defined by the protocol", "Blood glucose criteria must be met", "Body mass index (BMI) in the range 22-45"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of significant diabetic complications", "Evidence of serious cardiovascular complications", "Laboratory value abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00102466"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus and dyslipidemia."], "exclusion": ["Type 1 diabetes."], "nct_id": "NCT00362765"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Age 40-70", "Type 2 diabetes", "Peripheral neuropathy"], "exclusion": ["Serious cardiac history or other medical problems that would prevent safe participation in exercise"], "nct_id": "NCT00970060"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Individuals with Type 2 Diabetes", "HbA1c over 8%"], "exclusion": ["Individuals with bleeding disorders including GERD, PUD, any GI bleeding", "High blood pressure", "History of Coronary Artery Disease or exertional chest pain"], "nct_id": "NCT00179400"},{"minimum_age": 50.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Age 50 ~ 75 years"], "exclusion": ["angina pectoris or anginal equivalent symptoms", "insulin pump user or history of ketoacidosis", "history of myocardial infarction, heart failure, or coronary revascularization", "electrocardiographic evidence of Q-wave myocardial infarction, ischemic ST- segment or T-wave changes, or complete left bundle branch block", "uncontrolled arrythmia", "hypersensitivity to contrast dye", "renal failure", "uncontrolled arrythmia", "hypersensitivity to contrast dye", "renal failure"], "nct_id": "NCT00431977"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years", "GI symptoms for at least 2 months before entering study"], "exclusion": ["Very high body weight", "Significant diarrhea", "Ulcers Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply."], "nct_id": "NCT00142974"},{"minimum_age": 10.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["for children and adolescent participants only (Groups 1 and 2, respectively):", "Participant was male or female between 10 and 17 years of age.", "Participant or parent or legal guardian was capable of understanding and complying with the protocol requirements.", "Participant was capable of understanding an informed consent form (ICF) or assenting to participate. The parent or legal guardian of the participant must have been able to understand and sign an ICF prior to the initiation of any study procedures.", "Participant weighed at least 36 kg (79 pounds) and had a Screening body mass index (BMI) of at least 18 kg/m^2.", "Participants had a diagnosis of type 2 diabetes mellitus (T2DM) (non-insulin dependent) based on diagnostic criteria of the American Diabetes Association (ADA). Criteria included:", "Fasting plasma glucose level of \u2265 126 mg/dL where fasting is defined as no caloric intake for at least 8 hours, or", "2-hour plasma glucose level of \u2265 200 mg/dL during an oral glucose tolerance test, or", "random plasma glucose level of \u2265 200 mg/dL, or", "glycated hemoglobin (HbA1c) \u2265 6.5%.", "Diagnosis could have been historical (documented), or participants could have been diagnosed for this study.", "Participants had a fasting serum C-peptide concentration \u2265 0.8 ng/mL (\u2265 0.26 nmol/L) at the Screening Visit only.", "Participants may have been taking concomitant metformin if the dose was stable for at least 30 days prior to Day 1 (day of first dosing). Inclusion criteria for adult participants only (Group 3):", "Participant was male or female, and between 18 and 65 years of age, inclusive for gender and race matched adult participants with T2DM only. 10. Participant was capable of understanding and complying with protocol requirements and was willing to sign the ICF prior to the initiation of any study procedures for gender and race matched adult participants with T2DM only. 11. Participant weighed at least 50 kg (110 pounds) and had a Screening BMI between 23 kg/m^2 and 45 kg/m^2 (except for Asian or Asian-descendant participants for whom the range was between 20 kg/m^2 and 35 kg/m^2), inclusive for gender and race matched T2DM adult participants only. 12. Participants had a diagnosis of T2DM (non-insulin dependent) based on diagnostic criteria of the ADA. Criteria included:", "Fasting plasma glucose level of \u2265 126 mg/dL where fasting is defined as no caloric intake for at least 8 hours, or", "2-hour plasma glucose level of \u2265 200 mg/dL during an oral glucose tolerance test, or", "random plasma glucose level of \u2265 200 mg/dL, or", "HbA1c \u2265 6.5%. 13. Diagnosis could have been historical (documented) or participants could have been diagnosed for this study. 14. Participants may have been taking concomitant metformin if the dose was stable for at least 30 days prior to Day 1. 15. Participants may have been taking statin or antihypertensive drugs if the dose was stable for at least 30 days prior to Day 1. Inclusion criteria for all participants (Groups 1, 2, and 3): 16. Female participants of childbearing potential and male participants who were sexually active agreed to routinely use adequate contraception from Screening until 30 days after receiving the dose of study drug. NOTE: Women not of childbearing potential were defined as those who were surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation) or who were postmenopausal (defined as at least 45 years of age and 1 year since last regular menses). 17. Participant had a negative urine test result for selected substances of abuse (including alcohol and cotinine) at Screening and Check-in (Day -1). 18. Participant had clinical chemistry, hematology, and complete urinalysis (fasted for at least 8 hours) results within the reference range for the testing laboratory (except results associated with T2DM) unless the out-of-range results were deemed not clinically meaningful by the investigator or sponsor. 19. Participant had a negative test result for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV), and no known history of human immunodeficiency virus."], "exclusion": ["Participant was currently participating in another investigational study or took an investigational drug within 30 days prior to Day 1.", "Participant received alogliptin previously.", "Participant was a study site employee, or was an immediate family member (ie, spouse, parent, child, or sibling) of a study site employee involved in conduct of this study.", "Participant received or donated blood or blood products within 30 days prior to Screening or planned to donate blood during the study.", "Participant had a known hypersensitivity to alogliptin or related compounds.", "Participant had a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as consumption of more than 4 alcoholic drinks per day) within 1 year prior to study Day 1.", "Participant had an acute, clinically significant illness (excluding T2DM) within 30 days prior to study Day 1.", "Participant had any other condition or prior therapy that, in the opinion of the investigator, would have made the participant unsuitable for the study.", "Participant had a history or clinical manifestations of significant metabolic (excluding T2DM), hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, immunologic, musculoskeletal, or psychiatric disorder. 10. Participant had a hemoglobin value < 12 g/dL. 11. Participant had a systolic blood pressure > 140 mm Hg or had a diastolic blood pressure > 90 mmHg at Screening or Check-in (Day -1). 12. Adult participant had an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than 2 times the upper limit of normal (ULN), active liver disease, or jaundice at the Screening Visit or on Check-in (Day -1). 13. Pediatric participant had an ALT or AST level greater than 1.5 times the ULN at the Screening Visit or on Check-in (Day -1). 14. Participant had a serum creatinine level > 1.5 mg/dL. 15. Participant had a creatinine clearance (CrCl) < 50 mL/min (normalized to body surface area of 1.73 m^2). 16. Participant had a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy) or thoracic or nonperipheral vascular surgery within 6 months prior to Day 1. 17. Participant had a history or presence of a clinically significant abnormal 12-lead electrocardiogram (ECG) result as determined by the investigator or Takeda at Screening or Check-in (Day -1). 18. Participant had a history of cancer, other than basal cell carcinoma or Stage I squamous cell carcinoma of the skin that had not been in remission for at least 5 years prior to the first dose of study drug. 19. If female, participant was pregnant or lactating or intending to become pregnant before, during, or within 30 days after receiving study drug. 20. If male, participant intended to impregnate others during the study or for 30 days after receiving study drug. 21. Participant consumed or was unable to abstain from consumption of products containing alcohol, caffeine, or xanthine, and food or beverages containing grapefruit juice or Seville-type oranges within 72 hours prior to study Day 1 and for the duration of the study. 22. Participant used any tobacco (ie, nicotine) products (including but not limited to cigarettes, pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum) within 6 weeks prior to study Day 1, and was unwilling to abstain from these products for the duration of the study. 23. Participant used any nutraceutical preparations within 28 days prior to study Day 1. 24. Participant was currently taking ketoconazole, fluconazole, gemfibrozil, rifampin, or carbamazepine or taken within 28 days prior to Check-in (Day -1). 25. Participant had poor peripheral venous access. 26. Participant had a medical history of clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes or secondary forms of diabetes, including maturity-onset diabetes of the young (MODY)."], "nct_id": "NCT00957268"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Diabetes mellitus, Type 2", "Body Mass Index (BMI) 30-34.9", "Able to understand and comply with study process"], "exclusion": ["Pregnancy", "Prior bariatric surgery", "Diabetes mellitus, Type 1", "Renal impairment", "Cirrhosis or portal hypertension", "Diabetes secondary to a specific condition", "Recent internal malignancy (<5 years)", "Recent major vascular event", "Drug or alcohol dependence", "Uncontrolled psychiatric disease", "Crippling cardiopulmonary disease", "Prohibitive anatomic features (extensive prior surgery, giant paraesophageal hernia)"], "nct_id": "NCT00965302"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["New onset of Type 2 Diabetes.", "BMI>25kg/m2"], "exclusion": ["Antiobesity, oral hypoglycaemic medications or any other prescription medications that may interfere with the study results", "Pregnancy", "Unable to converse competently in English as special arrangements would need to be made for such people and this would be impractical in a group setting", "Attending another weight management programme", "Patients who would be unable to attend all the programme sessions for medical or other reasons", "Any patients from groups listed in A24"], "nct_id": "NCT00705952"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Newly diagnosed type 2 diabetes poorly controlled by diet only for one month", "Obese with a BMI of 23-35 kg/m2"], "exclusion": ["Those patients used any drugs for treatment of diabetes", "Patients with evidence of cardiac, hepatic, renal, other chronic diseases or acute diabetic complications including diabetic ketoacidosis or hyperosmolar hyperglycemic non-ketotic coma", "Women who were pregnant or planned pregnant."], "nct_id": "NCT00704236"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Diagnosed with type 2 diabetes", "Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents"], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Received any investigational product in other clinical studies within 12 weeks", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00251953"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Diagnosed with type 2 diabetes", "Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents", "Drug-na\u00efve (ie, no use of antidiabetic drug[s] for at least 24 weeks prior to visit 1)."], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Received any investigational product in other clinical studies within 12 weeks", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00252772"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Diagnosed with type 2 diabetes", "Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents", "Drug-na\u00efve (ie, no use of antidiabetic drug[s], for at least 24 weeks prior to visit 1)."], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Received any investigational product in other clinical studies within 12 weeks", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00252837"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Completed the last two visits of randomized treatment period in GALLANT 2/22, 5, 7, 8 or 14 studies."], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Previous enrollment in this long-term extension study", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00252876"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Diagnosed with type 2 diabetes", "Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents"], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Received any investigational product in other clinical studies within 12 weeks", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00251940"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who either completed at least 6 months in a previous treatment study GALLANT, GALLEX or ARMOR or met a pre-defined laboratory or clinical finding during participation in any of the said studies."], "exclusion": ["Received open-label treatment with tesaglitazar (since this is a post-treatment study)"], "nct_id": "NCT00255645"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Diagnosed with type 2 diabetes", "Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents"], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Received any investigational product in other clinical studies within 12 weeks", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00255541"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": Type 2 diabtes according to the WHO criteria Fasting blood glucose >7 HbA1c between 6-9 Normal liver function Normal renal function -"], "exclusion": [": Ongoing treatment with antidiabetic medicine Pregnancy and lactation -"], "nct_id": "NCT00254085"},{"minimum_age": 37.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Male or female aged 37", "75 years with type 2 diabetes diagnosed at age of 36 years or thereafter.", "Duration of diabetes for > 1 year and < 20 years with stable diabetic therapy within last 6 months.", "Patients with untreated resting mean sitting SBP < 130 mmHg and mean sitting DBP < 85 or treated resting mean SBP < 160 mmHg and mean sitting DBP < 90 mmHg with retinal photograph grading level >20/10 up to < 47/47 (on ETDRS severity scale)."], "exclusion": ["Patients with the following conditions are excluded from participation in the study:", "Cataract or media opacity of a degree which precludes taking gradable retinal photographs", "Angle closure glaucoma, which precludes pharmacological dilatation of the pupil", "History of or presence of proliferative retinopathy", "History or presence of clinical significant macular oedema (CSME)", "History or evidence of photocoagulation of the retina", "Other retinal conditions which may mask assessment, eg, retinal vein occlusion", "Positive micral dipstick test", "Presence of secondary diabetes", "Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception", "Need of treatment with ACE-inhibitor", "Haemodynamically significant aortic or mitral valve stenosis", "Known renal artery stenosis or kidney transplantation", "Hypersensitivity to study drug", "Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator"], "nct_id": "NCT00252694"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 Diabetes", "Currently on a basal insulin, that is, NPH, glargine or detemir", "Capable of self monitoring glucose >4/day", "Previously complaint with clinical recommendations", "Subject may be on oral antiglycemic medications but no change in treatment is permitted during study."], "exclusion": ["Hb A1c >9.0%", "Urinary ketosis", "Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatine >1.5 mg/dL) glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistance of another)", "Currently participating in another clinical trial", "Known or suspected allergy to insulin glargine or detemir", "Using other insulins, such as, bolus insulin or premixed insulin", "Sight or hearing impaired", "Pregnancy oor nursing of the intention of becoming pregnant or not using adequate contraceptive measures."], "nct_id": "NCT00457093"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetic patients"], "exclusion": ["Type 1 diabetic patients, gestational DM patients"], "nct_id": "NCT00455988"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with type 2 diabetes", "Currently being treated with the following: Dual or triple oral therapy", "on a stable combination and dose for at least 3 months.", "HbA1c between 7.5% and 10.0%.", "BMI >27."], "exclusion": ["Receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.", "Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.", "Treatment with the following medications: *Insulin as outpatient therapy within last 3 months; *Meglitinides, or acarbose within the last 3 months; *Regular use of any drugs that directly affect gastrointestinal motility; *Any previous (study) therapy with exenatide or glucagon-like peptide-1 (GLP-1) analogue; *Anti-obesity agent use within the last 3 months.", "Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry."], "nct_id": "NCT00360334"},{"minimum_age": 12.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Group A- Lean Adolescents a. Inclusion criteria: This group will consist of 20 lean adolescents between the ages of 12-18 years, Tanner stage 3-5 for pubertal development, have a BMI less than 85th and above 20th for age and an HbA1C less than or equal to 6% (normal range is 4-6%). They should not be taking any medications. A DXA scan will be performed to estimate lean and fat body mass. The body fat mass should be less than or equal to 25 % to be included in this group (in the lean range). The subjects will be matched for age and Tanner stage to the subjects in Group B and C. Menstruating females must have a negative urine pregnancy test for inclusion.The subject must weigh more than 43 kg.", "Group B- Obese Adolescents a. Inclusion criteria: This group will consist of obese adolescents, between the ages of 12-18 years and Tanner stage 3-5 for pubertal development. They must have: a BMI above or equal to 95th for age, but not greater than 40 kg/m2 . They must have a normal glucose tolerance, in other words subjects with undiagnosed impaired glucose tolerance or diabetes will not be considered for the study. To test them for diabetes or impaired glucose tolerance they will undergo a 2-hour Glucose tolerance test (2hr-GTT). The ADA criteria will be used for the diagnosis of diabetes and/or impaired glucose tolerance (fasting plasma glucose < 110 mg/dl and a 2 hour postprandial blood glucose < 140 mg/dl). They must have and normal liver function tests and not taking any medications. The subjects will undergo DXA scan for estimation of total lean and fat body mass. The fat mass should be more than or equal to 30% to be considered obese. The subjects in this group will be matched for age (plus minus 1year), Tanner stage (plus minus 1) and body fat mass (plus minus 5%) to the Type 2 diabetes adolescents?. Menstruating females must have a negative urine pregnancy test for inclusion.", "Group C- T2DM Adolescents a. Inclusion criteria The study group will consist of adolescents with T2DM, between the ages of 12-18 years, Tanner stage 3-5 for pubertal development, BMI above or equal to 85th for age (but less than 40 kg/m2) and HbA1c less than 8.5%. They must have T2DM diagnosed for at least 2years, treated with diet , oral hypoglycemic agents and or insulin. If on medications they need to be on a stable dose of insulin and / or oral hypoglycemic agent over the last 2 months. The subjects must be otherwise healthy except for hypothyroidism stable on treatment. Menstruating females must have a negative urine pregnancy test for inclusion. -"], "exclusion": ["Group A- Lean Adolescents a. Exclusion criteria: The subjects will be excluded if they have: a history of chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, etc), allergy to local anesthetics (ELAMAX Cream), evidence or history of chemical abuse, anemia and elevated liver enzymes (AST above 80 U/L and ALT above 110 U/L).", "Group B- Obese Adolescents a. Exclusion criteria: The exclusion criteria are the same as for control group A.", "Study Group C- T2DM Adolescents a. Exclusion Criteria: The exclusion criteria will be the same as in the control groups with one addition, subjects may not have been admitted to the hospital for diabetic ketoacidosis in the last 6 months."], "nct_id": "NCT00361946"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["treated for type 2 diabetes within one year prior to their entry into the trial, have a BMI at or above 30, and are 18 years of age or older"], "exclusion": ["1) end-stage renal disease (defined as being on dialysis), 2) active foot ulcers or infections (defined as an open wound or requiring drug therapy), 3) pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease (other than non-melanoma skin cancer) that precludes diet and physical activity changes"], "nct_id": "NCT00364312"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["All men or postmenopausal women with Type 2 diabetes optimally or suboptimally controlled (HbA1C < 9.0%) on oral hypoglycemic agents or diet only were asked to participate."], "exclusion": ["Those receiving insulin, alpha-glucosidase inhibitors, or hormone replacement therapy, with BMI>38 kg/m2, smoking or significant alcohol intake (>2 drinks/day), serum TG >4.0 mmol/L, and those with complications of diabetes were excluded. Subjects were also excluded if they regularly took fish oil and flax seed supplements or used steroids. Subjects were excluded during the course of the study if there were any changes to their regular antihypertensive, lipid, or oral hypoglycemic medications, if unable to consume >50% of supplements provided, had a significant weight change (defined as >2.5 kg), or if their level of physical activity did not remain constant over the course of the study."], "nct_id": "NCT00362011"},{"minimum_age": 40.0, "maximum_age": 65.0, "gender": "M", "inclusion": ["Male,", "BMI above 26,", "Age between 40 and 65,", "Living a sedentary lifestyle"], "exclusion": ["Women", "BMI under 26", "Age under 40 and over 65", "Trained subjects Control subjects: relatives to type 2 diabetic patients, T2D trial subjects"], "nct_id": "NCT00365495"},{"minimum_age": 18.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Men and women aged 18 to 79", "Type 2 diabetes, treated only by diet or oral drugs other than metformin", "HbA1c greater than or equal to 7% and less than or equal to 10%", "C-reactive protein greater than or equal to 2 mg/L"], "exclusion": ["Baseline use of metformin or insulin", "Type 1 diabetes, history of ketoacidosis or positive anti-GAD antibody", "History of congestive heart failure requiring drug therapy", "Active liver disease", "Kidney impairment", "Recent initiation or change in dose of statins, fibric acid derivatives, angiotensin receptor blockers, nonsteroidal anti-inflammatory agents, or corticosteroids"], "nct_id": "NCT00366301"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female, 30-65 yrs of age at the time of entry and have type 2 diabetes for a minimum period of 5 years.", "HbA1C ranging 8.0-10.0%", "Patients either receiving OHA and / or insulin"], "exclusion": ["Type 1 diabetes", "Patients with history of blindness, decreased vision", "Serious vascular complications :", "Cancer"], "nct_id": "NCT00727896"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["(arm 1):", "males or non-pregnant females aged 18-75 years and in good health;", "BMI <30 kg/m2."], "exclusion": ["(arm 1):", "known history of hepatitis, diabetes or a heart condition;", "using medications or fiber supplements;", "any health condition which might affect the results;", "non-compliance with the experimental procedures. Inclusion Criteria (arm 2):", "documented type 2 diabetes for at least 6 month duration without clinically manifest complications;", "age 18-75 years;", "BMI <30 kg/m2. Exclusion Criteria (arm 2):", "liver or kidney disease;", "gastrointestinal problems;", "using fiber supplements;", "non-compliance with the experimental procedures;", "pregnancy."], "nct_id": "NCT00728143"},{"minimum_age": 50.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female subjects \u2265 50 years of age.", "Impaired fasting glucose (\u2265 100 and < 126 mg/dl) in the last available blood test prior (\u2264 3 months) to randomization, or diagnosis of type 2 diabetes prior to randomization.", "All subjects must have at randomization a conventional clinic systolic/diastolic BP < 160/100 mmHg.", "Informed consent to participate in the study prior to any study procedures."], "exclusion": ["Known or suspected contraindications, including history of allergy to ASA.", "Uncontrolled essential hypertension of Grade 2-3, i.e., systolic BP \u2265 160 mmHg and/or diastolic BP \u2265 100 mmHg before randomization.", "Evidence of a secondary form of hypertension, to include coarctation of the aorta, hyperaldosteronism, renal artery stenosis, or pheochromocytoma.", "Known Keith-Wagener grade III or IV hypertensive retinopathy.", "History of hypertensive encephalopathy, cerebrovascular event, transient ischemic cerebral attack, or myocardial infarction prior to randomization.", "Type 1 diabetes mellitus.", "History of heart failure.", "Second or third degree heart block without a pacemaker.", "Concomitant unstable angina pectoris.", "Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia.", "Clinically significant valvular heart disease.", "Evidence of hepatic disease as determined by one of the following: ALT or AST values > 2 x UNL known before randomization, a history of hepatic encephalopathy, history of esophageal varices, or history of portocaval shunt.", "Diagnosis of chronic kidney disease prior to randomization.", "History of malignancy including leukemia and lymphoma (but not basal cell skin cancer), or any other severe, life-threatening disease within the past five years.", "Any previous history of a systemic autoimmune disease.", "History of drug or alcohol abuse within the last two years.", "Use of any disallowed concomitant medication.", "Inability to communicate and comply with all study requirements.", "Persons directly involved in the execution of this protocol."], "nct_id": "NCT00725127"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["Type II Diabetic patients", "HbA1c >8.0% (result from preceding 4 months)", "Written informed consent", "Life expectancy of at least 1 year.", "Patients' agree to discontinue current long acting insulin (if applicable).", "Patients who according to their GP are eligible to the study."], "exclusion": ["Type I diabetes", "Pregnancy and\\or lactation.", "Allergy to basal insulin", "Patients suffering from a disease that requires repeated hospitalizations E.g.: severe CHF, sever renal failure, active malignancy.", "Patients who are not able to give consent.", "Patients face difficulties in mobility and/or verbal communication with the treating physician. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00726674"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Individuals more than 18 years of age with DM2, either with new onset DM2 or known diabetics who did not take oral hypoglycemic agents for more than 2 weeks, presenting with fasting blood glucose (FBG) 300-500 mg/dl or random blood glucose (RBG) 400-700 mg/dl and who did not have any"], "exclusion": ["listed in Table 1, were eligible for the study. Exclusion Criteria:", "Acute metabolic complications (diabetic ketoacidosis, hyperosmolar hyperglycemia associated with dehydration).", "Acute complications of chronic cardiovascular, neurological, renal, and other diabetic complications.", "Any subject with unstable vitals signs (temperature > 101 degrees F, systolic blood pressure < 90 or > 180 mm hg, diastolic blood pressure < 60 or > 110 mm hg, heart rate < 60 or > 120 beats/minute).", "Electrolyte imbalances (serum bicarbonate level < 20 mEq/L, serum sodium < 125 & > 150 mEq/L, serum potassium < 3.5 & > 5.5 mEq/L).", "Evidence of an impaired sensorium and/or dementia.", "Age > 75 years", "Subjects with any acute medical illness.", "Type 1 diabetes or type 2 diabetics weighing less than 120 lbs", "Current addiction to illicit substances or alcohol abuse", "Pregnant or lactating subjects"], "nct_id": "NCT00732524"},{"minimum_age": 20.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Type 2 DM study participants will be C-Peptide positive (levels > 0.3 nmol/L)", "Receiving insulin, metformin and/or sulfonylurea/glitinide.", "Maintained on stable anti-hypertensive medication.", "BMI < 52 kg/m2.", "T2DM for at least 3 months with HBA1C under 10%."], "exclusion": ["Receiving TZDs, exenatide, sitagliptin or pramlintide therapy.", "Receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.", "Triglyceride levels > 400 mg/dl.", "BMI > 52 kg/m2."], "nct_id": "NCT00732147"},{"minimum_age": 35.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female with type 2 diabetes mellitus", "35 years old\u2264age\u226465 years old", "19kg/m2\u2264BMI\u226432kg/m2", "Uncontrolled blood glycemia (FPG\u22657.0mmol/L and 7.5%<HbA1c\u226410%) after oral antidiabetes drugs treatment for more than 3 months", "Treated by diet controlling, 1 secretagogue agent and another oral antidiabetes drug, with the daily dosage of the secretagogue agent not more than 50% of its maximum", "Not participated in other clinical studies within the past 3 months", "Well know this study and sign the informed consent form"], "exclusion": ["Unable to sign the informed consent form", "Treated by insulin, even transient usage within the past 1 year", "Type 1 diabetes mellitus", "Abnormal condition of gastrointestinal tract against the absorption of oral drugs", "Insufficient of liver and kidney function: ALT\u22652.5 times of the upper limit of the normal value range and serum creatinine\u2265the upper limit of the normal value range", "Encountered the cardiovascular events such as the angina pectoris, myocardial infarction, severe ventricular arrhythmia, cerebral hemorrhage, cerebral infarction, heart failure ect. within the past half year", "Usage of the other hormone medicines such as cortical hormone, immunosuppressive agents or cytotoxic drugs within the past 2 months", "psychotic", "Allergic history to sulfonylurea drugs 10. Diabetic coma or diabetic ketoacidosis 11. In use of the miconazole 12. Pregnancy or breeding women"], "nct_id": "NCT00736515"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Healthy male and female subjects aged 30-65 years", "Male and female non-insulin-dependent diabetic patients, sulfonylurea and/or Metformin aged 30-65 years"], "exclusion": ["Prior or current history of poor health", "Abnormal results following screening tests", "Pregnancy"], "nct_id": "NCT00732862"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["At least 18 years of age", "Have a diagnosis of type 2 diabetes mellitus in their medical chart", "Have suboptimal glycosylated hemoglobin (HgA1c > 7.5%) recorded in their chart as the most recent lab result", "Currently perform self-monitoring of blood glucose", "Able to understand written and spoken English"], "exclusion": ["Are currently using, or have previously used insulin", "Have cognitive, visual, hearing or other medical impairment", "Have terminal malignancies or dementia", "Have psychiatric illness not controlled with medications"], "nct_id": "NCT00149331"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to entry.", "Are not known to have had a cardiovascular event"], "exclusion": ["They are taking prescribed lipid lowering therapy", "Have triglycerides > or = 8.0 mmol/L"], "nct_id": "NCT00141232"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 18-75 years, inclusive", "Diagnosed with type 2 diabetes", "Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days", "Hemoglobin A1c value 7.5% to 9.5%, inclusive", "C peptide > 0.5 ng/mL", "Prescribed ADA diet"], "exclusion": ["History of type 1 diabetes or ketoacidosis", "History of pancreatitis", "Uncontrolled hypertension", "Allergy or toxic response to colesevelam or any of its components", "Serum LDL-C < 60 mg/dL", "Serum TG > 500 mg/dL", "Body mass index (BMI) > 45 kg/m2"], "nct_id": "NCT00147758"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes in male or female patients", "Between 18 and 75 years of age", "With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization"], "exclusion": ["Type 1 diabetics or type 2 diabetics currently on insulin therapy", "Patients unwilling or unable to discontinue their anti-diabetic medication(s)", "History of ketoacidosis", "History of therapy with rosiglitazone, troglitazone, pioglitazone"], "nct_id": "NCT00143520"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 18-75 years, inclusive", "Diagnosed with type 2 diabetes", "Hemoglobin (HbA1c) between 7.5% to 9.5%", "Prescribed an ADA accepted diet", "Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1"], "exclusion": ["History of type 1 diabetes or ketoacidosis", "History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment", "History of pancreatitis", "Uncontrolled hypertension", "Recent severe cardiovascular disease", "Allergy or toxic response to colesevelam or any of its components", "Body mass index (BMI) >45 kg/m2"], "nct_id": "NCT00147719"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": - A subject may be included in this study if he/she meets all of the following criteria:", "Male or female, age 18 to 75", "Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use the following acceptable birth control methods beginning at the Screening Visit and throughout the study:", "abstinence", "surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum", "IUD in place for at least 3 months", "barrier methods (condom or diaphragm) with spermicide", "surgical sterilization of the partner (vasectomy for 6 months)", "hormonal contraceptives for at least 3 months prior to the first dose", "Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months.", "Type 2 diabetes may be treated only with metformin (metformin hydrochloride tablets or metformin hydrochloride extended-release tablets) at a total daily dose of 500 mg to the maximum labeled dose. (See Appendix G for List of Drug Trade Names).The dose of metformin must be stable for >8 weeks prior to the Pre-Treatment Visit (Week -4) and throughout the course of the study. The subject must not be on any other pharmacologic or over-the-counter treatments for diabetes.", "HbA1C level of 7.0 to 10.0%", "Fasting C-peptide level of >0.33 nmol/l (1.0 ng/ml)", "ACTH stimulation test results with any cortisol level of >18 \u00b5g/dl at baseline or 60 minutes", "Normal complete blood count (CBC) with platelets and differential", "12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality. Subjects with QTc interval of >450 msec will be excluded from the study. 10. BMI of 27 to 42 kg/m2 (see Appendix B) 11. Subjects with a history of hypertension may be on a stable anti-hypertensive regimen for (except those drugs stated under Exclusion Criterion 8) for >6 weeks prior to the Pre-Treatment Visit (Week -4)) 12. Ability to comprehend and a willingness to provide informed consent"], "exclusion": ["A subject may be excluded from this study if he/she meets any of the following criteria:", "Previous participation in a clinical trial with DIO-902.", "History of any atherosclerotic disorder (myocardial infarction, unstable angina, cerebrovascular accident, peripheral vascular disease or congestive heart failure secondary to ischemic myocardial injury) that would, in the estimation of the Investigator, make it unsafe to stop all lipid lowering drugs for up to 12 weeks during the course of the study.", "Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other imidazole compounds.", "History of malignancy (except basal cell carcinoma) within the 3 years before the initial dose of the study medication.", "Excessive alcohol intake (>20 g per day for females (1.5 standard alcohol drinks) or >30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) or drug abuse. (1.0 fluid oz (US) = 29.57 ml)", "Any other clinically significant medical condition, as determined by the Investigator. These clinically significant medical conditions include, but are not limited to, uncontrolled hypertension, NYHA class III or IV CHF, proliferative diabetic retinopathy and neuropathic symptoms that limit activities of daily living.", "Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication.", "Concomitant therapy with the following: (See Appendix G for List of Drug Trade Names)", "weight loss medications", "oral or injected hypoglycemics (metformin is allowed) or insulin", "oral, parenteral or inhaled steroids; nasal, topical ocular, intravitreal, and low to moderate potency topical steroids are allowed", "dihydropyridine calcium channel blockers (amlodipine, diltiazem and verapamil are allowed)", "H2 antagonists and proton pump inhibitors (liquid and tablet antacids are allowed)", "midazolam, triazolam, alprazolam, terfenadine, astemizole, digoxin, coumarin derivatives, phenytoin, rifampin, HIV protease inhibitors, spironolactone, aliskiren, erythromycin or clarithromycin, cyclosporine or tacrolimus", "Subjects currently taking lipid lowering medications may be enrolled if the Investigator determines that the subject does not have any conditions that preclude cessation of lipid lowering treatment for up to 12 weeks. [All subjects will be required to discontinue all lipid lowering therapies during the 4 week Pre-Treatment Period and will then be randomized to receive either atorvastatin 10 mg or atorvastatin placebo during the first 8 weeks of the Treatment Period. All subjects will then receive atorvastatin 10 mg during weeks 8 to 16 of the Treatment Period.] Subjects may not be on any other lipid lowering agent through Visit 7 (Week 20) of the study.", "History of HIV 10. Positive hepatitis B (HbsAg) or positive hepatitis C (Hepatitis C antibody) test during Screening 11. Liver function tests must not be above the following cut-offs: ALT and/or AST >3.0X ULN, AP >1.5X ULN and total bilirubin >ULN. (If all LFTs are WNL and total bilirubin is elevated, a retest of direct and indirect bilirubin may be performed. Subjects with indirect total bilirubin up to 3X ULN (presumed Gilbert's syndrome) may be enrolled if all other LFTs are WNL.) 12. CK must not be >2.5X ULN if not clearly related to recent exercise, injury or unusual activity 13. Creatinine must not be >1.4 mg/dl in females and >1.5 mg/dl in males. 14. Thyroid stimulating hormone level >1.5X ULN 15. History of lactic acidosis 16. Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation (mannitol or sodium chloride) 17. Known intolerance to statin drugs 18. Any other condition which increases the risk of participation in the trial in the opinion of the investigator"], "nct_id": "NCT00494663"},{"minimum_age": 40.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type II diabetics; diagnosed on a clinical basis: positive family history; age of manifestation > 40 years; BMI >25; initial therapy without insulin", "Age: 40", "65 years", "Body mass index between 26 and 35 [Wascher 1998]", "Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant", "Treatment with concomitent therapy, including vasoactive drugs, is allowed during the study. Will not be changed during the study"], "exclusion": ["Participation in a clinical trial in the 3 weeks preceeding the study", "History or signs of macrovascular disease", "History of hypertensitivity to the trial drug or to drugs with a similar chemical structure", "Changes in concomitant therapy during the study"], "nct_id": "NCT00490867"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients whose fasting blood glucose levels during the observation period are between 130mg/dL and 200mg/dL.", "Patients whose HbA1c is 7.0% or above during the observation period."], "exclusion": ["Patients with serious cardiac, hepatic or renal complications.", "Patients with serious diabetic complications.", "Patients with complete biliary obstruction or ileus.", "Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception."], "nct_id": "NCT00497198"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Must voluntarily give written informed consent", "Must be between 18-75 years of age", "Must have Type 2 diabetes for \u2265 6 months", "HgbA1C between 7.0% and 9.5%", "FPG > 6.7 mmol/L (120 mg/dL)", "BMI: Lower limit of 27 kg/m2 and an upper Limit of 45 kg/m2", "Treatment with a stable dosage for \u2265 8 weeks of either Glucophage metformin) \u2265 1000 and \u2264 2500 mg/day OR Glucophage XR \u2264 2000 mg/day", "eGFR \u2265 70 mL/min"], "exclusion": ["History of any clinically significant atherosclerotic disorder including myocardial infarction (within 6 months of screening), angina, stroke, peripheral vascular disease or congestive heart failure", "Known hypersensitivity or idiosyncratic reaction related to fibrates or NSAIDs including photo-allergic or phototoxic reactions to fibrates", "Subjects in whom acute asthmatic attacks, urticaria, or rhinitis are precipitated by aspirin or other NSAIDs", "History of clinically significant (as determined by the investigator cardiac, hematologic, hepatobiliary, peptic ulcer, renal, immunologic, metabolic, urologic, pulmonary, endocrinologic, neurologic, dermatologic, psychiatric, and/or other major disease", "Type 1 Diabetes", "Evidence of Cushing's syndrome, untreated hypothyroidism or other disorders that may lead to secondary weight gain, insulin resistance, or Type 2 diabetes", "Proliferative diabetic retinopathy or significant neuropathic symptoms that also limit activities of daily living", "History of malignancy (except for treated or excised basal cell carcinoma)", "Surgery within the 90 days prior to screening except for minor dental or cosmetic procedures", "History of drug or alcohol abuse (as defined by the Investigator)", "History of opportunistic infection", "Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening", "Fever or symptomatic viral or bacterial infection within 2 weeks prior to screening", "Positive for HCV antibody", "Positive for HBsAg", "Known positive for HIV antibody", "Pharmacologic treatment with statins, unless dosage has been stable \u2265 three months and is unlikely to change over the course of the study.", "Treatment with any concomitant medication that has not been at a stable dose for at least 28 days prior to screening.", "Currently taking or planning to take during the trial: Sulphonylureas, Injected hypoglycemic (exanatide or insulin), Weight loss medications, Thiazolidenediones, Glucocorticoids (inhaled glucocorticoids are permitted), Digoxin, Anticoagulants, Phenytoin, Loratadine, Erythromycin, MAO-inhibitors, NSAIDs (ASA \u2264 81 mg/d is permitted), COX-2 Inhibitors, Cholestryramine or fibrates, DPP-IV inhibitors, Any herbal medications unless reviewed with study doctor", "Alanine aminotransferase ALT) or aspartate aminotransferase (AST laboratory values that exceed > 2.0 x upper limit of normal (ULN)", "White blood cell (WBC) count < 4.0 x 109 /L or >14.0 X 109 /L", "Hemoglobin < 105 g/L in females and < 110 g/L in males (< 10.5 g/dL in females and < 11.0 g/dL in males)", "Participation in another clinical trial and/or treatment received with any investigational agent within 30 days before the initial dose of study medication", "Female subject who is pregnant or lactating or of child bearing potential and not using acceptable methods of contraception (birth control pills, barriers or abstinence)", "Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule", "Other unspecified reasons that, in the opinion of the Investigator or sponsor make the subject unsuitable for enrollment"], "nct_id": "NCT00506298"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Diagnosis of Type 2 diabetes for \u2265 3 months treated with metformin, thiazolidinedione, or sulfonylurea (either monotherapy or combination) or diet alone (drug na\u00efve)", "Fasting plasma glucose: 126", "240 mg/dL", "Hemoglobin A1c: 6", "10%", "Estimated CrCl \u2265 60 mL/min", "ALT \u2264 1.5 x ULN and total bilirubin \u2264 2 x ULN", "Stable and well controlled hypertension and/or dyslipidemia", "Concomitant medications used for hypertension and/or dyslipidemia, thyroid hormone replacement therapy and low dose aspirin will be allowed if stable for at least 6 weeks"], "exclusion": ["Women of childbearing potential", "Symptomatic diabetes with polyuria and/or polydipsia", "History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome", "History of renal disease including diabetic nephropathy"], "nct_id": "NCT00508287"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": [": -", "Heterozygous or homozygous for the nsSNPs R61C, G401S, 420Del, G465R, G174S (see supplementary info (3)) or without any nsSNPs that could potentially alter gene function.", "Age 18", "40.", "Willingness to participate in this study."], "exclusion": [": -", "Fasting glucose > 100mg/dL on one occasion.", "Use of medication other than stable thyroid hormone replacement or oral contraception.", "Subjects must not be pregnant or < 6 months postpartum at the time of study.", "Prior abdominal surgery other than hysterectomy, appendectomy or tubal ligation."], "nct_id": "NCT00588172"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening", "A1c: 7.5-11% (at screening)", "BMI less than or equal to 45 kg/m2"], "exclusion": ["Significant cardiovascular history", "Active liver disease, renal impairment"], "nct_id": "NCT00960076"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception", "Subject is in good health and is a non-smoker"], "exclusion": ["Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder", "Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases", "Subject is a nursing mother", "Subject consumes excessive amounts of alcohol or caffeine", "Subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks"], "nct_id": "NCT00961480"},{"minimum_age": 25.0, "maximum_age": null, "gender": "A", "inclusion": ["Age 25 years or older", "Type 2 diabetes determined by physician diagnosis or self-report of type 2 diabetes confirmed by medical documentation or medication review", "Black/African American by self-report", "currently receiving care and able to provide contact information for a treating physician", "residing in Baltimore, Maryland."], "exclusion": ["Mentally incompetent to give informed consent", "Severe cognitive impairment on the Telephone Interview for Cognitive Status", "Unable to complete assessment (interview, tests, venipuncture)", "Comorbid conditions likely to lead to death in the next 3-5 years (e.g. cancer, AIDS, end-stage renal disease, active tuberculosis, Alzheimer's disease)", "Planning to relocate from Baltimore region during the time period of the study or other reasons rendering person unable to attend visits to participate in intervention and follow-up assessments"], "nct_id": "NCT00964587"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception", "Subject is in good health and is a non-smoker", "Subject is willing to avoid strenuous physical activity during the study", "Subject agrees to refrain from eating grapefruit or grapefruit products during the study"], "exclusion": ["Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder. Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases", "Subject consumes excessive amounts of alcohol or caffeinated beverages", "Subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks", "Subject has a history of significant multiple and/or severe allergies to prescription or non-prescription drugs or food", "Subject has a history of hypersensitivity to metformin, sitagliptin, or sitagliptin/Metformin", "Subject is a regular user or past abuser of any illicit drugs", "Subject is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies during the study.", "Subject is a nursing mother"], "nct_id": "NCT00961857"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Age > 18 years and < 55 years", "Male or Female", "BMI > 30 BMI <60", "Subjects with an HbA1c > 7.5 and \u2264 10.0%", "Subjects with Type 2 diabetes who have been treated for \u226410 years", "Subjects on Metformin and/or Sulfonylurea", "History of failure with nonsurgical weight loss methods", "Subjects willing to comply with trial requirements", "Subjects who have signed an informed consent form", "Women who are post-menopausal, surgically sterile or on oral contraceptives and who do not plan on becoming pregnant during the course of the trial."], "exclusion": ["Treatment represents an unreasonable risk to the subject", "Subjects on oral diabetic medications other than Metformin or Sulfonylurea", "Subjects on insulin", "Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis", "Subjects with a past medical history of hypoglycemia", "Subjects with abnormal gastric emptying at baseline, defined as < 90% stomach emptied at 4 hours", "Subjects with a weight loss of > 4.5 Kg (10 lbs) within the 12 Weeks of screening", "Subjects taking corticosteroids or drugs known to affect GI motility (i.e. Reglan)", "Pregnant or have intention of becoming pregnant for the duration of the trial", "Unresolved alcohol or drug addiction", "Subjects receiving weight loss medications (prescription, over-the-counter, or herbal dietary medications)", "Previous gastrointestinal surgery that could affect the ability to place the EndoBarrier Flow Restrictor or the function of the implant.", "Subjects with active and uncontrolled GERD", "Subjects with symptomatic kidney stones prior to implant", "Subjects with iron deficiency and/or iron deficiency anemia", "History of Inflammatory bowel disease or condition of the gastrointestinal tract, such as ulcers or Crohn's disease", "Subjects with symptomatic gallstones prior to implant", "Symptomatic coronary artery disease or pulmonary dysfunction", "Known infection (Subjects who have a known infection at time of screening can be enrolled if the infection is treated prior to their procedure; if they still have an infection on day of procedure they must be withdrawn)", "History of congenital or acquired anomalies of the gastrointestinal tract such as atresias or stenoses", "Pancreatitis or other serious organic conditions", "Subjects requiring prescription anticoagulation therapy", "Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period", "Subject or Family history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder", "Participating in another ongoing investigational clinical trial", "Mentally retarded or emotionally unstable, or exhibits psychological characteristics requiring medication that affects appetite (i.e. tricyclic antidepressants and atypical antipsychotic medications) which, in the opinion of the Investigator, makes the subject a poor candidate for device placement or clinical trial.", "Subjects with active H. pylori (Note: Subjects may be enrolled if they had a prior history of H. Pylori and were successfully treated or are diagnosed during baseline tests and undergo successful treatment before their procedure)", "Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia"], "nct_id": "NCT00973960"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Subject is in good health", "Subject has been a nonsmoker for at least 6 months", "Subject is willing to avoid strenuous activity from the screening visit until the end of the study", "Subject agrees not to consume grapefruit products during the study and to avoid all fruit juices 24 hours before and after study drug administration"], "exclusion": ["Any history of stroke or neurological disorder", "Subject has a history of cardiovascular, blood, endocrine or liver diseases", "Subject has a history of cancer"], "nct_id": "NCT00975052"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus type II"], "exclusion": ["Diabetes mellitus type I", "Gestation diabetes", "Induced diabetes"], "nct_id": "NCT00979394"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["is a male or a female of non-child bearing potential", "has type 2 diabetes (T2D) and is either being treated with diet and exercise alone or with a single or combination oral anti-hyperglycemic agent(s)", "has been a nonsmoker for at least 6 months"], "exclusion": ["has a history of stroke, chronic seizures, or major neurological disorder", "has a history of major endocrine (except T2D), gastrointestinal, cardiovascular, blood, liver, immune, kidney, respiratory, or genitourinary abnormalities or diseases", "has a history of cancer, except certain skin or cervical cancers or cancer that was successfully treated more than 10 years prior to screening", "has unstable or rapidly progressing diabetic retinopathy and/or neuropathy", "has had an eye infection or other inflammation of the eye in the 2 weeks prior to screening", "has glaucoma or is blind", "has had incisional eye surgery in the last 6 months or laser eye surgery in the last 3 months (Lasik is permitted)", "has a history of type 1 diabetes", "has symptomatic coronary artery disease", "consumes excessive amounts of alcohol and/or caffeine"], "nct_id": "NCT00979459"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00979823"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["male or female subjects aged between 35 and 70 years, inclusive", "type 2 diabetes with duration >6 months and <10 years", "for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas", "HbA1c >=7.0% and <=10.0%", "if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start", "written informed consent"], "exclusion": ["history or presence of cancer or any clinically relevant diseases", "chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months", "recurrent hypoglycemia", "abnormal lab tests at screening (ALAT and/or ASAT >=3 times ULN), creatinine >1.6 mg/dL in males and >1.4 mg/dL in females", "clinically relevant ECG findings at screening", "treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months", "treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months", "any systemic or topical treatment with drugs known to influence glucose metabolism"], "nct_id": "NCT00971659"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["HbA1c 7-11%", "On a stable dose of metformin for at least 6 weeks"], "exclusion": ["Type 1 Diabetes", "Antidiabetic medication other than or in addition to metformin", "FPG > 270 mg/dL"], "nct_id": "NCT00871936"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus with stable antidiabetic treatment since at least three months", "Total cholesterol concentrations >135mg/dl and/or concomitant lipid lowering therapy with HMGCoA inhibitors", "Serum creatinine \u22641.5mg/dl", "Urinary albumin excretion rate < 200\u03bcg/min", "Written informed consent"], "exclusion": ["History of myocardial infarction, stroke or hospital admission for angina within the previous 6 months", "History of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting", "Clinically manifest heart failure (grade III or above according to New York Heart Association criteria)", "Poor glycemic control (HbA1C >11%)", "Primary hyperlipidemia", "Uncontrolled thyroid diseases", "Infectious disease within 4 weeks of starting", "Acute liver disease or hepatic dysfunction", "Inflammatory muscle disease or evidence of muscle problems", "Concurrent treatment with systemic steroids, androgens, cyclosporin and other immunosuppressive drugs, fibrates, high-dose niacin or cholestyramine", "Pregnancy or lactating", "Women of childbearing potential without following a scientifically accepted form of contraception", "Life-threatening conditions or terminal concomitant diseases other than diabetes", "Specific contraindications or history of hypersensitivity to the study drugs or other statins", "Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial", "Evidence of an uncooperative attitude", "Any evidence that patient will not be able to complete the trial follow-up"], "nct_id": "NCT00157482"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Ages 18", "75 years, inclusive", "Diagnosed with type 2 diabetes", "Stable insulin therapy for 6 weeks", "Stable dose of any other antidiabetic medications for 90 days", "Hemoglobin A1c value between 7.5% to 9.5%", "C peptide greater than 0.5 ng/mL", "Prescribed ADA diet"], "exclusion": ["History of type 1 diabetes or ketoacidosis", "History of pancreatitis", "Uncontrolled hypertension", "Allergy or toxic response to colesevelam or any of its components", "Serum LDL-C less than 60 mg/dL", "Serum TG greater than 500 mg/dL", "Body mass index (BMI) greater than 45 kg/m2-"], "nct_id": "NCT00151749"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00151762"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes", "BMI= 26kg/m2", "Maximal treatment with metformin and sulfonylurea", "HbA1c between 7.5 and 9.5%"], "exclusion": ["Anterior treatment with glitazones", "Anterior treatment with insulin", "Known heart failure", "Hepatopathy", "Renal filtration less than 60ml/min, Hb<10g/dl", "Corticoids treatment"], "nct_id": "NCT00159211"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age \u2265 40 years", "History of diabetes mellitus type 2 for at least three months with stable antidiabetic treatment", "Systolic and/or diastolic blood pressure \u2265 135 or 85 mmHg, respectively. In alternative, antihypertensive therapy regardless of blood pressure values", "Serum creatinine \u2264 1.5 mg/dL", "Urinary albumin excretion rate < 200 \u00b5g/min", "Written informed consent for the trial participation."], "exclusion": ["Clinical or histological evidence of non-diabetic renal disease, including vascular disease of the kidney, obstructive uropathy, prostatic hypertrophy or incomplete bladder emptying", "Transplanted kidney", "Moderate to severe chronic heart failure (III-IV stage according to the NYHA classification).", "Cerebral hemorrhage, stroke or transient ischemic attack within three months prior to the trial enrolment", "Myocardial infarction within three months prior to the trial enrolment", "Unstable angina pectoris", "Mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy", "Secondary (e.g., Cushing disease, phaeochromocytoma, etc.) or severe refractory hypertension", "Poor glycemic control (HbA1c>11%)", "Connective tissue or autoimmune disease", "Hereditary angioneurotic edema", "Clinically relevant electrolyte imbalance (e.g., serum potassium > 5.5 mmol/L)", "Clinically relevant hematological disorders", "Anemia with hemoglobin concentrations < 10 g/dL", "Serious hepatic disease", "Pregnancy or lactating or planning a pregnancy", "Women of childbearing potential without following a scientifically accepted form of contraception", "Any other serious or terminal concomitant disease", "Any condition which may interfere with the absorption of the study treatments", "Any concomitant treatment with ACE inhibitors, angiotensin II blockers, calcium channel blockers, potassium sparing diuretics", "Chronic treatment with nonsteroidal antiinflammatory drugs, antidepressants and neuroleptics, lithium, cimetidine, immunosuppressive and/or antineoplastic drugs, chronic systemic glucocorticoid therapy more than 7 consecutive days in one month, antiarrhythmic drugs (e.g., chinidin, procainamide), anesthetics/narcotics", "History of hypersensitivity to delapril or other ACE inhibitors, manidipine or other dihydropyridine CCBs", "Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial", "Evidence of an uncooperative attitude", "Any evidence that allows predicting that the patient will not be able to complete the trial follow-up."], "nct_id": "NCT00157586"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["Male/female, age 18-78 inclusive", "Type 2 diabetes, taking glargine, metformin and/or thiazolidinedione for 3 months prior to screening, stable doses for 2 months prior to screening", "HbA1c 7.0-8.5% inclusive", "Fasting plasma glucose <240 mg/dL at screening", "Body Mass Index 22-41 kg/m2"], "exclusion": ["Pregnant or nursing", "Other investigational drugs within 30 days of screening", "Treatment with other anti-diabetic medications other than metformin, glargine and/or thiazolidinedione", "History of type 1 diabetes", "Abnormal kidney function", "History of acute diabetic complications", "Congestive heart failure requiring treatment", "Myocardial infarction, coronary artery surgery, stroke within 6 months of screening", "Liver disease, liver enzymes more than 3 times upper limit of normal", "Fasting triglycerides >700 mg/dL within past 12 weeks", "Acute infections or other conditions that may affect blood sugar or may interfere with interpretation of study data", "Treatment with corticosteroids", "Blood donation within past 12 weeks Other protocol-defined inclusion/exclusion criterial may apply."], "nct_id": "NCT00402909"},{"minimum_age": 21.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Patients with type 2 diabetes.", "Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c > 8% and < 11%).", "FBG > 130 mg/dl and < 240 mg/dl.", "BMI < 40 kg/m2 and >25 kg/m2.", "Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls."], "exclusion": ["C peptide < 0.30 nmol/l.", "Unexplained weight loss of more than 10% of body weight in the last 6 months.", "Pregnant women or women with the intention of becoming pregnant.", "Women with childbearing potential who will not use contraceptive protection.", "Breastfeeding women.", "Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery.", "Renal impairment defined as serum creatinine >1.4 mg/dl in women and >1.5 mg/dl in men.", "Hepatic impairment defined as GPT or GOT above 2x the normal threshold.", "Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids).", "History of drug or alcoholic abuse.", "Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry.", "Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator.", "Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment.", "Known hypersensitivity to insulin glargine. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial"], "nct_id": "NCT00627471"},{"minimum_age": 20.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients who are 20", "75 years old", "Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug", "Patients whose HbA1c is 6.5", "9.5%", "Patients who were not administered drugs prohibited for concomitant use within 12 weeks before administration of investigational drug."], "exclusion": ["Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or secondary diabetes (Cushing disease, acromegaly, etc)", "Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification", "Patients with serious diabetic complications", "Patients who are habitual excessive alcohol consumption.", "Patients with severe hepatic disorder or severe renal disorder.", "Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception"], "nct_id": "NCT00628212"},{"minimum_age": 55.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients 55 to 75 years old had type-2 diabetes and at least two of the following cardiovascular risk factors:", "urinary albumin excretion > 30 mg/L or > 30 mg/24 hours,", "treated or untreated hypertension,", "treated or untreated lipid abnormality,", "peripheral arterial disease,", "history of transient ischemic accident,", "tobacco consumption", "familial history of premature cardiovascular disease."], "exclusion": ["History of myocardial infarction, coronary artery disease, or stroke,", "Previous positive stress test or myocardial perfusion imaging,", "Negative stress test or myocardial perfusion imaging within the last three years"], "nct_id": "NCT00627783"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Participated in DIO-502"], "exclusion": ["Did not participate in DIO-502"], "nct_id": "NCT00622089"},{"minimum_age": 20.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["type 2 diabetic patients with disease duration of less than 15years", "age of 20-70 years", "BMI 22-27", "HbA1c 9-13%", "patients willing to receive intensive glucose control", "patients who are able to monitor their glucose level at home", "for normal glucose tolerance group : NGT subjects with same range of age and BMI", "for early diabetes group : patients with diabetic duration of less than 5 years and HbA1c level less than 7.5% for at least last 6 months"], "exclusion": ["previous history of insulin treatment", "patients taking alpha-glucosidase inhibitor or thiazolidinedione", "serum creatinine >= 1.5 mg/dL", "hemoglobin < 10 g/dL", "AST/ALT greater than 3 times normal range", "ischemic heart disease, congestive heart failure (NYHA grade >=2)", "chronic renal failure, proliferative diabetic retinopathy, CVA", "patients with gastroparesis or taking medications altering gastric motility", "usage of steroid or other agents affecting glucose metabolism", "pregnant or breast-feeding women"], "nct_id": "NCT00776243"},{"minimum_age": 30.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Good health except for having type 2 diabetes", "Being treated with diet, insulin, or oral hyperglycemic agents", "Male or non pregnant female", "Non-smoker", "HbA1c 8 or above", "Able to provide informed consent"], "exclusion": ["Presence of mental illness", "Co-existing chronic inflammatory condition or neurological disease or diseases associated with abnormal glutathione metabolism", "BMI over 35", "Smoker"], "nct_id": "NCT00775541"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Male or female (with non child-bearing potential)", "Diagnosed diabetes Mellitus patients treated with metformin alone or one other anti-diabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start.t", "HbA1c <11 % at screening (HbA1c value according to international DCCT standard)"], "exclusion": ["Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP", "History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease", "Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results."], "nct_id": "NCT00774553"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Men or women (not of childbearing potential) of Chinese ethnicity", "Weigh at least 50 kg and have a body mass index (BMI) between 19 and 24 kg/m2", "Must have normal physical examination, laboratory values, ECG, pulse and blood pressure unless the investigator considers an abnormality to not be clinically significant."], "exclusion": ["History of clinically significant hypoglycaemia (low blood sugar levels)", "Women who are pregnant or breastfeeding"], "nct_id": "NCT00770302"},{"minimum_age": 30.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Healthy male and female subjects aged 30-60", "Body Mass Index 21-30 kg/m2", "All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities", "EKG treadmill stress test for volunteers over 40 years of age.", "Female volunteers of childbearing potential will undergo HCG pregnancy test."], "exclusion": ["Prior or current history of poor health", "Abnormal results following screening tests", "Pregnancy", "History of allergy to sulfonylurea or related drugs"], "nct_id": "NCT00608179"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening."], "exclusion": ["Positive test results for HIV or hepatitis B or C.", "Treatment for drug or alcohol dependence."], "nct_id": "NCT00865033"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetic patients who require basal (long-acting) insulin for the control of hyperglycemia according to the opinion of the investigator.", "Inadequate Glucose control: Hemoglobin A1c (HbA1c) percentage in the range of \u2265 7.5 - 12.0%", "Stable body weight for previous 3 months (\u00b1 5 kg).", "Structured exercise lower than 4 hours per week.", "Metformin \u22651.5 g/day"], "exclusion": ["Any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol.", "Type 1 Diabetes Mellitus", "Previous treatment with insulin (< 6 months prior inclusion). Insulin therapy for less than 6 days at the time of an acute event is acceptable.", "Secondary diabetes mellitus (i.e. steroid induced, Cushing syndrome, chronic pancreatitis, cystic fibrosis, etc.) and maturity-onset diabetes of the young", "Proliferative retinopathy/maculopathy requiring treatment", "Hypoglycemia unawareness or recurrent major hypoglycaemia", "Pregnancy and breast-feeding", "Unstable coronary artery disease", "Heart Failure as defined by class IV according to NYHA classification", "Recent (< 6 months) history of myocardial infarction, stroke or T.I.A, ventricular arrhythmias, or unstable supra-ventricular arrhythmias.", "Renal Insufficiency. Creatinine clearance < 40 ml/min (MDRD formula).", "Acute (< 2 months) or Chronic infectious diseases requiring either hospitalization or antibiotic treatment for more than 2 weeks", "Recent (< 1 year) diagnosis of systemic malignancies except thyroid and skin cancer", "Major psychiatric diseases", "History of drug addiction", "Previous bariatric surgery", "Medication that affects weight such as", "Systemic corticosteroids (prednisone)", "Anti-obesity medication (Xenical\u00ae or Meridia\u00ae)", "Megace \u00ae", "Antidepressant medication associated with significant weight impact such as Zyprexa\u00ae, Remeron\u00ae based on investigator judgment.", "Growth hormone therapy or testosterone supplementation should be initiated for at least 6 months and at stable dose for 3 months prior to enrolment", "Medication that affects glycemic control and hypoglycemic unawareness based on investigator judgment."], "nct_id": "NCT00862875"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male or female (females must be of non-childbearing potential), between the ages of 18 and 70 years, inclusive.", "Diagnosis of Type 2 diabetes.", "Fasted C-peptide value \u2265 0.8 ng/mL.", "HbA1c \u2265 6.5% and \u2264 10.0% for monotherapy cohorts (study drug only) or HbA1c \u2265 7.5% and \u2264 10.0% for combination cohorts (study drug and on a stable regimen of metformin monotherapy that includes a morning dose for \u2265 8 weeks prior to first dose of study drug).", "BMI \u2265 25.0 kg/m2 and \u2264 40.0 kg/m2", "Additional criteria exist. Key"], "exclusion": ["Recent history (i.e. less than 6 months) or concomitant/ongoing clinically significant hematologic, renal, pulmonary, gastrointestinal, hepatic, psychiatric, neurologic, dermatologic or allergic disease (including drug allergies that are clinically significant and not remote, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), or other conditions at the discretion of the investigator.", "Significant cardiac disease, myocardial infarction within 6 months of study start, unstable angina, congestive heart failure, known arrhythmias of ventricular etiology, unexplained syncope or syncope/seizures related to arrhythmia.", "History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption.", "A positive test for drugs or alcohol.", "Active infectious diseases including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Past history and inactive hepatitis B and C, as confirmed by serological testing, are allowed.", "Women who are pregnant or breastfeeding.", "Donation or loss of \u2265 550 mL of blood (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to first dose of study drug.", "Additional criteria exist."], "nct_id": "NCT00952198"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "M", "inclusion": ["type 2 diabetic patients according to the criteria of the American Diabetes Association", "body mass index between 25 and 40 kg/m2", "Subject the therapeutic care of which bases only on the oral anti-diabetics excepted of glitazones and inhibitors of alpha-glucosidases", "Subject without cardiovascular event in the previous 6 months or perturbing disease the lipid balance assessment (dysthyroidism, pituitary disease, adrenal disease)", "No anemia, no coagulation disturb, creatinine clearance > 60 ml/min, fasting triglycerides < 4g/l"], "exclusion": ["Hypersensitivity to egg", "Subject with severe disease associated with diabete"], "nct_id": "NCT00950209"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetics in accordance with WHO.", "Male and female patients, between 18 and 75 years of age.", "Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.", "Normal blood creatine clearance and normal liver function test results.", "BMI less than or equal to 45kg/m2."], "exclusion": ["Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.", "Therapy with beta-blockers or thiazide diuretics within the prior 3 months.", "Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.", "Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.", "Receiving any investigational drug within 30 days of the baseline visit."], "nct_id": "NCT00955747"},{"minimum_age": 12.0, "maximum_age": 21.0, "gender": "A", "inclusion": ["Children with Type 2 Diabetes,", "Between the ages of 12-21 years,", "Tanner stage 4-5 for pubertal development,", "Menstruating females must have a negative urine pregnancy test for inclusion,", "Must have T2DM for at least 6 months,", "History of negative anti-glutamic acid decarboxylase (GAD) -65 and anti-islet cell antibodies,", "HbA1c < 8.5% and on a stable dose of an oral hypoglycemic agent (with or without insulin) over the last 2 months, or well controlled on diet."], "exclusion": ["A history of a chronic disease other than diabetes (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, dyslipidemia, cholelithiasis etc),", "BMI> 40 kg/m2,", "Weight of < 60 kg,", "Female with menstrual irregularities,", "Allergy to local anesthetics (ELAMAX Cream, Ethyl Chloride),", "Evidence or history of chemical abuse,", "Anemia (age specific normal range for hemoglobin will be used),", "Elevated liver enzymes (defined as more than 3 times the upper limit of the normal range for age),", "Elevated BUN or creatinine (defined as more than 3 times the upper limit of the normal range for age),", "Use of medications that may increase the blood sugars and admission to the hospital for diabetes related problems over the last 6 months."], "nct_id": "NCT00950677"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "M", "inclusion": ["healthy young males", "nonsmokers", "moderate alcohol users"], "exclusion": ["not on any medications that could alter glucose metabolism", "no history of blood disorders"], "nct_id": "NCT00950898"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Age 35-70 years old.", "Body Mass Index greater than 19kg/m^2 or less than 40kg/m^2 or a total weight less than 130 kilograms.", "Negative pregnancy test for women of childbearing potential.", "Absence of gastrointestinal symptoms.", "Signed informed consent.", "Treatment with diet and/or metformin. Subjects must be on stable therapeutic doses of metformin and/or lipid-lowering agents for more than 3 months."], "exclusion": ["Structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders. A screening Bowel Disease Questionnaire will be used to exclude subjects with irritable bowel syndrome. Patients with a history of dysphagia or intestinal motility disorders will be excluded.", "Prior history of pancreatitis.", "Prior history of hypertriglyceridemia (500mg/dL or greater).", "Currently using a bile-acid binding resin such as colesevelam, colestipol, colestimide or cholestyramine.", "To ensure homogeneity between treatment groups we will exclude subjects with insulin-treated type 2 diabetes mellitus, subjects who have received an inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors) or \"gliptins\" (a class of oral hypoglycemics), Byetta or sulfonylurea agent in the past three months.", "HbA1c greater than 9.0%.", "Patients who have not been stable on all medications for a period exceeding 3 months.", "Use of drugs or agents within the past 2 weeks or planned use in the subsequent 4 weeks during the study period that:", "Alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs) and newer antidepressants.", "Opiate-based analgesic drugs (Note: intermittent or chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAID) will be allowed).", "Antihistamines", "Anticholinergic agents", "Female subjects who are pregnant or breast-feeding. Females must be either surgically sterilized, postmenopausal (>12 months since last menses), or, if of childbearing potential, using reliable methods of contraception as determined by the physician.", "Clinical evidence (including physical exam and Electrocardiogram) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Any candidate participants with such disorders mentioned will be referred to their general physician."], "nct_id": "NCT00951899"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["patients with type 2 diabetes treated by oral antidiabetic agents (except glitazones) and/or insulin", "age> 18 years", "HbA1c > 6.5%"], "exclusion": ["renal failure", "heart failure", "primary hyperlipidemia", "pregnancy", "treatment that may modify lipid metabolism (glucocorticoids, oestrogens, retinoids, HIV antiviral drugs)"], "nct_id": "NCT00953498"},{"minimum_age": 20.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Age 20-80 years", "Diagnosis of type 2 diabetes", "Speaking and reading Hebrew"], "exclusion": ["Chronic medical condition requiring a specific diet", "Non Hebrew speaking", "Pregnant women"], "nct_id": "NCT00845793"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus according to the ADA criteria", "HbA1c between 6.5 % and 9.9 %", "Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3 months", "Age between 40 and 75 years", "BMI < 40"], "exclusion": ["Type 1 diabetes mellitus", "Pre-treatment with insulin within the last 6 months prior to screening", "Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks prior to screening", "Untreated hypertension stage II-III according to WHO criteria", "Planned or anticipated change in antidiabetic and/or concomitant medication during study participation", "Total cholesterol > 300 mg/dl (anamnestically)", "Major micro- or macrovascular complications as judged by the investigator", "Tobacco use within the last 6 months prior to screening", "Drugs with major impact on endothelial function like nitrates etc. 10. History of drug or alcohol abuse which in the opinion of the investigator will impair subject safety or protocol compliance 11. History of hypersensitivity to the study drugs or to drugs with similar chemical structures 12. History of severe or multiple allergies 13. Treatment with any other investigational drug within 3 months prior to screening 14. Progressive fatal disease 15. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women and > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator 16. Pregnancy or breast feeding 17. Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner 18. Lack of compliance or other similar reason that at the discretion of the investigator precludes satisfactory participation in the study 19. Hypopotassemia (K<3.5 mmol /l)"], "nct_id": "NCT00849576"},{"minimum_age": 20.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Non Smoking: Clinical diagnosis of type 2 diabetes mellitus.", "Non Smoking: Current basal and prandial insulin therapy for at least 6 weeks either alone or in combination with = 2 OHA", "Non Smoking: Negative urine cotinine test.", "Non Smoking: Non-smoker for at least 2 years.", "Smoking: Clinical diagnosis of type 2 diabetes mellitus.", "Smoking: Have been smoking for at least 5 years", "Non Smoking: Body Mass Index (BMI) of = 40 kg/m2.", "Non Smoking: Glycosylated hemoglobin (HbA1c) of = 12%.", "Non Smoking: If other medications (other than oral anti-diabetic agents) in addition to insulin are taken at screening, the subject must be on a stable regimen as defined by continued use of the same dose of each medication for a period of at least 12 weeks immediately prior to trial enrollment.", "Non Smoking: Forced expiratory volume in one second / forced vital capacity (FEV1/FVC) of = NHANES III predicted Lower Limit of Normal.", "Non Smoking: FVC of = 80% NHANES III predicted value.", "Non Smoking: DLco of = 70% (uncorrected) Miller predicted value.", "Non Smoking: No upper respiratory infections within the last 15 days or lower respiratory infection within the last 30 days.", "Non Smoking: Must be of non-childbearing potential or using adequate birth control measures", "Smoking: Positive cotinine test.", "Smoking: Current basal and prandial insulin therapy for at least 6 weeks either alone or in combination with = oral antihyperglycemic agents.", "Smoking: BMI of = 40 kg/m2.", "Smoking: HbA1c of 12%.", "Smoking: If other medications (other than oral anti-diabetic agents) in addition to insulin are taken at screening, the subject must be on a stable regimen as defined by continued use of the same dose of each medication for a period of at least 12 weeks immediately prior to trial enrollment.", "Smoking: FEV1/FVC = NHANES III Predicted Lower Limit of Normal", "Smoking: FEV1 and FVC of = 60% NHANES III predicted value.", "Smoking: DLco = 70% of (uncorrected) of Miller predicted value.", "Smoking: No upper respiratory infections within the last 15 days or lower respiratory infection within the last 30 days.", "Smoking: Must be of non-childbearing potential or using adequate birth control measures."], "exclusion": ["Diabetes mellitus type 1.", "Total daily insulin requirement of = 1.4 U/kg.", "Intake of any drug or herbal preparation which, in the evaluation of the Investigator, may interfere with the clinical trial results by causing clinically relevant interference with glucose utilization, insulin action, or recovery from hypoglycemia (eg, systemic corticosteroids, oral or inhaled glucocorticosteroids).", "History of hypersensitivity to the trial drug or to drugs with similar chemical structures.", "Treatment with any investigational drug within 90 days prior to enrollment of trial.", "Progressive fatal disease.", "History of malignancy within five years of trial entry (other than basal cell carcinoma).", "Evidence of severe secondary complications of diabetes (neuropathy, nephropathy as evidenced by creatinine > 1.6 mg/dL for females or > 1.8 mg/dL for males, Stage III or IV retinopathy (according to the MKC diabetic retinopathy scale, see Appendix 1.1 of protocol), or severe peripheral vascular disease).", "Previous history of anaphylaxis or angioedema.", "Evidence of clinically significant autonomic neuropathy (gastroparesis, orthostatic hypotension or hypoglycemia unawareness).", "Myocardial infarction or stroke within the preceding six (6) months.", "Positive hepatitis B (HBsAg) or positive Human Immunodeficiency Virus (HIV) serology or active Hepatitis C (HepCAb) at screening.", "History or presence of clinically significant cardiovascular, hepatic, gastrointestinal, neurological or infectious disorders capable of altering the absorption, metabolism or elimination of drugs, or constituting a significant risk factor when taking trial medication.", "ALT or AST > 3 times the upper limit of the normal reference range.", "Anemia (hemoglobin levels < 11 g/dL for females and < 12 g/dL for males).", "On-going respiratory infection.", "Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine", "Pregnancy, lactation, or the intent of becoming pregnant during the trial period.", "Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).", "Current drug or alcohol abuse (regular alcohol intake > 14 units/week), or history which in the opinion of the investigator would not make the subject a suitable candidate for participation in this trial. A unit of alcohol is defined as 8 g of ethanol, \u00bc liter of beer or 1 glass of wine or 1 measure of spirits.", "Investigator or site personnel directly affiliated with this trial, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted."], "nct_id": "NCT00934414"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;", "Patients treated since at least 3 months, by metformin and secreting insulinic (KNOWN or glinide);", "Patients uncontrolled with HbA1c \u2265 7.5% and < 10% at the inclusion.", "BMI < 40 ;", "Patients requiring a insulin treatment", "Patients agree to start a slow insulin treatment", "Patients already practising the glycemic self-monitoring or agree to learn it and practise it;", "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;", "Patient not taking part in another biomedical research study", "Patients agree to carry out at least 2 finger sticks per day;", "More than 18 years, there is no higher age limit."], "exclusion": ["Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;", "Patients in a situation which justifies of a clinical follow-up diabetologic more frequent than that (quarterly) envisaged by the study", "Patients requiring a transitory passage to insulin;", "Patients needing a hospitalization for the adaptation of insulin doses;", "Patients presenting a cardiologic event", "Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;", "Patients suffering from drug-addiction, alcoholism or psychological troubles", "Type 1 or secondary diabetes", "Patients who don't need strict metabolic objectives;", "Pregnant or parturient patients", "person with no freedom."], "nct_id": "NCT00937703"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Presence of a medical diagnosis of diabetes for at least 6 months", "HbA1c < 9%", "Age greater than 18 years", "Resident of Loma Linda, California area"], "exclusion": ["Allergy to peanuts", "Smokers", "History of irritable bowel disease or diverticulitis", "Statin therapy (unless stable statin dose for 3 months)"], "nct_id": "NCT00937222"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Men or women \u2265 18 and \u2264 80 years old", "Clinical diagnosis of type 2 diabetes mellitus", "HbA1c > 7.0% and \u2264 11.0%", "BMI \u2264 40 kg/m2", "Negative smoking status and urine cotinine test", "Written informed consent", "Receiving sc insulin 2-3 times daily administered as any of the following 3 regimens: self-mix regimen, pre-mix regimen, or long-acting analogue and regular or rapid-acting insulin analogue not to exceed 3 daily injections. Subjects may also have received oral antidiabetic agents including metformin or thiazolidinediones.", "No dose adjustments for insulin and oral antidiabetic agents within the preceding 6 weeks.", "FEV1 \u2265 70% of NHANES III predicted; TLC) \u2265 80% of predicted (Intermountain Thoracic Society); DLCO uncorrected \u2265 70% of predicted"], "exclusion": ["Total daily dose of insulin \u22651.4 IU/kg body weight", "Treatment with any sulfonylureas and/or meglitinides and/or alpha-glucosidase inhibitors within the preceding 8 weeks", "Treatment with pramlintide acetate (Symlin\u00ae), and/or any incretins (e.g., exenatide [Byetta\u00ae]) within the preceding 8 weeks", "Unstable diabetes mellitus control, defined as 2 or more episodes of severe hypoglycemia (requiring third party intervention) and/or any hospitalization or emergency room visit due to poor diabetic control or hyperglycemia requiring hospitalization within the preceding 6 months", "Exposure to an inhaled insulin at any time, treatment with an investigational drug within the preceding 3 months, and/or current participation in another clinical trial", "Allergy to insulin or to any drugs to be used as part of the clinical trial, or history of hypersensitivity to the investigational drug or to drugs of similar chemical structures", "History of active viral and/or cirrhotic hepatic disease and/or abnormal liver enzymes as evidenced by serum aspartate aminotransferase (AST)and/or alanine aminotransferase (ALT) \u2265 3 x Upper Limit of Normal (ULN)(Includes active hepatitis A, positive hepatitis B and/or hepatitis C serology)", "Serum creatinine > 1.8 mg/dL in women and > 2.0 mg/dL in men History of chronic obstructive pulmonary disease (COPD), asthma (any history of bronchospasm or asthma after the age of 14), and/or any other clinically important pulmonary disease confirmed by documented history, pulmonary function testing, or radiologic findings", "Congestive heart disease graded as class III or class IV according to New York Heart Association criteria and subjects currently being treated pharmacologically for ventricular dysrhythmias using amiodarone", "History of myocardial infarction, cardiac surgery, coronary angioplasty, and/or stroke within the preceding 3 months", "Symptomatic coronary artery disease, including crescendo angina, unstable angina, and/or unstable or symptomatic cardiac arrhythmias", "Poorly controlled arterial hypertension despite pharmacologic treatment, defined as systolic blood pressure (BP) > 180 mm Hg and/or diastolic BP > 110 mm Hg at screening", "History of malignancy within the preceding 5 years (other than excised basal cell carcinoma of the skin), any history of lung neoplasm, and/or subjects with current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity", "History of acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or positive human immunodeficiency virus (HIV) serology", "Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine", "Visit 1/Screening (Week -3), but prior to Visit 1 PFTs and before Visit 3/Baseline (Week 0), subject will be scheduled for PFTs after 30 days from resolution of respiratory infection. An additional hemoglobin and urine \u03b2-HCG (for women of childbearing potential age only) will be required", "Women who are pregnant, lactating or planning to become pregnant", "Women of childbearing potential (defined as pre-menopausal and not surgically sterilized or postmenopausal for less than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous and/or transdermal contraceptives; condoms and diaphragms with a spermicide, or intrauterine devices", "Current drug and/or alcohol abuse", "Subjects who in the opinion of the Investigator will be unable to comply with the requirements of the protocol", "Severe complications of diabetes mellitus, in the opinion of the Investigator, including: symptomatic autonomic neuropathy, disabling peripheral neuropathy, active proliferative retinopathy; nephropathy with renal failure, renal transplant and/or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene;and/or vascular claudication", "Any other concurrent medical or major psychiatric condition which, in the opinion of the Investigator, makes the subject unsuitable for the clinical trial, or could limit the validity of the ICF and/or impair the subject's ability to participate in the trial", "Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) acceptability and repeatability criteria."], "nct_id": "NCT00309244"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Provision of a written informed consent", "Men or women who are >=18 years of age", "Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control", "Completed the last two visits of randomized treatment period in GALLANT 4"], "exclusion": ["Type 1 diabetes", "New York Heart Association heart failure Class III or IV", "Treatment with chronic insulin", "History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)", "History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)", "Creatinine levels above twice the normal range", "Creatine kinase above 3 times the upper limit of normal", "Previous enrollment in this long-term extension study", "Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"], "nct_id": "NCT00300105"},{"minimum_age": 65.0, "maximum_age": null, "gender": "A", "inclusion": ["Community dwelling patients 65 years of age or older diagnosed with Type 2 Diabetes not controlled with diet and exercise", "Patients must have a HbA1c of 7-10% off medication, or as a result of a protocol wash-out from oral anti-hyperglycemic agents by the qualifying visit"], "exclusion": ["Patients with type 1 diabetes", "History of ketoacidosis or requires insulin use", "Alanine aminotransferase / aspartate aminotransferase > 2.5 X ULN, triglycerides > 600 mg/dL, creatinine clearance < 35 mL/min", "Fasting plasma glucose consistently > 260 mg/dL", "Poorly controlled hypertension"], "nct_id": "NCT00305604"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes diagnosed according to and in accordance with the WHO criteria", "Metformin treatment of \u2265 1 gram", "7,5 % \u2264 HbA1c \u2264 10%", "Age > 18", "BMI \u2265 25 kg/m2", "Informed consent", "Contraception, if appropriate"], "exclusion": ["Proliferating retinopathy", "Uremia, end stage renal disease, diabetic nephropathy or any other cause of impaired renal function with s-creatinine > 130 \u00b5M and/or albuminuria (>300 mg/day)", "Liver disease with ALAT and/or ASAT > 2 x normal value", "Complicated coronary artery disease, NYHA group III and IV", "Positive screening for islet cell auto antibodies and/or GAD-65 auto antibodies", "Occurrence of type 1 diabetes in first degree relatives", "Anaemia", "Pregnancy and/or breast feeding", "Treatment with medication affecting insulin secretion", "non-compliance Withdrawal criteria", "The subject may withdraw at will at any time", "Pregnancy discovered during the trial", "Severe illness", "Unacceptable side effects", "If self-measured fasting plasma glucose on three consecutive days exceeds 15 mM, the result is repeated in an immediately scheduled visit, and no treatable intercurrent cause for the hyperglycaemia can be found."], "nct_id": "NCT00411411"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years or older,", "have Type 2 diabetes,", "report at-risk drinking in past month,", "report poor diabetes treatment adherence."], "exclusion": ["current alcohol dependence or current psychoactive substance abuse or dependence (excluding nicotine),", "currently psychotic,", "unable to provide the name and contact information for a significant other to corroborate self-report,", "unable to provide the name and contact information for two people who could serve as locators, do not have access to a telephone."], "nct_id": "NCT00950040"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Caucasians over 18", "Emitted for non-acute coronary arteriography (CAG) in Gentofte hospital", "BMI 23-35 kg/m2", "Normal hemoglobin", "Who gives informed consent", "Those with type 2 diabetes: HbA1c 6-10%", "Those without type 2 diabetes: Normal oral glucose tolerance test (OGTT) according to WHO criteria"], "exclusion": ["Liver disease (ALAT > 2x normal)", "Diabetic nefropati (Creatinine > 130 \u00b5M or albuminuria)", "Treatment with medicine that cannot be paused 12 hours before intervention", "Pregnancy or breastfeeding", "Insulin- or glitazone treatment", "Healthy controls: close family history with diabetes", "Unstable angina pectoris", "Non-STEMI", "Atrial fibrillation", "Valvular disease", "LVEF < 50%", "Severe systemic disease", "Type 1 diabetes"], "nct_id": "NCT00923962"},{"minimum_age": 6.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus (Type 1 or type 2)", "BMI greater than 27 kg/m^2, or more than 3 kg weight increase since start of insulin therapy"], "exclusion": ["Subjects currently being treated with insulin detemir", "Subjects who were previously enrolled in this study;", "Subjects with a hypersensitivity to insulin detemir or to any of the excipients.", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months Female patients will be reminded to use adequate contraceptive during the study, where is relevant."], "nct_id": "NCT00849342"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 or Type 2 diabetes mellitus", "18 years or older", "Meet specific requirements for diabetic retinopathy", "Free of severe or chronically disabling conditions, except diabetes, diabetic retinopathy and diabetic macular edema", "Hemoglobin A1c (HbA1C) \u226413.0%"], "exclusion": ["History of panretinal photocoagulation for diabetic retinopathy, conditions that might affect the progression of diabetic retinopathy, or unstable angina", "Investigators, site personnel directly affiliated with the study and their families", "Presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss", "Presence of medical disorder, cancer, or elevated laboratory measurements that could represent a safety risk during the study", "Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control"], "nct_id": "NCT00604383"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": [": Type 2 diabetes HbA1c 6.0-8.0% age > 40 years"], "exclusion": [": History of alcoholism or alcohol abuse liver disease blood pressure > 150/90"], "nct_id": "NCT00167115"},{"minimum_age": 40.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Age 40-90", "Male or female", "Type 2 diabetes"], "exclusion": ["Known pregnancy or nursing.", "Females of child bearing potential must have been surgically sterilized or be post menopausal.", "Smoking", "Known vascular disease", "Inability to complete MRI scan", "Symptoms of claudication", "Use of a nitrate medicine", "Use of any cholesterol-lowering agent", "LDL < 70", "Acute illness", "Liver disease", "Contraindication to getting an MRI scan (i.e. electronic implant, shrapnel, cerebral aneurysm clip, welding history)."], "nct_id": "NCT00770679"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Non-diabetic obese (BMI > 30) adult men and women between the ages of 18 and 75 scheduled to undergo", "gastric bypass (GBP)", "gastric banding (BND)", "Type 2 diabetes (HbA1c 6-12%) adult men and women between the ages of 18 and 75 scheduled to undergo gastric bypass.", "Type 2 diabetes (HbA1c 6-12%) adult men and women between the ages of 18 and 65 for weight reduction with a very low caloric diet (VLCD).", "Type 2 diabetes mellitus scheduled to undergo sleeve gastrectomy (SG)."], "exclusion": ["Pregnancy.", "Age > 75 for surgery groups; Age > 65 for VLCD group.", "Treatment with glucocorticoids, anti-depressants, anti-psychotics, neuroleptics, weight loss medications, experimental medication.", "Greater than a 5% change in total body weight in the 90 days prior to the study.", "History of untreated gallstones; hepatic or renal insufficiency, abnormal thyroid stimulating hormone (TSH).", "Use of thiazolidinedione therapy.", "HbA1c > 12%.", "Use of dipeptidyl peptidase IV (DPP-IV) inhibitor or glucagon-like peptide 1 receptor (GLP-1R) agonist for greater than 12 months within 3 months of the study.", "Fasting triglycerides > 400.", "Significant cardiovascular, neurologic, renal, gastrointestinal, or hematologic disease.", "Inability to comply with or understand the study protocol as ascertained by the PI.", "We will not exclude individuals with body weight > 145 kg, but we do recognize that such individuals are above the table weight limitations of the dual-energy x-ray absorptiometry (DEXA) scan and body composition data will be unavailable for those individuals."], "nct_id": "NCT00627484"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes according to the American Diabetes Association Criteria.", "Treatment with individual maximal tolerated dose of metformin (850", "2000 mg) as monotherapy within the last 12 weeks.", "Glycosylated Hemoglobin greater than or equal to 6.5% and less than or equal to 9%.", "Dyslipidemia defined as high-density lipoprotein cholesterol less than or equal to 1.03 mmol/l (40 mg/dL) and/or triglycerides greater than or equal to 1.7 mmol/l (150 mg/dL).", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."], "exclusion": ["Type 1 diabetes mellitus.", "Insulin-dependent type 2 diabetes mellitus.", "Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks.", "Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks.", "Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Heparin (and heparin-like drugs)", "coumarin", "phenprocoumon", "hirudin", "Protein C", "Fondaparinux", "antithrombin III", "Peroxisome Proliferation Activating Receptor (gamma) agonists", "Treatment within the last 12 weeks with:", "fibrates", "gemfibrozil", "niacin", "months", "Rifampicin", "Changes in dosage of any statin treatment to lower low-density lipoprotein within 2 weeks before study entry and during study participation interval.", "Changes in dosage of any anticoagulant treatment with acetyl salicylic acid and/or clopidogrel within 2 weeks before study entry and during study participation interval.", "Start of statin and/or anticoagulant treatment during study participation interval.", "History of severe or multiple allergies and/ or acute severe infections.", "Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.", "Progressive fatal disease.", "Any elective surgery during study participation.", "History of drug or alcohol abuse within the last 5 years.", "A history of significant cardiovascular (New York Heart Association stage I", "IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase and/or aspartate aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, glomerular filtration rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema.", "Blood donation within the last 30 days."], "nct_id": "NCT00770653"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["Adults over age 21 diagnosed with type 2 diabetes for at least one year."], "exclusion": ["Patients under psychiatric care", "Currently pregnant", "Those who have not been diagnosed with type 2 diabetes"], "nct_id": "NCT00109720"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["The subject has completed the full dosing period in Protocol 137-150."], "exclusion": [], "nct_id": "NCT00107107"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus Type 2", "Currently treated with at least 2 oral anti-diabetic agents"], "exclusion": ["Severe Asthma, severe COPD", "Smoking"], "nct_id": "NCT00437489"},{"minimum_age": 0.25, "maximum_age": 3.0, "gender": "A", "inclusion": ["Children less than 4 years of age with Type I diabetes for at least 3 months"], "exclusion": ["Children greater than 4 years of age", "Monogenic diabetes"], "nct_id": "NCT00875290"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients with Type 2 Diabetes Mellitus with inadequate glycemic control"], "exclusion": ["Patients with Type 1 Diabetes Mellitus"], "nct_id": "NCT00106704"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 35 to 75", "Type 2 diabetes for longer than 3 months", "HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening", "FPG (fasting plasma glucose) greater than 126 mg/dL at screening", "BMI (body mass index) less than 40 kg/square meter"], "exclusion": ["Type I diabetes", "Type 2 diabetes patients currently treated with insulin", "Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin", "FPG (fasting plasma glucose) greater than 270 mg/dL at baseline", "Impaired liver or kidney function", "Triglycerides greater than 600 mg/dL", "Uncontrolled hypertension", "Pregnant or lactating women", "Women not using adequate contraception"], "nct_id": "NCT00057304"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 35 to 75", "Type 2 diabetes for longer than 3 months", "HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening", "FPG (fasting plasma glucose) greater than 126 mg/dL at screening", "BMI (body mass index) less than 40 kg/square meter"], "exclusion": ["Type I diabetes", "Type 2 diabetes patients currently treated with insulin", "Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin", "FPG (fasting plasma glucose) greater than 270 mg/dL at baseline", "Impaired liver or kidney function", "Triglycerides greater than 600 mg/dL", "Uncontrolled hypertension", "Pregnant or lactating women", "Women not using adequate contraception"], "nct_id": "NCT00057317"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["pregnant women", "GDM A2", "diabetes mellitus type 2", "singleton pregnancy"], "exclusion": ["diabetic nephropathy or proliferative retinopathy", "cannot swallow tablets"], "nct_id": "NCT00414245"},{"minimum_age": 16.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 diabetes mellitus as defined by the 2003 CDA guidelines (16) requiring insulin therapy starting within one year of diagnosis and continuously thereafter", "Male or female, age 16-45 years, A1c 0.066-0.090", "Physically inactive (see"], "exclusion": ["below)", "Willingness and ability to work closely with the study physicians, nurse and dietitian and follow intensive diabetes therapy including carbohydrate counting, glucose monitoring \u2265 4 times per day, and intensive insulin therapy--either by multiple daily injections (MDI--insulin aspart or lispro before meals and NPH or insulin glargine 1-2X/day) or continuous subcutaneous insulin infusion (CSII) by pump therapy using insulin aspart or lispro for the duration of involvement in the study. CSII will only be an option for those already on CSII prior to entry in the study. Exclusion Criteria:", "Participation during the previous 4 months in a regular program of exercise or aerobic sports greater than 2 times per week for at least 20 minutes per session, or in any resistance training.", "Hypoglycemia unawareness, or severe hypoglycemia requiring assistance from another person within the previous 3 months.", "\"Brittle\" diabetes, characterized by frequent and unpredictable hypoglycemia (even if not requiring assistance from others) and hyperglycemia.", "Restrictions in physical activity due to disease: intermittent claudication, severe peripheral neuropathy or active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis.", "Known or suspected clinically significant gastroparesis.", "Body mass index less than or equal to 32 kg/m2.", "Fasting serum c-peptide less than 0.2 nmol/l.", "Recent significant weight change (increase or decrease of 5% of body weight during the two months before enrollment).", "An expected requirement within the subsequent 6 months for medications (other than insulin) that will affect glucose metabolism (e.g. corticosteroids).", "If age < 18 yr, linear growth of 1cm during the previous year.", "Significant renal disease: serum creatinine greater than 200 mEq/l. or proteinuria > 1 g/24 hours.", "Uncontrolled hypertension: BP > 150 mm Hg systolic or > 95 mm Hg diastolic in a sitting position.", "Other illness, judged by the patient or investigators to make participation in this study inadvisable.", "Cognitive deficit resulting in inability to understand or comply with instructions.", "Pregnancy at the start of the study, or intention to become pregnant in the next year.", "Inability to communicate in English or French.", "Unwillingness to sign informed consent."], "nct_id": "NCT00148538"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents."], "exclusion": ["Patients that have not participated in the VADT."], "nct_id": "NCT00256607"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Any patient with type 2 diabetes", "Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)", "Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient"], "exclusion": ["Known or suspected allergy to study product(s) or related products.", "Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months"], "nct_id": "NCT00735501"},{"minimum_age": 12.0, "maximum_age": 18.0, "gender": "M", "inclusion": ["Healthy overweight (BMI >-95th) youth between 12 and 18 years of age", "Waist circumference >-75th percentile", "Sedentary (no structured exercise >2 times/week for past 6 months)", "Non-smokers, non-diabetic, no medical conditions", "Weight stable for past 3 months"], "exclusion": ["Smokers,", "diabetic,", "psychiatric disorders,", "syndromatic obesity"], "nct_id": "NCT00739180"},{"minimum_age": 20.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy", "7.0 % =< HbA1c < 10.0 %", "Body Mass Index (BMI) < 30.0 kg/m^2"], "exclusion": ["Subjects treated with thiazolidinediones or insulin", "Subjects with any serious medical conditions"], "nct_id": "NCT00154414"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["patients in stable clinical conditions after coronary revascularization (CABG and percutaneous angioplasty with/without stent implantation).", "Age > 30 years, male and female.", "Fasting glucose levels below 126 mg/dl."], "exclusion": ["Type 1 diabetes mellitus,", "known type 2 diabetes mellitus,", "pregnancy,", "impaired kidney and liver function,", "severe and not treated arterial hypertension."], "nct_id": "NCT00408577"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Subjects with a documented diagnosis of T2DM and have an HbA1c level at Visit 1 of \u22657.0% and \u22649.5% as measured by a central laboratory. Subjects with HbA1c <7.5% must have a fasting fingerstick glucose \u22657 mmol/L (126 mg/dL) at Week 0 prior to randomization.", "Subjects who are treatment-na\u00efve and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for \u22654 weeks at any time in the past, or Subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks", "Subjects who are 18 to 70 years of age inclusive at the time of Screening.", "Females of non-childbearing and childbearing potential are eligible to participate as follows:", "Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.", "Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries and who have a current documented tubal ligation [Hatcher, 2004] bilateral oophorectomy or total hysterectomy, or females who are post-menopausal). (Post-menopausal is defined as after one year without menses with an appropriate clinical profile, e.g. age appropriate, >45 years, in the absence of hormone replacement therapy. In addition to the above criteria, if the post-menopausal status is still questionable, a blood sample should be drawn for simultaneous measurement of follicle stimulating hormone and estradiol; values considered to confirm the post-menopausal state are respectively: FSH >40 MIU/mL and estradiol <40pg/mL (<140 pmol/L)).", "Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed."], "exclusion": ["Metabolic Disease", "Diagnosis of Type 1 diabetes mellitus.", "History of ketoacidosis which has required hospitalization.", "Thyroid disorder [TSH below the lower limit of the reference range (LLRR) of 0.4mIU/L or above the upper limit of the reference range (ULRR) of >5.5 mIU/L at Screening]. Hypothyroidism treated with the same dose and regimen of thyroid hormone replacement for at least 3 months prior to Screening is allowed.", "BMI of <22 or >43 kg/m2.", "Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening.", "Diabetic Medication", "Has taken insulin or any oral or injectable anti-diabetic medication \u22654 weeks at any time prior to screening.", "Has taken insulin or any oral or injectable anti-diabetic medication within 3 months of screening.", "Cardiovascular Disease", "Recent history or presence of clinically significant acute cardiovascular disease including:", "Documented myocardial infarction in the 6 months prior to Screening.", "Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.", "Unstable angina in the 6 months prior to Screening.", "Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.", "Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment. NYHA Class I may be included in accordance with the local prescribing information for pioglitazone.", "Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.", "Has a QTc interval (Bazett's) \u2265450msec at Screening on a single ECG or an average value from 3 ECGs taken 5 minutes apart (on local reading of ECG).", "Other clinically significant ECG abnormalities which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.", "Fasting triglycerides \u2265400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.", "Hepatic Disease Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including: Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.", "alanine transaminase (ALT).", "aspartate transaminase (AST).", "alkaline phosphatase (AP). Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.", "Pancreatic Disease", "Secondary causes of diabetes:", "history of chronic or acute pancreatitis", "Renal Disease", "Significant renal disease at Screening as manifested by: Glomerular filtration rate (GFR) <60mL/min (as estimated from serum creatinine at Visit 1 and demographic data using the MDRD equation).For the MDRD equation, please refer to the study procedures manual. Proteinuria of \u22651+ by urinary dipstick", "Recurrent genitourinary tract infections defined as \u22652 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening", "A positive qualitative urinary dipstick for leukocytes, red blood cells (RBC) or nitrites at Screening.", "Concurrent Disease", "Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), electrocardiogram, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity", "History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.)", "Has a history of malignancy within the past five years [other than superficial squamous cell carcinoma which is non-invasive on pathology or basal cell carcinoma which is successfully treated with local excision] and cervical cancer in situ treated definitively at least 6 months prior to Screening", "Concurrent Medication", "Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:", "Digoxin", "Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)", "Bile acid sequestrants", "Niacin (excluding routine vitamin supplementation)", "Antiobesity agents (including fat absorption blocking agents)", "Oral or injectable corticosteroids (inhaled and intranasal corticosteroids are permitted)", "Loop diuretics", "Monoamine oxidase inhibitors and tricyclic amines", "Antiretroviral drugs 10. St John's Wort 11. Oral chromium", "Pregnancy & Breast Feeding", "Is currently lactating or pregnant", "Other", "Current smoker who is unable to abstain from smoking while in the clinic at each visit", "Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:", "Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.", "Has an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine", "Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening", "In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent", "Known allergy to any of the tablet excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician"], "nct_id": "NCT00500331"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["adult patients, 18-65 years of age", "females who are either surgically sterile or post-menopausal", "type 2 diabetes treated with a stable dose of metformin", "BMI between 25-39kg/m2", "HbA1c between 7 and 10%", "fasting plasma glucose between 7 and 13.3mmol/L"], "exclusion": ["history of clinically significant cardiovascular disease", "history of clinically significant hepatic or renal disease or impairment", "recent therapy with insulin, thiazolidinedione, glucagon-like peptide-1 analogues, amylin analogues and/or DPP-IV inhibitors"], "nct_id": "NCT00961909"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Males or females between the ages of 18 and 75 years admitted to a general medicine or surgical services.", "A known history of type 2 diabetes mellitus > 3 months, receiving either diet alone, oral monotherapy, or with any combination of oral antidiabetic agents (sulfonylureas, meglitinides, metformin, thiazolidinediones, dipeptidyl peptidase (DPP) IV inhibitors).", "Patients admitted for non-cardiac elective or emergency surgery or trauma.", "Subjects must have an admission BG > 140 mg and < 400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate < 18 milliequivalent /L, potential hydrogen (pH) < 7.30, or positive serum or urinary ketones)."], "exclusion": ["Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).", "Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria [32].", "Patients with acute critical or surgical illness admitted to the ICU or expected to require admission to the ICU.", "Patients admitted for coronary artery bypass graft (CABG) or patients receiving continuous insulin infusion.", "Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine \u2265 3.0 mg/dl).", "Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.", "Female subjects are pregnant or breast feeding at time of enrollment into the study.", "Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.", "Female subjects are pregnant or breast feeding at time of enrollment into the study."], "nct_id": "NCT00979628"},{"minimum_age": 20.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Established diagnosis of type 2 diabetes mellitus", "Fasting serum C-peptide level > 0.6 ng/mL", "HbA1c between 7.0 and 10.0%", "Body Mass Index between 20 and 45 kg/m2"], "exclusion": ["Serum creatinine > upper limit of normal", "Proteinuria (albumin/creatinine ratio > 300 mg/g)", "Dysuria and/or urinary tract infection", "Significant renal, hepatic or cardiovascular diseases", "Ketosis", "Hypertension", "Severe gastrointestinal diseases"], "nct_id": "NCT00621868"},{"minimum_age": 21.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["diagnosed with type 2 diabetes mellitus", "21 to 65 years of age", "on stable doses of insulin (>/= 40 units/day) alone or with metformin for at least 3 months", "HbA1c level of >/=7.5% but </=10.0%", "fasting blood sugar level >/= 125 mg/dL but </= 279 mg/dL", "BMI 26-43 kg/m2", "direct bilirubin < 1.5x the upper limit of normal (ULN)", "serum creatinine < 1.5 mg/dL (males) or < 1.4 mg/dL (females)", "blood urea nitrogen (BUN)</=40 mg/dL", "all other clinical laboratory parameters (hematology, serum chemistry, and urinalysis) within normal limits or not clinically significant", "ECG normal, or abnormalities not clinically significant", "surgically sterile,postmenopausal,or using adequate contraception and have a negative pregnancy test at Screening", "able to perform daily self-monitoring of blood glucose (SMBG) tests", "willing and able to sign an informed consent form"], "exclusion": ["diagnosed with type 1 diabetes mellitus or has a history of ketoacidosis", "treatment with TZDs or any other oral antidiabetic (excluding metformin) within 3 months prior to screening or during study treatment", "change in lipid-lowering medication within 2 months of screening", "taken systemic corticosteroids within 1 month prior to screening or during study treatment", "history of or current/active cardiovascular disease", "significant current pulmonary conditions", "significant thyroid disease", "CPK value > 3x ULN", "a female who is pregnant or lactating", "systolic BP > 160 mm Hg or a diastolic BP > 90 mm Hg at screening", "previous or current history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to randomization", "liver function tests (ALT, AST, ALP) > 2 times ULN, or active liver disease at screening", "history of positive HIV", "positive hepatitis B test at screening", "weight loss or gain >/= 15 lbs within 3 months of screening", "history of substance abuse (including alcohol abuse) within 2 years prior to screening", "donated and/or received any blood or blood products within 3 months prior to randomization", "taken an investigational study medication within 30 days prior to screening or during the study"], "nct_id": "NCT00110864"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Subject na\u00efve to treatment", "HbA1c > 8.5 up to 11 %", "Lipid lowering therapy, antihypertensive, hormonal substitutes, thyroid hormone substitutes, and contraceptives are allowed as long as they are kept at a stable dosing"], "exclusion": ["Treatment with any oral antidiabetics or insulin", "Known type 1 Diabetes Mellitus", "Pregnant or breast feeding women", "Ketoacidosis history", "History of sensitivity to any of the active substances", "Renal dysfunction : serum creatinine > or = 1.5 mg/dL in male subjects > or = 1.4 mg/dL in female subjects", "Liver impairment (ALT, AST > 3-fold the upper limit of normal range)", "Systemic corticosteroid treatment 3 months prior to study or during the study", "Drug or alcohol abuse history", "Patients with history of acute coronary syndrome, cerebrovascular events/transient ischaemic attack in the last three months", "Presence of any condition (medical, psychological, social or geographic) current or previously seen that according to Investigators judgment jeopardizes the safety or restricts the participation of the patient during the study", "Neoplasias The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00957060"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes without microvascular or macrovascular complications treated with diet or up to 2 oral agents"], "exclusion": [], "nct_id": "NCT00952991"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["1) Type 2 diabetic patients with medium or moderate risk for complications (stratified by JADE Program, Care Levels 2 to 4) and followed up 3-4 monthly according to the JADE Program. Based on our 6000-patient registry, these risk levels clearly separate diabetes patients based on risk of future clinical events.", "2) Men/women aged 18-70 years (inclusive), functionally independent and with informed written consent."], "exclusion": ["1) Patients with one or no risk factors (low risk, Care Level 1 by JADE Program) as stratified by the JADE Risk Engine. 2) Patients with reduced life expectancy and unstable mood or major psychiatric conditions. 3) Patients who cannot communicate in Chinese language."], "nct_id": "NCT00950716"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 Diabetes for more than 12 months", "Currently treated with glucose lowering tablets or insulin", "HbA1c: 7.0-12.0%"], "exclusion": [], "nct_id": "NCT00106366"},{"minimum_age": 55.0, "maximum_age": 75.0, "gender": "F", "inclusion": ["Postmenopausal female, 55-75 years old", "History of Type II diabetes, as defined by the American Diabetes Association for more than 5 years that is either insulin requiring or treated with oral therapies such as sulfonylureas and metformin", "Body mass index (BMI) of 19-35", "Able to move without walkers and without a history of long periods (>3 months) of inactivity", "Additional Inclusion criteria for fracture participants:", "Fractures of the proximal humerus and femur as well as the ankle and foot should have occurred after the onset of diabetes and should have been caused by a low energy trauma such as falling from standing height. All fractures will be verified by radiographs."], "exclusion": ["Severe neuropathic disease such as neurogenic osteoarthropathies (i.e., Charcot joints) of the foot", "Steroid users or have disease conditions that could play a significant role in the development of osteoporosis such as idiopathic osteoporosis, immobilization, hyperparathyroidism, or hyperthyroidism", "Diseases that may affect bone metabolism: alcoholism, chronic drug use, chronic gastrointestinal disease, renal or hepatic impairment", "Chronic treatment with antacids, estrogen, adrenal or anabolic steroids, anticonvulsants, anticoagulants, or pharmacologic doses of Vitamin A supplements 6 months prior", "Diabetic patients on rosiglitazone or pioglitazone medications", "high energy trauma, e.g., due to motor vehicle accidents", "Pathological fractures of other origin, i.e., tumor, tumor-like lesions as well as focal demineralization visualized on radiographs", "History of fluoride, bisphosphonate, calcitonin or tamoxifen use", "History of unstable cardiovascular disease or uncontrolled hypertension", "MRI contraindications", "Body mass index greater than 35"], "nct_id": "NCT00703417"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male or female adult, aged 18 to 70 years", "Type 1 diabetes mellitus as established by medical history", "Current treatment with MDI or CSII therapy for at least 3 months prior to screening visit; and using the same insulin during the last 1 month", "HbA1c \u2265 8.5%", "Subjects should routinely practice at least 2-4 blood glucose measurements per day", "BMI \u2264 35 kg/m2", "Subject must be able and willing to perform self-blood glucose monitoring and accept wearing a continuous glucose monitor for the total duration of the study", "Willing to complete a routine medical visits every 3 months", "Willing to complete a total of 7 phone visits", "Able to speak, read, and write English"], "exclusion": ["On oral, inhaled or pre-mixed insulin", "On Symlin", "BMI > 35 kg/m2", "Pregnant or intends to become pregnant during the course of the study", "Severe unexplained hypoglycemia that required emergency treatment over the past 3 months", "History of hemoglobinopathies", "Diagnosis of anemia", "HbA1C greater than 12%", "Post-renal transplantation, currently undergoing dialysis, creatinine of >1.5mg/dl or a calculated creatinine clearance of <50 mL/min.", "Have extensive skin changes/diseases that inhibit wearing the sensor on normal skin", "Subjects who have a medical known allergy to adhesives", "Subjects who have an allergy to medication being used", "Currently participation in another investigational study protocol. Must have completed a previous study at least 30 days prior to being enrolled in this one", "Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial."], "nct_id": "NCT00978796"},{"minimum_age": 18.0, "maximum_age": 69.0, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes mellitus, according to the American Diabetes Association diagnostic criteria, \u2265 3 months at time of randomization", "HbA1c in the range of 6.5", "9.5% (inclusive) at screening", "Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 4 weeks prior to randomization", "Further criteria as defined in the clinical trial protocol"], "exclusion": ["Symptoms of hyperglycemia (i.e. polyuria and polydypsia)", "History of significant weight gain or loss (+/-5%) during the 4 weeks before randomization", "Fasting C-peptide level < 400 pmol/L at screening", "Change in the medicamentous treatment of elevated blood pressure, diabetes mellitus or dyslipidemia within 4 weeks prior to the randomization", "Use of any weight loss medication (over the counter prescription) or initiation of a prescribed weight management or exercise program within 4 weeks before randomization", "Current systemic anti-inflammatory therapy other than aspirin \u2264 100 mg/day or immunosuppressive treatment, in particular oral corticosteroids"], "nct_id": "NCT00924105"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, diagnosed at least 3 months prior to Screening (Visit 1)", "BMI 20 to 48 kg/m2, inclusive", "HbA1c 7.0%", "10.0%, inclusive", "Age 18 to 85 years, inclusive"], "exclusion": ["Currently taking more than one oral hypoglycemic agent", "Type 1 diabetes mellitus"], "nct_id": "NCT00970424"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["diabetes mellitus"], "exclusion": ["myocardial infarction", "acute ischemic syndromes", "second or third degree atrioventricular block", "active alcoholism", "thyroid dysfunction", "chronic obstructive pulmonary disease", "history of intolerance to pyridostigmine."], "nct_id": "NCT00953914"},{"minimum_age": 50.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Diagnosed type 2 diabetes", "Age: 50-79 years old", "LDL-cholesterol more than 2.9 mmol/l"], "exclusion": ["Current or previous (within 6 months) use of estrogen therapy", "Cancer", "Chronic gastrointestinal diseases", "Current use of antibiotics", "Any severe liver or renal diseases", "Systolic blood pressure more than 180 mmHg or phase 3 hypertension", "Any severe mental diseases", "Severe cardio- or cerebro-vascular diseases"], "nct_id": "NCT00363233"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus on diet and exercise therapy"], "exclusion": ["Patients with type 1 diabetes mellitus"], "nct_id": "NCT00363844"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes mellitus", "LDL-C > 130 mg/dL"], "exclusion": ["Insulin therapy", "Clinically relevant organ disease (creatininemia >2mg/dL, CHF NYHA III and IV)"], "nct_id": "NCT00141141"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Has type 2 diabetes mellitus", "Has moderate or severe renal insufficiency"], "exclusion": ["Has type 1 diabetes mellitus or a history of ketoacidosis", "Is on a new weight loss program", "Has active liver disease", "Is on dialysis or is likely to need dialysis during the study"], "nct_id": "NCT00509262"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Have Type 2 Diabetes Mellitus", "18 to 65 years of age"], "exclusion": ["History of Type 1 Diabetes or ketoacidosis", "Have been treated with lipid lowering medications 4 weeks before starting the study", "Have started on a weight loss program and not in the maintenance phase or have started weight loss medication within the last 12 weeks", "Have had surgery in the last 30 days", "History of active liver disease", "History of coronary heart disease or congestive heart failure", "Have had a stroke or transient ischemic neurological disorder in the past 6 months", "Are Human Immunodeficiency Virus (HIV) Positive"], "nct_id": "NCT00846391"},{"minimum_age": 19.0, "maximum_age": null, "gender": "A", "inclusion": ["Sedentary adults diagnosed by a physician with Type 1 diabetes or Type 2 diabetes. Sedentary adults are defined as persons 19 years of age and older that are not meeting the minimal physical activity recommendations from the U.S. Surgeon General's report."], "exclusion": ["Adults with:", "severe cardiovascular disease (high blood pressure, abnormal heart rhythm, peripheral artery disease, atherosclerosis, congestive heart failure, congenital heart disease, valvular heart disease and coronary artery disease)", "amputees", "severe foot ulcers", "severe neuropathy", "an amplified susceptibility to hypoglycemia", "those weighing 400 lbs. or more, or inability to adequately perform exercise"], "nct_id": "NCT00954694"},{"minimum_age": 50.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Age 50 ~ 75 years", "Duration of diabetes: more than 5 years", "More than two of the following risk factors in addition to diabetes: 1)dyslipidemia, 2)hypertension, 3)smoking, 4)family history of premature coronary artery disease"], "exclusion": ["Angina pectoris or anginal equivalent symptoms", "Insulin pump user or history of ketoacidosis", "History of myocardial infarction, heart failure, or coronary revascularization", "Electrocardiographic evidence of Q-wave myocardial infarction, ischemic ST- segment or T-wave changes, or complete left bundle branch block", "Uncontrolled arrythmia", "Hypersensitivity to contrast dye", "Renal failure"], "nct_id": "NCT00431717"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Diagnosis of Type 2 Diabetes Mellitus.", "Has glycosylated hemoglobin levels between 6.0% and 8.0%.", "Treatment with metformin (2,000 to 3,000 mg daily) for at least 3 months.", "Has reduced high-density lipoprotein cholesterol levels less than 40 mg/dl in males and less than 50 mg/dl in females, irrespective of treatment with statins.", "Has central obesity defined as a waist circumference greater than or equal to 94 cm for men and greater than or equal to 80 cm for females.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."], "exclusion": ["Has a diagnosis of Type 1 Diabetes Mellitus.", "Required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "other oral antidiabetic drugs than metformin or with insulin in the 3 months preceding study entry.", "Fibrates", "Rifampicin", "Has any disease with malabsorption.", "Has acute or chronic pancreatitis.", "Has familial polyposis coli.", "Has a medical history of myocardial infarction, transient ischemic attacks or stroke in the past 6 months.", "Has heart failure as defined by the New York Heart Association classification I-IV.", "Has significant liver impairment, with an alanine aminotransferase level greater than 2.5 the upper limit of normal range.", "Has significant renal impairment, with a serum creatinine level greater than 1.5 mg/dl for men and greater than 1.2 mg/dl for women.", "Has anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other hematologic disease.", "Has a diagnosis or suspicion of neoplastic disease.", "History of chronic alcohol or drug abuse.", "Known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients.", "Participation in another trial in the 3 months preceding study entry."], "nct_id": "NCT00772174"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": [": Healthy Subjects", "Healthy male or female subject as determined by a responsible physician, based on a medical evaluation including history, physical examination, vitals signs, laboratory tests, and cardiac monitoring.", "Female subjects must be of non-childbearing potential including pre-menopausal women with documented (medical report verification) hysterectomy, tubal ligation, or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.", "18", "60 years of age, inclusive, at the time of signing and dating the informed consent.", "BMI (body mass index) within the range 20-30 kg/m2, inclusive.", "Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Diabetic Subjects", "Male or female subjects, 18", "60 years of age, inclusive, at the time of signing the informed consent", "Female subjects must be of non-childbearing potential including pre-menopausal women with documented (medical report verification) hysterectomy, tubal ligation, or double oophorectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.", "Subjects should have no significant known medical conditions other than T2DM.", "BMI (body mass index) within the range 25-35 kg/m2, inclusive.", "T2DM diagnosed at least 3 months prior to Screening with", "Fasting plasma glucose (FPG) level \u2264 220mg/dL at the Screening visit,", "FPG level \u2264 250 mg/dL on Day -1 of Period 1", "For subjects taking no antidiabetic medications: HbA1c between 7 and 10%, inclusive, at Screening visit", "For subjects taking metformin or a sulfonylurea: HbA1c between 6.5 and 9.5%, inclusive, at Screening visit", "Subjects must be taking either no anti-diabetic medication, or metformin as monotherapy, or a sulfonylurea as monotherapy. (Subjects taking BOTH metformin and a sulfonylurea are not qualified for the trial). If taking metformin or a sulfonylurea, the dose must have been stable for at least 3 months prior to screening, and the subject must be willing to wash out from metformin or sulfonylureas from Day -7 prior to Period 1, through discharge from Period 4.", "Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form."], "exclusion": ["As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.", "Has any of the following laboratory abnormalities:", "Positive pre-study Hepatitis B surface antigen, positive Hepatitis C, or HIV result.", "History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by TSH at Screening", "A positive pre-study drug/urine screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.", "A pre-study urine cotinine screen indicating use of tobacco/ nicotine containing products.", "Has a history of any gastrointestinal or hepatic conditions that could impact absorption of the investigational compound.", "Has QTc at Screening > 450 msec. Note that if the initial QTc value is prolonged, the ECG should be repeated two more times (with 5 minutes between ECG readings) and the average of the 3 QTc values used to determine eligibility.", "Has clinically significant rhythm abnormalities identified during 24-hour Screening Holter assessment.", "History of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men. One drink is equivalent to 12 g alcohol (which equals 5 ounces (150 mL) of wine, 12 ounces (360 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.", "Smoked or used tobacco or nicotine-containing products within the previous 6 months.", "Has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.", "Exposure to more than four new chemical entities within 12 months prior to the first dosing day.", "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Acetaminophen may be used as needed for adverse events; however, use should be restricted to 4 hours after dosing if possible with a preferred maximum dose of 2 grams in 24 hours.", "Unwilling to abstain from", "Caffeine-or xanthine-containing products for 24 hours prior to dosing until the final post-dose assessment at each treatment level.", "Use of illicit drugs", "Alcohol for 24 hours prior to dosing until final post-dose assessment at each treatment level.", "Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until collection of the final pharmacokinetic and pharmacodynamic blood samples.", "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. This includes sensitivity to heparin, if heparin will be used to maintain catheter patency.", "Where participation in the study would result in donation of blood in excess of 500 mL within a 56 day period.", "Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study. Healthy Subjects", "As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.", "Has any of the following laboratory abnormalities:", "Positive pre-study Hepatitis B surface antigen, positive Hepatitis C, or HIV result.", "History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by TSH at Screening. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 3 months prior to Screening and who have a screening thyroid stimulating hormone (TSH) within the normal range may participate.)", "ALT and/or AST > 2 times the upper limit of normal at screening or prior to the first dose.", "Fasting triglycerides > 450mg/dL at screening or prior to the first dose.", "Total Bilirubin > 1.5 times the upper limit of normal at screening or prior to the first dose", "A positive pre-study drug/urine screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.", "A pre-study urine cotinine screen indicating use of tobacco/ nicotine containing products.", "Significant renal disease or loss of a kidney", "Significant ECG abnormalities,", "Systolic pressure > 150 mmHg or <80 mmHg or diastolic blood pressure > 95 mmHg or <60 mmHg at screening. Blood pressure assessments may be repeated once if needed, allowing adequate time for subject to rest.", "Previous use of insulin as a treatment within 3 months of Screening, or for >2 weeks when used for acute illness in the last 12 months prior to Screening, or if used for more than 1 year when associated with GDM.", "Has a history of any of the following conditions:", "Clinically significant symptoms of gastroparesis", "Cholelithiasis or obstructive or inflammatory gallbladder disease within 3 months prior to Screening", "Gastrointestinal disease that could affect fat or bile acid absorption, including inflammatory bowel disease, chronic diarrhea, Crohn's or malabsorption syndromes within the past year", "Gastrointestinal surgery", "Chronic or acute pancreatitis", "History of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men. 1 drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.", "Smoked or used tobacco or nicotine-containing products within the previous 6 months.", "Has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.", "Exposure to more than four new chemical entities within 12 months prior to the first dosing day.", "Is taking prohibited medications:", "Acetaminophen may be used as needed for adverse events; however, use should be restricted to 4 hours after dosing if possible with a preferred maximum dose of 2 grams in 24 hours.", "The use of anti-diabetic agents other than metformin or sulfonylureas is reason for exclusion and subjects will not be allowed to wash off of unapproved anti-diabetic medications in order to qualify for participation in this study. Subjects taking BOTH metformin and a sulfonylurea are not qualified for the trial.", "Subjects must wash out from the following medications during the 7-day period prior to first dose, and must remain off these medications through discharge from period 4: metformin, sulfonylureas, statins, fat absorption blocking agents, bile acid sequestrants", "All other prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and through discharge from Period 4.", "Unwilling to abstain from", "Caffeine-or xanthine-containing products for 24 hours prior to dosing until the final post-dose assessment at each treatment level", "Use of illicit drugs", "Alcohol for 24 hours prior to dosing until final post-dose assessment at each treatment level", "Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until collection of the final pharmacokinetic and pharmacokinetic blood samples", "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. This includes sensitivity to heparin, if heparin will be used to maintain catheter patency.", "Where participation in the study would result in donation of blood in excess of 500 mL within a 56 day period.", "Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study."], "nct_id": "NCT00607906"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Healthy, nonsmoking adults, aged 30-75 years (women must be post-menopausal)", "Diagnosed with Type 2 diabetes"], "exclusion": ["Insulin, more than one blood pressure lowering medication, daily aspirin, NSAID therapy, oral steroids within the last 6 weeks, oral contraceptives, and hormone replacement therapy", "Chronic disease such as cardiovascular disease or any complications of diabetes (retinopathy, neuropathy, etc).", "Allergies or aversions to pistachios", "Unwillingness to consume all foods provided and no other meals or snacks for the 10 weeks of diet intervention"], "nct_id": "NCT00956735"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any patient with type 1 and type 2 diabetes who are treated with NovoMix\u00ae 30", "Patient who signed on informed consent form"], "exclusion": ["Patients who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit", "Patients who were previously enrolled in this study", "Patients with a hypersensitivity to NovoMix\u00ae 30 or to any of the excipients", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months"], "nct_id": "NCT00737776"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "HbA1c over 7%", "No contraindication with NovoMix\u00ae 70"], "exclusion": ["Type 1 diabetes", "Subjects participating in a clinical trial or another observational study", "Subjects under previous basis-bolus insulin therapy", "Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method"], "nct_id": "NCT00704223"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["age 18-70 years", "type 2 diabetes mellitus", "with or without hypertension"], "exclusion": ["ischemic changes on resting electrocardiogram,", "clinical evidence of heart disease (angina, heart failure, unstable angina),cerebrovascular or peripheral vascular disease,", "significant cardiac arrhythmias,", "aortic stenosis,", "2nd or 3rd degree atrio-ventricular block, sinus node disease, or symptomatic bradycardia,", "bronchospastic lung disease with active wheezing,", "known hypersensitivity to adenosine,", "hemoglobin A1C (HbA1c) > 8.5%, *", "gout (If not already taking HCTZ),", "the use of Rosiglitazone,**", "estimated glomerular filtration rate (eGFR) < 60 ml/min,", "serum potassium > 5.0 mmol/L,", "use of potassium-sparing diuretics,**", "current smoker,*", "pregnancy,", "renal disease not related to diabetes mellitus,", "uncontrolled hypertension, systolic blood pressure (BP) >160 mm Hg and diastolic BP >100 mm Hg,*", "use of cyclic hormone replacement therapy", "past intolerance of angiotensin-converting enzyme (ACE) inhibitor therapy", "other major medical illnesses. Participants with evidence of a previous myocardial infarction on the first adenosine-stimulated positron emission tomography (PET) study will be withdrawn from the study.", "Screening systolic blood pressure < 105 mm Hg off of anti-hypertensive medications", "Participants can enroll in study and proceed with in-patient evaluations if during the run-in period adjustments of medications, diet and habits lead to improved glucose control [equivalent to HbA1c <8.5%, controlled hypertension and cessation of smoking.", "Participants who are currently taking these medications will not qualify for a screening visit. If medications were recently stopped by the participant's physician, he or she may be screened but the baseline assessment protocol must occur 3 months after stopping."], "nct_id": "NCT00865124"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "M", "inclusion": ["Healthy men aged between 18 and 40 years", "Lean subjects BMI 18.5-25 kg/m2 and overweight/obese subjects BMI >27 kg/m2 (including 18.5, 25 and 27)", "Alcohol consumption between 7 and 28 units/week (including 7 and 28)"], "exclusion": ["Smoking", "Family history of alcoholism", "History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders", "Recent blood donation", "More than 8 hours/week of intense exercise", "Blood haemoglobin concentration below 8.4 mmol/l", "Allergic to betadine or lidocaine."], "nct_id": "NCT00364767"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["diagnosed with type 1 or type 2 diabetes", "taking oral and/or insulin for diabetes control", "endocrinologist must assess and approve pt for participation in study", "ability to swallow without difficulty", "ability to meet weekly time and testing requirements for this study"], "exclusion": ["inability to do testing required for study including regular scheduled visits for independent review of non healing wound including assessment, pictures and measurements", "lack of intravenous access", "alcohol abuse, drug addiction or the use of illegal drugs", "positive HIV", "active liver disease", "in active treatment for cancer including radiation or chemotherapy", "inability to breathe into machine for respiratory quotients to monitor progress"], "nct_id": "NCT00967837"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Male or female aged 18", "55 years with type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included.", "Duration of diabetes for > 1 year and < 20 years with stable diabetic therapy within last 6 months.", "Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85 mmHg and with retinal photograph grading level > 20/10 up to < 47/47 (on ETDRS severity scale)."], "exclusion": ["Patients with the following conditions are excluded from participation on the study:", "Cataract or media opacity of a degree which precludes taking gradable retinal photographs", "Angle closure glaucoma, which precludes pharmacological dilatation of the pupil", "History or presence of proliferative retinopathy", "History or presence of clinical significant macular oedema (CSME)", "History or evidence of photocoagulation of the retina", "Other retinal conditions which may mask assessment, eg, retinal vein occlusion", "Positive micral dipstick test", "Presence of secondary diabetes", "Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception", "Need of treatment with ACE-inhibitor", "Haemodynamically significant aortic or mitral valve stenosis", "Known renal artery stenosis or kidney transplantation", "Hypersensitivity to study drug", "Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator"], "nct_id": "NCT00252720"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Participant has type 2 diabetes mellitus", "Males", "Females who are highly unlikely to become pregnant", "Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications"], "exclusion": ["Participant has a history of type 1 diabetes mellitus or history of ketoacidosis", "Participant required insulin therapy within the prior 8 weeks", "Participant is on or has been taking TZDs such as Actos\u00ae (pioglitazone) or Avandia\u00ae (rosiglitazone) within the prior 12 weeks of the screening visit"], "nct_id": "NCT00704132"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["Patient is highly unlikely to conceive", "Patient meets one of the 3 categories is na\u00efve to all antihyperglycemic agent (AHA) therapies, or is non-na\u00efve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c >=7.5 % and =<11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c >=7.0 % and =<9.0 %"], "exclusion": ["Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =<0.8 ng/mL", "Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic", "Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks", "Patient has undergone surgery within the prior 30 days or has major surgery planned during the study", "Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis", "Patient has received treatment with an investigational product within 12 weeks prior to Visit 1"], "nct_id": "NCT00722371"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Subject has a BMI < 42 kg/m2", "Subject is taking >1500 mg metformin per day for at least 8 weeks", "Subject has HbA1c value of 7.0% and < 11% at screening", "Subject is willing to follow AHA weight maintaining diet and exercise program", "Subject is a nonsmoker for at least 6 months"], "exclusion": ["Subject has type 1 diabetes", "Subject has a history of stroke or chronic seizure", "Subject has a history of neoplastic disease", "Subject has a history of gastrointestinal, cardiovascular, blood, liver kidney, respiratory, immunological or genitourinary disorders or diseases", "Subject is currently taking 2 or more diabetes medications", "Subject has glaucoma or is blind", "If female, subject is pregnant or breastfeeding", "Subject consumes > 3 alcoholic beverages per day", "Subject has had major surgery or has donated blood in the last 4 weeks"], "nct_id": "NCT00873821"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male and female subjects with type 2 diabetes mellitus on diet and exercise with/without metformin", "HbA1c>=6,0 % and <=8,5 % at screening", "BMI 25 to 35 kg/m\u00b2", "155>=BP systolic >=90 mmHg", "100>=BP diastolic>=45 mmHg The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "exclusion": [], "nct_id": "NCT00931372"},{"minimum_age": 13.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Subjects with type 1 diabetes confirmed by C peptide measurements.", "Male and Female subjects of all races will be included in this study.", "Subjects age must be between 13 to 50 years", "Duration of the disease (from time of diagnosis of diabetes) must be between 5 to 28 years.", "Subjects must be normotensive defined as a systolic blood pressure of \u2264 130 mmHg and diastolic of \u2264 85 mmHg in subjects 18 and older and for children (ages 13-17) blood pressure will be in the normal range based on standard tables which takes in to account gender, height and age.", "The mean 24 blood pressure must meet the same criteria as the office blood pressures outlined above.", "Subject must have normoalbuminuria (UAE < 30 mg/24 hrs)", "If subject is a female she must not be breast-feeding, and not of child-bearing potential, defined as post-menopausal for at least 1 year or surgically sterile; if she is of child bearing potential, then she must be practicing one of the following methods of birth control: 1) condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), 2) contraceptives (oral or parenteral) initiated three months prior to study drug administration, 3) maintain a monogamous relationship with a vasectomized partner, or 4) total abstinence from sexual intercourse."], "exclusion": ["Type 2 diabetics and other types of diabetics such as those with maturity onset diabetes or the young (MODY) will be excluded on the basis of established clinical criteria.", "Subjects who have a history of hypertension or is taking any hypertensive medications.", "Females who are pregnant or express a desire to become pregnant during the study. Females who are breast-feeding. Refer to details in inclusion criteria above regarding females.", "Subjects who have a history of taking ACE inhibitors within the last six months or have a current indication for ACE inhibitor therapy.", "Subjects (18 years of age and over) with a current blood pressure above 130mmHg/85mmHg. Subjects (13-17 years of age) who do not meet the normal range based on the standard tables", "Subjects who are currently microalbuminuric i.e. 24hr albumin > 30mg", "Subjects who have participated in an interventional clinical trial involving ABPM 6 months prior to this study.", "Subjects that have a diagnosis of chronic atrial fibrillation.", "Subjects with a lifestyle that would disrupt normal circadian rhythm (i.e. night-shift workers).", "Subjects with a current serious co-morbid condition for which life expectancy is <2 years.", "Subjects with a history of non-compliance, or psychiatric disturbance that would preclude successful completion of the study.", "Inability to give informed consent."], "nct_id": "NCT00729365"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Informed oral and written consent", "Caucasians aged > 18 years diagnosed with T2DM due to WHO criteria.", "Normal haemoglobin", "HbA1c 6-10%", "BMI 23-35 kg/m2"], "exclusion": ["Hepatic disease, ALAT > 2 x normal.", "Diabetic nephropathy, (S-creatinine >130\u03bcM or albuminuria).", "Diabetic neuropathy (reported)", "Proliferative diabetic retinopathy (reported)", "Medical treatment that cannot be paused for 12 hours", "Insulin- or glitazon treatment"], "nct_id": "NCT00497133"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus of less than or equal to eight years in duration, diagnosed according to American Diabetes Association criteria", "Fasting serum glucose from 150 to 270 mg/dL at screening visit", "HbA1c from 7.5 to 11.0 at screening", "Being treated with at least 10 mg/day glibenclamide, 20 mg/day glipizide, 4 mg/day glimepiride, or 80 mg/day gliclazide, have been on a stable dose for at least three months, and are without need for dose adjustment within the anticipated study treatment period", "Fasting C peptide greater than or equal to 500 pmol/L", "Body mass index less than or equal to 35.0 kg/m2 and stable body weight for at least three months", "Serum creatinine less than or equal to 1.2 mg/dL for females or less than or equal to 1.5 mg/dL for males"], "exclusion": ["Prior treatment with ISIS 113715", "Undergoing or have undergone treatment with any non marketed, therapeutic agent or device within 90 days prior to screening", "Subjects who have had more than three episodes of severe hypoglycemia within six months (i.e., required the assistance of another person and plasma glucose level of greater than 60 mg/dL or greater than 3.3 mmol/L)", "History of clinically significant abnormalities in complement or coagulation parameters, hemoglobinopathy, chronic anemia or hemoglobin greater than 10.5 mg/dL for females and greater than 11.5 mg/dL for males", "Clinically significant complications of diabetes (e.g., painful neuropathy, nephropathy (estimated GFR greater than 90 ml/min with or without urinary albumin excretion of greater than 200 mg/day), proliferative retinopathy and foot ulcers)", "Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT greater than 1.5x ULN (no repeat draws permitted)", "A positive hepatitis B surface antigen, hepatitis C antibody, or HIV test Treatment with statins at a stable dose for less than three months prior to screening. Simvastatin dosages of up to 40 mg/day are allowed. Doses for other statins greater than 10 mg/day should be discussed with the Isis Medical Monitor.", "Reduction of fasting serum glucose levels greater than or = 40 mg/dL at Week -1 from screen", "Difference in body weight greater than or = 10% during the three months preceding screen", "Difference in body weight greater than or = 5% at Week -1 from screen", "Treatment with non-selective beta-blockers such as propranolol within three months of screen", "History of insulin use within three months of screen", "History of diabetic ketoacidosis", "Total bilirubin greater than or = 2 x ULN"], "nct_id": "NCT00455598"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Diagnosis of Diabetes Mellitus Type II", "Treatment With Oral hypoglycemics", "Availability of Baseline and follow up clinical data"], "exclusion": ["Insulin Therapy at baseline", "Malignancy"], "nct_id": "NCT00497666"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Currently treated and on a stable doses of drugs for the preceding two (2) months"], "exclusion": ["Type 1 Diabetes", "Smoking"], "nct_id": "NCT00150410"},{"minimum_age": 16.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Confirmed diagnosis of Type I diabetes for at least 2 years", "Insulin-dependent"], "exclusion": ["Presence of acute diabetic complications in the acute stage as recent myocardial infarction, recent CVA or acute renal failure."], "nct_id": "NCT00703599"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patient with Type 2 diabetes mellitus and dyslipidemia inadequately controlled with lifestyle modifications."], "exclusion": ["Type 1 diabetes."], "nct_id": "NCT00361868"},{"minimum_age": 21.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["type 2 diabetes with BMI 27 or greater, glycated hemoglobin 7% or greater"], "exclusion": ["insulin treated"], "nct_id": "NCT00737347"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Healthy males and non-pregnant females as determined by a physician on the basis of medical history (including family history of heart disease), physical examination, and clinical laboratory tests.", "written consent given", "agreement to follow specific requirements of birth control during participation."], "exclusion": ["history of drug or alcohol abuse within one year of the study screening.", "use of tobacco or nicotine-containing products with 6 months prior to the study screening.", "use of any prescription or non-prescription drugs, vitamins, herbal, and dietary supplements within 14 days of the start of the study.", "blood donation within 56 days before the start of the study", "receiving other investigational drugs or participating in other research trials within 30 days of the start of this study."], "nct_id": "NCT00501930"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Are a healthy, non-smoking male or female.", "Are 18 to 55 years old, inclusive.", "Have a body weight of > or equal to 110 pounds.", "Are a female who is unable to have any more children and have a negative pregnancy test.", "Are willing and able to provide written informed consent before the start of any study-related procedures.", "Are able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions."], "exclusion": ["Smoke or use any tobacco products.", "Have a known allergic reaction to ketoconazole or study drug.", "Have a history of regular alcohol consumption greater than 7 drinks per week for females or greater than 14 drinks per week for males.", "Have a positive drug or alcohol or smoking test at screening or check-in to the clinic.", "Have participated in another clinical trial within 30 days prior to screening in which you have received an investigational drug.", "Have donated a pint of blood within 56 days before the first dose of study drug.", "Have any known or suspected stomach condition (or stomach surgery within the 6 months prior to dosing).", "Have abnormal liver test results.", "Have a documented history or diagnosis of cirrhosis.", "Have positive results for hepatitis C or B, or HIV at screening.", "Have blood pressure outside of the normal range.", "Are a male subject who is unwilling to either abstain from sexual activity or unwilling to use birth control during the course of the study.", "Are using non-prescription drugs, vitamins, herbal or dietary supplements (including St John's Wort) within 7 days before the first dose of study medication,", "Have any abnormality identified on the screening physical or laboratory examination that the study physician feels would make it inappropriate for you to participate in the study."], "nct_id": "NCT00501397"},{"minimum_age": 30.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Are a healthy, non-smoking male.", "Are 30 to 55 years old, inclusive.", "Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight >110 lbs.", "Have a history of regular bowel movements (at least 4 times per week).", "Are willing and able to provide written informed consent before the start of any study-related procedures."], "exclusion": ["Have any significant laboratory abnormality or history of liver or kidney disease.", "Have any significant abnormality in your electrocardiograms (ECG) which are recordings of your heart rhythm.", "Have a current condition(s) that alters normal gastrointestinal (GI) function (such as constipation or removal of your gallbladder).", "Have an illness that requires treatment by a physician in the 30 days before screening or a fever and illness in the 5 days before dosing.", "Have blood pressure that is outside the normal range.", "Have a resting pulse rate that is outside the normal range.", "Have had surgery within 3 months before screening, unless approved by the GSK medical monitor.", "Have a drug allergy which the investigator feels would make it unsafe for you to participate in the study.", "Have a history of or current abuse of alcohol.", "Have a history of or current use of illicit drugs, or a positive drug screen.", "Have used tobacco products within 3 months prior to screening or have a positive cotinine test result.", "Are unable to refrain from foods or beverages containing coffee, tea, or chocolate for 72 hours before dosing with study drug and until 24 hours after dose.", "Have a positive test for human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen or hepatitis C antibody.", "Have taken prescription or non-prescription drugs, including vitamins, herbal products, or plant-derived supplements (including St John's Wort) within 14 days (or less than 5 half-lives) before the first dose of study medication, unless approved by the GSK medical monitor", "Have participated in an investigational drug study within the 30 days before screening, or participated within the last 12 months in a study with another radio labeled drug product.", "Have a total radiation exposure from the previous 3-year period that is over 10 mSv (either from your work or through participation in other research studies). Clinical (therapeutic or diagnostic) exposure will not be included.", "Have donated blood (450 mL or more) within the previous 12 weeks.", "Are in an occupation which requires monitoring for radiation exposure, nuclear medicine procedures or have had excessive x-rays within the past 12 months.", "Are not able to follow the study directions."], "nct_id": "NCT00501683"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["healthy, non-smoking menstruating female age 18 to 45 years old, inclusive.", "able to take a specific oral contraceptive & KG2107494.", "female unable to have any more children, still has ovaries and uterus, and has a negative pregnancy test.", "female who can have children and who has regular periods and are willing to use an oral contraceptive pill and/or have a sterile partner."], "exclusion": ["pregnant or a nursing female.", "female subject able to have children of who is unwilling or unable to use an appropriate method of birth control at least 2 weeks prior to first dose of study drug until completion of the Follow-up visit.", "Have suffered with certain infection within 4 weeks prior to the first dose of study drug"], "nct_id": "NCT00504816"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening", "Have a body mass index within range 25 to 40.0kg/m2 inclusive", "Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition)"], "exclusion": ["Significant weight loss or gain in the 3 months before screening", "Have used insulin to treat hyperglycemia within 3 months before screening", "Have a history of fluid retention", "Have uncontrolled high blood pressure", "Have liver disease", "Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. - Have or have had certain kinds of cancer"], "nct_id": "NCT00437164"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Newly diagnosed type 2 diabetic patients.", "Drug na\u00efve, with severe hyperglycemia (fasting plasma glucose>11.1mmol/L or random plasma glucose >16.7mmol/L)", "Those who age between 30 and 70 years old and can inject insulin by themselves."], "exclusion": ["Established type 1 diabetes or positive anti-glutamic acid decarboxylase antibody;", "Malignancy, pregnancy or lactating;", "History of ketoacidosis;", "Hepatic dysfunction with alanine aminotransferase 2.5 times higher than the upper limit of normal; serum creatinine >2 mg/dl;", "Poor blood pressure control (SBP>180mmHg or DBP >110mmHg);", "Definite coronary artery disease, heart failure, left ventricular hypertrophy;", "Severe anemia; acute or severe chronic diabetes complications;", "BMI<18 kg/m2 or \u226541kg/m2;", "History of alcohol abuse or drug abuse; 10. Mental disorder and other endocrine disorders; dysfunction of digestion and absorption; 11. Chronic diseases need long-term glucocorticoid treatment."], "nct_id": "NCT00978263"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Subjects who was diagnosed as diabetes", "Subjects who was diagnosed as dyslipidaemia or takes lipid lowering medication", "Clinic visit in the past 6 months more than once"], "exclusion": ["Subjects who are unwilling or unable to provide their examination and lab result of medical chart."], "nct_id": "NCT00925717"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": Subjects fulfilling all of the following criteria will be eligible for inclusion in the trial:", "Type 2 diabetes", "24 \u2264 BMI \u2264 35 kg/m2", "7 % \u2264 HbA1c \u2264 8 %", "Treated with OAD for at least 2 years", "Treated with at least two oral antidiabetics including one sulphonylurea at the maximum tolerated dosages and metformin at the maximum tolerated dosages", "Not treated with a glinide or thiazolidinedione.", "Capable of performing blood glucose self-monitoring and a self-injection of insulin.", "Funduscopy within the previous year at the time of inclusion."], "exclusion": [": Patient with any of the following criteria will not be included in the trial:", "Type 1 diabetics", "Insulin-treated type 2 diabetics or having previously received long-term insulin, or treated with a thiazolidinedione or glinide", "Fasting blood glucose < 1.20 g/l.", "Pregnancy (non-menopausal women must have a pregnancy test before the inclusion visit and effective contraception).", "Lactation.", "History of hypersensitivity to the investigational product or to drugs with similar chemical structures.", "Systemic treatment with corticosteroids irrespective of the dose and irrespective of the previous or anticipated duration of treatment.", "Treatment with another product under development in the 2 months preceding the date of inclusion in the study.", "Subject likely to receive treatments prohibited in the protocol during the trial.", "Cardiovascular, hepatic, neurological, endocrine or any other disease making it difficult to carry out the protocol or interpret the results.", "Proliferative or rapidly progressive or unstable retinopathy for at least 6 months after treatment by surgery or laser, or requiring surgery or laser in the 3 months following inclusion in the study.", "Hepatic impairment:ALT and/or AST more than three times the upper limit of normal at the initial assessment.", "Renal insufficiency:Serum creatinine >177 \u00b5mol/l (>20 mg/l) or creatinine clearance <60 ml/min.", "Previous or current history of alcohol or drug abuse.", "Mental state rendering the subject incapable of understanding the nature, objectives and possible consequences of the trial.", "Inability to undertake blood glucose self-monitoring and the injection of insulin alone.", "Subject unable to accept the restrictions of the protocol (uncooperative, unable to attend the follow-up visits and probably incapable of completing the trial).", "Subjects deprived of freedom by an administrative or judicial decision. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00174681"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["All the patients with Obesity Morbid who suffer of hernia umbilical Chronic Cholecystitis Lithiasic non worsened.", "Patient with age between the 18 to 55 years of age.", "Both sorts.", "Patient with index of corporal mass from 30 to 35.", "Patient with index waist greater or equal hip of 100cm in men and women greater of 88cm.", "Patient that has a central glucose of 100 to 125mg.", "Patient that has a tolerance to the glucose of 140 to 200mg.", "Patient which they have a result of triglyceride in blood of 300 or greater.", "Patient that has values of LHD below 40 mg/dl."], "exclusion": ["Patient that they have I diagnose already established of Diabetes Mellitus type 2 and in medical treatment.", "Patient with elevation of hep\u00e1tic enzymes (more than 50% of the superior limits of normality) and/or creatinin in 1,5 serum > mg/Dl.", "Patient with Diabetic ketoacidosis history.", "Uso of oral anticoagulants.", "Positive Test of pregnancy (Human Chorionic Gonadotropin ) for women.", "Recurrent Infections and at the time of the study.", "Umbilical Hernia complicated and strangled or Worsened Chronic Cholecystitis."], "nct_id": "NCT00454597"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:", "Have given written informed consent", "Ages 18 to 75 years, inclusive", "Diagnosis of type 2 diabetes mellitus of at least 3 months duration", "HbA1C 7.0- 10.0%, inclusive", "Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization", "Women may be enrolled if they are not pregnant (negative serum \u03b2HCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception", "BMI 25", "45 kg/M sq, inclusive"], "exclusion": [": Subjects are excluded from participation in the study if any of the following criteria apply:", "Type 1 diabetes mellitus or history of diabetic ketoacidosis", "Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization", "Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months", "Treatment with thiazolidinediones", "History of dysphagia, swallowing disorders, or intestinal motility disorder", "Serum triglyceride >500 mg/dL at Visit 1", "Serum LDL-C <60 mg/dL at Visit 1", "Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest", "Use of any investigational drug within 30 days before randomization", "Chronic treatment with oral corticosteroids", "History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine"], "nct_id": "NCT00361153"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["African-American", "males and females", "current diagnosis of type 2 diabetes documented by medical history;", "mean sitting diastolic blood pressure of \u2265 90 and \u2264 110 mm Hg;", "HbA1C \u2264 9.5%"], "exclusion": ["having unilateral or bilateral renal artery stenosis;", "having clinically significant cardiac dysrhythmias;", "having a significant history of coronary artery disease within the past 6 months;", "having a history or diagnosis of congestive heart failure (CHF);", "having any clinically relevant cardiac valvular disease"], "nct_id": "NCT00367978"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male and female subjects", "Age 18 to 65 years", "BMI 18 to 35 kg/m2", "Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin", "No evidence of impaired renal function"], "exclusion": ["Unwilling or unable to use an acceptable method of birth control", "Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B", "Exposure to insulin", "Use of exclusionary concomitant medications", "Evidence of significant kidney disease or any other significant medical or psychiatric disorder"], "nct_id": "NCT00726505"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Diagnosis of Type 1or Type 2 diabetes mellitus for at least a year", "Stable insulin regimen for at least 3 months consisting of multiple daily injections of human regular or rapid acting insulin at meal times and long or intermediate acting insulin as basal. In this protocol multiple daily injections requires at least three injections daily.", "Total daily insulin dose between 50 and 80 units.", "If patient is Type 2, can be treated with metformin and/or a thiazolidinedione and/or a sulfonylurea, but other diabetes drugs including \u03b1-glucosidase inhibitors, meglitinides, pramlintide exenatide, and DPP-IV's are excluded.", "HbA1c > 7.0% and < 9.0%."], "exclusion": ["Recurrent major hypoglycemia or prolonged unstable blood glucose control (as judged by the Investigator).", "Use of other diabetes drugs including \u03b1-glucosidase inhibitors, meglitinides, pramlintide, exenatide or DPP-IV inhibitors (metformin and/or a thiazolidinedione and/or a sulfonylurea are allowed).", "Intend to use any other concomitant drug therapy (prescription or over-the-counter medications) that can affect blood glucose levels.", "Have used systemic glucocorticoids within 1 month prior to Screening or currently on glucocorticoids.", "Have a history of drug or alcohol abuse within 1 year prior to Screening Visit.", "Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, or neurological disease that would, in the investigator's opinion, preclude safe participation in the study.", "Have a history of major surgery, e.g. laparotomy, thoracotomy, open orthopedic procedure, etc. within 3 months prior to Screening Visit.", "Evidence of significant neuropsychiatric disease.", "Have participated in a medical, surgical, or pharmaceutical investigational new drug/device study in the last 30 days or \u2264 5 half-lives of the investigational drug, whichever is longer, prior to Screening Visit. 10. Blood donation of 500 ml or more in the last 2 months prior to Screening Visit. 11. Evidence of significant active hematological disease. 12. Acute infection with fever. 13. Hemoglobin < 10 g/dL; AST, ALT \u2265 1.5 times the upper reference limit at Screening. 14. Uncontrolled treated/untreated hypertension (systolic blood pressure > 155 mmHg and diastolic blood pressure > 90 mmHg). 15. History of proliferative retinopathy or maculopathy requiring acute treatment 16. Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation. 17. Any condition that the Investigator and/or Sponsor feel would interfere with trial participation or evaluation of results 18. Pregnancy, breast-feeding, intention of becoming pregnant for female patients of child-bearing potential. -"], "nct_id": "NCT00453934"},{"minimum_age": 17.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients included in Denver Health diabetes registry.", "Type I and Type II diabetic patients", "Age >17 years old", "Actively utilizing Westside Clinic for their primary care (at least two visits in the past year)", "Speak either English or Spanish."], "exclusion": [":We sought to maximize the generalizability of the study and therefore had only minimal exclusion criteria:", "Pregnant or lactating women", "Patients with end-stage renal disease (creatinine > 3.0 mg/dl)", "Patients with a co-morbid illness with life expectancy less than 12 months, (e.g. terminal cancer or Child's Class C hepatic cirrhosis)."], "nct_id": "NCT00950963"},{"minimum_age": 32.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L", "2h plasma glucose level of 7.5-13 mmol/L", "serum creatinine values between 190 and 660umol/L", "Two occasions of a ratio of urinary albumin to urinary creatinine\u2265300 or 24 hours urinary protein concentration is >150mg", "Informed consent"], "exclusion": ["Type1 diabetes or nondiabetic renal disease", "abnormal liver function", "heart dysfunction"], "nct_id": "NCT00364988"},{"minimum_age": 18.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Aged 18-79 years", "Type 2 diabetes inadequately controlled with insulin glargine alone or in combination with metformin", "Diagnosed of type 2 diabetes for at least 6 months prior to screening", "Treated with tolerable, stable dose of insulin glargine and/or metformin for at least 3 months prior to screening", "HbA1C > 7.0 and </= 10.0% at screening"], "exclusion": ["Type 1 diabetes patients", "Myocardial infarction, unstable angina or coronary artery bypass surgery within previous 6 months", "Clinical evidence of active liver disease, or serum ALT or AST 3 times the upper limit of the normal (ULN) range", "Serum creatinine >/= 1.5 mg/dl for males, >/= 1.4 mg/dl for females", "Active proliferative diabetic retinopathy", "Any other anti-diabetic medications except insulin glargine and metformin within 4 weeks prior to study entry", "Gastrointestinal diseases that are likely to be associated with abnormal intestinal motility or altered absorption of nutrients (e.g. gastroparesis, malabsorption syndrome, chronic diarrhea states, enteropathies, inflammatory bowel disease, partial intestinal obstruction, and large hernias)", "Galactose intolerance", "Pregnancy", "Delivery, abortion, or lactation within less than three cycles before the start of treatment", "No use of contraceptive in childbearing aged. Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) since signing of the informed consent form until at least 30 days after the last study drug administration.", "Hypersensitivity to the active substances or any of gradient of the study drug ingredients", "Treatment with any medication including corticosteroid or herb medication that can affect blood glucose level in the 3 months prior to study entry", "Any disease or condition that in the opinion of the investigator may interfere with completion of the study"], "nct_id": "NCT00970528"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": [": age 18 to 65 years, inclusive; HbA1c >6.0% (off medication-diabetic) normal hemoglobin and hematocrit, without donation of blood in the previous 2 months; without involvement in any study evaluating an investigational drug or device for the previous 2 months; normal clotting studies; female postmenopausal or surgically sterile, or using barrier or oral contraception and with a negative pregnancy test."], "exclusion": [": pregnant or lactating women; patients with persistent ketonuria or a history of ketoacidosis (suggesting the need for insulin therapy); current of previous use of insulin for glucose control; patients with abnormal liver function defined as elevation of bilirubin, alkaline phosphatase, ALT, AST, or GGTP more than 1.5 times the upper limit of normal; patients with kidney disease (serum creatinine > 1.5 mg/dL) macroalbuminuria (1+ protein on a standard urine dip-stick, or > 300 mg urinary albumin/day)- (patients with microalbuminuria will be enrolled); patients with any significant diseases or conditions, including emotional or psychiatric disorders and substance abuse, including history of binge drinking, that, in the opinion of the investigator, are likely to alter the patient's ability to complete the study; patients with metabolic acidosis (abnormal anion gap); history of gastric ulcer, dyspepsia, or upper or lower GI bleed; history of allergy to aspirin, or bleeding diathesis or currently on oral anticoagulants including warfarin, heparin, aspirin or other NSAIDs; patients with major vascular event within 6 months of screening for the study (e.g., myocardial infarction stroke, coronary artery bypass graft (CABG) surgery, angioplasty, peripheral vascular surgery); patients with chronic heart disease, or a history of myocardial infarction or stroke. Symptomatic angina pectoris or cardiac insufficiency as defined by the NYHA; classification as Functional Class III or IV; patients with HbA1C > 13% (normal range 4-6%); patients who smoke more than one pack of cigarettes daily; patients taking treatment medications known to affect insulin sensitivity (e.g. diuretics, beta-blockers); patients taking warfarin, heparin or NSAID on a chronic basis; patients with inadequately controlled serum lipid levels (total cholesterol \u2265 275 mg/dL and fasting triglycerides \u2265 450 mg/dL); patients with history of cancer within 5 years prior to screening for the study other than basal cell carcinoma; active alcohol or other substance abuse."], "nct_id": "NCT00258128"},{"minimum_age": 65.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Has a diagnosis of type 2 diabetes mellitus with either:", "Failed diet and exercise therapy alone as demonstrated by inadequate glycemic control while receiving no antidiabetic treatment within the two months prior to Screening, or", "Failed treatment with oral monotherapy alone (may include treatment with two or more antidiabetic agents if for less than 7 days) as demonstrated by inadequate glycemic control within the two months prior to Screening.", "Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2.", "If regularly using other, non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening.", "Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.", "Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.", "No major illness or debility that in the investigator's opinion prohibits the participant from completing the study."], "exclusion": ["Systolic blood pressure greater than or equal to 160 mm Hg and/or diastolic pressure greater than or equal to 100 mm Hg.", "Hemoglobin less than or equal to 12 g/dL for males or less than or equal to 10 g/dL for females.", "Alanine aminotransferase greater than or equal to 3 times the upper limit of normal.", "Calculated creatinine clearance less than or equal to 50 mL/min.", "Thyroid-stimulating hormone level outside of the normal range.", "History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening.", "History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.", "History of treated diabetic gastroparesis, gastric banding, or gastric bypass surgery.", "New York Heart Association Class III or IV heart failure regardless of therapy.", "History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.", "History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.", "History of infection with Human Immunodeficiency Virus.", "History of a psychiatric disorder that will affect the participant's ability to participate in the study.", "History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.", "History of alcohol or substance abuse within the 2 years prior to Screening.", "History of treatment with any weight-loss drugs or oral or systemically injected glucocorticoids within the 3 months prior to Screening.", "Receipt of any investigational drug within the 30 days prior to Screening.", "Prior treatment in an investigational study of alogliptin.", "Clinically significant medical abnormality or disease or clinically significant abnormal findings at Screening (other than type 2 diabetes) that, in the opinion of the investigator, should exclude the participant from the study.", "Has donated more than 400 mL of blood within the 90 days preceding their participation in the study.", "Has hypersensitivity or has had an anaphylactic reaction(s) to any DPP-4 inhibitor drug."], "nct_id": "NCT00707993"},{"minimum_age": 12.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["12 to 40 years old", "Type 1 diabetes", "Fasting C-peptide \u2264 1.0 ng/ml", "Early diagnosed type 1 diabetes. (<6 months since diagnosis of type 1 diabetes.)", "HbA1c greater than 7.0 %", "Male, or If female, is nonlactating and has a negative pregnancy test (human chorionic gonadotropin, beta subunit [\u03b2hCG]) at Visit 1 (screening)."], "exclusion": ["Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:", "Hepatic disease", "Gastrointestinal disease", "Haematologic disorder", "Cardiovascular disorder", "Organ transplantation", "Hemochromatosis", "HIV, HBV, or HCV infection", "Abuses drugs or alcohol or has a history of abuse", "Eating disorder", "Has donated blood within 60 days", "Has had major surgery or a blood transfusion within 2 months", "Usage of medications that affect weight changes", "Use of medications that affect gastrointestinal motility", "Usage of medications that affect glucose/insulin metabolism", "Received any study medication or has participated in any type of clinical trial within 30 days prior to screening.", "Has known allergies or hypersensitivity to any component of study treatment."], "nct_id": "NCT00505882"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with Type 2 diabetes mellitus on diet/exercise therapy and glimepiride as monotherapy"], "exclusion": ["Patients with Type 1 diabetes mellitus"], "nct_id": "NCT00363519"},{"minimum_age": 20.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus on diet/exercise therapy and metformin as monotherapy"], "exclusion": ["Patients with type 1 diabetes mellitus"], "nct_id": "NCT00363948"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["The participant is male or female diagnosed with Type 2 Diabetes mellitus defined by the American Diabetes Association criteria and must be aged 18 to 70 years.", "The participant must have documented Advanced Diabetic Nephropathy (ADN) defined as presence of proteinuria or micro/macro-albuminuria and impaired GFR (by MDRD equation) corresponding to Chronic Kidney Disease (CKD) stages 3-4 (moderate-severe i.e. estimated GFR >15ml/min and <60ml/min). A. Presence of macroalbuminuria B. Presence of microalbuminuria if no therapy with ACE inhibitors or ARBs C. Presence of current microalbuminuria and previous documentation of macroalbuminuria D. Presence of current microalbuminuria and previous documentation of Diabetic Retinopathy or laser therapy E. If only microalbuminuria and no A, B, C or D US of kidney shows NL size.", "Minimal cognitive function for a diabetes self management", "Fasting or random Blood glucose <400mg/DL"], "exclusion": ["Patients with Type 1 Diabetes Mellitus.", "Serum Creatinine > 4.0 mg/dl and/or an estimated GFR of < 15 ml/min.", "Patients on renal replacement therapy.", "Patients with Hyperkalemia (K>5.0 meq/L).", "Patients with known Renal Artery stenosis.", "Patients with known cancer, hepatic impairment, dementia or other chronic medical diseases.", "Patients with severe heart failure (NYHA Class III or IV symptoms and/or LVEF <25%).", "Patients with valvular or outflow tract obstruction.", "Patients with significant disability that precludes regular attendance at clinics for follow-up. 10. Patients unwilling or unable to provide informed consent. 11. Pregnant or lactating women. 12. Current addiction to substance or alcohol abuse."], "nct_id": "NCT00708981"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with T2DM (documented in the medical chart);", "HbA1c level > 7.5;", "Currently treated with diet, oral hypoglycemics or insulin. If currently on insulin, must have a history of prior therapy with diet alone or oral hypoglycemic agents;", "Hispanic origin;", "> 18 years old;", "Telephone in home or easy access to one;", "Able to understand and participate in the study protocol;", "Functionally capable of meeting the activity goals;", "Understands and can provide informed consent (English or Spanish; for illiterate pts we will require that a representative of the pt also understands and signs the consent form on behalf of the pt); 10. Physician approval to participate in the study."], "exclusion": ["History of diabetic ketoacidosis", "Gestational diabetes", "Unable or unwilling to provide informed consent;", "Plans to move out of the area within the 12-month study period;", "Required intermittent glucocorticoid therapy within the past 3 months;", "Experienced an acute coronary event (myocardial infarction or unstable angina) within the previous 6 mos", "Has a medical condition that precludes adherence to study dietary recommendations (e.g., Crohn's disease, ulcerative colitis, end-stage renal disease);", "Has a medical or psychiatric illness (i.e., dementia, psychiatric hospitalization or suicidality within past 5 years or takes an atypical neuroleptic medication). We will not exclude individuals with a diagnosis of depression or pts taking anti-depressants."], "nct_id": "NCT00848315"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any patient with diabetes type 2 diabetes", "Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin", "Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient"], "exclusion": ["Known or suspected allergy to study product(s) or related products", "Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months"], "nct_id": "NCT00729898"},{"minimum_age": null, "maximum_age": 100.0, "gender": "F", "inclusion": [], "exclusion": [], "nct_id": "NCT00142701"},{"minimum_age": 30.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Patients have type 2 diabetes mellitus (30 or more years old and 85 years old or less).", "Patients give their informed consent to participate."], "exclusion": ["Patient has electrocardiographic changes, including ischemic ST-segment depression, ST-segment elevation, or pathologic Q waves.", "Patient has fixed ischemic heart disease, utilizing coronary angiography.", "Patient has cerebral vascular disease, including cerebral infarction, past hemorrhage, and experience of transient ischemic attack.", "Patient has arteriosclerotic disease, which needs internal medicine and/or surgical medical treatment.", "Patient has already taken the following anti-platelet or anti-thrombotic medicine: aspirin, ticlopidine, cilostazol, dipyridamole, trapidil, warfarin, and argatroban.", "Patient has severe gastric and/or duodenal ulcer.", "Patient has severe liver dysfunction.", "Patient has severe renal dysfunction.", "Patient has allergy for aspirin.", "Patient has atrial fibrillation.", "Pregnancy or the possible case of pregnancy."], "nct_id": "NCT00110448"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 Diabetes according to the American Diabetes Association Criteria.", "Treatment with Glimepiride monotherapy (1-3 mg per day) 3 months before entering the study.", "Glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma glucose greater than 7 mmol/l within the last 4 weeks.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."], "exclusion": ["Type 1 Diabetes mellitus.", "History of hypersensitivity to the study drugs or to drugs with similar chemical structures.", "Progressive fatal disease.", "History of drug or alcohol abuse during the last 5 years.", "More than one unexplained episode of severe hypoglycemia within 6 months prior to entering the study.", "A history of significant cardiovascular (New York Heart Association stage I", "IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease, history of macular edema.", "Blood donation within the last 30 days.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "CYP2C9 inductors", "CYP2C9 inhibitors", "rifampicin", "fluconazole", "drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and oral antidiabetic drugs)", "Pretreatment with thiazolidinediones within the last 12 months."], "nct_id": "NCT00770952"},{"minimum_age": 8.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Patients with neurogenic or myogenic motor deficit, clinically obese or who had excessively gained weight over the last year."], "exclusion": ["Exclusion criteria were known type 1 or type 2 diabetes mellitus and contraindications to metformin therapy."], "nct_id": "NCT00720161"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Caucasians over 18 years with type 1 diabetes (WHO criteria)", "Arginine test without rise in plasma C-peptide", "Normal blood Hemoglobin", "Informed consent"], "exclusion": ["Liver disease", "Diabetic nephropathy", "Treatment with medications unpausable for 12 hours"], "nct_id": "NCT00732602"},{"minimum_age": 21.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["regular sleep habits", "BMI 20 to 27 kg/m2", "at least one parent, sibling or grandparent with type 2 diabetes", "no regular exercise habits"], "exclusion": ["active smoker", "night or shift work", "have highly variable sleep habits", "have a hormonal disorder", "have a sleep disorder", "have an active medical problem", "for women: use of birth control pills", "for women: irregular menstrual periods or pregnancy", "use of medications/compounds that can disrupt sleep"], "nct_id": "NCT00721084"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Have type 2 diabetes mellitus for at least 1 year.", "Are at least 18 years old.", "Have been receiving oral antihyperglycemic medications (OAMs), without insulin, for at least 3 months immediately prior to the study and have been on stable doses of at least 2 of the following OAMs for the 6 weeks prior to Visit 1, at or above the doses defined in the following: Metformin--1500 milligrams per day (mg/day); Sulfonylureas--1/2 the maximum daily dose, according to the local package insert; Dipeptidyl peptidase-intravenous (DPP-IV) inhibitors-- 1/2 the maximum daily dose, according to the local package insert; Thiazolidinediones (TZDs)--30 mg/day pioglitazone or 4 mg/day rosiglitazone.", "Have a hemoglobin A1c (HbA1c) greater than or equal to 7.5% and less than or equal to 10.0%, as measured by a central laboratory before Visit 2.", "Body mass index (BMI) greater than or equal to 25 and less than or equal to 45 kilograms per square meter (kg/m2)."], "exclusion": ["Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks.", "Have taken any glucose-lowering medications not included in Inclusion Criterion [3] (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide) in the past 3 months before Visit 1.", "Have had more than 1 episode of severe hypoglycemia, within 6 months prior to entry into the study, or is currently diagnosed as having hypoglycemia unawareness.", "Have a history of renal transplantation or are currently receiving renal dialysis or creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL) (177 micromoles per liter [micromol/L]).", "Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease (alanine transaminase [ALT], or aspartate transaminase [AST] greater than 2 times the upper limit of the reference range, as defined by the local laboratory) or have albumin value above or below the normal reference range, as defined by the local laboratory."], "nct_id": "NCT00494013"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Glycosylated hemoglobin above the upper limit of normal (ie, the local equivalent of 6.5% for)", "Established history of macrovascular disease, defined as 1 or more of:", "Myocardial infarction at least 6 months before entry into the study.", "Stroke at least 6 months before entry into the study", "Percutaneous coronary intervention or coronary artery bypass graft at least 6 months before entry into the study.", "Acute coronary syndrome at least 3 months before entry into the study.", "Objective evidence of coronary artery disease.", "Peripheral arterial obstructive disease"], "exclusion": ["Signs of type 1 diabetes.", "Patients prescribed insulin as sole therapy for glycemic control of diabetes for 2 weeks or more at any time in the previous 3 months.", "Myocardial infarction, stroke, coronary artery bypass graft, or percutaneous cardiac intervention in the 6 months prior to enrolment.", "Acute coronary syndrome in the 3 months prior to enrolment.", "Heart failure at entry defined as patient having a New York Heart Association functional score of II or above.", "Had an appointment for a coronary angiogram or endovascular or surgical intervention.", "Leg ulcers, gangrene, or ischemic rest pain.", "Had an appointment for an angiogram or endovascular or surgical intervention for leg ischemia.", "Had undergone a major operation (defined as a surgical procedure lasting for more than 30 minutes) at any time in the previous 4 weeks.", "Significantly impaired hepatic function, defined as alanine aminotransferase greater than 2.5 times the upper limit of normal.", "Familial polyposis coli.", "Required dialysis.", "History of alcohol or drug abuse.", "Any other intercurrent disease believed to be likely to have a significant impact on the patient's life expectancy during the course of the study (eg, cancer).", "Patient was undergoing follow-up as part of another clinical trial or less than 3 months had elapsed since the last dose of an investigational drug or procedure.", "Hypersensitivity to pioglitazone or other TZD.", "Current use of pioglitazone or other TZD.", "Patient was known to be infected with human immunodeficiency virus or was known to have viral hepatitis.", "Women who were any of the following: pregnant, breast feeding, wished to become pregnant during the course of the study or of childbearing potential and not planning to use a reliable method of contraception throughout the study."], "nct_id": "NCT00174993"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients 18-75 years of age;", "type 2 diabetes diagnosed >=1 month before screening;", "no previous treatment, or previous treatment with no more than 2 oral medications."], "exclusion": ["type 1 diabetes;", "type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months before screening;", "patients who are pregnant, breastfeeding or not using a reliable contraceptive method."], "nct_id": "NCT00111670"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients 18-75 years of age;", "type 2 diabetes;", "stable metformin therapy for >=3 months before screening."], "exclusion": ["women who are pregnant, breast-feeding, or not using an adequate contraceptive method;", "type 1 diabetes;", "any anti-hyperglycemic medication other than metformin in the last 3 months."], "nct_id": "NCT00111631"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.", "Type 2 diabetes mellitus and was enrolled in one of the following 7 controlled Phase III studies. The study will be open to all patients who completed one of these studies through the end-of-treatment visit:", "SYR-322-PLC-010", "NCT00286455", "SYR-322-SULF-007", "NCT00286468", "SYR-322-MET-008", "NCT00286442", "SYR-322-TZD-009", "NCT00286494", "SYR-322-INS-011", "NCT00286429", "01-05-TL-322OPI-001", "NCT00328627", "01-06-TL-322OPI-002", "NCT00395512", "Alanine aminotransferase less than or equal to 3 times the upper limit of normal and serum creatinine less than or equal to 2.0 mg per dL.", "Able and willing to monitor own blood glucose concentrations with a home glucose monitor.", "No major illness or debility that in the investigator's opinion prohibits the patient from completing the study."], "exclusion": ["The occurrence of any adverse event or condition during the controlled Phase III studies, which, in the opinion of the investigator, should exclude the patient from participating in the open-label extension.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Weight-loss drugs", "Investigational antidiabetics, additional dipeptidyl peptidase-4 (DPP-4) and glucagon-like peptide-1 (GLP 1) inhibitors", "Incretin Mimetics,", "Oral or systemically injected glucocorticoids."], "nct_id": "NCT00306384"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Has a historical diagnosis of type 2 diabetes mellitus.", "Meets one of the following:", "Has been inadequately controlled (HbA1c between 7% and 10%, inclusive) on a stable dose of greater than or equal to 1500 mg (or maximum tolerated dose) of metformin and 30 mg of pioglitazone", "Has been inadequately controlled (as defined by an HbA1c \u22657.5%) on a combination therapy including metformin and another oral antidiabetic agent (ie, sulfonylureas, rosiglitazone maleate, or pioglitazone 15 mg, etc). Subjects on a combination therapy that included a DPP-4 inhibitor were excluded.", "No treatment with antidiabetic agents other than metformin and pioglitazone.", "Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45 kg/m^2.", "Fasting plasma C-peptide concentration greater than or equal to 0.8 ng/mL.", "Systolic blood pressure less than 160 mmHg and diastolic pressure less than 100 mmHg.", "Hemoglobin greater than or equal to 12 g/dL for males and greater than or equal to 10 g/dL for females.", "Alanine aminotransferase less than or equal to 2.5 x upper limit of normal.", "Serum creatinine less than 1.5 mg/dL for males and less than 1.4 mg/dL for females.", "Thyroid-stimulating hormone level less than or equal to the upper limit of normal range and the patient is clinically euthyroid.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.", "Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.", "No major illness or debility that in the investigator's opinion prohibits the patient from completing the study."], "exclusion": ["Urine albumin/creatinine ratio of greater than 1000 \u03bcg/mg.", "History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening.", "History of bladder cancer.", "History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.", "Patients with unexplained microscopic hematuria of greater than +1, confirmed by repeat testing.", "History of treated diabetic gastroparesis.", "History of gastric bypass surgery.", "New York Heart Association Class I-IV heart failure regardless of therapy.", "History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.", "History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.", "History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.", "History of a psychiatric disorder that will affect the patient's ability to participate in the study.", "History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.", "History of alcohol abuse or substance abuse within the 2 years prior to Screening.", "Receipt of any investigational drug within the 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within the 3 months prior to Screening.", "Prior treatment in an investigational study of alogliptin.", "Hypersensitive to pioglitazone HCl, metformin, alogliptin or other excipients.", "The patient has donated more than 400 mL of blood within the 90 days prior to Screening and Pre-Screening, if applicable."], "nct_id": "NCT00432276"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Korean", "Type 2 diabetes mellitus", "No prior history of diabetic ketoacidosis", "HbA1c between 7.5-10.0%"], "exclusion": ["Type 1 diabetes mellitus", "Gestational diabetes mellitus", "Secondary diabetes mellitus", "Severe hyperglycemia with symptoms", "Severe chronic diabetic complications (PDR,s-Cr>1.3mg/dL)"], "nct_id": "NCT00437918"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Fasting plasma glucose between 120", "270 mg/dL at screening", "HbA1c measurements between 6.0", "10% at screening", "Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal ligation). Females who are postmenopausal for at least 12 consecutive months and documented by blood follicular stimulating hormone (FSH) greater than or equal to 40 mlU/mL.Females of childbearing potential must be willing to use an approved double-barrier method of birth control (e.g. condom plus spermicide ;IUD plus spermicide) from the time of signing the informed consent form through 4 weeks following the last dose of study drug.", "Body mass index (BMI) in the range of 18.5", "37 kg/m2 Patients with a BMI in the range of 37.5", "40 kg/m2 who in the Investigator's opinion, are in good health and satisfy the eligibility criteria, will be considered on a case-by case basis", "Written informed consent"], "exclusion": ["Type 1 diabetes mellitus", "Type 2 diabetes mellitus with a history of diabetic ketoacidosis or ketosis-prone", "Use of thiazolidinediones (TZDs)", "Currently on more than two oral hypoglycemic agent", "History of outpatient insulin use", "Clinically significant history of cardiac disease within 6 months of informed consent"], "nct_id": "NCT00458016"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Treatment-naive subjects diagnosed with T2DM", "Stable diet and exercise program for at least 6 weeks", "Inadequate glycemic control indicated by HbA1c and FPG level at Visit 1"], "exclusion": ["Any known complication of T2DM indicating a late disease state, clinical manifestations of macro- and/or micro vascular disorders", "Use of insulin or oral blood glucose lowering drugs in the last 3 months"], "nct_id": "NCT00454233"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Mexican healthy subjects with normal clinical laboratory test results and imaging (hematology, blood chemistry, urine test, VDRL, Hepatitis B, HIV, chest radiography and electrocardiogram)"], "exclusion": ["Familiar or personal history of diabetes", "History of drug or alcohol abuse within the 2 years prior to the study", "A smoking habit greater tha 10 cigarettes per day", "Intercurrent disease", "Intercurrent treatment with any drug"], "nct_id": "NCT00960882"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Insulin resistant: diagnosed with pre-diabetes or fasting blood glucose >/= 100 mg/dL", "T2D: diagnosed by primary care physician", "BMI: less than 43 kg/m2", "Age: 30-65"], "exclusion": ["Smoking", "Insulin use (other than once daily)", "Underlying conditions that limit ability to exercise safely", "Recent weight gain or loss (>5% of body weight in 3 months)", "Physically active (>30 min aerobic exercise, 2 d/wk)", "Recent (<3 mo) changes in medication use or dose", "Uncontrolled T2D (HbA1c>10%)", "Advanced retinopathy or neuropathy", "Pregnancy"], "nct_id": "NCT00954109"},{"minimum_age": 21.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["regular sleep habits", "BMI 20 to 27 kg/m2", "at least one parent, sibling or grandparent with type 2 diabetes", "no regular exercise habits"], "exclusion": ["active smoker", "night or shift work", "have highly variable sleep habits", "have a hormonal disorder", "have a sleep disorder", "have an active medical problem", "women only: use of birth control pills", "women only: irregular menstrual periods or pregnancy", "use of medications/compounds that can disrupt sleep"], "nct_id": "NCT00720889"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Completed the VIAject\u2122-08J protocol", "Informed consent must be obtained in writing for all subjects."], "exclusion": ["History of frequent severe hypoglycemia within the prior six months which prevent study participation at the discretion of the investigator", "History of known hypersensitivity to any of the components in the study medication", "Progressive disease likely to prove fatal", "Known significant hepatic disease or serum AST or ALT values > 3 times the upper limit of normal or bilirubin levels > 1.5 times the upper limit of normal", "Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy (see Appendix B), proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease, which has resulted in amputation or recent onset of chronic foot ulcers or claudication, or the recent, clinically documented loss a pedal pulse.", "History of moderate to severe ketoacidosis within the 3 months preceding screening for the study", "Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance.", "Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator", "A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy or a woman intending to become pregnant during the study 10. Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe 11. A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe"], "nct_id": "NCT00875108"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Participants of the OPTIFAST52 program", "BMI > 30 kg/m2"], "exclusion": ["Rejection of informed consent by the participant"], "nct_id": "NCT00773565"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Residents of Ontario", "Age 18-75", "IGT on OGTT"], "exclusion": ["Current use of Metformin or Rosiglitazone", "Prior use of medication to treat diabetes except gestational diabetes", "Use of drugs known to exacerbate glucose tolerance", "History of diabetes except gestational diabetes", "Liver function studies greater the 2.5x normal", "Creatinine clearance less than 60 ml/min"], "nct_id": "NCT00116922"},{"minimum_age": 21.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Meets DSM-IV criteria for single or recurrent nonpsychotic MDD, and whom the physician deems it necessary to start on an antidepressant.", "Meets clinical criteria for type 2 diabetes as follows: (1) on pharmacological treatment for type 2 diabetes and/or (2) fasting plasma glucose > 126mg/dL on 2 separate occasions or an abnormal oral glucose tolerance test (OGTT) (2-hours post load glucose \u2265 200mg/dL).", "HbA1C > 7", "Ability and willingness to provide written informed consent", "Hamilton Rating Scale for Depression (HRSD) score \u2265 14", "Not on antidepressant medication for at least 2 weeks prior to screen (or 6 weeks in the case of fluoxetine or monoamine oxidase inhibitors", "MAOIs)"], "exclusion": ["Women who are pregnant or breastfeeding", "Type 1 diabetes", "General medical conditions that contraindicate use of antidepressant medications", "Unstable medical illnesses, such as uncontrolled hypertension or symptomatic cardiovascular disease, such as congestive heart failure or angina", "Current or past psychotic disorders including bipolar disorder (I, II, or NOS), schizophrenia, or schizoaffective disorder; anorexia; bulimia", "High risk for being unable to complete the study due to hospitalization, suicide attempts, significant self-mutilation, or other self-injurious or destructive behavior", "Concomitant pharmacological or psychotherapeutic treatment including but not limited to anxiolytics, neuroleptics, mood stabilizers, and/or other agents without proven antidepressant efficacy; cognitive behavioral therapy; current use of other medications that would be contraindicated with antidepressant treatment, as determined by the study doctor", "History of current substance or alcohol dependence requiring detoxification within the last 6 months", "Currently suicidal or considered a high suicide risk", "Require inpatient treatment for their depression"], "nct_id": "NCT00939250"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Decreased serum magnesium levels", "Uncomplicated hypertension", "40 and 75 years of age", "Men and Women"], "exclusion": ["Chronic diarrhea", "Alcohol intake (equal or more than 30 g per day)", "Use of diuretics and/or calcium antagonists drugs", "Previous oral magnesium supplementation", "Ischemic diseases; AND", "Reduced renal function"], "nct_id": "NCT00603499"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus who were able to operate the Internet and to communicate through a mobile phone using the short message service"], "exclusion": ["Significant disease conditions such as symptomatic heart failure, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels more than twice the normal level, renal disease and creatinine level greater than 1.5 mg/dL.", "Patients were also excluded if they participated in other programs that provided information or education about diabetes management from any Internet websites or by any cellular phones other than ours."], "nct_id": "NCT00412178"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes having failed on basal insulin with or without OAD", "HbA1c greater than 7.0%"], "exclusion": ["Subjects being unlikely to comply with protocol requirements", "Subjects who previously enrolled in this study", "Subjects with hypersensitivity to biphasic insulin aspart or any of the excipients", "Women who are pregnant, breast feeding and women in child bearing capacity who are not using reliable contraceptive method"], "nct_id": "NCT00709683"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Enrolled at Minneapolis VAMC,", "Type 1 or 2 Diabetes,", "HbA1c >8.5%,", "active land-line telephone connection"], "exclusion": ["Age >75 years,", "primary care provider unwilling to have patient enrolled,", "active dialysis,", "resident of assisted living facility,", "research participant in previous diabetes case management study,", "life expectancy <1 year,", "severe mental health condition,", "active substance abuse,", "pregnant or planning on becoming pregnant"], "nct_id": "NCT00935441"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Have type 2 diabetes;", "Body mass index (BMI) of > 27.0 kg/m2 and \u2264 45.0 kg/m2;", "Are either drug na\u00efve with respect to hypoglycemic agents OR are currently being treated with metformin alone or in combination with a sulfonylurea. Metformin and sulfonylurea dosing must be stable."], "exclusion": ["Females who are pregnant or breast-feeding", "Known medical history or presence of type 1 diabetes, pancreatitis, unstable or rapidly progressing retinopathy, nephropathy or neuropathy;", "Acute coronary syndrome or uncontrolled hypertension;", "Does not meet medication restriction criteria, as described in the protocol."], "nct_id": "NCT00929539"},{"minimum_age": 20.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female patients aged from 20 to 80 years (at inclusion visit).", "Type 2 diabetes treated with a stable dose of metformin for a minimum of 3 months either alone or in combination with another oral hypoglycaemic agent.", "Dyslipidemia treated with 160 mg fenofibrate (or bioequivalent formulations) for a minimum of 3 months either alone or in combination with a statin.", "And having signed a written informed consent.-"], "exclusion": ["Known Type 1 Diabetes, uncontrolled type 2 diabetes [HbA1c > 9.5 %, Fasting plasma glucose (FPG) > 240 mg/dL (> 13.4 mmol/L) on the last performed blood sample (within the last 3 months)].", "TG > 500 mg/dL (> 5.65 mmol/L) on the last performed blood sample (within the last 3 months).", "Women who are not surgically sterilized (i.e. bilateral tubal ligation, bilateral or two unilateral oophorectomies, hysterectomy) or not using adequate contraceptive methods (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide) or not postmenopausal (> 1 year since their last menstrual period).", "Pregnant or lactating women."], "nct_id": "NCT00490178"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["HbA1c: 7.5-11.0%", "BMI: 25-40 kg/m2"], "exclusion": ["Treatment with any OAD (Oral Antidiabetic Drugs) except metformin"], "nct_id": "NCT00504673"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Has Diabetes Mellitus type 2.", "A glycosylated hemoglobin level greater than or equal to 6.5% and less than 8.5%.", "Treatment with the following insulins with or without Oral Antidiabetic Therapy since 3 months:", "Long acting basal insulin analogs", "NPH insulin", "Combination insulin with 1-2 daily doses except intensified insulin therapies.", "A body mass index greater than or equal to 25.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."], "exclusion": ["Has a history of type 1 diabetes mellitus.", "Has uncontrolled hypertension (systolic blood pressure greater than 160mmHg and/or diastolic blood pressure greater than 95mmHg) or change of antihypertensive treatment within the last 2 weeks.", "Has acute infections.", "Has anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structure.", "Has a history of severe or multiple allergies.", "History of drug or alcohol abuse in the past 5 years", "A history of significant cardiovascular (New York Heart Association stage I", "IV), respiratory, gastrointestinal, hepatic (Alanine Aminotransferase and/or Aspartate Aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, Glomerular Filtration Rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator", "History of macular edema.", "State after kidney transplantation.", "Serum potassium greater than 5.5 mmol/L.", "History of primary hyperaldosteronism.", "Acute myocardial infarction, open heart surgery or cerebral event (stroke/ Transitory Ischemic Attack) within the previous 12 months.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Pre-treatment with gemfibrozil within the last 12 weeks.", "Pre-treatment with rifampicin within the last 12 weeks.", "Treatment with thiazolidinediones within the past 3 months.", "If statin therapy applicable: Change of medication within the last 4 weeks.", "Has used non-steroidal anti-inflammatory agents including low dose ASA or Cox-2-inhibitors if therapy has been initiated within the last 4 weeks.", "Treatment with any other investigational drug within 4 weeks before trial entry.", "Any elective surgery during study participation.", "Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.", "History of dehydration, precoma diabeticorum or shock or diabetic ketoacidosis within the past year prior to screening visit.", "Acute or scheduled investigation with iodine containing radiopaque material.", "Uncontrolled unstable angina pectoris.", "Medical history of acute and clinically relevant pericarditis, myocarditis, endocarditis, recent pulmonary embolism, hemodynamic relevant aortic stenosis, aortic aneurysm."], "nct_id": "NCT00770445"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Has Type 2 Diabetes Mellitus, and is a patient on insulin treatment for at least 3 months.", "Has a body mass index less than 36 kg/m\u00b2", "Has a glycosylated hemoglobin level greater than or equal to 6.0% and less than 10%.", "Patient is on hemo-dialysis with or without residual excretion", "An insulin dose greater than 20 IE/day"], "exclusion": ["Has a history of type 1 diabetes.", "Has acute infections.", "History of hypersensitivity to the study drugs or to drugs with similar chemical structures.", "History of severe or multiple allergies.", "Has a progressive fatal disease other than kidney failure.", "Has a history of drug or alcohol abuse within the last 5 years.", "A history of significant cardiovascular (e.g. Coronary heart failure based on New York Heart Association stage III", "IV), respiratory, gastrointestinal, hepatic (e.g. alanine aminotransferase greater than 2.5 times the normal reference range) or hematological disease.", "History of primary hyperaldosteronism", "Acute myocardial infarction, open heart surgery or cerebral event (stroke/transient ischemic attack) within the last year prior to study start.", "Any further antidiabetic treatment except pioglitazone and insulin.", "History of macular edema.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Treatment with any other investigational drug within 3 months before trial entry.", "Treatment with steroids within 3 months before trial entry.", "Treatment with thiazolidinediones within the past 3 months.", "If statin therapy applicable: Change of medication within the last 4 weeks.", "Pre-treatment with gemfibrozil within the last 12 weeks.", "Pre-treatment with rifampicin within the last 12 weeks.", "Has uncontrolled unstable angina."], "nct_id": "NCT00770640"},{"minimum_age": 30.0, "maximum_age": 60.0, "gender": "M", "inclusion": ["type 2 diabetes mellitus with HbA1c 8.0-12.0%,", "fasting S-triacylglycerol 2.0-10.0 mmol/L,", "body mass index 25-40 kg/m2 and/or waist/hip ratio > 0.90."], "exclusion": ["fasting total cholesterol >10 mmol/L,", "blood pressure 170/110 mmHg", "other significant disease", "Use of any corticosteroid, anticoagulant or lipid-lowering drug 2 weeks prior to inclusion."], "nct_id": "NCT00605787"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Clinical Diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to enrollment", "Fasting Plasma Glucose between 126 and 240 mg/dL", "Hemoglobin-A1c (HbA1c) between 6.8% and 10.0%", "Fasting C-peptide > 0.8 ng/mL"], "exclusion": ["Treatment with any pharmacotherapy for Type 2 Diabetes Mellitus within previous 6 weeks prior to screening", "Prior treatment with Thiazolidinedione, including Troglitazone, Rosiglitazone, pioglitazone", "BMI > 42 kg/m2", "Presence of any diabetic complications requiring chronic therapy", "Presence or history of any form of hepatic disease", "Serum creatinine > 1.8 mg/dL", "History of cardiac arrhythmias or abnormal cardiac electrophysiology", "Any reason that, in the Investigator's judgment, would have interfered with the ability of the subject to comply with the requirements of the protocol"], "nct_id": "NCT00952445"},{"minimum_age": 21.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Glycosylated haemoglobin >=7 and <= 10%", "Age >=21 and <= 65", "Body Mass Index >=18.5 and <=38 kg/m2", "African American origin", "Signed and dated informed consent prior to admission to the study"], "exclusion": ["Any finding of the medical examination considered clinically relevant by the Investigator", "Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency New York Heart Association (NYHA) II-IV, known cardiovascular disease including hypertension >160-100 mmHg (under current treatment), stroke and transient ischemic attack (TIA).", "Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes", "Clinically relevant diseases of central nervous system or psychiatric disorders or relevant neurological disorders besides polyneuropathy", "Diagnosis of sickle cell anemia or known chronic anemia", "History of chronic or relevant infections (for example human immunodeficieny virus (HIV), Hepatitis B)", "History of relevant allergy/hypersensitivity", "Intake of drugs with a long half life (>24hours) within at least one month or less than 10 half lives of the respective drug prior to administration except allowed co medication", "Alcohol abuse, drug abuse 10. Any laboratory value of clinical relevance that is outside an acceptable range 11. Change of drug dosing of allowed co medication 12. Any (electrocardiogram) ECG value outside the reference range and of clinical relevance. 13. Fasted glucose >270 mg/dl or randomly determined blood glucose >400 mg/dl on two consecutive days during screening or wash out 14. Serum creatinine above upper limit normal at screening"], "nct_id": "NCT00935220"},{"minimum_age": 50.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type II Diabetes.", "Mild-moderate diabetes retinopathy.", "Diffuse clinically significant macular edema (demonstrated by angiofluoresceingraphy, associated or not to cystic changes).", "Age between 50 to 75 years.", "Foveal thickening greater than 300 microns tested with Optical Coherence Tomography (OCT).", "Visual acuity better than 0,05.", "None of the"], "exclusion": [".", "Informed consent signed.", "Data protection consent signed. Exclusion Criteria:", "Bad metabolic control in recruitment stage (as criteria from Endocrinology Department of each Center) or Glicosilated Hemoglobine greater than 9%.", "Uncontrolled hypertension. Greater than 150/90.", "Systemic treatment with oral corticosteroids, diuretics or immunosupressors 3 months before or during the study.", "Record of ocular hypertension induced by corticosteroids.", "Glaucoma or ocular hypertension.", "Unbalanced heart failure.", "Any other pathology that could cause macular edema.", "Associated ischemic maculopathy. (Parafoveal avascular area thickening greater than 1000 microns)", "Patients with Clinically Significant Macular Edema with posterior hyaloid thickening or macular traction in biomicroscopy or OCT.", "Patients with panretinophotocoagulation.", "Patients that will probably need a panretinophotocoagulation during the study (6 to 12 months).", "Record of ocular herpes infection.", "Lens opacification that may interfere with clinical, photographical or OCT examinations.", "Toxoplasmosis, active or not in the study eye.", "Vitrectomy in either eye.", "Record of Central Serose Coroidopathy.", "Pseudophakic patients with less than 6 months since surgery.", "Patients with any other situation that may interfere in study completion based in Investigator\u00b4s opinion."], "nct_id": "NCT00309192"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": [": Non-Diabetes:", "Fasting blood glucose < 7.0 mmol/L or a random blood glucose of < 11.1 mmol/L Diabetes:", "Poorly controlled type 2 diabetes (fasting plasma glucose greater than or equal to 7.0 or random plasma glucose greater than or equal to 10.0 mmol/L)", "Newly diagnosed type 2 diabetes (fasting plasma glucose greater than or equal to 7.0 mmol/L or random plasma glucose greater than or equal to 11.1 mmol/L)", "Age > 30", "English-speaking", "Agrees to participate in the study and lives in the Lower Mainland"], "exclusion": ["Scheduled to undergo surgery other than infrainguinal bypass surgery", "Under 30 years of age", "Living outside of Lower Mainland", "Cannot speak and understand English"], "nct_id": "NCT00456105"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male or female patients aged 18 to 70 years, with type 2 diabetes mellitus (non-insulin dependent diabetes) for at least 6 months prior to study start", "HbA1c between 7.0 and 9.5%", "On stable dose metformin monotherapy", "Stable body weight"], "exclusion": ["Poorly controlled type 2 diabetes (very low or very high blood sugar levels, or other indicators of poor control)", "Acute infections prior to dosing", "Patients with type 1 diabetes (insulin-dependent diabetes)", "Taking diabetes medication (other than metformin) Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00605475"},{"minimum_age": 20.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Age between 20 and 65 years", "BMI between 23 and 34", "Oral agents or insulin to control T2DM", "Inadequate control of diabetes as defined as HbA1c >/ 7.5", "Understanding of the mechanisms of action of the treatment"], "exclusion": ["More than 10 years of T2DM diagnosis", "More than 7 years of insulin use", "Previous abdominal operations", "Coagulopathy", "Liver cirrhosis", "Unable to comply with study requirements, follow-up schedule or give valid consent.", "Currently pregnant."], "nct_id": "NCT00456352"},{"minimum_age": 70.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Insulin naive", "Treatment with oral anti-diabetic drugs (OADs) for at least 3 months and not achieving therapeutic targets", "HbA1c between 8%", "10.5%"], "exclusion": ["Secondary diabetes, MODY (Maturity Onset Diabetes of the Young)", "Previous treatment with insulin (except for short-term treatment with insulin for intercurrent illness as judged by the Investigator)", "Proliferative retinopathy, maculopathy requiring treatment,", "Hypoglycaemia unawareness as judged by the Investigator, recurrent major hypoglycaemia", "End stage liver disease (increased liver enzymes 4 fold), end stage renal disease assessed by MDRD (Modification of Diet in Renal Disease) less than 30 ml/min or dialysed patient, acute heart failure, any acute cardiovascular event or cerebrovascular event less than 6 months", "Acute disease with poor prognosis", "History of alcoholism, drug abuse, or psychiatric disease or personality disorders likely to invalidate voluntary consent or to prevent good compliance with the trial protocol", "Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation (patients having a score of less than 15 in a previous MMSE (Mini-Mental State Examination) in the last six months) and any conditions as judged by the investigator", "Legal incapacity or limited legal capacity (patients under guardianship or curatorship)", "Concomitant medication for Alzheimers treatment (Memantine, Anticholinesterasique treatment)", "Participation in another clinical trial less than one month before inclusion in this trial", "Illness requiring repeated hospitalisation", "Known or suspected allergy to the insulin or any compositional component", "Anticipated change or new use in concomitant medication known to interfere with glucose metabolism, such as systemic corticotherapy more than 5 mg/day (prednisone)", "Any other condition that the Investigator feels would interfere with trial participation or evaluation of results", "Terminal illness"], "nct_id": "NCT00506662"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["type 2 diabetes mellitus for at least 1 year", "treated with oral antidiabetic agents or insulin at stable doses for at least 3 months", "HbA1c between 6 and 12% inclusive", "baseline retinopathy severity not to exceed 53/<53 on the ETDRS scale", "unlikely to require laser surgery or vitrectomy within upcoming year"], "exclusion": ["prior treatment with insulin glargine", "treatment with insulin analogs (eg insulin lispro or aspart) in the year prior to enrollment"], "nct_id": "NCT00174824"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Blood glucose criteria must be met", "Not currently on drug therapy for type 2 diabetes", "Body mass index (BMI) in the range 22-45"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of serious diabetic complications", "Evidence of serious cardiovascular conditions", "Laboratory value abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00101673"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["After the physician decision has been made to use insulin detemir, any subject with Type 1 or Type 2 diabetes mellitus is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician."], "exclusion": ["Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit;", "Subjects currently being treated with insulin detemir;", "Subjects who previously enrolled in this study", "Subjects with a hypersensitivity to insulin detemir or to any of the excipients", "Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures. (Adequate contraceptive measures are an intrauterine device, oral contraceptives and barrier methods)"], "nct_id": "NCT00701155"},{"minimum_age": 13.0, "maximum_age": 20.0, "gender": "A", "inclusion": ["greater than or equal to the 85th percentile in BMI", "in 9th through 11th grades at participating schools"], "exclusion": ["BMI greater than or equal to 40", "previously diagnosed type 1 or type 2 diabetes", "blood pressure in the range of stage 2 hypertension", "medications that significantly interfere with weight"], "nct_id": "NCT00841334"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Diabetic patients registered in the particular centre for more than 12 months", "Patients should have visited the centre at least once in the last 3-6 months apart from the initial visit", "Patients willing to sign informed consent form"], "exclusion": ["Repetition of any patient as patients should not be included twice for any reason", "Unwilling to participate or unable to comply with protocol requirements"], "nct_id": "NCT00874159"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus", "Body mass index (BMI) of 27 to 45 kg/m2 with weight </= 136 kg (300 lbs.", "Capacity to provide written informed consent", "Systolic blood pressure between 90 and 160 mm Hg, inclusive.", "Diastolic blood pressure between 65 and 100 mm Hg, inclusive.", "Resting heart rate between 65 and 90 beats per minute, inclusive."], "exclusion": ["a recent (i.e., within 1 year) myocardial infarction", "unstable angina", "malignant arrhythmias", "history of cerebrovascular, renal, or hepatic disease", "history of seizures", "protein wasting diseases (e.g., Cushing's syndrome)", "uncontrolled hypertension (> 160/100 mm Hg)", "type 1 diabetes", "uncontrolled thyroid disease", "pregnancy or lactation", "electrolyte abnormalities", "clinically significant psychosocial impairment (principally, major depression)", "treatment with steroids"], "nct_id": "NCT00729196"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Has type 2 diabetes.", "Has received no treatment with antidiabetic medication in the 12 weeks prior to Screening, other than short-term use defined as less than or equal to 15 days.", "A glycosylated hemoglobin greater than or equal to 7.5% and less than or equal to 10.0% at Screening.", "Body mass index less than or equal to 45 kg/m2.", "Has received counseling on lifestyle modification for type 2 diabetes, including diet and exercise.", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.", "Stable condition as determined by a physician."], "exclusion": ["Type 1 diabetes.", "Unstable angina or heart failure of any etiology with New York Heart Association functional class III or IV.", "History of myocardial infarction, cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass graft, or transient ischemic attack in the 6 months prior to Screening.", "Male participant has a serum creatinine level greater than or equal to 1.5 mg per dL or female subject has a serum creatinine level greater than or equal to 1.4 mg per dL.", "Has a triglyceride level greater than 500 mg per dL.", "Male participant has a hemoglobin level less than 10.5 g per dL or female subject has a hemoglobin level less than 10.0 g per dL.", "Alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.", "History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within 2 years prior to Screening.", "Has been discontinued from a thiazolidinedione or metformin therapy due to lack of efficacy or clinical or laboratory signs of intolerance.", "Previous history of cancer, other than basal cell or stage 1 squamous cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.", "History of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.", "Any disease or condition at Screening or Randomization that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.", "Currently participating in another investigational study or has participated in an investigational study within 30 days prior to randomization.", "Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Antidiabetic medications other than study medication", "Chronically used oral or parenteral glucocorticoids", "Niacin greater than 200 mg per day, including niacin-containing products such as Advicor", "Chronically used steroid-joint injections"], "nct_id": "NCT00727857"},{"minimum_age": null, "maximum_age": null, "gender": "F", "inclusion": ["Healthy pregnant women in 2nd Trimester of pregnancy scheduled for the measurement of fasting glucose value"], "exclusion": ["Pregnant women with pre-existent (Type 1 or 2) diabetes or already diagnosed diabetes of pregnancy"], "nct_id": "NCT00502359"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["BMI of 27-40 kg/m2", "30-75 years of age", "Stable body weight for the preceding 6 months", "Diagnosis of type 2 diabetes for at least 6 months prior to enrollment", "HbA1c of 6.5 to 9.0", "Treatment by diet or oral agents only"], "exclusion": ["Pregnancy or lactation", "Active cardiac, pulmonary, renal, liver, or gastrointestinal disease", "Untreated thyroid disease or hypertension", "Hypertriglyceridemia with levels of TG > 500 mg/dl", "Use of insulin", "Use of specific medications that may alter lipid or glucose metabolism (other than the statins)", "Use of medications that commonly cause significant alterations in body weight (e.g., corticosteroids)."], "nct_id": "NCT00622960"},{"minimum_age": 15.0, "maximum_age": null, "gender": "A", "inclusion": ["(1) patients fulfilling the diagnosis of type 2 diabetes mellitus19 and receiving oral hyperglycemic agent or insulin treatment with regular follow-up at outpatient clinics, (2) neurologically asymptomatic, i.e. absence of subjective motor or sensory symptom, and absence of motor or sensory sign on neurological examinations, (3) absence of renal impairment or other systemic disease, (4) absence of bleeding tendency, obvious limb edema, poor cardiopulmonary function, acute symptoms of poor diabetic control or any other contraindication for skin biopsy."], "exclusion": ["Use of anti-coagulant; any causes with bleeding tendency; moderate to severe limb edema; history of poor wound healing; poor hygiene and poor care patients; uremia under dialysis."], "nct_id": "NCT00155142"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female patients aged greater than or equal to 18 years.", "Diagnosis of type 2 diabetes as defined by WHO criteria for at least 2 months but no longer than 3 years.", "Type 2 diabetes not previously treated by a pharmacological agent. Note:", "a) insulin use is accepted if it is not within 6 months prior to screening visit and only for the following reasons:", "prior use for management of gestational diabetes,", "short-term (less than or equal to 1 month) use to maintain glycemic control for hospitalization, medical procedures, or intervention.", "b) use of an oral antidiabetic agent is accepted if it is not within 6 months prior to screening visit and only if it was prescribed for no more than 4 months.", "HbA1C greater than or equal to 7% and less than or equal to 10%.", "Having signed the informed consent form."], "exclusion": [": General:", "Weight loss > 5 kg within 3 months prior to screening visit.", "Pregnancy or lactation.", "Absence of medically approved contraceptive methods for females of childbearing potential.", "Marijuana or hashish users.", "Administration of other investigational drugs within 30 days prior to screening visit.", "Previous participation in a rimonabant study.", "Presence or history of allergic reaction or intolerance to multiple drugs.", "Presence of any other condition (e.g., geographic, social) that the Investigator feels that would restrict or limit the patient's participation for the duration of the study. Related to endocrine and metabolic disorders:", "Presence of any clinically significant endocrine disease according to the Investigator. Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit.", "Fasting C-peptide < 1.0 ng/mL. Related to other disorders:", "Presence of any severe medical or psychological condition that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.", "Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer. Related to laboratory findings:", "Positive test for hepatitis B surface antigen and/or hepatitis C antibody.", "Abnormal TSH level (TSH > ULN or < LLN).", "Hemoglobin < 11 g/dL and/or neutrophils < 1,500/mm3 and/or platelets < 100,000/mm3.", "Positive urine pregnancy test.", "Positive urine test for marijuana or hashish metabolites. Related to previous or concomitant medications:", "Oral antidiabetic agent except if it is not within 6 months prior to screening visit and only if it was prescribed for no more than 4 months.", "Insulin except if it is not within 6 months prior to screening visit and only for management of gestational diabetes or short-term use to maintain glycemic control for hospitalization, medical procedures, or intervention.", "Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc)."], "nct_id": "NCT00257257"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subjects with type 2 diabetes, currently treated with insulin glargine or other intermediate- or long-acting insulin, with or without oral antidiabetic medications, but experiencing inadequate glycemic control and willing and capable of participating in a regimen of intensive insulin administration. A subject who has been on an intermediate- or long acting insulin for >/=6 months but <5 years, and, in spite of dosage adjustments based on home blood glucose monitoring, is unable to achieve a HbA1c of <7%.", "BMI >/= 20kg/m2 and </=45 kg/m2", "Fasting C-peptide >/=0.8 ng/mL (>/= 0.26 nmol/L)", "HbA1c between 7.0% and 10.5%, inclusive", "Use of oral or systemically injected glucocorticoids is generally not allowed within 3 months before randomization; inhaled, intra articular, and topical corticosteroids are allowed", "Hemoglobin </=11 g/dL for male subjects and >/=10 g/dL for female subjects", "Creatinine clearance >60 mL/min (calculated using the Cockcroft Gault formula)", "Thyroid stimulating hormone level is normal or clinically euthyroid as demonstrated by further thyroid tests (e.g., T4, T3, thyroid-binding globulin)", "Female subjects of childbearing potential (i.e., not surgically sterile and/or not postmenopausal) must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study including the 8 week Posttreatment Follow-up Period", "Able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor as per the protocol recommendations of self administration", "No major illness or debility that in the investigator's opinion prohibits the subject from actively participating in their diabetes management and completing the study", "Able and willing to provide written informed consent"], "exclusion": ["History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening.", "History of treated diabetic gastroparesis", "Current ongoing symptomatic biliary disease or history of pancreatitis", "History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux en Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantly affect upper gastrointestinal function", "Recent clinically significant cardiovascular and/or cerebrovascular disease including but not limited to the following:", "Previous history of stroke or transient ischemic attack within 1 month before Screening.", "Acute coronary syndrome, which includes the following:", "Documented MI within the 2 months before Screening and during the period up until receiving the first dose of study medication", "Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within the 2 months before Screening and during the period up until receiving the first dose of study medication", "Unstable angina not responsive to nitroglycerin within the 2 months before Screening and during the period up until receiving the first dose of study medication", "Unstable cardiac rhythm, however, as an example, controlled atrial fibrillation is allowed", "Current or history of heart failure (New York Heart Association class I to IV).", "Resting systolic pressure is >160 mm Hg and/or diastolic pressure >100 mm Hg.", "QTc interval (Fridericia) >470 ms confirmed by a central reader at Screening", "History of stroke or other central nervous system disorder that would negatively impact the subject's ability to participate in a program of intensive insulin management (eg, physically or mentally incapable of performing home blood glucose monitoring or administering and/or adjusting insulin dosage)", "Hemoglobinopathy that may affect determination of HbA1c", "History of human immunodeficiency virus infection", "History of total bilirubin >1.5 \u00d7 ULN unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin <35% of total bilirubin", "ALT or aspartate aminotransferase (AST) >2.5 \u00d7ULN", "Fasting triglyceride level >850 mg/dL at Screening or Week -1 (Visit 5).", "Acute symptomatic (within 3 months before Screening) infection with hepatitis B or hepatitis C; however, subjects with past or chronic hepatitis B or hepatitis C are allowed provided the requirements for ALT, AST, and total bilirubin are met", "History of a psychiatric disorder that will affect the subject's ability to participate in the study", "History of alcohol or substance abuse within 1 year before Screening", "Positive urine drug screen at Screening, unless the subject is taking a medically approved medication for which a positive drug screen simply verifies the use of this medication", "Hypoglycemia unawareness which has impaired cognitive function and required outside assistance", "Female subject is pregnant (confirmed by laboratory testing), lactating, or <6 weeks postpartum", "Known allergy to any GLP 1 analogue, insulin, other study medications' excipients, excipients of albiglutide, or Baker's yeast", "Receipt of any investigational drug within the 30 days, or 5 half lives whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization, or receipt of albiglutide in previous studies", "Current use of any GLP 1 analogue", "History of type 1 diabetes mellitus, diabetic complications (e.g., active proliferative retinopathy or severe diabetic neuropathy) that in the opinion of the investigator would preclude effective participation in the study, or a history of ketoacidosis or hyperosmolar coma", "Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., insulin glargine or lispro insulin)", "History or family history of medullary carcinoma", "History or family history of multiple endocrine neoplasia type 2"], "nct_id": "NCT00976391"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Duration of type 2 diabetes mellitus for at least one year", "Insulin naive patients", "OHA treatment for at least 12 weeks", "HbA1C between 7.5-10.0%", "Body Mass Index (BMI) below 30.0 kg/m2"], "exclusion": ["Impaired renal function", "Impaired hepatic function", "Pregnant, breast-feeding (within a year after delivery), intention of becoming pregnant or not using adequate contraceptive methods"], "nct_id": "NCT00604253"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["mild to moderate hypertension", "naive to antihypertensive medication or on two or less antihypertensive medications", "impaired glucose tolerance", "mild obesity"], "exclusion": ["Diagnosis of Type 1 or Type 2 diabetes", "History of severe heart failure", "AST, ALT levels more than twice the normal range"], "nct_id": "NCT00847899"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Between eighteen (18) and eighty (80) years of age", "Type 1 or Type 2 diabetes mellitus", "Diabetes is under adequate control", "Diabetic foot ulcer located on the mid or forefoot", "Diabetic foot ulcer has been present for at least four (4) weeks and no more than two (2) years prior to screening", "Diabetic foot ulcer is \u2265 1.0cm\u00b2 and \u226410cm\u00b2 in size", "Diabetic foot ulcer is grade 1 or 2 according to the Wagner Grading system."], "exclusion": ["Ulcer is over an active Charcot deformity of the mid-foot (\"Rocker-Bottom Foot\") or over the talus, distal calcaneous, navicular, or cuboid bones or a deformity that interfere with off-loading in the opinion of the investigator", "Ulcer due to a non-diabetic aetiology", "Ulcer has tunnels or sinus tracts that cannot be completely debrided.", "Clinical evidence of infection", "Osteomyelitis", "Subject has vasculitis, severe rheumatoid arthritis, other collagen or vascular diseases or other medical conditions, outside of diabetes, known to impair wound healing."], "nct_id": "NCT00434538"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female subjects > 18 years of age", "Clinical diagnosis of type 2 diabetes mellitus or on insulin or oral hypoglycemic agents", "Body mass index of > 30 kg/m2", "The subject must we willing and able to monitor their blood glucose with a glucometer at least 2 times per week."], "exclusion": [], "nct_id": "NCT00108459"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["adult patients, 40-80 years of age;", "type 2 diabetes;", "normal renal function, or impaired but stable renal function;", "stable with regard to medication or treatment regimen taken for renal impairment or diabetes."], "exclusion": ["patients with a renal transplant;", "end-stage renal disease, requiring dialysis;", "nephrotic syndrome, or a history of nephrectomy;", "type 1 diabetes mellitus."], "nct_id": "NCT00933972"},{"minimum_age": 3.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Type 1 diabetes mellitus", "Diagnosed 6 or more months ago", "Patient of the Alberta Children's Hospital Diabetes Clinic"], "exclusion": ["Adrenal insufficiency", "Uncompensated hypothyroidism", "Clinical autonomic neuropathy", "Celiac disease", "Lack of family support", "Unwilling or unable to follow the study protocol", "Subjects with less than 4 hypoglycemic events per month"], "nct_id": "NCT00706693"},{"minimum_age": 1.0, "maximum_age": 6.0, "gender": "A", "inclusion": ["Type 1 diabetes for at least 6 months prior to enrollment", "Seen for diabetes care at Children's National or Virginia Commonwealth", "Child ages 1-6"], "exclusion": ["Non-English speaking primary caregiver", "Child with significant developmental delay"], "nct_id": "NCT00847327"},{"minimum_age": 17.0, "maximum_age": null, "gender": "A", "inclusion": ["Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L", "2h plasma glucose level of 7.5-13 mmol/L", "Body mass index (BMI) of 22 kg/m2", "Two occasions of a ratio of urinary albumin to urinary creatinine\u2265300 or 24 hours urinary protein concentration is >150mg.", "Informed consent"], "exclusion": ["Type1 diabetes or nondiabetic renal disease"], "nct_id": "NCT00361023"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis as Type 2 Diabetes", "Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control", "Outpatients"], "exclusion": ["Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes", "Significant heart diseases", "Significant diabetic complications Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00368134"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients must have a diagnosis of type 2 diabetes", "Body mass index (BMI) >=22 to <=45 kg/m2, at screening", "Patients must be taking a stable dosage of metformin as monotherapy at screening", "Patients must have a HbA1c between >=7% and <=9.5% at Week 2", "Patients must have a fasting plasma glucose (FPG) <=270 mg/dL (15 mmol/L) at Week -2"], "exclusion": ["Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin", "History of diabetic ketoacidosis or type 1 diabetes mellitus", "History of pancreas or beta-cell transplantation", "History of active proliferative diabetic retinopathy", "History of hereditary glucose-galactose malabsorption or primary renal glucosuria", "Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant", "Taken thiazolidinedione therapy in the past 16 weeks before screening"], "nct_id": "NCT00968812"},{"minimum_age": 21.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes who are drug-naive", "Screening HbA1c \u2265 6.8% and \u2264 9.7%", "Screening fasting or random C-peptide > 0.5 ng/mL", "< 35 years old must be negative for anti-GAD antibodies", "Body Mass Index < 35 kg/m2"], "exclusion": ["Symptoms of poorly controlled diabetes", "History of diabetic ketoacidosis, hyperosmolar nonketotic coma, or insulin therapy within one year of screening", "Receipt of oral antihyperglycemic medications for more than six months in total since diagnosis", "Significant cardiovascular history"], "nct_id": "NCT00950599"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients diagnosed with type 2 diabetes mellitus", "Aged over 18 years, either sex", "HbA1c level more than 7%", "Patients treated only with oral anti-diabetic drugs or diet"], "exclusion": ["Patients with severe health problems including renal disease, liver disease, cardiovascular disease and other chronic ill health conditions", "Patients with mental health problems", "Patients treated with insulin therapy", "Patients refused to give informed consent", "Pregnant and lactating women", "Patients taking cinnamon supplements and other herbal supplements known to be effective"], "nct_id": "NCT00846898"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Age 18-50 years", "Sandy Lake First Nation permanent resident, with total travel outside of the community less than one month per year.", "Aboriginal Ethnicity", "BMI = 23-40 kg/m2", "According to Prochaska and DiClemente's transtheoretical model, also referred to as the Stages of Change Theory, potential participants must be at least at the contemplation stage.", "Willing and able to follow the study protocol"], "exclusion": ["DM detected by OGTT", "Pregnancy, lactation or intention to become pregnant within six months from recruitment", "Any pre-existing condition compromising macronutrient metabolism, quality of life or ability to participate according to protocol. Individuals with the following conditions will be excluded automatically: heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, liver or kidney disease", "Insurmountable language barriers"], "nct_id": "NCT00707460"},{"minimum_age": 21.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["regular sleep habits", "BMI 20 to 27 kg/m2", "at least one parent, sibling or grandparent with type 2 diabetes", "no regular exercise habits"], "exclusion": ["active smoker", "night or shift work", "have highly variable sleep habits", "have a hormonal disorder", "have a sleep disorder", "have an active medical problem", "women only: use of birth control pills", "women only: irregular menstrual periods or pregnancy", "use of medications/compounds that can disrupt sleep"], "nct_id": "NCT00721019"},{"minimum_age": 19.0, "maximum_age": null, "gender": "A", "inclusion": ["Completion of study CLAF237A2307 within 4 weeks of entering into the extension", "Written informed consent", "Ability to comply with all study requirements", "Blood glucose criteria must be met"], "exclusion": ["Premature discontinuation from study CLAF237A2307"], "nct_id": "NCT00300287"},{"minimum_age": 20.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus with HbA1c > 7.0%", "Body mass index > 27 and < 43 kg/m2", "Candidate for general anesthesia"], "exclusion": ["Prior bariatric surgery of any kind", "Cardiovascular conditions including significant coronary artery disease, peripheral vascular disease, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension", "Kidney disease or chronic renal insufficiency with a creatinine level > 1.8 mg/dl", "Known history of chronic liver disease (except for NAFLD/NASH)", "Gastrointestinal disorders, malabsorptive disorders, or inflammatory bowel disease", "Psychiatric disorders including dementia, active psychosis, severe depression requiring > 2 medications, history of suicide attempts, alcohol or drug abuse within the previous 12 months", "Severe pulmonary disease defined as FEV1 < 50% of predicted value", "Pregnancy"], "nct_id": "NCT00432809"},{"minimum_age": 10.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Type I Diabetes Mellitus", "Age of 10-16 year old"], "exclusion": ["Significant Developmental Delay", "Any other condition that in the opinion of the medical treatment team would interfere with his/her ability to participate"], "nct_id": "NCT00848822"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Newly diagnosed type 2 diabetes mellitus patients", "HbA1c > 6.5 and < 9.0%", "Fasting fingertip capillary blood glucose (FCBG) < 9 mmol/L after 2 weeks diet control"], "exclusion": ["History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse", "Liver disease", "Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks Other protocol-defined inclusion/exclusion criteria applied to the study."], "nct_id": "NCT00928889"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["To be eligible, the following inclusion criteria (1-3) must be met:", "Age >= 18 years", "Diagnosis of diabetes mellitus (type 1 or type 2)", "Able and willing to provide informed consent. Subject-level"], "exclusion": ["A patient is not eligible if any of the following exclusion criteria (4-6) are present:", "A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).", "Patient is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first year of the study.", "Blood pressure >180/110 (systolic above 180 OR diastolic above 110). Study Eye Criteria To be a study eye, all of the inclusion criteria (a-e) and none of the exclusion criteria (f-m) listed below must be met. A patient can have only one study eye. If both eyes are eligible and undergoing vitrectomy, the first eye having surgery will be the study eye. The eligibility criteria for a study eye are as follows: Inclusion", "Vitrectomy being performed as treatment for DME.", "E-ETDRS visual acuity 20/800 or better (E-ETDRS visual acuity score >= 3 letters).", "Definite retinal thickening due to diabetic macular edema based on clinical exam involving the center of the macula.", "Presence of vitreomacular traction associated with macular edema OR edema is felt to be too diffuse to respond to focal or grid laser OR edema judged to be inadequately responsive to previous treatment(s) and unlikely to benefit from further focal photocoagulation.", "Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs. Exclusion", "Macular edema is considered to be due to a cause other than diabetic macular edema.", "An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary abnormalities, subfoveal hard exudates, fibrous metaplasia, nonretinal condition).", "An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, post-surgical cystoid macular edema, etc.).", "History of retinal macular photocoagulation, intravitreal corticosteroids, or other treatment for DME within 3.5 months prior to enrollment. 10. History of peripheral scatter photocoagulation within 4 months prior to enrollment or anticipated need within the 4 months following enrollment. 11. History of prior pars plana vitrectomy. 12. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 6 months or anticipated within the next 6 months following enrollment. 13. History of YAG capsulotomy performed within 2 months prior to enrollment."], "nct_id": "NCT00709319"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included.", "Duration of diabetes for > 1 year and < 15 years with stable diabetic therapy within last 6 months.", "Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85 mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale)."], "exclusion": ["Patients with the following conditions are excluded from participation in the study:", "Cataract or media opacity of a degree which precludes taking gradable retinal photographs", "Angle closure glaucoma, which precludes pharmacological dilatation of the pupil", "History of retinopathy", "History or presence of clinical significant macular oedema (CSME)", "History or evidence of photocoagulation of the retina Other retinal conditions which may mask assessment, eg, retinal vein occlusion", "Positive micral dipstick test", "Presence of secondary diabetes", "Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception", "Need of treatment with ACE-inhibitor", "Haemodynamically significant aortic or mitral valve stenosis", "Known renal artery stenosis or kidney transplantation", "Hypersensitivity to study drug", "Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator"], "nct_id": "NCT00252733"},{"minimum_age": null, "maximum_age": 0.07692307692307693, "gender": "A", "inclusion": ["HLA genotypes that increase risk of type 1 diabetes: heterozygous for DRB1*03, DQA1*0501, DQB1*0201 / DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 \u2260 *0403 or related alleles), or homozygous for DRB1*03, DQA1*0501, DQB1*0201, or homozygous for DRB1*04, DQA1*03011, DQB1*0302 (DRB1*04 \u2260 *0403 or related alleles)."], "exclusion": ["Premature, low birthweight, or major congenital malformations or serious chronic disease"], "nct_id": "NCT00141986"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Confirmed diagnosis of Type II diabetes for at least 2 years", "Type 2 diabetics on oral hypoglycemic agents and/or insulin", "Fasting blood sugar of >200mg% on at least two occasions", "Willing to keep a weekly diary and undergo observation for 12 months"], "exclusion": ["Presence of of previous and/or acute diabetic complications such as myocardial infarction, CVA or nephropathy"], "nct_id": "NCT00703612"},{"minimum_age": 18.0, "maximum_age": 77.0, "gender": "A", "inclusion": ["Male and females, \u226518 to \u226477 years old, with type 2 diabetes mellitus", "Subjects must have central laboratory pre-randomization A1C \u22657.0 and \u2264 10.0%", "C-peptide \u2265 1.0 ng/mL (0.34 nmol/L)", "Body Mass Index \u2264 45 kg/m\u00b2", "Must be able to perform self monitoring of blood glucose"], "exclusion": ["aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3* upper limit of normal (ULN)", "Serum Total bilirubin >2 mg/dL (34.2 \u00b5mol/L)", "Creatinine kinase >3* ULN", "Serum creatinine \u22651.50 mg/dL (133 \u00b5mol/L) for male subjects, \u22651.40 mg/dL (124 \u00b5mol/L) for female subjects", "Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases"], "nct_id": "NCT00736879"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male or females between the ages of 18 to 70 diagnosed with Type 2 diabetes.", "Body mass Index (BMI) between 18 kg/m2 and 37 kg/m2.", "HbA1c levels between 6.5 and 9.0 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or 6.2-9.0% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1% and fasting plasma glucose between 110 and 240 mg/dL (inclusive) while on diabetic medications.", "If taking drugs for diabetes, must be medically able and willing to discontinue diabetes medications for the duration of the study.", "Female subjects must be surgically sterilized or postmenopausal.", "Non-smoker for at least 3 months.", "Negative alcohol screen."], "exclusion": ["Type 1 diabetes.", "Use of insulin therapy or oral antidiabetic medication other than metformin, sitagliptin or a sulfonylurea.", "Sitting blood pressure above 150/95 mmHg on 2 evaluations at least 10 minutes apart at screening.", "Treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.", "Previous treatment with EGT0001474.", "Vaccination within 30 days prior to the first dose of study medication."], "nct_id": "NCT00924053"},{"minimum_age": 30.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Insulin resistant: diagnosed with pre-diabetes or fasting blood glucose >/= 100 mg/dL", "T2D: diagnosed by primary care physician", "BMI: less than 43 kg/m2", "Age: 30-65"], "exclusion": ["Smoking", "Insulin use (other than once daily)", "Underlying conditions that limit ability to exercise safely", "Recent weight gain or loss (> 5% of body weight in 3 months)", "Physically active (> 30 min aerobic exercise, 2 d/wk)", "Recent (< 3 mo) changes in medication use or dose", "Uncontrolled T2D (HbA1c > 10%)", "Advanced retinopathy or neuropathy", "Pregnancy"], "nct_id": "NCT00972452"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes on stable insulin regimen with or without oral agents for at least 3 months", "HbA1c > 7%", "No significant cardiovascular, renal or other serious medical diseases"], "exclusion": ["HbA1c < 7%", "Chronic renal, hepatic, cardiovascular, or other serious medical illness", "Females of childbearing age not using adequate contraception", "Use of GLP mimetic"], "nct_id": "NCT00606034"},{"minimum_age": 20.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Documented type 2 diabetes with total disease duration \u226410 years", "BMI of at least 35 kg/m^2", "Patient is a surgical candidate for either RYGBP, GBS or vertical sleeve gastrectomy (VSG)"], "exclusion": ["Any illness that might confound the results of the study or pose additional risk to the patient by participation", "History of stroke, seizures, or other major neurological disorder", "History of cancer", "Patient uses or has used any medication that can alter body weight", "Patient is unwilling or unable to follow study procedures"], "nct_id": "NCT00957957"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Stable weight (<5% variation) within the last three months", "Age: 35 to 50 years old for middle-age group, and 65 to 80 y old for elderly group", "Body mass index (BMI): 20 to 29.9kg/m2", "T2DM with diagnosis above 35 years and less than 5 years (Middle-age group)", "T2DM with diagnosis above 65 years and less than 5 years (Elderly group)", "Use of oral antidiabetic drugs (that must at stable dose within the last 3 months)", "Not have participated in any study of intervention with drugs in the last six months."], "exclusion": ["Use of estrogen, progestogen, active antipsychotics and systemic corticosteroids", "Use of DPP-IV inhibitors and incretin mimetics (current or within 1 month before)", "Continuous use of insulin or glitazone", "Hepatic cirrhosis, renal failure or any clinical condition with impaired insulin sensitivity", "Smoking", "Obesity", "Uncontrolled systemic or disabling diseases", "T2DM treated by non pharmacological methods", "Patients submitted to bariatric surgery", "Latent autoimmune diabetes of the adult (positive anti-GAD antibodies)"], "nct_id": "NCT00843232"},{"minimum_age": 21.0, "maximum_age": 100.0, "gender": "A", "inclusion": ["Men and postmenopausal women with type 2 diabetes treated with diet plus oral hypoglycemic agents (Sulfonylureas, Biguanides, Thiazolidinediones , and new secretagogues (Repaglinide)) at a stable dose for at least 3 months prior to starting the study", "HbA1c between 6.5 and 8.0% at recruitment", "living within a 40 km radius of St. Michael's Hospital", "Diabetes diagnosed > 6 months prior to randomization"], "exclusion": ["diabetic complications: clinically significant gastroparesis, retinopathy, nephropathy, neuropathy, hepatic disease, or CHD (current clinically significant CHD e.g. unstable angina)", "taking insulin or acarbose", "smoking or significant alcohol intake (> 1 drink/day)", "serum triglycerides > 4.0 mmol/L"], "nct_id": "NCT00438698"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level", "Patient agreeing to take part in the study and capable of completing a self-questionnaire."], "exclusion": ["Hypersensitivity to insulin or to one of the excipients", "Treatment with insulin for at least 6 months", "Participant in a clinical trial for diabetes on entry into the observational study"], "nct_id": "NCT00700960"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Patients between 18 and 85 years of age, inclusive.", "Patients with type 2 diabetes", "Patients have been treated with metformin, at a stable dose for at least 3 months prior to Visit 1", "Patients have HbA1c of 7.0% to 8.9%, inclusive.", "Patients have a body mass index >27 kg/m2 and <40 kg/m2 and meet local CT scan body weight requirements. For South Asian, Japanese, and Chinese patients, a body mass index >=25 kg/m2 is acceptable as the lower limit.", "Patients have a history of stable body weight (not varying by >2 kg in the 3 months prior to Visit 1).", "Medications for the treatment of high blood pressure are stable with respect to treatment regimen for 4 weeks prior to Visit 1.", "Stable regimen of lipid-lowering agents for 6 weeks prior to Visit 1."], "exclusion": ["Have received treatment in the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.", "Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.", "Have a history of renal transplantation, or are currently receiving renal dialysis.", "Have had a clinically significant history of cardiac disease or presence of active cardiac disease within 1 year prior to Visit 1, including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty; or is expected to require coronary artery bypass surgery or angioplasty during the course of the study.", "Have known hemoglobinopathy or clinically significant, chronic anemia.", "Known or are likely to become transfusion dependent during the study.", "Have active, symptomatic proliferative retinopathy.", "Are receiving chronic treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility. (i.e. metoclopramide, cisapride, and chronic use of macrolide antibiotics)", "Have severe gastrointestinal disease, including gastroparesis.", "Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 months immediately prior to Visit 1.", "Have taken exenatide, liraglutide or any other GLP-1 receptor agonist in the past 6 months, either in a clinical study or as commercially available medication. Patients with known allergy to exenatide should be excluded.", "Have used any prescription or over the counter drug to promote weight loss within 3 months prior to Visit 1, or intend to use such a drug during the study. (Examples: Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Acomplia [rimonabant]).", "Have participated in a structured weight loss program within 3 months prior to Visit 1, or intend to participate in such a plan during this study.", "Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to Visit 1: Insulin; Thiazolidinediones; Alpha-glucosidase inhibitors; Sulfonylureas; Oral DPP-IV inhibitors; Meglitinides.", "Are taking warfarin, or a coumarol derivative."], "nct_id": "NCT00701935"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Not currently on drug therapy for type 2 diabetes", "Body mass index (BMI) in the range 20-40", "Blood glucose criteria must be met"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of significant diabetic complications", "Evidence of serious cardiovascular conditions", "Laboratory value abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply."], "nct_id": "NCT00110240"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Not currently on drug therapy for type 2 diabetes", "Body mass index (BMI) in the range 22-45", "Blood glucose criteria must be met"], "exclusion": ["Pregnancy or lactation", "Type 1 diabetes", "Evidence of significant diabetic complications", "Evidence of serious cardiovascular conditions", "Laboratory value abnormalities as defined by the protocol", "Other protocol-defined exclusion criteria may apply"], "nct_id": "NCT00102388"},{"minimum_age": 18.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["History of T2DM treated with Metformin"], "exclusion": ["FPG >= 260 mg/dL (14.4mmol/L) Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00728351"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Type 2 diabetes newly diagnosed within 6-12 months", "FBG: 11.1-17.0 mmol/L", "Body mass index (BMI) larger than 25.0 kg/m2"], "exclusion": ["Known or suspected allergy to trial product(s) or related products", "Recurrent major hypoglycaemia as judged by the Investigator"], "nct_id": "NCT00494988"},{"minimum_age": 35.0, "maximum_age": 65.0, "gender": "M", "inclusion": ["Male type II diabetes patients diagnosed for more than 5 years and aged between 35 and 65 years.", "Subjects treated with metformin alone or metformin and one other oral anti-diabetic drug.", "Subjects should have FPG in the range of 6.0 to 11.0 mmol/L at screening and HbA1c less than 10% (HbA1c value according to international DCCT standard)."], "exclusion": ["History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.", "Renal dysfunction.", "Use of insulin, glitazones, warfarin and amiodarone within 3 months before enrolment and use of potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics within 14 days before administration of IP."], "nct_id": "NCT00960791"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes for at least 24 months", "BMI between 18 and 30 kg/m2", "Insulin naive subjects", "OAD treatment with max two OADs alone or combined with other therapy", "HbA1c between 7-12%"], "exclusion": ["Type 1 diabetes", "Receipt of any investigational drug within the last three months prior to this trial", "Current or previous treatment with thiazolidiones within the last 6 months", "OAD treatment with three or more OADs within the last 4 months"], "nct_id": "NCT00605111"},{"minimum_age": 21.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Current diagnosis of Type II Diabetes Mellitus with A1c level above the upper limit of normal", "Subject currently performs routine finger stick blood sugar testing", "Subject is ambulatory", "None or stable medication regimen without significant side effects for at least 6 months, willingness and ability to maintain the stable medication regimen throughout the course of the study.", "Hemoglobin A1c levels within a 0.8% range of patient mean A1c level for the last two documented determinations, that must be within 2 years of the baseline testing date.", "Willingness to test finger stick blood sugars according to protocol.", "Willingness to have lab test blood draws performed according to protocol", "Willingness to maintain stable diet and activity regimen for the duration of the study.", "Willing and able to abstain from partaking in any non-essential existing or new treatments to improve serum blood sugar levels.", "Adequate contraceptive measures for female subjects", "Male or female", "Any ethnic group", "Between 21 and 80 years of age"], "exclusion": ["Change in medical regimen within 6 months prior to initiation of study", "Any signs of Type I diabetes", "Active infectious process within 3 weeks of study initiation causing wide fluctuations in finger stick blood sugar level.", "Change in BMI of greater than 6% within a 6 month period prior to study initiation", "Any planned revascularization procedure", "Symptomatic congestive heart failure", "Leg or foot ulceration or open wounds", "Gangrene", "History of intermittent claudication", "Hemodialysis", "Currently being treated for malignancy", "Currently being treated with oral or intravenous catabolic steroids.", "Reported consumption of more than 14 alcoholic drinks per week.", "Pregnant, breast feeding,or planning pregnancy prior to the end of participation.", "Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements.", "Uncontrolled hypertension", "Uncontrolled atrial fibrillation or other uncontrolled arrythmias, e.g. tachycardia, bradycardia", "Uncontrolled seizure disorder", "Uncontrolled, unstable, or untreated medical conditions which may significantly impact the subjects health or ability to complete the entire study, in the opinion of the investigator"], "nct_id": "NCT00863954"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patient with type 2 diabetes inadequately controlled by OAD therapy based on the discretion of individual physician", "Patient willing to sign informed consent", "Particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels"], "exclusion": ["Subjects with diagnosed type 1 diabetes mellitus", "Subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits)", "Subjects with hypersensitivity to Levemir\u00ae or to any of the ingredients", "Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months."], "nct_id": "NCT00865397"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["40-75 years old (30 -75 years old if South Asian origin)"], "exclusion": ["Current diagnosis of diabetes", "Terminal illness or mental incapacity"], "nct_id": "NCT00950313"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Body Mass Index (BMI) between 27 kg/m2 and 43 kg/m2 and HbA1c between 7.0% and 10%"], "exclusion": ["History of major psychiatric disorder", "Blood pressure greater than 160/100", "Use of any antihyperglycemic agent other than metformin", "Triglycerides greater then 600 mg/dL"], "nct_id": "NCT00430742"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Treatment with metformin alone for at least three months", "HbA1c (glycosylated haemoglobin A1c) 7.5-10.0% (both inclusive)", "Body Mass Index (BMI) less than or equal to 45.0"], "exclusion": ["Previous treatment with insulin, glucagon like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors", "Treatment with anti-diabetic drugs other than metformin within the last three months", "Any serious medical condition", "Females who are pregnant, have the intention of becoming pregnant or are breastfeeding"], "nct_id": "NCT00700817"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose", "Signed informed consent", "Treatment in accordance with the summary of product characterisation"], "exclusion": ["Any contraindication to metformin or repaglinide"], "nct_id": "NCT00709917"},{"minimum_age": 6.0, "maximum_age": null, "gender": "A", "inclusion": ["After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician"], "exclusion": ["Subjects who are unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for the final visit;", "Subjects currently being treated with insulin detemir;", "Subjects who previously enrolled in this study or studies related to NovoMix 30;", "Subjects with a hypersensitivity to insulin detemir or to any of the excipients;", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 8 months."], "nct_id": "NCT00709475"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Informed consent obtained before any trial-related activities", "Type 2 diabetes", "HbA1c between 7-9%", "Insulin naive", "Inadequate control with oral antidiabetics therapy as judged by investigator"], "exclusion": ["Patients with type 1 diabetes", "Hypersensitivity to Levemir\u00ae or to any of the excipients", "Pregnancy, or desire of pregnancy within next 6 months", "HbA1c greater than or equal to 9%", "Known or suspected allergy to the trial product or to any of the excipients", "Subjects who are unlikely to comply with protocol"], "nct_id": "NCT00700830"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes (diagnosed more than 12 months ago)", "HbA1c greater than 7.0 and less than 12.0% at screening", "Currently on any OAD in more than 3 months ago", "BMI (Body Mass Index) less than 35kg/m2"], "exclusion": ["Previous treatment with insulin in more than 7 days within the last 3 months", "Uncontrolled treated/untreated hypertension (systolic blood pressure greater than 180mmHg and/or diastolic blood pressure less than 110mmHg)"], "nct_id": "NCT00455858"},{"minimum_age": 35.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 diabetes for at least 12 weeks", "HbA1c: 8.0-10.0%", "Current treatment with OAD on monotheray or OAD on combination therapy", "Body mass index (BMI): 21.0-35.0 kg/m2"], "exclusion": ["Known or suspected allergy to trial product(s) or related products", "Recurrent major hypoglycaemia as judged by the Investigator", "Uncontrolled hypertension", "Any other significant condition or concomitant disease such as endocrine, cardiac, neurological, malignant or other pancreatic disease as judged by the Investigator"], "nct_id": "NCT00491725"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["For MAIN period (NN1250-3582):", "Type 2 diabetes mellitus for at least 6 months", "Ongoing daily treatment with insulin (premix, self-mix, basal only, basal bolus) for at least 3 months with/without oral anti-diabetics drug (OAD) prior to trial start", "HbA1c 7.0-10.0 % (both inclusive)", "Body Mass Index (BMI) below or equal to 40.0 kg/m^2", "For EXTENSION period (NN1250-3667):", "Completion of the 52 week treatment period in NN1250-3582"], "exclusion": ["For MAIN period (NN1250-3582):", "Treatment with other insulin regimens than premix, self-mix, basal only, basal bolus within 3 months", "Cardiovascular disease within the last 6 months", "Uncontrolled treated/untreated severe hypertension", "Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures", "Cancer and medical history of cancer"], "nct_id": "NCT00972283"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with type 2 diabetes", "BMI less than 45.0 kg/m2", "Insulin naive", "Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%"], "exclusion": ["Any clinically significant disease other than type 2 diabetes", "Currently using daily insulin", "Thiazolidinione use or other injectable diabetes medications within the last 3 months"], "nct_id": "NCT00873223"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Diet and lifestyle changes or metformin monotherapy for at least three months", "HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)", "Body Mass Index (BMI) less than or equal to 40 kg/m^2"], "exclusion": ["Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator)", "Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial", "Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening", "Current smoker or history of smoking within 6 months prior to screening", "Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease)", "Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator", "Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator", "Known autonomic neuropathy, as judged by the Investigator", "Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening", "Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg"], "nct_id": "NCT00620282"},{"minimum_age": 18.0, "maximum_age": 99.0, "gender": "A", "inclusion": ["Type 2 diabetes", "Currently treated with maximum doses of any kind of OAD alone or any kind of oral combination therapy for at least 2 months", "Body mass index (BMI) below 40.0 kg/m2", "HbA1c between 7.5-13.0%"], "exclusion": ["History of drug or alcohol dependence", "Mental incapacity, unwillingness or language barriers precluding adequate", "Subjects previously screened to participation or having already participated in this trial", "Receipt of any investigational drug within the last month prior to this trial", "Known or suspected allergy to trial products or related products"], "nct_id": "NCT00624364"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months", "HbA1c (Glycosylated Haemoglobin A1c) between 7.5%", "12.0% (both inclusive)", "FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L", "BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)"], "exclusion": ["Metformin contraindications according to local practice", "Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial"], "nct_id": "NCT00627445"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any insulin n\u00e4ive type 2 diabetic patient that able to use the drug as judged by the investigator"], "exclusion": ["In accordance with approved label"], "nct_id": "NCT00771680"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male and female patients age 18 to 70 years.", "Ability to provide written informed consent", "Mentally stable and able to comply with the procedures of the study protocol", "Clinical history compatible with impaired fasting glucose or early T2D as defined by a plasma glucose concentration between 110-159 mg/dl following a 12 hour overnight fast performed off any anti-diabetogenic agent for at least 2 weeks (6 weeks for thiazolidinediones)", "Stable body weight (+ 5%) for at least 2 weeks", "Female Patients: Agree to use adequate contraception if reproductively capable. Adequate contraception includes either a hormonal or barrier method, or surgical sterilization."], "exclusion": ["Diagnosis of type 1 diabetes", "Receiving insulin, exenatide (Byetta\u00ae), or sitagliptin (Januvia\u00ae) treatment or taking > 2 oral anti-diabetogenic agents for the treatment of diabetes", "BMI > 44 kg/m2", "Allergy to any sulfa-containing compounds", "Uncontrolled hypertension (Systolic Blood Pressure >160 or Diastolic Blood Pressure > 100 mmHg)", "Uncontrolled hyperlipidemia (triglycerides > 500 or LDL > 160 mg/dl)", "Elevation of liver function tests > 2 times the upper limit of normal", "Estimated Glomerular Filtration Rate (GFR) < 55 ml/min/1.73m2 (46)", "Hyperkalemia (serum potassium > 5.5 mmol/L) 10. Moderate anemia (hemoglobin concentration < 12 g/dl in men and < 11 g/dl in women) 11. Female patients: pregnant or lactating 12. Hepatic cirrhosis 13. Known active alcohol or substance abuse 14. Active cardiovascular disease 15. Use of any investigational agent within 6 weeks of the baseline visit 16. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial"], "nct_id": "NCT00775684"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Currently treated with human insulin or insulin analogues for at least 3 months, with or without combination with OADs", "HbA1c between 8.0-10.5%", "Body mass index (BMI) below 35.0 kg/m2", "Able and willing to perform self-monitoring of blood glucose"], "exclusion": ["Total daily insulin dose of 1.80 IU/kg or more", "Known or suspected allergy to trial product or related products", "Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures"], "nct_id": "NCT00600626"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes for at least 12 months since diagnosis", "Insulin naive subjects", "OAD treatment for at least 4 months alone or combined with no more than two OADs", "Body mass index (BMI) below 35.0 kg/m2", "HbA1c between 7.5-10.0%", "Able and willing to use twice a day injections for the entire trial period"], "exclusion": ["Current or previous treatment with thiazolidiones within the last 6 months", "OAD treatment with three or more OADs within the last 6 months", "Acute insulin treatment for longer than 7 days in a row within the last 6 months", "Secondary diabetes", "Known maturity onset of diabetes of young (MODY)", "Known or suspected allergy to trial product or related products"], "nct_id": "NCT00604396"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Duration of type 2 diabetes for at least 6 months since diagnosis", "Current treatment with one or two oral antidiabetic drugs for at least 3 months or with one or two oral antidiabetic drugs, given for at least 3 months in combination with intermediate or long-acting insulin/insulin analogue once daily", "BMI below 40 kg/m2", "HbA1c between 7-12%", "Able and willing to perform self-monitoring of capillary blood glucose"], "exclusion": ["Current antidiabetic treatment with combination of three or more oral antidiabetic drugs", "Previous treatment with short-acting human insulin, short-acting insulin analogue or biphasic insulin/insulin analogue within the last 6 months (7 days or less within the last 6 months is allowed)", "Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator", "Known or suspected allergy to trial product or related products", "Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures", "Receipt of any investigational drug within 4 weeks prior to this trial", "Previous participation in this trial"], "nct_id": "NCT00605020"},{"minimum_age": 35.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Insulin naive diabetes", "Current treatment with OHA, secondary failure", "Body mass index (BMI) below 40 kg/m2", "HbA1c over 8.5%", "Willing and able to start with insulin therapy and to perform self-blood glucose monitoring"], "exclusion": ["History of drug or alcohol abuse", "Receipt of the investigational drug within the last month prior to this trial", "Known or suspected allergy to trial products or related products", "Severe uncontrolled hypertension", "Any disease or condition, which the Investigator feels, would interfere with the trial"], "nct_id": "NCT00600366"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["After the physician has taken the decision to use NovoMix\u00ae30, Levemir\u00ae or NovoRapid\u00ae (alone or combined), any subject with type 2 diabetes who is not treated with these insulins or who has started on these insulin within the last 4 weeks before inclusion into this study is eligible for the study.", "The selection of the subjects will be at the discretion of the individual physician."], "exclusion": ["Subjects treated with NovoMix\u00ae 30, Levemir\u00ae or NovoRapid\u00ae (alone or in combination) for more than 4 weeks before inclusion into this study.", "Subjects who were previously enrolled in this study.", "Subjects with a hypersensitivity to NovoMix\u00ae 30, Levemir\u00ae or NovoRapid\u00ae or to any of the excipients.", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months."], "nct_id": "NCT00869908"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes for at least 12 months", "Currently treated with Oral Antidiabetic Drugs", "BMI lesser than or equal to 40 kg/m2", "HbA1c greater than or equal 7.5 and lesser than or equal to 11%"], "exclusion": ["Proliferative retinopathy or maculopathy", "Recurrent major hypoglycaemia", "uncontrolled hypertension or any disease or condition (such as renal, hepatic or cardiac) that according to the judgement of the Investigator makes the subject unsuitable for participation in the trial"], "nct_id": "NCT00104182"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes who is treated with any one or more of the oral antidiabetic drug (metformin, SU, repaglinide, TZDs) is eligible for the study. The selection of the subjects will be at the discretion of the individual physician. Particular attention should be paid to the drug interactions that are listed within the product label"], "exclusion": ["Subjects currently being treated with insulin detemir or any other insulin regimen including regular(bolus) insulin", "Subjects with a hypersensitivity to insulin detemir or to any of the excipients", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months. Women of childbearing potential who are not using adequate contraceptive methods"], "nct_id": "NCT00842192"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["After the physician decision has been made to use biphasic insulin aspart 30 or insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before.Particular attention should be paid to the drug interactions that are listed within the product label"], "exclusion": ["Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit", "Subjects currently being treated with biphasic insulin aspart 30 or insulin detemir", "Subjects who were previously enrolled in this study", "Subjects with a hypersensitivity to biphasic insulin aspart 30 or insulin detemir or to any of the excipients", "Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months"], "nct_id": "NCT00842894"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Subjects with type 2 diabetes mellitus", "Current treatment using a long-acting insulin analogue/intermediate-acting insulin preparation (except insulin glargine) or a pre-mixed insulin/insulin analogue preparation (except Mix30) on a twice daily regimen for at least 12 weeks, with stable insulin dose for the last 4 weeks (a brand of insulin preparation and dosing regimen has not been changed in the preceding 12 weeks)", "HbA1c below 10.0%", "Body Mass Index (BMI) < 30.0 kg/m^2"], "exclusion": ["Known hypoglycaemia unawareness or recurrent major hypoglycaemia", "Current treatment with total insulin dose of more than 100 U or IU/day", "Current treatment or expected to start treatment with systemic corticosteroid", "Treatment with oral anti-diabetic drugs (OADs: including alpha-glucosidase inhibitor and insulin sensitizer [thiazolidinedione: TZD]) within the last 12 weeks prior to screening"], "nct_id": "NCT00842361"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Current treatment with oral antidiabetes drugs (OADs) for at least 2 months", "HbA1c between 7.0-11.0% if on OAD monotherapy", "HbA1c between 7.0-10.0% if on OAD combination therapy", "BMI less than or equal to 40 kg/m2"], "exclusion": ["Current regular smoking or regular smoking within the last 6 months", "Current acute or chronic pulmonary disease (except for asthma)", "Proliferative retinopathy requiring treatment", "Clinically significant disease history including kidney or liver disease, or heart disease which limits physical activity or results in discomfort with physical activity", "Pregnancy"], "nct_id": "NCT00411892"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with insulin glargine and metformin"], "exclusion": ["HbA1c <7% or greater than (>)10% at screening", "At the time of screening age < legal age of majority", "Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method", "Type 1 diabetes mellitus", "Metformin not at a stable dose of at least 1.5 gram per day for at least 3 months prior to the screening visit", "Use of oral or injectable antidiabetic or hypoglycemic agents other than metformin, sulfonylurea (SU) and TZDs (for example, alpha glucosidase inhibitor, other glucagon like peptide-1 [GLP-1] receptor agonists, dipeptidyl peptidase-IV [DPP-IV] inhibitors, insulin etc.) within 3 months prior to the time of screening, use of weight loss drugs if not at a stable dose for at least 3 months prior to the screening visit", "History of hypoglycemia unawareness", "Body Mass Index (BMI) less than or equal to (<=) 20 kilogram per square meter (kg/m^2)", "History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)", "History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening", "Hemoglobinopathy or hemolytic anemia, blood or plasma products transfusion within 3 months prior to the time of screening", "Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization", "Known history of drug or alcohol abuse within 6 months prior to the time of screening", "Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram or vital signs at the time of screening that in the judgment of the Investigator or any sub investigator precludes safe completion of the study or constrains efficacy assessment such as active malignant tumor or other major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period", "Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively", "Laboratory findings at the time of screening: amylase and/or lipase, alanine aminotransferase >3 times upper limit of the normal (ULN) laboratory range; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody, positive serum pregnancy test in females of childbearing potential; and calcitonin >=20 picogram per milliliter (pg/mL) (5.9 picomole per milliliter [pmol/L])", "Patients who are considered by the Investigator or any sub investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, patient being investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol etc.)", "Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 months prior to the time of screening", "Use of any investigational drug within 3 months prior to screening", "Renal impairment defined with serum creatinine > 1.4 mg/dL in women and > 1.5 mg/dL in men", "History of hypersensitivity to insulin glargine or to any of the excipients", "Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening", "Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)", "Allergic reaction to any GLP-1 receptor agonist in the past (for example, exenatide, liraglutide) or to metacresol", "Additional exclusion criteria during or at the end of the run-in phase before randomization: informed consent withdrawal (patient who was not willing to continue or failed to return), mean fasting SMPG calculated from the self-measurements for the 7 days prior to Visit 12 (Week -1) was >140 mg/dL (7.8 mmol/L) and HbA1c measured at Visit 12 (Week -1) is <7% or >9%, amylase and/or lipase > 3 times the ULN at Visit 12 (Week -1), patients with fasting plasma glucose (FPG) above the threshold value described for rescue (that is, FPG >240 mg/dL [13.3 mmol/L]), patients with any adverse event, which, by the judgment of the Investigator precludes the inclusion in the double-blind randomized treatment phase, and lack of compliance to protocol or to insulin glargine treatment during the run-in phase"], "nct_id": "NCT00975286"},{"minimum_age": 7.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["for Participants with Type 1 Diabetes:", "Between the ages of 7 and 16", "Diagnosed with type 1 diabetes within 3 months Inclusion Criteria for Participants without Type 1 Diabetes:", "Between the ages of 7 and 16"], "exclusion": ["for Participants with Type 1 Diabetes:", "Pregnant or lactating", "Chronic disease other than T1DM, well-controlled asthma, or Hashimoto's thyroiditis", "Other current serious medical illness", "Psychiatric illness", "Psychoactive drug dependence", "Neurological illness (except T1DM-related): stroke, seizure, major loss of consciousness, head injuries, encephalitis, or hydrocephalus, blindness, deafness", "Use of psychoactive medications or exposure to neuroleptics (except that exposures of less than 1 month, occurring more than 5 years ago, will be allowed)", "Use of dopamine depleting agents or stimulants such as Ritalin, Cylert, Adderall", "Pre-maturity at birth of more than 4 wks early with complications (e.g. on respirator at NICU)", "Inability to complete MRI scan (e.g. claustrophobia, metal implants)", "Full set (top and bottom) of orthodontic braces (Half set braces, fillings, and retainers are OK) Exclusion Criteria for Participants without Type 1 Diabetes:", "Same as above (except cannot have type 1 diabetes) HY5: Must have been a participant in our earlier study."], "nct_id": "NCT00879203"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Taking oral diabetes medication", "At least 40 years old", "In a union-sponsored health plan with full medication coverage for at least a year", "Able to understand English or Spanish", "Informed consent"], "exclusion": ["Currently in a diabetes education program", "Will lose health care eligibility within a year", "Unable to receive phone calls or mail"], "nct_id": "NCT00179374"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Glucocorticosteroid treatment for 12 months at least", "Bone age < 15 years for a boy and < 13 years for a girl", "Child measured height <", "2 SD, Child currently treated by GH"], "exclusion": ["Known diabetes (type 1 or type 2)", "A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures"], "nct_id": "NCT00163189"},{"minimum_age": null, "maximum_age": 65.0, "gender": "M", "inclusion": ["Male scheduled to undergo bilateral nerve sparing radical prostatectomy for prostate cancer."], "exclusion": ["Patient is > 65 years of age", "Patient has been diagnosed with Type 1 or Type 2 diabetes", "Patient is actively smoking on a daily basis"], "nct_id": "NCT00106392"},{"minimum_age": 25.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Males or postmenopausal or surgically sterilized females, who have type 2 diabetes mellitus", "Medically stable on the basis of physical examination, medical history, laboratory safety test results, vital signs and ECG performed at Screening", "Body Mass Index (BMI) between 22 and 39.9 kg/m2, inclusive", "On a generally stable antihyperglycemic agent regimen (i.e., with no change in medication, or only 1 dose step change in dose) for at least 2 months prior to the Screening Visit, including volunteers who are:(a) Not currently on antihyperglycemic therapy and have an HbA1c =7.0% and =10.0%, or (b) On a single oral antihyperglycemic agent [metformin, a sulfonylurea, a meglitinide (e.g., repaglininide or nateglinide), a DPP-4 inhibitor (sitagliptin or vildagliptin), or an alpha-glucosidase inhibitor (e.g., acarbose)] and have an HbA1c >=6.5% and <=9.5%, or (c) On low-dose dual oral agent therapy (i.e., <50% maximum labeled doses of both agents) and have an HbA1c >=6.5% and <=9.5%", "On Day -1, FPG concentrations between 120 mg/dL and 260 mg/dL, inclusive."], "exclusion": ["Taking non-oral antihyperglycemic agent (e.g., insulin, exenatide or other GLP-1 analogues), or taking a thiazolidinedione (i.e., a PPARg agonist) within 3 months of Day -1", "History of a recent severe hypoglycemic episode, recurrent hypoglycemic episodes (i.e., within the past year), or a history of hypoglycemic unawareness", "History of clinically significant diabetic complications, including retinopathy, nephropathy, neuropathy or gastroparesis", "Positive test for alcohol and/or drugs of abuse", "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements", "Any condition that, in the opinion of the investigator, would compromise the well being of the volunteer or the study or prevent the volunteer from meeting or performing study requirements."], "nct_id": "NCT00871507"},{"minimum_age": 17.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Signed Written Informed Consent", "Age\u2265 17 and <80 years,", "Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment)", "Oral antidiabetic agents na\u00efve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication \u2264 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment)", "HbA1c \u2265 7.0% and \u226410.0%"], "exclusion": ["Women of child bearing potential", "body mass index (BMI)\u226535 Kg/m2 or BMI <18.5 Kg/m2", "Hemoglobin A1c (HbA1c)>10.0% or <7.0%", "Active liver disease and/or significant abnormal liver function", "Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma", "Congestive heart failure defined as New York Heart Association (NYHA) class III or IV and /or left ventricular ejection fraction \u226440%", "Significant cardiovascular history with the past 6 months", "Severe retinopathy, persistent uncontrolled hypertension (SBP\u2265180mmHg, or DBP\u2265105mmHg)", "Severe chronic gastrointestinal disease", "History of alcohol abuse or illegal drug abuse within the past 12 months", "Diagnosed anemia", "Creatine kinase \u22653 X ULN", "Serum creatinine \u22651.5 mg/dL(133\u03bcmol/L) [males], \u22651.4 mg/dL(124 \u03bcmol/L)[females]", "Alanine amino transferase (ALT) and/or aspartate amino transferase (AST)> 1.5 X ULN and/or total bilirubin > 2 X ULN", "Hemoglobin <12g/dL [males], <11g/dL [females]", "Allergies and Adverse Drug Reactions", "Prohibited Treatments and/or Therapies", "Prisoners or subjects who are involuntarily incarcerated", "Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness", "Subjects decline to participate"], "nct_id": "NCT00778622"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subject has type 2 diabetes mellitus verified by prescription of oral antihyperglycemic medications.", "Subject is 18 to 75 years of age, inclusively.", "Subject is male or a nonpregnant, nonlactating female, at least six weeks postpartum. A urine pregnancy test is required for all female subjects unless subject has had a hysterectomy, tubal ligation, or is > 2 years postmenopausal.", "Subject has a body mass index (BMI) of 18", "35 kg/m2.", "Subject has voluntarily signed and dated an informed consent form, approved by an Independent Ethics Committee/Institutional Review Board and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study."], "exclusion": ["Subject uses exogenous insulin for glucose control.", "Subject states that he/she has an infection (requiring medication or hospitalization).", "Subject states that he/she has current hepatic disease.", "Subject states that he/she has had surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks.", "Subject has a first-degree relative enrolled in the current study.", "Subject states that he/she has an active malignancy (subjects with cutaneous malignancies, other than melanoma, may be included in the study).", "Subject states that he/she has had a significant cardiovascular event < 12 weeks prior to study entry.", "Subject states that he/she has end stage organ failure, including clinically advanced renal disease as assessed by the study physician.", "Subject states that he/she is status post-organ transplantation. 10. Subject states that he/she has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 11. Subject states that he/she has active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes. 12. As determined by the study physician, subject is taking daily medications or dietary supplements at doses that would interfere with nutrient absorption, metabolism, excretion or gastric motility. 13. Subject states that he/she has an allergy or intolerance to any ingredient found in the study products."], "nct_id": "NCT00306072"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["(1-4) must be met:", "Age \u226518 years", "Diagnosis of diabetes mellitus (type 1 or type 2)", "At least one eye meets the study eye criteria", "Able and willing to provide informed consent. Study Level"], "exclusion": ["A patient is not eligible if any of the following exclusion criteria (5-13) are present:", "History of chronic renal failure requiring dialysis or kidney transplant.", "A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control). Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.", "Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at the time of study entry.", "Known allergy to any corticosteroid or any component of the delivery vehicle.", "History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 2 times per week. 10. History of steroid-induced intraocular pressure elevation that required IOP-lowering treatment in either eye. 11. Warfarin (coumadin) currently being used. 12. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, patient can become eligible. 13. Patient is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next 8 months. The patient must have at least one eye meeting all of the inclusion criteria (a-e) and none of the exclusion criteria (f-t) listed below: Study Eye Inclusion Criteria", "Best corrected electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity score of \u226569 letters (i.e., 20/40 or better).", "Definite retinal thickening due to diabetic macular edema based on clinical exam.", "Retinal thickness in the Optical Coherence Tomography (OCT) central subfield measuring 250 microns or more.", "Maximal laser has not already been given and investigator believes that either peribulbar steroids or laser may benefit the eye (note: subjects may be enrolled without having received prior macular laser).", "Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs and OCT. Study Eye Exclusion Criteria", "Macular edema is considered to be due to a cause other than diabetic macular edema.", "An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal condition).", "An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.).", "History of prior treatment with intravitreal, peribulbar, or retrobulbar corticosteroids for DME. 10. History of focal/grid macular photocoagulation within 15 weeks (3.5 months) prior to randomization. Note: Patients are not required to have had prior macular photocoagulation to be enrolled. 11. History of panretinal scatter photocoagulation (PRP) within 4 months prior to randomization or anticipated need for PRP in the 4 months following randomization. m. History of prior vitrectomy. n. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 6 months or anticipated within the next 6 months following randomization. o. History of YAG capsulotomy performed within 2 months prior to randomization. p. Intraocular pressure \u226525 mmHg. q. History of open-angle glaucoma (either primary open-angle glaucoma or other cause of open-angle glaucoma; note: angle-closure glaucoma is not an exclusion). A history of ocular hypertension is not an exclusion as long as (1) intraocular pressure is <25 mm Hg, (2) the patient is using no more than one topical glaucoma medication, (3) the most recent visual field, performed within the last 12 months, is normal (if abnormalities are present on the visual field they must be attributable to the patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous. Note: if the intraocular pressure is 22 to <25 mm Hg, then the above criteria for ocular hypertension eligibility must be met. r. History of prior herpetic ocular infection. s. Exam evidence of ocular toxoplasmosis. t. Exam evidence of pseudoexfoliation. A patient may have two \"study eyes\" only if both are eligible at the time of randomization."], "nct_id": "NCT00369486"},{"minimum_age": 11.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Children with juvenile arthritis or nephrotic syndrome", "Before or during puberty"], "exclusion": ["Diabetes Type 1 and 2", "Endocrine disease, except well substituted hypothyroidism"], "nct_id": "NCT00174187"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patient with Type 2 Diabetes treated with stable dose of metformin and with dyslipidemia not appropriately controlled with a statin treatment."], "exclusion": ["Type 1 diabetes."], "nct_id": "NCT00362323"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "M", "inclusion": ["Able to read and write", "Males", "Between 30-80 years old", "Have type 2 diabetes", "Diagnoses of hypogonadism or low testosterone"], "exclusion": ["On insulin monotherapy", "Use of testosterone therapy within the last 6 months", "Male breast cancer", "History of prostate cancer", "History of clinically significant sleep apnea"], "nct_id": "NCT00141492"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Documented evidence of Type 2 diabetes as defined by the ADA guidelines and documented evidence of Hypertension (various SBP/DBP ranges)."], "exclusion": ["A previous history or intolerance or hypersensitivity to calcium channel blockers, ARBs or ACE inhibitors."], "nct_id": "NCT00159692"},{"minimum_age": 45.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Clinical diagnosis of type 2 diabetes mellitus", "stable blood glucose control", "clinical findings consistent with length-dependent sensorimotor polyneuropathy, stage N2a"], "exclusion": ["foot ulceration", "unstable heart disease", "co-morbid conditions limiting exercise", "disorders of the central nervous system causing weakness or sensory loss", "received treatment with medications known to have neuropathy as a prominent side effect including vincristine, vinblastine, cis-platin, and paclitaxel", "medical conditions that may be associated with neuropathies such as alcoholism, liver disease, kidney disease, toxic exposure, vitamin deficiency, autoimmune disorders, cancer, or hypothyroidism"], "nct_id": "NCT00955201"},{"minimum_age": 55.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Mild to moderate Alzheimer's disease (MMSE 14-26)", "Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)"], "exclusion": ["Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study", "Significant cardiovascular disease in the past 6 months", "Illness other than Alzheimer's disease that could contribute to cognitive impairment", "History of stroke or seizure disorder"], "nct_id": "NCT00930059"},{"minimum_age": null, "maximum_age": 70.0, "gender": "F", "inclusion": ["Is female and has not experienced menses for at least 5 years.", "Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.", "Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).", "Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods.", "Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor.", "Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening."], "exclusion": ["Has a fasting triglyceride level greater than 500 mg/dL.", "Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays.", "Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice.", "Has Vitamin D (25-OH-D) less than 20 ng/mL.", "Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.", "Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.", "Has any of the following disorders:", "Rheumatoid Arthritis", "Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism.", "A personal history of kidney stones.", "Has a clinical history after age 45 of wrist, hip, or leg fractures.", "Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.", "Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.", "Has signs and/or symptoms of heart failure.", "Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.", "Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.", "Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.", "Has a history of breast cancer.", "Is taking or has ever taken pioglitazone or other Thiazolidinediones.", "Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study."], "nct_id": "NCT00708175"},{"minimum_age": 40.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["be at least 40 years old", "have at least one dental implant that has been in function for at least 6 months", "have at least 6 natural teeth", "have good general oral health", "not be pregnant or breastfeeding or planning to become pregnant within the next year", "if you are a pre-menopausal woman you or your male partner must be surgically sterile or you must be using reliable birth control (i.e., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch) now and throughout the study or abstain from sex throughout the study"], "exclusion": ["not have an active oral infection, including periodontitis and rampant caries", "not have a history of chronic systemic illness or infection, history of oral cancer, life expectancy of less than 5 years", "not have had cancer treatment in the last 12 months"], "nct_id": "NCT00933491"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Men or women who are 30 to 75 years of age (inclusive) at Study Visit 1.", "Clinical diagnosis of type 2 diabetes (defined according to IDF Guidelines) for a minimum of 6 months prior to Study Visit 1", "Patients for whom the GP is the primary medical provider of diabetes care and for whom referral to another doctor for diabetes care is not anticipated within 3 months of Study Visit 1", "Patients who give informed consent to participate."], "exclusion": ["Patients with type 1 diabetes mellitus", "Patients with any previous episode of ketoacidosis", "Patients who required chronic use (>/= 6 months) of insulin at any time in the past, with the exception of females during pregnancy", "Patients receiving insulin treatment at Study Visit 1 or within the previous 6 months, with the exception of patients who received short-term treatment (= 7 days) with insulin to maintain glycaemic control for an acute event (e.g. hospitalisation or medical procedure/intervention, infection or trauma).", "Treatment with glucocorticoid at Study Visit 1 or within the previous 6 months, with the exception of topical or inhaled glucocorticoid", "Females who are pregnant or considering pregnancy or stopping contraception within the course of the study", "Patients with end-stage renal disease, defined as glomerular filtration rate (GFR) by the MDRD (Modification of Diet in Renal Disease) formula < 15 ml/min/1.73 m2, or on renal replacement therapy with haemodialysis, peritoneal dialysis or renal transplant.", "Patients with psychiatric disease, active drug or alcohol abuse or other cognitive impairment that may interfere with treatment compliance.", "Receipt of any investigational drug within 30 days of Study Visit 1.", "Patients receiving diabetes care from another doctor (specialist endocrinologist, general physician, or another GP) Other eligibility criteria considerations The HbA1c at entry for newly recruited patients will be monitored centrally. If there is a significant risk that more than 25% of the total study population will have a baseline HbA1c </= 6.5%, then recruitment of subsequent patients will be restricted to those with HbA1c > 6.5%."], "nct_id": "NCT00499824"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Diabetic patients must be on diet therapy alone or diet plus a sulfonylurea, or diet plus metformin, or diet plus sulfonylurea/metformin and have a HbA1c \u2265 7.0%.", "Patients must have the following laboratory values: Hematocrit \u2265 34 vol% Serum creatinine \u2264 1.8 mg/dl AST (SGOT) \u2264 2 times upper limit of normal ALT (SGPT) \u2264 2 times upper limit of normal Alkaline phosphatase \u2264 2 times upper limit of normal", "Patients must have been on a stable dose of allowed chronic medications for 30 days prior to entering the study.", "Body weight must be stable (\u00b1 3-4 pounds) over the three months prior to study", "The normal healthy control group will be age, weight (BMI), and gender matched with the diabetic group and must have a normal OGTT according to ADA criteria.", "Subjects with IFG/IGT will have a FPG (100-125mg/dl) and/or 2-h plasma glucose (140-199mg/dl) according to ADA criteria."], "exclusion": ["Patients must not have type 1 diabetes.", "Patients must not have a fasting plasma glucose of greater than 270 mg/dl or HbA1c > 10.0%.", "Patients must not have received a thiazolidinedione or insulin for more than one week during the year prior to randomization.", "Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 2."], "nct_id": "NCT00845182"},{"minimum_age": 18.0, "maximum_age": 95.0, "gender": "A", "inclusion": ["Age > 18 years of age", "Morbid obesity (BMI > 40 kg/m2)", "Confirmed T2D diagnosis/date of onset"], "exclusion": ["Age < 18 years of age", "BMI < 40 kg/m2", "Type 1 diabetes", "Chronic use of non-steroidal anti-inflammatory agents (NSAIDs)", "Chronic use of systemic corticosteroids", "Anticipated inability to maintain current statin, angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blocking agent (ARB) regimen"], "nct_id": "NCT00960765"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["age 18 or older", "diagnosis of type 2 diabetes mellitus", "body mass index of 30 or greater", "a member of the Diabetes Education Center in Calgary, AB, Canada, for at least 6 months prior to study enrollment"], "exclusion": ["taking a weight loss medication (sibutramine or orlistat)", "weight loss >10 lbs in 2 months preceding study enrolment", "consumption of dinner at restaurants more than twice weekly", "current diagnosis of cancer", "psychiatric illness under care of a psychiatrist", "surgery in the 3 months prior to the study, or expected during the study period", "history of bulimia or anorexia nervosa"], "nct_id": "NCT00254124"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Participant has T2DM.", "Participant is on dialysis on day of signing informed consent.", "Participant is unlikely to conceive or uses acceptable methods of birth control: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.", "Participant has hemoglobin A1c \u22657% and \u22649% measured at or within 2 weeks prior to Visit 4/Week -2.", "Participant is \u226585% compliant with study medication during the single-blind placebo run-in (as determined by tablet/capsule count) and compliant with diet, exercise and other run-in treatments during the run-in period."], "exclusion": ["Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.", "Participant is losing weight in a weight loss program and is not in the maintenance phase (defined as <2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.", "Participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).", "Participant has cirrhosis or active liver disease.", "Participant has been on dialysis for < 6 months.", "Participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.", "Participant has severe active peripheral vascular disease.", "Participant has a history of malignancy \u2264 5 years prior to signing informed consent, or > 5 years without documentation of remission/cure.", "Participant is under treatment for hyperthyroidism.", "Participant has a hypersensitivity or contraindication to glipizide."], "nct_id": "NCT00509236"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with type 2 diabetes", "If treated with a thiazolidinedione (TZD) alone, the TZD dose must have been stable for at least 120 days", "The dose of TZD must be: Rosiglitazone (\u22654 mg/day) or pioglitazone (\u226530 mg/day)", "The metformin dose has been stable for at least 90 days", "Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 10.0%, inclusive.", "Have a body mass index (BMI): 25 kg/m2 < BMI < 45 kg/m2."], "exclusion": ["Have participated in this study previously or any other study using exenatide (AC2993/LY2148568) or glucagon-like peptide-1 (GLP-1) analogs, or have been previously treated with exenatide or GLP-1 analogs", "Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.", "Have been treated with exogenous insulin for more than 1 week within the 2 months prior to screening", "Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or similar over-the-counter medications) within 3 months prior to screening.", "Are currently treated with any of the following excluded medications:", "Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within 3 months prior to screening", "Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within 3 months of screening", "Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin) within 3 months prior to screening", "Pramlintide acetate injection within 3 months prior to screening", "Drugs that directly affect gastrointestinal motility, including, but not limited to: Metoclopramide, cisapride, and chronic macrolide antibiotics", "Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding study start"], "nct_id": "NCT00603239"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["normal renal function or renal impairment", "stable hemodialysis treatment for at least 3 months before screening and able to tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of >200mL/min (cohort 3 only)", "neither pregnant nor lactating", "HbA1c 6-10.5% inclusive", "females of childbearing potential must be practicing adequate contraception."], "exclusion": ["inability to meet the PK objectives of the study", "history of hypoglycemia unawareness or severe hypoglycemia", "liver function tests greater than or equal to 2 times the ULN", "clinically significant cardiovascular and/or cerebrovascular disease", "positive test results for hepatitis B, hepatitis C, or HIV", "documented hypertension or hypotension at screening", "known hepatic or biliary abnormalities", "current use of sulfonylureas", "active history of tobacco use within 6 months before screening", "donation of blood in excess of 500mL within 56 days before albiglutide dosing", "receipt of any investigational drug within the 30days or 5 half lives, whichever is longer, before dosing", "previous or current receipt of exenatide or any other GLP-1 agonist"], "nct_id": "NCT00938158"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 1 diabetes for more than 1 year", "Subject treated by any kind of insulin regimen and whatever the number of injections", "HbA1c = 7.5% and = 10%"], "exclusion": ["Type 2 diabetes", "Treatment by oral anti-diabetic drugs", "Severe medical conditions"], "nct_id": "NCT00117780"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years or older", "Diagnosed with type 2 diabetes", "On a stable dose of metformin of at least 1500 mg per day"], "exclusion": ["History of type 1 diabetes", "Pregnant", "HIV positive", "On a weight loss program or medication", "Has a history of blood disorder, certain cancers, heart, liver or kidney disease"], "nct_id": "NCT00701090"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": [": 18-70 years old, type 2 diabetes, non significant coronary atherosclerosis on inclusion coronary angiogram (ie no coronary stenosis > 70%), HbA1c<9%"], "exclusion": [": significant coronary stenosis (>70%), lack of informed consent, unstable hypertension, renal failure, contra-indication to metformin or gliclazide, pregnancy, atrial fibrillation, contraindication to MRI, or to adenosine, brachial artery calcifications"], "nct_id": "NCT00169624"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female patients with type 2 diabetes and insufficient glycaemic control.", "Age 18 or over and not older than 80 years"], "exclusion": ["Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months.", "Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent."], "nct_id": "NCT00621140"},{"minimum_age": 10.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Girls and boys ages 10 to 18 years old", "Body mass index more than 95th percentile for age and gender", "Insulin resistance based on:", "Fasting parameters: Fasting insulin level, HOMA IR", "Oral glucose tolerance testing", "Mitochondrial function > 1 median for normal based on control cohort"], "exclusion": ["Underlying medical problem with potential to affect growth, pubertal development or glucose homeostasis", "Chronic medical therapy with glucocorticoids, growth hormone, estrogen, progesterone, testosterone, or other medications with the potential to alter growth, pubertal development or glucose homeostasis within the proceeding 6 months", "Personal history of DM", "Inability to have MRI scan performed due to metal prosthesis or implant"], "nct_id": "NCT00962806"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Must be in VISN 18 VISTA database", "Diabetic", "Using insulin"], "exclusion": ["Unwilling to participate"], "nct_id": "NCT00148304"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Healthy male and/or female subjects between the ages of 18 and 55 years", "Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight >50 kg (110 lbs)."], "exclusion": ["Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening."], "nct_id": "NCT00959426"},{"minimum_age": 21.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["regular sleep habits", "BMI 20 to 27 kg/m2", "at least one parent, sibling or grandparent with type 2 diabetes", "must exercise regularly"], "exclusion": ["active smoker", "night or shift work", "have highly variable sleep habits", "have a hormonal disorder", "have a sleep disorder", "have an active medical problem", "women only: use of birth control pills", "women only: irregular menstrual periods or pregnancy", "use of medications/compounds that can disrupt sleep"], "nct_id": "NCT00724087"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": [": Healthy controls ages 30-80"], "exclusion": ["Presence of type 1 diabetes or type 2 diabetes", "Presence of clinically significant neuropathy, (Dyck stage >2b) defined by abnormal neurologic testing (neurologic physical exam, nerve conduction, autonomic and quantitative sensory tests)", "History of major macrovascular events such as myocardial infarction or stroke within the past 3 months", "Participation in another clinical trial concurrently or within 30 days prior to entry into this study.", "Uncontrolled or untreated hypothyroidism as evidenced by TSH concentrations >4.8 uU/ml", "Other serious medical conditions which, in the opinion of the investigator, would compromise the subject's participation in the study, including sensitivity to aspirin", "Abnormalities of liver function defined as any liver enzymes (AST, ALT, SGPT, SGOT) greater than 3 times the upper limit of normal", "History of NYHA Class IV congestive heart failure.", "Allergy to Niaspan or aspirin 10. Use of drugs known to affect prostaglandin metabolism such as angiotensin converting enzyme inhibitors (ACE) inhibitors and angiotensin receptor blockers (ARBs) will be allowed with stable use for 3 months. 11. Pregnancy or breastfeeding 12. History of peptic ulcer disease 13. Current history of smoking -"], "nct_id": "NCT00930839"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes for at least 6 months", "Treated with maximal, tolerable dose of metformin (\u2265 1000mg/day) and sulfonylurea (glimepiride\u2265 4 mg/day or equivalent dose of other SU) for at least 3 months prior to the screening visit", "7.0 < HbA1c < 11 %", "Fasting serum C-peptide > 0.33 nmol/L", "BMI < 30 kg/m\u00b2", "Patients who is willing to monitor BG using SMBG"], "exclusion": ["Type 1 Diabetes", "Clinical evidence of active liver disease, or serum ALT 3 times the upper limit of the normal range", "Serum creatinine: \u2265 1.5 mg/dl for males, \u2265 1.4 mg/dl for females", "Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)", "History of alcohol or other substance abuse", "Pregnancy or not using contraceptive in childbearing aged women", "Breast feeding women", "History of hypersensitivity to the study drugs or to drugs with a similar chemical structure", "Treatment with any medication including corticosteroid or herbal medicines that can affect blood glucose level within 3 months prior to study entry except metformin and sulfonylurea. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00708578"},{"minimum_age": 25.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Clinically stable Type 2 Diabetes Mellitus", "Females without childbearing potential", "Body mass index (BMI) >= 18.5 kg/m2 and <= 39.9 kg/m2", "Hemoglobin A1c levels >= 6.5% and <= 10%", "Fasting blood glucose levels >= 140 mg/dL and <= 270 mg/dL", "Systolic blood pressure >= 95 mmHg and <= 160 mmHg, and diastolic blood pressure >= 50 mmHg and <= 100 mmHg, and pulse rate >= 50 bpm", "Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing", "Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months", "Treatment with diet and exercise should be unchanged for more than 3 months"], "exclusion": ["Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus", "History of diabetic complications which need treatment", "Treatment with insulin, thiazolidinediones, thiazide diuretics\u3001beta blockers or systemic steroids within 3 months prior to informed consent", "Serum creatinine > upper limit of the normal range", "Patients with significant complications"], "nct_id": "NCT00707954"},{"minimum_age": 7.0, "maximum_age": null, "gender": "A", "inclusion": ["Any subject with Type 1 or Type 2 diabetes mellitus is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician"], "exclusion": ["Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit", "Currently being treated with insulin detemir", "Previously enrolled in this study", "Hypersensitivity to insulin detemir or to any of the excipients", "Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures."], "nct_id": "NCT00738153"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years of age or older,", "Known diagnosis of type 2 diabetes for at least 3 months", "HbA1c >6.5% and </= 8.5%", "BMI </= 40 kg/m2"], "exclusion": ["Requires oxygen therapy", "OSA is severe (AHI>70 or SaO2<70%)", "Work in transport related industries", "Previous diagnosis of OSA", "Known MVA due to sleepiness in the previous 5 years", "Insulin-requiring", "Use of GLP-1 mimetic (e.g. Byetta) for < 6 months or > 6 months but weight not stable", "Unstable angina"], "nct_id": "NCT00509223"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female age 18-80 years; stage 1 or 2 hypertension currently receiving 0 or 1 antihypertensive medication; mean sitting systolic blood pressure >/=140mmHg to </=170mmHg, or mean sitting diastolic blood pressure >/=90 to </=105mmHg. Subjects taking one hypertensive medication had their medication withdrawn and entered a wash-out phase prior to randomization."], "exclusion": ["Subject taking two or more antihypertensive medications, known contraindication to angiotensin-converting enzyme (ACE) inhibitors or alpha- or beta-blocker therapy, subject has Type 1 or Type 2 diabetes"], "nct_id": "NCT00624065"},{"minimum_age": 21.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["We will include up to 500 patients both male and female over the age of 21 diagnosed with type 1 or type 2 diabetes mellitus", "All patients must have secondary complications caused by the diabetes and not responding to conventional medical management", "Under an Endocrinologists supervision for their diabetes management", "Endocrinologist must assess and approve patient for participation in this study", "Ability to swallow without difficulty", "Ability to commit to the weekly time requirements associated with the study"], "exclusion": ["Other causes of complications not related to diabetes", "Lack of intravenous access", "Pregnancy", "Alcohol abuse, drug addiction or the use of illegal drugs", "Positive HIV", "Inability to perform breathe into machine for respiratory quotients"], "nct_id": "NCT00361907"},{"minimum_age": 12.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Adolescents ages 12-18 years", "Tanner stage III-V", "T1DM > 2 years", "HgbA1c <8 or >10 for previous 2 years"], "exclusion": ["Subjects with known history of hypercholesterolemia or family history of hypercholesterolemia", "Family history of premature cardiovascular disease", "Hypertension defined as subjects with blood pressure greater than the 90th percentile for age", "Anemia defined as Hgb <11.0 g/dl", "ADHD", "Congenital heart disease", "Pituitary tumor", "Known allergy to ultrasound gel", "Recent head injury", "Chromosomal abnormalities"], "nct_id": "NCT00933101"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients with diabetes mellitus type 2 under stable medication", "HbA1c between 7% an 10%", "age between 18 and 80 years", "signed informed consent"], "exclusion": ["Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm)", "CAD with reduced left ventricular ejection fraction (LVEF <45%)", "Pregnancy, chronic or acute infection, fever", "Diabetes mellitus type 1", "Newly diagnosed diabetes, uncontrolled diabetes", "Neoplasm", "Known allergy to study drug", "Severe liver/kidney disease", "HIV, Hepatitis", "Participation at other studies within the last 30 days"], "nct_id": "NCT00936234"},{"minimum_age": 25.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes", "25 (OH) vitamin D levels < 25 ng/ml", "Age 25 to 80 years", "Not on insulin for diabetes treatment", "HbA1c 5.5% -9.5%", "Mild/moderately increased blood pressure (systolic 120-160, diastolic 80-100) off BP medications"], "exclusion": ["Pregnancy", "Patients with systolic >160 or diastolic >100 mmHg", "High urine calcium or history of recurrent kidney stones", "Cardiovascular disease", "Stage 3 or worse chronic kidney disease"], "nct_id": "NCT00736632"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 gram per day for at least 3 months prior to screening visit"], "exclusion": ["HbA1c less than (<) 7% or greater than (>) 10% at screening", "At the time of screening age < legal age of majority", "Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method", "Type 1 diabetes mellitus", "Treatment with another antidiabetic pharmacological agent than metformin within the 3 months preceding the screening", "FPG at screening >250 milligram per deciliter (mg/dL) (13.9 millimole per liter [mmol/L])", "Body mass index (BMI) less than or equal to (<=) 20 kilogram per square meter (kg/m^2)", "Weight change of >5 kg during the 3 months preceding the study", "History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease", "History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening", "Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening", "Within the last 6 months prior to screening, history of myocardial infarction, stroke, or heart failure requiring hospitalization", "Known history of drug or alcohol abuse within 6 months prior to the time of screening", "Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period", "Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure or diastolic blood pressure >180 millimeter of mercury (mmHg) or >95 mmHg, respectively", "Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: >2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: >3 times ULN; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/ mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody; and positive serum pregnancy test in females of childbearing potential", "Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram or vital signs at the time of screening that, in the judgment of the investigator or any sub-investigator, precludes safe completion of the study or constrains efficacy assessment", "Patients who are considered by the investigator or any sub-investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as attending scheduled visits, being able to do self-injections; likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol; investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)", "Use of other oral or injectable antidiabetic or hypoglycemic agents than metformin (for example, sulfonylurea, alpha-glucosidase inhibitor, thiazolidinedione, rimonabant, exenatide, dipeptidyl-peptidase-4 inhibitors, insulin) within 3 months prior to the time of screening", "Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening", "Use of any investigational drug within 3 months prior to study", "Participation in any previous study with lixisenatide", "Renal impairment defined with serum creatinine >1.4 mg/dL in women and serum creatinine >1.5 mg/dL in men", "Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening", "Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol"], "nct_id": "NCT00707031"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Healthy male and female subjects as determined by medical history, physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will be eligible to participate in the study.", "Men and women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile)"], "exclusion": ["Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations Part C of the study (maximum age 65 years): Inclusion criteria:", "Drug naive patients with T2DM or patients who are on metformin-monotherapy (at current dose for \u2265 8 weeks) with inadequately controlled blood glucose levels (HbA1c >7 %and <10 %) Men and women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) Exclusion criteria:", "Poorly controlled diabetes with either new onset or worsening of symptoms of polyuria and polydipsia, weight loss, fatigue, abdominal pain, or other significant signs and symptoms", "Any of the following medical conditions: uncontrolled hypertension, unstable angina pectora, Cushing's syndrome, Addison's disease, uncontrolled hyperthyroidism or hypothyroidism, significant liver disease or renal failure, malignant diseases, or immunodeficiency (e.g., HIV/AIDS or organ-transplant), or history of myocardial infarction, congestive heart failure defined as New York Heart Association (NYHA) stage II and above, significant valvular disease, cardiac arrhythmia, or transient ischemic attack or cerebrovascular accidents (occurred within 6 months prior to entry into the study), or family history of Long QT Syndrome"], "nct_id": "NCT00707590"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["T2 insulin na\u00efve patients", "Patients whom their physician is considering initiation of Lantus treatment", "Poor glycemic control 7,5 %10 %", "T2 treatment with OADs more than 3 months", "BMI<40 kg/m2"], "exclusion": ["Impaired renal function (Cr>2mg/dl or current renal dialysis)", "Acute or chronic metabolic acidosis", "Active liver disease or serum ALT or AST >2,5 than normal", "History of hypoglycemia unawareness", "Diabetic retinopathy with surgery in the previous 3 months or planned within 3 months after study entry", "Pregnancy, breast feeding The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00701831"},{"minimum_age": 35.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with Type 2 Diabetes mellitus (but without history of ketoacidosis);", "BMI > 25 and < 40 kg/m2;", "Willingness to participate and to fast during Ramadan;", "Patients should be either:", "Insulin na\u00efve patients", "Patients already receiving insulin"], "exclusion": ["Pregnancy (as determined by pregnancy blood test at inclusion visit)", "Breast- feeding", "Women of childbearing potential who do not have adequate contraceptive protection", "Need for treatment during the study period with medications that may interfere with the study protocol", "Treatment with any investigational drug (only if in trial) in the last 3 months before entry into the study", "History of drug or alcohol abuse", "Severe and unbalanced diabetic retinopathy", "Clinically relevant cardiovascular, gastrointestinal, hepatic, renal, neurological, endocrine, hematological or other major systemic diseases that may interfere with the study protocol or complicate the interpretation of study results", "Night shift workers"], "nct_id": "NCT00258804"},{"minimum_age": 10.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.", "Has HbA1c 6.0% to 11.0%, inclusive, at screening.", "Has a body weight of >= 50 kg at screening."], "exclusion": ["Received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.", "Currently participates in any other interventional study.", "Is currently treated with any of the following excluded medications:", "Sulfonylurea chlorpropamide", "Thiazolidinedione within 3 months of screening.", "\u0391lpha glucosidase inhibitor within 3 months of screening.", "Meglitinide within 3 months of screening.", "Insulin within 3 months of screening.", "Pramlintide within 3 months of screening."], "nct_id": "NCT00254254"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["Pre-menopausal female of child-bearing potential.", "Body Mass Index (BMI) between 19 and 35 kg/m^2, inclusive."], "exclusion": ["On implanted contraceptives for 6 months, or injectable contraceptives for 12 months prior to the study.", "Evidence of diabetes mellitus.", "Participation in a study involving administration of an investigational compound within the past 3 months."], "nct_id": "NCT00254800"},{"minimum_age": 18.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, as defined by the American Diabetes Association, for at least one year at the time of screening.", "HbA1c measured at visit 1 in the range of \u2265 7.0 and < 9.0 %.", "Stable metformin treatment (dose \u2265 1.5g/day for at least 3 months prior to enrollment in the study). No other antidiabetic medications are permitted for 3 months prior to enrollment."], "exclusion": ["Pregnant or breast-feeding women.", "Women of childbearing potential not protected by medically approved contraceptive method of birth control.", "BMI >40kg/m2", "Diabetes other than type 2 diabetes.", "Subjects with \"brittle-diabetes\" or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months, previous history of diabetes related dehydration leading to hospitalization, history or evidence of ketoacidosis.", "Presence or history of cancer within the past five years.", "Evidence within the past 6 months of myocardial infarction, stroke, retinopathy requiring laser surgery, or heart failure requiring hospitalization.", "Impaired hepatic tests, impaired renal function.", "History or evidence of clinically relevant renal or urological disorder.", "The investigator will evaluate whether there are other reasons why a patient may not participate."], "nct_id": "NCT00361738"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Diabetes Mellitus, Type 2", "25 < BMI < 45 kg/m\u00b2", "7,5% < HbA1c < 9%", "Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months"], "exclusion": ["Type 1 diabetes mellitus", "Treatment with OADs only", "Treatment with thiazolidinediones, with exenatide or with pramlintide", "Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)", "Active proliferative diabetic retinopathy,", "Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception)", "Breast-feeding", "History of hypersensitivity to the study drugs or to drugs with a similar chemical structure.", "Treatment with systemic corticosteroids in the 3 months prior to study entry", "Treatment with any investigational product in the 2 months prior to study entry", "Previous treatment with insulin glulisine", "Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol", "Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult", "Impaired hepatic function", "Impaired renal function", "History of drug or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00360698"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Males and females 40 to 75 years of age (inclusive at the time of screening)", "Type 2 diabetes mellitus as defined by the WHO criteria, diagnosed for at least 1 year", "Subjects receiving 1.5 to 3g of metformin alone at a constant dose for at least 8 weeks prior to visit 1", "Patients with 6.5% < HbA1c > 8% at visit 1 and visit 2", "25 < BMI < 35"], "exclusion": ["Patient with type 1 diabetes", "Treatment with other hypoglycaemic agents than metformin in the last 3 months", "FPG >200 mg/dL at visit 2", "Hypersensitivity to the studied treatments (rosiglitazone, metformin chlorhydrate, gliclazide)", "Congestive heart failure (NYHA class I to IV), unstable or severe angina, recent myocardial infarction", "Respiratory insufficiency", "Subjects who have required the use of insulin for glycaemic control in the past 6 months prior to visit 1 (except during pregnancy or acute episodes such as hospitalization, trauma or infection) or subjects with a history of metabolic acidosis including diabetic ketoacidosis", "Anemia defined by haemoglobin concentration <11.0 g/dL for males and <10.0 g/dL for females", "Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels \u2265135.0 \u00b5mol/L in males and \u2265110.0 \u00b5mol/L in females and/or creatinine clearance <40 mL/min", "Presence of clinically significant hepatic disease, with ALT, AST, total bilirubin, alkaline phosphatase >2.5 times the upper limit of the normal reference range", "Subjects with chronic diseases requiring periodic ot intermittent treatment with oral or IV corticosteroids", "Subjects receiving danazol, miconazole or phenylbutazone", "Active alcohol, drug or medication abuse within the last 6 months or any condition that would indicate the likelihood of poor subject compliance", "Women who are lactating, pregnant or planning to become pregnant", "Any clinically significant abnormality identified at screening which, in the investigator's judgement, makes the subject unsuitable for inclusion in the study", "Use of any other investigational agent within 30 days or 5 half-lives (whichever is longer) prior to visit 1", "Subjects who receive or anticipate receiving radiocontrast dye during the study"], "nct_id": "NCT00367055"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female: Females are post menopausal or surgically sterile; Males are surgically sterile, abstinent, or utilizing an acceptable barrier contraceptive method. Must also agree to continue abstinence and/or to use an acceptable barrier contraceptive method for at least four weeks after their injections of ISIS 113715", "Aged 18 to 65 years", "Weight > 50 kg", "Body mass index > 29 kg/m\u00b2"], "exclusion": ["Pregnant, breastfeeding, or intends to become pregnant", "Positive hepatitis B virus, hepatitis C virus, or HIV test", "History of clinical significant abnormalities in complement or coagulation parameters or taking medication that may affect coagulation (e.g., heparin, warfarin), except aspirin or non-steroidal anti-inflammatory agents (NSAID)", "Current or history of significant skin disorders", "History of alcohol or drug abuse", "History of liver or renal disease", "Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > one year)", "Liver function tests greater than the Upper Limit of Normal (ULN)", "Clinically significant and currently active diseases or active infection requiring antiviral or antimicrobial therapy"], "nct_id": "NCT00365781"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients, 18-75 years of age;", "type 2 diabetes, taken off current sulfonylureas and/or metformin therapy for >=1 week prior to dosing with GK Activator (2);", "normal renal function, or moderate or severe impairment."], "exclusion": ["type 1 diabetes;", "treatment with insulin or PPAR gamma agonist within 6 months of screening."], "nct_id": "NCT00368368"},{"minimum_age": 9.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Overweight (>85th percentile BMI for age and gender) African American child age 9-12 with family history of type 2 diabetes in a first or second degree relative. Parents are secondary subjects."], "exclusion": ["Inability to give informed consent or unwillingness to be randomized", "Prior diagnosis of diabetes in the child planning to participate", "Pregnancy (women who become pregnant during the study will be omitted from the analysis. Pregnant women will not participate in the exercise sessions).", "Uncontrolled hypertension (SBP> 160 or DBP>100) (JNC V, 1993)", "Uncontrolled dyslipidemia by NCEP III criteria (NCEP, 2001)", "Evidence of significant cardiovascular, pulmonary disease, or other serious illness", "Evidence of alcohol or drug abuse (identified by self-report)", "Musculoskeletal disease serious enough to prevent participation in exercise sessions", "Known or suspected major psychiatric disorder", "Inability to participate in aerobic exercise activities", "Inability to comply with a calorie or fat restricted diet", "Age over 65 years"], "nct_id": "NCT00723853"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus (ADA criteria)", "BMI (body mass index) > 25 kg/M2", "Hemoglobin A1c (HbA1c) < 11%; Blood pressure < 160 (systolic) and 100 (diastolic) mm Hg", "Triglyceride levels < 500 mg/dl."], "exclusion": ["Pregnancy or breast-feeding", "Previous use of insulin or oral antidiabetic drugs", "Investigational drug within the previous 3 months", "Use of agents affecting glycemic control (systemic steroids and weight loss drugs)", "Patients with history of alcohol or illicit drug abuse", "Patients with liver enzymes higher than three times the upper limit of normal", "Serum creatinine > 1.4 mg/dl."], "nct_id": "NCT00725257"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Have type 2 diabetes", "Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.", "Have a fasting glucose concentration <280 mg/dL at Visit 1", "Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.", "Are between 18 and 70 years of age, inclusive.", "Have body mass index \u226525 kg/m2 and \u226445 kg/m2.", "Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).", "Can swallow oral study drug capsule, without splitting or crushing."], "exclusion": ["Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:", "Are breastfeeding.", "Test positive for pregnancy at the time of screening.", "Intend to become pregnant during the study.", "Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant\u00ae; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.", "Treated with any of the following medications:", "Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening", "Alpha-glucosidase inhibitor within 2 months of screening.", "Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.", "Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.", "Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.", "Have a history of renal transplantation or are currently receiving renal dialysis.", "Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.", "Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.", "Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.", "Have had organ transplantation.", "Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.", "Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry."], "nct_id": "NCT00729326"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).", "Fasting glucose (FG) <", "240 mg/dL, while on metformin or antidiabetic diet alone.", "HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%"], "exclusion": ["Women of childbearing potential"], "nct_id": "NCT00162305"},{"minimum_age": 18.0, "maximum_age": 82.0, "gender": "A", "inclusion": ["Signed and dated written informed consent in accordance with the GCP and local legislation.", "Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication."], "exclusion": ["Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.", "Pre-menopausal women (last menstruation =< 1 year prior to signing informed consent) who:", "are nursing or pregnant,", "or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.", "Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.", "Drug abuse which, in the opinion of the investigator, would interfere with trial participation.", "Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication."], "nct_id": "NCT00736099"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Diabetes mellitus, type 2, for at least 6 months", "Treatment regimens: diet and exercise, metformin as monotherapy or in combination with another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must be able to tolerate metformin at a dose of at least 1500 milligrams (mg) daily for 6 weeks prior to randomization.", "Glycosylated hemoglobin (HbA1c) value of \u22657.0% to \u22649.5%, except participants on diet and exercise therapy who must have had HbA1c value of >8.0% to \u22649.5%", "Body mass index (BMI) between 25 and 40 kilograms per meter squared (kg/m^2), inclusive", "Stable weight for 3 months prior to screening", "Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method"], "exclusion": ["Diabetes mellitus, type 1", "Use of a glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or are being treated with insulin", "Gastric emptying abnormality, history of bariatric surgery, or chronic use of drugs that affect gastrointestinal motility", "Use of medications to promote weight loss", "Clinically-relevant cardiovascular event within 6 months prior to screening", "Poorly controlled hypertension", "Electrocardiogram (ECG) reading considered outside the normal limits or indicating cardiac disease", "Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or alanine transaminase (ALT) levels >3.0 times the upper limit of normal", "Serum creatinine \u22651.5 milligrams per deciliter (mg/dL) or a creatinine clearance <60 milliliters per minute (mL/minute)", "Uncontrolled diabetes, defined as >2 episodes of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to study entry.", "Uncontrolled endocrine or autoimmune abnormality", "History of a transplanted organ", "Chronic use of systemic glucocorticoid therapy", "Active or untreated malignancy", "Use of central nervous system (CNS) stimulants"], "nct_id": "NCT00734474"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Male or female subjects, 18", "60 years of age, inclusive, at the time of signing the informed consent", "A female subject is eligible to participate if she is of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. FSH and estradiol levels will be checked at Screening for postmenopausal women. Simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory.", "Except as noted elsewhere, subjects should have no significant known medical conditions other than T2DM, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECGs. A subject with a clinical abnormality or laboratory parameters that meets"], "exclusion": ["but is outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.", "BMI (body mass index) within the range 25-35 kg/m2, inclusive.", "T2DM diagnosed at least 3 months prior to Screening", "Subjects must be treating their T2DM using one of the following regimens: Diet and exercise therapy, Metformin as monotherapy, Sulfonylurea as monotherapy, Metformin and sulfonylurea in combination, DPP-IV inhibitors, either as monotherapy or in combination with other agent(s) on this list at half maximal dose or less, Exenatide, either as monotherapy or in combination with other agent(s) on this list All doses of anti-diabetic medication must have been stable for at least 3 months prior to Screening, and the subject must be willing to wash out from their antidiabetic medications from Day -7 through Day 7.", "Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Exclusion Criteria:", "Has positive pre-study Hepatitis B surface antigen or positive Hepatitis C, result within 3 months of screening. Positive test for HIV antibody. History of uncorrected thyroid dysfunction. ALT and/or AST > 2 times the upper limit of normal at screening. Fasting triglycerides > 450mg/dL at screening. Total Bilirubin > 1.5 times the upper limit of normal at screening. A positive pre-study drug/urine screen and tobacco screen.", "Significant renal disease", "Significant ECG abnormalities", "Systolic pressure > 150 mmHg or <80 mmHg or diastolic blood pressure > 95 mmHg or <60 mmHg at screening.", "Previous use of insulin as a treatment within 3 months of Screening, or for >2 weeks when used for acute illness in the last 12 months prior to Screening, or if used for more than 1 year when associated with GDM.", "Has a history of gastrointestinal disease that could affect absorption within the past year, Gastrointestinal surgery, Chronic or acute pancreatitis.", "History of regular alcohol consumption", "Smoked or used tobacco or nicotine-containing products within the previous 6 months.", "Has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.", "Exposure to more than four new chemical entities within 12 months prior to the first dosing day.", "Is taking prohibited medications.", "Unwilling to abstain from caffeine-or xanthine-containing products for 24 hours prior to dosing until Day 7, Use of illicit drugs or nicotine-containing products, Alcohol for 24 hours prior to dosing until Day 7, Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until collection of the final pharmacokinetic blood samples", "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. This includes sensitivity to heparin, if heparin will be used to maintain catheter patency.", "Where participation in the study would result in donation of blood in excess of 500 mL within a 56 day period.", "Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.", "Unwillingness or inability to follow the procedures outlined in the protocol."], "nct_id": "NCT00733577"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Adult employees of Onondaga County"], "exclusion": ["Not an employee of Onondaga County", "Less than age 18"], "nct_id": "NCT00739336"},{"minimum_age": 20.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus patients treated with constant dose of glimepiride on top of diet and exercise", "Patients who gave informed consent to participate in the study"], "exclusion": ["Patients with HbA1c of < 7.0 % and > 11.0 %", "Patients with any following laboratory test abnormality :", "ALT and/or AST: > 3 X ULN", "Neutrophils: < 1,000/mm3 and/or platelets < 100,000/mm3", "Hemoglobin: <11 g/dL", "Creatinine: >= 1.3 mg/dL in case of male or >= 1.0 mg/dL in case of female The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00924573"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Volunteers with Body Mass Index 18.0-28.0 kg/m2"], "exclusion": ["Clinically relevant medical history"], "nct_id": "NCT00924430"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["is in good health", "is a nonsmoker", "is willing to follow all study guidelines"], "exclusion": ["has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant", "is a nursing mother", "is unwilling to consume the required high-fat breakfast"], "nct_id": "NCT00929201"},{"minimum_age": 55.0, "maximum_age": null, "gender": "A", "inclusion": ["A diagnosis of type 2 diabetes mellitus first made at age 30 years or older", "Age 55 years or older at entry", "Ability to provide informed consent", "A substantially elevated risk of cardiovascular disease, indicated by:", "A history of major macrovascular disease defined as any one of: stroke, myocardial infarction, hospital admission for transient ischaemic attack, hospital admission for unstable angina, coronary artery bypass graft, percutaneous transluminal coronary angioplasty (with or without stenting), peripheral revascularisation (angioplasty or surgery) or amputation secondary to vascular disease or", "A history of major microvascular disease defined as any one of nephropathy (albumin:creatinine ratio >300ug/mg), retinal photocoagulation therapy, proliferative retinopathy (new blood vessels on the disc or elsewhere, vitreous haemorrhage, pre-retinal haemorrhage, or fibrous proliferations on the disc or elsewhere), macular oedema (retinal thickening within one disc diameter of the macular centre) or blindness in either eye (corrected visual acuity 6/60 or worse, persisting for three months or more) not known to be due to non-diabetic causes or", "A first diagnosis of type 2 diabetes made 10 or more years prior to entry or", "Another major risk factor for vascular disease defined as any one of: current daily cigarette smoking, total cholesterol greater than 6.0 mmol/l (with or without cholesterol lowering treatment), HDL cholesterol <1.0 mmol/l, microalbuminuria (albumin:creatinine ratio 30-300ug/mg) or", "Age 65 years or over"], "exclusion": ["A definite contraindication to treatment with an ACE inhibitor or a thiazide-like diuretic", "A specific indication for treatment with an ACE inhibitor other than perindopril 2-4 mg daily (see also section 5.2.3) or a thiazide-like diuretic", "A definite and specific indication for treatment with gliclazide or a haemoglobin A1c control target of 6.5% or less", "A definite contra-indication to treatment with gliclazide or a haemoglobin A1c control target of 6.5% or less", "A definite indication for long-term full-dose or bed-time insulin therapy", "Participation in a trial within the month prior to the Registration Visit or current participation in another trial Other potential reasons for ineligibility include:", "High probability of non-adherence to study treatment or follow-up", "Current clinical instability (e.g. a major cerebral or coronary event or sight-threatening retinopathy or macular oedema within the previous few weeks)", "Life threatening non-vascular disease other than diabetes and its complications", "Moderate or severe dementia", "Major disability that is likely to prevent regular attendance at study clinics Final decisions about eligibility were made at the discretion of the study investigator and the potential study participant, in the light of any requirements or guidance from local ethics committees and other regulatory bodies."], "nct_id": "NCT00145925"},{"minimum_age": 25.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["informed consents be given before treatment", "the newly-diagnosed type 2 diabetic patients", "fasting blood glucose (FBG) level ranging from 7.0\uff5e16.7 mmol/L", "age ranging from 25\uff5e70 years old", "body mass index (BMI) ranging from20\uff5e35kg/m2", "never be treated with any anti-hyperglycemic agents or anti-hyperlipidemic agents"], "exclusion": ["having any severe acute or chronic complications", "renal dysfunction, blood creatinine\u2265150\u00b5mol/L", "blood aminotransferase level rising up(more than 2 times of the normal level)", "any severe cardiac disease including congestive cardiac failure, unstable angina and myocardial infarct in 12 months", "serious hypertension (systolic pressure\u2265180mmHg and/ or diastolic pressure\u2265110mmHg)", "chronic or acute pancreatic disease", "severe systematic diseases or malignant tumor", "allergic to the drugs using in the trial", "any factors interfering the result 10. female patients incline to be pregnant 11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs 12. poor compliance"], "nct_id": "NCT00147836"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["18 to 70 years of age", "Clinical diagnosis of type 2 diabetes", "HbA1c >7.5% to 11%", "FPG <270mg/dL (15mmol)", "Current treatment with diet and/or exercise alone, or no more than 15 days of an anti-diabetic medication or insulin within 12 weeks of screening"], "exclusion": ["Clinically significant renal or hepatic disease", "Presence of anemia", "Presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring therapy", "Systolic blood pressure >170mmHg or diastolic blood pressure >100mmHg, while on anti-hypertensive treatment", "Chronic disease requiring intermittent or chronic treatment with corticosteroids", "Any female lactating, pregnant, or planning to become pregnant", "History of hepatocellular reaction, severe edema or a medically serious fluid related event associated with any thiazolidinedione", "Presence of acute or chronic metabolic acidosis", "History of diabetic ketoacidosis"], "nct_id": "NCT00499707"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Male, non-fertile female or female of childbearing potential using a medically approved birth control method", "Patients who have received metformin for at least three months prior to visit 1 and have been on a stable dose for a minimum of 8 weeks prior to visit 1", "Agreement to maintain the same dose of metformin throughout the study", "Age in the range of 18-85 years inclusive.", "HbA1c in the range of 6.5", "8.0% (inclusive) at visit 1", "Agreement to maintain prior diet and exercise habits during the full course of the study", "Ability to comply with all study requirements and signed informed consent to participate in the study."], "exclusion": ["Pregnant or lactating female A history of:", "type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing's syndrome and acromegaly.", "acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months. Any of the following significant laboratory abnormalities:", "ALT, AST greater than 2 times the upper limit of the normal range at visit 1.", "Direct bilirubin greater than the upper limit of the normal range at visit 1.", "Serum creatinine levels equal to or greater than 1.5 mg/dL (132 umol/L) males, equal to or greater than 1.4 mg/dL (123 umol/L) females, or a history of abnormal creatinine clearance at visit 1.", "Clinically significant TSH values outside of normal range at visit 1.", "Clinically significant laboratory abnormalities, confirmed by repeat measurement, other than hyperglycemia, hyperinsulinemia, and glycosuria at visit 1 Treatment with any oral anti-diabetic other than metformin within 3 months prior to visit 1 Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00494884"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Subjects with a documented diagnosis of T2DM and HbA1c \u22657.0% and \u22649.5% measured by the central laboratory at Visit 1.", "Note: Subjects with HbA1c <7.5% must have a fasting fingerstick glucose \u22657 mmol/L (126 mg/dL) at Week 0, prior to randomization.", "Note: The proportion of subjects who are randomized with an HbA1c <7.5% will be limited to be no more than 20% (approximately 51 subjects)", "Subjects who are treatment-na\u00efve, and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for \u22654 weeks at any time in the past, or subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks", "Subjects who are 18 to 70 years of age inclusive at the time of Screening.", "Females of childbearing and non-childbearing and potential are eligible to participate as follows:", "Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.", "Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries who have a current documented tubal ligation, or who are surgically sterile (i.e. documented total hysterectomy or bilateral oophorectomy), or females who are post-menopausal. All females must have a negative urine pregnancy test on the day of, and prior to randomization.", "Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed."], "exclusion": ["Metabolic Disease", "Diagnosis of Type 1 diabetes mellitus", "History of ketoacidosis which has required hospitalization", "Thyroid disorder", "TSH <0.4 MIU/L (<0.4 MCIU/mL) or >5.5 mIU/L (>5.5 MCIU/mL) at Screening", "BMI of <22 kg/m2 or >43 kg/m2", "Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening", "Diabetic Medication", "Has taken insulin, or any oral or injectable anti-diabetic medication within 3 months of screening", "Has taken insulin or any oral or injectable anti-diabetic medication \u22654 weeks at any time in the past", "Cardiovascular Disease Recent history or presence of clinically significant acute cardiovascular disease including:", "Documented myocardial infarction in the 6 months prior to Screening.", "Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.", "Unstable angina in the 6 months prior to Screening.", "Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.", "Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment or the NYHA Class criteria in accordance with the local prescribing information for pioglitazone.", "Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.", "Based on local readings, the subject has an initial QTc interval (Bazett's)\u2265450msec at Screening, and after two additional ECGs taken 5 minutes apart, the average of the QTC interval from the three ECGs is \u2265450msec.", "Other clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.", "Fasting triglycerides \u2265400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.", "Hepatic Disease Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including: Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "alkaline phosphatase (AP) Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.", "Pancreatic Disease", "Secondary causes of diabetes:", "history of chronic or acute pancreatitis", "Renal Disease Significant renal disease at Screening as manifested by:", "Glomerular filtration rate (GFR) <60mL/min (as calculated by Quest at Visit using the Modification of Diet in Renal Disease (MDRD) equation \u2022\u22651+ protein on urine dipstick", "Trace or \u22651+ leukocyte esterase on urine dipstick", "Trace or \u22651+ blood on urine dipstick", "Positive nitrite on urine dipstick", "Recurrent genitourinary tract infections defined as \u22652 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening.", "Concurrent Disease", "Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), ECG, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.", "History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.).", "History of malignancy within the past 5 years other than superficial squamous cell carcinoma (non-invasive on pathology) or basal cell carcinoma (successfully treated with local excision).", "History of cervical cancer in situ treated definitively at least 6 months prior to Screening.", "Concurrent Medication Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:", "Digoxin", "Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)", "Bile acid sequestrants", "Niacin (excluding routine vitamin supplementation)", "Antiobesity agents (including fat absorption blocking agents)", "Oral or injectable corticosteroids (inhaled, topical and intranasal corticosteroids are permitted)", "Loop diuretics", "Monoamine oxidase inhibitors and tricyclic amines", "Antiretroviral drugs", "St John's Wort", "Oral chromium 9.Breast Feeding 10.Other", "Current smoker who is unable to abstain from smoking while in the clinic at each visit", "Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:", "Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study", "Has an average weekly intake of alcohol of >21 units or an average daily intake of >3 units (males) or an average weekly intake of >14 units or an average daily intake of >2 units (females). One unit is equivalent to a half pint of beer or 1 measure of spirits or 1 glass of wine", "Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening.", "In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent.", "Known allergy to any of the tablet or capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contraindicates participation."], "nct_id": "NCT00495469"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["The subject is healthy and overweight/obese, defined as having a body mass index greater than 25 but less than 35kg/m2, inclusive.", "The subject is an adult male or a female of non-childbearing potential between the age of 18 and 65 years, inclusive, at the time of signing informed consent.", "The subject and their partner are willing to use double-barrier method of contraception from the first day of study drug administration until 5 half-lives of the drug have elapsed following the last day of study drug administration.", "The subject demonstrates an ECG with values within ranges specified in the protocol at screening or baseline.", "The subject is capable of giving written informed consent, which includes the ability to read, comprehend and comply with the protocol requirements and restrictions as described in the consent form."], "exclusion": ["Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any medication that is chemically related to the study drug or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation in the study.", "Has a known allergy to any of the tablet formulation excipients of GSK376501 or pioglitazone (as applicable).", "Has sensitivity to heparin or history of heparin-induced thrombocytopenia.", "Has a history of alcohol abuse or dependence within 12 months prior to the study.", "Has a positive alcohol test at screening or baseline and/or is unwilling to abstain from alcohol for 72 hours prior to the start of dosing until discharged from the clinic and for 72 hours prior to the follow-up visit.", "Is unwilling to abstain from caffeine- or xanthine-containing products for 24 hours prior to each dose and throughout each in-house period, and for 24 hours prior to the follow-up visit.", "The subject smokes or has used tobacco or nicotine-containing products within the 6 months prior to the study, or is positive for urine cotinine at screening or at baseline.", "Is unwilling to refrain from the use of tobacco or illicit drugs during the trial, and/or tests positive for urine cotinine or drugs of abuse at screening or at baseline. At minimum, the list of drugs or classes of drugs that will be screened for include the following: amphetamines, barbiturates, benzoylecgonine, benzodiazepines, cannabinoids, cotinine, and opiates.", "Where participation in the study would result in donation of blood in excess of 500 ml within a 56 day period.", "Has a systolic blood pressure outside the range of 140 to 90mmHg, a diastolic blood pressure outside the range of 90 to 60mmHg and/or a heart rate outside the range of 90 to 45bpm, inclusive, at screening or at baseline.", "Experiencing clinically significant ECG abnormalities at screening or at baseline.", "Has a history or current evidence of a positive HIV test.", "Has a history of or a positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.", "Has laboratory safety screening tests outside of ranges specified in the protocol at screening or at baseline. T.", "Pregnant or lactating women, or woman of childbearing potential.", "Has a history of rhabdomyolysis.", "Has congestive heart failure or a history of congestive heart failure with New York Heart Association Class I-IV symptoms", "Has a history of thyroid dysfunction or an abnormal thyroid function test as assessed by TSH at screening.", "Has a history or current evidence of sleep apnea.", "Has had previous exposure to GSK376501, with the exception of subjects randomized into a previously completed study with GSK376501 may participate only in the cohort evaluating pioglitazone.", "Has had treatment with any other new molecular entity (investigational drug) during the previous 30 days or 5 half-lives, or twice the duration of the biological effect of the drug (whichever is longer), prior to the first dose of current study medication. For the purposes of this study, a new molecular entity is defined as any compound that has not yet reached Phase 3 development. The washout is defined from last dose of study medication in the previous study until the first dose of study drug.", "Has been exposed to more than four new molecular entities within 12 months prior to the first dosing day.", "Has used the following prescription or non-prescription medications within 14 days or 5 half lives, whichever is longer, prior to the first dose of study medication: vitamins (at a dose greater than the recommended daily allowance), or dietary or herbal supplements, including St. John's Wort.", "Is unable or unwilling to discontinue use of acetaminophen 72 hours prior to each dose and throughout each in-house period and no use within 72 hours of the follow-up visit.", "Requires the use of a prohibited medication .", "Is unable or unwilling to abstain from the consumption of grapefruit or grapefruit juice for 7 days prior to the first dose of study medication until the final pharmacokinetic sample has been collected."], "nct_id": "NCT00495014"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female subjects, aged 40-80 with T2DM and Microalbuminuria previously treated by diet and exercise alone, a single oral antidiabetic agent, or combination oral antidiabetic therapy."], "exclusion": ["Pregnancy or lactation, use of any TZD (pioglitazone or Rosiglitazone) or insulin, renal disease or renal dysfunction , any degree of congestive heart failure, clinically significant hepatic disease or anemia, presence of unstable or severe angina or coronary insufficiency, high blood pressure"], "nct_id": "NCT00500955"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["adult patients, 18-75 years of age;", "type 2 diabetes diagnosed >= 1 month before screening;", "drug-naive, or pretreated with maximum tolerated dose (MTD) of metformin;", "BMI 25-45kg/m2."], "exclusion": ["type 1 diabetes;", "any anti-hyperglycemic medication other than metformin, or weight-lowering drug, during last 3 months."], "nct_id": "NCT00502710"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subjects with a diagnosis of Type 2 DM as defined by the criteria of the American Diabetes Association.", "Exceptions were granted to those subjects over the age of 75 on a case-by-case basis and only with the expressed permission of the study sponsor.", "Females who were post-menopausal (i.e., >6 months without a menstrual period), surgically sterile, or using acceptable contraceptive measures (oral contraceptive, Norplant, Depo-Provera, an IUD, a diaphragm with spermicide or condoms).", "Subjects previously treated by either diet and exercise or oral therapy. Any subjects who were receiving MET or MET plus Sulfonylurea (SU) must have been receiving no more than MET 1000mg/day for at least three months prior to study entry. Subjects must have stopped previous treatment with thiazolidinediones (TZDs) at least three months prior to screening.", "Subjects with a Body Mass Index (BMI) >=27 kg/m2.", "Subjects who signed the Informed Consent.", "Subjects who received monotherapy treatment within the last three months prior to study entry or drug-naives who had HbA1c levels between 7% and 10%, inclusive. Subjects who received prior combination treatment had HbA1c of at least 6.5% to 8.5%, inclusive.", "Subjects with FPG of <270 mg/dL at screening and visit 2, must have had a FPG >=126 mg/dL at either screening or at the MET titration period (visit 2, run-in) for entry into the treatment phase of the study."], "exclusion": ["Females who were lactating, pregnant, or planning to become pregnant.", "Any clinically significant abnormality identified on the chest X-ray, screening physical examination, laboratory tests, or electrocardiogram, which, in the judgment of the investigator, would preclude safe completion of the study.", "Use of TZDs or any investigational drug for glycemic control within three months prior to study entry irregardless of the treatment regimen, or use of any other investigational agent (not related to glycemic management) within 30 days or five half-lives (whichever is longer) preceding study entry.", "Subjects with FPG >=270 mg/dL at screening.", "Subjects with prior history of hepatocellular reaction to or severe edema associated with troglitazone or any current TZD.", "History of significant hypersensitivity to TZDs, biguanides, or compounds with similar chemical structures.", "Subjects currently using insulin or who discontinued its use for glycemic control within the last three months prior to study entry.", "History of acute or chronic metabolic acidosis.", "Presence of clinically significant renal or hepatic disease (i.e., male subjects with serum creatinine >1.5 mg/dL; female subjects with serum creatinine >1.4 mg/dL; ALT, AST, total bilirubin, GGT, or alkaline phosphatase >2.5 times the upper limit of the reference range).", "Anemia defined by hemoglobin concentration <11.0 g/dL for males or <10.0 g/dL for females.", "Presence of unstable or severe angina or coronary insufficiency, or any congestive heart failure requiring pharmacologic treatment.", "Systolic BP >170mmHg or diastolic BP >100mmHg while on anti-hypertensive treatment.", "Recent history or suspicion of current drug abuse or alcohol abuse (defined as the consumption of more than 35 units of alcohol per week.", "Non-compliance with study medication during MET titration period (run-in).", "Subjects, who received or anticipated receiving radiocontrast dye during the MET titration (run-in) or the randomized treatment period of the study.", "Subjects unwilling or unable to comply with the procedure described in the protocol.", "Subjects who were unable to read or understand the English language were excluded from the study due to the administration of the QOL assessments."], "nct_id": "NCT00501020"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["African American male or female aged 30 years or older diagnosed with type 2 diabetes mellitus", "Able to provide 2 contact persons outside his/her household with active, verified telephone numbers"], "exclusion": ["Mentally incompetent to give informed consent", "Refuses to give informed consent", "Comorbid health condition likely to lead to death in next 24 months"], "nct_id": "NCT00022750"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Have been taking a basal insulin Glargine, at dose of \u2265 20 units/day, for at least 3 months prior to study start.", "Have been taking basal insulin Glargine at dose of \u2265 20 units/day, in combination with 1 of the following oral antidiabetic medication (OAM) regimens, for at least 3 months prior to study start:", "Metformin or immediate-release metformin or extended-release metformin alone at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to study start; or", "Metformin or immediate-release metformin or extended-release metformin at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to study start and sulfonylurea at a stable dose for 6 weeks prior to study start.", "Have an HbA1C > 7.0% and \u2264 10.0%.", "Have a body mass index (BMI) between \u2265 25 and \u2264 45 kg/m2."], "exclusion": ["Are currently taking OAM that is not described above and not allowed with concurrent use of insulin per local product label.", "Have taken more than 1 week within 1 month prior to the study start any glucose-lowering medications not included above either alone or in combination formulations, or have used a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phenylpropanolamine, rimonabant or similar over-the-counter medications).", "Have taken any insulin other than Glargine within the 3 months prior to study start for more than 1 week.", "Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, and inhaled preparations) within 4 weeks prior to the study start.", "Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.", "Have previously completed or been withdrawn from this study after enrollment."], "nct_id": "NCT00960661"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Patients being treated with Lantus once daily, Levemir once or twice daily or NPH insulin once or twice daily as a single insulin for at least three months 10.0% > or = HbA1c > or = 7.5%", "BMI < or = 40 kg/m\u00b2", "If patients are taking oral antidiabetics (OADs), the dose must be stable for at least 1 month", "Ability and willingness to perform blood glucose monitoring using a blood glucose meter and ability and willingness to use a patient diary", "Provision of written informed obtained prior to enrollment in the study"], "exclusion": ["Type 1 diabetes mellitus", "Current or previous treatment with an insulin other than basal insulin (biphasic insulin, short acting insulin, rapid-acting insulin analogue)", "Treatment with GLP-1 receptor agonists or with DPPIV inhibitors in the 3 months before screening", "Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before screening or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus exam performed in the 2 years prior to screening)", "Unable or unwilling to enter either of the treatment arms", "Women who are pregnant or lactating (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)", "History of hypersensitivity to the study drugs or to drugs with a similar chemical structure", "Treatment with systemic corticosteroids in the 3 months prior to study entry", "Treatment with any investigational product in the 2 months prior to study entry", "Current treatment with any non-selective beta-blockers", "Likelihood of requiring treatment during the study period with drugs not permitted by this clinical protocol", "Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult", "Impaired hepatic function as shown by ALT and/or AST greater than three times the upper limit of normal at screening", "Impaired renal function as shown by serum creatinine >135 \u00b5mol/l in men and > 110 \u00b5mol/l in women at screening", "History of drug or alcohol abuse", "Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study", "Patient unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study", "Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00965549"},{"minimum_age": 20.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["20-45 years healthy male subjects", "Body weight :50-90kg, BMI between 18.5-25", "Blood glucose level of 70-110mg/dL on the FPG test"], "exclusion": ["have a family history of diabetes", "Serum AST(SGOT), ALT(SGPT)>1.25 times upper limit of normal", "Creatinine clearance rate<80mL/min", "show SBP =<100mmHg or >=150mmHg, or DBP=<65mmHg or >=95mmHg, or tachycardia (PR>=100times/min)", "have a history of drug abuse or show positive for drug abuse or cotinine at urine screening", "smokers", "can not digest high-fat or high-calorie food(applicable only for the 10mg dose group subjects"], "nct_id": "NCT00961025"},{"minimum_age": 14.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["Young (18 to 40 years) patients with diabetes (not on insulin therapy) during the past 6 months and having BMI <25 kg/m2.", "Drug na\u00efve patients", "Patients on mono-therapy with metformin (< 1g/day)."], "exclusion": ["Type 1 diabetes", "Type 2 Diabetes on any other oral hypoglycemic agent other than metformin", "Pregnancy or lactation", "Insulin or Sulfonylurea treatment within the past 3 months", "Has received any investigational drug with the past 60 days", "History of prior allergy or hypersensitivity to any drug (unless approved by investigator)", "HbA1c < 7.5% or > 8.5%.", "Unstable glycemic control, requiring addition of 2nd oral agent/insulin or frequent up-titration of dose of metformin.", "Any patient on insulin.", "Females of child bearing potential who are not using adequate contraception during the study period.", "Insulin dependent or history of ketoacidosis requiring hospitalization", "Acute infections", "Advanced end-organ damage (CLD, CRF etc.)", "Diabetes with clinically significant or advanced end-organ damage"], "nct_id": "NCT00964184"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes;", "Both genders", "Age 40-80", "fasting c-peptide >=1.0 ng/L", "Therapy with metformin or sulphonylureas", "HbA1c >7.0%", "No contraindications to sitagliptin use"], "exclusion": ["Type 1 diabetes", "Age <40 or >80", "fasting c-peptide <1.0 ng/L", "Therapy with TZD", "HbA1c <=7.0%", "Acute concomitant diseases", "Immunological disorders", "Recent (within 3 months) cardiovascular events or surgery", "Pregnancy and lactation", "Inability to provide informed consent"], "nct_id": "NCT00968006"},{"minimum_age": 20.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["Healthy male subjects aged 20-45 years at screening", "Body weight over 50 kg, inclusive, and within 20% of ideal body weight"], "exclusion": ["Has a present illness or medical history of hepatic, renal, respiratory, cardiovascular disease, blood tumor, mental disorder, and endocrinologic disorder, especially diabetes mellitus", "Has a sign or symptom or history related to an acute or chronic pancreatitis", "Has a known allergy or hypersensitivity to exenatide or other drugs such as aspirin, antibiotics, and so on", "Has ever been exposed to exenatide", "Shows SBP >= 150 mmHg or <= 90 mmHg or DBP >= 100 mmHg or <= 50 mmHg", "Has a presence or history of drug abuse", "Uses any prescription drug, herbal medicine within 2 weeks or OTC drugs or vitamin within 1 week prior to study drug administration", "Has been participated in other clinical trial within 2 months", "Has experience of a blood donation during 2 months or a blood transfusion during 1 month prior to study drug administration", "Heavy smoker more than 10 cigarettes/day within 3 months prior to screening", "Continuous drinker (over 21 units/week, 1 unit = 10 g of pure alcohol) or subject who can't quit drinking nor smoking during clinical trial period", "Subjects not eligible at the discretion of investigators"], "nct_id": "NCT00964262"},{"minimum_age": 25.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Patients must have been diagnosed with Type 2 Diabetes for at least one year before screening", "Patients must be taking a stable dose of oral (by mouth) anti-diabetic monotherapy or a combination of two anti-diabetic medications", "Males or postmenopausal or surgically sterile women (post-menopausal is defined as no menses for at least 18 months prior to study start or no menses for 6 to 18 months)", "Body mass index (weight in kg/height in m2) should be between 20 to 39.9 kg/m2"], "exclusion": ["History of Type 1, brittle diabetes or secondary forms of diabetes", "History of repeated severe hypoglycemic episodes", "History of diabetic complications including retinopathy, nephropathy, neuropathy, gastroparesis, or ketoacidosis", "History of, or currently active illness including but not limited to cardiovascular disease, hematological disease, respiratory disease, hepatic or gastrointestinal disease, endocrine/metabolic disorders, neurologic or psychiatric disease, or malignant neoplasms considered by the Investigator to be clinically significant"], "nct_id": "NCT00963768"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients who are aged \u2267 18 years old.", "Patients whose HbA1c is \u2267 7.0 % and < 10.0%.", "Patients whose BMI is \u2267 20.0 and \u226640.0 \u338f/\u33a1.", "Patients who took metformin monotherapy for at least 56 consecutive days at the screening visit."], "exclusion": ["Patients with type 1 diabetes or secondary form of diabetes.", "Patients with heart failure symptoms.", "Patients with serious diabetic complications.", "Patients with severe hepatic disorder or severe renal disorder.", "Patients who are the excessive alcohol addicts.", "Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception."], "nct_id": "NCT00971243"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Able to provide written informed consent", "Adult patients aged between 18 and 60 years (inclusive)", "Male or female of Chinese ethnicity", "Type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years", "severe obesity, includes BMI 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or BMI greater than 27.5 to less than 35 kg/m", "HbA1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 anti-diabetic drugs (OAD) with good drug compliance"], "exclusion": ["On anti-obesity drugs", "On insulin treatment at the time of the recruitment", "On glitazone or incretins (dipeptidyl peptidase-4 inhibitor or glucagons-like peptide-1) treatment", "On any implantable device including cardiac pacing", "Anticipated to have MRI examinations", "Fasting C-peptide level less than 0.5g/L", "Renal impairment (defined as serum creatinine greater than 150mol/L and/or estimated glomerular filtration rate less than 60 mL/min/1.73m)", "Significant liver impairment (ALT more than 3 times upper limit of normal range)", "Active malignant disease. Patients with malignant disease who have been disease-free for at least 5 years are eligible", "Active infection", "Active and uncontrolled thyroid diseases", "Childbearing age female patients without reliable contraceptive methods", "Life expectancy less than 12 months", "Administration of another investigational drugs or procedures within 4 weeks before screening", "Any medical illness or condition as judged by the investigators as ineligible to participate the study", "Special population, e.g. prisoner, mentally disabled, investigators' student or employees"], "nct_id": "NCT00975533"},{"minimum_age": 20.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients diagnosed as having type 2 Diabetes.", "Patients who have not been on insulin treatment within 6 months.", "Patients who have been taking OADs for at least 90 days.", "Patients with an HbA1c level in the range of 7.5% to 11.0%.", "Patients with a Body-Mass Index (BMI) of 35 kg/m\u00b2 or below."], "exclusion": ["Patients having pre-proliferative or proliferative retinopathy (except for old retinopathy with no need for treatment).", "Patients having or suspected of having malignancy", "Patients having serious complications of the heart, liver, or kidney.", "Patients hypersensitive or allergic to insulin or insulin analog preparations or a history of it.", "Patients receiving systemic steroids.", "Are currently enrolled in a clinical trial of a non-approved drug. Or patients who participated in other clinical trials including post-marketing clinical trials within 90 days prior to informed consent being obtained.", "Patients of child-bearing potential. Breastfeeding patients. Patients with a positive result in a pregnancy test performed for women of child-bearing potential."], "nct_id": "NCT00971997"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes and inadequate glycemic control, defined as A1C \u2265 6.6 and \u2264 9.5%", "Stable dose of metformin AND/OR a sulfonylurea, for at least 4 weeks prior to the enrollment visit", "Inadequate blood pressure (BP) control, defined as systolic BP (SBP) \u2265 130 and < 165 mmHg, AND/OR diastolic BP (DBP) \u2265 80 and < 105 mmHg", "C-peptide \u2265 0.8 ng/mL", "Estimated GFR by the Modification of Diet in Renal Disease (MDRD) formula > 60 mL/min/1.73m\u00b2 and < 150 mL/min/1.73m\u00b2", "Urine albumin:creatinine ratio (UACR) < 300 mg/g", "BMI \u2264 45.0 kg/m2"], "exclusion": ["Administration of diuretics or other medication approved for the treatment of hypertension (with the exception of either ACEI or ARB), at any dose during the 12 weeks prior to the enrollment visit", "History of adverse reaction to radio-contrast dye", "Allergy or contraindication to use of thiazide diuretics", "Aspartate Aminotransferase (AST) > 3X Upper limit of normal (ULN)", "Alanine aminotransferase (ALT) > 3X ULN", "Serum Total Bilirubin > 1.5X ULN", "Serum Creatinine (Scr) \u2265 1.50 mg/dL (133 \u03bcmol/l) for men; SCr \u2265 1.40 mg/dL (124 \u03bcmol/l) for women", "Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncologic, endocrine, psychiatric, or rheumatic diseases"], "nct_id": "NCT00976495"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral anti-hyperglycemic agent or a combination of two oral anti-hyperglycemic agents", "Subject is willing to follow a weight-maintaining diet and exercise program during the study", "Subject is a nonsmoker or is willing to limit smoking to 10 cigarettes per day while in the clinical research unit"], "exclusion": ["Subject has a history of stroke, chronic seizures, or major neurological disorder", "Subject has a history of cancer, except certain skin and cervical cancers or cancer that was successfully treated 10 or more years prior to screening", "Subject has a history of type 1 diabetes", "Subject has used contact lenses within the last 6 months", "Subject has used any lipid-lowering therapy in the last 3 months, except statins, Zetia, or Vytorin", "Subject has more than 3 alcoholic beverages per day", "Subject has more than 6 servings of caffeine a day", "Subject has participated in a previous MK8245 study"], "nct_id": "NCT00972322"},{"minimum_age": 20.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients who are 20", "75 years old", "Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug", "Patients whose HbA1c is between 7.0% and 10.0%", "Patients who took Sulfonylurea for diabetes over 12 weeks before administration of investigational drug", "Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug"], "exclusion": ["Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)", "Patients with Class III/IV heart failure symptoms according to NYHA functional classification", "Patients who are gastrointestinal disorder (diarrhea, vomiting)", "Patients with serious diabetic complications", "Patients who are the excessive alcohol addicts", "Patients with severe hepatic disorder or severe renal disorder", "Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception"], "nct_id": "NCT00974090"},{"minimum_age": 18.0, "maximum_age": 49.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, diagnosed for at least 1 year at the time of screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 gram/day (g/day) for at least 3 months prior to the screening visit", "Patients with obesity (BMI greater than equal to [>=] 30 kg/m^2) and aged from 18 years to less than 50 years"], "exclusion": ["HbA1c less than (<) 7.0 percent (%) or HbA1c greater than (>) 10% at screening", "Type 1 diabetes mellitus", "Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method", "FPG at screening >250 milligram/deciliter (mg/dL) (>13.9 millimole/ liter [mmol/L])", "Weight change of more than 5 kg during the 3 months preceding the screening visit", "History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)", "History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening", "Hemoglobinopathy or hemolytic anemia or receipt of blood or plasma products within 3 months prior to the time of screening", "Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization", "Known history of drug or alcohol abuse within 6 months prior to the time of screening", "Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram (ECG) or vital signs at the time of screening that in the judgment of the investigator or any sub-investigator could have precludes safe completion of the study or constrains efficacy assessment such as major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period", "Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively", "Laboratory findings at the time of screening : Amylase and/or lipase >3 times the upper limit of normal (ULN) laboratory range; alanine aminotransferase (ALT): >3 times ULN; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen (HBsAg) and/or Hepatitis C antibody (HCAb), positive serum pregnancy test in females of childbearing potential, and calcitonin >=20 picogram per milliliter (pg/mL) (5.9 picomole per liter)", "Patients who are considered by the investigator or any sub-investigator as inappropriate for the study for any reason (for example, impossibility to meet specific protocol requirements [such as scheduled visits, being able to do self-injections], likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)", "Use of other oral or injectable antidiabetic or hypoglycemic agents than metformin (for example, sulfonylurea, alpha glucosidase inhibitor, thiazolidinedione, exenatide, dipeptidyl peptidase IV (DPP-IV) inhibitors, insulin) within 3 months prior to the time of screening", "History of bariatric surgery, anti-obesity treatment, or unstable diet within 3 months prior to the time of screening", "Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 months prior to the time of screening", "Use of any investigational drug within 3 months prior to screening", "Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening", "Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)", "Allergic reaction to any glucagon like peptide-1 (GLP 1) agonist in the past (for example, exenatide, liraglutide) or to metacresol", "History of a serious hypersensitivity reaction to sitagliptin", "Moderate or severe renal impairment (creatinine clearance inferior to 50 milliliter/minute [mL/min])", "Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in period (>2 injections missed or >2 capsules missed); and patient with any adverse event which could have precludes the inclusion in the study, as assessed by the investigator"], "nct_id": "NCT00976937"},{"minimum_age": 18.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Japanese Subjects with type 2 diabetes mellitus.", "Strictly/relatively treatment na\u00efve Subjects with HbA1c \u2265 7.0% and \u2264 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with HbA1c \u2264 8%.", "Provision of informed consent."], "exclusion": ["Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.", "The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history."], "nct_id": "NCT00972244"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Patients with Type 2 Diabetes Mellitus who were inadequately controlled (baseline A1c of 7.0~11.0%)on metformin monotherapy (1500mg metformin)for \u2265 2 months before baseline visit", "Age of 18-80 years", "Body Mass Index of 18-40 kg/m2"], "exclusion": ["Type 1 of diabetes", "Myocardial Infarction, Unstable Angina, or Coronary Artery Bypass Graft within the previous 6 months", "Congestive Heart Failure (III or NYHA class IV)", "Liver disease such as cirrhosis or Chronic Active Hepatitis", "History of Lacticacidemia", "Use of any Oral Anti-diabetic Drug other than Metformin within the 2 months", "Use of insulin before screening visit", "ALT or AST >3 times the upper limit of Normal range", "Creatinine >1.5 mg/dl", "Other situation (pregnant or lactating females, history of drug or alcohol abuse, night-shift workers, clinically significant laboratory abnormality on screening or any medical condition that would affect the completion or outcome of the study)"], "nct_id": "NCT00975065"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Has been diagnosed with type 2 diabetes mellitus", "Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening", "Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening", "Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening", "Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:", "Hormone replacement therapy (female subjects)", "Oral contraceptives (female subjects)", "Antihypertensive agents", "Lipid-lowering agents", "Thyroid replacement therapy", "Antidepressant agents", "Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL\u00ae], sibutramine [MERIDIA\u00ae], topiramate [TOPAMAX\u00ae]) and over the counter antiobesity agents"], "exclusion": ["Has ever been exposed to exenatide (exenatide once weekly [exenatide LAR], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog", "Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening", "Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:", "Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening", "Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN\u00ae) within 30 days of screening", "Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening", "Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR\u00ae) steroids known to have a high rate of systemic absorption"], "nct_id": "NCT00877890"},{"minimum_age": 50.0, "maximum_age": null, "gender": "A", "inclusion": ["Men or women with: a) newly detected type 2 diabetes based on a fasting plasma glucose greater than or equal to 7.0 mmol/l (126 mg/dL) or a 2 hour plasma glucose (FPG) greater than or equal to 11.1 mmol/l (200 mg/dL) on an oral glucose tolerance test, or b) a history of type 2 diabetes", "Hemoglobin A1c (A1C) 6.5-9.5% inclusive (for assays with upper limit of normal of 6%) within one month of screening", "Age \u2265 50 years and evidence of vascular disease defined as \u22651of:", "prior myocardial infarction", "prior stroke", "coronary, carotid or peripheral artery revascularization \u2265 4 years earlier", "previous documented myocardial ischemia on either an exercise stress test or on any cardiac imaging, or previous unstable angina with ECG changes or cardiac enzyme elevation OR", "Age \u2265 55 years and evidence of subclinical vascular disease defined as \u22651 of:", "microalbuminuria or proteinuria", "history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram", "50% stenosis on any imaging of coronary, carotid or lower extremity arteries", "ankle/brachial index <0.9 OR", "Age \u2265 60 years and at least 2 of the following cardiovascular disease risk factors:", "current tobacco use", "LDL-c \u22653.4 mmol/L (130 mg/dL) or on a lipid lowering medication", "HDL-c < 1.0 mmol/L (40 mg/dL) for men and < 1.3 mmol/L (50 mg/dL) for women or triglycerides \u2265 2.3 mmol/L (200 mg/dL)", "BP lowering medication use or untreated SBP \u2265 140 mmHg or DBP \u2265 95 mmHg", "Waist to hip ratio > 1.0 for men and > 0.8 for women", "On no insulin and on less than or equal to 2 anti-diabetes drugs where at least one drug is at or below the half-maximal dose (as indicated in the MOP) with stable dosing for 10 weeks prior to screening"], "exclusion": ["Type 1 diabetes", "Current need for insulin treatment", "Symptomatic hyperglycemia requiring immediate therapy in the judgment of the physician", "An acute cardiovascular event within 30 days prior to randomization", "Symptomatic heart failure (i.e. New York Heart Association class II or higher) or any episode of previous pulmonary edema or known ejection fraction < 0.4 or current use of loop diuretics", "Any fracture within the past 1 year", "Currently planned coronary, carotid or peripheral artery revascularization or cardiac valve surgery", "Coronary, carotid or peripheral artery revascularization within the 4 years prior to screening in the absence of angina, MI, or stroke in the intervening period", "End stage renal disease requiring renal replacement therapy", "Receiving drug therapy to treat liver disease", "A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer (other than prophylactic)", "Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 2.5 times the upper limit of normal", "A prior heart transplant or awaiting a heart transplant", "Previous or current hypercalcemia, hyperparathyroidism, osteomalacia or other contraindication for vitamin D therapy", "Regular use of or indication for greater than 400IU of vitamin D daily", "Clinically or medically unstable with expected survival < 1 year", "Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data", "Any other factor likely to limit protocol compliance or reporting of adverse events", "Inability to discontinue a TZD (if taking one) in the judgement of the physician/investigator", "Contraindications to or history of hypersensitivity to the investigational products", "History of renal stones within the past 2 years", "Participation in another clinical trial of an investigational agent"], "nct_id": "NCT00879970"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Present with type 2 diabetes", "Patients have been treated with a stable dose of the following for at least 3 months prior to screening:", "100 mg/day sitagliptin and", "\u22651500 mg/day metformin, or maximum tolerated dose (extended release or immediate-release).", "Have inadequate glycemic control as evidenced by an HbA1c between 7.1% and 9%, inclusive.", "Have a body mass index (BMI) \u226520 kg/m2 and <45 kg/m2"], "exclusion": ["Are currently enrolled in, or discontinued within the last 30 days (or longer, if local guidelines require) from, a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.", "Have previously completed or withdrawn from this study or any other study investigating exenatide.", "Have a known allergy or hypersensitivity to exenatide, sitagliptin or excipients contained in exenatide or sitagliptin.", "Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening.", "Are currently treated with any of the following excluded medications:", "Thiazolidinediones (TZD) within 3 months of screening.", "Sulfonylurea (SU) within 3 months of screening.", "Dipeptidyl peptidase-4 [DPP-4] inhibitors, with the exception of sitagliptin, within 3 months of screening.", "Meglitinide derivatives (for example, repaglinide or nateglinide) within 3 months of screening.", "Alpha-glucosidase inhibitors (for example, miglitol or acarbose) within 3 months of screening.", "Exogenous insulin within the 3 months prior to screening.", "Drugs that directly affect gastrointestinal motility, including, but not limited to: metoclopramide, cisapride, and chronic macrolide antibiotics.", "Systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous (IV), or intramuscular (IM) route used regularly (for longer than 1 month) or used within 1 month immediately prior to screening.", "Any other oral antidiabetic (OAD) agent, other than sitagliptin or metformin, within 3 months prior to screening."], "nct_id": "NCT00870194"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 Diabetes inadequately controlled on a maximum of three oral anti-diabetic agents", "HbA1c between 7 and 10% inclusive", "Fasting Blood Glucose between 126 and 200 mg/dL", "Body Mass Index (BMI) in the range of 30.0 to 45.0 kg/m2", "Stable oral anti-diabetic therapy for at least 3 months", "Subjects who are able and willing to perform self monitoring of plasma glucose for the entire trial period", "Able and willing to sign informed consent and return for follow-up assessments"], "exclusion": ["Type 1 Diabetes", "Subjects at high risk of general anesthesia or surgery", "Subjects with prior pancreatitis", "Subjects treated with insulin within three months of screening", "Female with a positive pregnancy test, planning to become pregnant during screening, active treatment, or the follow up period, breastfeeding, or judged to be using inadequate contraceptive methods.", "Subjects who underwent previous intra abdominal, GI tract surgery or a major abdominal trauma.", "Subjects with other implanted electrical stimulation devices", "Subjects with motility disorders of the GI tract such as gastroparesis", "Subjects who are receiving medications known to affect gastric motility", "Subjects with history of peptic ulcer disease", "Subjects with any serious health condition, such as cancer, cardiac diseases, immunodeficiency disorders, liver disease, pulmonary disease, renal insufficiency, coagulopathy or a major depressive disorder.", "Subjects with severe diabetic complications, such as retinopathy or nephropathy", "Subjects with metabolic or endocrine disorders like primary or secondary Cushing syndrome", "Subjects who received another investigational agent within 30 days prior to screening", "Evidence of current or recent alcohol or drug abuse within the past year prior to screening", "Subjects who are unlikely to be available for follow-up as specified in the protocol", "Subjects with a past or present psychiatric condition that may impair his or her ability to comply with the study procedures", "Subjects with history of volvulus", "Subjects with history of known small bowel adhesions or any known GI adhesions", "Subjects with deficiencies of known vitamins, e.g. B12", "Subjects with known celiac disease or inflammatory bowel disease", "Subjects with conditions that, in the judgment of the investigator, precludes successful participation to the study."], "nct_id": "NCT00872846"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetic", "BMI \u2264 40 kg/m\u00b2", "HbA1c > 7%", "Treated with basal insulin (NPH, Insulin Zinc, insulin glargine or insulin detemir), and at least, two OAD including an insulin secretagogue (sulfonylurea or glinide, at any dosage) and metformin (at the maximum tolerated dosage), for more than 6 months"], "exclusion": ["Type 1 diabetes mellitus", "Treatment with OADs only", "Treatment with thiazolidinediones", "Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)", "Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus performed in the 2 years prior study entry)", "Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception)", "Breast-feeding", "History of hypersensitivity to the study drug or to drugs with a similar chemical structure or to insulin glargine", "Treatment with systemic corticosteroids, irrespective of the dose of administration and irrespective of the prior or foreseeable treatment duration", "Treatment with any investigational product in the last 2 months before study entry, except for insulin glargine", "Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol", "Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult", "Impaired hepatic function as shown by ALT and/or AST greater than three times the upper limit of normal at study entry", "Impaired renal function as shown by serum creatinine >135 \u03bcmol/l in men and > 110 \u03bcmol/l in women at study entry", "History of drug or alcohol abuse", "Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study", "Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study", "Subject deprived of freedom by a judicial or administrative decision", "Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00174642"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 Diabetes defined according to ADA criteria", "Enteral nutrition therapy", "Two blood glucose readings > 130 mg/dl within 48-hrs prior to or within a 48-hour period during enteral nutrition therapy", "Men and women age >/= 18", "Ability for patient or legally authorized representative to understand and sign an informed consent document"], "exclusion": ["Subjects with conditions that are anticipated to have short term (i.e. < 2 months survival) based on discussions with the treatment team and attending physician.", "Subjects admitted to the CT ICU or any unit with pre-established protocols for glycemic management.", "Subjects with known type 1 diabetes (who will absolutely require a long or intermediate acting insulin preparation).", "Subjects with known type 2 diabetes who currently receive 30 units or more of an intermediate or long acting insulin.", "Pregnancy"], "nct_id": "NCT00177398"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years of age or older", "Have type 2 diabetes", "Have a sedentary lifestyle", "Interested in starting a walking program", "Regular computer users who check e-mail at least 5 times a week and have access to a personal computer (PC) with XP or Windows 2000 operating system, 128 MB of memory, and an available universal serial bus (USB) port.", "Can identify a primary care doctor, endocrinologist or cardiologist and obtain written clearance to start a walking program.", "Willing to provide written informed consent", "Can communicate in English"], "exclusion": ["Used a pedometer in past 30 days", "Currently pregnant", "Cannot comfortably walk at least one block", "Cannot obtain written clearance to start a walking program from primary care doctor, endocrinologist or cardiologist"], "nct_id": "NCT00151021"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [":\u00b7", "Current diagnosis of type 2 diabetes", "Diagnosed at least 3 months prior to the start of the study but not more than 15 years from the start of the study", "Stable regimen (i.e., no changes in therapeutic regimen) for the past three months", "Baseline HbA1c of 7.0 to 8.9%, inclusive"], "exclusion": ["Using insulin", "Using oral agents that target post-prandial hyperglycemia (Note: These medications may be added during the study)", "Known history of anemia or disorders associated with anemia", "Has previously used the devices being tested in the study"], "nct_id": "NCT00401622"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00404963"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["type 2 diabetics", "age < 80 years", "to be able to read and to understand French", "to be affiliate national insurance", "to give a light and read consent"], "exclusion": ["incapacity to carry out a questionnaire"], "nct_id": "NCT00403741"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Men and women aged 18-70 with Type 2 diabetes as defined by:", "Fasting plasma glucose > 126 mg/dL at entry", "Or a two-hour OGTT glucose > 200mg/dL", "Or current treatment with one or two oral anti-diabetic drugs, except TZD", "Or currently using insulin", "Fasting plasma glucose < 200mg/dL at entry", "BMI >27.0 and <45.0kg/m2", "Adequate contraception for women (including, but not limited to: oral contraception, hysterectomy, tubal ligation, or post-menopausal as defined by > 6 months without a menstrual cycle and FSH > 40 mIU/ml)."], "exclusion": ["Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp < 140/90 on medications).", "Prior use of other thiazolidinediones (rosiglitazone [AVANDIATM], pioglitazone [ACTOSTM])", "Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc.", "Pregnancy", "Alcohol or other drug abuse", "Unwilling or unable to abstain from caffeine (48h) and tobacco (24h) prior to metabolic rate measurements", "Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)", "Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc.", "HbA1C of > 10%.", "NYHA class III/IV CHF is an exclusionary cardiac condition.", "history of deep vein thrombosis (DVT) or pulmonary embolism (PE)", "varicose veins", "major surgery on the abdomen, pelvis, or lower extremities within previous 3 months", "cancer (active malignancy with or without concurrent chemotherapy)", "rheumatoid disease", "bypass graft in limb", "known genetic factor (Factor V Leiden, etc) or hypercoagulable state", "diagnosed peripheral arterial or vascular disease, or intermittent claudication", "family history of primary DVT or PE (pulmonary embolism)", "peripheral neuropathy"], "nct_id": "NCT00402012"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes for at least 1 year", "Insulin na\u00efve", "Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)", "7% \u2264 HbA1c \u2264 10.5 %", "Body mass index (BMI) < 40 kg/m\u00b2", "Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary"], "exclusion": ["Type 1 diabetes", "Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)", "Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors", "Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)", "Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)", "Breast-feeding", "History of hypersensitivity to the study drugs or to drugs with a similar chemical structure", "Treatment with systemic corticosteroids in the 3 months prior to study entry", "Treatment with any investigational product in the 2 months prior to study entry", "Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol", "Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult", "Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry", "Impaired renal function as shown by serum creatinine \u2265 1.5 mg/dL (\u2265 133 \u03bcmol/L) in men and \u2265 1.4 mg/dL (124 \u03bcmol/L) in women at study entry", "History of drug or alcohol abuse in the last year The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00405418"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug", "Glycosylated haemoglobin (HbA1c) 6.0", "9.0% at screening for patients treated with metformin and one other oral antidiabetic drug", "HbA1c 6.5", "10.0% at screening for patients treated with metformin alone", "HbA1c 6.5", "10.0% at beginning of the placebo run-in phase"], "exclusion": ["Myocardial infarction, stroke or transient ischemic attack (TIA)", "Impaired hepatic function", "Renal failure or renal impairment", "Treatment with rosiglitazone or pioglitazone within 6 months prior to screening", "Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within 3 months prior to screening"], "nct_id": "NCT00622284"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Healthy male subjects aged 18 to 55 years inclusive.", "Body Mass Index (BMI) is between 19-35kg/m2 (inclusive), with a minimum body weight of 45kg.", "Subject must read and write at a comprehension level that is sufficient to provide written informed consent, and be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.", "Subject has provided informed consent to participate in the study as indicated by providing a signed and dated written informed consent form prior to the initiation of any study procedures."], "exclusion": ["General", "Presence of any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or 12-lead ECG, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study. These include any unstable medical disorder; disorders that would interfere with the action, absorption, distribution, metabolism, or excretion of bupropion or GSK189075; disorders which may pose a safety concern or interfere with the accurate assessment of safety or efficacy.", "Laboratory", "Clinically significant abnormalities at Screening including:", "Systolic blood pressure outside the range of 90", "140 mmHg, diastolic blood pressure outside the range of 50", "90 mmHg, and pulse rate at rest > 100 and < 45 bpm.", "Positive tests for hepatitis B surface antigen, hepatitis C antibodies, and HIV.", "Positive cotinine, drug and/or alcohol test.", "Significant ECG abnormalities are defined as follows:", "Parameter Range", "Heart Rate < 40 and >100 bpm", "PR Interval <120 and > 220 ms", "QRS duration < 70 and >120 ms", "QTC Interval (Bazett) > 450 ms", "ALT, alkaline phosphatase, or total bilirubin \u00b3 1.5 times the upper limits of normal (Note: Subjects with an increased total bilirubin may enter the study only if direct bilirubin is within normal limits).", "Fasting triglycerides >400 mg/dL (>11.3 mmol/L).", "Clinically significant abnormalities of T3 and TSH.", "Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):", "A validated web-based calculator is found at:", "http://nephron.com/cgi-bin/MDRDSIdefault.cgi", "To calculate estimated GFR (mL/min/1.73m2) manually:", "= 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)", "= exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))", "Any other clinically significant laboratory abnormality as determined by the Principal Investigator in consultation with the GSK Medical Monitor.", "Central Nervous System", "Current diagnosis or a previous history of mania, psychosis, major depression, or other major psychiatric disorder.", "Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure; those treated with other medications or treatment regimes that lower seizure threshold; those undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines or benzodiazepine-like agents).", "Note: A single childhood febrile seizure is not exclusionary.", "History or current diagnosis of anorexia nervosa or bulimia.", "Subjects who, in the investigator's judgement, pose a homicidal or suicidal risk, have ever made a suicide attempt, or have ever been homicidal.", "Hepatic and Gastrointestinal systems", "History of hepatic disease or known hepatic or biliary abnormalities, (with the exception of previously documented diagnosis of Gilbert's syndrome) and/or a history of biliary or gastrointestinal disorder, which might affect absorption, distribution, metabolism, or excretion of drugs (except appendectomy or cholecystectomy more than 12 weeks prior to the study).", "Endocrine system", "Untreated or unstable thyroid disease. Subjects taking thyroid medications must be on a stable dosing regimen for at least 4 weeks prior to the first dose of study drug until completion of the Follow-up visit.", "Cardiac system", "Subject has a history of clinically significant cardiac rhythm disorder or QTc interval \u00b3450 milliseconds at Screening.", "Subject has history of ischemic heart disease, including stable/unstable angina or acute myocardial infarction.", "Uncontrolled hypertension with systolic blood pressure >140mm Hg and diastolic blood pressure >90mm Hg. Drugs and Alcohol", "Subject has a history of alcohol abuse or an average weekly intake of greater than 21 units per week (one unit = 1 glass of wine = 1 measure of spirits = \u00bd pint of beer).", "Unwilling or unable to abstain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.", "Use of tobacco in any form (smoking cigarettes, cigars, and/or pipes, or chewing tobacco-containing products), for 4 weeks prior to Screening until completion of the Follow-up visit.", "Unwilling or unable to abstain from the use of prescription or non-prescription drugs, vitamins, or dietary/herbal supplements within 1 week prior to the first dose of study drug until completion of the Follow-up visit.", "Subject is currently using medications that may alter gastric/small bowel motility, result in diarrhea, or bind concomitant medications. For example, but not limited to: erythromycin, antacids, prokinetic agents and cholestyramine.", "Subject has a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation in this study. \u2022 Concomitant medications usage that includes:", "Use of agents that are known to inhibit or induce cytochrome P450 enzymes within 14 days prior to the first dose of study medication , including grapefruit-containing products and St. John's Wort.", "Use of bupropion hydrochloride or GSK189075 within the last 6 months prior to Screening.", "Use of anti-depressant medication for clinically significant depression.", "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose in Treatment Period 1, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.", "Note: Occasional use of acetaminophen and ibuprofen according to directions provided in the product label may be acceptable during the study, at the discretion of the Principal Investigator. Acetaminophen will be limited to doses up to 2 grams/day and ibuprofen at doses up to 1.2 grams/day.", "Drug hypersensitivity", "History of hypersensitivity to WELLBUTRIN SR, ZYBAN, GSK189075 or any of their constituents or closely related compounds.", "History of sensitivity to heparin or heparin-induced thrombocytopenia.", "Other", "Past treatment with a new molecular entity (investigational drug) or any other trial during the previous 30 days, or 5 half-lives, whichever is longer. A new molecular entity is defined as any compound not in Phase", "(The washout period of 30 days is counted from the last dose of study drug in the previous study until the first dose of study drug).", "Participation in the study would result in subject's donation of blood in excess of 500mL within a 56-day period."], "nct_id": "NCT00625859"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": [": Type-2 diabetes, defined as:", "Age at onset of diabetes \u2265 40 years", "Fasting serum C-peptide \u2265 300 pmol/l or a non-fasting or glucagon-stimulated serum C-peptide \u2265 600 pmol/l", "No history of ketonuria or ketoacidosis.", "BMI \u2264 27 kg/m2.", "Fasting plasma-glucose \u2265 6.5 mmol/l after at least one month of diet-only treatment.", "HbA1c \u2264 9.5% at ongoing oral anti-hyperglycaemic agents. HbA1c \u2265 6.5% after minimum one month of diet-only treatment.", "Weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment."], "exclusion": ["Type-1 diabetes", "Insulin-treated type-2 diabetes", "Secondary diabetes, heart-failure", "Serum-creatinine above the upper limit", "Serum-ASAT elevated more than 3 fold above the upper limit", "Factor II-VII-X decreased below 0.7", "Ongoing coexisting illnesses with a life-shortening prognosis", "Mental retardation or reduced intellectual behaviour", "Pregnancy", "History of drug-abuse or HbA1c>10.5% at two separate visits with at least one month interval during treatment-periods."], "nct_id": "NCT00118950"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosed with Type 2 diabetes mellitus", "Has access to Internet", "Has e-mail address", "Established patient at one of four participating practices at University of Colorado Hospital"], "exclusion": ["Non-English speaking"], "nct_id": "NCT00119938"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Must have type 2 diabetes.", "Must be 30-75 years of age at the time of Visit 1.", "Must be on insulin glargine and oral antidiabetic medicines for at least 90 days.", "Must be on at least 30 units of glargine per day at enrollment.", "Have an A1C between 7.5% and 12.0% at Visit 1."], "exclusion": ["Must not have used rapid/short-acting insulin on a regular basis in the last 6 months.", "Must not have more than one episode of severe hypoglycemia in the last 6 months.", "Must not have a body mass index (BMI) of greater than 45 (morbid obesity).", "Must not have congestive heart failure that requires medications.", "Must not have had a kidney transplant or currently receiving dialysis"], "nct_id": "NCT00110370"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Women must not be pregnant and must not be breastfeeding.", "Have Type II diabetes.", "Not taking any medicine for diabetes, or taking one oral medicine for their diabetes."], "exclusion": ["Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor."], "nct_id": "NCT00111800"},{"minimum_age": 21.0, "maximum_age": 72.0, "gender": "A", "inclusion": ["diagnosed with type 2 diabetes mellitus", "21 to 72 years of age", "taking rosiglitazone and metformin (or Avandamet) for at least 3 months, and on a stable dose of rosiglitazone (or Avandamet) for at least 2 months", "glycosylated hemoglobin (HbA1c) level of >/=7.5% but </=10.0%", "fasting blood sugar level >/= 125 mg/dL but </= 279 mg/dL", "BMI 26-43 kg/m2", "direct bilirubin < 1.5x the upper limit of normal (ULN)", "serum creatinine < 1.5 mg/dL (males) or < 1.4 mg/dL (females)", "blood urea nitrogen (BUN)</=40 mg/dL", "all other clinical laboratory parameters (hematology, serum chemistry, and urinalysis) within normal limits or not clinically significant", "ECG normal, or abnormalities not clinically significant", "surgically sterile, postmenopausal, or using adequate contraception and have a negative pregnancy test at Screening", "willing and able to sign an informed consent form"], "exclusion": ["diagnosed with type 1 diabetes mellitus or has a history of ketoacidosis", "treatment with insulin, TZDs (excluding rosiglitazone) or any other oral or injected antidiabetic (excluding metformin or Avandamet) within 3 months prior to screening or during study treatment", "change in lipid-lowering medication within 2 months of screening", "taken systemic corticosteroids within 1 month prior to screening or during study treatment", "history of or current/active cardiovascular disease", "significant current pulmonary conditions", "significant thyroid disease", "CPK value > 3x ULN", "a female who is pregnant or lactating", "systolic BP > 160 mm Hg or a diastolic BP > 90 mm Hg at screening", "previous or current history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to randomization", "liver function tests (ALT, AST, ALP) > 2 times ULN, or active liver disease at screening", "history of positive HIV", "positive hepatitis B test at screening", "weight loss or gain >/= 15 lbs within 3 months of screening", "history of substance abuse (including alcohol abuse) within 2 years prior to screening", "donated and/or received any blood or blood products within 3 months prior to randomization", "taken an investigational study medication within 30 days prior to screening or during the study"], "nct_id": "NCT00110851"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["The subject has an HbA1c value <=11.0%", "The subject has a body mass index (BMI) of 25 kg/m^2 to 45 kg/m^2, inclusive"], "exclusion": ["Is currently treated with certain medications, including exogenous insulin"], "nct_id": "NCT00111540"},{"minimum_age": 21.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Age 21-70 years", "Diabetic subjects having HbA1c greater than or equal to 7.5% and less than or equal to 9.5 % at Visit 1", "Sex: male or female. Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods.", "Type 2 diabetes duration less than 10 years but at least 6 months", "Type 2 diabetic Subjects taking no more than two (2) oral anti-diabetic agents [Sulfonylurea, Metformin or thiazolinedione (TZD)].", "Stable anti-diabetic drugs for at least three (3) months prior to enrollment and six (6) months for thiazolinedione (TZD).", "Fasting blood glucose values > 120 and < 240 mg/dl at baseline", "Stable HbA1c, described as no significant change (\u2264 0.5% variation) between a historical value in the subjects' medical record within 3 months prior to enrollment and the A1c value gathered at baseline.", "If subject is under anti-depressant medication, the treatment needs to be stable for at least six (6) months prior to enrollment.", "BMI between 28 and 45 (kg/m2)", "Stable weight, defined as no significant weight change over the three months prior to enrollment as reported by the subject (\u00b15 kg).", "Stable medications (including anti-hypertensive and lipid-lowering) for at least one month prior to enrollment.", "Compliant, willing and able to participate in the follow-up visits for the study duration.", "Alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial.", "Able to provide voluntary informed consent."], "exclusion": ["Gastroparesis or intestinal pseudo-obstruction.", "Receiving medications known to affect gastric motility.", "Taking appetite suppressant or weight loss medications within 1 month of enrollment.", "Diabetic subjects on insulin.", "Past or current psychiatric condition that may impair his or her ability to comply with the study procedures.", "Severe eating disorders such as bulimia or binge eating.", "Obese due to a clinically diagnosed endocrine problem.", "Pregnant (proven by positive \u03b2hCG), or lactating.", "History of anemia (<10 g/dl) over past 3-months.", "Prior bariatric surgery.", "History of peptic ulcer disease.", "Use of another investigational device or agent in the 30 days prior to enrollment.", "Participation in another clinical study.", "Life threatening co-morbidity or life expectancy of less than one year.", "Myocardial Infarction or one or more episodes of unstable angina within six months prior to enrollment.", "Implanted with a permanent pacemaker, an automatic implantable defibrillator, or other electro-stimulation device.", "History of life threatening disease within 5 years of enrollment.", "Use of routine ulcerogenic drugs.", "Use of prescription, over the counter or herbal weight loss products."], "nct_id": "NCT00779363"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.", "Male or female between 18 and 55 years of age.", "A female subject is eligible to participate if she is of non-childbearing potential, defined as:", "pre-menopausal females with a documented tubal ligation or hysterectomy; or", "postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory].", "Body weight \u2265 50 kg and BMI within the range 19", "30 kg/m2 (inclusive).", "Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.", "Demonstrates an average QTc interval < 450 msec (or < 480 msec in subjects with Bundle Branch Block), an average PR interval < 200 msec, and a QRS duration < 110msec (manual or machine read) at screening or baseline"], "exclusion": ["A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.", "A positive test for HIV antibody.", "The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).", "Exposure to more than four new chemical entities within 12 months prior to the first dosing day.", "Previous exposure to GSK376501.", "Unwillingness or inability to follow the procedures outlined in the protocol.", "Subjects will be excluded if they experience symptomatic or asymptomatic arrhythmia of any clinical significance during screening.", "The subject has a positive pre-study drug/alcohol screen and is unwilling to abstain from 72 hours prior to dose until follow-up. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.", "Urinary cotinine levels indicative of smoking or history or use of tobacco or nicotine-containing products within 6 months prior to screening.", "Has a history of alcohol abuse or dependence within 12 months prior to the study. Alcohol abuse is defined as an average consumption of greater than 7 drinks per week for women or greater than 14 drinks per week for men. One alcohol drink is defined as the equivalent of 12 g of alcohol as follows: 5 oz/150 ml wine, 12 oz (360 ml) beer or 1.5 oz (45 ml) of 80 proof distilled spirits.", "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort, kava, ephedra [ma huang], gingko biloba, DHEA, vohimbe, saw palmetto, ginseng, red yeast rice) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication and is unwilling to abstain from use of these medications until the last pharmacokinetic sample has been collected, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.", "Use of caffeine- or xanthine-containing products for 24 hours prior to the start of dosing until collection of the final pharmacokinetic and sample of each study period.", "Consumption of any food or any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, Seville oranges, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts, mustard) and charbroiled meats from 7 days prior to the first dose of study medication until the last pharmacokinetic sample has been collected.", "Use of acetaminophen within 48 hours of the first dose and is unable or unwilling to discontinue use of acetaminophen until the last pharmacokinetic sample has been collected.", "Use of aspirin, aspirin-containing compounds, salicylates or nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours days of the first dose and is unwilling to abstain from use of these medications until the last pharmacokinetic sample has been collected.", "Use of liquid antacids (e.g. Maalox, Mylanta, Amphogel, milk of magnesia) or chewable antacids (e.g. TUMS) within 48 hours of the first dose and is unwilling to abstain from use of these medications until the last dose of study medication.", "History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.", "Alkaline phosphatase value higher than 1.5 times the upper limit of normal at screening or at baseline.", "Aspartate aminotransferase (AST), alanine aminotransferase (ALT), direct (conjugated) bilirubin, or CPK values higher than 1.25 times upper limit of normal at screening or at baseline.", "Fasting triglyceride level > 400 mg/dL (4.52 mmol/L) at screening or at baseline.", "Donation of blood or blood products in excess of 500 mL within a 56 day period.", "History of sensitivity to heparin or heparin-induced thrombocytopenia.", "History of rhabdomylosis.", "History of or current congestive heart failure (NYHA Class I-IV symptoms", "refer to Appendix 3)", "History of thyroid dysfunction or an abnormal thyroid function test as assessed by TSH as screening."], "nct_id": "NCT00605449"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male and female patients with a diagnosis of type 2 diabetes mellitus, currently treated only with a stable total daily dose of preferably* >/= 1500 mg metformin and a dose of a sulphonylurea drug that has been documented, by the Investigator, to be the individual maximum tolerated dose of that sulphonylurea drug. Both the dose and dosing regimen of metformin and the sulphonylurea must be stable (i.e. unchanged) for 10 weeks prior to informed consent, and must not be changed for the duration of the trial", "Glycosylated haemoglobin A1 (HbA1c) >/= 7.0 and </= 10.0% at the screening Visit 1a and at Visit 2 (start of placebo run-in phase)", "Age >/= 18 and </= 80 years at Visit 1a (screening)", "BMI (Body Mass Index) </= 40 kg/m2 at Visit 1a (screening)", "Signed and dated written informed consent, at the latest by the date of Visit 1a, in accordance with GCP and local legislation *Patients currently treated with a total daily dose of less than 1500 mg metformin can be included in the trial if the Investigator has documented that the dose is the maximum tolerated dose of metformin for that patient."], "exclusion": ["Myocardial infarction, stroke or TIA (transient ischaemic attack) within 6 months prior to the date of informed consent", "Impaired hepatic function, defined by serum levels of either alanine transaminase (ALT/SGPT), aspartase transaminase (AST/SGOT), or alkaline phosphatase (ALP) above 3 times the upper limit of normal (ULN), as determined at Visit 1a", "Renal failure or renal impairment (serum creatinine >/= 1.5 mg/dl) as determined at Visit 1a", "Treatment with rosiglitazone or pioglitazone within 3 months prior to the date of informed consent", "Treatment with GLP-1 analogues (e.g. exenatide) within 3 months prior to the date of informed consent", "Treatment with insulin within 3 months prior to the date of informed consent", "Treatment with anti-obesity drugs (e.g. sibutramine, rimonabant, orlistat) within 3 months prior to the date of informed consent", "Current treatment with systemic steroids (i.e. at the time of informed consent) or a change in the dosage of thyroid hormones within 6 weeks prior to the date of informed consent", "Pre-menopausal women (last menstruation </= 1 year prior to the date of informed consent) who:", "are nursing or pregnant", "or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to periodic pregnancy testing during their participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner. No exception will be made. 10. Known hypersensitivity or allergy to the investigational product or its excipients or to the trial background therapy (i.e. metformin in combination with a sulphonylurea) or sulphonamides 11. Dehydration (as confirmed by the Investigators clinical opinion) 12. Current acute or chronic metabolic acidosis"], "nct_id": "NCT00602472"},{"minimum_age": 21.0, "maximum_age": 99.0, "gender": "A", "inclusion": ["adults without prior history of pancreatic disease (other than diabetes)"], "exclusion": ["use of unapproved medications", "contraindications to the MRI procedure", "contraindications to frequent blood draws", "pregnancy", "use of more than 2 alcoholic drinks/day"], "nct_id": "NCT00602953"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug", "Diagnosis of type 2 diabetes prior to informed consent", "Glycosylated haemoglobin A1 (HbA1c)at screening: For patients undergoing wash out of previous medication: HbA1c 6.5", "9.0% For patients not undergoing wash-out of previous medication: HbA1c 7.0", "10.0%", "Glycosylated haemoglobin A1 (HbA1c) 7.0", "10.0% at the beginning of Placebo Run-in", "Age 18 -80 years", "BMI (Body Mass Index) less than 40 kg/m2", "Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation"], "exclusion": ["Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent", "Impaired hepatic function", "Known hypersensitivity or allergy to the investigational product or its excipients or metformin or placebo", "Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent", "Treatment with an injectable GLP-1 analogue (e.g. exenatide) within 3 months prior to informed consent", "Treatment with insulin within 3 months prior to informed consent", "Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent", "Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse", "Participation in another trial with an investigational drug within 2 months prior to informed consent 10. Pre-menopausal women who:", "are nursing or pregnant,", "or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. 11. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent. 12. Renal failure or renal impairment 13. Unstable or acute congestive heart failure 14. Acute or chronic metabolic acidosis (present in patient history) 15. Hereditary galactose intolerance"], "nct_id": "NCT00601250"},{"minimum_age": 19.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus, diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled with basal insulin with or without sulfonylurea"], "exclusion": ["HbA1c less than (<) 7 percent (%) or greater than (>) 10% at screening", "At the time of screening age <legal age of majority", "Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method", "Type 1 diabetes mellitus", "Treatment with basal insulin for less than 3 months prior to screening or insulin regimen changed during the last 3 months prior to screening", "Basal insulin dose at screening <10 units/day and/or during the last 2 months dose not stable (+/- 20%)", "Sulfonylurea not at a stable (unchanged) dose for at least 3 months prior to screening", "FPG at screening >250 milligram/deciliter (mg/dL) (>13.9 millimole/liter [mmol/L])", "History of hypoglycemia unawareness", "Weight change of more than 5 kilogram (kg) during the 3 months preceding the screening visit", "History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease", "History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening", "Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening", "Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization", "Known history of drug or alcohol abuse within 6 months prior to the time of screening", "Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period", "Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure or diastolic blood pressure >180 millimeter of mercury (mmHg) or >95 mmHg, respectively", "Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: >2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: >3 times ULN; total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody and positive serum pregnancy test in females of childbearing potential", "Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram, or vital signs at the time of screening that, in the judgment of the investigator or any sub-investigator, precludes safe completion of the study or constrains efficacy assessment", "Patients who are considered by the investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol)", "Patient was an investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol", "Use of other oral or injectable antidiabetic or hypoglycemic agents other than sulfonylurea or basal insulin (for example, metformin, alpha glucosidase inhibitor, thiazolidinedione, rimonabant, exenatide, dipeptidyl peptidase 4 inhibitors, fast acting insulin for 1 week or more etc.) within 3 months prior to the time of screening", "Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening", "Use of any investigational drug within 3 months prior to screening", "Participation in any previous study with lixisenatide", "End-stage renal disease defined by a serum creatinine clearance of <15 milliliter/minute (mL/min) (calculated by the Cockcroft and Gault formula) and/or patients on dialysis", "Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening", "Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol", "Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in phase (>2 injections missed); and patient with any adverse event which could have precludes the inclusion in the study, as assessed by the investigator"], "nct_id": "NCT00866658"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Participant has type 2 diabetes", "Participant is either not taking antihyperglycemic medications for the last 10 weeks OR is taking a single oral antihyperglycemic medication (but not a Peroxisome Proliferator-Activated Receptor gamma [PPARg] agonist) OR is taking a low-dose combination oral antihyperglycemic medication (not a PPARg agonist) at dose less than or equal to 50% of the maximum dose", "Female participant is unable to have children"], "exclusion": ["Participant has a history of type 1 diabetes or ketoacidosis", "Participant has been treated with a PPARg agonist in the last 12 weeks", "Participant has been treated with insulin in the last 12 weeks", "Participant has had prescription lipid-modifying drug therapy in the last 12 weeks", "Participant has a history of coronary artery disease", "Participant has had a stroke or transient ischemic attack", "Participant has congestive heart failure"], "nct_id": "NCT00868790"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age > 18 years", "Known diagnosis of type 2 diabetes by history with outpatient prescription of oral hypoglycemic medication or insulin", "Hemoglobin A1c > 8.0% within the prior 12 months, or if not known, fasting blood glucose greater than 200 mg/dl on sliding scale regular insulin.", "Partners-affiliated primary care physician"], "exclusion": ["Screening HbA1c returns less than 8%.", "Diabetic ketoacidosis (DKA) as a primary reason for admission (admission blood glucose > 250 mg/dl with arterial pH < 7.30 or serum bicarbonate level < 15 mg/dl), or development of DKA during admission.", "Hyperosmolar hyperglycemic syndrome as a primary reason for admission (admission blood glucose > 400 mg/dl and plasma osmolality > 315 mOsm/kg.", "Pregnancy, ruled out by urine HCG test at screening after consent is obtained in all women who continue to have menstrual cycles.", "Anemia with hemoglobin < 9 g/dl, recent blood transfusion, or need for blood transfusion (interferes with interpretation of hemoglobin A1c assay)", "End stage liver disease with prothrombin time > 15 seconds and albumin <3 mg/dl", "End stage renal disease: Stage IV (glomerular filtration rate <30 mg/dl) or V chronic kidney disease", "Treatment with corticosteroids", "ICU transfer", "Inability to self-administer insulin", "Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose < 60 mg/dl (tachycardia, diaphoresis, hunger, confusion, fatigue).", "Projected survival < 1 year"], "nct_id": "NCT00869362"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "F", "inclusion": ["Chinese women aged 30-70 y", "Fasting glucose >=5.6 mmol/l; post-load glucose >=7.8 mmol/l"], "exclusion": ["Diabetes renal diseases", "Confirmed CVD, chronic liver,kidney diseases,Thyroid disease", "Medications affecting glucose or lipid metabolism"], "nct_id": "NCT00951912"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes type 2, detectable C-peptide, HbA1c 7-10%", "Pretreatment with basal insulin +/- Metformin or/and +/- Pioglitazone 3 Age > 18 years, BMI <= 45 kg/m2"], "exclusion": ["Uncontrolled hyperglycemia during Run-in", "Myocardial infarction, stroke or TIA within 3 months prior to informed consent", "Liver impairment; gastric surgery; medical history of cancer in last 5 years", "Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation", "Unsufficient birth control, pregnancy and nursing"], "nct_id": "NCT00954447"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Diagnosed with type 2 Diabetes Mellitus (T2DM)", "HbA1c > or = 7.5%, or HbA1c < or = 10%", "Continuous oral antidiabetic (OAD) treatment for more or equal than three months before randomisation with stable daily doses of one or more OADs (if on two or more OADs, one must be less or equal than half maximum tolerated dose)", "Willing and able to perform blood glucose monitoring using a blood glucose meter", "Willing and able to keep a daily patient diary", "Willing and able to provide written informed consent before enrolment in the study"], "exclusion": ["Type 1 diabetes mellitus", "Body mass index (BMI) > 45 kg/m\u00b2", "Works night shifts", "History of ketoacidosis or hyperosmolar hyperglycaemic state", "History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months", "History of congestive heart failure", "Hypoglycaemia unawareness", "Have had more than one episode of hypoglycaemia (per protocol definition) within 24 weeks before screening", "Impaired renal function defined as, but not limited to, serum creatinine > or = 1.5 mg/dL (133 \u00b5mol/L) males or > or = 1.4 mg/dL (124 \u00b5mol/L) females", "Active liver disease (alanine transaminase (ALT) greater than two times the upper limit of the reference range, as defined by the local laboratory)", "Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol", "Had a blood transfusion or severe blood loss within the 3 months before screening, or have known haemoglobinopathy, haemolytic anaemia or sickle cell anaemia", "Current or previous use of insulin", "Known hypersensitivity / intolerance to insulin glargine or any of its excipients", "Have taken exenatide in the six weeks before screening or for a total of 30 days or more in the 24 weeks before screening", "Currently receiving treatment with non-selective -blockers", "Currently receiving chronic (longer than two weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received such therapy within the four weeks preceding the screening visit", "Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma).", "Currently participating in another investigational study or recent study participation ending < 30 days before screening", "Female patients who are pregnant or breastfeeding", "Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be willing to agree to use a medically accepted contraceptive regimen for the duration of the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00950534"},{"minimum_age": 55.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["People ages 55", "75 years old with type 2 diabetes, not receiving oral hypoglycemic agents or insulin.", "Fasting plasma glucose < 250 mg/dl (<14 mM) (tGHb < 14%)."], "exclusion": ["Subjects will be screened for hematological abnormalities, liver disease, kidney disease, macroalbuminuria (>300 mg/24 hours), untreated thyroid disease, congestive heart failure, angina, life-threatening malignancies, proliferative retinopathy, diabetic neuropathy, peripheral vascular disease, serious psychological disorders, a body mass index > 35, and a fasting triglyceride of > 400 mg/dl.", "Presence of any of the above will be considered exclusion criteria."], "nct_id": "NCT00108225"},{"minimum_age": 20.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus", "Less than 8.0% in HbA1c", "Less than 300 mg/g Cr of urinary albumine level", "Concomitant therapy with SU and/or Biguanide", "Untreated hypertension and hypertension treated with ARB or ACEI"], "exclusion": ["History of heart failure and concomitant heart failure", "History of administration of TZD agent", "Severe hepatic dysfunction with more than 3 times higher than upper limit of normal range of GOT, GPT or rGPT", "Severe renal dysfunction with more than 2.5 of Cr", "History of AE with TZD agent", "Insulin treatment", "Concomitant urinary track infection"], "nct_id": "NCT00846716"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Uncontrolled blood sugar:", "Random blood sugar \u2265 200mg/dl", "Pre-prandial blood sugar greater than 180 mg/dl on two occasions within 24 hours.", "Patient may be off insulin or on subcutaneous inpatient insulin regimen less than 36 hours.", "Transition from an Insulin Drip in the intensive care units to subcutaneous insulin upon transfer to general ward.", "Patient is able to eat and oral feeding is expected."], "exclusion": ["Patients receiving inpatient oral hypoglycemic agents", "Patients with chronic kidney disease stages 4 & 5 (estimated GFR of <30ml/min) and on dialysis", "Patient with chronic liver disease", "Patient with hypoglycemia unawareness", "Pregnancy", "Patients who are on \"NPO\" for medical reasons.", "Patient is expected to stay in the hospital for less than 3 days.", "Patient on a new inpatient insulin regimen for > 36 hours."], "nct_id": "NCT00841919"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations", "Body mass index (BMI) of 18 to 32 kg/m2, inclusive BMI = weight (kg)/[height(m)]2"], "exclusion": ["WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product", "Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN)", "History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months", "History of allergy to SGLT@ inhibitors, DPP$ inhibitors or sulfonylurea or related compounds", "Prior exposure to dapagliflozin, sitagliptin and glimepiride within 3 months of Day -1", "History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections"], "nct_id": "NCT00842556"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["Postpartum Women (6-12 weeks)who experienced GDM during index pregnancy 18 years to 42 years of age", "English-speaking", "Written consent for participation in the study"], "exclusion": ["(Medical):", "Cholestasis during the past pregnancy", "Serum AST and/or ALT level exceeding more than twice normal laboratory values", "History or clinical manifestation of cardiovascular disease", "History or clinical manifestation of diabetes or use of anti-diabetic drugs before pregnancy", "History or clinical manifestation of any other significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic disorders, or cancer", "Regular use of medications for weight control, psychosis and hormonal birth control", "Current use of medication to treat diabetes Exclusion Criteria (Psychiatric and Behavioral):", "History or clinical manifestation of any eating disorder", "Individuals who smoke", "History of drug or alcohol abuse (up to 14 drinks a week are allowed) within the past two years Other Exclusion Criteria:", "Pregnancy or pregnancy planned during the coming year", "Not willing or unable to adhere to the clinical evaluation schedule over the twelve -month study period"], "nct_id": "NCT00849849"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "F", "inclusion": [": In order to be eligible for this study, the following criteria must be met:", "Subjects must be willing to travel to the clinic for all regularly scheduled study visits, and to the lifestyle intervention program site for the ILI (the John Martinez School).", "Subjects must have had a 2 hour 75 gram Oral Glucose Tolerance Test (OGTT) with fasting glucose between 100 and 126, or 2 hour glucose between 140 and 200 mg/dl in order to participate in this study within the 4 months prior to enrollment.", "Willingness to undergo fasting blood testing: HOMA-IR, fasting lipid profile (including total cholesterol, HDL, LDL cholesterol and triglycerides) at the beginning of the study (if not previously obtained with the OGTT) and repeated at 12 months.", "Subjects must have no medical contraindications to exercise or dieting."], "exclusion": ["Subjects will be excluded from the study if they have diabetes or other serious medical or psychiatric condition that would preclude participation in the ILI program.", "Subjects will be excluded if they are taking medications that potentially cause significant weight gain or weight loss (including prescription medication, over the counter medication, or herbal supplements)..", "Women who are pregnant or planning to become pregnant will not be enrolled in this study.", "Any behavioral or psychosocial issue that will interfere with the subject's completion of the program, including an eating disorder will prohibit subjects from participating in this study.", "Subjects cannot participate if they have concurrent membership in a comprehensive weight management program."], "nct_id": "NCT00848757"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Greater than 18 years old", "Fully understanding and willing to undergo study procedures", "Available for follow-up", "Understand and willing to sign informed consent", "Pharmacologic agents with the potential to change ectopic fat content (i.e. pioglitazone) are allowed if the patient has been on a stable dose for at least 3 months and plans to continue the same dose for the duration of the study"], "exclusion": ["Contraindication to MRI (i.e. metallic implants, severe claustrophobia, weight above 320lb)", "Contraindication to phlebotomy (i.e. no accessible veins, hemoglobin <10 mg/dL)", "History of pancreatic disease other than diabetes", "Regular use of more than 2 alcoholic drinks per day", "Pregnancy", "Non-English speaking"], "nct_id": "NCT00840307"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["Provision of signed written and dated informed consent", "BMI between 19 and 30 kg/m2", "Subjects must be willing to use barrier methods of contraception"], "exclusion": ["History of any clinically significant disease", "Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product", "History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs", "Laboratory blood sample result showing elevated liver enzymes (ASAT, ALAT) and muscle enzymes (CK)."], "nct_id": "NCT00841048"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "M", "inclusion": ["Healthy males;", "Aged 18-65 years;", "Body Mass Index (BMI) of 18-35 kg/m2;", "Willing and able to participate in the whole study and must provide written informed consent."], "exclusion": ["Participation in a clinical research study involving investigational drugs or dosage forms within the previous 4 months;", "Subjects who have previously been enrolled in this study;", "Subjects who have ever sought advice from or been referred to a GP or counselor for abuse or misuse of alcohol, non medical drugs, medicinal drugs or other substance abuse e.g. solvents;", "Subjects who admit to any current or previous use of Class A drugs such as opiates, cocaine, ecstasy, lysergic acid diethylamide (LSD) and intravenous amphetamines (Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs of abuse test and have been abstinent for at least 12 months;)", "Positive drugs of abuse test result (Section 7.8);", "Regular alcohol consumption in males >21 units per week (1 Unit = \u00bd pint beer, a 25 mL shot of 40% spirit or a 125 mL glass of wine);", "Current smokers and those who have smoked within the last 12 months.", "A breath carbon monoxide reading of greater than 10 ppm at screening;", "Radiation exposure from clinical trials, including that from the present study and from diagnostic x rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;", "Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the PI (Section 7.8 )", "History of adverse reaction or allergy to study drug or its excipients, e.g. lactose.", "History of significant allergy. If subject suffers from hayfever they must not have or be expecting to have symptoms during the study period;", "Donation of blood within the previous three months;", "Subjects will be excluded from the study if they are considered by the PI to be at risk of transmitting, thorough blood or other body fluids, the agents responsible for acquired immunodeficiency syndrome (AIDS) or other sexually transmitted disease or hepatitis;", "Positive HBV, HCV or HIV results;", "Subjects receiving prohibited medication as described in Section 6.10;", "Clinically significant medical history, examination finding or laboratory abnormality which in the opinion of the Investigator makes the subject unsuitable to include in the study;", "Failure to satisfy the PI of fitness to participate for any other reason."], "nct_id": "NCT00937872"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["present with type 2 diabetes mellitus", "HbA1c between 7.1% and 11.0% inclusive", "body mass index (BMI) of >18kg/m2 and <35kg/m2, inclusive", "treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulfonylurea (SU), or BG + TZD + SU for 90 days prior to study start"], "exclusion": ["Have received chronic (>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start.", "Have been treated with drugs that promote weight loss within 90 days prior to study start.", "Have been treated with drugs that directly affect gastrointestinal motility for > 21 consecutive days within 90 days prior to study start.", "Have had prior exposure to exenatide BID or QW or participated in the clinical trial of exenatide BID or QW (including the case that the study drug was not administered).", "Have been treated for >2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: Insulin, Dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 analogs", "Have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication.", "Are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start.", "Have donated blood within 30 days prior to study start."], "nct_id": "NCT00935532"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "M", "inclusion": ["Be a healthy male within the age range of 18 to 60 years.", "Voluntarily sign a Research Ethics Committee (REC)-approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.", "Have biochemistry, coagulation, haematology and urinalysis test results that are within normal, allowable limits (if out-of-range, must be considered clinically significant to be exclusionary) and performed within 21 days of receiving first dose of test material.", "Have a BMI (Body Mass Index) between 18.0 and 32.0 kg/m2.", "Be clear of any history of HIV and hepatitis B and C.", "Have no significant disease or clinically significant abnormal laboratory value as deemed by the investigator on the laboratory evaluations, medical history, or physical exam.", "Have a normal 12-lead ECG or an ECG with abnormality considered to be clinically insignificant.", "Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.", "Agree to use an acceptable double barrier method for birth control from the Screening visit through 3 months after the last dose of test material.", "Agree to refrain from consumption of grapefruits and/or grapefruit juice from 7 days prior to Day -1 of treatment visit 1 through to the end of subject's final study visit on Day 29."], "exclusion": ["Subject has had a major illness in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavourable for enrolment.", "Subject has renal or liver impairment.", "Subject has a history of gastro-intestinal surgery or has a current gastrointestinal disease which may influence drug absorption.", "Subject has a history, within 3 years, of drug abuse (including Benzodiazepines, opioids, amphetamine, cocaine, and THC) or a positive drug result at the Screening Visit.", "Subject smokes more than 5 cigarettes a day.", "Subject has a history of alcoholism, and/or is currently drinking more than three drinks per day [one drink is equal to one unit of alcohol (one glass of wine, half a pint of beer, one measure of a spirit)].", "Subject has participated in a clinical trial within the past three months (defined as three months from the date of last dose of an investigational medicinal product), with the exception of the SRT-2104-004 study (EudraCT number: 2008-007364-41).", "Subject has a history of difficulty in donating blood or accessibility of veins in left or right arm.", "Subject has donated blood (one unit or 350 mL) within three months prior to receiving test material.", "Subject is taking herbal products, over-the-counter medication or prescription drug therapy for which 5 times the half-life is longer than 21 days (i.e., the Screening Period) prior to enrolment into the study."], "nct_id": "NCT00933062"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Be a healthy male or female within the age range of 18 to 55 years.", "Voluntarily sign a Research Ethics Committee (REC)-approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.", "Have Hematology, Coagulation, Clinical Chemistry and Urinalysis test results that are within normal, allowable limits (if out-of-range, must be considered clinically significant to be exclusionary) and performed within 21 days of receiving first dose of test material.", "Have a BMI (Body Mass Index) between 18.0 and 30.0 kg/m^2.", "Be clear of any history of HIV and hepatitis B and C.", "Have no significant disease or clinically significant abnormal laboratory value as deemed by the investigator on the laboratory evaluations, medical history, or physical exam.", "Have a normal 12-lead ECG or an ECG with abnormality considered to be clinically insignificant.", "Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.", "All subjects and their partner must agree to use an acceptable double barrier method for birth control from the Screening visit through 3 months after the last dose of test material.", "All female subjects must be of non-childbearing potential. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy. (Menopausal status will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) of 20", "138 mIU/ml and oestradiol < 20 pg/ml at entry. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or oestradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at the discretion of the principal investigator following consultation with the sponsor.", "Subject agrees to refrain from consumption of grapefruits and/or grapefruit juice from 7 days prior to day -1 of treatment visit 1 through to the end of subject's final study visit."], "exclusion": ["Subject has had a major illness in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavorable for enrollment.", "Subject has renal or liver impairment.", "Subject has a history of gastro-intestinal surgery or has a current gastrointestinal disease which may influence drug absorption.", "Subject has a history, within 3 years, of drug abuse (including Benzodiazepines, opioids, amphetamine, cocaine, and THC) or a positive drug result at Screening.", "Subject smokes more than 5 cigarettes a day.", "Subject has a history of alcoholism, and/or is currently drinking more than three drinks per day [one drink is equal to one unit of alcohol (one glass of wine, half a pint of beer, one measure of a spirit)].", "Subject has participated in a clinical trial within the past three months (defined as three months from the date of last dose of an investigational medicinal product).", "Subject has a history of difficulty in donating blood or accessibility of veins in left or right arm.", "Subject has donated blood (one unit or 350 mL) within three months prior to receiving test material.", "Subject is taking herbal products, over-the-counter medication or prescription drug therapy (with the exception of hormone replacement therapy for female subjects) for which 5 times the half-life is longer than 21 days (i.e., the Screening period) prior to enrollment into the study."], "nct_id": "NCT00938275"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations", "Body Mass Index (BMI) of 18 to 32 kg/m\u00b2, inclusive. BMI = weight (kg)/ [height (m)]\u00b2", "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45"], "exclusion": ["WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period", "Any significant acute or chronic medical illness", "Current or recent (within 3 months) gastrointestinal disease", "Current smoker or recent (within 1 month) history of regular tobacco use", "Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population", "Abnormal urinalysis at screening", "Glucosuria at screening", "Abnormal liver functions tests (ALT, AST or total bilirubin > 10 % ULN)", "Presence of edema on physical exam", "History of diabetes mellitus", "History of heart failure", "History of renal insufficiency", "History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months", "Positive urine screen for drugs of abuse either at screening or before dosing", "Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody", "History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)", "History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)", "Prior exposure to dapagliflozin within 3 months of Day -1", "Exposure to any investigational drug or placebo within 4 weeks of Day -1", "Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration", "Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration", "Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration"], "nct_id": "NCT00930865"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Men and women ages 18 to 45 inclusive", "Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations", "Body Mass Index (BMI) of 18 to 32 kg/m\u00b2, inclusive. BMI = weight (kg)/ [height (m)]\u00b2"], "exclusion": ["WOCBP who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product", "Any significant acute or chronic medical illness", "Current or recent (within 3 months) gastrointestinal disease", "Any major surgery within 4 weeks of study drug administration", "History of allergy to DPP4 inhibitor or related compounds", "Prior exposure to saxagliptin"], "nct_id": "NCT00935467"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "F", "inclusion": ["Female age 18 to 55 years", "Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result", "Healthy as determined by laboratory results and medical history", "Waist circumference > 87 cm", "Stable weight defined as < 4.5 kg gained or lost in past year", "Agreement to maintain current level of physical activity throughout the study", "Diagnosed with Type II diabetes mellitus with fasting blood glucose 100", "250 mg/dl (5.6", "13.9 mmol/L)", "Ability to comprehend and complete the questionnaires and forms", "Agreement to comply with study procedures, test article consumption, and has access to a microwave oven 10. Voluntary, written, informed consent to participate in the study"], "exclusion": ["Pregnant, breastfeeding, or planning to become pregnant during the course of the trial", "Use of prescription or over the counter products known to effect weight including but not limited to the following:", "megestrol acetate;", "somatropin;", "sibutramine;", "orlistat;", "paroxetine;", "dextroamphetamine;", "methylphenidate;", "atomoxetine;", "quetiapine;", "olanzepine;", "risperidone, within 4 weeks of randomization and during the trial", "Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary", "Alcohol use > 2 standard alcoholic drinks per day", "Significant cardiac history defined as a history of:", "myocardial infarction (MI);", "coronary angioplasty or bypass graft(s);", "valvular disease or repair;", "unstable angina pectoris;", "transient ischemic attack (TIA);", "cerebrovascular accidents (CVA);", "congestive heart failure; or", "coronary artery disease (CAD)", "History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.", "Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg", "Unstable renal and/or liver disease", "History of alcohol or drug abuse within the past year 10. Unstable psychiatric disorder requiring hospitalization within the past 6 months 11. Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV) 12. History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia 13. Participation in another clinical research trial within 30 days prior to randomization and during the trial 14. Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN 15. Serum creatinine > 125 umol/L 16. Anemia of any etiology defined as hemoglobin < 110 g/L 17. Uncontrolled and/or untreated thyroid disorder 18. Unstable medications (Dosage must be stable for 90 days prior to randomization) 19. History of food allergies or sensitivities, including lactose intolerance 20. Vegetarians 21. Cognitively impaired and/or unable to give informed consent 22. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject"], "nct_id": "NCT00931034"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Subjects of any race and gender within the age range of 30 to 70 years.", "All female subjects must be of non-child-bearing potential. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months, or at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or women who underwent tubal ligation. Menopausal status will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) 40", "138 mIU/ml and oestradiol < 20 pg/ml at entry, unless this information is available in the subject's medical record. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or oestradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at the discretion of the principal investigator following consultation with the sponsor and medical monitor", "All male subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 12 weeks following the last dose of study drug.", "Willingness to provide written informed consent to participate in the study", "HbA1c \u2265 7.5 and \u2264 10.5", "Fasting glucose \u2265 160 and \u2264 240 mg/dL", "Body Mass Index (BMI) \u2265 25.0 kg/m^2 and \u2264 40.0 kg/m^2", "On stable metformin medication for at least 3 months (\u2265 1.0 g/day) prior to Screening", "No prior history of HIV 1 or 2 10. Absence of disease markers for hepatitis B & C virus 11. Absence of significant disease or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or physical examination during the screening; normal end organ function 12. Have a normal 12-lead ECG or one with abnormality considered to be clinically insignificant 13. Have a normal chest X-ray (P. A. View) or one with abnormality considered to be clinically insignificant 14. Comprehension of the nature and purpose of the study and compliance with the requirement of the entire protocol"], "exclusion": ["Any major illness in the past three months or any significant ongoing chronic medical illness not related to diabetes", "Renal or liver impairment, defined as serum creatinine level of \u2265 1.4 mg/dL for females and \u2265 1.5 mg/dL for males, and greater than two times the upper limit of normal for liver enzymes, respectively.", "History of or current gastro-intestinal diseases influencing drug absorption, except for appendectomy", "History, within 3 years, of drug abuse (including Benzodiazepines, opioids, amphetamine, cocaine, and THC)", "History of alcoholism (more than two years), moderate drinkers (more than three drinks per day) or having consumed alcohol within 48 hrs prior to dosing [one drink is equal to one unit of alcohol (one glass wine, half pint beer, one measure of spirit)]", "Participation in any clinical trial within the past three months", "History of difficulty in donating blood or accessibility of veins in left or right arm", "Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of test material", "Use of any prescription drug therapy, with exception of any prescription medication administered at a stable dose for at least 6 weeks prior to Screening, provided the medication is not contraindicated by the metformin label 10. Use of any alternate anti-diabetic therapy, except metformin, within three months of enrollment"], "nct_id": "NCT00937326"},{"minimum_age": 31.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Diabetes diagnosed after the age of 30", "Insulin not required within 6 months of first being diagnosed with Non-insulin Dependent Diabetes Mellitus", "No history of diabetic ketoacidosis", "Patients may be currently treated with diet, oral hypoglycemics or insulin", "Patients must have proteinuria defined as: Urine protein >1+ on dipstick at the initial screening visit", "Patients with hypertension (high blood pressure) must have a sitting blood pressure >200/110 mm Hg at Visit 1"], "exclusion": ["Patients with insulin-dependent diabetes mellitus (juvenile onset)", "Patients treated with an ACE inhibitor or angiotensin II antagonist (AIIA) for >5 years", "Patients treated with ACE inhibitor or AIIA therapy for 5 years or less may enter the study provided therapy is discontinued during the 6 week screening period prior to randomization", "History of myocardial infarction (MI) (heart attack) or coronary artery bypass graft (CABG) surgery within the past 1 month", "History of cerebral vascular accident (CVA) (stroke) or percutaneous transluminal coronary angioplasty (PTCA) within the past 6 months", "History of transient ischemic attacks (TIA) within the past year. Patients with unstable angina are excluded until stabilized", "Heart failure requiring ACE inhibitor therapy", "Steroids (oral or parenteral) or immunosuppressives are not permitted. Debilitating psychological illness", "Evidence of significant hepatic (liver) dysfunction: History of allergy to losartan", "Known positive test for HIV or patients known to be hepatitis B or C antigen carriers", "Pregnant or nursing women", "Females of childbearing age must either be surgically sterilized or, if sexually active, using an effective form of contraception and may enter only if an exclusionary pregnancy test is done within approximately 72 hours prior to randomization", "Pregnancy tests will be done every 3 months during the study and at the time of discontinuation"], "nct_id": "NCT00308347"},{"minimum_age": 21.0, "maximum_age": 75.0, "gender": "A", "inclusion": [": Inclusion_Criteria:", "Male and female patients with a diagnosis of type 2 diabetes mellitus and previo usly treated with metformin alone or with metformin and one other oral antidiabetic d rug", "HbA1c 7.0 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug", "HbA1c 7.5 10.0% at screening for patients treated with metformin alone", "HbA1c 7.5 10.0% at beginning of the placebo run-in phase", "Age > 21 and < 75 years", "MI > 25 and < 40 kg/m2 (Body Mass Index)"], "exclusion": [": Exclusion_Criteria:", "Clinically relevant cardiovascular disease", "Impaired hepatic function", "Renal insufficiency or impaired renal function", "Treatment with rosiglitazone or pioglitazone within 6 months prior to screening", "Treatment with insulin within 3 months prior to screening"], "nct_id": "NCT00309608"},{"minimum_age": 16.0, "maximum_age": null, "gender": "A", "inclusion": ["Has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.", "Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.", "Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.", "(For sub-study) Currently participating in open ended assessment period of main study 2993 LAR105"], "exclusion": ["Has been previously exposed to exenatide (Byetta\u00ae), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog.", "Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.", "Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:", "Alpha glucosidase inhibitor or meglitinide within 30 days of screening;", "Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;", "Regular use (> 14 days) of drugs that directly affect gastrointestinal motility;", "Regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;", "Regular use (> 14 days) of medications with addictive potential such as opiates and opioids;", "Prescription or over-the-counter weight loss medications within 6 months of screening.", "(For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy"], "nct_id": "NCT00308139"},{"minimum_age": 45.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus treated with oral hypoglycemic agents or diet only", "Without any symptom or finding of heart failure", "Normal liver enzymes and renal functions"], "exclusion": ["Any known coronary artery disease, congestive hearth failure, renal disease or liver disease", "Any treatment for heart failure or diuretics for any reasons."], "nct_id": "NCT00300911"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes > 12 months.", "Post-prandial blood glucose (glucose > 200 mg/dl) levels consistent with an ADA diagnosis of diabetes as confirmed during the screening visit.", "Male and female between the ages of 18 and 65 years.", "HbA1c > 7.0%.", "Use of treatment regimens including diet and exercise and/or drug therapy for diabetes are allowed. Drug therapy may include alpha-glucosidase inhibitors (e.g. acarbose, voglibose, miglitol) and oral hypoglycemic agents such as sulfonylureas and metformin and thiazolidinediones (TZDs). Insulin use is not allowable", "No changes in medication dosage within 60 days prior to entering trial.", "Subjects with a body mass index (BMI) >25 and < 35.", "Fasting triglycerides < 400. [32]", "Willing to complete all study related requirements. 10. Subject will provide written consent to participate in the trial and this consent must be given voluntarily."], "exclusion": ["Diagnosis of type I diabetes.", "Hypoglycemic event requiring EMS intervention < 12 months.", "Diabetic Ketoacidosis (DKA) < 12 months.", "Subjects taking any supplement containing chromium within the previous 90 days prior toenrollment.", "Creatinine > 2.0 x ULN; AST or ALT > 2.0 x ULN; Total Bilirubin > 1.5 x ULN.", "COPD, CHF, Angina, HTN, MI, or any other CVD requiring hospitalization within the previous 12 months.", "History of cerebrovascular accident (CVA), pulmonary embolism (PE), or an unresolved deep vein thrombosis (DVT).", "History of CABG, PTCA, or any other reperfusion therapy < 12 months.", "Uncontrolled high blood pressure (seated: systolic > 160 mmHg or diastolic > 90 mmHg) 10. History of any serious immunosuppressive disorder or undergoing current immunosuppressive therapy. 11. Female subjects who are pregnant or nursing, or are planning on becoming pregnant during the study. No hormone replacement therapy for post-menopausal subjects. 12. Hepatic disease, impaired thyroid, or impaired renal function, or other diseases known to affect glucose or lipid metabolism. TSH must be within range of normality to enter trial. 13. Diagnosed or self-reported alcoholism or substance-abuse problems 14. Any psychiatric or mental health issue that would prevent the subject from completing the study 15. Any illness or complication factor that, in the opinion of the investigator, would jeopardize the subject's health or well being by participating in the study or would interfere with the subject successfully completing the study. 16. Current participation in any other clinical research trial for any product or device, or participation in said clinical trials within 30 days prior to enrollment."], "nct_id": "NCT00308451"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["6 months or longer history of type 2 diabetes", "treatment by diet, exercise, or oral medication", "current daily consumption of 2 or more cups of coffee", "BMI >21kg/M2 and < 45kg/M2"], "exclusion": ["Required use of insulin", "Current cigarette smoking", "Current use of medications that impact glucose metabolism", "Pregnancy", "Other major medical disorders"], "nct_id": "NCT00432887"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 Diabetes Mellitus", "Insulin naive", "One or more oral antihyperglycemic medications", "HbA1c greater than or equal to 8.0% and less than or equal to 10.5%", "Non-smoker"], "exclusion": ["Taking a TZD dose greater than what is indicated", "Have not taken insulin within 6 months of entry into study", "Have had more than 2 episodes of sever hypoglycemia during the 6 months prior to study entry", "Have had more than 1 hospitalization or emergency room visit due to poor diabetic control during the 6 months prior to study entry", "Have had pneumonia in the 3 months prior to study entry", "Systemic glucocorticoid therapy", "Clinical signs or symptoms of liver disease, acute or chronic hepatitis", "History of renal transplantation", "Have an active or untreated malignancy", "Have a current diagnosis or past history of clinically relevant pulmonary disease", "Taking or have taken exenatide during the 6 weeks prior to study entry"], "nct_id": "NCT00437112"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subjects with type 2 DM diagnosed for at least 3 months but no longer than 10 years before screening;", "BMI \u2264 40 kg/m\u00b2;", "A negative pregnancy test for all females of childbearing potential"], "exclusion": ["A history of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening;", "Current therapy with any oral anti-diabetic drugs or previous use in the 4 weeks other than sulfonylureas or metformin (8 weeks in case of thiazolidinedione) before screening;", "Concomitant treatment prohibited during the study period;", "Any oral anti-diabetic drugs other than study medication", "Any insulin therapy over 7 days consecutively or intermittently in order to treat acute metabolic decompensation or systemic infection during the study", "Intermittent use of systemic corticosteroids or large dose of inhaled steroids", "Subjects with clinically significant renal (serum creatinine level >1.5 mg/dL in male and >1.4 mg/dL in female) or hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2x upper limit of normal (ULN));", "Subjects with acute and severe cardiovascular disease (e.g. heart failure, myocardiac infarction, stroke etc.)", "Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study in the opinion of the investigator and/or sponsor;", "Pregnant or lactating females;", "History of drug or alcohol abuse;", "Subjects with known hypersensitivity to glimepirides, or metformin; Night-shift workers;", "Treatment with any investigational product in the last 3 months before study entry; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00437554"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start", "Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than 2 weeks within 3 months prior to study start, and have not received any insulin formulation for more than 14 days (other than in emergency situations) and within 14 days prior to study start", "Have an HbA1c between 6.5% and 10.0%, inclusive", "Have a body mass index (BMI) between 25 kg/m^2 and 40 kg/m^2, inclusive"], "exclusion": ["Have type 1 diabetes or known latent autoimmune diabetes in adults", "Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start", "Are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)", "Have used any prescription drug to promote weight loss within 3 months prior to study start", "Have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry", "Have previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs"], "nct_id": "NCT00434954"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Drug na\u00efve Indigenous Australians with Type 2 Diabetes", "Permanent resident of Darwin for at least 1 year immediately before and expected to be for at least 1 year after study commences", "Participants must be able to give informed voluntary consent", "Both males and females (females of child bearing potential excluded if not on reliable means of contraception)"], "exclusion": [], "nct_id": "NCT00437970"},{"minimum_age": 40.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Type 2 diabetic patients admitted to department of Internal Medicine in Assaf Harofeh Medical Center"], "exclusion": ["Type 1 diabetes mellitus"], "nct_id": "NCT00437775"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus managed by SU will be candidate for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function."], "exclusion": ["Patient with serious cardiovascular disease or serious hepatic disease will not be eligible."], "nct_id": "NCT00432679"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 Diabetes", "HbA1c >", "7.0% and <", "10.0 %", "Mean serum triglyceride <", "600 mg/dL", "Body mass index <", "41 kg/m2", "Fasting c-peptide >", "1.0 ng/mL"], "exclusion": ["History of myocardial infarction (MI)", "coronary angioplasty or bypass graft(s)", "valvular disease or repair", "unstable angina pectoris", "transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months", "Congestive heart failure NYHA Class III and IV", "Uncontrolled hypertension", "History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease"], "nct_id": "NCT00162240"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age \u2265 18 years and the presence of type 2 diabetes mellitus or metabolic syndrome, not currently treated by thiazolidinediones. Diagnosis of metabolic syndrome is determined by criteria defined by the National Cholesterol Education Program Adult Treatment Panel III, modified to use World Health Organization (WHO) proposed waist circumference cut-points for Asians. Therefore, this requires subjects to have three or more of the following criteria:", "waist circumference of > 90 cm in men and > 80 cm in women;", "serum triglycerides of >= 150 mg/dl;", "high-density lipoprotein-cholesterol (HDL-C) levels of < 40 mg/dl in men and < 50 mg/dl in women;", "impaired fasting glucose of 110 to 125 mg/dl; or", "blood pressure of >= 130/85 mmHg or treated hypertension.", "Patients with objective documentation of myocardial ischemia undergoing percutaneous coronary angiography and the coronary arteriogram showing one or more \u2265 20% and < 70% stenosis, which will be left untreated at physician's discretion, in at least one coronary artery", "The baseline MDCT coronary angiogram revealing one or more discernible plaque(s) untreated by stenting in at least one coronary artery", "Ability to perform all tasks related to glycemic control and risk factor management", "Written informed consent signed"], "exclusion": ["Class III or IV heart failure", "Creatinine > 2.0 mg/dl", "Hepatic disease (ALT > 3 times the upper limit of normal)", "Poorly controlled diabetes mellitus (hemoglobin A1c [HbA1c] > 13%)", "Fasting triglycerides > 1000 mg/dl in the presence of moderate glycemic control (HbA1c < 9.0%)", "Non-cardiac illness expected to limit survival to less than two years", "Current alcohol or drug abuse", "Chronic steroid use judged to interfere with the control of diabetes, exceeding 10 mg", "Unable to understand or cooperate with protocol requirements"], "nct_id": "NCT00155350"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Type 1 diabetes mellitus", "Male or female aged 18-50 years inclusive", "Body weight between 50-100kg and BMI between 18 and 30 kg/m2", "Diagnosed 6 or more months ago, unstable diabetes with frequent episodes of hypoglycemia", "No other medical problems"], "exclusion": ["History or presence of clinical significant gastrointestinal pathology or symptoms, liver or kidney disease or any condition that might interfere with the absorption, distribution, metabolism or excretion of the drug", "Positive pregnancy test or lactation", "Lack of family support", "Unwilling or unable to follow the study protocol", "Concurrent medical problems"], "nct_id": "NCT00867594"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Clinical diagnosis of type 2 diabetes", "Who undergoes twice daily injection of premixed insulin", "Whose HbA1c is more than 6.5% and less than 8.0%"], "exclusion": ["Whose change of HbA1c is more than 1.0% during 12 weeks observational period"], "nct_id": "NCT00369148"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of Type 1 or 2 diabetes mellitus.", "Diagnosis of painful DPN for at least 12 months but less than 5 years in duration."], "exclusion": ["Neurologic Disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.", "Presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain."], "nct_id": "NCT00156078"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 2 diabetes mellitus.", "Patients who have been treated by the single use of AII antagonist at usual for at least 8 weeks or patients who have been treated by the combined use of AII antagonist at usual doses and calcium channel blocker or a antihypertensive drug other than ACE inhibitors for at least 8 weeks.", "Patients who show a systolic blood pressure (blood pressure) > 135 mm Hg or a diastolic blood pressure > 85 mm Hg, which is measured (in a sitting position) on an outpatient basis at the time of start of the observation period, and show the mean (blood pressure level measured at home after getting up before the start of study) of systolic blood pressure > 130 mm Hg or diastolic blood pressure > 80 mm Hg measured at home after getting up for last 5 days during the last 2-week observation period.", "Patients whose consent is obtained at age 20 years or over.", "Patients whose consent is obtained from themselves in written form. With regard to 2) and 3), however, the case, in which the mean of the systolic blood pressure levels measured at home after getting up for last 5 days during the first 1-week observation period is > 180 mm Hg or the mean diastolic blood pressure level is > 110 mm Hg, is included in the present study."], "exclusion": ["Patients with secondary hypertension.", "Patients who show a systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg on the measurement (in a sitting position) on an outpatient basis at the time of start of the observation period.", "Patients with severe hepatic dysfunction.", "Patients with severe renal dysfunction.", "Patients with a past history of hypersensitiveness to study drugs.", "Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant during the study period.", "Patients who have participated in the trial within 3 months before the start of the observation period or who attend the trial simultaneously with the present study.", "Other patients judged as being inappropriate for the subjects of the study by investigators."], "nct_id": "NCT00144144"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure >150 mmHg at Visit 3 (Randomisation visit)", "Diagnosis of Type 2 diabetes mellitus", "=18 years of age at the date of signing the informed consent", "Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)", "Ability to provide written informed consent"], "exclusion": ["Pre-menopausal women (last menstruation <=1 year prior to start of run-in period) who:", "are not surgically sterile; and/or", "are nursing or pregnant, or", "are of child-bearing potential and are NOT practicing acceptable means of birth control or do NOT plan to continue practising an acceptable method throughout the study. The only acceptable methods of birth control are:", "Intrauterine device (IUD);", "Oral contraceptives (started at least three months prior to start of run-in period)", "Implantable or injectable contraceptives and", "Estrogen patch", "Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.", "Known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma)", "Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in periods", "Patients with Type 1 diabetes mellitus", "Renal dysfunction as defined by the following laboratory parameters: Serum creatinine >3.0 mg/dL (or >265 \u00b5mol /L) or known creatinine clearance <30 mL/min or clinical markers of severe renal impairment", "Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney", "Clinically relevant hypokalaemia or hyperkalaemia", "Uncorrected sodium or volume depletion 10. Primary aldosteronism 11. Hereditary fructose intolerance 12. Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency 13. Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV (Refer to Appendix 10.3) 14. Contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period) 15. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator 16. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve 17. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C >10% 18. Patients who have previously experienced symptoms characteristic of angioedema during treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II receptor antagonists 19. History of drug or alcohol dependency within six months prior to signing the informed consent form 20. Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol 21. Any investigational drug therapy within one month of signing the informed consent 22. Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo) 23. History of non-compliance or inability to comply with prescribed medications or protocol procedures 24. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine"], "nct_id": "NCT00877929"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetes diagnosis at least 2 years ago", "Body Mass Index (BMI): 26-40 kg/m^2 (both inclusive)", "HbA1c: 7.5-10% (both inclusive)", "FPG values at least 140 mg/dl (7.8 mmol/l)"], "exclusion": ["Use of drugs, which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action or glucose utilization (steroids or non-specific beta-blockers)", "Current addiction to alcohol or substances of abuse or positive results on urine screen for drug and alcohol use", "Known or suspected allergy to trial products or related products"], "nct_id": "NCT00115973"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 Diabetes, HbA1c > 7.0% and < 10.0%, mean serum triglyceride < 600 mg/dL, body mass index < 41 kg/m2, fasting c-peptide . 1.5 ng/mL."], "exclusion": ["History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease."], "nct_id": "NCT00162175"},{"minimum_age": null, "maximum_age": 100.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00021944"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Subjects with type 1 diabetes", "Duration of diabetes for at least 12 months", "Treatment with insulin aspart for at least 3 months before trial start", "Body Mass Index (BMI) below 35.0 kg/m2", "HbA1c below 12.0%"], "exclusion": ["Total insulin dosage more than 1.4 IU/kg/day", "Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the investigator)", "Known hypoglycaemia unawareness as judged by the investigator", "Known hypersensitivity or allergy"], "nct_id": "NCT00604656"},{"minimum_age": 21.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Written informed consent", "Body mass index not exceeding 32.0 kg/m2", "If female, subject must meet one of the following criteria: a) surgically sterile (hysterectomy or bilateral tubal ligation) OR b) at least two years postmenopausal OR c) using a dual method of contraception and have a negative serum pregnancy test if of childbearing potential", "Diagnosis of type 1 or type 2 diabetes according to the American Diabetes Association", "Fasting plasma glucose of \u2265 126 mg/dL or current treatment with oral hypoglycemic agents or insulin", "Microalbuminuria defined as albumin to creatinine ratio in a spot collection (first void) of 30", "300 mg/gram confirmed by two samples two to three days apart", "Serum creatinine of no more than 1.5 mg/dL for men and no more than 1.1 mg/dL for women"], "exclusion": ["Female subjects who are pregnant or lactating", "Non-diabetic renal disease", "History of allergic or anaphylactic reaction to human, humanized, chimeric, or murine monoclonal antibodies", "Coronary artery bypass graft surgery, myocardial infarction, cerebrovascular accident, percutaneous transluminal angioplasty, transient ischemic attack, history of unstable angina, known heart failure, uncontrolled cardiac arrhythmia, or uncontrolled hypertension within six months prior to Day 0", "Bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal", "History of cancer of any type in the past 5 years, except non- melanomatous skin cancer, localized bladder cancer, or in situ cervical cancer.", "Clinically significant and uncontrolled medical condition considered a high risk for participation in an investigational study", "Trauma or surgical procedures (including dental) within six months prior to Day 0", "Planned elective surgery during the study and for 3 months following the end of the study", "Participation in studies of investigational drugs within 6 weeks prior to first dose"], "nct_id": "NCT00102297"},{"minimum_age": null, "maximum_age": 70.0, "gender": "A", "inclusion": ["Ankle-brachial index of <0.9 at rest in at least one leg", "History of intermittent claudication (unilateral or bilateral) which was stable for 6 months", "Evidence of superficial femoral artery stenosis or occlusion on duplex scan", "Blood pressure <=160/90 mmHg", "Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors"], "exclusion": ["Limiting coronary artery disease", "Renal Failure", "History of hypertension", "History of type 2 diabetes mellitus"], "nct_id": "NCT00168467"},{"minimum_age": 19.0, "maximum_age": null, "gender": "M", "inclusion": ["clinical diagnosis of type 1 or type 2 diabetes.", "Score below 25 from IIEF EF domain during 4 weeks of treatment run-in period.", "Failure rate above 50% from sexual attempt above 4 during 4 weeks of treatment run-in period."], "exclusion": ["Lab abnormality.", "Uncontrolled diabetic mellitus(HbA1c > 12%).", "High or low blood pressure, orthostatic hypotension.", "Hyper- or hypo-thyroidism."], "nct_id": "NCT00705861"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Healthy subjects with normal glucose tolerance (NGT)", "Impaired glucose tolerance (IGT)", "Impaired fasting glucose (IFG)"], "exclusion": ["Any severe cardiac disease", "Liver", "Kidney diseases", "Type 1 or type 2 diabetes", "Chronical and acute inflammatory diseases", "Lipid lowering drugs", "Cortisone", "Antibiotics", "Non-steroidal antiinflammatory drugs", "Including low dose acetylsalicylic acid"], "nct_id": "NCT00403689"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age > 18 years", "Type 1 or 2 Diabetes Mellitus", "Wagner grading of foot lesions 3 or 4 on lower limb not healing for 4 weeks."], "exclusion": ["Impending urgent amputation due to ongoing or exacerbated infection;", "Exposed calcaneus bone with no prospect of weight bearing potential even if defect has been healed;", "Dialysis-dependent renal failure;", "Any of the following medical conditions which preclude safe treatment in a monoplace chamber: clinical depression; severe dementia; claustrophobia; seizure disorder; active asthma; severe chronic obstructive pulmonary disease; previous thoracic surgery; previous spontaneous or trauma induced pneumothorax; history of severe congestive heart failure with left ventricular ejection fraction less than 20%; unstable angina; chronic sinusitis; chronic or acute otitis media or major ear drum trauma; severe kyphoscoliosis; arthritis; or morbid obesity;", "History of chemotherapy with use of Bleomycin;", "Participation in another investigative drug or device trial currently or within the last 30 days;", "Current candidates for vascular surgery, angioplasty or stenting;", "Major large vessel disease;", "Undergone vascular surgery or angioplasty within the last 3 months;", "Women who are currently pregnant or are breast feeding or women of childbearing potential who are not currently taking adequate birth control."], "nct_id": "NCT00621608"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Age 18-45 years,", "obese (30 kg/m2 < BMI < 40 kg/m2) physically inactive (<30 minutes pr. day)", "and weight stabile for at least three months (\u00b1 2 kg of current body weight)"], "exclusion": ["cardiovascular disease,", "type 2 diabetes, pregnancy or orthopaedic difficulties causing inability to undertake an exercise program"], "nct_id": "NCT00700245"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["between the ages of 18 and 35 years", "post-puberty", "willing and able to provide informed consent", "stable medical and psychosocial status providing a high likelihood of follow-up and compliance with study protocol", "all ethnic backgrounds will be included in this study."], "exclusion": ["evidence of clinically relevant systemic disease associated with disorders of glucose metabolism", "chronic use of glucocorticoid or appetite suppressants", "concomitant use of drugs known to alter glucose metabolism (i.e., metformin, thiazolidinediones, sulfonylurea receptor agonists and inhibitors of alpha-glucoside hydrolase) or other medications known to alter blood levels being tested in this study", "inability to provide the requested fasting blood sample", "pregnancy", "menopause", "alcohol dependency (as determined by CAGE screening questionnaire); (8) inability to provide informed consent", "previous diagnosis or treatment for any hematologic-oncologic disorder", "history or current treatment for an eating disorder", "current treatment for weight loss", "history of bariatric surgery", "history of neurosurgical procedure", "participation in another clinical trial involving an investigational drug", "history of psychiatric disorder, which in the opinion of the investigator would affect the conduct of the proposed trial", "age younger than 18 or older than 35 at the time of recruitment", "weight that exceeds the capacity of equipment used for weight measurements."], "nct_id": "NCT00966407"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age >/= 18 years.", "Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases", "At least one measurable lesion or evaluable disease", "Life expectancy of at least 12 weeks", "ECOG Performance Status of 0, 1 or 2", "PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]. Low-dose aspirin is permitted (</= 100 mg daily).", "Adequate bone marrow, liver and renal function", "Ability to understand and to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures"], "exclusion": ["History of cardiac disease congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).", "Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level >125 mg/dL at screening, or HbA1c 7%", "Active clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0)", "History of having received allogeneic organ transplant", "Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.", "Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management"], "nct_id": "NCT00962611"},{"minimum_age": 16.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 diabetes mellitus as defined by the 2003 CDA guidelines with duration &#8805;1 year, requiring insulin therapy starting within one year of diagnosis and continuously thereafter.", "Male or female, age &#8805;16 years, HbA1c 0.066-0.099 (normal non-diabetic range 0.040-0.060).", "Habitual performance during the previous 4 months of exercise &#8805;3 times per week, including at least 90 minutes per week of vigourous aerobic exercise (of sufficient intensity to cause sweating; e.g. jogging, soccer, basketball, racquet sports), and/or &#8805;150 minutes per week of aerobic exercise of at least moderate intensity (e.g. brisk walking, moderate-paced bicycling) but no resistance training. Subjects must agree to maintain their habitual volume and intensity of aerobic activity during run-in and intervention periods, minimizing variation due to seasons, but they will be permitted to vary specific exercises chosen.", "Willingness and ability to work closely with the study physicians, nurse and dietitian and follow their recommendations for insulin therapy and adjustments of diet."], "exclusion": ["Participation during the previous 4 months in any resistance training.", "Hypoglycemia unawareness, or severe hypoglycemia requiring assistance from another person within the previous 3 months", "\"Brittle\" diabetes, characterized by frequent and unpredictable hypoglycemia (even if not requiring assistance from others) and hyperglycemia.", "Restrictions in physical activity due to disease: intermittent claudication, severe peripheral neuropathy or active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis.", "Known or suspected clinically significant gastroparesis.", "Body mass index &gt;35 kg/m2, or weight &gt;147 kg (exceeding capacity of DEXA or CT scanners)", "Fasting serum c-peptide &#61619;0.2 nmol/l.", "Increase or decrease of &#61619;5% of body weight during the previous two months.", "An expected requirement within the subsequent 6 months for medications (other than insulin) that will affect glucose metabolism (e.g. corticosteroids).", "If age&lt;18 yr, linear growth of &#61619;1cm during the previous year.", "Significant renal disease: serum creatinine &#61619;200 mEq/l. or proteinuria &gt;1 g/24 hours.", "Uncontrolled hypertension: BP &gt;150 mm Hg systolic or &gt;95 mm Hg diastolic in a sitting position.", "Other illness, judged by the patient or investigators to make participation in this study inadvisable.", "Cognitive deficit resulting in inability to understand or comply with instructions.", "Pregnancy at the start of the study, or intention to become pregnant in the next year.", "Inability to communicate in English or French.", "Ischemic ECG changes during baseline maximal cardiopulmonary stress test, unless subsequently cleared for participation by a cardiologist after appropriate investigation.", "Low aerobic fitness: Aerobic fitness more than 15% below the mean for age and gender, based on baseline maximal treadmill exercise test. This criterion is included in order to reduce likelihood of candidates entering the trial by exaggerating their habitual activity. Very few people engaging in regular aerobic activity would have such low treadmill performance.", "Unwillingness to sign informed consent."], "nct_id": "NCT00410436"},{"minimum_age": 8.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Age 8-16 years", "Type 1 diabetes diagnosed by standard American Diabetes Association criteria", "Type 1 diabetes duration of at least 6 months", "Residence in northeastern U.S.", "Established clinic patient", "Fluency in English or Spanish"], "exclusion": ["Major psychiatric disorder (e.g., major depression, severe eating disorder, mental retardation)", "Unstable living environment (e.g., Department of Social Services or Department of Youth Services involvement)"], "nct_id": "NCT00961974"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age 18 and older", "Diabetes Type I or II", "Chronic ulcer on the foot", "Ulcer present for at least 6 weeks", "Wagner Grade 1 or 2"], "exclusion": ["Chronic rest pain", "Critical ischemia", "Gangrene", "Ankle-Arm-Index < 0,5", "Critical ischemia treated within 6 weeks before possible enrollment", "Ulcer of Grade 3 or worse according to the Wagner Classification", "Osteomyelitis", "Affection of toes", "Necessity of surgical intervention", "Malalignment of the foot sustaining the ulcer", "Treatment of Ulcer with Prostaglandins or vasodilatators within the last 2 weeks", "Current therapy with corticoids", "Infection with HIV; Hepatitis", "Suppression of immune system (due to illness or medication)", "Medication with Vitamin-K-Antagonists", "Known hemophilia", "Sever Hypalbuminemia < 2 g/dl", "Severe anemia", "Ulcer other than of diabetic origin", "Pregnant or breast-feeding women", "Known coagulopathies", "Implants such as artificial heart valves, joint replacement, bone replacement, osteosynthesis material", "Patients participating on other studies", "Chemotherapy within the last 60 days", "Mentally disabled patients"], "nct_id": "NCT00954343"},{"minimum_age": 12.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Age between 12-18 years", "Diagnosis of type I diabetes for at least a year", "Home close to participating center", "Guardian able and willing to cooperate with the trial for at least 1 month and prepared to sign the Informed Consent Form."], "exclusion": ["Recent (within 3 months) admission to emergency room or intensive care unit (ICU) due to any condition unrelated directly to diabetes.", "Any other pre-existing medical pathology unrelated to diabetes.", "Inability of the patient or his guardian to use the Guardian RT."], "nct_id": "NCT00361608"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Body Mass Index (BMI): 18.0", "24.9 or 30.0", "39.9 kg/m2 (extremes included);", "Essential hypertension I or II WHO:", "140 mmHg \u2264 BPs \u2264 179 mmHg and BPd \u2264 109 mmHg at the end of the placebo run-in phase;"], "exclusion": ["Secondary hypertension;", "Diabetes mellitus type 1, insulin dependent diabetes mellitus type 2, fasting blood glucose \u2265 160 mg/dl;", "Subjects keeping to a hypocaloric diet (except special diet for diabetics) to reduce body weight;", "History or presence of angioneurotic oedema;", "Subjects developing a hypertensive crisis during wash-out or placebo run-in period;"], "nct_id": "NCT00160498"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Patients between 18 and 65 years of age", "Patients with type 1 diabetes mellitus for more than 5 years duration", "One or more of the following:", "Hypoglycemia unawareness", "judged by history of blood sugars <54 on glucometer without symptoms and/or hypoglycemic episodes requiring assistance from either family, glucagon administration or emergency services", "Poor diabetes control (HbA1c>8% or >2 visits/yr to hospital for treatment of ketoacidosis) despite intensive insulin therapy", "Progressive complications of type 1 diabetes mellitus", "Body Mass Index (BMI) \u226426"], "exclusion": ["c-peptide > 0.3ng/ml basal or stimulated;", "untreated proliferative diabetic retinopathy;", "HbA1C >12%;", "creatinine clearance <60;", "serum creatinine consistently >1.6 mg/dl;", "macroalbuminuria >300mg albumin in 24 hours;", "presence of panel reactive antibodies (PRA) >20%;", "previous/concurrent organ transplantation (except previous unsuccessful islet cell transplant;", "malignancy or previous malignancy (except non-melanomatous skin cancer); 10. x-ray evidence of pulmonary infection; 11. active infections; 12. active peptic ulcer disease, gall stones, hemangioma, or portal hypertension 13. serological evidence of HIV, HbsAg or HCV; serological evidence of active EBV (IgM>IgG) or EBV negative serology; 14. PPD conversion or positive PPD without historic completion of appropriate prophylactic treatment; 15. abnormal liver function test; 16. anemia (hemoglobin <12.0); 17. hyperlipidemia (fasting serum triglycerides >200mg/dl and/or fasting serum cholesterol >240 mg/dl and/or fasting LDL cholesterol >140 mg/dl); 18. BMI above 26; 19. unstable cardiovascular status; prostate specific antigen (PSA) >4; 20. pregnancy or breastfeeding; 21. sexually-active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable); 22. alcohol abuse, substance abuse or smoking within the previous 6 months; insulin requirement >1u/kg/day and any condition or any circumstance that makes it unsafe to undergo an islet cell transplant."], "nct_id": "NCT00306098"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Stable weight (< 5% variation) within the last three months", "Age: 35 to 50 years old for middle-age group, and 65 to 80 years old for elderly group.", "BMI: 20 to 29.9 kg/m2", "Normal glucose tolerance (NGT) for groups Elderly and Middle-age"], "exclusion": ["Use of estrogen, progestogen or systemic corticosteroids.", "Hepatic cirrhosis, renal failure or any clinical condition with impaired insulin sensitivity", "Smoking", "Obesity", "Uncontrolled systemic or debilitating diseases"], "nct_id": "NCT00843479"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetic nephropathy", "CKD at stage 1~4"], "exclusion": ["Type 1 diabetes or nondiabetic renal disease", "An elevated plasma K level."], "nct_id": "NCT00774904"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus type 2 defined by the criteria of the American Diabetes Association", "Fasted plasma glucose greater than 126 mg/dL", "Plasma glucose levels greater than 200 mg/dL 2 hours after OGT", "Casual plasma glucose greater than 200 mg/dL combined with diabetic symptoms.", "Endothelial dysfunction defined by FMD <4%", "No changes of medication for 2 months", "Significant PAOD (level IIb, III)"], "exclusion": ["Ejection fraction <30%", "Malignoms", "Terminal renal failure with hemodialysis", "Relevant cardiac arrhythmias", "Acute inflammation defined as CRP >0,5 mg/dl", "PAOD (level IV)"], "nct_id": "NCT00771797"},{"minimum_age": 65.0, "maximum_age": null, "gender": "A", "inclusion": ["at least 65 years of age", "BMI 27", "42 kg/m2", "at increased health risk (taking at least 1 medication for hypertension, hyperlipidemia, or type 2 diabetes)"], "exclusion": ["difficulties chewing or swallowing food", "digestive diseases that may affect the ability to follow a high fiber diet", "cognitive impairment", "depression", "recent weight change (+/- 10 lbs in the last 12 months)", "poorly controlled blood pressure", "history of non-skin cancer in last 5 years", "cardiovascular disease event in past 6 months or severe pulmonary disease or renal failure", "major liver dysfunction", "current smoker or quit less than months prior", "history of prior surgical procedures for weight control or liposuction", "use of estrogen or testosterone replacement therapy", "current use of insulin or sulfonylurea agents", "current use of corticosteroids > 5 days/month on average", "current use of medications for treatment of psychosis or manic-depressive illness", "use of weight-loss medications in previous 3 months", "dependence on others for food procurement or preparation", "ischemic changes on exercise treadmill test"], "nct_id": "NCT00955903"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female outpatients, 18 to 65 years of age with mild to moderate hypertension", "Patients who are eligible and able to participate in the study"], "exclusion": ["Severe hypertension", "Secondary form of hypertension.", "Type 1 or type 2 diabetes mellitus", "Serum potassium out side laboratory reference range", "Any history of hypertensive encephalopathy or cerebrovascular accident Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00933920"},{"minimum_age": 18.0, "maximum_age": 99.0, "gender": "A", "inclusion": ["Patients are eligible for inclusion if the following criteria are fulfilled:", "Patients with diabetes type 1 or type 2.", "Older than 18 years.", "Patients scheduled for cardio- vascular surgery and/ or acute ulcer infection.", "Hyperglycaemia: Capillary P-glucose above 8 mmol/L.", "Informed consent obtained."], "exclusion": ["Patients having any of the following at randomization will not be included in the study:", "Unconsciousness: not possible to wake up.", "Ketoacidosis: pH less or equal to 7.30.", "Hyperosmolar syndrome: S-Na more or equal to 150 mmol/L.", "Kidney failure: calculated GFR < 30 mL/min.", "Pregnancy.", "Mental condition making the subject unable to understand the concepts and risk of the study"], "nct_id": "NCT00700154"},{"minimum_age": 50.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age 50-75 years", "Non-smoker >2 years", "Body mass index = 18-35 kg/m2"], "exclusion": ["History of CAD or cerebrovascular disease that would preclude exercise", "Implantable defibrillator", "Active cancer", "Chronic pulmonary, thyroid, renal, liver, or hematological disease", "HIV positive or prone to malnutrition", "Sickle cell anemia", "Type 1 diabetes, or currently on medication to treat type 2 diabetes", "Poorly-controlled type 2 diabetes", "Poorly-controlled hypertension", "Taking medications including: beta-blockers, oral steroids, warfarin, certain statins, hormone replacement therapy (HRT), oral contraceptives (OCP), thiazolidinediones (TZD), or chronic steroids or nonsteroidal analgesics (NSAIDS) that may not be safely discontinued temporarily for specific procedures (i.e. for 72 hours prior)", "Allergic to lidocaine or heparin", "Recent weight change (>5kg in 3 months)", "Currently pregnant or nursing", "Physical impairment limiting exercise", "Dementia or unstable clinical depression"], "nct_id": "NCT00701051"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": [": Potential participants must meet all of the following inclusion criteria:", "Informed consent obtained from participants", "Age 18-45 years", "Healthy non-diabetic subjects will have normal fasting blood sugar (<100 mg/dl), body mass index (BMI) 18.5-24.9, no history of type 2 diabetes in first degree relative", "Type 1 diabetes defined by: American Diabetes Association (ADA) criteria or judgment of physician\u037e diabetes onset younger than age 18, duration >5", "years, BMI 18.5-24.9. Insulin dose <0.8 units/kg/day. Fasting c-peptide < 0.1 ng/ml", "Obese hyper-insulinemic subjects will have BMI > 30 and fasting insulin>20 and c-peptide> 4.6 ng/ml and normal fasting blood sugar <100 mg/dl.", "Able to tolerate PET imaging: not claustrophobic, able to lie supine for 1.5 hours", "Normal liver and renal function tests including normal spot urine microalbumin /creatinine\u037e normal CBC including hematocrit >31.8% in women, >36.7% in men, white blood cell (WBC) count >3.4 K/mm3 and platelet count >162 K/mm3", "Adequate collateral circulation in the wrist as assessed by Allen Test."], "exclusion": [": Potential participants must not have any of the following exclusion criteria:", "Previous or current treatment with drugs influencing beta cell function or insulin sensitivity (e.g. oral hypoglycemic agents, glucocorticoids)\u037e or with antipsychotic, antianxiety, or antidepressant medications (eg monoamine oxidase (MAO) inhibitors, 5-hydroxytryptamine (5-HT) inhibitors, tricyclic antidepressants)\u037e or treatment with reserpine\u037e or treatment with beta2receptor agonists (eg, terbutaline)\u037e or treatment with anticoagulant medication.", "History of movement disorder such as Parkinson's Disease or Huntington's Disease", "History of or psychiatric illness such as depression, bipolar disease, anxiety or schizophrenia.", "If a female of childbearing age, currently pregnant, breastfeeding or not using a form of birth control", "Previous or current use of cocaine, methamphetamine, ecstasy", "Current daily intake of caffeine >500 mg/day (>45 cups of coffee\u037e >10 12oz cans of soda)", "Current history of cigarette smoking", "Consumption of more than 1 alcoholic drink per day", "Evidence of chronic infection 10. History of malignancy 11. Any prior participation in other research protocols within the past year that involve radiation, with the exception of plain radiography studies (i.e., chest xrays). 12. Medical implant"], "nct_id": "NCT00771576"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["A female is eligible to enter and participate in this study if she is of Non-child-bearing potential with a negative pregnancy test at screening or of Childbearing potential, has a negative serum pregnancy test at screening, is not lactating, and agrees to adequate contraception.", "Satisfactory medical evaluation based upon medical history, medication history, physical examination, and clinical laboratory data obtained at the Screening visit.", "Body weight > 50 kg. BMI within the range of 19 to 40 kg/m2.", "Signed and dated written informed consent prior to participation in any protocol-specific procedures, including screening procedures.", "The subject is able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions.", "Additional Inclusion Criteria for Subjects with Renal Insufficiency: Subjects with renal insufficiency must be considered by the investigator to be clinically stable. Subjects must continue to meet this criterion of stable renal function upon check-in into the clinic"], "exclusion": ["History of regular alcohol consumption averaging >7 drinks per week for women or >14 drinks per week for men within 6 months of Screening. One drink is equivalent to 12 g alcohol = 5 ounces (oz; 150 ml) of wine or 12 oz (360 ml) of beer or 1.5 oz (45 ml) of 80 proof distilled spirits.", "A positive drug or alcohol test at Screening or Check-in.", "Smokers will be allowed to enrol in the study; however, smoking that interferes with the collection/recording of ongoing study procedures will not be allowed. Smoking status will be recorded in the CRF.", "The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication for the current study.", "The subject has donated more than 450mL blood within the 56 day period prior to the first scheduled administration of GSK189075.", "Known or suspected gastroparesis, gastric surgery within the 6 months prior to screening, or any other gastrointestinal condition that would likely interfere with absorption of GSK189075.", "Subjects with clinical laboratory values outside rages as specified in the protocols", "Any subject with either documented cirrhosis or a history consistent with a diagnosis of cirrhosis.", "Urinary tract or bladder infection within 4 weeks of the first scheduled administration of study drug.", "Positive hepatitis B surface antigen, or HIV at Screening. If negative test results have been documented within the last 2 months, it will not be necessary to repeat these tests. Subjects with positive results for hepatitis C antibodies may be eligible if they have normal liver enzymes and no history of hepatitis and are approved by the GSK medical monitor.", "Any history of myocardial infarction, cardiac syncope.", "A history of clinically significant cardiac arrhythmias (individual cases to be discussed with the GSK Medical Monitor).", "A history of unstable angina in the past 6 months.", "Cardiac conduction abnormalities denoted by ranges specified in the protocol", "Systolic blood pressure < 80 mmHg or > 180 mmHg", "Diastolic blood pressure < 60 mmHg or > 100 mmHg", "Use of prescription or non-prescription drugs (including high dose vitamins, herbal and dietary supplements [including St. John's Wort]) within 7 days prior to administration of the first dose of study medication, unless in the opinion of the investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety. Some allowable exceptions are found in the Permitted Medications section (Section 9.1). Additional Exclusion Criteria for Subjects with Renal Insufficiency", "Patients on a new drug regimen (defined as starting a new drug or changing dosage regimen of a current drug within 7 days prior to administration of GSK189075). No restrictions will be placed on the use of insulin, 1,25 dihydroxyvitamin D3 (Rocaltrol), erythropoietin, and calcium- or aluminum-containing phosphate binders.", "Subjects whose current medication therapy is not in agreement with the information provided in Sections 9.1, 9.2, or 9.3 of this protocol.", "Serum albumin less than 2.5 g/dL.", "Hemoglobin less than 8.5 g/dL. Additional Exclusion Criteria for Subjects with Normal Renal Function", "Any clinically relevant abnormality identified on the screening physical or laboratory examination. Any abnormalities of outside the normal reference range at Screening may be repeated once and must be reviewed with the GSK Medical Monitor prior to enrollment of a subject into the study.", "Hemoglobin or hematocrit below the reference range at Screening"], "nct_id": "NCT00501462"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["kidney transplantation(> 6 months ago) ; stable graft function", "diabetes mellitus type 2", "acceptable glycemia (HbA1c < 8%)", "creatinin clearance (MDRD)>30 ml/min 1,73m\u00b2)", "proteinuria > 30 mg/24 hr"], "exclusion": ["type 1 diabetes", "pregnant or breast feeding women", "congestive heart failure (>stage 1 NYHA)", "creeping creatinin", "treatment for rejection within 3 months prior to inclusion", "ALT, AST > 2.5 fold the upper limit of normal", "uncontrolled hypertension", "hypo- or hyperthyroidism"], "nct_id": "NCT00507494"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patient with type 2 diabetes, aged 18 years or more", "Bilateral diabetic macular edema involving the center of the macula with central retinal thickness 300 \u00b5m or more"], "exclusion": ["Patient with type 1 diabetes", "Tractional macular edema", "Patient with renal insufficiency : clearance of creatinin < 30 ml/min according to COCROFT or MDRD, patient under dialysis", "Other causes for macular edema (uveitis, epiretinal membrane)", "Proliferative diabetic retinopathy requiring panretinal photocoagulation at inclusion", "Cataract surgery or panretinal photocoagulation during the 6 months before inclusion, laser photocoagulation at the posterior pole or intra ocular steroid injection during the 3 months before inclusion", "Any ocular condition precluding access to the posterior pole, or ocular pathologies not related to diabetes (age related macular degeneration venous occlusion\u2026)", "Previous vitrectomy in the eyes", "Pregnant or breast-feeding female"], "nct_id": "NCT00970723"},{"minimum_age": 35.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)"], "exclusion": ["Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.", "Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions."], "nct_id": "NCT00407537"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Caucasians without type 2 diabetes mellitus", "Normal OGTT (75 g of glucose) according to WHO's criteria", "Patients fulfilling the criteria for laparoscopic gastric banding", "Normal Hemoglobin", "Informed consent"], "exclusion": ["Liver disease (ALAT > 2 x normal level)", "Nephropathy (s-creatinin > 130 \u00b5M or albuminuria)", "Relatives (parents/siblings) with T2DM", "Medical treatment witch cannot be stopped for 12 hours"], "nct_id": "NCT00625040"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["1.Subject is >= 18 years old.", "2.Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.", "3.Subject has Type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Phase.", "4.Subject has been receiving a stable dose (i.e., same type and regimen) of angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin receptor blocking agents (ARB) for at least 2 months prior to the Screening Phase.", "5.If female, subject must be not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). The reason for non-childbearing potential must be specified in the subject's eCRF.", "6.If male, subject must be surgically sterile or if sexually active and of childbearing potential, the site must document the lack of desire for future procreation and subject must agree to use a condom and a second reliable barrier of contraception from the Screening Visit through two months following completion of their participation in the study.", "7.For entry into the Treatment Phase the subject must satisfy the following criteria based on Screening laboratory values:", "a.Estimated GFR > 20 mL/min/1.73 m2 by simplified MDRD formula", "b.UACR between 100 and 3000 mg/g as determined at the initial Screening visit or by the mean of the 2 morning void urine specimens obtained prior to the second Screening visit.", "c.Serum albumin > 3.0 g/dL.", "d.HbA1c <= 10%.", "e.Pro-BNP <= 500pg/mL.", "f.Negative urine pregnancy test for female subjects."], "exclusion": ["1.Subject has a history of significant peripheral edema (2 + or greater), or facial edema unrelated to trauma, or a history of myxedema in the 6 months prior to Screening.", "2.Subject receiving loop diuretics > 30 mg BID of furosemide or > 0.5 mg BID of bumetanide or > 25 mg BID of ethacrynic acid.", "3.Subject has a history of pulmonary edema.", "4.Subject has a history of pulmonary hypertension, chronic obstructive pulmonary disease, emphysema, pulmonary fibrous disease, asthma or other lung disease that requires oxygen.", "5.Subject has a documented history of heart failure, defined as New York Heart Association (NYHA) Class II, III or IV heart failure.", "6.Subject has a body mass index (BMI) > 40.", "7.Subject has elevated liver enzymes (ALT and/or AST) > 1.5 x the upper limit of normal (ULN).", "8.Subject has a hemoglobin < 9.5 g/dL.", "9.Subject has a history of an allergic reaction or significant sensitivity to atrasentan or its excipients.", "10.Subject has a history of a chronic gastrointestinal disease, which in the Investigator's opinion may cause significant GI malabsorption.", "11.Subject has a history of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism or pheochromocytoma).", "12.Subject has poorly controlled hypertension (systolic blood pressure \u2265 160 mmHg and or diastolic blood pressure \u2265 90 mmHg) or hypotension (systolic blood pressure <= 90 mmHg).", "13.Subject has significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy less than 1 year.", "14.Subject is expected to receive an increased dose of current RAAS inhibitor (ACEi, ARB, renin or aldosterone inhibitor) during the course of the study. Conversions from one product to another (e.g., ACEi to ARB) must be at equivalent doses.", "15.Subject has clinically significant coronary artery disease (CAD) within 3 months prior to the Screening Period, defined as one of the following:", "Hospitalization for MI or unstable angina; or", "New onset angina with positive functional study or coronary angiogram revealing stenosis; or", "Coronary revascularization procedure.", "16.Subject has a history of viral or bacterial infection within 4 weeks of Screening or HIV infection.", "17.Subject has scheduled or planned surgery with general anesthesia within 12 weeks of Screening Visit.", "18.Subject has a history of drug or alcohol abuse within 6 months prior to the Screening Visit.", "19.Subject has evidence of poor compliance with diet or medication that may interfere, in the Investigator's opinion, with adherence to the protocol.", "20.Subject has received any investigational drug within 30 days prior to study drug administration.", "21.For any reason, subject is considered by the Investigator to be an unsuitable candidate to receive atrasentan oral solution or is put at risk by study procedures"], "nct_id": "NCT00920764"},{"minimum_age": 7.0, "maximum_age": 20.0, "gender": "A", "inclusion": ["Type 1 diabetes diagnosed less than 12 months prior to study entry", "Age: 7-20 years old.", "HbA1c>/=8.0", "Signing inform consent form"], "exclusion": ["Any significant disease or conditions, including psychiatric disorders that in the opinion of the investigator are likely to effect his compliance or ability to complete the study.", "Patients participating in other device or drug studies.", "Any contraindication to insulin glargine and or insulin Apidra and or Insulin NPH according to SmPC.", "Inability, of adolescent or parent, to understand/complete the Treatment satisfaction questionnaire."], "nct_id": "NCT00925977"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": [": Potential participants must meet all of the following inclusion criteria:", "Informed consent obtained from participants", "Age 18 45 years", "Healthy nondiabetic subjects will have normal fasting blood sugar (<100 mg/dl), BMI 18.5 24.9, no history of type 2 diabetes in first degree relative", "Type 1 diabetes defined by: ADA criteria or judgment of physician\u037e diabetes onset younger than age 18, duration >5 years, BMI 18.5 24.9. Insulin dose <0.8 units/kg/day. Fasting c-peptide < 0.1 ng/ml", "Obese hyperinsulinemic subjects will have BMI > 30 and fasting insulin>20 and c-peptide> 4.6 ng/ml and normal fasting blood sugar <100 mg/dl.", "Able to tolerate PET imaging: not claustrophobic, able to lie supine for 1.5 hours", "Normal liver and renal function tests including normal spot urine microalbumin/creatinine\u037e normal complete blood count (CBC) including hematocrit >31.8% in women, >36.7% in men, white blood cell count (WBC) >3.4 K/mm3 and platelet count >162 K/mm3", "Adequate collateral circulation in the wrist as assessed by Allen Test."], "exclusion": [": Potential participants must not have any of the following exclusion criteria:", "Previous or current treatment with drugs influencing beta cell function or insulin sensitivity (e.g. oral hypoglycemic agents, glucocorticoids)\u037e or with antipsychotic, antianxiety, or antidepressant medications (eg monoamine oxidase (MAO) inhibitors, 5HT inhibitors, tricyclic antidepressants)\u037e or treatment with reserpine\u037e or treatment with beta2receptor agonists (eg, terbutaline)\u037e or treatment with anticoagulant medication.", "History of movement disorder such as Parkinson's Disease or Huntington's Disease", "History of or psychiatric illness such as depression, bipolar disease, anxiety or schizophrenia.", "If a female of childbearing age, currently pregnant, breastfeeding or not using a form of birth control", "Previous or current use of cocaine, methamphetamine, ecstasy ( 3,4 methylenedioxymethamphetamine (MDMA))", "Current daily intake of caffeine >500 mg/day (>45 cups of coffee\u037e >10 12oz cans of soda)", "Current history of cigarette smoking", "Consumption of more than 1 alcoholic drink per day", "Evidence of chronic infection 10. History of malignancy 11. Any prior participation in other research protocols within the past year that involve radiation, with the exception of plain radiography studies (i.e., chest xrays). 12. Medical implant"], "nct_id": "NCT00738907"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Aged 18-75 years old", "Overweight (BMI greater than or equal to 25)", "Sedentary (self-report less than 30 minutes of moderate physical activity most days of the week)", "Has a family member (parent, grandparent, or sibling) with diabetes or pre-diabetes"], "exclusion": ["Participants unable to engage in physical activity (oxygen dependent, wheel chair bound, amputations, Class 3 or 4 NY Heart Association classification for Congestive Heart Failure)", "Non-English speaking"], "nct_id": "NCT00775216"},{"minimum_age": 25.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients who have given voluntary written consent to participate in this study prior to conducting Screening Visit procedures;", "Male and female patients 25 years of age or older with a diagnosis of type 2 diabetes; \u2022 If a woman is of childbearing potential (WOCBP) she must agree to use appropriate birth control (double barrier methods, hormonal contraceptives, or intrauterine device)for the duration of the study (WOCBP is defined as all women who are not surgically sterile or are not at least 1 year post-menopausal). All WOCBP must have a negative serum pregnancy test at the Screening Visit;", "At the Screening Visit, ALL patients must have a history of overt diabetic nephropathy, as defined by the following:", "A SCr measurement of 1.3 mg/dL to 3.3 mg/dL (women) or 1.5 mg/dL to 3.5 mg/dL (men) inclusive, and", "A 24-hour urine collection PCR \u22651200 mg/g;", "Patients must be receiving an ACE-I or an ARB, for at least 3 months prior to the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period), where the dose of the ACE-I or the ARB is considered appropriate for that patient and has been stable for at least 2 months;", "Patients must be on stable blood pressure medications for 2 months prior to the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period), with a seated blood pressure at the Qualifying Visit of \u2264160/90 mmHg;", "At the Qualifying Visit (only applies to those patients who enter into the Optional Run-in Period), the following eligibility parameters must be met in order to be randomized:", "A SCr measurement within 25% of the SCr measurement at the Screening Visit; and", "A 24-hour urine collection PCR \u2265600 mg/g."], "exclusion": ["Patients with type 1 diabetes;", "Patients with a diagnosis of chronic renal disease other than diabetic renal disease with or without hypertensive renal disease;", "Patients receiving a renin inhibitor or an aldosterone antagonist or a combination of an ACE-I and an ARB within 2 months of the Qualifying Visit (Screening Visit for those patients not entering into the Optional Run-in Period);", "Patients with a history of solid organ transplantation;", "Patients with a history of myocardial infarction, coronary re-vascularization procedures (including percutaneous transluminal coronary angioplasty), cerebrovascular accident ortransient ischemic attack within 1 month prior to the Screening Visit;", "Patients with a diagnosis of Class III or IV congestive heart failure at any time (as defined by the New York Heart Association);", "Patients with a history of neoplastic disease (except basal or squamous cell carcinoma of the skin) within 5 years prior to the Screening Visit;", "Patients with any history of dialysis within 2 years prior to the Screening Visit;", "Patients in whom dialysis or renal transplantation is anticipated by their physician within 1 year after the Screening Visit; 10. Patients who used SCr altering drugs within 1 month prior to the Screening Visit; 11. Patients who require systemic immunosuppression therapy for >2 weeks (except for inhalant steroids); 12. Patients with clinically significant liver disease or transaminase (alanine aminotransferase and aspartate aminotransferase) levels >2.5 x upper limit of normal measured at the Screening Visit; 13. Patients with bilirubin levels >1.5 x upper limit of normal measured at the Screening Visit; 14. Patients with a history of allergic or other adverse response to vitamin B preparations; 15. Patients who require >50 mg of vitamin B6 daily; 16. Patients who have a history of dysphasia and swallowing disorders; 17. Patients with a history of hypersensitivity to Pyridorin or any of the excipients in the Pyridorin formulation; 18. Patients who have taken pyridoxamine or any other investigational drug within 30 days prior to the Screening Visit, or have participated in a previous Pyridorin trial or another clinical trial within 30 days prior to the Screening Visit; 19. Patients with a current history of drug or alcohol abuse; 20. Patients unlikely to comply with the study protocol (e.g., an inability and unwillingness to participate in adequate training, an uncooperative attitude, inability to return for follow-up visits, or unlikelihood of completing the study); 21. Women who are lactating, pregnant or intend to become pregnant during the course of the study; and 22. Patients who are employees of NephroGenex or its representatives."], "nct_id": "NCT00734253"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Male and female patients affected by type 2 diabetes with stable metabolic control (HbA1c < 9%), and stable systemic blood pressure control (SBP/ DBP < 160/90 mmHg).", "Presence of early nephropathy (overnight albumin excretion rate > 20 microg/ min for at least 6 months), without overt renal insufficiency (serum creatinine concentration < 2 mg/dl).", "Age between 18 and 75 years.", "Written signed informed consent; patient willing and able to comply with all study procedures and scheduled visits."], "exclusion": ["History of any form of allergic reactions or hypersensitivity or intolerance or contraindication to acetylsalicylic acid or nitrates.", "Patients under the age of 18 or above 75.", "Patients who are not able to give an informed consent or inadequate comprehension of study risks and requirements.", "Patients who are unable to comply with the requirements of the study protocol.", "Chronic alcohol or drug abuse (current or within the past year).", "Pregnancy and lactation.", "If women of child-bearing potential, a pregnancy test must be performed before inclusion and after the study, and reliable contraceptive methods followed.", "Evidence for non-diabetic renal disease.", "Patients with duodenal/gastric ulcer history, or gastrointestinal bleeding over the last 6 months.", "Patients with liver insufficiency (ASAT, ALAT > 2 times the upper normal limit).", "Patients with platelet counts < 100,000 cells/mm3.", "Patients with hemorrhagic diathesis.", "Patients on antiinflammatory or immunosuppressive therapy over the last 6 months."], "nct_id": "NCT00157508"},{"minimum_age": 35.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Subjects with type 2 diabetes.", "Stable FPG of >=7.0 and <=12.0mmol/L.", "Subjects had to have been established on SU treatment or SU+MET treatment for at least 2 months.", "Serum creatinine level > 130 micromol/L."], "exclusion": ["Subjects taking > 2 concomitant oral anti-diabetic agents.", "Subjects with HbA1c >=10%.", "Subjects already receiving diuretic medication.", "Subjects unstable or severe angina.", "CHF NYHA class i-iv.", "Subjects with clinically significant hepatic disease."], "nct_id": "NCT00306696"},{"minimum_age": 50.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Males and females, age 50-75 years", "Type 2 diabetes of at least 2 years duration", "BMI 20-45 Kg/m2", "Stable treatment for the last two months with metformin in monotherapy (at least 2 gr/die)", "HbA1c >=7.0% and <=9.0%"], "exclusion": ["Type 1 diabetes", "Previous treatment with thiazolidinediones in the last six months", "Contraindication/intolerance to metformin or SUs or TZDs", "Documented coronary or cerebrovascular events in the previous 3 months", "Serum creatinine > 1.5 mg/dl", "History of congestive heart failure, NYHA I or higher", "Chronic use of glucocorticoids", "Ischemic ulcer or gangrene", "Liver cirrhosis or severe hepatic dysfunction (ALT increase of 2.5 times the upper normal limit)", "Pregnancy or breast feeding", "Cancer, substance abuse, or any health problem that may interfere with the compliance to the study protocol or limit life expectancy"], "nct_id": "NCT00700856"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 1 diabetes with pump or multi-injection treatment and attending a functional insulinotherapy class", "Social Security membership or benefit from Social Security", "Informed consent, with a signed and approved form"], "exclusion": ["Underage patient, major patient under guardianship or protected by the Law", "Pregnant, parturient or breastfeeding woman", "Person with no freedom (prisoner), person in an emergency situation, person hospitalized without consent and not protected by the Law", "Antecedents of pathologies causing diabetes instability (coeliac disease, gastroparesis, non-balanced psychiatric pathology) and not optimally treated, acute pathology less than 3 months ago (infectious, cardio-vascular, metabolic), pregnancy"], "nct_id": "NCT00973492"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the following criteria:", "Symptoms of diabetes plus casual plasma glucose concentration >200 mg/dL (11.1 mmol/L) or", "Fasting plasma glucose >126 mg/dL (7.0 mmol/L) or", "2-hour post-load glucose >200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (GTT).", "Presumed NAFLD, defined by one of the following criteria:", "Alanine aminotransferase (ALT) \u226547 U/L for females and \u226556 U/L for males", "Aspartate aminotransferase (AST) \u226547 U/L for females and \u226560 U/L for males", "Enlarged liver (demonstrated by ultrasound or other imaging technique)", "Diagnostic histological findings shown on prior biopsy (in the last 5 years)."], "exclusion": ["Bilirubin >2 \u00d7 ULN", "ALT >155 U/L for females and >185 U/L for males.", "AST >155 U/L for females and >200 U/L for males.", "Patients taking any antidiabetic medications, with the exception of metformin and sulfonylureas. If the HbA1c is <11%, patients may be enrolled who have been withdrawn from all other diabetic medications as specified in the protocol, at the discretion of the Principal Investigator."], "nct_id": "NCT00501592"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": [": obese family history of diabetes"], "exclusion": [": non-obese diabetes"], "nct_id": "NCT00727779"},{"minimum_age": null, "maximum_age": null, "gender": "F", "inclusion": ["Type 1 diabetes", "Pregnancy before gestational week 14"], "exclusion": ["Other diseases that might influence the risk of severe hypoglycemia"], "nct_id": "NCT00435565"},{"minimum_age": 21.0, "maximum_age": 95.0, "gender": "A", "inclusion": ["greater than 21 years of age.", "diagnosed with type 2 diabetes for at least 1 year.", "have no severe complications (on dialysis, blindness, amputations, history of stroke)", "able to speak, read and hear English.", "married or cohabiting for > 1 year.", "have a telephone."], "exclusion": ["have a diagnosed psychiatric disorder.", "refuse audiotaping or other study procedures."], "nct_id": "NCT00250731"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.", "Colonoscopy within 2 years as part of IBS diagnostic evaluation.", "Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency."], "exclusion": ["Symptoms of constipation.", "History of other gastrointestinal diseases.", "Type 1 or 2 diabetes.", "Lactose intolerance not controlled by lactose-free diet."], "nct_id": "NCT00724126"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Confirmed IBS diagnosis per Rome II for diagnosis of IBS.", "Colonoscopy within 2 years as part of IBS diagnostic evaluation.", "Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency."], "exclusion": ["Symptoms of constipation.", "History of other gastrointestinal diseases.", "Type 1 or 2 diabetes.", "Lactose intolerance not controlled by lactose-free diet."], "nct_id": "NCT00731679"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any hospitalized subject with hyperglycaemia requiring intravenous insulin therapy is eligible for the study based on the discretion of the physician."], "exclusion": ["Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude;", "Subjects with a hypersensitivity to NovoRapid or to any of the excipients.", "Subjects with conditions considered as contraindications."], "nct_id": "NCT00700648"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Impaired glucose tolerance", "Age 40 to 75 years"], "exclusion": ["Diabetes mellitus type 1 or 2", "Hypersensitivity to study medication", "Malignant tumor", "Alcohol or drug abuse", "Overt heart failure", "Severe hepatic, renal, neurological, psychiatric, or hematological disease", "Prior treatment with glitazones or statins", "Established indication for statin treatment (e.g. coronary artery disease [CAD])"], "nct_id": "NCT00306826"},{"minimum_age": 19.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male and Female", "19-65 years of age", "Type 1 and 2 diabetes", "Computer literate", "Independent care of diabetes", "Insulin pump allowed (Spirit pump only)", "Females on birth control", "Can demonstrate competency in the use of the Accuchek Aviva meter, reliability in doing regular home blood sugar determinations"], "exclusion": ["Creatinine clearance < 30 cc/min", "Severe loss of vision (diabetic retinopathy)", "Severe diabetic neuropathy", "Known or suspected diabetic gastroparesis", "Patients with heart disease", "Patients with liver disease", "Drug or substantial alcohol use", "Use of pharmacological doses of glucocorticoids or other medications that affect blood sugar and blood pressure", "Females that are pregnant or are capable of becoming pregnant", "Insulin pump use other than Accucheck Spirit pump"], "nct_id": "NCT00956800"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Must have been diagnosed with celiac disease by biopsy for \u2265 6 months.", "Have a Anti-Tissue Transglutaminase (tTG) \u2264 10 EU as measured by serology.", "Must be on a gluten-free diet for at least the past 6 months."], "exclusion": ["Have any chronic active GI disease other than celiac disease (e.g., IBS, Crohn's, Colitis).", "Have diabetes (Type 1 or Type 2).", "Chronically consumes non-steroidal anti-inflammatory agents (\"NSAIDs\") or takes proton-pump inhibitors.", "Consuming oral corticosteroids or immune suppressants."], "nct_id": "NCT00362856"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Be of non-childbearing potential.", "Diagnosis of dry AMD as defined by the Age-Related Eye Disease Study (AREDS, 2005), including uni- or multi-focal GA, without foveal involvement.", "BCVA of 20/320 or better in the worst eye."], "exclusion": ["Diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions.", "Diagnosis or history of Alzheimer's disease, dementia or neurodegenerative disorders.", "Diagnosis or recent history of clinically significant cerebrovascular disease.", "Uncontrolled hypertension.", "Uncontrolled Type 1 or Type 2 diabetes mellitus."], "nct_id": "NCT00877032"},{"minimum_age": 18.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Age of 18-80 years", "Have a recent MI (<5days)", "Have ASAT >100 U/L or CKMB > 50 U/L.", "Have LVEF <40%.", "Are on optimal medical treatment and considered unsuitable for surgical intervention."], "exclusion": ["Evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization.", "Significant concomitant disease such as infections, pulmonary disease or connective tissue disease.", "Participating in other studies.", "Inability to participate.", "Diseases that require surgery.", "Planned revascularisation.", "Known hypersensitivity to IVIG."], "nct_id": "NCT00430885"},{"minimum_age": 45.0, "maximum_age": 69.0, "gender": "A", "inclusion": [": Subjects were considered eligible if they were 45 years old or older but younger than 70 years old at study entry, had type 2 diabetes and met both \"(1) and (2)\" or both \"(1) and (3)\" described below. [Note: Those who met all three \"(1), (2) and (3)\" were also considered eligible for inclusion.](1) Glycemic control Those with HbA1c 6.9% or greater despite treatment with any of the three regimens given below. Diet and exercise therapy alone, Diet and exercise therapy plus 1 oral anti-diabetic drug, Diet and exercise therapy plus, GI and 1 other oral anti-anti-diabetic drug (2) Blood pressure control Those with the following casual blood pressure (BP) level as measured on an outpatient basis, Systolic BP 140 mmHg or diastolic BP 90 mmHg while not on an antihypertensive agent, Systolic BP 130 mmHg or diastolic BP 80 mmHg while on 1 or 2 ARB, ACEI or long-acting CCB Those receiving antihypertensive agents other than ARB, ACEI or long-acting CCB were not eligible for study entry, with the exception of those who were receiving these agents for other purposes than blood pressure lowering. (3) Lipid metabolism Those with the following fasting lipid levels while not on a lipid-lowering agent LDL-cholesterol, 120 mg/dL (as calculated by using the Friedewald formula) Triglycerides, 150 mg/dL HDL-cholesterol, < 40 mg/dL Subjects receiving 1 lipid-lowering agent were judged eligible for study entry if they met any of the above criteria. However, care needs to be taken to ensure that those on fibrates discontinue the fibrate treatment at the start of the study when they are assigned to the intensive therapy arm."], "exclusion": ["Those with poorly controlled hypertension despite pharmacological therapy (systolic BP 200 mmHg or diastolic BP 120 mmHg)", "Those on insulin therapy", "Those with non-diabetic renal disease", "Those in whom type 1 and other diabetes due to pathogenic mechanisms other than those associated with type 2 diabetes is strongly suspected", "Those who tested anti-GAD antibody*-positive", "Those with LDL-cholesterol 200 mg/dL", "Those suspected of having secondary hypertension other than renal parenchymal hypertension", "Those suspected of having hereditary lipid disorder with a strong family history of lipid metabolic disorder", "Those who were receiving antihypertensive agents other than ARB, ACEI, long-acting CCB, except where they were receiving these agents for other purposes than blood pressure lowering 10. Those who were receiving 3 or more antihypertensive agents (i.e., ARB, ACEI, and long-acting CCB), except where they were receiving these agents for other purposes than blood pressure lowering 11. Those with more serious retinopathy than proliferative retinopathy 12. Renal failure (serum Cr: 2.0 mg/dL in men; 1.5 mg/dL in women) 13. Those with a history of cardiac failure or those with cardiac failure 14. Those who were pregnant or potentially pregnant 15. Those who met any of the following criteria and who had BNP 100 pg/mL, Myocardial infarction, Angina pectoris (or a history of disease), History of coronary artery bypass graft (CABG), History of percutaneous coronary angioplasty (PTCA), Other cardiac disease, ECG findings of left ventricular hyperplasia, Abnormal ECG findings (excluding isolated extrasystole or right bundle branch block [RBBB]) 16. Those judged by the physician in charge to be ineligible for study entry (Follow-up study) Inclusion criteria: Of the subjects in the randomized controlled study comparing intensive therapy and conventional therapy in type 2 diabetic patients (J-DOIT3), those who provide written informed consent to participate in the follow-up study will be enrolled regardless of completion or discontinuation from the randomized controlled study (If the subject is unable to provide informed consent for any reason, consent from his/her legal representative is allowed). Exclusion criteria: A subject who is assessed as ineligible by the investigator will be excluded from the follow-up study"], "nct_id": "NCT00300976"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Adults with Type 1 or 2 diabetes", "Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months"], "exclusion": ["Patients must not be in poor or unstable health."], "nct_id": "NCT00159731"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Adults with Type 1 or 2 diabetes", "Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months"], "exclusion": ["Patients must not be in poor or unstable health."], "nct_id": "NCT00159679"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Mentally stable and able to comply with study procedures", "Clinical history compatible with type 1 diabetes, with onset of disease at less than 40 years of age; insulin dependence for at least 5 years at study entry; AND sum of age and insulin-dependent diabetes duration of at least 28", "Absent stimulated C-peptide (less than 0.3 ng/ml) 60 and 90 minutes post mixed-meal tolerance test", "Involvement of intensive diabetes management, defined as:", "Self monitoring of glucose values no less than a mean of three times each day, averaged over each week", "Administration of three or more insulin injections each day or insulin pump therapy", "Under the direction of an endocrinologist, diabetologist, or diabetes specialist, with at least three clinical evaluations during the past 12 months prior to study enrollment", "At least one episode of severe hypoglycemia, defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, in which the participant was unable to treat him/herself and which was associated with either a blood glucose level less than 54 mg/dl or prompt recovery after an oral carbohydrate, intravenous glucose, or glucagon administration in the 12 months prior to study enrollment.", "Reduced awareness of hypoglycemia. More information about this criterion, including the specific definition of hypoglycemia unawareness, is in the protocol."], "exclusion": ["Body mass index (BMI) greater than 30 kg/m2 or weight less than or equal to 50 kg", "Insulin requirement of more than 1.0 IU/kg/day or less than 15 U/day", "HbA1c greater than 10%", "Untreated proliferative diabetic retinopathy", "Systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg", "Measured glomerular filtration rate using iohexol of less than 80 ml/min/1.73m2. More information about this criterion is in the protocol.", "Presence or history of macroalbuminuria (greater than 300 mg/g creatinine)", "Presence or history of panel-reactive anti-HLA antibody levels greater than background by flow cytometry. More information about this criterion is in the protocol.", "Pregnant, breastfeeding, or unwilling to use effective contraception throughout the study and for 4 months after study completion", "Active infection, including hepatitis B virus, hepatitis C virus, HIV, or tuberculosis. More information about this criterion is in the protocol.", "Negative for Epstein-Barr virus by IgG determination", "Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection in the past year", "History of malignancy except for completely resected squamous or basal cell carcinoma of the skin", "Known active alcohol or substance abuse", "Baseline Hgb below the lower limits of normal, lymphopenia, neutropenia, or thrombocytopenia", "History of Factor V deficiency", "Any coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or individuals with an INR greater than 1.5", "Severe coexisting cardiac disease, characterized by any one of the following conditions:", "Heart attack within the last 6 months", "Evidence of ischemia on functional heart exam within the year prior to study entry", "Left ventricular ejection fraction less than 30%", "Persistent elevation of liver function tests at the time of study entry", "Symptomatic cholecystolithiasis", "Acute or chronic pancreatitis", "Symptomatic peptic ulcer disease", "Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with the ability to absorb oral medications", "Hyperlipidemia despite medical therapy, defined as fasting LDL cholesterol greater than 130 mg/dl (treated or untreated) and/or fasting triglycerides greater than 200 mg/dl", "Currently receiving treatment for a medical condition that requires chronic use of systemic steroids except for the use of less than or equal to 5 mg prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only", "Treatment with any anti-diabetic medication other than insulin within 4 weeks prior to study entry", "Use of any study medications within the past 4 weeks", "Received a live attenuated vaccine within the past 2 months", "Any medical condition that, in the opinion of the investigator, might interfere with safe participation in the trial", "Treatment with any immunosuppressive regimen at the time of enrollment.", "A previous islet transplant.", "A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and the transplant occurred more than 6 months prior to enrollment"], "nct_id": "NCT00434850"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "age > 18 years old who are at high risk based on any one of the following criteria:", "HbA1C > 8.5", "LDL > 130", "BP > 140/90 within the last 6 months"], "exclusion": ["patients who are pregnant upon entry in the study (however if a patient becomes pregnant in the course of the study, she can continue with the study)", "unable to communicate in either English or Spanish", "in nursing homes (and therefore unable to attend outpatient visits)"], "nct_id": "NCT00308386"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female volunteers, aged 18 to 65 years, inclusive.", "Subjects must be obese (class 1: BMI of 30.0 to 34.9 kg/m2 or class 2: BMI of 35 to 39.9 kg/m2 in non-Asians and BMI of 27.0", "31.9 kg/m2 or 32.0", "36.9 kg/m2 in Asians) at the Screening Visit.", "Female subjects must be postmenopausal (with amenorrhea for at least 2 years prior to scheduled dosing and confirmatory FSH test in the range of 23-116 IU/L) or surgically sterile (with physician or insurance documentation of bilateral tubal ligation at least 6 months prior to Screening Visit or of a hysterectomy and/or bilateral oophorectomy) and agree not to undergo in vitro fertilization during the study and for 6 months post treatment."], "exclusion": ["Type 1 diabetes.", "Type 2 diabetes.", "History of myocardial infarction, stroke, including transient ischemic attack, in the last 2 years.", "Asthma or chronic obstructive pulmonary disease controlled by regular use of inhaled steroids.", "Subjects with rheumatoid arthritis, lupus, or multiple sclerosis regularly requiring steroids or disease-modifying anti-rheumatic agents.", "Subjects with psoriasis requiring oral steroids.", "Subjects planning to undergo gastric bypass or resection surgery, or who have had such a procedure in the 6 months prior to the Screening Visit."], "nct_id": "NCT00779519"},{"minimum_age": 19.0, "maximum_age": 76.0, "gender": "M", "inclusion": ["Affiliated or beneficiary of a social security category", "Having signed the inform consent form", "Having signed the genetic consent form"], "exclusion": ["Antiaggregant platelet treatment", "Type 2 diabetes", "Body Mass Index > 25", "Severe renal disease", "CRP > 10", "Abnormal clotting test", "Allergies to local anesthetics"], "nct_id": "NCT00725166"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Mentally stable and able to comply with study procedures", "Clinical history compatible with type 1 diabetes with onset of disease at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28", "Absent stimulated C-peptide (less than 0.3 ng/ml) 60 and 90 minutes post-mixed-meal tolerance test", "Involvement of intensive diabetes management, defined as:", "Self-monitoring of glucose values no less than a mean of three times each day averaged over each week", "Administration of three or more insulin injections each day or insulin pump therapy", "Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three clinical evaluations during the past 12 months prior to study enrollment", "At least one episode of severe hypoglycemia in the past 12 months, defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, compatible with hypoglycemia in which the individual required assistance of another subject was unable to treat him/herself person and which was associated with either a blood glucose level less than 54 mg/dl or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration in the 12 months prior to study enrollment", "Reduced awareness of hypoglycemia. More information about this criterion, including specific definition of hypoglycemia unawareness, is in the protocol."], "exclusion": ["Body mass index (BMI) greater than 30 kg/m2 or weight less than or equal to 50 kg", "Insulin requirement of more than 1.0 IU/kg/day or less than 15 U/day", "HbA1c greater than 10%", "Untreated proliferative diabetic retinopathy", "Systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg", "Measured glomerular filtration rate using iohexol of less than 80 ml/min/1.73mm2. More information about this criterion is in the protocol.", "Presence or history of macroalbuminuria (greater than 300 mg/g creatinine)", "Presence or history of panel-reactive anti-HLA antibody levels greater than background by flow cytometry. More information about this criterion is in the protocol.", "Pregnant, breastfeeding, or unwilling to use effective contraception throughout the study and 4 months after study completion", "Presence or history of active infection, including hepatitis B, hepatitis C, HIV, or tuberculosis.", "Negative for Epstein-Barr virus by IgG determination", "Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection in the past year", "History of malignancy except for completely resected squamous or basal cell carcinoma of the skin", "Known active alcohol or substance abuse", "Baseline Hgb below the lower limits of normal, lymphopenia, neutropenia, or thrombocytopenia", "History of Factor V deficiency", "Any coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or individuals with an INR greater than 1.5", "Severe coexisting cardiac disease, characterized by any one of the following conditions:", "Heart attack within the last 6 months", "Evidence of ischemia on functional heart exam within the year prior to study entry", "Left ventricular ejection fraction less than 30%", "Persistent elevation of liver function tests at the time of study entry", "Symptomatic cholecystolithiasis", "Acute or chronic pancreatitis", "Symptomatic peptic ulcer disease", "Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with the ability to absorb oral medications", "Hyperlipidemia despite medical therapy, defined as fasting LDL cholesterol greater than 130 mg/dl (treated or untreated) and/or fasting triglycerides greater than 200 mg/dl", "Currently receiving treatment for a medical condition that requires chronic use of systemic steroids except for the use of 5 mg or less of prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only", "Treatment with any antidiabetic medication other than insulin within the past 4 weeks", "Use of any study medications within the past 4 weeks", "Received a live attenuated vaccine(s) within the past 2 months", "Any medical condition that, in the opinion of the investigator, might interfere with safe participation in the trial", "Treatment with any immunosuppressive regimen at the time of enrollment.", "A previous islet transplant.", "A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and the transplant occurred more than 6 months prior to enrollment."], "nct_id": "NCT00434811"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study", "Diagnosis of type 2 (non-insulin dependent) diabetes mellitus as defined by the diagnostic criteria of the American Diabetes Association and currently taking glyburide, glipizide, glimepiride, or metformin alone, or glyburide, glipizide, or glimepiride in combination with metformin", "Glycosylated hemoglobin level greater than or equal to 7.0%", "Fasting C-peptide level greater than or equal to 0.7 ng/mL."], "exclusion": ["Type 1 (insulin-dependent) diabetes mellitus.", "Prior exposure to a thiazolidinedione, except subjects who discontinued use of troglitazone in March or April of 2000, provided they were not experiencing adverse effects and were not then taking thiazolidinediones.", "Participating in another investigational study or had participated in an investigational trial within the preceding 2 months.", "History of ketoacidosis.", "The subject had significant diabetic nephropathy, defined as a serum creatinine level greater than or equal to 1.5 mg/dL for men and greater than or equal to 1.4 mg/dL for women, or urinary protein excretion greater than or equal to 2 plus as measured by the Combistix (or equivalent) method, except subjects with proteinuria are eligible if repeat testing within 2 weeks indicates the proteinuria had resolved.", "Anemia with a hemoglobin level less than12 g/dL for men and less than10 g/dL for women.", "The subject had a history of drug or alcohol abuse within the preceding 2 years.", "The subject had a diastolic blood pressure greater than100 mm Hg or a systolic blood pressure greater than180 mm Hg.", "The subject had evidence of ongoing cardiac rhythm disturbance, delayed QT waves, or second-degree atrioventricular heart block. Uncomplicated first-degree atrioventricular block was allowed.", "Significant cardiovascular disease including, but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV.", "History of myocardial infarction, acute cardiovascular event, or cerebrovascular accident within the preceding 6 months.", "Previous history of cancer that was not in remission for at least 5 years before administration of the first dose of study drug. Except, basal cell or Stage I squamous cell carcinoma.", "The subject had a BMI less than 20 or greater than 48 (calculated as weight [kg]/height [m2]).", "Alanine aminotransferase level greater than or equal 2.5time the upper limit of normal or a history of liver disease, jaundice, hepatitis, or biliary tract disease (except for uncomplicated and treated gall stones by either lithotomy or cholecystectomy).", "Unwilling or unable to comply with the protocol or attend scheduled appointments.", "Unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available.", "Evidence of acute or unstable chronic pulmonary disease or, if a chest x-ray was available, has unexplained pulmonary lesions.", "Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Antidiabetic agents other than study drug and companion medications (metformin and insulin).", "Weight loss agents, including pharmaceuticals and over-the-counter brands.", "Continuous (greater than 2 weeks) steroid therapy or expected recurrent steroid therapy, including all injectable, inhaled, topical, and oral steroid formulations.", "Niacin therapy.", "Chronic condition for which the recurrent use of glucocorticoids could be expected", "Any other serious disease or condition at screening or randomization that might have affected life expectancy or made it difficult to successfully manage and follow the subject according to the protocol."], "nct_id": "NCT00494312"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female aged 18-65 years (both inclusive)", "Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months", "Body mass index 18.0-28.0 kg/m^2 (both inclusive)"], "exclusion": ["Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening", "Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)", "Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period"], "nct_id": "NCT00961324"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Completed a baseline Education and Research Towards Health (EARTH) study examination", "Diagnosed with type 2 diabetes mellitus AND hypertension and/or hyperlipidemia", "Able to read and understand English", "Able to walk"], "exclusion": ["Diagnosed with CVD at study entry", "Currently receiving active treatment for any non-skin cell cancer", "Any medical condition that study physicians believe would interfere with study participation or evaluation of results", "Mental incapacity and/or cognitive impairment that would preclude adequate understanding of, or cooperation with, the study procedures", "Kidney insufficiency, as indicated by serum creatinine level greater than 2.0 mg/dL for women and greater than 2.4 mg/dL for men", "Pregnant"], "nct_id": "NCT00608387"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of Type 1a Diabetes Mellitus based on ADA Criteria", "\u22645 years since T1D was diagnosed", "\u2265 18 years of age", "\u2264 40 years of age at the time of diagnosis of Type 1a diabetes", "Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or IA-2", "Detectable fasting C-peptide level", "C-peptide increase during screening mixed meal tolerance test with a minimal stimulated value of \u2265 0.2 pmol/mL", "Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or IA-2. If insulin antibody positive only, determination must be within 2 weeks of insulin initiation"], "exclusion": ["BMI > 30 kg/m2", "Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days", "Current use of inhalable insulin", "Previous immunotherapy for T1D", "Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days prior to screening, unless approved by the medical monitor", "History of any organ transplant, including islet cell transplant"], "nct_id": "NCT00453375"},{"minimum_age": 15.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Approved to be scheduled for laparoscopic gastric bypass surgery for VSO at Cincinnati Children's or University Hospital", "Age at time of gastric bypass surgery date >15 and <21 years, or >30 and <45 years", "BMI >40", "Weight at age 18 consistent with severe adolescent obesity (if height < 5'5\" weight > 200 pounds or if height >5'5\", weight > 250)"], "exclusion": ["Diagnosis of cirrhosis, total bilirubin >1 mg/dL, prothrombin time > 13.3 sec", "Prior myocardial infarction", "Serum creatinine >1.7mg/dL", "Systemic (PO, IV, IM) glucocorticoid therapy within the previous six weeks prior to blood sampling", "Peri-menopausal (irregularity of menstrual periods over the past 3 months (67) or demonstrated abnormally high follicle stimulating hormone levels (68)", "Severe T2DM (on insulin for control of hyperglycemia, or HbA1c > 8.5)"], "nct_id": "NCT00360373"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients must be male or female age 21 or older.", "Patient must sign (and be given) a copy of the written informed consent form.", "Patients must have the diagnosis of diabetes mellitus (type 1 or type 2). Patients with the following will be considered to be sufficient evidence that diabetes is present:", "Current regular use of insulin for the treatment of diabetes mellitus OR", "Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes OR", "Documented diabetes by WHO criteria", "Patients must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen Equivalent) in the study eye.", "Patients must have a mean retinal thickness on OCT \u2265 250 microns in the central subfield."], "exclusion": ["Patients with a history of chronic renal failure requiring dialysis or kidney transplant.", "A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control), including:", "Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.", "Patients with HbA1C > 10%OR", "Patients with systolic blood pressure greater than 170 mmHg and/or diastolic blood pressure greater than 100 mmHg (Note: If blood pressure is brought below 170/100 mmHg by anti-hypertensive treatment, patient can become eligible).", "Past panretinal photocoagulation (PRP) for diabetes within 12 weeks of screening or PRP expected to be needed in the next three months in the study eye.", "Focal laser therapy to the retina of the study eye within 12 weeks of screening.", "Any intraocular surgery or ocular laser procedures in the study eye within 12 weeks of screening.", "Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at the time of study entry."], "nct_id": "NCT00306904"},{"minimum_age": 7.0, "maximum_age": 11.0, "gender": "A", "inclusion": ["Overweight, sedentary children", "Black or white race", "Attending specific schools in Augusta, GA area from which this study is recruiting"], "exclusion": ["Unable to participate in testing or vigorous exercise program", "Diabetes", "Taking medication that would affect study results", "Sibling enrolled in project"], "nct_id": "NCT00108901"},{"minimum_age": 15.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["Age: 15", "40 years old.", "BMI: 18.5", "24.9", "No medical or chronic health problems.", "If pregnant, singleton.", "First blood sample can be obtained before 13 weeks gestation.", "Plans to continue pregnancy till term and deliver at our hospital"], "exclusion": ["Hypertension.", "Diabetes Mellitus.", "Ischemic heart disease.", "Metabolic disorders e.g. hyperlipidemia, hypercholesterolemia.", "Endocrinological diseases e.g. thyroid or adrenal diseases.", "Chronic Debilitating diseases e.g. SLE, or Cancer.", "BMI less than18.5 or greater than 25.", "Anorexia or Bulimia.", "Polycystic ovarian disease. 10. In pregnant group:", "Multiple gestations.", "Hyperemesis or dehydration.", "History of Gestational Diabetes, Preeclampsia, or other complications with previous pregnancies", "If abnormal weight gain during pregnancy, will continue in the study but would not be included in establishing normal levels."], "nct_id": "NCT00454623"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age 18 years or older", "Have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy", "Willing not to inject insulin or wear an insulin pump insertion set within 3 inches from the Sensor site during Sensor wear", "Willing to use only the blood glucose meter(s) provided to them for self-monitoring of blood glucose (SMBG) during Sensor wear", "Willing to participate in one, 8-hour in-clinic session and be willing to take 4 fingersticks per hour and have 4 blood draws per hour for the entire 8-hour duration", "Willing to take a minimum of 6 fingersticks per day during home use (2 for calibration purposes, 4 for comparative purposes)", "Willing to refrain from the use of acetaminophen during the Sensor insertion period and for at least 24-hours prior to Sensor insertion", "Willing not to schedule a magnetic resonance (MRI) scan, computed tomography (CT) scan, or x-ray, for the duration of the study", "Able to speak, read, and write English"], "exclusion": ["Have extensive skin changes/diseases that preclude wearing the Sensor on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites", "Subjects who have a known allergy to medical-grade adhesives", "Are pregnant as demonstrated by a positive pregnancy test within 72 hours of insertion", "Have a hematocrit that is less than 30%, or greater than 55%", "Current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study)", "Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis B or C)"], "nct_id": "NCT00722241"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Insulin requiring diabetics (type 1 or type 2)", "Using a pen device for injections at least once per day, for at least two months prior to baseline (Study Visit Two).", "18 to 75 years of age, inclusive.", "Body Mass Index from 18 to 50 kg/m\u00b2, inclusive.", "Hemoglobin A1c from 5.5 to 9.5 percent (%), inclusive.", "Largest single dose of insulin a day less than or equal to 40 units"], "exclusion": ["Current status or history of a medical condition that would contraindicate treatment with the study product or other conditions which, in the opinion of the Investigator, would place the subject at risk or have the potential to confound interpretation of the study results (i.e. recent history of ketoacidosis, hypoglycemic unawareness, etc.).", "Hemophilia or any other disorder which causes excessive bleeding or requires frequent transfusions.", "History of intravenous drug abuse (self-reported).", "Bleeding disorder, hemophilia or subject is currently taking anti-coagulant medications (e.g., heparin, Coumadin\u00ae, warfarin).", "Self-reported blood borne infection.", "Pregnant (from medical history only)."], "nct_id": "NCT00928057"},{"minimum_age": 20.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients with type 2 diabetes", "Urinary albumin-to-creatinine ratio: >=300 mg/g creatinine twice in the first morning urine sample", "Serum creatinine level: =<2.5 mg/dl", "Patients aged 20-75 years"], "exclusion": ["Type 1 diabetes", "Hereditary diabetes or secondary diabetes", "Non-diabetic nephropathy", "Familial hypercholesterolemia", "Secondary hypertension", "Unstable angina pectoris or history of myocardial infarction/stroke within 6 months prior to consent acquisition", "Malignant tumor or life threatening disease", "History of angioedema", "Patients undergoing LDL apheresis 10. Biliary system obstruction or severe liver injury 11. Liver dysfunction 12. Allergy for ACE-Is, ARBs or HMG-CoA reductase inhibitors 13. Pregnant or nursing patients 14. Others: patients who are not suitable for this trial"], "nct_id": "NCT00253786"},{"minimum_age": 18.0, "maximum_age": 99.0, "gender": "A", "inclusion": ["Sometimes has trouble taking medicines as they're prescribed", "Has diabetes type 2, or hypertension, or high cholesterol for which they take prescription medicines", "Is a patient of 18 doctors conducting the intervention"], "exclusion": ["Subjects under age 18"], "nct_id": "NCT00846300"},{"minimum_age": 45.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes", "Macular edema involving the center of the macula demonstrated on OCT", "Clear ocular media", "Untreated patients", "Older than 45 years", "BCVA of the fellow eye at least 20/100"], "exclusion": ["Renal diabetic disease, uncontrolled hypertension or stroke history", "Other ocular disease", "Ocular surgery excepting uncomplicated phacoemulsification", "History of photocoagulation (panretinal or focal)", "History of another intravitreal treatment (like triamcinolone)"], "nct_id": "NCT00417716"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["type 1 diabetes"], "exclusion": ["severe hypo- or hyperglycemia during last 6 months", "acute illness"], "nct_id": "NCT00970567"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["The study will include 40 patients aged 18 years or older with DM, defined as patients with fasting plasma glucose above 126 mg/dL or", "symptoms of DM with random blood glucose concentration of above 200 mg/dL, or", "patients treated with oral hypoglycemics or insulin.", "In addition, prior to their enrollment in the study patients' BP will be assessed by 24 hour ambulatory BP monitoring.", "All patients will have to be treated with ACE inhibitors, aspirin and statins for at least one month prior to their enrollment in the study.", "Patients' medication regimen will not be altered during the study period.", "Patients will sign a written informed consent before their inclusion in the study."], "exclusion": ["Patients will be excluded from the study if their systolic BP is between bellow 110 mmHg or above 150 mmHg mmHg.", "Major exclusion criteria will be:", "acute coronary syndrome in the 6 months previous to the study,", "renal failure with creatinin levels above 1.5 mg/dL,", "hyperkalemia (K > 5 mg/dL),", "hematologic or solid malignancies,", "pregnancy", "a platelet count below 100,000."], "nct_id": "NCT00732407"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["diabetes type II", "age 40-70"], "exclusion": ["hospitalization for myocardial infarction, heart surgery, or congestive heart failure during the preceding 3 months", "significant cardiac arrythmia, hypertrophic cardiomyopathy, severe aortic stenosis, or pulmonary embolus", "recent symptoms of chest discomfort", "currently smoking or significant pulmonary pathology", "serious musculoskeletal problems that would limit ability to exercise", "current active involvement in a regular exercise program (> 3 times per week)", "open wounds on the weight bearing surface of the feet", "not able to ambulate independently", "stroke or other central nervous system pathology 10. stage 2 hypertension (resting blood pressure > 160 systolic or > 100 diastolic)"], "nct_id": "NCT00970294"},{"minimum_age": 18.0, "maximum_age": 72.0, "gender": "A", "inclusion": ["Male and female adults with biopsy proven celiac disease on a gluten-free diet for at least the past 6 months", "Anti-Tissue Transglutaminase (anti-tTG) \u2264 10 EU.", "BMI between 18.5 and 38, inclusive."], "exclusion": ["Has chronic active GI disease other than celiac disease", "Has diabetes (Type 1 or Type 2).", "Unable to abstain from alcohol consumption or NSAID use for 48 hours prior to each intestinal permeability collection throughout the study.", "Has hemoglobin value below 8.5 g/dL"], "nct_id": "NCT00492960"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["(Type 1 diabetic subjects):", "Type 1 diabetes treated continuously with insulin from time of diagnosis", "Age 18-55", "Anti-GAD positive", "HIV antibody negative", "Normal CBC", "Negative intermediate PPD test performed and read by study staff", "HCG Negative (females)"], "exclusion": ["Type 1 diabetic subjects):", "History of chronic infectious disease, such as HIV", "History of tuberculosis, TB risk factors, or history of + PPD, or BCG vaccination", "Treatment with glucocorticoids (other than intermittent nasal steroids) or disease or condition likely to require steroid therapy", "Other conditions or treatments associated with increased risk of infections such as patients with previous history of severe burns, or treatment with immunosuppressive medications of any type (e.g. imuran, methotrexate, cyclosporine, etanercept, infliximab) for any reason", "Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs", "Fasting or stimulated (1 mg glucagon stimulation test) c-peptide > 0.2 pmol/mL", "History of keloid formation", "HbA1c > 8.0%", "History or evidence of chronic kidney disease (serum creatinine > 1.5 mg/dL)", "History of proliferative diabetic retinopathy that has not been treated with laser therapy", "Pregnant or not using acceptable birth control", "Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example HIV+ or taking immunosuppressive medications for any reason). Inclusion Criteria (Control Non-diabetic Subjects):", "Age 18-45 Exclusion Criteria (Control Non-diabetic Subjects):", "History of autoimmune diseases or diabetes", "History of HIV History of autoimmune disease or type 1 diabetes (use of insulin continuously since diagnosis) in first degree family members"], "nct_id": "NCT00607230"},{"minimum_age": 20.0, "maximum_age": 50.0, "gender": "M", "inclusion": ["Healthy men", "Age 20-50 years", "Caucasian", "BMI 20-30 kg/m2"], "exclusion": ["Diabetes in subject and 1.degree relatives", "Any disease of clinical relevance"], "nct_id": "NCT00256256"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["Type II Diabetes on medication & angioplasty within the past 6 months."], "exclusion": ["Myocardial infarction or repeat angioplasty with the past 5 months.", "Unable to perform exercise or pharmacologic stress test."], "nct_id": "NCT00162357"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Stable coronary artery disease with planned percutaneous coronary intervention with stent implantation.", "Type II-diabetics and/or an IRIS II score greater than or equal to 50 (measure for the identification of patients with insulin resistance and increased vascular risk).", "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."], "exclusion": ["A planned percutaneous coronary intervention with stent implantation less than 15 days after the screening visit.", "Planned multi-vessel intervention.", "Use of systemic corticosteroids within the last 3 months prior to screening visit.", "Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.", "History of severe or multiple allergies.", "Treatment with any other investigational drug within 3 months before trial entry or earlier participation in the present study.", "Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.", "Progressive fatal disease.", "History of drug or alcohol abuse within the last 10 years.", "A history of significant cardiovascular (New York Health Association stage II", "IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the normal reference range), renal (creatinine greater than 1.2 mg/dL in women and greater than 1.5 in men and/or glomerular filtration rate less than 45), neurological, psychiatric and/or hematological disease as judged by the Investigator.", "Pre-treatment with peroxisome proliferator-activated receptor (gamma) agonists within the 3 months prior to screening.", "If insulin therapy applicable: initiation of insulin therapy within the last 3 months.", "If statin therapy applicable: change of medication within the last 4 weeks.", "Myocardial infarction within 3 months prior to screening visit.", "Blood donation within last 30 days."], "nct_id": "NCT00771004"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus,", "Stable antidiabetic regimen for 3 months", "Hemoglobin A1c <8.6%", "Stable antihypertensive medication regimen for 3 months or more, including either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker"], "exclusion": ["Any clinically significant abnormality on history, physical examination, or laboratory testing which could preclude safe completion of the study", "Significant cardiac conditions", "Lung disease", "Cigarette smoking", "Chronic kidney disease (Stage 3 or greater)", "Type 1 diabetes", "Known contraindication to alpha- or beta-blocker therapy"], "nct_id": "NCT00732511"},{"minimum_age": 19.0, "maximum_age": null, "gender": "A", "inclusion": ["Body mass index \u2265 27 with one risk factor for cardiovascular disease OR overweight/obese individuals with type 2 diabetes on standard hypoglycemic agents", "Recently prescribed Xenical at the St. Paul's Hospital Lipid Clinic"], "exclusion": ["Patients with previous experience using Xenical", "Patients currently using other weight loss medications.", "Unable to provide informed consent.", "Less than 19 years of age"], "nct_id": "NCT00152360"},{"minimum_age": 18.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["type 1 diabetes", "recurrent severe hypoglycemia within the preceding 6 months", "attending the Newcastle Diabetes Centre"], "exclusion": ["previous use of rapid- and long-acting insulin analogs used in an multiple daily insulin injection regimen", "previous use of continuous subcutaneous insulin infusion pump", "alcohol or drug abuse", "seizures unrelated to hypoglycemia."], "nct_id": "NCT00360984"},{"minimum_age": 0.0027397260273972603, "maximum_age": 20.0, "gender": "A", "inclusion": ["pediatric patients with type 1 diabetes"], "exclusion": [], "nct_id": "NCT00173628"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Type 1 diabetes mellitus"], "exclusion": [": -"], "nct_id": "NCT00368394"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["The patient is male or female, 18-70 years of age", "The patient has either type 1 or type 2 diabetes", "The patient has mild to moderate diabetic neuropathy", "The patient is free from other clinically significant illness or disease, as determined by medical history, physical examination, laboratory evaluations, and other safety tests"], "exclusion": ["Being treated with anticoagulants other than aspirin, such as warfarin, digoxin, Plavix", "BMI>40", "A significant disorder or a condition other than diabetes that can cause symptoms or physical conditions that mimic peripheral neuropathy or interfere with cognition", "Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma potentially affecting nerve function", "Women of childbearing potential who do not refrain from sexual activity or use adequate contraception", "Pregnant or lactating women", "An ALT or AST value >2X upper limit of normal (ULN)", "Clinically significant cardiovascular disease within the last six (6) months"], "nct_id": "NCT00307749"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "F", "inclusion": ["BMI 30 or more", "Less than 20 weeks gestation", "member of Kaiser Permanente Northwest (NW)", "receive pre-natal care at Kaiser Permanente NW", "speaks English"], "exclusion": ["no current treatment for cancer", "no bariatric surgery", "no current renal disease", "no multiple birth anticipated", "no hyperemesis requiring hospitalization", "no diabetes (type 1 or 2)"], "nct_id": "NCT00950235"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 1 or 2 Diabetes", "Diagnosed with peripheral neuropathy", "Symptoms of: pain and/or numbness", "Bilateral symptoms (pain in both legs)", "Have been treated non-surgically", "Aged 18-80", "All genders and all races"], "exclusion": ["Cardiac or renal pedal edema", "Medical condition which does not allow surgery", "Inadequate glycemic control", "Skin ulcer", "Charcot's foot", "Symptoms of radiculopathy/sciatic-type nerve pain", "Inadequate nutrient circulation in the feet", "Weight greater than 300 lbs.", "Psychiatric problems or alcohol/drug abuse", "Pregnancy"], "nct_id": "NCT00703209"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["A diagnosis of type 1 or 2 diabetes mellitus and documented painful, symmetrical, sensorimotor polyneuropathy for at least 6 months", "Either no analgesic medication or on stable analgesic medication for at least 4 weeks"], "exclusion": ["Female patients who are fertile and of child-bearing potential", "Clinically significant or unstable hepatic, respiratory, renal, hematologic, cardiovascular or peripheral vascular disease", "Painful conditions that may confound the evaluation of neuropathic pain"], "nct_id": "NCT00452777"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Diagnosed with type 1 diabetes mellitus within 3 months prior to study entry", "Positive for IAA, GAD65, or IA2 antibodies OR positive for GAD65 or IA2 antibodies after 2 weeks of starting insulin treatment"], "exclusion": ["History of treatment with any oral hypoglycemic agent for more than 3 months", "Ongoing use of medications known to influence glucose tolerance", "History of immunosuppressive or steroid therapy for more than 3 months within the 2 years prior to study entry", "Severe active liver, heart, kidney, or immunodeficiency disease that may limit life expectancy or may require immunosuppression during the study", "Prior complications related to routine vaccinations", "Prior participation in a trial for prevention of type 1 diabetes mellitus. Individuals who are known to have been in the placebo arm of a completed prevention trial are not excluded.", "Any condition that may interfere with a participant's ability to comply with the study", "Pregnancy or planned pregnancy within the time frame of the study"], "nct_id": "NCT00057499"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 2 diabetes mellitus patients with 5 to 15 years of diagnosis", "Microalbuminuria (defined as a urinary albumin/creatinine ratio between 30 and 300 mg/g)", "A1c less than 9% in the last year"], "exclusion": ["Acute diabetic complications", "A1c greater than 9% in the last year", "Acute infectious process", "Hepatic disease", "Thyroid disease"], "nct_id": "NCT00737126"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Have the capacity to understand and sign an informed consent form.", "Signed informed consent (must be obtained before any specific procedure is performed).", "Presence of clinically significant macular edema, with visual acuity less than 0.4 corrected to EDRS scale, which is refractory to at least two sessions of laser photocoagulation, defined as: A) Thickening of the retina at or within 500 \u03bcm of the center of the macula. B) Hard exudates at or within 500 \u03bcm of the center of the macula, if associated with thickening of the adjacent retina. C) A zone or zones of retinal thickening 1 disc area or larger, any part of which is within 1 disc diameter of the center of the macula.", "Male or female aged 18-80 years, inclusive.", "Type 1 or type 2 diabetes of at least 1 year duration. Type 1 diabetes is defined clinically as a diagnosis made before the age of 36 years with a continuous need for insulin within a year of diagnosis. Type 2 diabetes is defined clinically as a diagnosis made at age of 36 or above without a need for continuous insulin therapy within a year of diagnosis.", "Postmenopausal women (no menstrual cycle for a period of a minimum of 1 year) or surgically sterilized and have a negative serum pregnancy test on entry in the study. Men must agree to use adequate birth control during the study for 6 months after the infusion of the study agent.", "Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.", "Stable diabetic therapy within the last 6 months, i.e. absence of major change in glycemic control (e.g. 2% change in HbA1c) or change in daily number of insulin injections.", "HbA1c 6.2-10%.", "The screening laboratory test must meet the following criteria: white blood cell count >5x10/L; absolute neutrophil count >1x10/L; platelet count >50x10/L; haemoglobin >100 g/L; serum creatinine <2 mg/dl; aspartate aminotransferase < 3 times the upper normal limit; alanine aminotransferase <3 times the upper normal limit; alkaline phosphatase < 2 times the upper normal limit, \u03b3-GT< 2 times the upper normal limit", "Patients are considered eligible according to the following tuberculosis (TB) screening criteria: A)Have no history of latent or active TB prior to screening. B)Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination. C)Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study agent. D) Within 1 month prior to the first administration of study agent, either have a negative tuberculin skin test, as outlined in appendix B, or have a newly identified positive tuberculin skin test during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent. E)Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current active TB or old inactive TB."], "exclusion": ["Vitreoretinal traction.", "Retinal detachment.", "Proliferative diabetic retinopathy requiring immediate panretinal photocoagulation.", "Any previous eye surgery in the last 6 months before the beginning of the study (intravitreal injections are not considered ocular surgery).", "Macular Edema of ischaemic type.", "Macular Edema caused by retinal conditions other than diabetes.", "Cataract or media opacities of a degree which precludes accurate retinal photographs or OCT measurement.", "Hard exudates under the fovea.", "Uncontrolled hypertension (blood pressure above 180/110 mmHg).", "Angle closure glaucoma which precludes pharmacological dilatation of the pupil.", "Use in the previous 6 months of oral corticosteroids or in the previous month of anti-inflammatory medication.", "Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion) (this includes fathers who plan on fathering a child within 6 months after their last infusion).", "Have had any previous treatment with monoclonal antibodies or antibody fragments.", "History of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an exclusion criterion.", "Documentation of seropositivity for human immunodeficiency virus (HIV).", "A positive test for hepatitis B surface antigen or hepatitis C virus (HCV).", "Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of the results.", "Have a known history of serious infections (e.g. hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.", "Have or have had an opportunistic infection (e.g. herpes zoster, cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than tuberculosis) within 6 months prior to screening.", "Positive PPD test.", "Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB.", "Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g. nodes in the posterior triangle of the neck, infraclavicular, epitrocheal, or periaortic area), or splenomegaly.", "Currently have a known malignancy or have a malignancy within the previous 5 years, with the exception of basal or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.", "Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease.", "Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.", "Use of any investigational drug within 6 months prior to screening.", "Presence of transplanted solid organ (with the exception of corneal transplant > 3 months prior to screening).", "Have a concomitant diagnosis or history of congestive heart failure.", "Blood donation for the duration of the study", "Have allergy or other contraindication to fluorescein"], "nct_id": "NCT00505947"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Age 18 to 80, weight stable for at least 3 months", "At lifetime maximal body weight and impaired glucose tolerance (ICT) by the World Health ORganization criteria:", "fasting plasma glucose level of 100- 125mg/dL or", "plasma glucose level between 140 to 149mg/dL following a 75gram oral glucose load"], "exclusion": ["Actively losing weight", "Smokers", "Alcohol consumption > 2 drinks/day", "Prescription drug use", "Recreational drug use", "Type 2 Diabetes", "Conditions that contraindicate treatment with pioglitazone such as CHF, impaired liver or kidney function or known sensitivity to pioglitazone"], "nct_id": "NCT00843791"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Subject is in overall general good health.", "If female, subject must be of:", "Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal or surgically sterile); or", "Childbearing potential, but must have a negative pregnancy test at randomization, and must be compliant with one of the following: Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period of 1 week after study completion or premature discontinuation from the study (to account for elimination of the drug); Have a male partner who is confirmed to be sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; Use of contraceptive(s) with a documented failure rate of less than 1% per year, including but not limited to: implants of levonorgestrel, use of injectable progestogen, oral contraceptives (either combined or progestogen only), an intrauterine device (IUD) or spermicide plus a mechanical barrier (condom/diaphragm).", "Subjects must be newly diagnosed with a first recognized episode of genital herpes as described in (a) or (b) below (See Appendix 3): a.HSV-2 seropositive at screen, with documented clinical signs and symptoms consistent with genital herpes at screen or within 4 months prior to randomization or b.HSV-2 seronegative at screen, AND HSV-2 culture positive or HSV-2 PCR positive with documented clinical signs and symptoms consistent with genital herpes at screen or within 4 months prior to randomization.", "Subject must be willing and able to provide written informed consent and comply with the protocol."], "exclusion": ["Subject is known or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV).", "Subject received an investigational drug in the 30 days prior to the randomization visit.", "Subject is receiving systemic antiviral or immunomodulatory treatments.", "Subjects who have received systemic antiherpetic treatments (e.g., valacyclovir, acyclovir, ganciclovir, famciclovir) within 3 days of starting study drug, or immunomodulatory treatments in the 30 days before starting study drug.", "Subject has clinically significantly impaired renal function as defined by creatinine clearance less than 50ml/min (calculated using the Cockcroft-Gault formula).", "Subjects with a history or evidence of decompensated liver disease, or clinically significantly impaired hepatic function defined as an ALT (alanine transaminase) level >3 times the normal upper limit.", "Subject is known to be hypersensitive to valacyclovir, acyclovir, ganciclovir or famciclovir.", "Subject has malabsorption or vomiting syndrome or other gastrointestinal dysfunction that may impair drug pharmacokinetics.", "Female subject who is contemplating pregnancy within the duration of the study drug dosing period.", "Female subject who is pregnant and/or nursing.", "Subject with current alcohol or drug abuse.", "Subjects who have received suppressive (daily) therapy for genital herpes prior to randomization. Suppressive therapy is defined as daily antiherpetic therapy of at least 4 weeks duration.", "Subjects with a history of ocular HSV (herpes simplex virus) infection."], "nct_id": "NCT00306293"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age >= 18 years Subjects <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.", "Diagnosis of diabetes mellitus (type 1 or type 2) \u2022 Any one of the following will be considered to be sufficient evidence that diabetes is present: Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for definitions)", "At least one eye meets the study eye criteria.", "Fellow eye meets criteria.", "Able and willing to provide informed consent.", "Any candidate identified by a study investigator as being able to successfully tolerate a 3 month deferral of laser photocoagulation."], "exclusion": ["Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.", "Subjects in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.", "Participation in an investigational trial within 30 days of NIR participation that involved treatment with any drug that has not received regulatory approval at the time of study entry. \u2022 Note: subjects cannot receive another investigational drug while participating in the study during the first 6 months... 10. Major surgery within 28 days prior to participation or major surgery planned during the next 6 months. \u2022 Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter. 11. Subject is expecting to move out of the area during the 6 months of the study."], "nct_id": "NCT00846092"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Duration of diabetes: 5 years or more", "Type 1 diabetes with C-peptide < 200 pmol/L and a simultaneous plasma glucose between 60 and 250 mg/dl", "Complex insulin program supervised by an endocrinologist for at least 6 months", "Hypoglycemic unawareness diagnosed using Clarke Awareness Questionnaire", "Body weight < 70 kg", "Body Mass Index < 30 kg/m^2", "Insulin requirement < 40 units/day by multiple daily injections or < 30 units /day by external insulin pump or < 0.6 unit/kg/day with a HbA1c < 7.0 % ( Normal < 6 %)", "No overt cardiovascular disease", "No laser treatment for retinopathy", "Retinopathy diagnosed by ophthalmologist to be stable and requiring no further evaluation for at least one year", "Women of child bearing age will have a negative pregnancy test at screening and time of trial initiation", "Women enrolled in the trial should be willing to practice birth control while on immunosuppression", "No psychologic issues that would interfere with adherence to safe clinical practice", "Blood type (ABO) compatibility", "No evidence of chronic liver disease (aspartate aminotransferase (AST) < 2.5 times normal, alanine aminotransferase (ALT) < 2.5 times normal, international normalized ratio (INR) < 1.4, No evidence of fatty liver on abdominal ultrasound."], "exclusion": ["Ongoing infection", "Ongoing alcohol or drug abuse", "Clinical portal hypertension", "Gall stones", "Liver hemangioma on ultrasound interfering with islet infusion", "Lack of updated immunization", "Unstable cardiovascular status as defined by:", "Myocardial infarction/acute coronary syndrome in last year", "Significant coronary atherosclerosis on angiography", "Active ischemia at evaluation", "Pre-trial low-density lipoprotein (LDL) cholesterol > 100 and triglycerides > 200 mg/dl with or without lipid lowering therapy", "Active peptic ulcer disease", "Previous organ transplantation except islet transplantation", "Negative serology for Epstein-Barr Virus (EBV) or ongoing acute EBV infection", "Previous malignancy unless", "5 years ago", "basal cell cancer", "squamous cell cancer", "Requiring steroid therapy for any reason", "Positive Purified Protein Derivative (PPD", "Tuberculosis Skin Test)", "Serological evidence of HIV, Hepatitis C or Hepatitis B", "Chronic anemia", "Single Antigen B (SAB) normalized value >1500", "Renal disease", "Iothalamate clearance < 70 cc/min", "24 hour urine protein > 500 mg/24 hours"], "nct_id": "NCT00437398"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["HbA1c > 8.5% for more than one year prior to enrolment.", "Diabetes-duration > 5 years.", "Age at onset of diabetes < 35 years", "Fasting C-peptide < 300 pmol/l", "Age > 18 years at enrolment."], "exclusion": ["Clinical or biochemical signs of kidney-, liver- or heart-failure.", "Other coexisting serious morbidity, which will affect the study-participation or outcome of the study i.e. cancer.", "Known abuse of any medication or alcohol", "Hypoglycaemia unawareness.", "Pregnancy or planned pregnancy in the study-period."], "nct_id": "NCT00118937"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Males or females at least 18 years of age, of any ethnic origin", "Type 1 or 2 diabetes mellitus", "Pain score greater than or equal to 4 on the 11-point numeric pain rating scale"], "exclusion": ["Neurologic disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.", "Presence of severe pain associated with conditions other than diabetic peripheral neuropathy, that could confound the assessment or self-evaluation of pain due to DPN."], "nct_id": "NCT00143156"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["1) Age \u226518 years", "2) Clinical diagnosis of T2DM and HbA1c \u22659% at the screening visit", "3) Self-identified as Black or African American", "4) Subject must be taking at least one oral medication for diabetes, hypertension, or hyperlipidemia and must be willing to use the MEMS cap and bottle for 12 months", "5) Subjects must be able to communicate in English", "6) Subjects must have access to a telephone (landline or cell phone) for the 12 week intervention period"], "exclusion": ["1) Mental confusion on interview suggesting significant dementia", "2) Participation in other diabetes clinical trials", "3) Alcohol or drug abuse/dependency", "4) Active psychosis or acute mental disorder", "5) Life expectancy <6 months"], "nct_id": "NCT00929838"},{"minimum_age": 19.0, "maximum_age": 35.0, "gender": "M", "inclusion": ["Men aged between 19 and 35 years", "Body mass index between 15th and 85th percentile (Must et al. 1991)", "Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant", "Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant"], "exclusion": ["Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study", "Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia", "Treatment in the previous 3 weeks with any drug", "Symptoms of a clinically relevant illness in the 3 weeks before the first study day", "History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs", "History of hypersensitivity to the trial drug or to drugs with a similar chemical structure"], "nct_id": "NCT00431665"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Complete the core study and consent for extension"], "exclusion": ["Patient unable to comply with core study requirements"], "nct_id": "NCT00770081"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["16 (8 males, 8 females) Type 1 diabetic patients aged 18-45 yr.", "HbA1c > 7.0%", "Had diabetes for 2-15 years", "No clinical evidence of diabetic tissue complications", "16 (8 males, 8 females) Healthy volunteers aged 18-45 yrs.", "Body mass index < 27kg \u00b7 m-2"], "exclusion": ["Prior or current history of poor health", "Abnormal results following blood and physical examination", "Pregnancy"], "nct_id": "NCT00608101"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["HIV infected", "Currently taking an anti-HIV drug regimen", "Insulin Resistant:fasting glucose between 5.56 and 7mmol/L and/or two hour post-glucose load between 7.78 and 11.11mmol/L"], "exclusion": ["Cancer", "Acute illness that would interfere with the study", "Hypogonadism", "Hypothyroidism", "Untreated hypertension", "CD4 count less than 300 cells/mm3", "Viral load greater than 35,000 copies/ml", "Untreated hepatitis C virus infection", "Pregnancy", "Diabetes"], "nct_id": "NCT00109746"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Overweight/obese men and women with type 2 diabetes mellitus that is managed with oral anti-hyperglycemic agent(s).", "Body mass index (BMI) 27 to 45 kg/m2, inclusive.", "Ability to complete a 1 year study"], "exclusion": ["Pregnancy", "Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months prior to screening", "History of symptomatic heart valve disease", "Serious or unstable current or past medical conditions"], "nct_id": "NCT00603291"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Males and females between the ages of 35-70.", "Good health as determined by past medical history,physical examination, vital signs, electrocardiogram and laboratory tests at the time of screening.", "Patients on diuretics or thyroid hormone therapy must be on a stable dose (at least 3 months prior to screening) and the maintenance dose may not be adjusted during the study."], "exclusion": ["Individuals with a body mass index less than 19 or greater than 40 kg/m^2, or a total weight > 130 kg, will be excluded from study.", "Subjects less than 35 years will not be studied in order to minimize the possibility of studying subjects with type 1 diabetes.", "No history of a) significant nephropathy, (i.e., plasma creatinine > 1.4 mg/dl in women and 1.5 mg/dl in men, and/or proteinuria); b) clinically significant atherosclerotic vascular disease (e.g., history of heart attack or angina); c) a known systemic illness.", "Pregnant or lactating females."], "nct_id": "NCT00364377"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Females Or Males Over 18 Years Old", "Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology", "Left Ventricular hypertrophy Demonstrated By Echocardiography", "Mild To Moderated hypercholesterolemia", "Willing To Participate And Sign The Informed Consent Form (ICF)"], "exclusion": ["Type 1 Or 2 Diabetes Mellitus", "Familiar hypercholesterolemia", "Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl", "History Of Myocardial Infarction Or Stable Chronic Angina", "Triglycerides >250 mg/dl"], "nct_id": "NCT00738972"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years of age and greater,", "Diabetes diagnosis (Type 1 and Type 2, awaiting a living or cadaveric renal transplant, renal transplant candidates admitted to MUSC medical center for a donor kidney, FBG >100 mg/dL per admission screening labs, random BG >120mg/dL per admission screening labs, and", "Willing and able to provide informed consent"], "exclusion": ["History of an active GI bleed in the previous 3 mos,", "Scheduled to receive a simultaneous pancreas transplant,", "History of a functioning pancreatic transplant,", "Patient currently managed on an insulin pump,", "Unable or unwilling to provide informed consent, and", "Unable to commit to the study protocol including the outpatient follow-up phase of care"], "nct_id": "NCT00609986"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any subject with coexisting kidney disease and type 1 or type 2 diabetes is eligible for the study, including: newly-diagnosed subjects, insulin na\u00efve and subjects who have received insulin or an insulin analogue before", "Subjects with kidney disease (stage I-IV) including transplant patients will be eligible for the study, if initiated with NovoRapid\u2122\""], "exclusion": ["Subjects who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit", "Subjects with stage V of chronic kidney disease", "Subjects who previously enrolled in this study", "Known or suspected allergy to trial product(s) or related products"], "nct_id": "NCT00849316"},{"minimum_age": 14.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Adolescent with thpe 1 diabetes", "Adolescents in the study must intend to remain in the care of participating clinics for the extent of the study", "Adolescents in the study must be literate in English."], "exclusion": ["Only one patient per family can participate", "Patients who participated in preliminary studies related to the development of the cell phone technology will be excluded."], "nct_id": "NCT00605839"},{"minimum_age": 35.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Subjects between the ages of 35 and 85 years", "Subjects with impaired glucose tolerance and type 2 diabetes, who had atherosclerosis detected by carotid ultrasound and/or CT", "Subjects who had vascular FDG uptake by FDG-PET"], "exclusion": ["Subjects with insulin treatment", "Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease", "Subjects taking more than three antidiabetic medications", "Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones (TZDs) within 8 weeks prior to randomization", "Subjects with cardiac failure (New York Heart Association Class > III) or left ventricular dysfunction (LVEF < 40%)", "Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease"], "nct_id": "NCT00722631"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Type 1 Diabetes Mellitus", "Normal lung function"], "exclusion": ["Smokers"], "nct_id": "NCT00143104"},{"minimum_age": 25.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Caucasian male", "Age: 25-55 years", "Chronic Hepatitis C (PCR positive) and fibrosis \u2264 F2 (if liver biopsy done)", "Genotypes 1 or 3", "Due to commence antiviral therapy", "BMI < 30"], "exclusion": ["Cirrhosis or F3 fibrosis on liver biopsy (if done)", "> 20 g ETOH per day", "Type 2 Diabetes (need an OGTT if fasting BGL> 5.7)", "Concurrent HIV", "Other cause of liver disease"], "nct_id": "NCT00707603"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Male and female adults with celiac disease (as demonstrated by duodenal/jejunal biopsy or by capsule endoscopy plus positive anti-tTG)", "Marsh score \u2265 II at screening", "Positive serum anti-tTG antibodies as determined by screening serology", "Willing to comply with a gluten-free diet for the duration of the study"], "exclusion": ["Has refractory Celiac Disease or severe complications of celiac disease (eg, EATL-, ulcerative jejunitis, perforation, etc.)", "Has chronic active GI disease other than Celiac Disease", "Has diabetes (Type 1 or Type 2) or other autoimmune disease that might interfere with the conduct of the study", "Has hemoglobin value below 8.5 g/dL"], "nct_id": "NCT00620451"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Subjects > 18 and < 60 years old.", "Patients with diabetes type 1 should fulfill the following criteria:", "ICT Insulin therapy was necessary within the first 3 months after diagnosis;", "HbA1c-Wert < 7%."], "exclusion": ["Diabetes type 1 or 2 (for the healthy group).", "Biochemical evidence of impaired hepatic or renal function.", "History of cardiovascular disease.", "Uncontrolled hypertension.", "Current inflammatory, malignant or psychiatric disease.", "Pregnancy"], "nct_id": "NCT00929812"},{"minimum_age": 16.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["16-50 years", "Biopsy proved HSP", "Proteinuria \u2265 3.0 g/24hr", "Scr < 5.0 mg/dl"], "exclusion": ["Cytotoxic drug treatment such as CTX, CsA, MMF for morn than 1 month-3 months prior to enrolled", "Pregnancy", "Active/serious infections", "Previous diagnosed diabetes mellitus type 1 or 2"], "nct_id": "NCT00301613"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["All subjects will be on stable doses of insulin using MDI or CSII (Basal insulin- Lantus or Levemir; Bolus- Humalog, Novolog, Apidra, Humulin Regular), for three months prior to enrollment.", "Type 1 diabetes duration > 3 years.", "6.5% \u2264 A1c \u2264 9.0%.", "Male or female \u2265 18 and \u2264 65 years of age.", "Ability and willingness to adhere to the protocol including multiple daily oral doses of study drug or placebo and week-long CGM wear.", "LDL-C > 100 mg/dl.", "Willing to adhere to colesevelam dosage instructions, including administration of drugs with a known interaction at least 4 hours prior to colesevelam. Females using oral contraceptives containing ethinyl estradiol and norethindrone must be willing to administer their doses at least four hours prior to using colesevelam."], "exclusion": ["Advanced retinopathy needing laser procedure or vitrectomy.", "Unstable nephropathy (serum creatinine > 2.0 mg/dl or macroproteinuria (albumin excretion rate > 200 ug/ min).", "Any unexplained severe hypoglycemia within the last six months.", "BMI > 35.0.", "Currently on a pre-existing bile acid sequestrant therapy, glyburide, levothyroxine, phenytoin, or warfarin.", "Pregnant, planning a pregnancy, or not using an adequate method of birth control.", "Any other condition, as determined by the investigator, which could make the subject unsuitable for the trial, impairs the subject's suitability for the trial, or impairs the validity of the informed consent.", "Use of any medication known to modify glucose values other than insulin (i.e. corticosteroids or oral antidiabetics).", "A history of bowel obstruction.", "Serum triglyceride (TG) concentrations >500 mg/dL.", "A history of hypertriglyceridemia induced pancreatitis."], "nct_id": "NCT00938405"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": ["Body Mass Index (BMI) > 25 kg/m\u00b2", "Visceral Fat Area (VFA) > 100 cm\u00b2", "Triglycerides (TG) > 150 mg/dL and < 700 mg/dL, and/or HDL-cholesterol < 40 mg/dL(Dyslipidemia)", "At least 1 criteria of the following 2 comorbidities:", "Impaired Glucose Tolerance or Type 2 diabetes", "Hypertension"], "exclusion": ["Patient with a secondary obesity.", "Patients who have received the diet therapy for less than 8 weeks before start of the observation period.", "Patients whose body weight changed by more than the variation of \u00b1 2kg for screening period.", "Low compliance to drug intake (< 80%) and dietary instruction during the observation period.", "Patients with type 1 diabetes.", "Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial combined hyperlipidemia and familial type III hyperlipidemia).", "Patients with a LDL-cholesterol > 190 mg/dL at any of Weeks -8 or -4.", "Patients with a secondary hypertension."], "nct_id": "NCT00434096"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female between 30 to 80 years of age, inclusive.", "Established diagnosis of T2DM (based on diagnostic criteria of the American Diabetes Association (ADA), WHO guidelines or local national guidelines).", "Subjects who are undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI.", "Subjects' prior anti-hyperglycemic diabetic therapy: Diet and exercise only (drug na\u00efve), with HbA1c >7.0 and \u00a3 10.0%. HbA1c > 6.5 and <= 8.5%.", "Left ventricular ejection fraction (EF) \u00b3 40% as assessed by contrast ventriculography (or previously documented in medical notes within one month prior to index procedure by other methods e.g. echocardiography or nuclear study)", "Female subjects must be postmenopausal (i.e., >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1a, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.", "Willingness and ability to give informed consent prior to entering the study and available to complete the study."], "exclusion": ["Type 1 diabetes and/or history of diabetic ketoacidosis.", "Exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit.", "Subjects treated with triple OAD therapy or high dose dual combination OAD therapy [1].", "Subjects who have required chronic insulin use in the last 6 months (except during pregnancy or acute episodes such as hospitalization, trauma or infection).", "ST segment elevation myocardial infarction in the last 30 days.", "Subjects who have a history or are scheduled to receive coronary artery bypass graft surgery (CABG), valve repair or replacement, aneurysmectomy or planned major non-cardiac surgery during the study period.", "Subjects who have severe cardiac valvular disease", "Stroke or resuscitated in the past 6 months", "History of congestive heart failure (NYHA class I", "IV)", "History of significant hypersensitivity or reaction (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to any TZD, SU, biguanide or insulin", "Prior history of severe edema or edema requiring medical treatment.", "Chronic disease requiring chronic or intermittent treatment with oral, intravenous, or injected corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).", "Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months.", "Untreated hypo- or hyperthyroidism", "A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer.", "Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude safe completion of the study.", "Blood pressure: SBP >170 or DBP > 100 mmHg", "Significant anemia (Hemoglobin < 11 g/dL for males and < 10 g/dL for females).", "Significant renal disease manifested by serum creatinine (> 1.5mg/dL for males or > 1.4mg/dL for females), or where the use of metformin is contra-indicated.", "Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 2.5 times upper limit of normal (ULN) or bilirubin >2x ULN).", "History of myopathy or history of elevated creatine kinase (CK) > 3 times upper normal limit.", "Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer).", "Women who are lactating, pregnant or planning to become pregnant during the course of the study.", "Unwillingness or inability to comply with the procedures described in this protocol."], "nct_id": "NCT00116831"},{"minimum_age": 40.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Females must be non-pregnant, non-lactating and post-menopausal.", "A glycosylated hemoglobin level greater than 7.5% and less than 10%.", "Has an age of onset of Type 2 Diabetes greater than 35 years of age.", "Is on metformin monotherapy up to the maximum tolerated daily dose.", "Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.", "Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.", "Has one or more cardiovascular comorbidities as follows:", "stable angina pectoris", "previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography", "peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.", "and/or two or more of the following major cardiovascular risk factors:", "hypertension (blood pressure >130/80 mmHg or treatment)", "dyslipidemia (low-density lipoprotein-cholesterol >100 mg/dl or treatment and/or high-density lipoprotein-cholesterol <40 mg/dl in men and <45 mg/dl in women or treatment)", "smoking (>10 cigarettes/day)"], "exclusion": ["Has Type 1 Diabetes.", "Is on insulin therapy.", "Is severely obese defined as a body mass index greater than or equal to 40mg/m2", "Has diabetic retinopathy.", "Has evidence of hepatic dysfunction including liver transaminase greater than three times the upper limit of normal.", "Is unable to remain on a stable dose of the following class of medications 30 days prior to randomization and throughout the six months of the study:", "antihypertensives", "statins", "other hypolipidemic and antiplatelet drugs", "Has a history of alcohol or other drug abuse.", "Has had a new diagnosis of cancer or recurrent cancer within five years of screening.", "Has a need for chronic (greater than two weeks) immunosuppressive therapy.", "Has had heart failure based on the New York Heart Association Functional Class I through IV.", "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:", "Other antidiabetic drugs (except metformin)", "Fibrates", "Rifampicin", "Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents", "Other drugs that are highly protein bound, including:", "sulphonamides", "chloramphenicol", "probenecid", "monoamine oxidase inhibitors", "fluoroquinolones antibiotics", "oral miconazole", "Has participated in another clinical study within the past three months."], "nct_id": "NCT00770835"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["T2DM according to WHO criteria", "Written consent", "Age > 18 years"], "exclusion": ["Kidney or hepatic disease", "Treatment with insulin or glitazone"], "nct_id": "NCT00862589"},{"minimum_age": 40.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Men or women aged from 40 to 79 years", "Patients with pre-existing T2DM", "HbA1C <9%", "Written informed consent"], "exclusion": ["unable to comply with the protocol, Likely to leave the trial before completion", "having participated in an another trial 3\u00e0 days before V1", "Pregnant or childbearing potential not using birth control method", "Type 1 diabetic patients, T2Dm insulin therapy Patients with one of the following pathology:", "with muscular disorders known or increase CK , or hepatic deficiency or transaminase increase", "with symptomatic gall-bladder disease or/and renal insufficiency", "with abnormal thyroid function", "with proliferative retinopathy", "with recent cardiovascular event, uncontrolled hypertension", "with known chronic alcohol intake", "with other severe pathology", "with TC>= 7.0 mmol/L and/or TG>= 4mmol/L at V1", "Patients treated with Warfarin", "Patients with specific ECG dysfunction"], "nct_id": "NCT00703482"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Informed consent signed before any study activities.", "Age of 18 years old or above.", "A body mass index (BMI) within the limits of 18.5 to 24.9 (normal range)."], "exclusion": ["Any clinical signs of acute or chronic inflammation detectable during study visit 1.", "Severe acute or chronic diseases (e.g. acute respiratory tract infection, systemic lupus erythematosus, rheumatoid arthritis).", "Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.", "Use of any vasoactive substances (e.g. anti-hypertensive drugs), immune-suppressant or anti-inflammatory drugs (e.g. corticosteroids, aspirin, other COX2 inhibitors) or anti-coagulation treatment.", "Diseases of the skin which could interfere with catheter insertion in the abdominal wall.", "Pregnancy in women subjects."], "nct_id": "NCT00708266"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Overweight individuals (with a BMI of \u2265 25 kg/m2)", "Between the ages of 30 and 70 years"], "exclusion": ["Concurrent documented cardiac, or renal disease as recorded by history of myocardial infarction or abnormal creatinine", "History of known food allergy and/or dietary restriction", "Diabetes requiring insulin", "Pregnancy", "Diarrhea defined as watery stools more than 3 times a day for more than 3 days"], "nct_id": "NCT00737815"},{"minimum_age": 18.0, "maximum_age": 64.0, "gender": "A", "inclusion": ["BMI of 30", "40kg/m", "Females may be included if they are surgically sterile or post-menopausal"], "exclusion": ["Change in body weight >4% in the last 3 months", "History of eating disorders", "had bariatric surgical intervention for obesity", "have type I or II diabetes", "Thyroid disorder not under control", "Renal or hepatobiliary disease", "Excessive alcohol consumption", "Use of drugs of abuse", "donated of blood in the last 3 months"], "nct_id": "NCT00494767"},{"minimum_age": 21.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetic for at least 6 months.", "Healthy volunteers.", "Type 2 diabetic subjects will have some nominal ability to secrete endogenous insulin as demonstrated by a post-stimulation C-peptide concentration of at least 6 ng/ml.", "All subjects will be mentally fit to give informed consent.", "Hemoglobin A1C value below 11% (normal range = 4.4-5.8%) prior to study enrollment."], "exclusion": ["Hemoglobin A1c values > 11%", "Severe cardiovascular, hepatic, or renal disease", "Past current history of drug or alcohol abuse", "Diabetic gastroparesis", "Uncontrolled hypertension ( > 140-90 mmHg)", "Marked hyperlipidemia (serum LDL > 158mg/dl, or serum TG >691 mg/dl)", "Medications that interfere with glucose homeostasis", "Coumadin or other anticoagulation medications", "History of thrombosis or thrombophlebitis", "Current malignancy", "Smoker", "Pregnancy", "Contact precautions"], "nct_id": "NCT00508599"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Regardless of whether they are currently receiving antihypertensive therapy, systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg.", "Whether or not use oral hypoglycemic agents or insulin injections, the fasting plasma is higher than 7.0 mmol/L, or postprandial blood glucose higher than 11.1 mmol/L."], "exclusion": ["With life-threatening disease.", "With the various effects of metabolic diseases such as hyperthyroidism, hypothyroidism, etc.", "Stroke, myocardial infarction and other serious cardiovascular and cerebrovascular diseases occurred within 3 months.", "Serum creatinine level higher than 176.8 mmol/L", "Dementia or severe cognitive decline", "Unable to do a long-term follow-up or do not agree to participate in this trial."], "nct_id": "NCT00968786"},{"minimum_age": 35.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["overweight or obese (BMI between 25 and 40 kg /m2)", "waist circumference above 88 cm for women and 102 cm for men", "fasting plasma insulin above 90 pmol/L", "fasting plasma glucose below 7.0 mmol/L and 2-h plasma glucose below 11.1 mmol/L"], "exclusion": ["Individuals with diagnosed diabetes or any chronic, metabolic or acute disease", "Individuals who had a major surgery within the last 3 months", "Individuals who had a significant weight loss (\u00b110%) within the last 6 months", "Individuals taking any medication known to affect lipid or glucose metabolism", "Subjects with dietary incompatibility with fish consumption (allergy, intolerance or dislike) and/or calcium supplementation", "Smokers"], "nct_id": "NCT00400036"},{"minimum_age": 20.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Age between 20 and 50 y", "BMI 25.0-29.9 kg/m2", "Normal fasting glucose <6.1 mmol/L", "Blood pressure (systolic blood pressure 100-150 mmHg, diastolic blood pressure 60-90 mmHg)", "Weight stable in last 3 months (\u00b12 kg)"], "exclusion": ["pregnant, lactating or (post)menopausal women", "regular smokers", "people with intensive fitness training eg athletes", "habitual consumption of green or black tea (more than 1 or 2 cups a day, respectively)", "not more than 300 mg/day caffeine consumption"], "nct_id": "NCT00867555"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["known T2DM,", "over 18 years old,", "known hypertension with a systolic BP (SBP) between 130-170 mm Hg at the previous visit to the internal outpatient department and at the last visit to the internist (which is the same day as baseline measurement) and treated with one or more anti-hypertensive drugs, which have not been changed for the preceding three months. At baseline the SBP should be between 140-160 mm Hg, measured by the investigator."], "exclusion": ["patients with orthostatic hypotension,", "known heart failure (NYHA III-IV) and/or patients with pulmonary disease (for example asthma, chronic obstructive pulmonary disease and pulmonary fibrosis),", "patients with insufficient knowledge of the Dutch language to understand the requirements of the study,", "additional criteria were hospitalization in the past 3 months, deafness, blindness and cognitive abilities deemed insufficient for operation of a study device."], "nct_id": "NCT00951119"},{"minimum_age": 30.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["30-55 years of age", "Diabetic being treated with diet and any of the following: insulin, or other diabetic specific drug such as metformin, sulfonylurea or sitagliptin.", "Healthy subjects age and gender matched to diabetes patient"], "exclusion": ["Use of any anti-inflammatory or antioxidant medications other than small daily doses of Aspirin (ASA:325 mg) and a daily multivitamin", "Co-existing chronic inflammatory conditions such as Crohn's disease, rheumatoid arthritis, chronic or acute infections", "Any concurrent neurological disease except for mild diabetic autonomic or peripheral neuropathy", "Postmeal C peptide > 0.3 mg/dl", "Normal healthy subjects who have any abnormal inflammatory marker, hyperlipidemia, or concurrent disease", "Diseases associated with abnormal glutathione metabolism", "Elevated serum creatinine levels, abnormal complete blood count (CBC), abnormal liver function tests or elevated serum homocysteine", "Morbid obesity", "History of hypoglycemic unawareness", "Pregnant women and women who are breastfeeding", "Patients with poor venous access", "Smokers", "Subject who consumes an excess of alcohol or abuses drugs", "History or or presence of bleeding disorder or use of anticoagulant drug", "History of oxalate renal calculi"], "nct_id": "NCT00845130"},{"minimum_age": 34.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["type II", "fluoroscopy in carotid once a year during 2 years"], "exclusion": ["type 1 diabetes", "history or clinical evidence of coronary artery disease or cerebral or peripheral vascular disease", "the presence of albuminuria (defined as 24 hour urine albumin excretion \u2265 30 mg)", "renal dysfunction (defined as creatinine blood level \u2265 2.0 mg/dL)", "hepatic dysfunction (defined as alanine aminotransferase and/or aspartate aminotransferase blood level \u2265 3 \u00d7 upper normal limit)", "smoking within the past 3 months prior to commencement of the study", "use of any medication likely to alter IMT such as calcium channel blocker, thiazolidinedione, antiplatelet agent (clopidogrel, cilostazol)", "use of glucocorticoid", "pregnancy", "severe concomitant disease such as cancer", "infection", "Cushing's syndrome", "acromegaly, or any other disorder likely to alter glycemia", "primary hypercholesterolemia", "hypothyroidism or hyperthyroidism", "use of any hormonal drugs", "alcoholism or drug abuse"], "nct_id": "NCT00842972"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Must have been randomized within the previous topiramate obesity and diabetes studies: PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study", "Must consent to participate and use data from previous clinical trials in connection with results from the genetic analyses"], "exclusion": ["Patients who received a blood transfusion within 60 days before collecting DNA samples"], "nct_id": "NCT00304603"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Is male or female >= 18 and <= 70 years of age", "Has a documented history of type 2 diabetes mellitus for a minimum of four months prior to the screening visit", "Has a documented history of or current presentation with Stage 1 or Stage 2 hypertension and meets one of the following criteria:", "Has controlled hypertension (sSBP <130 mmHg AND sDBP <80 mmHg) on >=2 antihypertensive medications NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications OR", "Has uncontrolled hypertension (sSBP >=130 and <=170 mmHg AND/OR sDBP >=80 and <=105 mmHg) on one or two antihypertensive medications OR", "Has newly diagnosed or previously untreated hypertension (sSBP >=130 and <=170 mmHg AND/OR sDBP >=80 and <=105 mmHg", "At Randomization, sitting systolic blood pressure (sSBP) >= 130 mmHg or sitting diastolic blood pressure (sDBP) >= 80 mmHg and sSBP <= 170 mmHg and sDBP <= 105 mmHg", "Has been on a stable dose of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) for a minimum of four months prior to the screening visit"], "exclusion": ["Has any clinically significant abnormality identified in the screening physical examination, laboratory tests or electrocardiogram which, in the judgement of the investigator, would preclude safe completion of the study", "Is female of childbearing potential", "Has any of these cardiac conditions: uncontrollable or symptomatic arrhythmias, unstable angina, sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker), bradycardia (heart rate <55 bpm), and stroke within three months of study screening, and history of myocardial infarction.", "Has Congestive Heart Failure NYHA (New York Heart Association) class II-IV", "Has type 1 diabetes mellitus", "Has newly diagnosed type 2 diabetes (within 4 months of screening visit)", "Has HbA1c > 8.5%", "Has the following, as it relates to subject's antidiabetic therapy:Initiated or changed dosage or formulation of thiazolidinediones (TZDs) within 6 months of screening visit.", "A history of acute or chronic acidosis, including diabetic ketoacidosis", "Has current clinical diagnosis of chronic obstructive pulmonary disease (COPD, e.g., chronic bronchitis) or asthma", "Has a history of bronchospastic disease not undergoing active therapy in whom, in the investigator's opinion, treatment with study medication could provoke bronchospasm", "Has evidence of any of the following clinically significant diseases that could impair the absorption, metabolism, or excretion of orally-administered medication:", "renal disease defined as estimated Glomerular Filtration Rate (eGFR) <60mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula below: GFR (mL/min/1.73m2) = 186 x [Serum Creatinine (umol/L) x 0.0113]-1.154 x Age(years)-0.203 (x 0.742 if female)", "hepatic disease (i.e., ALT or AST levels greater than three times the upper limit of normal range, history of hepatic impairment, or by clinical assessment)", "Chronic biliary disorders", "Has endocrine disorders (e.g., pheochromocytoma, active and untreated hypo or hyperthyroidism)", "Has any known contraindication to ACE inhibitors, alpha- or beta-blocker treatment", "Has systemic disease, including cancer, with reduced (<12 months) life expectancy", "Has used an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication", "Has a history of a psychological illness or any condition that would interfere with the subject's ability to understand or complete the requirements of the study"], "nct_id": "NCT00430040"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": [": To be eligible to enroll and remain in the study, patients must meet the following criteria:", "Be at least 21 years old.", "Have type I or type II diabetes mellitus and require oral anti-hyperglycemic agents or insulin.", "Have peripheral neuropathy related to diabetes."], "exclusion": ["Patients are to be excluded from the trial if any of the following conditions are met:", "Have a history of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.", "Be unable to meet study requirements, including approximately 7-9 out-patient visits over a 12 month period."], "nct_id": "NCT00056290"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["type 1 diabetes", "age 18-80 years", "microalbuminuria"], "exclusion": ["blood pressure> 160/100 mmHg", "persistent macroalbuminuria", "pregnancy or in risc of this", "P-Potassium>5.7 mmol/l", "Eplerone treatment"], "nct_id": "NCT00843388"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["GDM in last pregnancy", "BMI 30-40", "Age 18-40", "1-5 years since last pregnancy", "Non-smoking", "English or Spanish speaking", "Planning to have a baby but willing to use birth control during the 3 month weight loss program"], "exclusion": ["3 or more miscarriages", "History of infertility", "Type 1 or Type 2 diabetes", "Any weight loss since last pregnancy (based on last pre-pregnancy weight)", "History of major psychiatric illness, drug abuse, or unsafe dieting practices", "History of bariatric surgery, major medical conditions that prohibit physical activity or dietary intervention (MD consent may be required)"], "nct_id": "NCT00924599"},{"minimum_age": 18.0, "maximum_age": 39.0, "gender": "F", "inclusion": ["18", "39 years, inclusive", "30 \u2264 BMI", "History of irregular menstrual cycles", "Clinical and/or biochemical androgen excess (determined during screening)"], "exclusion": [": Medical Exclusion Criteria", "History or clinical manifestation of; cardiovascular disease, diabetes (Type 1 or Type 2), any other significant endocrine or metabolic disorder.", "Regular use of medications for weight control, psychosis and thyroid disease. A 3 month washout period will be permitted for contraceptives. Psychiatric and Behavioral Exclusion Criteria", "Pregnant or breast-feeding women"], "nct_id": "NCT00921492"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Age < 75 years, regardless of sex;", "Final diagnosis of type 2 diabetes;", "Plasma glucose is under control (fasting plasma glucose<10mmol/L, glycosylated hemoglobin<8.0%) with oral glucose-lowering agents (confine to Repaglinide, \u03b1-glycosidase inhibitors, Gliquidone) and /or insulin;", "Even through RAS blocker (ACEI/ARB) is administrated at a fixed dose (the same as the starting dose, refer to appendix 4) for more than 6 weeks, blood pressure is still \u2264 160/90 mmHg;", "Patient is without dialysis and GFR is <60ml/min/1.73m2;", "Overt proteinuria is present two times within 2 weeks (urine albumin > 300mg/d in a 24-h collection)"], "exclusion": ["Diabetic ketoacidosis within the last 6 months;", "Incapable of following study requirements to control diet;", "Glomerular filtration rate < 15 ml/min/1.73m2;", "Hypercalcemia or hyperkalemia (> normal upper limit);", "Other serious disease within the last 3 months;", "With obvious symptoms or signs of liver diseases, ALT or AST > two times normal upper limit;", "Severe edema or serous cavity effusion;", "Drug abuse", "Final diagnosis of malignant tumor;", "Receiving the long-term systematic steroid hormone treatment;", "Gestation already, prepares to be pregnant in the period of the trial, lactating women;", "Participate in other product clinical trial within 30 days prior to this trial."], "nct_id": "NCT00363987"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT", "Fasting triglyceride levels >140 and < 400 mg/dl and values varying less than 35% between two screening measurements", "Normal liver function tests and white blood cell count"], "exclusion": ["Type 2 Diabetes for > 3 years or HbA1c \u2265 7.5", "Known or suspected Type 1 Diabetes", "Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin", "Creatinine > 2.0 mg/dl or other evidence of active kidney disease", "Hepatic enzyme elevation > 2x normal", "Known Nonalcoholic Fatty Liver Disease", "Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems", "Recent history of nausea or vomiting", "Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks", "A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months", "Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (>1 g/day)", "Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation."], "nct_id": "NCT00974272"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "F", "inclusion": ["Healthy women using or not contraceptive agents or hormone supplementation", "For pre-menopausal women: regular menstrual cycle for the last 3 months (25- 35 days)", "LDL-Cholesterol concentration between 2.5 and 4.0 mmol/L", "Stable body weight (+/- 2 kg) for 6 months before the beginning of the study", "Smoking or not"], "exclusion": ["Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia", "Subjects taking medications for hyperlipidemia or hypertension", "Endocrine disorders", "Body mass index > 35 kg/m2", "Food allergies", "Women with extreme nutritional habits such as vegetarism or alcohol consumption > 2 drinks/day", "Elite athletes"], "nct_id": "NCT00930137"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Informed consent obtained before any trial-related activities", "Subjects diagnosed with type 1 or type 2 diabetes. If type 2 diabetics, treatment with or without oral anti diabetic medication is allowed", "Current users of vial/syringe (pen na\u00efve) treated with short-acting insulin (insulin aspart, glulisine or lispro) and once daily long-acting insulin (detemir or glargine) or once daily long-acting insulin (detemir or glargine) alone", "Treatment with insulin (i.e. aspart, glulisine, lispro, detemir or glargine) for at least 6 months", "Body Mass Index (BMI) less than 45.0 kg/m^2", "HbA1c less than or equal to 9.0% at screening visit based on analysis from central laboratory", "Able and willing to adhere to the trial-specific insulin regimen for the entire trial period"], "exclusion": ["Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or inadequate contraceptive techniques during the trial period (adequate contraceptive measures are considered as intrauterine device, oral contraceptives and barrier methods)", "Previous participation in this trial (screening visit)", "Systemic drugs that may influence glycaemic control (e.g., corticosteroids)", "Known or suspected allergy to trial product(s) or related products", "Known or suspected abuse of alcohol or drug abuse", "Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation", "Previous treatment with sitagliptin", "Clinically significant, active (or over the past 12 months) disease of the gastrointestinal, neurological, genitourinary, or haematological systems", "Cardiac disease defined as: Decompensated heart failure (New York Heart class III or IV, unstable angina pectoris within the past 6 months of study enrolment, myocardial infarction within the past 12 months and a clinically significant history of arrhythmias or conduction delays on electrocardiogram (ECG) over the past 12 months", "Any other severe acute or chronic illness as judged by the Investigator", "Recurrent major hypoglycaemia (defined as severe central nervous system dysfunction associated with hypoglycaemia, requiring the assistance of another person) or hypoglycaemia unawareness (defined as a condition in which subjects no longer experience the usual warning signs of hypoglycaemia; the symptoms of hypoglycaemia may be different, less pronounced or even absent) or hospitalisation for diabetic ketoacidosis during the previous six months", "Any other conditions that the Investigator judges would interfere with trial participation or evaluation of results (i.e. planned any diagnostic or therapeutic medical intervention such as surgery)", "Participated in another clinical trial and received an investigational drug within the last 4 weeks"], "nct_id": "NCT00773279"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients >18 years old.", "Severe GH deficiency as diagnosed by an inadequate GH stimulation in three different tests:", "peak response < 3 \u00b5g/l during an insulin tolerance test;", "< 3 \u00b5g/l during glucagon test;", "< 9 \u00b5g/l during GHRH-arginine stimulation test)."], "exclusion": ["GH replacement therapy prior to inclusion.", "History of diabetes Type 1 or 2.", "Biochemical evidence of impaired hepatic or renal function.", "History of cardiovascular disease.", "Uncontrolled hypertension.", "Current inflammatory or malignant disease.", "Pregnancy."], "nct_id": "NCT00929799"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years", "Presence of GAD65 antibodies", "Detectable C-peptide level", "Patients requiring treatment with diet and/or oral hypoglycaemic agents (OHA)", "Written informed Consent Key"], "exclusion": ["Treatment with insulin", "Intolerance to OHA", "Secondary diabetes mellitus", "History of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, HIV, hepatitis)", "Treatment with any vaccine within one month prior to first Diamyd\u00ae dose or planned treatment with vaccine up to 2 months after the second Diamyd\u00ae dose", "Participation in other clinical trials with a new chemical entity within the previous 3 months", "Pregnancy (or planned pregnancy within one year after 2nd administration)", "Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study", "Significant illness other than diabetes within 2 weeks prior to first dosing", "Unwillingness to comply with the provisions of the protocol", "Clinically significant history of acute reaction to drugs in the past", "Treatment with immunosuppressants"], "nct_id": "NCT00456027"},{"minimum_age": 35.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Patients with clinical Diagnosis of Type 2 diabetes requiring only behavioral or lifestyle intervention.", "Fasting blood glucose in the range of 110-180 mg/dl", "Age range", "35 to 60 years", "Willing to participate in the study and perform all measurements"], "exclusion": ["Presence of any chronic disease or organ failure", "Concurrent use of medication to control blood glucose levels"], "nct_id": "NCT00502008"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Male or female aged 18-35 years (both inclusive) (young group) or at least 65 years (geriatric group)", "Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months", "Body mass index 18.0-28.0 kg/m^2 (both inclusive)"], "exclusion": ["Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening", "Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)", "Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period"], "nct_id": "NCT00964418"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "F", "inclusion": ["Overweight/obese women with PCOS as per 1990 NIH criteria (see below)", "Non-smokers", "Age>18 years, premenopausal", "Acceptable to have/be on treatment for type 2 diabetes mellitus and/or dyslipidaemia", "Acceptable to be taking the oral contraceptive pill"], "exclusion": ["Uncontrolled hypertension (BP>160/100mmHg)", "Known co-morbidities including liver or renal disease", "Already taking fish oil supplements", "Other intercurrent illness (major surgery, CV event)", "Smokers", "Alcohol intake >20g/day", "Pregnancy", "Any metallic implant (contraindication for MRI)."], "nct_id": "NCT00620529"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["must have Type 1 diabetes mellitus for more than 5 years", "diabetes must be complicated by at least one of the following situations that persist despite intensive insulin management efforts. The complicating situations are (1) Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels of < 3.0 mmol/L; (2) Metabolic lability/instability, characterized by MAGE \u2265 11.0 mmol/L and wide swings in blood glucose despite optimal diabetes therapy; and (3) Despite efforts at optimal glucose control, progressive secondary complications of diabetes, including retinopathy, neuropathy, or nephropathy"], "exclusion": ["Severe co-existing cardiac disease", "Active alcohol or substance abuse", "Psychiatric disorder making the subject not a suitable candidate for transplantation", "Active infection including hepatitis C, hepatitis B, HIV, or TB", "Any history of or current malignancies except squamous or basal skin cancer", "BMI > 28 kg/m2 or body weight > 85 kg at screening visit", "Positive fasting C-peptide response on assessment (2 positive results)", "Creatinine clearance < 80 mL/min/1.73 m2", "Serum creatinine > 150 \u00b5mol/L", "Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h)", "Baseline Hb < 105g/L in women, or < 130 g/L in men", "Baseline LFT's outside of normal range", "Untreated proliferative retinopathy", "Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding", "Previous transplant, or evidence of sensitization on PRA", "Insulin requirement > 1.0 IU/kg/day", "HbA1C > 0.12", "Hyperlipidemia (fasting LDL cholesterol > 3.4 mmol/L, treated or untreated; and/or fasting triglycerides > 2.3 mmol/L)", "Under treatment for a medical condition requiring chronic use of steroids", "Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5", "Untreated Addison's disease", "Untreated Celiac disease", "Untreated thyroid disease"], "nct_id": "NCT00175266"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["American Indian women", "Aged 18-40 years", "Living in Albuquerque area", "Not having diabetes"], "exclusion": ["Pregnancy", "Planning to become pregnant within 2 years", "Diagnosed with diabetes fasting blood glucose > 126 planning to move out of town in next 2 years"], "nct_id": "NCT00438126"},{"minimum_age": 6.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Type 1 Diabetes Mellitus six years of age and older who are receiving care in the diabetic clinic at Children's Mercy Hospital"], "exclusion": ["T1 Diabetes Mellitus patients not receiving care in the diabetes clinic at Children's Mercy Hospital or not meeting the age requirements"], "nct_id": "NCT00450489"},{"minimum_age": 11.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Patients 11-17 years of age who are seen in the Insulin Resistance Clinic for the first time", "Historical control: Patients 11-19 years of age seen in the Insulin Resistance Clinic during the prior four months"], "exclusion": ["Co-morbid syndrome (Downs, Turner's, Prader Willi etc)", "Diagnosis of Type 2 Diabetes", "Taking Metformin before the initial visit", "Taking medication for or diagnosis of a psychiatric condition prior to initial visit", "Developmentally delayed"], "nct_id": "NCT00493259"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Males and females (ages 18-75 years)", "Type II DM treated with oral anti-diabetic medication (sulfonylurea, metformin, glitazones, or combination therapy)", "Must have been following a restrictive diet", "Diagnosis of combined dyslipidemia"], "exclusion": ["Homozygous familial hypercholesterolemia", "Conditions which may cause secondary dyslipidemia", "Uncontrolled diabetes mellitus", "Abnormal pancreatic, liver, or renal function", "Abnormal serum creatine kinase (CK) above the pre-specified level", "Significant heart disease"], "nct_id": "NCT00309751"},{"minimum_age": 10.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Good general health", "Aged 10 to 18 yrs (females: Tanner stage II-V;and males:testes size>6ml)", "IGT based on 2-hr plasma glucose>140mg/dl and <200mg/dl during an OGTT."], "exclusion": ["Baseline creatinine>1.0mg", "AST and ALT>2.5 ULN", "Anemia (Hct<30)", "Pregnancy (females must have a negative urine pregnancy test during the study)", "Cardiac or pulmonary or other significant chronic illness", "Plans to increase the frequency or intensity of a regular exercise program", "Psychiatric disorder or substance abuse of anorexic agents."], "nct_id": "NCT00413335"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["diabetes (Type I or Type II)", "enrolled in health plan with participating employer", "age 18 or older", "willing and able to provide informed consent"], "exclusion": ["gestational diabetes"], "nct_id": "NCT00254501"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "M", "inclusion": ["Type 1 diabetic patients;", "Diabetes duration =/> 1 year;", "HbA1c ~ 7,5%;"], "exclusion": ["Recent onset of DM;", "BMI < 18 OR > 35 kg/m2;", "T2DM;", "History of major heart/renal disease;", "Severe untreated proliferative retinopathy;", "History of recurrent severe hypoglycaemia;", "(History of) brain disorders;", "Alcohol abuse,(History of) drug abuse, benzodiazepines, selective beta-blockers, oral steroids, oral anticoagulants;", "Current psychiatric disease/treatment;", "(history of) eating disorders;", "History of severe head trauma accompanied by loss of consciousness;", "Any endocrine disease not well controlled for at least 3 months;", "Inability to undergo MRI;", "Visual acuity < 0.3;", "Known or suspected allergy to trial product or related products"], "nct_id": "NCT00626080"},{"minimum_age": null, "maximum_age": 85.0, "gender": "F", "inclusion": ["Postmenopausal women to age 85, inclusive", "Finish treatment of 12 months or longer with Forteo", "Signed informed consent prior to initiation of any study-mandated procedure."], "exclusion": ["Hip and spine DXA T-score >-1.0", "Patients with 25-(OH) vitamin D levels less than 15 ng/mL at Visit", "(Patient can be repleted with vitamin D 50,000 units biweekly for up to 2 months and re-screened anytime during the 2 months while continuing Forteo.)", "Baseline renal insufficiency (calculated creatinine clearance less than 40.0 mL/min (MDRD) at Visit 1 and/or Visit 2 or urine dipstick greater than or equal to 2+ protein without evidence of contamination or bacteriuria (may be repeated one time at least a week apart if there is suspicion of contamination). Patients with calculated creatinine clearance equal to or greater than 40.0 mL/min and less than 60.0 mL/min or serum creatinine greater than the upper limit of normal at Visit 1 must be retested between Visit 1 and", "Patients with calculated creatinine clearance greater than 60.0 mL/min and serum creatinine within normal limits at Visit 1 do not require re-test.", "Patients who require re-test of creatinine clearance between Visit 1 and 2 will be excluded if there is an increase in serum creatinine greater than 0.5 mg/dL between Visit 1 and Visit 2.", "Serum calcium <8.5 or >11.0 mg/dl at Visit 1", "AST or ALT greater than twice the upper limit of normal", "Serum alkaline phosphatase greater than 1.5 times the upper limit of normal (liver fraction)", "No history of retinopathy or nephropathy especially in the presence of uncontrollable IDDM with Hb1 AC > 10%", "Hypersensitivity to bisphosphonates", "Treatment with biphosphonates while on Forteo", "Prior treatment with i.v. biphosphonates", "Estrogen, calcitonin, raloxifene use prior to Forteo treatment are not exclusions, but concomitant therapy during with any bone agents during the trial will not be permitted", "Any prior use of strontium ranelate or sodium fluoride", "Chronic use of systemic corticosteroids (oral or i.v.) within the last year: NOTE: Use of corticosteroids in forms such as topical creams, nasal or inhaled formulations or those injected locally (intra-articularly) are NOT exclusionary.", "Prior exposure to anabolic steroids or growth hormone within 6 months prior to randomization", "Treatment with any investigational drug(s) and/or devices within 30 days prior to randomization.", "History of iritis or uveitis, except when secondary to trauma, and must have resolved for more than 2 years prior to randomization.", "Cancer exclusions:", "Patients with a new diagnosis or active treatment for any malignancy less than or equal to 12 months prior to Visit 1.", "Patients with evidence of any metastases on or prior to randomization, or with a history of metastases", "Subjects with evidence of paraneoplastic syndrome, especially those characterized by hypercalcemia during screening or by history", "Patients with the following may be included: basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, and Carcinoma in-situ (CIS) of the prostate (Stage I only) that has been surgically removed.", "Previous major solid organ or bone marrow transplant recipient or on a transplant waiting list", "Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA (L1-L4) e.g., implantable devices, scoliosis, ankylosing spondylitis, DJD. (Less than two lumbar spine vertebral bodies evaluable)", "Active primary hyperparathyroidism or hypoparathyroidism", "Subject with complete thyroidectomy", "Active hyperthyroidism", "Hypothyroidism not treated with adequate replacement therapy", "History of multiple myeloma or Paget's disease", "Patients with severe dental problems or current dental infections, or with recent or impending dental surgery within three months of dosing", "Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol"], "nct_id": "NCT00361595"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Clinical diagnosis of type 1 diabetes for at least 1 year", "Nonsmokers for prior 6 months", "BMI less than or equal to 35kg/m2", "HbA1c > or = 7% and < or = 11%", "Serum creatinine < or = 1.8 mg/dL in female subjects and < or = 2.0 mg/dL in male subjects", "FEV1 > or = 70% of predicted, DLco > or = 70% , TLC > or = 80% predicted", "Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day", "Urine cotinine < or = 100 ng/mL"], "exclusion": ["History of chronic obstructive pulmonary disease, asthma, any other clinically significant pulmonary disease confirmed by documented history, pulmonary function testing or radiologic findings", "Evidence of severe complications of diabetes", "Aminotransferase and/or alanine aminotransferase > than 3 times the upper limit of normal"], "nct_id": "NCT00308308"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide (a basal level of </= 0.2 ng/ml before IV administration of 1 mg of glucagon, and a glucagon stimulated C-peptide </= 0.8 ng/ml) and diagnosis of diabetes for at least 5 years.", "Recipient of renal transplant with good function (serum creatinine </= 1.6 mg/dl, creatinine clearance >/=60 ml/min and albumin excretion </= 300 mg/24 hr) for >3 months.", "Stable immunosuppression consisting of any combination of sirolimus, tacrolimus, MMF or </= 5 mg/day of corticosteroids for at least 3 months, without major complications.", "No history of acute rejection episodes related to renal graft in last 12 months and low risk for developing acute rejection (first renal transplant, PRA <25%, negative kidney crossmatch by B, T, flow cytometry)", "Under the continuing care of a renal transplant nephrologist/surgeon.", "No evidence of liver disease (liver enzymes < twice the upper limit of normal for each of ALT and AST, bilirubin < 2 mg/dl, albumin > 3.5 g/dl, and PT and PTT </= 1.1 x the upper limit of normal).", "Ability to comply with post-transplant regimen, including immunosuppression, insulin pump therapy and metabolic testing. Patients will be required to perform self-monitoring of blood glucose a minimum of four times daily, and provide complete records of blood glucose levels and insulin doses.", "Ability to give informed consent.", "Age greater than or equal to 18 years or less than or equal to 65 years.", "Subjects that have always been managed on a sirolimus/tacrolimus/MMF/low-dose corticosteroid (</=5mg) immunosuppressive regimen and never required conversion must provide a signed letter from their transplant nephrologist /surgeon documenting this.", "Subjects converted to a sirolimus/tacrolimus/MMF/low-dose corticosteroid immunosuppressive regimen, must provide proof of informed consent regarding immunosuppressive conversion in one of the following formats.", "Subjects that converted to sirolimus/tacrolimus/MMF/low-dose corticosteroids (</=5mg) due to best patient care (not to qualify for islet transplantation) must provide a signed letter from their transplant nephrologists/surgeon indicating the medical reason(s) for immunosuppression conversion (with the date indicated).", "Subjects that converted to a sirolimus/tacrolimus/MMF/low-dose corticosteroid (</=5mg) immunosuppressive regimen for the purpose of qualifying for islet transplantation must provide a signed immunosuppression conversion consent form."], "exclusion": ["Poor renal allograft function (serum creatinine > 1.6 mg/dl, creatinine clearance < 60ml/min, albumin excretion >300 mg/24hr)", "History of acute rejection related to renal graft in last 12 months or \"high risk\" for acute rejection (more than one previous renal transplant, PRA >25%, positive kidney crossmatch by B, T, flow cytometry)", "Current immunosuppression therapy with corticosteroids >5mg/day.", "Significant liver disease (including elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST, bilirubin > 2 mg/dl, albumin < 3.5 g/dl, liver masses including portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e., gallstones).", "Significant cardiovascular disease, including non-correctable coronary artery disease with ejection fraction < 50% and/or recent myocardial infarction (within last 12 months); extensive peripheral vascular disease not correctable by surgery or untreated proliferative retinopathy.", "Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB.", "Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix.", "Recent history of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy.", "Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment.", "Presence of preformed antibodies on panel reactive antibody screening > 25%.", "Body mass index (BMI) greater than 30.", "Age less than 18 years or greater than 65 years.", "Presence of a chronic disease that must be chronically treated with one or more of the following medications: glucocorticoids, diazoxide, bumetanide, haloperidol, chlorpromazine, desipramine, doxepin, imipramine, levodopa, morphine, L-asparaginase, cyclophosphamide, isoniazid, heparin, nalidixic acid, or any other agents that may adversely influence glycemic control and which may confound the interpretation of Graft Success post-transplant.", "Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy, and women presently breast feeding are ineligible due to the unknown effects of these drugs on the fetus and nursing infant.", "Active alcohol or substance abuse, including cigarette smoking (must be abstinent for > 3 months).", "Hyperlipidemia (total cholesterol > 260 mg/dl, LDL > 130 mg/dl, and/or triglycerides > 300 mg/dl) despite appropriate treatment.", "Anemia (Hgb < 12 g/dl) or other hematologic disorders that require medical attention.", "Increased risk of bleeding (platelet count < 80,000; INR > 1.5), other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy (i.e., heparin or warfarin)."], "nct_id": "NCT00708604"},{"minimum_age": 25.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Patients with type II DM on a stable medication regimen (on diet / oral hypoglycaemic agents / insulin injections)", "Age 25", "70 years", "HbA1C > 7%", "AHI >= 15", "Able to give written informed consent"], "exclusion": ["Patients with severe co-existing illness or poor functional performance", "Patients with peripheral vascular diseases, vasculitis / Raynaud's syndrome or thrombocytopenia", "Sleep disorders other than OSA", "Patients who refuse nCPAP treatment for OSA", "Excessive sleepiness causing potential harm (e.g. driver)", "HbA1C >=7%", "Habitual drinker (defined as more than 3 times a week)", "Pregnant or lactating women"], "nct_id": "NCT00876980"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["diabetes mellitus 2", "insulin therapy", "stable therapy modality within the last 3 months", "deteriorated glucose metabolism (Hba1c > 7%)", "insulin resistance, defined as more than 1 unit of insulin per kg and day"], "exclusion": ["acute vascular event within the last 3 months", "planed weight reducing therapy", "acute and chronic inflammatory disease", "therapy with corticosteroids", "pregnancy"], "nct_id": "NCT00401453"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["diabetic nephropathy characterised by a daily proteinuria superior to 500 mg", "type II diabetes"], "exclusion": ["type 1 diabetes", "serum creatinine > 2.5 mg/dL or creatinine clearance lower than 30 ml/min", "serum potassium > 5.5 mEq/L", "intolerance or allergy to ACE inhibitors or BRA", "pregnancy", "hepatitis C or B", "HIV", "current chemotherapy treatment"], "nct_id": "NCT00419835"},{"minimum_age": 1.0, "maximum_age": 5.0, "gender": "A", "inclusion": ["Children with Type I diabetes:", "Children must be 5 years of age or less at the time of entry into the study.", "Children must have had a diagnosis of type I diabetes for at least 1 year at time of entry.", "Children must be receiving two or more insulin injections daily."], "exclusion": ["Children will be excluded if they have additional medical problems requiring treatment with agents known to affect blood glucose such as steroids or L-asparaginase.", "Children must not have any other chronic illness in addition to diabetes."], "nct_id": "NCT00727220"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Clinical diagnosis of DM and with use TZDs"], "exclusion": ["Patients with the diagnosis of congestive heart failure", "Liver cirrhosis (according to abdominal echo)", "Renal insufficiency (Cr \u2265 1.7 mg/dL)", "Patient with concomitant use of insulin, and/or diuretics before TZDs were excluded", "Pregnant"], "nct_id": "NCT00975169"},{"minimum_age": 18.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Ambulatory patients with type 2 diabetes mellitus and ischemia of one or both lower limbs, defined as lack of limb improvement with conventional care (medications, debridements) after a recent amputation or a patient graded III or IV in the Leriche-Fontaine functional classification."], "exclusion": ["Patients older than 75 years", "Hypercoagulable states", "Cardiac ejection fraction < 30%", "Active vasculopathy in brain, kidneys or heart", "Neoplastic disease", "Active infection", "Diabetic ketoacidosis or hyperosmolar hyperglycemic state", "Gangrene of the extremity requiring immediate surgery."], "nct_id": "NCT00730561"},{"minimum_age": 13.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Between 13 and 18 years of age at inclusion", "Tanner stage 4-5", "BMI > 40 kg/m2 or BMI > 35 with at least one comorbidity (type 2-diabetes, obstructive sleep apnea, serious hypertension or cerebral pseudotumor)", "At least one year multidisciplinary treatment completed"], "exclusion": ["Tanner stage < 4", "Substantial risk for lack of compliance", "Obesity syndrome (e.g., Prader Willi syndrome)", "Obesity related to brain damage", "Serious general disease", "Monogenic obesity"], "nct_id": "NCT00923819"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes", "albumin-to-creatinine ratio >= 300 mg/g creatinine in first morning urinalysis", "serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men"], "exclusion": ["type 1 diabetes", "non-diabetic nephropathy", "history of myocardial infarction", "history of cardiac bypass grafting within 3 months", "history of percutaneous coronary intervention (PCI) within 6 months", "history of carotid artery or peripheral artery revascularization within 6 months", "stroke or transient ischemic attack (TIA) within 1 year", "unstable angina pectoris", "heart failure of NYHA functional classes III or IV", "rapid progression of kidney disease within 3 months", "severe orthostatic hypotension", "serum potassium level =<3.5 mEq(mmol)/L or =>5.5 mEq(mmol)L", "history of rapid elevation of the serum creatinine level after starting treatment with AII receptor antagonists or ACE inhibitors", "poor glycemic control: HbA1c level =>11%", "history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months"], "nct_id": "NCT00141453"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [": Documented + HIV ELISA. Diabetes mellitus (DM) will be defined as: Documented diagnosis of type 2 diabetes mellitus or FPG greater than or equal to 126 mg/dl on two occasions or casual blood glucose greater than or equal to 200 mg/dL and symptoms of diabetes. Impaired Fasting Glucose (IFG) defined as: FPG greater than or equal to 100 mg/dl and less than 126 mg/dl on one or more occasions within past year. Age 18+, male or female."], "exclusion": [": Type 1 Diabetes. Known current pregnancy or pregnancy within 6 mo. Documented hemoglobinopathy. Changes in antiretroviral therapy within 3 months. History of anemia (Hb less than 9g/dL in past 6 months). Active opportunistic Infection or opportunistic Infection within 3 mo. Creatine greater than 1.8 mg/dL or known end stage renal disease (ESRD). Changes in diabetes therapies within 3 mo (excluding dose adjustments). Subject is deemed unable to comply with requirements of study participation. Use of oral corticosteroid within the past 3 mo (stable dose inhaled steroids will be allowed). Blood transfusion within 3 months."], "nct_id": "NCT00433628"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 1 diabetes", "A1C <9%", "Mild neuropathy", "Mild retinopathy", "Mild nephropathy"], "exclusion": ["History of drug or alcohol dependence, heart disease, viral illness, liver disease, advanced kidney disease", "Pregnant or nursing", "Severely overweight"], "nct_id": "NCT00116207"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \u2265 95 mmHg and < 110 mmHg at Visits 1 and 2", "Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP \u2265 90 mmHg and < 110 mmHg at Visit 2", "All patients must have a msDBP \u2265 90 mmHg and < 110 mmHg at Visit 5 (randomization)"], "exclusion": ["Severe hypertension", "Pregnant or nursing (lactating) women", "Pre-menopausal women not taking accepted form of birth control", "Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1", "History of cardiovascular conditions", "Uncontrolled Type 1 or Type 2 diabetes mellitus", "Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00778921"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": [": (The unit of randomization is the medical clinic)", "Clinics were excluded if they participated in an effective quality improvement program within the last two years.", "Clinics must have 3-22 full time equivalent providers", "Clinics must be located in Minnesota or Western Wisconsin", "Clinics must be willing to implement a diabetes registry", "Must be a single specialty, general internal medicine or family practice clinic"], "exclusion": [], "nct_id": "NCT00108927"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type II diabetes", "Body mass index 28-45kg/m2", "HbA1c 6%-10%"], "exclusion": ["Significant weight loss in the previous 3 months", "Weight gain during the run-in period", "Other serious systemic conditions, except controlled hypertension, mild asthma, and primary hypothyroidism", "History of GI disorders", "Previous surgery for weight loss"], "nct_id": "NCT00156897"},{"minimum_age": 12.0, "maximum_age": 21.0, "gender": "A", "inclusion": [": ***Subjects must be patients of the Texas Children's Hospital Diabetes Care Center***. All of the following criteria must be met:", "Between 12-21 years of age at the time of enrollment.", "Have been diagnosed with Type 1 diabetes for at least 1 year and in good control (HbA1C less than 8.5%).", "Subjects must be otherwise healthy except for the Type 1 Diabetes and treated hypothyroidism.", "Menstruating women must have a negative pregnancy test.", "Hemoglobin equal to or greater than 12 g/dL before each study.", "Weight greater than 44 kg.", "Tanner stage greater than 3"], "exclusion": ["Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis etc or on treatment that might directly or indirectly affect glucose homeostasis, except for diabetes and hypothyroidism; stable on medications.", "Lack of a supportive family environment as detected by the clinicians and/or social workers.", "Positive pregnancy test in menstruating young women.", "BMI greater than 90th percentile for age or less than 10th percentile for age.", "Lactating and nursing mothers."], "nct_id": "NCT00456300"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Age 18-45 years,", "type 1 diabetes duration 1-15 years,", "absent or minimal retinopathy (EDTRS 20).", "Age- and gender-matched healthy controls"], "exclusion": ["smoking,", "systemic diseases other than diabetes,", "retinal diseases other than diabetic retinopathy,", "pregnancy,", "bleeding disorders,", "aspirin allergy,", "use of anti-platelet agents,", "non-steroidal anti-inflammatory agents,", "angiotensin converting enzyme inhibitors,", "angiotensin receptor antagonists,", "Vitamin E in large doses."], "nct_id": "NCT00406991"},{"minimum_age": 13.0, "maximum_age": 17.0, "gender": "A", "inclusion": [":diagnosed for at least 6 months, age 13-17; Internet access, parental consent -"], "exclusion": [": Any sensory deficits that would preclude seeing or hearing. -"], "nct_id": "NCT00848705"},{"minimum_age": 13.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Between 13 and 17 years of age, inclusive", "Diagnosed with type 1 diabetes for > 1 year", "Hemoglobin A1c between 7.5 and 10% inclusive", "Currently using carbohydrate to insulin ratio", "Acceptable form of birth control"], "exclusion": ["Use of oral hyperglycemic agents or medications affecting blood sugar levels", "Recurrent severe hypoglycemia requiring assistance in past 6 months", "History of hypoglycemia unawareness", "History of gastroparesis requiring use of drugs that stimulate gastrointestinal motility", "Previous use of pramlintide"], "nct_id": "NCT00842075"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [": Non-diabetic patients with metabolic syndrome AND/OR pre-diabetes are eligible for this project based on the following criteria:", "Metabolic Syndrome: Patients with BMI \u2265 25 kg/m2, with at least 3 of the following risk factors for metabolic syndrome:", "Waist circumference (>40 inches men, >35 inches women)", "Blood pressure \u2265130 mmHg (systolic) or \u226585 mmHg (diastolic) OR history of diagnosed hypertension", "Low HDL level (<40mg/dL men, <50 mg/dL women)", "Elevated triglyceride level \u2265150 mg/dL", "Fasting glucose \u2265100mg/dL and <126mg/dL", "Pre-diabetes: Patients with a BMI \u226525 kg/m2 and pre-diabetes (fasting glucose \u2265100 mg/dL and <126mg/dL) All measures should have been taken within one year of enrollment into the study. A permission for physical activity form must be signed by the participant's physician in order to take part in the study."], "exclusion": ["Previous diabetes or diabetes diagnosed as a result of the screening", "Age <18 years old", "Women who are currently (or within past 6-weeks) pregnant or lactating", "Any patient deemed by their physician not to be a candidate", "Any patient planning to leave the area before the end of the GILS", "Any patient who is unable to provide informed consent"], "nct_id": "NCT00869609"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["1) Current prescription of insulin or an oral hypoglycemic agent", "2) A1c > 7.0%", "3) fasting glucose levels > 130 mg/dl", "4) referred to see a consultant and are seen during the active intervention phase. Patients with either Type I or Type II DM will be included A Primary Care Provider for a Cleveland CBOC"], "exclusion": ["1) primary care obtained at more than one site (based on stop codes with evidence of more than 1 CBOC involved in care during the last 6 months)", "2) documented dementia, aphasia, and psychosis"], "nct_id": "NCT00119041"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["At Visit 3, mean seated diastolic blood pressure (SeDBP) \u2265 95 mmHg and < 110 mmHg, AND mean seated systolic blood pressure (SeSBP) \u2265140 mmHg and < 180 mmHg", "At Visit 4, mean SeDBP \u2265 90 mmH", "No significant disorder in blood, kidney, liver, cardiovascular system or endocrinology system"], "exclusion": ["Patients with known or suspect secondary hypertension", "Unstable angina", "History of acute myocardial infarct, or PTCA or surgical cardiac procedures 3 months before entry into this study", "Prior or current congestive heart failure (NYHA grade III or IV), hypertrophic obstructive cardiomyopathy, valvular disease or rheumatic heart disease", "Arrhythmia of clinical significance", "Bilateral renal artery stenosis, isolated renal artery stenosis, post kidney transplantation", "Acute glomerular nephritis", "Gout sufferers, even with the normal serum uric acid at entry", "Retinal hemorrhage /exudate", "Type 1 diabetes mellitus", "Uncontrolled type 2 diabetes mellitus", "Hypovolemia", "Patients with autoimmune disease"], "nct_id": "NCT00872586"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["PCOS, BMI>/=30", "previous pregnancy affected by hypertension or gestational diabetes", "thrombophilia", "Type I or II diabetes mellitus", "autoimmune diseases", "twin pregnancy", "renal diseases", "previous pre-eclampsia in relatives"], "exclusion": [], "nct_id": "NCT00412230"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Patient age over 18 years.", "Patient schedule for colonic surgery which requires a bowel anastomosis (right colon, left colon, sigma).", "Patient is able to understand and to sign the Informed Consent Form."], "exclusion": ["Patient has known allergy to nickel.", "Emergency procedure, i.e. patients with bowel obstruction, bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischaemic bowel, carcinomatosis.", "Patients with Crohn's disease needed more than one anastomosis.", "Patient underwent previous major abdominal surgery.", "Patients under steroid treatment.", "Patient albumin level less than 3 g/dl", "Patients under immuno-suppression or cytotoxic treatment.", "Patients who are participating in another trial which may affect the outcomes data on this study.", "Patients with contraindications to general anaesthesia. 10. Patients who refuse consent."], "nct_id": "NCT00250328"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["Male", "Type 1 diabetes duration between zero and fifteen years", "current insulin therapy"], "exclusion": ["Female", "proliferative retinopathy", "microalbuminuria", "symptomatic diabetic neuropathy", "cardiovascular disease", "taking medications", "smoking"], "nct_id": "NCT00703989"},{"minimum_age": 5.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Native American youth between ages of 5 and 18 who are eligible for health care at Rosebud Sioux Reservation (Rosebud, SD) and willing to be measured and participate in a 2 hour glucose tolerance test and who have parental consent."], "exclusion": ["Those who have diabetes previously identified or those with chronic steroid use, or identified conditions that affect weight balance such as cancer."], "nct_id": "NCT00498030"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["Aged 18-40", "fasting glucose concentration of less than 95 mg/dl."], "exclusion": ["Individuals with a BMI < 19 or > 40 kg/m^2", "active systemic illness", "medication that can alter gastric emptying, insulin secretion & action", "history of abdominal surgery (other than appendectomy or tubal ligation)."], "nct_id": "NCT00588380"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["IGT according the criteria of the WHO", "standardised office blood pressure > 140/90 mmHG or treated hypertension", "40", "75 years of age", "signed informed consent"], "exclusion": ["known hypersensitivity towards telmisartan or losartan", "concommitant treatment with ACE-inhibitors", "BMI > 35 kg/m2", "inability to perform self-control of blood pressure", "acute coronary syndrome or cerebrovascular event within the last 3 months", "Revascularisation within the last 3 months", "heart failure > NYHA 2"], "nct_id": "NCT00407862"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["History of type 2 diabetes mellitus who are na ve to hypoglycemic treatment, inadequately controlled by diet and exercise alone or oral medications.", "Hemoglobin A1c level of 6.5 % to 8.0 % inclusive. Subjects not taking hypoglycemic drugs with HgbA1c of 6.0% to 6.5% must have a diagnosis of Diabetes Mellitus (DM).", "Fasting blood glucose levels reasonably stable for at least 2 months or during the two-week lead-in-period.", "Ethnicity: All ethnic groups.", "Gender: Both men and women.", "Female with reproductive potential must not be pregnant or lactating, and using reliable contraception methods.", "Age >18 years old."], "exclusion": ["Taking insulin.", "History of diabetic ketoacidosis or hyper osmolar non-ketotic coma.", "Diabetes Mellitus related end-organ damage:", "Evidence of diabetic autonomic and peripheral neuropathy", "Diabetic proliferative retinopathy, based on eye exam by ophthalmologist", "Diabetes nephropathy defined by > 500 mg/24 hour urinary albumin excretion", "Any disease likely to limit life span and/or increase risks of interventions:", "Screening carotid B-mode ultrasound indicating clinically significant stenos in the common carotid arteries requiring intervention by angioplasty or resection.", "Cancer treatment in the past 5 years, with the exception of cancers that have been cured, and carry a good prognosis.", "Infectious disease: HIV positivity, active tuberculosis, or pneumonia.", "Cardiovascular disease:", "Hospitalization for treatment of heart disease in the past 12 months.", "New York Heart Association Functional Class > 2.", "Left Bundle branch block on EKG.", "Third degree atrioventricular block on EKG.", "Uncontrolled hypertension with average systolic blood pressure of > 160 mmHg on two screening visits and diastolic blood pressure > 95 mmHg on two screening visit.", "Pulse rate > 95 beats per minute on both screening visits.", "Stroke or transient ischemic attack in the past 12 months.", "Gastrointestinal disease:", "Chronic hepatitis or cirrhosis.", "Episode of alcoholic hepatitis or alcoholic pancreatitis.", "Inflammatory bowel disease requiring treatment in the past 12 months.", "Recent or significant abdominal surgery (e.g. gastrectomy, gastric bypass).", "Renal disease: Serum creatinine > 1.5 mg/dL for men, and > 1.4 mg/dL for women.", "Lung disease:", "Chronic obstructive airway disease or asthma requiring daily therapy.", "Use of home oxygen.", "Anemia: Hematocrit of < 36.0% in men or < 33% in women. 10. Conditions or behaviors likely to affect the conduct of the study", "Unable or unwilling to give informed consent.", "Unable to communicate with the clinic staff.", "Unwilling to accept treatment assignment by randomization.", "Weight loss of > 10% in the past 6 months.", "Unable to walk without any assisted device.", "Major psychiatric disorder which would impede conduct of the research.", "Excessive alcohol intake (more than 2 drinks/day) 11. Medications", "Psychoactive agents such as Monoamine oxidase inhibitors and Antidepressive agents (lithium, prozac, zoloft, serzone, paxil, effexor)", "Systemic use of glucocorticoids steroids within previous 6 weeks."], "nct_id": "NCT00878605"},{"minimum_age": 11.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["clinical diagnosis of prehypertension or stage 1 hypertension", "age 11-18 years", "english speaking"], "exclusion": ["stage 2 or secondary hypertension", "target organ damage or symptomatic hypertension", "type 1 or 2 diabetes", "treated with anti-hypertensive medications or other blood pressure altering medications", "are unwilling to stop use of vitamins, minerals or antacids containing calcium or magnesium", "do not have full medical clearance from a physician to participate"], "nct_id": "NCT00431288"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Diabetes mellitus", "Use NovoPen\u00ae, NovoPen\u00ae 1.5, NovoPen\u00ae 3, NovoLet\u00ae 1.5 or NovoLet\u00ae 3 for at least 3 months", "Body mass index (BMI) for normal weight between 19-25 kg/m2", "Body mass index (BMI) for obese between 25-33 kg/m2"], "exclusion": ["Pregnancy or plans thereof", "Local reactions on injection sites", "Acute, severe infection diseases", "Coagulation disorders"], "nct_id": "NCT00871416"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["acute coronary syndrome", "age > 30 yrs"], "exclusion": ["previously diagnosed diabetes", "ACS due to substance abuse or trauma"], "nct_id": "NCT00589459"},{"minimum_age": 18.0, "maximum_age": 39.0, "gender": "A", "inclusion": ["Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment", "Age 18 to 39 years, inclusive", "Male patient or female patient using adequate contraceptive methods", "Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA"], "exclusion": ["History of a malignancy", "Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated more than ten percent above the upper limit of normal, elevation of AST or ALT more than 3 times the upper limit of normal", "Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator", "Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin", "Pregnant or nursing women or women intending to become pregnant", "Known or suspected allergy to atorvastatin or any component of thr trial product", "Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of normal", "Patients who had a severe blood loss (>= 400 mL, e.g. blood donation) within 2 months prior to visit 2", "Any significant laboratory abnormality", "A serum LDL-cholesterol above 150 mg/dL at time of screening", "Unwillingness to comply with study procedures"], "nct_id": "NCT00974740"},{"minimum_age": 20.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Not exercising regularly, healthy, non-diabetic."], "exclusion": ["Diabetes, heart disease, hepatitis, HIV, impaired glucose tolerance, abnormal liver enzymes, abnormal TSH levels, other abnormal lab values."], "nct_id": "NCT00846248"},{"minimum_age": 35.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["with metabolic syndrome Metabolic syndrome was defined based upon the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian-Americans as presenting at least 3 of the following components: 1) waist circumference \u2265 90 cm for men or \u2265 80 cm for women; 2) triglycerides \u22651.7mmol/l; 3) HDL cholesterol <1.03 for men or <1.30 for women; 4) blood pressure \u2265130/85 mmHg, or current use of antihypertentive medications; 5) fasting glucose \u22655.6mmol/l or previously diagnosed type 2 diabetes or on oral antidiabetic agents or insulin.", "Being able to comply with the specified feeding conditions", "Being able to eat flaxseeds", "Being between the ages of 35 and 60 years"], "exclusion": ["Pregnancy or lactation", "Use of insulin", "Severe kidney disease", "Cardiovascular diseases, stroke, cancer and psychological disorders", "Flaxseed allergies or frequently eating flaxseeds or sesame (>90 grams/week)", "Drug or alcohol abuse."], "nct_id": "NCT00733772"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["adult subjects with a BMI > 30 kg/m2", "3 or more characteristics of the metabolic syndrome"], "exclusion": ["inability to give informed consent", "age < 18 years", "known diabetes mellitus", "fasting plasma glucose > 7,0 mmol/l or HbA1c > 6,2%", "presence of any medical condition that might interfere with the current study protocol", "immunodeficiency of immunosuppressive treatment", "anti-inflammatory drugs (100 mg of aspirin/day is allowed)", "signs of current infection", "history of recurrent infections", "pregnancy or breast feeding", "liver disease", "renal disease", "neutropenia"], "nct_id": "NCT00928876"},{"minimum_age": 18.0, "maximum_age": 50.0, "gender": "M", "inclusion": ["Patients with type 1 diabetes", "Informed oral and written consent", "Caucasians over the age of 18 years with type 1 diabetes (diagnosed according to the criteria of WHO) receiving long acting insulin", "C-peptide negative glucagon test", "Normal blood haemoglobin concentration", "Healthy control subjects", "Informed oral and written consent", "Caucasians over the age of 18 years", "Normal 75 g- oral glucose tolerance test (OGTT) according to the criteria of WHO", "Negative islet cell autoantibodies (ICA) and GAD-65 autoantibodies", "No first-degree relatives with diabetes", "Normal blood haemoglobin concentration"], "exclusion": ["Patients with type 1 diabetes", "Residual beta-cell function (evaluated with glucagon test)", "Impaired hepatic function (aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) > 2 times upper normal limit)", "Diabetic nephropathy (serum-creatinine > 130 \u00b5M and/or albuminuria)", "Diabetic neuropathy", "Proliferative diabetic retinopathy", "Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using inadequate contraceptive measures", "Healthy control subjects", "Impaired hepatic function (ASAT or ALAT > 2 times upper normal limit)", "Impaired renal function (serum-creatinine > 130 \u03bcM and/or albuminuria)", "First-degree relatives with diabetes", "Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using inadequate contraceptive measures"], "nct_id": "NCT00876213"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Type 1 diabetes (of at least 15 years duration) as assessed by medical history."], "exclusion": ["Macroalbuminuria", "Symptomatic gastroparesis. Diabetic nephropathy with a creatinine clearance less than 60 cc/min.", "Evidence of chronic infection.", "History of any malignancy.", "Any chronic medical condition that unduly increases the risk for the potential enrollee as judged by study investigators.", "Pregnancy, breastfeeding or planned pregnancy within two years.", "Supplementation with thiamine > 2mg per day and/or alpha-lipoic acid", "Chronic alcoholism/alcohol abuse."], "nct_id": "NCT00117026"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["(all of the following inclusion criteria must be met for the patient to be enrolled in the study):", "acute heart failure, defined according to current ESC Guidelines", "HbA1c > 7.5% at admission in Cardiology Unit", "glycemia > 180 mg/dL at admission in Cardiology Unit", "the patients signed the Informed Consent"], "exclusion": ["(if any of the following criteria are met, patients cannot be enrolled in the study):", "heart failure in acute infarction or cardiogenic shock", "creatinemia > 3.5 mg/dL at admission or in hemodialytic therapy", "cirrhosis", "acute infective pathology", "cardiac revascularization during the hospitalization or in the preceding 3 months", "life expectance < 12 months", "age < 18 years", "pregnant women", "informed consent not signed", "subject included in other protocols"], "nct_id": "NCT00922402"},{"minimum_age": 70.0, "maximum_age": null, "gender": "A", "inclusion": ["Stage 3-5 CKD not on dialysis", "Patients \u2265 70 years of age", "Haemoglobin < 110g/L at screening", "Transferrin saturation \u2265 15% at screening"], "exclusion": ["Clinical history of type 2 diabetes mellitus", "Anticipating or scheduled to go on renal replacement therapy in the next year, including renal transplant", "Uncontrolled hypertension on two separate measurements during screening", "Use of any erythropoietic protein within 12 weeks of screening"], "nct_id": "NCT00364845"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["You are a man or a woman between the ages of 18-60, inclusive.", "You have a body mass index (BMI) between 20 and less than 40 kg/m2. BMI is a number calculated from your height and weight.", "You have a lipoma (a benign fatty tumor) that is 1 inch or more in diameter under the skin of your abdomen or on another area of your body that is easily accessible to study (such as the thigh).", "You have not gained or lost more than 11 pounds in the last 3 months.", "Your exercise routine has been stable for the last 3 months or you are sedentary. Sedentary means you do less than 60 minutes of exercise per week."], "exclusion": ["You have a history of heart or blood vessel disease.", "Your blood pressure is above 140/90 mmHg.", "You have type 1 diabetes.", "You have a history of kidney or liver disease.", "You have thyroid disease that has not been treated.", "You are a smoker.", "You use a Beta-2 (B2) adrenergic stimulator (a type of drug used to treat asthma), a beta adrenergic blocker (a type of drug used to treat blood pressure) or glucocorticoid medications (a type of drug used to treat immune system disease).", "You have a problem with alcoholism or other substance abuse.", "You are pregnant or breast feeding."], "nct_id": "NCT00624416"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Difficult to control Type 1 diabetes mellitus (defined above). Documentation of negative basal and stimulated C-peptide (a basal level of < 0.2 ng/ml before IV administration of 1 mg of glucagon, and a glucagon stimulated C-peptide < 0.8 ng/ml) and diagnosis of diabetes for at least 5 years. When possible, patients will be evaluated with continuous glucose monitoring (GlucoseSensor \u00ae) to determine the frequency and extent of hypo- and hyperglycemic episodes.", "No evidence of chronic renal failure or significant proteinuria (serum creatinine < 1.6 mg/dl, creatinine clearance >80 ml/min, and albumin excretion </= 300 mg/24 hr).", "No evidence of liver disease (liver enzymes < twice the upper limit of normal for each of ALT and AST, bilirubin < 2 mg/dl, albumin > 3.5 g/dl, and PT and PTT </= 1.1 x the upper limit of normal).", "Frequent episodes of symptomatic hypoglycemia (i.e. loss of consciousness, headaches, anxiety, irritability, trembling, sweating) more than once per week, documented hypoglycemic unawareness (i.e. no adrenergic and/or neurogenic symptoms with blood glucose < 54 mg/dl) two or more times in the past two months, or hypoglycemic episodes that required the assistance of another person more than once per month or hospitalization more than once over the past 20 months.", "Ability to comply with post-transplant regimen, including immunosuppression, insulin pump therapy and metabolic testing. Patients will be required to perform self-monitoring of blood glucose a minimum of four times daily, and provide complete records of blood glucose levels and insulin doses.", "Ability to give informed consent.", "Age greater than or equal to 18 years or less than or equal to 65 years."], "exclusion": ["Significant liver disease (including elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST, bilirubin > 2 mg/dl, albumin < 3.5 g/dl, liver masses, portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e. gallstones).", "Significant cardiovascular disease, including non-correctable coronary artery disease with ejection fraction < 50% and/or recent myocardial infarction (within last 12 months); extensive peripheral vascular disease not correctable by surgery or untreated proliferative retinopathy.", "Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB.", "Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix.", "Recent history of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy.", "Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment.", "Presence of preformed antibodies on panel reactive antibody screening > 20%.", "Body mass index (BMI) greater than 30.", "Age less than 18 years or greater than 65 years.", "Presence of a chronic disease that must be chronically treated with one or more of the following medications: glucocorticoids, diazoxide, bumetanide, haloperidol, chlorpromazine, desipramine, doxepin, imipramine, isoproterenol, levodopa, morphine, L-asparaginase, cyclophosphamide, isoniazid, heparin, nalidixic acid, or any other agents that may adversely influence glycemic control and which may confound the interpretation of Graft Success post-transplant.", "Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy, and women presently breast feeding are ineligible due to the unknown effects of these drugs on the fetus and nursing infant.", "Active alcohol or substance abuse, including cigarette smoking (must be abstinent for > 3 months).", "Hyperlipidemia (total cholesterol > 260 mg/dl, LDL > 130 mg/dl, and/or triglycerides > 300 mg/dl) despite appropriate treatment.", "Anemia (Hgb < 12 g/dl) or other hematologic disorders that require medical attention.", "Increased risk of bleeding (platelet count < 80,000; INR > 1.5), other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy (i.e. heparin or warfarin)."], "nct_id": "NCT00706420"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Caucasian over 18 years with T1DM (diagnosed according to WHO's criteria) treated with long-acting insulin", "No residual beta-cell function (arginine test without increment in plasma C-peptide - see below)", "BMI <30 kg/m2", "Normal haemoglobin", "Informed consent"], "exclusion": ["Residual beta-cell function (increment in plasma C-peptide during arginine test", "see below)", "Known liver disease or affected liver enzymes (ALAT/ASAT > 2 x upper normal limit)", "Diabetic nephropathy (se-creatinin > 130 \u00b5M and/or albuminuria)", "Proliferative diabetic retinopathy (anamnestic)", "Treatment with medication that cannot be discontinued for 14 hours"], "nct_id": "NCT00704795"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of type 2 diabetes", "Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min using the four variable MDRD (Modification of Diet in Renal Disease Study Group) formula", "Presence of microalbuminuria or proteinuria less than 3.5 g/d", "Diagnosis of hyperlipidemia currently treated with a \"statin\" drug"], "exclusion": ["Not meeting inclusion criteria", "HDL-C > 40 mg/dL for men, > 50 mg/dL for women", "TG (triglycerides) < 150 mg/dL and > 800 mg/dL", "Documented intolerance to Niaspan or Aspirin", "Treatment with other lipid-lowering agents (fibrates, BAS [bile acid sequestrants], or ezetimibe)", "Elevated transaminases (AST or ALT >1.3 x ULN)", "Unstable type 2 diabetes (FBG >200 mg/dL or HbA1c >9.5%)", "Known seropositivity for Hepatitis B, C, or HIV", "Documented history of malignancy", "Age < 18 years", "Pregnant women or nursing mothers", "Inability to give informed consent", "Start or change in \"statin\" dose < 2 months ago"], "nct_id": "NCT00108485"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Patients with Type 1 diabetes may be enrolled if they meet all of the following criteria:", "Have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician; diabetes onset younger than age 18, duration >5 years", "Have fasting C-Peptide \u2264 0.1 ng/ml", "BMI between 18 and 29 kg/m2", "Able to tolerate PET and MR imaging", "No metal implants", "No claustrophobia", "Healthy volunteers may be enrolled if they meeting all of the following criteria:", "Have no history of Type 1 diabetes", "Fasting blood glucose \u2264 100 mg/dL", "Negative islet autoantibody testing", "BMI between 18 and 29 kg/m2", "Able to tolerate PET and MR imaging", "No history of previous allergic reactions to drugs", "No metal implants", "No claustrophobia"], "exclusion": ["Clinically significant renal dysfunction;", "Clinically significant liver dysfunction as determined by history, physical examination, and standard liver function testing at screening (AST, ALT, Total/Direct Bilirubin, Alkaline Phosphatase);", "Coagulopathy;", "History of allergic reactions to any drug", "Current use of any medications except for insulin for Type 1 diabetes", "Clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG (including but not limited to QTc>450 msec);", "Clinically significant psychiatric disease; Clinically significant pulmonary, renal or hepatic impairment or cancer, have clinically significant infectious disease, including AIDS or HIV infection, or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2; subjects will be asked about this. No testing will be performed.", "Have a history of alcohol or substance abuse or dependence;", "Are women of childbearing potential not refraining from sexual activity or not using adequate contraception. Women must not be pregnant (negative serum \u03b2-HCG at the time of screen) or lactating at screening, and must agree to take appropriate steps not to become pregnant during the study and for 30 days following the study.", "Currently receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days.", "Have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study.", "Claustrophobia", "Metal implants (pace-maker, artificial joints, non-removable body piercings)"], "nct_id": "NCT00958997"},{"minimum_age": 11.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Attendance at out-patients clinics at Bristol Royal Hospital for Children, Southmead Hospital in Bristol, Weston General Hospital, The Royal United Hospital in Bath, Gloucestershire Royal Hospital in Gloucester or the Musgrove Park branch of the Taunton and Somerset Hospital Aged 11-16 years old (inclusive) on the first day of the study Type 1 diabetes Duration at least 12 months on the first day of the study"], "exclusion": ["chronic illnesses with dietary management implications (e.g. cystic fibrosis and coeliac disease) special educational needs (e.g. Down's syndrome) making the patient unable to co-operate with CBT in care of social services primary responsibility for care elsewhere English not spoken as a first language Known psychological/ psychiatric problems for which the patient has already been referred"], "nct_id": "NCT00360061"},{"minimum_age": 3.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Males and females subjects with T1DM aged 3-18 years", "Positive GAD 65 and/or islet cell antibody", "HbA1c at diagnosis above 6%", "Insulin regimen with 3 injection of insulin daily (as described below)", "White blood count between 3,000-10,000 and platelets > 100,000", "Normal ALT and AST, creatinine < 1.8 mg/dl", "T1DM duration equal or less than 4 weeks"], "exclusion": ["Infection requiring IV antibiotics at diagnosis or within past 14 days from study entry", "BMI over 85th percentile for age and gender", "Unstable household", "Unable to provide compliance with study drug, insulin and study visits,", "Evidence of psychiatric disease in the potential study subject and/or primary care taker", "And chronic diseases, including additional autoimmune disorders with the exception of euthyroid autoimmune thyroiditis"], "nct_id": "NCT00730392"},{"minimum_age": 3.0, "maximum_age": 25.0, "gender": "A", "inclusion": [": T1DM of less than 6 weeks duration in patients between 3 and 25 years of age. Besides T1DM, no concurrent illness."], "exclusion": [": Treatment with immunosuppressive or immunostimulatory medications such as azathioprine, nicotinamide, superoxide dismutase-desferroxamine, aminoguanidine, oral insulin or other experimental therapies at the present time or in the past. Abnormal pre-treatment white blood cell count (WBC) or thrombocytopenia. Known active diseases, e.g. cardiac, renal, hepatic diseases or immunodeficiency. History of cancer, neuropathy seizure disorders (except typical history of febrile seizures in childhood), peripheral vascular disease, coagulation abnormalities, autoimmune disease (except type 1 diabetes) or cerebrovascular disease. Ongoing use of medications known to influence glucose tolerance (e.g. sulfonylureas, metformin, diphenylhydantoin, thiazide or other potassium depleting diuretics, beta-adrenergic blockers, niacin) except insulin. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial. Inability to give informed consent or assent. Participation in a clinical trial within the previous 6 weeks. Lactating or pregnant female individual (individuals will be advised not to volunteer for the protocol if they plan to become pregnant during the time of the study and they are instructed to use an effective method of contraception). Age above 25 years, since there may be several subtypes of T1DM."], "nct_id": "NCT00024518"},{"minimum_age": null, "maximum_age": null, "gender": "F", "inclusion": [": paraffin blocks of 329 patients with histologic diagnosis of CIN 2, CIN 3 or Stage I cervical cancer. -"], "exclusion": [": -"], "nct_id": "NCT00937547"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Subjects with Type 1 or Type 2, insulin-dependent or non insulin-dependent diabetes mellitus.", "Subjects with a history of distal symmetric polyneuropathy, secondary to diabetes, diagnosed in accordance with the American Academy of Neurology criteria.", "Female subjects, who are of non-reproductive potential (>=12 months post-menopausal or surgically sterile) or who are using adequate contraception which includes abstinence or double barrier methods (diaphragm and condom with spermicidal cream, intrauterine device and condom with spermicidal cream). Male subjects with partners of child-bearing potential must also use adequate contraception.", "Subjects must be able to read, understand, and provide written informed consent before enrolling in the study at screening."], "exclusion": ["History of diabetic foot ulcers or lower extremity amputation.", "Diabetic amyotrophy or non-diabetic cause of lower limb neuropathy/neuropathic symptoms.", "Clinically significant illness which, in the opinion of the investigator, would compromise a subject's suitability to participate in the study for reasons of safety or would confound the efficacy assessments."], "nct_id": "NCT00927914"},{"minimum_age": 0.08333333333333333, "maximum_age": 20.0, "gender": "A", "inclusion": ["pediatric type 1 DM"], "exclusion": [": -"], "nct_id": "NCT00173641"},{"minimum_age": 50.0, "maximum_age": null, "gender": "M", "inclusion": ["Men older than 50 yrs of age", "Non-smoking (more than 5 years)", "BMI greater than 25 kg/m2 and less than 50 kg/m2"], "exclusion": ["CAD, CHF, Myocardial infarction within 6 months or other symptomatic heart disease", "History of stroke, peripheral arterial disease", "Currently being treated for active cancer", "On oral agents or insulin therapy for diabetes", "Poorly controlled Dyslipidemia (abnormal concentration of lipids or lipoproteins in the blood)", "Poorly controlled hypertension (BP > 180/95)", "Other systematic disorders that are not medically treated and stable", "Physical impairment limiting normal activity and other contraindications to exercise", "Aerobically conditioned", "Abnormal response to exercise (chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP > 240/120)", "Taking warfarin/coumadin", "Taking oral steroids", "Abnormal renal function or liver function", "Chronic pulmonary disease severe enough to require oxygen", "Anemia", "MMSE < 24, dementia"], "nct_id": "NCT00971594"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia", "Must be able to swallow tablet", "Negative pregnancy test (when appropriate)"], "exclusion": ["Renal insufficiency", "Hepatic insufficiency", "Diabetes (any type)"], "nct_id": "NCT00847080"},{"minimum_age": 21.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Coronary artery disease", "Normal HDL-cholesterol levels in blood:", "> 40 mg/dl (1.03 mmol/L) in males", "> 50 mg/dl (1.29 mmol/L) in females"], "exclusion": ["Type 1 or 2 diabetes mellitus", "Acute coronary syndrome", "Unstable angina pectoris", "Myocardial infarction during the last 8 weeks", "Therapy with niacin", "Active infections", "Ventricular arrhythmias", "Systolic blood pressure > 160 mmHg or diastolic blood pressure > 95 mmHg", "Cancer", "Pregnant or lactating", "Alcoholism"], "nct_id": "NCT00457379"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type I Diabetes Mellitus for at least 5 years", "Unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars", "Group I must have healthy kidneys", "Group II (islet after kidney) must have a stable kidney allograft for at least 6 months"], "exclusion": ["Unstable diabetic eye disease", "Poor kidney function", "Type II Diabetes as determined by blood tests", "Any history of cancer, except certain skin cancers", "Pregnant or unwilling to use adequate birth control", "Very high hemoglobin A1c levels", "Poor control of blood pressure, despite use of medications", "Very high insulin requirements", "History of exposure to HIV", "Active Hepatitis B or Hepatitis C infection"], "nct_id": "NCT00605592"},{"minimum_age": 8.0, "maximum_age": 35.0, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00105352"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female patients \u226518 years of age", "Patients treated with up to two high blood pressure medications in a stable dose considered adequate by the investigator, for a minimum of two months, with blood pressure not controlled according to the following criteria:", "Systolic Blood Pressure \u2265140 mmHg and/or Diastolic Blood Pressure \u226590 mmHg for low risk patients (no known target organ damage and without risk factor or presenting 1 - except Type 2 diabetes mellitus", "risk factor);", "Systolic Blood Pressure \u2265130 and/or Diastolic Blood Pressure \u226585 mmHg for medium risk patients (no known target organ damage and 2 or more risk factors", "except Type 2 diabetes mellitus);", "Systolic Blood Pressure \u2265130 and/or Diastolic Blood Pressure \u226580 mmHg for high risk patients (known target organ damage, and/or Type 2 diabetic patients and/or any clinically identifiable cardiovascular disease). OR", "Systolic Blood Pressure \u2265160 mmHg and/or Diastolic Blood Pressure \u2265100 mmHg at Visits 1 and 2 for previously untreated patients", "Patients previously treated but who stopped their medications will be considered untreated after one month without treatment", "Obs: -The target organ are: Brain, Heart, Kidney, Retina.", "The risk factors are: Smoking, Dyslipidemia, Age > 60 years old, and Family history of cardiovascular diseases (women < 65 years old and men < 55 years old"], "exclusion": ["Systolic Blood Pressure \u2265180 mmHg and/or Diastolic Blood Pressure \u2265110 mmHg at Visit 1 or Visit 2", "Evidence of a secondary form of hypertension, to include coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma", "Known Keith-Wagener grade III or IV hypertensive retinopathy", "History of hypertensive encephalopathy", "Cerebrovascular accident or myocardial infarction 12 months prior to Visit 1", "History of transient ischemic attack 12 months prior to Visit 1", "Percutaneous coronary intervention or coronary artery bypass graft surgery 12 months prior to Visit 1", "Diabetes mellitus type 1", "Diabetes mellitus type 2 under insulin treatment", "Poorly controlled type 2 diabetes mellitus", "History of heart failure Grade II", "IV according to the NYHA classification", "Second or third degree heart block without a pacemaker", "Concomitant unstable angina pectoris", "Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia", "Clinically significant valvular heart disease", "Women of child-bearing potential", "Pregnant or nursing (lactating) women", "Any surgical or medical condition which, at the discretion of the investigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period", "Additional protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00400777"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["The patients which had been included in the previous study between 1997", "2000, oral glucose tolerance test included."], "exclusion": ["Pregnancy"], "nct_id": "NCT00145288"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Aged at least 18 years with an ability and willingness to give written informed consent.", "Body mass index 25-35 kg/m2", "Users of at least 2 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions.", "Non-smoking"], "exclusion": ["Any condition/illness that may affect the study outcomes or would make participation potentially harmful such as pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, Gastroesophageal reflux disease GERD, a history of ulcer, according to a detailed medical history.", "Abnormal hepatic function (liver function test > twice the normal range), abnormal renal function (creatinine > 1.1 mg/dl), fasting plasma glucose in the diabetic range (>/= 126 mg/dl), or blood pressure > 140/90 mmHg.", "Present alcoholism or drug abuse or use of medications that could interfere with the treatment including bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, antihypertensives."], "nct_id": "NCT00305097"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["Patients with type 1 or type 2 diabetes", "Age over 40", "Chronic diabetic foot ulcer (duration over 30 days)", "Grade 1 to 3, stage A and C according to the University of Texas Wound Classification, except stage B and D", "Wound area over 0.5 cm\u00b2", "Social Security membership or benefit from Social Security", "Informed consent, with a signed and approved form", "Possibility to have clinical follow-up and compliance during 3 months"], "exclusion": ["Urgent need for locoregional surgery", "Clinical criteria for infection, defined by the presence of pus or/and at least 2 local signs among the following: heat, erythema, lymphangitis, lymphadenopathy, oedema, pain", "Other pathology that could interfere with the healing process (vasculitis, connectivitis, dysimmunity, immunosuppressive treatment or corticoids, ongoing radiotherapy or chemotherapy )", "Any severe pathology that would constitute a contra-indication to the patient's inclusion", "Ongoing therapeutic research protocol", "Underage patient, major patient under guardianship or protected by the Law", "Pregnant, parturient or breastfeeding woman", "Person with no freedom (prisoner), person in an emergency situation, person hospitalized without consent and not protected by the Law"], "nct_id": "NCT00935051"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 1 Diabetes with hypoglycemia unawareness that received a Islet Transplant here at Washington University", "\"control\" subjects were matched to the transplant recipients base upon age, height, weight, & race (and could not have diabetes)"], "exclusion": ["well controlled Type 1 diabetes", "transplant failure", "unable to match potential subject to a recipient"], "nct_id": "NCT00870831"},{"minimum_age": null, "maximum_age": null, "gender": "M", "inclusion": ["Males with metabolic syndrome"], "exclusion": ["Conditions with insulin resistance including;", "Type 2 diabetes mellitus,", "Infections,", "Stresses,", "Uremia,", "Acromegaly,", "Glucocorticoid excess,", "Hypertension ,", "Cirrhosis and", "Any addiction or drug therapy and conditions witch cause changes in hs-CRP and fibrinogen levels including infection, trauma, infarction, inflammatory arthritis, various neoplasm and liver diseases."], "nct_id": "NCT00433082"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Patients diagnosed with Diabetes Mellitus, type I or II, treated or untreated", "Diabetic neuropathy treated or untreated"], "exclusion": ["Patients with unstable glycemic control", "Patients who have been hospitalized for a diabetes complication in the 3 months prior to randomization", "Patients with peripheral neuropathy attributable to any cause other than diabetes", "Non-measurable sural nerve sensory response on nerve conduction studies", "Amputation of any part of lower extremity", "Patients with a history of myocardial infarction or known coronary artery disease", "Grade III or IV heart failure on New York Heart Association criteria The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00502515"},{"minimum_age": 18.0, "maximum_age": 54.0, "gender": "A", "inclusion": [": Type 1 diabetes mellitus with or without diabetic nephropathy; 19-54 years old; no other kidney disease"], "exclusion": [], "nct_id": "NCT00024921"},{"minimum_age": 20.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Body Mass Index \u226525 kg/m\u00b2", "Viceral Fat Area \u2265 100 cm\u00b2", "Diet therapy for more than 8 weeks before start of the placebo observation period", "Stable weight (variation < \u00b13kg within 8 weeks before start of observation period)", "At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol), Hypertension"], "exclusion": [], "nct_id": "NCT00459004"},{"minimum_age": 25.0, "maximum_age": null, "gender": "A", "inclusion": ["Uncontrolled diabetes patients (defined as HbA1c 6.0 or greater).", "25 years or older", "English or Spanish speaking"], "exclusion": ["Uncorrectable hearing or visual impairment", "Moderate to severe cognitive deficits"], "nct_id": "NCT00973830"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["28 (14 males, 14 females) conventionally treated Type 1 diabetic patients with HA1C > 8.5%", "28 (14 males, 14 females) intensively treated Type 1 diabetic patients with HA1C < 7%", "28 (14 males, 14 females) non-diabetic controls", "Age 18-45 yr.", "Had diabetes for 2-15 years if diabetic subject", "No clinical evidence of diabetic tissue complications, no cardiovascular disease", "Body mass index 21-27kg \u00b7 m-2", "Normal bedside autonomic function", "Normal results of routine blood test to screen for hepatic, renal, and hematological abnormalities", "Female volunteers of childbearing potential: negative HCG pregnancy test"], "exclusion": ["Prior history of poor health: any current or prior disease condition that alters carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease", "Hemoglobin of less than 12 g/dl", "Abnormal results following screening tests", "Pregnancy", "Subjects unable to give voluntary informed consent", "Subjects with a recent medical illness", "Subjects with known liver or kidney disease", "Subjects taking steroids", "Subjects taking beta blockers", "Subjects on anticoagulant drugs, anemic, or with known bleeding diseases"], "nct_id": "NCT00605774"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["28 (14 males, 14 females) conventionally treated Type 1 diabetic patients with HA1C > 8.5%", "28 (14 males, 14 females) intensively treated Type 1 diabetic patients with HA1C < 7%", "28 (14 males, 14 females) non-diabetic controls", "Age 18-45 yr.", "Had diabetes for 2-15 years if diabetic subject", "No clinical evidence of diabetic tissue complications, no cardiovascular disease", "Body mass index 21-27kg \u00b7 m-2", "Normal bedside autonomic function", "Normal results of routine blood test to screen for hepatic, renal, and hematological abnormalities", "Female volunteers of childbearing potential: negative HCG pregnancy test"], "exclusion": ["Prior history of poor health: any current or prior disease condition that alters carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease", "Hemoglobin of less than 12 g/dl", "Abnormal results following screening tests", "Pregnancy", "Subjects unable to give voluntary informed consent", "Subjects with a recent medical illness", "Subjects with known liver or kidney disease", "Subjects taking steroids", "Subjects taking beta blockers", "Subjects on anticoagulant drugs, anemic, or with known bleeding diseases"], "nct_id": "NCT00608816"},{"minimum_age": 10.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Children/adolescents with type 1 diabetes mellitus", "Usage of NovoPen\u00ae 1.5 for at least 3 months", "Duration of insulin treatment more than 1 year", "Normal weight according to Tanner scales", "The means of the last 2 HbA1c measurements taken within the last 6 months must be less than 10.5%"], "exclusion": ["Pregnancy or desire to become pregnant", "Clinical relevant peripheral neuropathy as judged by the investigators", "Pronounced lipodystrophy in accordance with investigator's evaluation", "Use of drugs that can influence the trial", "Coagulation disorders (use of anti-coagulants)", "Serious, chronic diseases, making it highly unlikely that the subject can complete the trial"], "nct_id": "NCT00872560"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Diabetes mellitus (type 1 or 2)", "Diabetic macular edema in study eye associated to diabetic retinopathy", "Diffuse macular edema defined as macular thickening determined by biomicroscopy and fluorescein angiography.", "Best corrected visual acuity between 34 (20/200) and 68 letters (20/50).", "Macular thickness greater than 300 mcm on OCT."], "exclusion": ["Uncontrolled systemic disease", "Start of medical therapy for diabetes or change in treatment from oral to insulin four months before initial visit.", "HbA1c levels greater than 10%", "Presence of retinal venous occlusion, cystoid macular edema,or other condition that would contribute to macular edema.", "Presence of epiretinal membrane", "Presence of vitreomacular traction in the study eye.", "Aphakic or anterior chamber intraocular lens in the study eye.", "Neovascularization of disc or elsewhere in the study eye.", "History or presence of choroidal neovascularization in the study eye.", "Presence of rubeosis irides in the study eye.", "Eye opacity that interfere with clinical documentation and photography.", "Intra-ocular surgery 90 days before initial visit.", "Previous vitrectomy in study eye.", "Previous history of intravitreal or periocular corticoid or any other intravitreal drug in study eye.", "Scheduled surgery for study eye.", "Patients with known allergies to fluorescein, iodo-povidone or any component of study drug."], "nct_id": "NCT00407849"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Renal impairment (moderate and severe)", "Currently on stable doses of background medication of SU, TZD, acarbose, meglitinide, insulin or any combination thereof, or on no antidiabetic drugs at all", "HbA1c 7.0%", "10.5%, inclusive", "Male or female subjects between the ages of 18 and 85 years, inclusive."], "exclusion": ["Type 1 diabetes mellitus or history of diabetic ketoacidosis, mature onset diabetes of the young (MODY)", "Kidney transplant"], "nct_id": "NCT00958269"},{"minimum_age": 25.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female between 25 and 80 years of age (inclusive);", "Documented diabetes mellitus Type 2 (Based upon ADA criteria);", "Peripheral polyneuropathy: Vibration Perception Threshold (VPT) 25-45 Volts at hallux on either leg.", "Adequate lower extremity vascular status:", "Palpable pedal pulse in both feet;", "No intermittent claudication;", "No history of lower extremity vascular bypass surgery or angioplasty", "The subject is able to understand the information in the informed consent form and is willing and able to sign the consent."], "exclusion": ["Amputation of any kind or an ulceration within the last two (2) years including at Screen;", "History or active Charcot neuroarthropathy on either foot;", "Previous surgery to spine or lower extremity with residual symptoms of pain or difficulty with movement;", "Severe rheumatoid arthritis or osteoarthritis that would cause discomfort during causal walking or stair climbing;", "Current treatment with systemic steroids, immunosuppressives, or radiotherapy;", "Peripheral vascular disease defined as any nonpalpable foot pulse, history of claudication, or a history of lower extremity vascular bypass surgery or angioplasty;", "Glycated hemoglobin (HbA1c) >9 at Screen.", "Uncontrolled heart (Hypertension: BP > 160/90), or lung disease (uncontrolled asthma or shortness of breath) in the last 2 months prior to Screen;", "End stage kidney disorder requiring hemodialysis or serum creatinine > 2.5X (normal upper limit); 10. The following supplements within 2 months prior to Screen: alpha lipoic acid; B12 injection; >10mg of B6; or, > 800mcg of folate; 11. Taking either an opiate at any dose or on the maximum dose of any anticonvulsant; 12. Pregnant or nursing; 13. Life expectancy < 12 months; 14. Initiated therapies for Painful Diabetic Neuropathy (pregabalin, gabapentin, duloxetine etc.) in the last 2 months prior to Screen; 15. Initiated new hyperglycemic, insulin, statin or hypertensive therapies within 2 months prior to Screen (dose modifications of current therapies are allowed at the discretion of the investigator); 16. Current alcohol or drug abuse (or history of such abuse within the past 3 years); and, 17. Not willing or able to follow procedures specified by the protocol and/or the instructions of the study personnel."], "nct_id": "NCT00726713"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Have a clinical diagnosis of diabetes mellitus type I or II for at least 12 months prior to the study.", "Have received a diagnosis of mild to moderate sensorimotor diabetic neuropathy from a neurologist (a doctor who specializes in disorders of the nervous system) or endocrinologist (a doctor who specializes in diabetes). This type of neuropathy is a loss of sensation and muscle function that occurs in the legs and hands in a stocking and glove distribution. Subjects with diabetic neuropathy that results in loss of sensation or muscle function in only one nerve and results in loss of nerve function of the blood vessels and causes low blood pressure, will not be eligible.", "If female and of childbearing potential, agree to use a medically acceptable physical barrier method during the study.", "Have blood pressure < 140/90 mm Hg", "Body mass index (BMI) < 38 kg/m2 Key"], "exclusion": [": Subjects with the following are NOT eligible to participate in this study:", "Have moderate to severe ischemic heart disease, any history of congestive heart failure, or have had a myocardial infarction (heart attack) within the previous 6 months.", "Have chronic foot or leg ulcers for >1 month, gangrene in the legs, or any previous amputation of the lower extremity.", "Have symptoms of intermittent claudication (or leg pain during exercise associated with peripheral artery disease) and/or an ankle brachial index (or a calculation of the difference between arm and leg blood pressures) of less than (<) 0.75.", "Have a history of cancer within the past 5 years (except for curable non-melanoma cancer of the skin, superficial bladder cancer in complete remission, or any other cancer that has been in complete remission for at least 5 years).", "Have colon polyps. If patients have a history of benign colonic polyps that have been removed, they must have evidence of a normal colonoscopy within the last 12 months.", "Require any drug that depresses patients' immune systems (such as methotrexate, cyclophosphamide, or cyclosporine) when they receive the study drug and for 30 days afterwards.", "Have a known disorder that affects patients' immune systems (such as HIV/AIDS, hepatitis B virus [HBV], hepatitis C virus [HCV], sarcoidosis, tuberculosis, rheumatoid arthritis, or autoimmune disorders)."], "nct_id": "NCT00406458"},{"minimum_age": 19.0, "maximum_age": 29.0, "gender": "A", "inclusion": ["Patients with and without Type II Diabetes Mellitus", "Hemodynamically Stable", "Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass"], "exclusion": ["Age less than 18 or greater than 80 years of age", "refuse informed consent", "Co-existing valvular heart disease", "Acute or evolving myocardial infarction", "hypersensitivity to propofol or formulation component", "Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery"], "nct_id": "NCT00734383"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Type 1 diabetes mellitus for at least 12 months", "Glycosylated haemoglobin (HbA1c) between 7.5 and 9% (both inclusive)"], "exclusion": ["Donation or loss of more than 500 ml blood or plasma within three months prior to this trial", "Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) or not able or willing to refrain from smoking and the use of nicotine gum or transdermal nicotine patches during the in-house periods", "Prior or current treatment with metformin or thiazolidinediones"], "nct_id": "NCT00964964"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of Type II diabetes or hypertension in their medical chart.", "30 years or older.", "Fluent in English."], "exclusion": ["Uncorrectable hearing or visual impairment.", "Too ill to participate."], "nct_id": "NCT00973180"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "M", "inclusion": ["Male patients 18-65 years of age", "Type I diabetes mellitus", "Currently on continuous subcutaneous insulin infusion therapy"], "exclusion": ["Proliferative retinopathy or maculopathy requiring actue treatment within last 6 months", "Use of systemic corticoids in last 3 months", "Treatment with medication known to interfere with glucose metabolism"], "nct_id": "NCT00772356"},{"minimum_age": 2.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Insulin detemir naive", "Type 1 diabetes for at least 12 months", "HbA1c lesser than or equal to 11.0%"], "exclusion": ["Significant concomitant diseases"], "nct_id": "NCT00435019"},{"minimum_age": 35.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Has an Abdominal obesity with a waist circumference greater than 102 cm (men) and greater than 88 cm (women).", "Has a body mass index greater than 30 kg/m^2.", "Has hypertension not adequately controlled (seated diastolic blood pressure greater than 95 mmHg and less than or equal to 110 mmHg as median value of three readings) by monotherapy with either beta-blocker or calcium channel blocker.", "Has a Homeostasis Model Assessment Insulin Resistance index greater than 3.99.", "Has hyperlipidemia with fasting levels for total cholesterol greater than 250 mg/dL (6.45 mmol/L) or low-density lipoprotein cholesterol greater than 160 mg/dL (4.13 mmol/L) or triglycerides greater than 250 mg/dL (2.82 mmol/L)."], "exclusion": ["Existing Hydrochlorothiazide therapy at start of study.", "Diabetes mellitus type 1 or 2 [known or newly detected (Screening: fasting plasma glucose greater than 7.0 mmol/L)].", "Chronic renal impairment or S-creatinine greater than or equal to 1.8 mg/dL.", "Presence of single kidney or state after kidney transplantation or known bilateral renal artery stenosis or interventional treatment for renal artery stenosis in the last year.", "Hyperkalemia (potassium greater than 5.5 mmol/L).", "Known electrolyte imbalance, e.g. hypocalcaemia or hypokalemia resistant to treatment.", "Nephrotic syndrome.", "Thyroid dysfunction.", "Primary or secondary hyperaldosteronism.", "Cushing syndrome.", "Known or suspected familial hypercholesterolemia.", "Severe hepatic impairment (cholestasis (bilirubin greater than 2.0 mg/dL) or alanine aminotransferase and/or aspartate aminotransferase greater than 3 times the upper limit of normal and/or \u03b3-glutamyl transpeptidase greater than 5 times the upper limit of normal).", "History of chronic heart failure.", "History of overt coronary heart disease.", "History of silent myocardial infarction.", "Hemodynamically relevant stenosis of the mitral and/or aortic valve.", "History of stroke.", "Stage 3 hypertension (systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 110 mmHg).", "Angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy in the previous 4 weeks.", "Lipid-lowering therapy with cholesterol synthesis enzyme inhibitors or anticipated initiation of such a therapy.", "History of autoimmune disease.", "History of cancer in the last 5 years or wasting disease.", "Intake of prohibited concomitant medication.", "Has known hypersensitivity/allergy to the study drugs.", "Has drug addiction and/or extensive use of alcohol.", "Psychological and/or emotional problems which would render the informed consent invalid or limit the ability of the patient to comply with the study requirements.", "Participation in a clinical investigation within 30 days prior to enrolment in this trial."], "nct_id": "NCT00775814"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Patients with untreated mild-to-moderate essential hypertension, clinically diagnosed according to the World Health Organization criteria (systolic blood pressure =140-179 mm Hg and/or diastolic blood pressure =90-109 mm Hg on 3 consecutive occasions; standardized after 5 minutes in sitting position)", "Patients with newly diagnosed essential hypertension or previously treated patients from whom antihypertensive therapy can be safely withdrawn for the duration of the study.", "18 to 65 years of age, males and non-reproductive females (surgically sterilized or post-menopausal)", "Written informed consent", "Patient is willing and able to comply with all trial requirements"], "exclusion": ["Secondary hypertension", "Severe essential hypertension", "Current pharmacological treatment that could affect blood pressure", "Significant renal insufficiency [Serum creatinine > 159 \u00b5mol/L (> 1.8 mg/dl)]", "History of cerebrovascular disease", "Type 1 Diabetes or poorly controlled Type 2 Diabetes", "Body mass index (BMI) >32", "Total cholesterol > 6.9 mmol/L (> 266 mg/dl)", "Triglycerides > 3.5 mmol/L ( > 174.3 mg/dl)", "Autoimmune diseases or severe allergies", "Patients with a history of HIV infection, AIDS, hepatitis B or C, or other immunosuppressive disorders", "Current diagnosis or a history of malignancy", "Drug or alcohol abuse within the past 2 years", "Pregnancy or breastfeeding", "Present history of mental diseases", "Participation in any drug trial within three month of onset of current trial", "Previous participation in a clinical trial with a Qb based vaccine (DerQb, NicQb, AllQb)"], "nct_id": "NCT00500786"},{"minimum_age": 18.0, "maximum_age": 72.0, "gender": "A", "inclusion": ["Healthy, HIV-negative volunteers between the ages of 18-72 years"], "exclusion": ["Any subject with states known to be associated with insulin resistance, such as impaired fasting glucose (glucose > 110 mg/dl), overweight (body mass index [BMI] > 27), dyslipidemia (triglycerides > 150 mg/dl), hypertension (blood pressure [BP] > 130/85 mmHg or on medication), renal disease, systemic use of glucocorticoids, growth hormone, niacin, or antipsychotics.", "Women will be tested for pregnancy immediately prior to study and excluded if pregnant."], "nct_id": "NCT00259727"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Self-identified as a first generation Korean American", "Age 30 years or older", "Resides in Washington-Baltimore area", "Expresses willingness to participate in all aspects of the study over its full course", "Written consent to participate in the screening/eligibility visit", "Self-identified with DM and HbA1c >= 8% within 6 months of screening", "Written consent to participate in the clinical trial: agreeing to participate in study data collection procedures, receiving DM self -help education, using HGMT, and permitting contact with their own medical care provider."], "exclusion": ["Unable to give informed consent", "Physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases)", "Hematological condition that would affect A1C assay, e.g., hemolytic anemia, sickle cell anemia."], "nct_id": "NCT00505960"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Scheduled for Surgical Procedure", "Self Management of Diabetes", "Currently on Evening Insulin Glargine prescribed by Primary Care Physician", "Age 18 or over", "Able to Communicate Clearly over the Phone", "Pre-screened by Anesthesia Department > 48 hours prior to Surgery"], "exclusion": ["On Glucocorticoid Medication", "On Insulin Glargine Dual Dosing or Sliding Scale Regimen", "History of Hypoglycemia Unawareness", "Pregnancy or Lactating Female", "On Insulin Glargine for < 3 months"], "nct_id": "NCT00309465"},{"minimum_age": null, "maximum_age": 17.0, "gender": "A", "inclusion": ["New onset type 1 diabetes", "Less than 48 hours since first insulin injection", "Child and/or parent able to read and write English", "Family intends to continue treatment at our institution for the next two years", "Informed consent from adolescents greater than 16 years of age, or if less than 16 years, informed consent from the parent/guardian with assent from the child."], "exclusion": ["Chronic medical conditions other than treated hypothyroidism or mild asthma", "Concerns of the diabetes team regarding future treatment adherence making twice daily insulin preferable to the split evening injection regimen (e.g., cognitive impairment, severe family dysfunction)."], "nct_id": "NCT00146484"},{"minimum_age": 40.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["One or more of the following:", "Familiar History of early-onset cardiovascular disease (male < 55 or female < 65).", "Type 2 Diabetes mellitus or type 1 with microalbuminuria.", "Essential High Blood Pressure.", "Chronic Kidney Disease.", "Primary hyperlipidemia. The presence of two or more of the following:", "Current smoker.", "Physical inactivity.", "High blood pressure (recently diagnosed).", "Abdominal perimeter: > 102 cm. males; > 88 cm. females.", "Total cholesterol > 240 mg/dL.", "HDL cholesterol \u2264 40 mg/dL males, \u2264 50 mg/dL females."], "exclusion": ["Age < 40 or > 74 years old.", "Previous Cardiovascular Event."], "nct_id": "NCT00734123"},{"minimum_age": 21.0, "maximum_age": null, "gender": "F", "inclusion": ["Histologically-confirmed operable invasive breast cancer or ductal carcinoma in situ (DCIS) who undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment", "Body mass index > 25", "Age \u2265 21 years", "No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry", "Signed informed consent"], "exclusion": ["History of diabetes mellitus requiring medical therapy", "Treatment with other investigational drugs within 6 months of study entry", "Significant renal impairment with a creatinine > 1.4 mg/dl", "Other serious intercurrent medical illness"], "nct_id": "NCT00930579"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type II diabetes", "Subject has a diabetic foot ulcer 5cm squared or greater", "Subject's diabetic foot ulcer is chronic"], "exclusion": ["HgbA1c of 12% or greater", "Presence of cellulitis", "Presence of osteomyelitis"], "nct_id": "NCT00605189"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or female patients, age 18 or older", "Given informed consent", "Diagnosed as having mild to moderate essential hypertension"], "exclusion": ["Severe hypertension", "Significant preexisting cardiovascular and cerebrovascular disease", "Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II", "Advanced renal impairment Other protocol-defined inclusion/exclusion criteria may apply."], "nct_id": "NCT00367094"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Age 18 to 45 yrs", "Serum 25-OHD < or = 20 ng/mL", "At least 1 menses in the last 3 months (females) and normal serum testosterone (males)"], "exclusion": ["Significant cardiac, hepatic, oncologic, or psychiatric disease", "History of diabetes mellitus, malabsorption, kidney stones, or recent alcohol excess/abuse (15 drinks per week in the last month)", "Fasting glucose > 126 mg/dl or 2 hour OGTT > 200 mg/dl", "Use of medications known to affect serum phosphate levels including phosphate-binding antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (> 1000 units per day), excessive doses of vitamin A (> 20,000 units/day), calcitriol, growth hormone, or anti-convulsants", "Use of metformin or insulin sensitizing agents", "Serum calcium < 8 or > 11 mg/dL, creatinine > 1.5 mg/dL, or Hgb < 11 gm/dL", "Liver function tests > 2 times the upper limit of normal", "TSH < 0.1 or > 7 uU/mL", "WBC < 2,000 or > 15,000/cmm", "Platelet count < 100,000 or > 500,000/cum", "Hormone replacement therapy or testosterone use", "Urine uhCG positive (females), testosterone < 270 ng/dL (males)"], "nct_id": "NCT00491322"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["type 1 insulin-dependent diabetic patients in relatively good general condition", "non-smoker", "body weight < 80 kg", "C-peptide < 0.03 nmol/l (<0.09 \u00b5g/l) 6 min. after glucagon IV (1mg) (glycemia > 180 mg/dl)", "EBV antibody positive", "cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma C-peptide positivity may result in subsequent loss of \u00df-cell graft function; the \u00df cell implant should be identified as a clinical trial"], "exclusion": ["history of thrombosis or pulmonary embolism", "abnormal liver function", "HLA antibodies"], "nct_id": "NCT00623610"},{"minimum_age": 50.0, "maximum_age": 70.0, "gender": "M", "inclusion": [": For all participants:", "male gender", "50-70 yrs For diabetic patients only:", "BMI >30 kg/m2", "Well-controlled diabetes: fasting plasma glucose concentration must be <10.0 mmol/l at the time of screening.", "Must be on sulphonylurea- or metformin therapy for at least 6 months with a constant dose for at least two months, or on dietary treatment for at least 6 months2. For obese controls only:", "BMI > 30 kg/m2", "normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L) For lean controls only:", "BMI 18-25 kg/m2", "normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)"], "exclusion": [": For all participants:", "Female gender", "Age below 50 or above 70 years", "Hemoglobin levels <8.4 mmol/L", "Allergic to cow milk or dairy products", "Allergic to fish oil", "Vegetarian", "Tobacco smoker", "Current or recent (<4 weeks) use of fish oil supplements or more then four times fish/week; 24.35 g of EPA-DHA of fish per month (800 mg/day) as judged by the questionnaire.", "Received inoculations within 2 months of starting the study or planned to during the study", "Donated or intended to donate blood from 2 months before the study till two months after the study", "Unstable body weight (weight gain or loss > 3 kg in the past three months)", "Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, gastrointestinal disease, renal dysfunction)", "Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)", "abuse of drugs and/or alcohol", "participation in another biomedical study within 1 month before the first screening visit For obese, type 2 diabetic subjects only:", "severe diabetes which requires application of insulin", "diabetes-related complications For obese subjects and lean controls only:", "hyperglycemic according to WHO criteria (OGTT, fasting blood glucose >6.0mM, after 2 hr>11mM)", "systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg", "Urinary glucose concentrations (>0.25 g/l)"], "nct_id": "NCT00977262"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [": Group I (n=25 PAD patients). This sample will represent the population of veterans with PAD with mild mobility impairment secondary to intermittent claudication in the gastrocsoleus muscles. Inclusion Criteria for PAD Subjects:", "diagnosis of PAD (acute or chronic occlusive arterial disease), with or without diabetes mellitus", "positive Edinburgh Claudication Questionnaire", "Fontaine stage IIa only (mild claudication, walking distance > 200 feet (one-half block)", "ambulatory, without assistive devices", "calf muscle claudication within 10 minutes of treadmill walking and calf muscle exercise Group II (n=25 normal control/reference subjects). This reference sample will represent the population of adults without PAD and related problems. They will undergo the PET-exercise testing for perfusion and glucose metabolism measurements, but will not perform the exercise training intervention. Inclusion Criteria for Controls:", "healthy adults, matched by age and sex to PAD subjects"], "exclusion": [": Exclusion Criteria for PAD and Control Subjects", "PAD secondary to Buerger's disease, autoimmune arteritis, fibromuscular dysplasia, chronic and repetitive occupational trauma, venous stasis, hypercoagulability disorder, or arterial embolic disease.", "inability to perform ankle dorsi and plantar flexion exercise", "cigarette smoking within last 6 months", "severe claudication, leg rest pain, skin ulceration, necrosis or gangrene (Fontaine stage >= IIa)", "poorly controlled diabetes mellitus (bA1c >= 9%)", "poorly controlled hypertension (resting BP > 140/90 mmHg)", "Raynaud's syndrome", "changes in prescribed cardiovascular medications within the past 6 months", "exertional angina, dyspnea, fatigue, or dizziness", "severe coronary artery disease", "congestive heart failure", "severe COPD", "exercise intolerance limited by leg pain of nonvascular origin (e.g., arthritis, orthopedic pain)", "transmetatarsal or more proximal lower-extremity amputation", "nonambulatory in the last 6 months", "severe leg weakness preventing leg exercise", "surgery related to PAD during preceding 3 months", "myocardial infarction within preceding 3 months", "unstable claudication symptoms during preceding 3 months", "terminal disease with < 6 months prognosis", "dementia (Minimental score < 24) (Folstein et al., 1975)", "pregnancy (Females of childbearing potential will be given a pregnancy test prior to acceptance into the study.)"], "nct_id": "NCT00118560"},{"minimum_age": null, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type II Diabetes Mellitus.", "Antecubital forearm veins allowing technically good sampling for platelet studies.", "HbA1c 6-9 % (Mono-S method).", "Below 70 years"], "exclusion": ["History of a cardiovascular disease; Ischemic heart disease, Stroke, Peripheral vascular disease.", "Acute or chronic renal or liver disease", "Contraindication to insulin treatment", "Treatment with Glitazones, Sulphonylurea, antiplatelet drugs,", "Thrombocytopenia <150 X109/l."], "nct_id": "NCT00771693"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "M", "inclusion": ["Be male within the age range of 18 to 55 years.", "Voluntarily sign an Independent Review Board (IRB/IEC)-approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.", "Have Hematology, Coagulation, Clinical Chemistry and Urinalysis test results that are within normal, allowable limits (if out-of-range, must be considered clinically significant to be exclusionary) and performed within 21 days of receiving first dose of test material.", "Have a BMI (Body Mass Index) between 18.0 and 30.0 kg/m2.", "Be clear of any history of HIV 1 and 2 and hepatitis B and C.", "Have no significant disease or clinically significant abnormal laboratory value as deemed by the investigator on the laboratory evaluations, medical history, or physical exam.", "Have a normal 12-lead ECG or an ECG with abnormality considered to be clinically insignificant.", "Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.", "Subject and their partner must agree to use an acceptable double barrier method for birth control from the Screening visit through 3 months after the last dose of test material.", "Subject agrees to refrain from consumption of grapefruits and/or grapefruit juice from time of study enrollment through end of subject's final study visit."], "exclusion": ["Subject has had a major illness in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavorable for enrollment.", "Subject has renal or liver impairment.", "Subject has a history of gastro-intestinal surgery or has a current gastrointestinal disease which may influence drug absorption.", "Subject has a history, within 3 years, of drug abuse (including Benzodiazepines, opioids, amphetamine, cocaine, and THC) or a positive drug result at Screening.", "Subject has a history of smoking, within 3 months, or is currently a smoker.", "Subject has a history of alcoholism (more than two years), and/or is currently drinking more than three drinks per day [one drink is equal to one unit of alcohol (one glass of wine, half a pint of beer, one measure of a spirit)].", "Subject has participated in a clinical trial within the past three months.", "Subject has a history of difficulty in donating blood or accessibility of veins in left or right arm.", "Subject has donated blood (one unit or 350 mL) within three months prior to receiving test material.", "Subject is taking herbal products or prescription drug therapy for which 5 times the half-life is longer than 21 days (i.e., the Screening period) prior to enrollment into the study."], "nct_id": "NCT00933530"},{"minimum_age": 35.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Type 2 diabetic patients with ages between 35 and 75 years (inclusive) and defined according to the 1998 WHO criteria and no history of unprovoked ketosis and not requiring continuous insulin treatment within 1 year of diagnosis", "Plasma creatinine 150-350 mmol/l (inclusive) who had no microscopic haematuria and no ultrasonographic evidence of obstructive uropathy which is amenable to surgical intervention"], "exclusion": ["patients with malignancy or other life-threatening diseases", "ultrasonographic evidence of obstructive uropathy which is amenable to surgical intervention", "non-diabetes related renal disease such as glomerulonephritis proven on renal biopsy reversible kidney disease, to be ruled out by ultrasonographic examination", "patients with clinically unstable psychiatric illnesses", "Patients who have 2 consecutive values of plasma creatinine concentration which differ by more than 20% within 3 months prior to recruitment."], "nct_id": "NCT00309127"},{"minimum_age": 19.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant."], "exclusion": ["A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes.", "Simultaneous transplant of another solid organ, such liver or heart.", "Patient unable to take oral medication.", "Patient unable to give informed consent.", "Hypersensitivity to sitagliptin."], "nct_id": "NCT00936663"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients on CIPII and treated in the Isala Clinics, Zwolle, The Netherlands", "Age >18 years", "Uncontrolled diabetes mellitus type 1"], "exclusion": ["Failure to obtain informed consent", "Any condition prevention proper handling of the device, for instance hearing impairment or visual impairment", "Known allergy to sensor (parts)", "Currently pregnant or trying to conceive"], "nct_id": "NCT00501072"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Any subject with type 1 diabetes who is treated with human rapid and intermediate (NPH) insulin in basal-bolus regimen"], "exclusion": ["Subjects currently being treated with insulin aspart and insulin detemir", "Subjects who were previously enrolled in this study", "Subjects with a hypersensitivity to insulin aspart or to any of the excipients", "Subjects with a hypersensitivity to insulin detemir or to any of the excipients", "Women who are pregnant or have the intention of becoming pregnant within next 6 months"], "nct_id": "NCT00873639"},{"minimum_age": 8.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Type 1 Diabetes for \u2265 12 months or more (including Cpeptide negative secondary diabetes)", "Children between 8 and 18 years old", "Adults between 18 and 60 years old", "Patients treated with basal-bolus insulin regimens, pump or multiple daily injection, only with analogs, for at least 6 months", "Performing at least 2 finger sticks glucose controls per day", "Able and motivated to use the device", "HbA1c \u2265 8% twice with HPLC method(DCA 2000 excluded)", "Written informed consent obtained prior to enrollment in the study"], "exclusion": ["Blindness or impaired vision so the screen cannot be recognized", "Allergy to sensor", "Active proliferative retinopathy not stabilized by laser or vitrectomy occurence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during study", "Treatment with systemic corticosteroid or medication known to influence insulin sensitivity in the 3 months prioir to visit 1", "Pregnancy", "Manifest psychiatric disturbance", "Presence of any conditions (medical, including clinically significant abnormal laboratory test, psychological, social or geographical) actuel or anticipated that the investigators feels would compromise the patient safety or limit his/her successful participation in the study.", "Hemoglobinopathy that interfers with HbA1c measurement"], "nct_id": "NCT00726440"},{"minimum_age": 16.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Within 5 years of diagnosis of type 1 diabetes", "Between the ages of 16 to 45 years", "Have at least one diabetes-related autoantibody present", "Have mean C-peptide level > 0.2 nmol/L on a mixed meal tolerance test", "Be taking insulin", "Complete written informed consent"], "exclusion": ["Taking inhaled or oral steroids (for example Advair, Orapred)", "Have an active infection", "Have serologic evidence of HIV, Hepatitis C, Hepatitis C, or tuberculosis", "Have ongoing use of medications known to affect glucose tolerance", "Have a live vaccine 90 days prior to, or during this study", "Taking any other experimental medication within the past 28 days", "Have prior treatment with rilonacept", "Have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies", "Pregnant or lactating females", "Males and females unwilling to use an acceptable method of contraception for the duration of the study"], "nct_id": "NCT00962026"},{"minimum_age": 12.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Recent diagnosis (within 100 days of enrollment) of T1DM", "Positive for at least one diabetes autoantibody (Glutamate decarboxylase [GAD-65GAD65], IA2, ZnT8, ICA and Insulin, if obtained within 10 days of the onset of exogenous insulin therapy)", "Peak stimulated C-peptide level > 0.2 pmol/mL following a mixed-meal tolerance test (MMTT)", "Willingness to provide written informed consent (either the subject or the subject's legally authorized representative)."], "exclusion": ["Severe reaction or anaphylaxis to human monoclonal antibodies", "History of malignancy or significant cardiovascular disease (including history of myocardial infarction, angina, use of anti-anginal medicines (e.g., nitroglycerin), or abnormal stress test)", "History of recent or ongoing uncontrolled bacterial, viral, fungal, or other opportunistic infections", "Evidence of infection with hepatitis B virus (HBV) as defined by hepatitis B surface antigen, HBsAg; hepatitis C virus (HCV) defined by anti-HCV antibodies; human immunodeficiency virus (HIV); or toxoplasmosis", "Positive tuberculin skin test (PPD)", "Clinically active infection with Epstein-Barr virus (EBV)-EBV viral load \u2265 10,000 copies per 10^6 PBMCs; cytomegalovirus (CMV) -CMV viral load \u226510,000 copies per mL whole blood; or tuberculosis (TB)", "Diagnosis of liver disease or hepatic enzymes, as defined by ALT and/or AST \u2265 2 times the upper limit of normal", "Prior or current treatment that is known to cause a significant, ongoing change in the course of T1DM or immunologic status, including high-dose inhaled, extensive topical or systemic glucocorticoids", "Current or prior (within the last 30 days) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin", "Current use of any medication known to influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, \u03b2-adrenergic blockers, niacin)", "Any of the following hematologic abnormalities, confirmed by repeat tests at least 1 week apart:", "White blood count <4000/\u03bcL or >14,000/\u03bcL;", "CD4+ count below the lower limit of normal;", "Platelet count <150,000 /\u03bcL; or", "Hemoglobin <10 g/dL.", "Females who are pregnant, lactating, or planning on pregnancy during the 2-year study period", "History of bone marrow transplantation, or autoimmune disease associated with lymphopenia", "Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial", "Prior participation in a clinical trial that could potentially affect T1DM or immunologic status", "Receipt of a live vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette-Gu\u00e9rin, and smallpox) in the 6 weeks before enrollment", "Participation in an investigational clinical trial within the last six weeks."], "nct_id": "NCT00965458"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Neuroaxial blockade (thoracic)"], "exclusion": ["Weight below 40 kg", "Lithium therapy", "Type I diabetes or type II requiring insulin"], "nct_id": "NCT00435422"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Male and female patients between the ages of 18 and 85 years", "Patients must have a minimum of 3 posterior teeth in all quadrants", "A mean gingival index (GI) of >1.5 on the posterior teeth", "Diagnosis of Diabetes type 1 or 2, adequately controlled by diet and/or medications, as determined by the patient's physician"], "exclusion": ["Allergy to any herbal medications", "Pregnancy or lactation", "Periodontal treatment in the last three months"], "nct_id": "NCT00731432"},{"minimum_age": 20.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Histologically proven NAFLD less than 18 months prior to inclusion. For those with pure steatosis, ALAT or aspartate aminotransferase (ASAT) must be elevated above the upper limits of normal, and impaired glucose tolerance or diabetes mellitus type 2 must be present.", "Body weight within +/- 5 kg compared with the weight at the time of biopsy."], "exclusion": ["Treatment for more than 1 week with metformin or glitazones the last 6 months before inclusion.", "Treatment with insulin.", "Hypersensitivity to metformin.", "Treatment with cimetidine.", "Heart failure requiring pharmacological treatment.", "Coronary heart disease (New York Heart Association [NYHA] class 3 or 4).", "Chronic obstructive lung disease (moderate or severe).", "Breast-feeding or pregnant.", "Metabolic acidosis.", "Renal failure (male [\u2642]: creatinine > 135 micromol/L, female [\u2640] > 110 micromol/L).", "Average alcohol consumption > 24 g/day the last year.", "Serum ALAT or serum ASAT > 5 x upper limit of normal (ULN) at screening.", "Cirrhosis.", "Platelets < 100 000.", "Haemochromatosis.", "Alfa-1-antitrypsin-deficiency.", "Wilson's disease.", "Thyroid dysfunction (0.2 mU/L < thyroid stimulating hormone [TSH] < 5.0 mU/L).", "Chronic infection with hepatitis B or C virus or HIV.", "Autoimmune hepatitis (antinuclear antibodies [ANA] > 1/256 or smooth muscle antibodies [SMA] > 1/128).", "Primary biliary cirrhosis (antimitochondrial antibodies [AMA] > 1/64).", "Primary sclerosing cholangitis.", "Previous participation in another clinical trial the last 6 months.", "Legal incapability."], "nct_id": "NCT00303537"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["central venous catheter placement", "Need for extracorporeal renal replacement therapy (acute and chronic renal failure)", "Age over 18 years", "Written informed consent", "Needed catheter length 15 cm or 20 cm"], "exclusion": ["Known infectivity with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV)", "Any infection associated with one or more positive blood cultures within 10 days prior to catheter implantation", "Bacteremia with a former catheter within 10 days prior to catheter implantation", "Known pregnancy", "Lactation", "Participation in another clinical study during the preceding 30 days"], "nct_id": "NCT00621712"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients 18 years of age or older", "Confirmed diagnosis of Multiple Myeloma", "Stable renal function defined as two serum creatinine determinations of < 3 mg/dL", "Calculated creatinine clearance of greater than or equal to 30 mL/min", "ECOG Performance Status of 0 or 1", "Life expectancy of greater than or equal to 9 months", "If the patient is of child-bearing potential, a negative pregnancy test is required at screening, while postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.", "Ability to comply with trial requirements and give informed consent."], "exclusion": ["IV Bisphosphonate therapy for more than 3 years.", "Patients with a diagnosis of amyloidosis.", "Known hypersensitivity to zoledronic acid or other bisphosphonates", "Pregnant patients or lactating patients.", "Women of childbearing potential not on a medically recognized form of contraception", "Patients with uncontrolled cardiovascular disease, hypertension, and Type 2 diabetes mellitus."], "nct_id": "NCT00104104"},{"minimum_age": 7.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Type 1 diabetes for at least one year", "Current treatment of basal-bolus regimen for at least 12 weeks using an intermediate/long-acting human insulin and insulin aspart and/or soluble human insulin", "HbA1C below 11.0%", "Willing to comply with Investigator's instructions", "Able and willing to perform self-monitoring of capillary blood glucose and to take measures in case of hypoglycaemia"], "exclusion": ["Impaired renal function", "Impaired hepatic function", "Known hypoglycaemia unawareness or recurrent major hypoglycaemia (as judged by the Investigator or Sub-Investigator)", "Proliferative retinopathy or maculopathy requiring acute treatment", "Uncontrolled treated/untreated hypertension", "Current treatment with total daily insulin dose of more than 2.00 IU/kg", "Current treatment or expected at the screening to start treatment with systemic corticosteroids"], "nct_id": "NCT00605137"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus treated with diet, oral hypoglycaemic agents or insulin) for a minimum of 2 years (24 months)", "Systolic hypertension prior to entry into the washout period. At Visit 3 patients must have a mean sitting systolic blood pressure in the range of 140-180 mmHg, and a mean sitting diastolic blood pressure <110mmHg", "A mean daytime ambulatory systolic blood pressure greater than or equal to 135 mm Hg at baseline"], "exclusion": ["Poorly controlled type 2 diabetes mellitus (HbA1c \u2265 10%)", "Secondary hypertension of any aetiology, such as renal artery stenosis, coarctation of the aorta or pheochromocytoma", "History of malignant hypertension", "Body mass index > 37", "Single functioning kidney", "Known sensitivity or intolerance to angiotensin-converting enzyme inhibitors", "History of angioedema", "Known syncopal disorder", "Pregnant woman or a woman of childbearing potential who is sexually active and not using an appropriate method of birth control (double barrier or oral contraceptives)", "Concomitant therapy with any antihypertensive medications, including those used for indications other than hypertension (e.g., diuretics for any reason, minoxidil for hair loss, propranolol HCl for migraine, terazosin HCl for benign prostatic hyperplasia, 5-phosphodiesterase inhibitors (Viagra, Cialis, Levitra) within 48 hours of clinic visit, ACE-inhibitors for congestive heart failure, or any agent which could cause a change in blood pressure), except for stable doses of NSAIDs, or tricyclic agents taken at bedtime. Patients who are unwilling to discontinue these medications or patients in whom the Investigator feels it is clinically inappropriate to discontinue these medications should not participate in the study", "Concomitant therapy with lithium and/or major psychotropic agents such as phenothiazines", "Concomitant therapy with oral steroids or ACTH", "Concomitant therapy with cold and/or flu medications containing sympathomimetic agents. Intermittent use of therapies containing ephedrine is permitted except within 72 hours of clinic visits for mean trough SiSBP", "Concomitant therapy with any vitamin supplement that may contain pyridoxine or pyridoxine derivative such as pyridoxal phosphate or pyridoxal", "Hypertension induced by oral contraceptives. Replacement hormones (thyroid, testosterone, estrogens) are permitted if the patient has been on a stable dose for at least three months", "Existing symptomatic cerebro-vascular disease including previous transient ischemic attack (TIA) or stroke within 12 months prior to screening", "Myocardial infarction, percutaneous coronary intervention and coronary artery bypass surgery within 6 months prior to screening", "Clinically significant AV conduction disturbance, i.e., second or third degree AV block, sick sinus syndrome or clinically significant bradycardia (resting heart rate < 60 beats/minute) without a permanent pacemaker", "Presence of atrial flutter or atrial fibrillation", "Potentially life-threatening ventricular arrhythmias, decompensated valvular disease, presence of hemodynamically significant obstructive valvular disease, or cardiomyopathy", "Serum potassium < 3.5 or > 5.5 mEq/L", "The presence of severe hepatic impairment as manifested by AST (SGOT) > 2.5 times the upper limit of normal or ALT (SGPT) > 2.5 times the upper limit of normal", "Any clinically significant laboratory value which in the Investigator's judgement could be clinically significant to the outcome of this study. This includes, but is not limited to, hematocrit, haemoglobin or platelet count", "Any moderate to severe renal impairment, as manifested by serum creatinine more than 200 micromol/L", "A history of clinically important gastrointestinal resection, malabsorption or cirrhosis of the liver", "Any concurrent severe disease that, in the Investigator's judgement, could preclude participation or survival", "Use of any investigational drug or device, or participation in any drug study during or within 30 days prior to baseline", "Inability to be taken off of all current antihypertensive medications", "Unwillingness or inability to give consent or to follow the protocol procedures", "Arm circumference greater than 41 cm"], "nct_id": "NCT00157729"},{"minimum_age": 21.0, "maximum_age": 80.0, "gender": "M", "inclusion": ["Current diagnosis of Type I or Type II Diabetes Mellitus.", "Ulcer present for minimum 4 weeks", "Have adequate circulation to the foot", "Can return for follow-up visits", "Be able to read and sign the Informed Consent form before enrollment"], "exclusion": ["Active Charcot's foot ulcer on the foot to be studied", "Presence of any serious disease that can affect wound healing including end stage renal failure requiring hemodialysis or renal transplantation, active malignant disease requiring treatment, hepatic, hematologic, neurologic, or immune disease", "Alcohol or drug abuse problems", "Treatment with oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents", "Presence of infectious disease that can preclude EPC measurements (including HIV, Hepatitis B and C)", "Pregnancy"], "nct_id": "NCT00739323"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [":) To be eligible, the following inclusion criteria (1-6) must be met:", "Age greater than or equal to 18 years.", "Diagnosis of diabetes mellitus (type 1 or type 2). Any one of the following will be considered to be sufficient evidence that diabetes is present:", "Current regular use of insulin for the treatment of diabetes", "Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes", "Documented diabetes by ADA and/or WHO criteria", "At least one eye meets the study eye criteria.", "If only one eye eligible, fellow eye meets criteria", "Able and willing to provide informed consent.", "Patient understands that (1) if both eyes are eligible at the time of randomization, one eye will receive intravitreal triamcinolone ancetonide and one eye will receive laser, and (2) if only one eye is eligible at the time of randomization and the fellow eye develops DME later, then the fellow eye will not receive intravitreal triamcinolone ancetonide if the study eye received intravitreal triamcinolone ancetonide (however, if the study eye was assigned to the laser group, then the fellow eye may be treated with the 4mg dose of the study intravitreal triamcinolone ancetonide formulation, provided the eye assigned to laser has not received an intravitreal injection; such an eye will not be a study eye but since it is receiving study drug, it will be followed for adverse effects). (Subject-Level"], "exclusion": [":) A patient is not eligible if any of the following exclusion criteria (7-13) are present:", "History of chronic renal failure requiring dialysis or kidney transplant.", "A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).", "Patients in poor gylcemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled.", "Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at the time of study entry. 10. Known allergy to any corticosteroid or any component of the delivery vehicle. 11. History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4 months prior to randomization or topical, rectal,or inhaled corticosteroids in current use more than 2 times per week. 12. Patient is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the 3 years of the study. 13. Blood pressure greater than 180/110 (systolic above 180 or diastolic above 110).", "If blood pressure is brought below 180/110 by anti-hypertensive treatment, patient can become eligible. (Study Eye Inclusion Criteria:) The patient must have at least one eye meeting all of the inclusion criteria (a-d) and none of the exclusion criteria (e-x) listed. A patient may have two study eyes only if both are eligible at the time of randomization. The eligibility criteria for a study eye are as follows:", "Best corrected E-ETDRS visual acuity score of greater than or equal to 24 letters (i.e., 20/320 or better) and less than or equal to 68 letters (i.e., worse than 20/40).", "There will be an enrollment limit of approximately 10% of eyes with visual acuity of 64 to 68 letters.", "Definite retinal thickening due to diabetic macular edema based on clinical exam involving the center of the macula.", "Mean retinal thickness on two OCT measurements greater than or equal to 250 microns in the central subfield.", "Media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs. (Study Eye Exclusion Criteria:)", "Macular edema is considered to be due to a cause other than diabetic macular edema.", "An eye should not be considered eligible: (1) if the macular edema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggests that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema.", "An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hare exudates, nonretinal condition).", "An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.).", "Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).", "History of prior treatment with intravitreal corticosteroids. 10. History of peribulbar steroid injection within 6 months prior to randomization. 11. History of focal/grid macular photocoagulation within 15 weeks (3.5 months) prior to randomization.", "Note: Patients are not required to have had prior macular photocoagulation to be enrolled.", "Note: If prior macular photocoagulation has been performed, the investigator should believe that the patient may possibly benefit from additional photocoagulation. 12. History of panretinal scatter photocoagulation (PRP) within 4 months prior to randomization. 13. Anticipated need for PRP in the 4 months following randomization. 14. History of prior pars plana vitrectomy. 15. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 6 months or anticipated within the next 6 months following randomization. 16. History of YAG capsulotomy performed within 2 months prior to randomization. 17. Intraocular pressure greater than or equal to 25 mmHg. 18. History of open-angle glaucoma (either primary open-angle glaucoma or other cause of open-angle glaucoma; note: angle-closure glaucoma is not an exclusion).", "A history of ocular hypertension is not an exclusion as long as (1) intraocular pressure is less than 25 mmHg, (2) the patient is using no more than one topical glaucoma medication, (3) the most recent visual field, performed within the last 12 months, is normal (if abnormalities are present on the visual field they must be attributable to the patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.", "Note: if the intraocular pressure is 22 to less than 25 mmHg, then the above criteria for ocular hypertension eligibility must be met. 19. History of steroid-induced intraocular pressure elevation that required IOP-lowering treatment. 20. History of prior herpetic ocular infection. 21. Exam evidence of ocular toxoplasmosis. 22. Aphakia. 23. Exam evidence of pseudoexfoliation. 24. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis. (Fellow Eye Inclusion Criteria:) In patients with only one eye meeting criteria to be a study eye at the time of randomization, the fellow eye must meet the following criteria:", "Best corrected E-ETDRS visual acuity score of greater than or equal to 19 letters (i.e., 20/400 or better).", "No prior treatment with intravitreal corticosteroids.", "Intraocular pressure less than 25 mmHg.", "No history of open-angle glaucoma (either primary open -angle glaucoma or other cause of open-angle glaucoma; note: angle-closure glaucoma is not an exclusion).", "A history of ocular hypertension is not an exclusion as long as (1) intraocular pressure is less than 25 mmHg, (2) the patient is using no more than one topical glaucoma medication, (3) the most recent visual field, performed within the last 12 months, is normal (if abnormalities are present on the visual field they must be attributable to the patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.", "Note: if the intraocular pressure is 22 to less than 25 mmHg, then the above criteria for ocular hypertension eligibility must be met.", "No history of steroid-induced intraocular pressure elevation that required IOP-lowering treatment.", "No exam evidence of pseudoexfoliation."], "nct_id": "NCT00105404"},{"minimum_age": 21.0, "maximum_age": 50.0, "gender": "A", "inclusion": [": Overweight, age 21-50 years,Women must be premenopausal, Normal glucose tolerance, weight stable for at least 6 months with a weight change no greater than 5 lbs."], "exclusion": [": Exclusion criteria were type 1 or type 2 diabetes, polycystic ovarian disease, BMI <26.5 or weight >300 pounds, weight change >5 pounds in last 6 months, regular exercise >2 hours per week, pregnancy, currently breastfeeding, cholesterol medications, any disorders of glucose or lipid metabolism, use of medication that could affect body composition or glucose metabolism (including oral contraceptives and blood pressure medications), current use of tobacco, use of illegal drugs in last 6 months, history of hypoglycemic episodes, major food allergies or food dislikes, women with inconsistent or absence of monthly menstrual cycles, and a medical history that counter-indicated inclusion in the study."], "nct_id": "NCT00726908"},{"minimum_age": 25.0, "maximum_age": 50.0, "gender": "F", "inclusion": ["BMI (body mass index): 27-40 kg/m2", "Gender: Women only", "Age: 25-50", "Menopausal status: pre-menopausal", "Weight stable for last 2-months", "Not on a weight loss plan", "No ethnic restrictions", "No plans to move from the area over the next 6-months", "Willing to accept random assignment", "Possess English speaking and reading skills to understand and complete forms such as informed consent and study evaluation"], "exclusion": ["Hypertension", "Diabetes (type 1 or 2) or history of gestational diabetes", "Heart disease diagnosis", "Renal or lever disease", "Active neoplasms", "Pregnant, lactating, within 6-months of birth, or planning to become pregnant in the next 6-months", "Hyperthyroidism, unless treated and under control", "Medications known to affect weight / energy expenditure", "Excessive alcohol intake (self-reported, > 3 drinks/day)", "Postmenopausal, including surgical menopause", "Currently under psychiatric care, or severely clinically depressed (>17 on Beck Inventory)"], "nct_id": "NCT00866151"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 diabetes for more than 12 months", "Current treatment: Basal-bolus insulin regimen for more than three months (i.e. at least one daily injection of long-acting insulin (including insulin glargine) and fast-acting insulin with each main meal)", "HbA1c (glycosylated haemoglobin A1c) between 7.0 and 11.0%", "Able and willing to maintain consistent physical activity level throughout the entire study period", "Able and willing to maintain consistent eating habits throughout the entire study period"], "exclusion": ["Proliferative retinopathy that has required acute treatment within the last six months", "Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator", "Liver, kidney or heart problems as judged by the Investigator", "Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures", "Known or suspected allergy to trial products or related products", "Receipt of any investigational drug within one month prior to this trial"], "nct_id": "NCT00509925"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Body Mass Index > 27 kg/m2 and < 40 kg/m2.", "Waist circumference > 102 cm in men and > 88 cm in women.", "Microalbuminuria >= 20 mg/g creatinine and < 300 mg/g creatinine in at least two of three morning urine samples taken on 3 separate days prior to the baseline visit.", "Type 2 diabetes and/or dyslipidaemia."], "exclusion": ["Breastfeeding or pregnant women or who expect to become pregnant.", "Non-use of approved methods of contraception in women of child-bearing potential.", "History of very low calorie diet in the 3 months prior to the screening visit (<1200 kcal/day).", "Change in weight > 5 kg in the 3 months prior to the screening visit.", "History of surgery for weight loss (such as vertical banded gastroplasty, gastric by-pass, etc.)", "History of bulimia or anorexia nervosa according to DSM-IV definition.", "Any clinically significant endocrine disorder, in the opinion of the investigator, especially known alterations in the blood concentration of TSH and free T4.", "Type 1 Diabetes", "Triglyceridaemia > 400 mg/dl (4.52 mmol/l)", "Severe renal dysfunction", "Chronic Hepatitis or clinically known significant liver disease or ALT and/or AST > 3x the upper limit of the normal range at the screening visit.", "Hypertension at the screening visit.", "Presence of any condition (medical, including clinically significant abnormal laboratory tests, physiological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study.", "History of abuse of alcohol or other substances (except smoking).", "Hypersensitivity or intolerance to the active ingredient or any of the excipients, such as lactose. Concomitant medication prior to the screening visit", "Administration of any treatment undergoing clinical investigation (drug or medical device) in the 30 days prior to the screening visit.", "Previous treatment with rimonabant.", "Administration of any of the following products in the 3 months prior to the screening visit", "Anti-obesity drugs (such as, sibutramine or orlistat).", "Other weight loss drugs (phentermine,amphetamines).", "Weight loss herbal preparations.", "Nicotinic acid, fibrates, bile acid sequestrants or Omega 3 drugs (e.g. Omacor).", "Prolonged use (more than a week) of systemic corticosteroids or neuroleptics", "Antidepressants (including bupropion)", "Insulin, thiazolidinediones, \u03b1-glucosidase inhibitors, meglitinides or any group of antidiabetic drugs (except combination of biguanides and sulfonylureas)", "In type 2 diabetes patients, start of or change in treatment with sulfonylureas and/or metformin, in the 4 weeks prior to the screening visit.", "Start of or change in treatment with antihypertensive drugs in the 12 weeks prior to the screening visit.", "Start of or change in treatment with statins and/or ezetimibe in the 8 weeks prior to the screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00458081"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Simultaneous kidney/pancreas transplant recipients", "Insulin dependent Type 1 or 2 diabetes pretransplant", "Recipient age 18-65 years", "Donor age 5-65 years", "Women must have negative serum pregnancy test and practice birth control for study duration", "Negative T-cell crossmatch", "Parent (or guardian) is able to understand the consent form and give written informed consent"], "exclusion": ["Prior treatment with daclizumab", "Known sensitivity or contraindication to tacrolimus, MMF, or steroids", "Patient with significant or active infection", "Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum", "Patients whose life expectancy is severely limited by diseases other than renal disease", "Ongoing substance abuse, drug or alcohol", "Major ongoing psychiatric illness or recent history of noncompliance", "Insufficient cardiovascular reserve", "Malignancy within last 5 years, excluding nonmelanoma skin cancers", "Serologic evidence of infection with HIV or Hepatitis B surface antigen positive", "Investigational drug within 30 days prior to transplant surgery", "Anti-T cell therapy within 30 days prior to transplant surgery"], "nct_id": "NCT00363116"},{"minimum_age": 40.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Adults age 40--75 years-of-age, non-pregnant", "Informed consent", "History of type 2 Diabetes Mellitus", "Stable weight for the last 3 months (no change greater than +5% of body weight)", "ADMA > 0.50 \u00b5M/L (mean of non-diabetic reference group) (Devangelio 2007)", "On stable medical therapy for at least 3 months", "A working telephone"], "exclusion": ["Any history of known coronary heart disease, including a history of congestive heart failure, myocardial infarction, coronary re-vascularization, or stroke", "Pregnancy", "Chronic kidney disease, serum creatinine >2.0mg/dl, chronic liver disease, or uncontrolled hypertension (>160/100).", "Current participation in a formal weight loss program or planning to start such a program during the next 3 months", "Collagen vascular disease, infection, or other inflammatory condition", "Electrocardiogram (EKG) evidence of ischemia or infarction", "Macular edema (swelling of the back of the eye), recent excessive weight gain (over 5% of weight in 30 days), elevated liver function tests > 2.5 X the upper limit, or history of osteoporosis"], "nct_id": "NCT00770367"},{"minimum_age": 50.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["People with type 2 diabetes mellitus who currently are receiving the maximal dose of metformin monotherapy (2500 mg/day).", "These subjects will have had a stable glycohemoglobin (tGHb) in an unacceptably high range (8-11%) for at least 4 months prior to beginning the study.", "Subjects with tGHB > 11% (HbA1c > 10%) will not be recruited into the study."], "exclusion": ["Hematological abnormalities", "liver disease", "kidney disease", "macroalbuminuria (>300 mg albumin/24 hours)", "untreated thyroid disease", "congestive heart failure", "angina", "life-threatening malignancies", "proliferative retinopathy", "severe diabetic neuropathy", "peripheral vascular disease", "serious psychological disorders", "a body mass index > 35", "and a fasting triglyceride of >400 mg/dl.", "Subjects taking slow-release metformin will not be studied.", "Subjects taking medications other than metformin, known to affect fuel metabolism such as:", "insulin", "the sulfonylureas", "glucagon-like peptide 1 (GLP-1) analogs and metabolic inhibitors", "pramlintide", "prednisone and similar steroids", "thyroid hormone", "antipsychotic medications", "thiazide diuretics", "medroxyprogesterone", "high dose aspirin, also will be excluded.", "If concentrations of serum folate, B12 or iron are low, the subject will be excluded from the study until corrected, i.e. until normal concentrations are recorded."], "nct_id": "NCT00607867"},{"minimum_age": 10.0, "maximum_age": 18.0, "gender": "F", "inclusion": ["Apparently healthy, ambulant girls aged 10", "18 years", "Unmarried girls", "Girls with intact uterus", "Resident in the villages chosen for the study"], "exclusion": ["Girls with any severe and/or debilitating illness", "Past history of allergy to any medication"], "nct_id": "NCT00923702"},{"minimum_age": 20.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["body mass index (BMI) \u2265 30", "at least three out of five ATP III criteria for metabolic syndrome. These criteria are defined as: [1] Triacylglycerol \u2265150 mg/dL, [2] HDL <40 mg/dL in men or <50 mg/dL in women, [3] Fasting glucose \u2265100 mg/dL, [4] Systolic blood pressure \u2265 130 mmHg and/or diastolic blood pressure \u226585 mg/dL, and [5] waist circumference \u2265102 cm in men or \u226588 cm in women."], "exclusion": ["diagnosis of type I or II diabetes", "diagnosis of CVD", "diagnosis of cancer", "diagnosis of any other serious medical condition", "use of any medications that affect glucose, insulin, cholesterol, or reproductive hormones", "smoker", "drink more than 2 alcoholic beverages/d", "consume a diet high in whole grains (>3 servings/d)", "pregnant or lactating"], "nct_id": "NCT00455065"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Individuals with or without binge eating disorder and their family members who participated in the initial family study of binge eating disorder and agree to be followed up at 2.5 and 5 years."], "exclusion": ["Unwilling or unable to participate in the follow-up study."], "nct_id": "NCT00777634"},{"minimum_age": 35.0, "maximum_age": 50.0, "gender": "M", "inclusion": ["Age 35 to 50 Chinese men", "Metabolic syndrome as defined according to 1998 World Health Organisation with modification using Asian definition for obesity (body mass index \uf0b325kg/m2, waist circumference 80cm in women and 90 cm in men)", "Low IGF-1 level or IGF-1 level in low normal range (<200 ug/L)"], "exclusion": ["Any malignancy within the past 5 years", "A diagnosis of acromegaly", "Uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure>105mmHg)", "A history of carpel tunnel syndrome", "Poor glycemic control (HbA1c>8%)", "Diabetic microangiopathy", "Previous cardiovascular event", "Anaemia as defined as haemoglobin <11g/dL", "Active thyroid diseases", "Any medical illness that will render the subject vulnerable to fluid retention state, e.g. renal impairment, heart failure or as judged by the investigators as ineligible to participate the study."], "nct_id": "NCT00307411"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": [": Group A:", "Males and females aged 18 to 80 yrs", "Diabetes mellitus type 1 or 2", "Haemoglobin level above the treatment threshold level (as described in the drug description)", "Receiving no darbepoetin alfa treatment", "Best Corrected Visual Acuity (BCVA) better than 20/200", "No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation. Group B:", "Males and females aged 18 to 80 yrs", "Diabetes mellitus type 1 or2", "Anaemia (due to renal failure), haemoglobin level under the treatment threshold level before the initialisation of the therapy (as described in the drug label)", "Starting to receive darbepoetin alfa treatment (darbepoetin alfa, Aranesp, Amgen)", "BCVA better than 20/200", "No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation."], "exclusion": ["History of retinal disease other than DR", "History of intraocular surgery, including laser treatment in the past 4 month", "A major change in the insulin treatment of the patient in the past 4 month or during the follow up period.", "Inability to communicate in German or English", "Dementia; inability to follow commands", "Epilepsy"], "nct_id": "NCT00704652"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2007) and:", "Smoking history of at least 10 pack-years", "Post-bronchodilator forced expiratory volume in 1 second (FEV1) \u2264 65% and \u2265 30% of the predicted normal value", "Post-bronchodilator FEV1/FVC (force vital capacity) < 70%"], "exclusion": ["Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or during the run-in period", "Patients who have had a respiratory tract infection within 6 weeks prior to screening or during the run-in period", "Patients with a body mass index less than 15 or more than 40 kg/m^2", "Patients with concomitant pulmonary disease", "Patients with a history of asthma", "Patients with diabetes Type I or uncontrolled diabetes Type II", "Any patient with lung cancer or a history of lung cancer", "Patients with a history of certain cardiovascular comorbid conditions Other protocol-defined inclusion/exclusion criteria applied to the study."], "nct_id": "NCT00846586"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Ambulatory patients over the age of 18 years with diabetes mellitus.", "Current enrolment in ADEC program (>6 months)or new enrolment in ADEC program (<6 months).", "Confirmed diagnosis of diabetes mellitus, according to the current Canadian Diabetes Guidelines.", "Informed consent provided"], "exclusion": ["History of only gestational diabetes.", "Non-GHC member.", "GHC patients with diabetes who do not attend the ADEC program.", "Unable to give informed consent.", "Any conditions/circumstances that prevent the patient from attending ADEC sessions or participating fully in the program.", "Refusal to allow research staff access to medical records, including hospital charts."], "nct_id": "NCT00498147"},{"minimum_age": 18.0, "maximum_age": 39.0, "gender": "A", "inclusion": ["New onset Typ 1 diabetes (< 6 weeks insulin therapy)", "Age 18-39 years", "GADA and/or IA-2A positive"], "exclusion": ["Kidney disease", "Pregnancy", "Lactating"], "nct_id": "NCT00960635"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["failing maximal oral treatment, defined as mean fasting blood glucose over 8 mmol/l and HbA1C over 7.5% for three months or more", "BMI 25", "35 kg/m2", "fasting plasma C-peptide level over 0.3 nmol/l", "stable metformin and sulfonylurea dose for at least three months", "stable weight for at least three months (change maximal 2 kg)"], "exclusion": ["fasting glucose over 25 mmol/l", "use of alpha-glucosidase inhibitors or thiazolidinediones in the two months preceding the study", "renal or liver failure defined as serum creatinine over 150 micromol/l, liver enzymes over 1.5 upper normal limit", "heart failure", "pregnancy", "alcohol more than two units per day", "inflammatory or infectious diseases", "unstable chronic disease", "discontinuation of smoking within three months of randomisation date", "allergy for or intolerance of glimepiride or novorapid."], "nct_id": "NCT00151697"},{"minimum_age": 10.0, "maximum_age": 37.0, "gender": "A", "inclusion": ["Complete Protocol CP-MGA031-01 (i.e., all subjects who complete Study Day 728, regardless of how many doses of study drug are received).", "Provide written informed consent."], "exclusion": [": None"], "nct_id": "NCT00870818"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Outpatients 18 years and older.", "Male or female patients are eligible.", "Female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use is disallowed.", "Patients with mild to moderate essential diastolic hypertension (grades 1 and 2 WHO classification) measured by calibrated standard sphygmomanometer.", "Patients must have a MSDBP >= 90 mmHg and < 110 mmHg at Visit 1 (week -2 to -4), and a MSDBP >= 95 mmHg and < 110 mmHg at Visit 2 (week 0).", "Patients must have an absolute difference of =< 10 mmHg in their average sitting diastolic blood pressure between Visits 1 and 2.", "Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent)."], "exclusion": ["Severe hypertension (grade 3 WHO classification; MSDBP >=110 mmHg diastolic and/or MSSBP >= 180 mmHg systolic).", "Inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks).", "Known Keith-Wagener grade III or IV hypertensive retinopathy.", "History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 1 (week -2 to -4).", "Transient ischemic cerebral attack during the last 12 months prior to Visit 1 (week -2 to -4).", "Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, or pheochromocytoma, etc.", "Type 1 Diabetes Mellitus.", "Type 2 Diabetes Mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (HbA1c) >8% at Visit 1 (week -2 to -4).", "Administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at Visit 0 (week -4 to -6).", "Known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers.", "Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00409760"},{"minimum_age": 10.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Clinical diagnosis of Type 1 Diabetes and using daily insulin therapy for at least one year.", "Age 10 to 17 years, inclusive.", "HbA1c < 10.0%.", "BMI 5-95th % for age and gender.", "Stable Continuous Subcutaneous Insulin Infusion regimen for at least 1 month and not anticipating a change prior to the subject's completion of the study.", "Subject uses a downloadable insulin pump.", "Normal thyroid function (measured within the previous year).", "For females, subject not intending to become pregnant during the study.", "No expectation that subject will be moving out of the area for the duration of the study.", "Informed consent form signed and understood by the parent/guardian and Child Assent form signed/understood by subjects."], "exclusion": ["The presence of a significant medical disorder (including epilepsy, or any cause of seizures other than hypoglycemia) that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.", "A recent injury to body or limb, Addison's disease, muscular disorder or disease in the judgment of the investigator that will affect the completion of the exercise protocol.", "Asthma which has been medically treated within the last year.", "Medically diagnosed cardiac disease, hypertension, or autonomic dysfunction.", "Use of pseudoephedrine 48 hours prior to the visit (if used in the 48 hours prior to the scheduled visit, the visit will be deferred)", "Severe hypoglycemia resulting in seizure of loss of consciousness in the 3 months prior to a visit.", "Active infection (if at the time of the scheduled visit and infection is present, the visit will be deferred).", "Anticipating a significant change in exercise regimen between visits (i.e. starting or stopping an organized sport).", "Treatment with systemic or inhaled corticosteroids in the last 6 months.", "Current treatment with B-blockers or presenting with high blood pressure.", "Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver.", "Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study", "Known allergy to Terbutaline", "Treatment with atenolol (Tenormin), carteolol (Cartrol), labetalol (Normodyne, Trandate), metoprolol (Lopressor), nadolol (Corgard), phenelzine (Nardil), propranolol (Inderal), sotalol (Betapace), theophylline (Theo-Dur), timolol (Blocadren), tranylcypromine (Parnate), other medications for asthma, heart disease or depression.", "Treatment with ephedrine, phenylephrine, phenylpropanolamine, or pseudoephedrine.", "The presence of an irregular heart beat, increased heart rate glaucoma or an overactive thyroid gland."], "nct_id": "NCT00974051"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["msDBP \u2265 90 mmHg and < 110 mmHg at the visit prior to Visit 3 (Visit 2 or optional Visit 201)", "msDBP \u2265 95 mmHg and < 110 mmHg at Visit 3 (Day 1 / randomization).", "All patients must have an absolute difference of \u2264 10 mmHg in their msDBP during the last 2 visits of the single-blind run-in period (Visit 2 and 3 or Visits 201 and 3)."], "exclusion": ["Severe hypertension", "Pregnant or nursing (lactating) women", "Women of child-bearing potential", "Previous or current diagnosis of heart failure (NYHA Class II-IV).", "Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1.", "Uncontrolled Type 1 or Type 2 diabetes mellitus", "Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures", "History of malignancy within 5 years", "History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention"], "nct_id": "NCT00739973"},{"minimum_age": 18.0, "maximum_age": 30.0, "gender": "A", "inclusion": ["Healthy lean women (with body mass indices [BMI] < 25 kg/m2)", "Overweight otherwise healthy men (with BMI > 27 kg/m2)", "Overweight otherwise healthy women (with BMI > 27 kg/m2)."], "exclusion": ["A history of any illness that may affect the concentrations of the hormones to be studied, e.g. infectious diseases, renal or hepatic failure, type 1 or type 2 diabetes mellitus, cancer or lymphoma, hypogonadism, malabsorption or malnourishment, hypo- or hyperthyroidism, hypercortisolism, alcoholism or drug abuse, anemia, or eating disorder", "On medications known to affect the hormones to be measured (glucocorticoids, anti-seizure medications, and thyroid hormones)", "A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. coli derived proteins"], "nct_id": "NCT00140231"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "F", "inclusion": ["PCOS"], "exclusion": ["age <18 or >35 years", "BMI >35 kg/m2", "neoplastic, metabolic, hepatic, renal, and cardiovascular disorders", "Current or previous use of oral contraceptives, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic and anti-obesity drugs or other hormonal drugs."], "nct_id": "NCT00953355"},{"minimum_age": 8.0, "maximum_age": 16.0, "gender": "A", "inclusion": ["Type I diabetic children", "Tanner stage II-IV", "Patients of the Schneider's national institute of childhood diabetes. Duration of diabetes", "more than one year.", "HbA1C between 8 and 12 at time 0.", "Mandatory 4 daily self blood glucose measurements and daily recording of adverse events.", "A signed informed consent of the parents and child."], "exclusion": ["Additional chronic significant disease such as cardiac, liver, renal disease .", "Children who exercise regularly more than 180 min per week.", "Cardiac symptoms: history of chest pain , syncope , palpitations or dyspnea during exercise.", "Eating disorders.", "Participation in a study during the past month."], "nct_id": "NCT00491465"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Obesity WHO III"], "exclusion": ["Contraindications of aerobic endurance training"], "nct_id": "NCT00875186"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["Male or female outpatients >= 18 years and < 86 years", "Patients with essential diastolic hypertension", "At visit 1, the patient must have mean sitting diastolic blood pressure >= 95 mmHg and < 10 mmHg; patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure < 100 mmHg", "At visit 2, patients must have a mean sitting diastolic blood pressure of >= 95 mmHg and < 100 mmHg", "At visit 3, patients must have a mean sitting diastolic blood pressure of >= 90 mmHg and < 110 mmHg"], "exclusion": ["Severe hypertension >= 180/110 mmHg", "Known or suspected contraindications, including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures", "Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2", "History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack, myocardial infarction or other types of revascularization", "Malignant hypertension", "All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment", "Pregnant or nursing women", "History of heart failure", "Angina pectoris", "Second or third degree heart block", "Life threatening or symptomatic arrhythmias", "Clinically significant valvular heart disease", "Evidence of a secondary form of hypertension", "Known or moderate malignant retinopathy", "Evidence of hepatic disease", "Evidence of renal impairment Other protocol-defined exclusion criteria may apply."], "nct_id": "NCT00413413"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Healthy male and female subjects aged 18-45", "Type 1 diabetes mellitus patients aged 18-45", "Body Mass Index 21-38 kg/m2", "Normal results of routine blood test to screen for hepatic, renal, and hematological abnormalities and an EKG stress test.", "Female volunteers of childbearing potential will undergo HCG pregnancy test. Only women who are not pregnant will participate in the study. Diabetic Subjects:", "HBA1C= 5.5-11.0%", "Duration of Type 1 Diabetes > 3 yr", "Normal bedside autonomic function"], "exclusion": [": All Subjects", "Prior or current history of poor health", "Abnormal results following screening tests", "Pregnancy", "Subjects unable to give voluntary informed consent", "Subjects with a recent medical illness", "Subjects with a history of hypertension, heart disease or cerebrovascular disease", "Subjects with known liver or kidney disease", "Subjects with recent weight loss or consuming a low carbohydrate diet", "Subjects taking steroids", "Subjects taking beta-blockers", "Subjects on anticoagulant drugs, anemic or with known bleeding diatheses", "Evidence of diabetic neuropathy, autonomic neuropathy, proteinuria, extensive background or proliferative retinopathy, hypertension, or cardiovascular disease"], "nct_id": "NCT00600730"},{"minimum_age": 1.0, "maximum_age": 75.0, "gender": "A", "inclusion": [":1. Donors with a degenerative disease phenotype or genetic disorders such as Type I Diabetes, heart disease, or infertility (azoospermia and premature ovarian failure)"], "exclusion": [":1. Unable to read or understand English.", "Unable to provide skin biopsy sample due to skin condition in the underarm area."], "nct_id": "NCT00628199"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Completed the VIAject\u2122-06J protocol", "Informed consent must be obtained in writing for all subjects"], "exclusion": ["History of frequent severe hypoglycemia within the prior six months which prevent study participation at the discretion of the investigator", "History of known hypersensitivity to any of the components in the study medication", "Progressive disease likely to prove fatal", "Known significant hepatic disease or serum AST or ALT values > 3 X upper limit of normal or bilirubin levels > 1.5 X upper limit of normal", "Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy (see Appendix B), proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease, which has resulted in amputation or recent onset of chronic foot ulcers or claudication, or the recent, clinically documented loss a pedal pulse.", "History of moderate to severe ketoacidosis within the 3 months preceding screening for the study", "Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance.", "Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator", "A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy or a woman intending to become pregnant during the study 10. Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe 11. A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the subject in the study to be inappropriate or unsafe"], "nct_id": "NCT00875459"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [], "exclusion": [], "nct_id": "NCT00407381"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["people with no health insurance"], "exclusion": ["people with any type of health insurance coverage"], "nct_id": "NCT00151190"},{"minimum_age": 30.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Patients with Type II Diabetes Mellitus (non-insulin-dependent), not taking any anti-diabetic agent.", "Fasting blood glucose level below 250mg/dL", "Age 30 to 60 years", "Both genders", "HbA1c of 6.0% to 13.0%, inclusive", "Body mass index (BMI) below 40 kg/m2", "Female subjects not pregnant, not lactating, post-menopausal, surgically sterile or using effective contraceptive measures are included.", "Provide signed Informed Consent"], "exclusion": ["Subject unable to give Informed Consent", "Patients with Type I Diabetes Mellitus a. History of ketoacidosis", "Serum creatinine > 2.0 mg or above", "Liver Function Test; Elevated liver enzymes: ALT/AST (2.5 times the upper limit of the reference range), Bilirubin Testing", "Accept three fold, A/G ratio", "Accept two fold", "Hypercholesterolemia (more than 300mg)", "Myocardial Infarction (MI) within 6 months", "Severe or unstable angina", "Elevated triglycerides >500 mg/dL", "Abnormal EKG reading 10. Abnormal assessment in stress Echocardiography (ultrasound imaging)for Left Ventricular ejection fraction for congestive heart failure 11. Anemia (Hb <11 g/dl for men or <10 g/dl for women) 12. Blood Dyscrasia, Decrease in Hematocrit", "Accept two fold, Low WBC count", "Accept one fold, Decrease platelet count", "Accept three fold 13. Macular edema/ macular degeneration 14. Patients who are taking insulin 15. Subjects with systolic blood pressure >170 mmHg or diastolic blood pressure >90 mmHg 16. Active participation in another trial 17. Subject physically unable to perform exercise due to neurologic or orthopedic conditions. 18. Patients taking antipsychotic medications. 19. Subjects testing positive for the illicit drugs (cocaine, amphetamines, heroin) 20. Subjects who smoke tobacco products 21. Females who are lactating, pregnant, or planning to become pregnant 22. Signs and symptoms of Congestive heart failure (such as shortness of breath or swelling in upper extremities) 23. History of severe edema or a medically serious fluid retention"], "nct_id": "NCT00737152"},{"minimum_age": 25.0, "maximum_age": 60.0, "gender": "F", "inclusion": ["Females aged 25-60", "BMI 28-35 kg/m2", "No known diagnosis of diabetes", "No known diagnosis of coronary heart disease", "Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no more than 1 hour per week)", "Stable weight (variation < 3 kg within 6 months of screening visit)", "Ability to give informed consent", "Ability to follow verbal and written instructions", "Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods) 10. Nonsmoker (tobacco, marijuana) 11. Outpatient visits every 2 weeks throughout the study period are required. While most of these visits are short (15 minutes)ability to commute to the performance site in Boston, on a regular basis, is necessary."], "exclusion": ["Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria", "Coronary heart disease (history of myocardial infarction or unstable angina pectoris)", "Uncontrolled hypertension hypertension (BP > 150/90 mmHg on or off antihypertensive medication)", "Uncontrolled dyslipidemia (LDL > 200 or TG > 400 on or off lipid lowering medication)", "Tobacco, marijuana or intravenous drug use", "Shift workers (night shift or alternating day/night shifts)", "Recent weight loss (> 3 kg within 4 months of the screening visit)", "Gastroparesis", "Inflammatory bowel disease 10. Malignancy treated with chemotherapy within the past 3 years 11. History of pancreatitis 12. Depression requiring hospitalization or diagnosis of psychosis 13. Renal insufficiency (creatinine clearance < 50 ml/min) 14. Transaminases > 2x above the normal range 15. Pregnancy within 6 months of the screening visit 16. Breastfeeding 17. Failure to use medically approved contraceptive methods 18. History of an eating disorder (anorexia, bulimia or laxative abuse) 19. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling) 20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit 21. Previous participation in a clinical study with exenatide 22. Presence or history of allergic reaction to multiple drugs"], "nct_id": "NCT00456885"},{"minimum_age": 25.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Insulin resistance, impaired glucose tolerance"], "exclusion": ["unstable chronic disease, acute disease"], "nct_id": "NCT00259168"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["21 years of age or older", "Have Type 1 Diabetes Mellitus as defined by American Diabetes Association criteria or judgment of physician for at least 2 years (including those who may also be treated with metformin, thiazolidinedione, exenatide, or pramlintide).", "Use of an insulin pump", "If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, have stability on the medication for at least 1 month prior to enrollment in the study", "Willingness to use lispro (Humalog) insulin for the duration of the inpatient study", "Demonstration of proper mental status and cognition for the study"], "exclusion": ["Age <21", "Pregnancy", "Hematocrit <36% (females); <38% (males)", "Symptomatic coronary artery disease (e.g. history of myocardial infarction, history of acute coronary syndrome, history of therapeutic coronary intervention, history of coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, positive stress test or catheterization with coronary blockages >50%).", "Congestive heart failure", "History of a cerebrovascular event", "Use of a medication that significantly impacts glucose metabolism (oral steroids)", "Atrial fibrillation", "Uncontrolled hypertension (resting blood pressure >140/90)", "History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans", "Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the FreeStyle NavigatorTM CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants)", "Active enrollment in another clinical trial", "Allergy or adverse reaction to lispro insulin", "Known adrenal gland problem, pancreatic tumor, or insulinoma", "Current alcohol abuse, substance abuse, or severe mental illness", "Retinopathy and renal failure", "Uncontrolled anxiety or panic disorder", "Known bleeding diathesis or dyscrasia", "Renal insufficiency (creatinine >1.5)", "Any comorbid condition affecting glucose metabolism"], "nct_id": "NCT00977808"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age 18 years or older;", "Have been diagnosed with type 1 diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;", "Willing not to inject insulin or wear an insulin pump infusion set within 3 inches from either Sensor site;", "Willing to participate in an 8-hour in-clinic session on study Days 5, 10, and 15 and be willing to take 4 fingersticks per hour and have 4 blood draws per hour for the 8-hour duration of each of these in-clinic sessions;", "Willing to take a minimum of 6 fingersticks per day during home use;", "Willing to refrain from the use of acetaminophen during this study and for at least 24-hours prior to enrollment;", "Willing not to schedule an magnetic resonance (MRI) scan, computed tomography (CT) scan, x-ray, for the duration of the study;", "Able to speak, read, and write English."], "exclusion": ["Have extensive skin changes/diseases that preclude wearing the Sensor on normal skin (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites;", "Subjects who have a known allergy to medical-grade adhesives;", "Are pregnant as demonstrated by a positive pregnancy test within 72 hours of insertion;", "Have a hematocrit that is less than 30%, or greater than 55%;", "Current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study);", "Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis B or C)."], "nct_id": "NCT00939289"},{"minimum_age": 10.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Male and female patients between 10 and 18 years of age, diagnosed with type 1 diabetes within 18 months", "Fasting C-peptide level above 0.1 nmol/l", "Presence of GAD65 antibodies", "Written informed consent (patient and parent/guardian) Key"], "exclusion": ["Secondary diabetes mellitus or MODY", "Treatment with immunosuppressants", "Treatment with any vaccine within 1 month prior to first Diamyd\u00ae dose or planned treatment with vaccine up to 2 months after the second Diamyd\u00ae dose", "Participation in other clinical trials with a new chemical entity within the previous 3 months", "History of certain diseases or conditions (e.g. epilepsy, anaemia, alcohole or drug abuse)", "HIV or hepatitis", "Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study", "Pregnancy (or planned pregnancy within one year after 2nd administration)"], "nct_id": "NCT00435981"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "A", "inclusion": ["Informed consent", "Homozygous for Arginine at codon 16 or homozygous Gly at codon 16", "No regular usage of medication other than oral contraceptives"], "exclusion": ["History of cerebrovascular, cardiovascular, or peripheral vascular disease", "Smoking", "Alcohol usage of more than 10 units per week", "Inability to abstain from xanthine-derivatives (coffee, tea, cola, chocolate, cacao) or alcohol for 2 days", "BMI above 30 kg/m2", "Participation to any other trial in the preceding 3 months", "Ongoing disease of any kind", "Pregnancy"], "nct_id": "NCT00160056"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Type 1 diabetes", "Current treatment with any insulin in any regimen", "Body mass index (BMI) below 38.0 kg/m2", "HbA1c below or equal to 13.0%"], "exclusion": ["Total daily insulin dosage more than 100 IU/day", "Current acute or chronic pulmonary disease (excluding asthma)", "Recurrent major hypoglycaemia", "Proliferative retinopathy or maculopathy requiring acute treatment", "Smoker", "Chest X-ray with clinically significant abnormalities"], "nct_id": "NCT00725036"},{"minimum_age": 13.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Patients who have been referred for outpatient therapy services will be included if they have Type 1 Diabetes and are 13-17 years of age."], "exclusion": ["Potential participants will be excluded if they have the following co-existing diagnoses: mental retardation, pervasive developmental disorders, substance abuse, eating disorders, psychosis, other acute psychiatric or medical needs, such as suicidality.", "Potential participants will be excluded if they are not fluent in the English language.", "If a family is not eligible or declines to participate in the group therapy research, they will be referred for individual therapy."], "nct_id": "NCT00622271"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Age 18-60 years", "Type-1 diabetes diagnosed between 5-40 years of age", "Normal weight(BMI 18-27),", "Insulin treatment from time of diagnosis."], "exclusion": ["Severe complications to diabetes", "Abnormal liver or kidney function", "Haemoglobin below the lower limit", "Macroalbuminuria", "Systemic disease", "Pregnancy."], "nct_id": "NCT00603031"},{"minimum_age": 6.0, "maximum_age": 12.0, "gender": "A", "inclusion": ["Male and female children age 6-12 diagnosed with ADHD of any subtype according to DSM-IV criteria. A structured diagnostic interview (Kiddie Sads Present and Lifetime Version) will be conducted to confirm diagnosis of ADHD and assess for comorbid mental health disorders.", "Primary caregiver (parent or guardian) has given informed consent; child participant gives ongoing assent throughout the study."], "exclusion": ["Changes to participants' ADHD medication within 6 weeks of study onset.", "Diagnosis of additional mental health disorder using the Kiddie Sads.", "Diagnosis of cancer.", "Antibiotic use for periods greater than 2 weeks within the 10 weeks prior to the study", "Diagnosis of Type 1 diabetes and insulin use", "Low serum ferritin/iron deficiency (<30 ng/ml)"], "nct_id": "NCT00704990"},{"minimum_age": 20.0, "maximum_age": null, "gender": "A", "inclusion": [":(three or more of following five factors)", "waist circumference(male: more than 90cm, female: more than 80cm)", "blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg)", "fasting plasma glucose: more than 100mg/dL", "fasting triglycerides: more than 150mg/dL", "High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL)"], "exclusion": [": (any one of following factors)", "uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug", "Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL", "triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL", "subjects taking antilipidemic drug", "past history of coronary heart disease or cerebrovascular disease"], "nct_id": "NCT00976274"},{"minimum_age": 15.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Age 14-50 years at onset of signs or symptoms of FSGS", "Biopsy proven FSGS", "Estimated glomerular filtration rate (GFR) \u2265 40 ml/min/1.73 m2", "Urine protein > 3.5 g/24h", "Biopsy confirmed primary FSGS (including all subtypes)", "Willingness to follow the clinical trial protocol, including medications, and baseline and follow-up visits and procedures"], "exclusion": ["Secondary FSGS", "Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil levamisole, methotrexate, or nitrogen mustard in the last 90 days", "Active/serious infection", "Malignancy", "Previously diagnosed diabetes mellitus type 1 or 2", "Clinical evidence of cirrhosis or chronic active liver disease", "History of significant gastrointestinal disorder", "Allergy to study medications, and Inability to consent/assent"], "nct_id": "NCT00302536"},{"minimum_age": 21.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Age 21-65", "BMI 27-40 kg/m2", "Fluently speaks and reads English", "Access to the Internet at home or at work", "Valid email address", "Access to a scale for weekly weigh-ins", "Agree not to seek additional weight loss treatment", "Agree to come back regardless of amount of weight lost", "Participant in NCT00377208"], "exclusion": ["Current, planned, or previous pregnancy within 12 months", "Planned or past weight loss surgery", "Recent weight loss of >= 15 lbs in the past 6 months", "History of:", "Myocardial infarction", "Stroke", "Type 1 and Type 2 diabetes", "Unstable angina", "Congestive heart failure", "Inability to exercise due to severe arthritis or other musculoskeletal problems", "Cancer (except non-melanoma skin cancer)", "Evidence of severe cognitive impairment or major psychiatric illness", "Plans to move in the next 6 months", "Answering yes to any question on the Physical Activity Readiness Questionnaire (PAR-Q)"], "nct_id": "NCT00709501"},{"minimum_age": 50.0, "maximum_age": null, "gender": "A", "inclusion": ["Subjects must have predominantly classic, minimally classic, or occult with no classic lesions, as determined by the Investigator, secondary to AMD, with a total lesion size (including blood, scarring, and neovascularization) of < 12 total disc areas (21.24 mm2), and a GLD \u22645.4 mm", "Subjects must be age 50 or older"], "exclusion": ["Subjects with prior or concurrent subfoveal CNV therapy including thermal laser photocoagulation (with or without photographic evidence), photodynamic therapy, injections with Macugen\u00ae, intravitreal or subretinal steroids, transpupillary thermotherapy (TTT), and systemic anti-angiogenic or intravitreal anti-angiogenic agents in study eye. (Note: This includes subjects with no known history, but with photographic evidence of prior therapy)", "Subjects who underwent previous radiation therapy to the eye, head or neck", "Subjects that have been previously diagnosed or have retinal findings consistent with Type 1 or Type 2 Diabetes Mellitus"], "nct_id": "NCT00454389"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) \u2265 95 mmHg and < 110 mmHg at Visits 1 and 2", "Patients who have been treated for hypertension within the 4 weeks prior to", "Visit 1 must have a msDBP \u2265 90 mmHg and < 110 mmHg at Visit 2", "All patients must have a msDBP \u2265 90 mmHg and < 110 mmHg at Visit 4"], "exclusion": ["Severe hypertension", "Pregnant or nursing (lactating) women", "Women of child-bearing potential", "Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)", "Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1", "Uncontrolled Type 1 or Type 2 diabetes mellitus", "Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures", "History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention Other protocol-defined inclusion/exclusion criteria may apply."], "nct_id": "NCT00777946"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Age 18 years or older", "Diagnosis of diabetes mellitus (Type I or II) requiring insulin or hypoglycemic agents to control blood sugars.", "Cutaneous, lower extremity ulcer of the foot that is \u22651.5 and \u226410.0 cm\u00b2 in size and Wagner Classification Grade 1 in appearance. Note", "Ulcer area must be calculated at Screening Visit and on the Treatment Day (Day 1) using measurements obtained by tracing the ulcer perimeter after debridement to confirm patient eligibility prior to randomization.", "Documented ulcer presence for \u22656 weeks prior to signing the informed consent form", "Recently debrided ulcer (within 2 weeks from screening visit)", "Ulcer free of all necrotic soft tissue", "Affected limb transcutaneous partial pressure oxygen (TcpO2) >40mmHg; or a toe pressure \u226540mmHg; or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic waveforms) at screening", "Inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 monofilament in the peri-ulcer area", "Willing to adhere to wearing off-loading orthopedic shoe for up to 16 weeks (i.e., through 2 weeks after ulcer closure) starting on Day -14 (the first day of the screening run-in period)", "Willing to adhere to wearing customized shoes during the durability phase of the study", "Females of child-bearing potential must have a negative serum beta human chorionic gonadotropin hormone (\u00dfhCG) test result from a sample obtained in the 7 days prior to Treatment Day 1 and be neither breastfeeding nor intending to become pregnant during the study", "All individuals (study patients/partners) of childbearing potential must agree to use a method of contraception deemed acceptable by the Investigator or agree to remain abstinent throughout the study", "Be able to understand and sign an informed consent form before entering into the study, and must be willing to comply with all study procedures"], "exclusion": ["Any unstable medical condition judged by the Investigator or Medical Monitor that would cause the study to be detrimental to the patient", "Hemoglobin Alc (HbA1c) test result of >12% documented at the Screening Visit", "Ulcers caused primarily by untreated vascular insufficiency; or ulcers with an etiology not related to diabetes", "Ulcers on the heel", "More than three ulcers on the target lower extremity", "The ulcer to be studied is not anatomically distinct from another ulcer(s) (i.e., separated by <1 cm from another ulcer or would interfere with standard of care treatment of another ulcer). Only a single ulcer can be treated in this study.", "Ulcers which decrease in area by >30% during the screening 2-week run-in period", "Ulcers with underlying osteomyelitis", "Patients presenting with the clinical characteristics of cellulitis at the ulcer site (suppurative inflammation involving particularly the subcutaneous tissue, often mild erythema, tenderness, malaise, chills and fever)", "If either beta hemolytic streptococci (in any amount) or total bacterial load of >1e6 CFU/gram of tissue is present in the screening biopsy sample at the ulcer site, the patient should be given a single 7-day course of topical antibiotics and then redebrided and biopsied for quantitative culture. A second biopsy exceeding the limits above will result in exclusion from the study due to the high risk of local infection than may adversely affect ulcer closure.", "Revascularization surgery on the leg with the wound to be treated \u22648 weeks prior to signing the informed consent form", "Surgery to lengthen Achilles tendon on the leg with the wound to be treated \u22648 weeks prior to signing the informed consent form", "Necrosis, purulence, or sinus tracts that cannot be removed by debridement on foot to be treated", "Needs concurrent topical antimicrobials to treat the ulcer site, or received such therapies within 7 days prior to signing the informed consent form", "Received dermal substitute or living skin equivalent (e.g., Dermagraft\u00ae or Appligraf\u00ae) within 30 days prior to signing the informed consent form", "Received prior PDGF-BB (Regranex\u00ae/becaplermin) therapy within 30 days prior to signing the informed consent form", "Has known sensitivity to products of bovine origin", "Life expectancy of less than 12 months", "Patients with a definite diagnosis of any immunodeficiency disorder", "Viral hepatitis [patient must have a negative hepatitis B surface-antigen (HBsAg) and hepatitis C antibody (HepCAb) test results obtained within 2 weeks prior to the Treatment Day (Day 1)]", "Active, uncontrolled connective tissue disease", "Renal failure as defined by serum creatinine >2.5 mg/dL", "Liver function studies (e.g., AST, ALT) that are >2.0 times upper limit of normal", "Poor nutritional status as measured by serum albumin <3.0 g/dL", "Active cancer or a history of cancer in the 5 years prior to signing the informed consent form (however, history of basal cell carcinoma is allowed)", "Active (i.e., recent onset of erythema, edema, and increased temperature of the foot with normal radiographs ) Charcot or other structural deformity that would prevent adequate off-loading of the study foot", "Treatment with any systemic corticosteroid, immunosuppressive chemotherapeutic agent, antiviral, or previous/current radiation therapy to lower extremity within 30 days prior to signing the informed consent form", "Received another investigational drug or biologic within 30 days prior to signing the informed consent form or currently participating in an investigational drug or biologic study", "A psychiatric condition or chronic alcohol or drug abuse problem, determined from the patient's medical history, which in the Investigator's opinion may pose a threat to patient compliance", "History of non-compliance with treatment or clinical visit attendance (i.e., this study requires that patients will comply with the protocol and ulcer care regimen)"], "nct_id": "NCT00493051"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Eligible participants with non-treated OSA syndrome were aged between 18 to 65 years, with a body-mass index (BMI) \u2265 30 kg/m2 or \u2265 27 kg/m2 in the presence of other risk factors such as controlled systemic hypertension, type 2 diabetes, dyslipidemia and/or visceral obesity (as defined by a waist circumference \u2265 102 cm in men and \u2265 88 cm in women)."], "exclusion": ["Exclusion criteria were uncontrolled systemic hypertension defined as blood pressure > 145/90 mm Hg, previous pharmacological or surgical treatment for weight loss, had already used CPAP or had severe diurnal hyper somnolence requiring immediate treatment."], "nct_id": "NCT00729963"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["All patients (men, women) who are African American or Hispanic over the age of 21 who have been diagnosed with type 2 diabetes and have a HbA1c of greater than 8.0%. Subjects with neuropathic pain will be included in the study. Their pain will be assessed via a validated pain scale. Their primary care providers will treat their pain as necessary."], "exclusion": ["Pregnant women, patients on dialysis, patients with liver disease or liver enzymes elevated three times above normal, patients with blood pressure greater than 160 systolic or 95 diastolic on two consecutive visits, patients with history of severe depression (as determined by hospitalization or the HAM-D survey) or suicide attempts, patients on therapy for depression, patients already taking SSRI's, and patients with psychotic features or bipolar disease."], "nct_id": "NCT00624013"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 1 diabetes (WHO criteria)", "Diabetic nephropathy (2 out of 3 consecutive 24 hour urinary samples with albumin excretion > 300 mg/24hour and diabetic retinopathy in the absence of signs of other kidney or urinary tract disease) 27 or diabetic glomerulosclerosis verified by biopsy.", "Hypertension: Blood pressure > 135 mmHg systolic and/or 85 mm Hg diastolic repeatedly.", "Age from 18 to 70 years."], "exclusion": ["Age < 18 years or > 70 years.", "Pregnancy or fertile women not using adequate anticonceptive (intrauterine device, sterilization, or oral anticonceptive)", "Malignant hypertension.", "Blood pressure > 180/105 mm Hg", "Known renal artery stenosis", "GFR < 30 ml/min/1.73 m\u00b2", "Serum potassium > 4.8 mmol/ l", "Heart failure, myocardial infarction, unstable angina or coronary bypass operation within the previous three months.", "Abuse of drugs or alcohol.", "Not able to understand the written information.", "Known intolerance to ACE inhibitors.", "Chronic use of non steroid inflammatory drugs or aspirin (above 1 g/day)"], "nct_id": "NCT00118976"},{"minimum_age": 18.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["apparently healthy"], "exclusion": ["diagnosis of any chronic disease", "wheat allergy"], "nct_id": "NCT00930956"},{"minimum_age": 30.0, "maximum_age": 74.0, "gender": "A", "inclusion": ["Outpatients who are able to visit the study site throughout the run-in period", "Aged 30 and 74 years", "Type II diabetes mellitus", "Patients with urinary albumin to creatinine ratios within the following ranges at 2 measuring points during the run-in period 1) the first-morning voided urine, iin the range of 100 to 300 mg/g Creatinine 2) < 100 mg/g Creatinine at either point of Visit 2 or 3, but in the range of 100 to 300 mg/g Creatinine at follow-up", "Serum creatinine level of < 1.5 mg/dL in male and < 1.3 mg/dL in female", "Normotensive or hypertensive patients", "Patients taking AT1 antagonists or ACE inhibitors at screening, but are able to stop those drugs during the study", "Patients who are able to provide written informed consent in accordance with the Good Clinical Practice (GCP) and other relevant laws such as the Pharmaceutical Affairs Law"], "exclusion": ["Age of onset of type 2 diabetes is < 30 years", "Type I diabetes", "Urinary albumin to creatinine ratio of > 300 mg/g Creatinine", "HbA1c 9%", "Seated SBP 180 mmHg or DBP 110 mmHg", "Findings suggesting a renal disease other than diabetic nephropathy; such as post renal transplantation, history of non-diabetic renal disease, marked haematuria, complication of urinary tract infection", "Cardiovascular diseases:", "Patients with unstable angina, myocardial infarction, CABG, PTCA within 6 months before", "CHF with NYHA III-IV", "TIA within 6 months", "Stroke within 6 months", "AV block (grade II-III) or AF", "Serious arrhythmia", "Known or suspected secondary HT", "History of angioedema during administration of ARB/ACE-i", "Hypersensitivity 10. History of sudden exacerbation of renal function due to ARB/ACE-i 11. Markedly poor bile secretion 12. Hepatic dysfunction: SGPT (ALT) or SGOT (AST) 100 IU/L 13. Serum potassium level < 3.5 mEq/L or 5.1 mEq/L 14. Unable to discontinue ARB/ACE-i 15. Require prolonged administration of any medications affecting blood pressure, except diuretics, or blockers, and CCB 16. Untreated sodium depletion 17. Pre-menopausal females who meet any one of the following:", "Pregnant or possibly pregnant", "Breast-feeding", "Hope to be pregnant during the study period", "Even when a patient is confirmed not to meet the above criteria at the start of the study, a female patient who has the potential to be pregnant during the study is to undergo pregnancy tests. If the result turns positive, the study medication should be discontinued. 18. Malignant tumour or other diseases requiring oral or injection immunosuppressants 19. Non-compliance 20. History of drug or alcohol abuse 21. Participated in other clinical studies within 3 months 22. Any other conditions investigators judged as ineligible"], "nct_id": "NCT00153088"},{"minimum_age": 18.0, "maximum_age": 64.0, "gender": "A", "inclusion": ["Healthy male and female subjects, age 18-64, who have signed the consent form", "Subjects with a body mass index (BMI) 18-30 kg/m2", "Subjects who are willing to abstain from sex or use a barrier method of birth control (Women 1 week, Men 4 months after leaving the trial)", "Subjects with a negative pregnancy test and drug screen", "Subjects with laboratory values within normal limits (CBC/differential, CMP, enzymes, ECG, vital signs, urinalysis)", "Subjects with ability to comprehend and complete the questionnaires and forms", "Subjects who are likely to comply with study procedures and test article consumption", "Subjects whose schedules permit a 10-12 hour stay in the clinic followed by daily evaluations for one week (7 days)", "Subjects who are available for a 14-day follow up phone call (women) and 4-month follow up phone call (men).", "Subjects who are likely to abstain from taking unauthorized medications or supplements or participating in any other clinical trial or experimental treatment during this trial", "Subjects who are likely to follow the low isoflavone diet program"], "exclusion": ["\u00b7 Subjects with any allergic reaction or sensitivity to soy, isoflavones, or any component of the test article product", "Subjects who consume >5 alcoholic beverages per week", "Subjects who are pregnant, lactating, or at risk of becoming pregnant", "Subjects who have blood (or urine) levels outside the normal range for any of the hepatic, renal, hematologic, lipid or coagulation parameters measured.", "Subjects on Hormone Replacement Therapy or Birth Control Pills within the past three months.", "Subjects on any other clinical trial or experimental treatment in the past 3 months", "Subjects with a history of diabetes (Type 1 or Type 2 diabetes mellitus) or other endocrine disorders, uncontrolled hypertension, prior cerebrovascular accident or seizure disorder, cardiovascular, hepatic or renal disease, active cancer, hematologic disorder, thromboembolic disease, or HIV infection."], "nct_id": "NCT00504335"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients diagnosed with an acute myocardial infarction or unstable angina pectoris according to the joint ESC and ACC recommendations [58].", "Classification of impaired glucose tolerance (IGT) or type 2 diabetes (T2DM) by means of an oral glucose tolerance test (OGTT) according to WHO [59].", "Patients who have signed a written informed consent consistent with ICH-GCP guidelines and local legislations prior to participation in the trial."], "exclusion": ["No informed consent.", "<18 years old.", "Previous known type 2 diabetes.", "Admission plasma glucose >12 mmol/L.", "Impaired renal function (S-creatinine \u2265 130 \u03bcmol/L or need of renal dialysis).", "BMI>30.", "Known Type 1 diabetes, GAD positive or C-peptide<0.30.", "Patients with severe concomitant disease (i.e. malignancy, liver failure).", "Patients who at discharge are planned for Coronary Artery Bypass Grafting or percutaneous coronary intervention. 10. Congestive heart failure (NYHA III-IV). 11. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception. 12. Patients who, in the opinion of the investigator, will have difficulties to comply with the protocol (examples: alcohol or drug abuse, psychiatric disorder, resident outside of the catchment area)."], "nct_id": "NCT00627744"},{"minimum_age": 12.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Adults 12 to 45 years old who are in good general health", "Confirmed diagnosis of insulin requiring type 1 diabetes mellitus with good glycemic control", "Measurable C-peptide levels"], "exclusion": ["Females must not be pregnant or lactating and willing to practice contraception", "No prior malignancy, other than non-melanoma skin cancer", "Body Mass Index (BMI) > 32 at screening"], "nct_id": "NCT00451321"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["28 (14 males, 14 females) Healthy volunteers aged 18-45 yr.", "28 (14 males, 14 females) Type 1 diabetic patients aged 18-45 yr.", "HbA1c < 11.0%", "Has been diagnosed Type 1 DM", "No major diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)", "Body mass index < 40kg/m-2"], "exclusion": ["pregnancy Medical history-", "Hepatic Failure/Jaundice", "Renal Failure", "Acute Cerebrovascular/ Neurological deficit Physical Exam-", "Pneumonia", "Fever greater than 38.0 C", "Blood labs according to protocol"], "nct_id": "NCT00607646"},{"minimum_age": 1.0, "maximum_age": null, "gender": "A", "inclusion": ["Must have a diagnosis of T1D and have stored umbilical cord blood in an AABB and/or FACT accredited cord bank.", "TID diagnosis will be defined as having a clear history of polydipsia, polyphagia, polyuria, and weight loss consistent with a clinical diagnosis, diagnosis will mot be based solely upon the presence of autoantibodies.", "Cord blood meets all selection and testing criteria (see below).", "Able to complete mixed meal tolerance / glucagon stimulation test.", "Normal screening values for CBC, Renal function and electrolytes (BMP).", "Willing to comply with intensive diabetes management"], "exclusion": ["Complicating medical issues that would interfere with blood drawing or monitoring.", "Chronic use of steroids or other immunosuppressive agents for other conditions.", "Positive infectious disease markers from mothers' blood or cord at time of collection (See below for details).", "Any evidence of illness on planned infusion date (i.e. fever >38.5 C, vomiting, diarrhea, wheezing, or crackles)."], "nct_id": "NCT00305344"},{"minimum_age": 18.0, "maximum_age": 85.0, "gender": "A", "inclusion": ["central venous catheter placement", "Need for extracorporeal renal replacement therapy (acute and chronic renal failure)", "Anticipated duration of dialysis therapy less than or equal to 30 days", "Age between 18 and 85 years", "Written informed consent"], "exclusion": ["Known Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) infection", "Known pregnancy"], "nct_id": "NCT00621114"},{"minimum_age": 10.0, "maximum_age": 20.0, "gender": "A", "inclusion": ["Male and female patients between 10 and 20 years of age", "Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening", "Fasting C-peptide level at time of screening above 0.1 nmol/L", "Elevated GAD65 antibodies (GADA) at time of screening Main"], "exclusion": ["Treatment with immunosuppressants or any anti-diabetic medications other than insulin", "A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)", "Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine", "Participation in other clinical trials with a new chemical entity within the previous 3 months", "Pregnancy or planned pregnancy within 1 year after the last Diamyd dose", "Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study"], "nct_id": "NCT00723411"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with type 1 diabetes mellitus who need insulin basal+ bolus regimen", "6.5 <=HbA1c <= 11% at visit 1", "BMI <35 kg/m\u00b2", "Provision of signed and dated informed consent prior to any study procedures", "Ability and willingness to complete study diaries and questionnaires", "Demonstrated ability to use the self-glucose-monitoring device, and to self-inject insulin", "A negative pregnancy test for all females of childbearing potential."], "exclusion": ["Hypersensitivity to insulin Glulisine, insulin Glargine or one of their excipients", "Pregnant women", "Active proliferative diabetic retinopathy", "Impaired hepatic or renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], "nct_id": "NCT00964574"},{"minimum_age": 6.0, "maximum_age": 45.0, "gender": "A", "inclusion": ["Age 6-45", "Within 3 months (100 days) of diagnosis of T1DM based on ADA criteria", "At least one diabetes-related autoantibody", "Stimulated C-peptide level >0.2 pmol/ml by MMTT conducted 21 days after diagnosis of T1DM and within 37 days of randomization", "At least three months from last live immunization received and willing to forgo live vaccinations for three months following last dose of study treatment"], "exclusion": ["Immunodeficiency, chronic lymphopenia, active infection, positive PPD result or a history of malignancy", "Serologic evidence of current or past HIV, Hepatitis B or C", "Pregnancy, lactation, or intention of pregnancy while on study", "Current use of immunosuppressive agents, or medications known to influence glucose tolerance or glycemic control", "Current participation in another T1DM treatment study"], "nct_id": "NCT00505375"},{"minimum_age": 18.0, "maximum_age": 64.0, "gender": "A", "inclusion": ["Signed Informed Consent. Patients must have willingness and complete competence to cooperate and language barriers must not preclude adequate understanding", "Diabetes mellitus (Type I or II), as defined by the American Diabetes Association 1997, lasting > 1 year", "Males or females 18 to 64 years (older patients are excluded because of age-related changes in reflexes, quantitative sensory testing endpoints, and nerve conduction endpoints)", "Patient must have a symmetric sensory-motor peripheral polyneuropathy attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy determined by performing complete medical and neurological examinations including physical and neurological history, history of medications, history of exposure to other toxins, and laboratory studies", "Severity of diabetic polyneuropathy must be Stage 1 or 2a", "Insulin regimen, weight, diet, and activity level must be relatively stable in the opinion of the investigator (for example, HbA1C must not vary by more than \u00b1 2 Vol.% within 6 months preceding the study i.e. if the index measure = 10% the range would be 8-12%)", "NIS[LL]+7 tests \u2265 97.5 percentiles (corresponding to 4.43 transformed score points)", "NIS[LL] \u2265 2 points (NIS[LL] is based on questions 17-24, 28, 29, 34, 35, and 37 of the NIS)", "One of the following:", "an abnormality of nerve conduction attributes in two separate nerves, i.e. \u226599th percentile for DL or \u22641st percentile for NCV or amplitude or", "an abnormality of HRDB, i.e. \u2264 1st percentile 10. TSS (feet) \u22645 11. Females must either be surgically sterilised (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 1 year postmenopausal or practicing an acceptable method of contraception, including oral contraceptives with a stable regimen for at least two months, depo-medroxyprogesterone, a barrier method alone (diaphragm, condoms, or contraceptive sponge with spermicidals), or an IUD that has been in place for at least two months"], "exclusion": ["Patients with proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, pan dysautonomia, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpetic neuralgias, etc.), the presence of which might obscure accurate assessment of severity of the diabetic polyneuropathy under assessment, with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both", "Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality which might interfere with the assessment of the severity of dPNP Myopathy of any cause which might interfere with the assessment of the severity of dPNP", "Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia", "Patients with a history of ophthalmological findings suggesting a high risk for visual loss i.e., significant maculopathy or proliferative retinopathy", "Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial", "Patients with any active neoplastic disease except basal cell carcinoma", "Patients with atrial fibrillation unless controlled and stabilised by medication (changed to this criterion by Amendment 1)", "Patients with clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study", "Patients who have had organ transplants of any kind 10. Patients with significant hepatic or renal disease (ASAT or ALAT >2 times normal, serum creatinine >1.8 mg/dL (>159 \u00b5mol/l) for males or >1.6 mg/dL (>141 \u00b5mol/l) for females) 11. Patients with a recent history (within last 12 months) of drug or alcohol abuse 12. Use of any investigational drug within the last 6 months 13. History of severe or anaphylactic reaction to multiple drugs, sulfur products, or biologic products (changed to this criterion by Amendment 1) 14. Ketoacidosis or hypoglycaemia within last 3 months resulting in hospital admission 15. Antioxidant therapy (vitamins E > 400IU, C > 200mg, and beta-Carotene > 30mg) or pentoxyphylline within last 1 month before start of trial 16. Use of evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months 17. Use of thioctic acid > 50mg/day within last 3 months 18. History of use of medications or vitamins known to cause peripheral neuropathy including but not limited to use of phenytoin or carbamazepine over 15 or more years, or use of pyridoxine > 100mg/d within the past 12 months 19. Bilateral sural nerve biopsies 20. Existing foot ulcers 21. Pregnant or lactating females 22. Continued use of medications listed in protocol 6.3.3 (first paragraph) 23. Medication non-compliance (deviation of more than \u00b110% of dosages to be taken (1 tablet/day))"], "nct_id": "NCT00977483"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Patients with type 1 diabetes mellitus treated with insulin 4 times daily.", "Age: 18-60 years", "Fertile women use adequate contraception, e.g. contraceptive pills", "C-peptide <300 pmol/L", "BMI >/= 25", "HbA1c >/=8%"], "exclusion": ["Pregnant and patients planning to become pregnant during the investigation period", "Reduced eyesight", "Known kidney disease, s-creatinin >100", "Liver disease, Alat > 50", "Neuropathic patients diagnosed by clinical examination"], "nct_id": "NCT00145379"},{"minimum_age": 18.0, "maximum_age": 64.0, "gender": "A", "inclusion": ["Subject is healthy, as determined by medical history", "Over 18 years of age and not yet 65 years old", "Provides written informed consent", "Able to attend all scheduled visits and to comply with all trial procedures", "Women may be menopausal of 1 year or more or sugically sterile. Women of child-bearing potential must agree to be abstinent or to use a licensed form of barrier or hormonal contraception for the entire study period, and have a negative pregnancy test within 24 hours prior to vaccination."], "exclusion": ["Breast-feeding", "Receipt of an investigational drug, biologic or device in the 4 weeks preceding the trial vaccination", "Planned participation in another clinical trial during the present trial period", "History of Guillain-Barr\u00e9 Syndrome", "Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy", "Hypersensitivity to any of the vaccine components (including eggs or egg products or thimerosol and gelatin) or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances", "Chronic illness that could interfere with trial conduct or completion", "Blood or blood-derived products received in the past 3 months", "Has received any inactivated vaccine within 2 weeks or live vaccine within 4 weeks prior to enrollment into this study 10. Vaccination planned within the 4 weeks following the trial vaccination 11. Known current HIV, hepatitis B (HBsAg) or hepatitis C infection or seropositivity 12. Prior vaccination against influenza within the past 6 months 13. Allergy shot in the 7-day period prior to enrollment and must not be scheduled to receive any allergy shots in the 7-day period after enrollment 14. On coumadin or heparin therapy or has known thrombocytopenia or bleeding disorder contraindicating vaccination 15. Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent 16. Febrile illness temperature >= 37.5\u00b0C on Day 0, prior to enrollment and vaccination 17. Any condition, that, in the opinion of the investigator, would pose a health risk to the participant 18. History of alcohol or drug abuse in the last 5 years 19. Planned travel outside the US between vaccination and the second study visit 20. Presence of any active skin disease at the injection site that, in the opinion of the Investigator, would impact vaccine delivery or assessment of vaccination site"], "nct_id": "NCT00170547"},{"minimum_age": 21.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Type 2 diabetic patients with known duration of disease: 3-10 years", "Age: 35-75 years", "BMI<32 kg/m2", "Hypercholesterolemia: fasting serum low density lipoprotein (LDL)", "Cholesterol concentration < 4.16 mmol/L (<160 mg/dl)", "Normotriglyceridemia: fasting plasma triglyceride concentration < 2.75 mmol/L (250 mg/dl)", "Creatinine levels < 1.8 mg /dl", "Liver transaminases < 20% over the upper limit with no active liver disease and CK < 50% above the upper limit", "Blood pressure less than 160/100 mmHg were accepted as eligible for enrollment"], "exclusion": ["Hypertension, cardiovascular disease or metabolic diseases other than T2DM as determined by medical history, physical examination and routine laboratory tests", "Alcohol consumption (more than 10 drinks/week)", "Poor glycemic control (HbA1c<9%)", "Patients requiring insulin, patients with type 1 diabetes", "Patients taking any medicine known to interfere with metabolism of statins or with insulin sensitivity as summarized in an exclusionary drug table", "Patients receiving any hypolipidemic medication or diet during the last 2 months before enrollment"], "nct_id": "NCT00704314"},{"minimum_age": 30.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Type 2 diabetes mellitus", "Aged 30-70 years of age", "Hypertension at screening defined as:", "an average cuff systolic blood pressure > 130 mmHg and/or diastolic blood pressure >80 mmHg in untreated patients OR", "patients receiving antihypertensive therapy (i.e., medications specifically prescribed to treat hypertension)", "Overt nephropathy defined by 24 hour proteinuria >= 900 mg and by serum creatinine below 265 mol/l (3.0 mg/dl)"], "exclusion": [": None"], "nct_id": "NCT00153023"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Subjects must be between the ages of 18 and 55 years old.", "Subjects must have bipolar I disorder, schizophrenia, schizoaffective disorder or MDD as defined by DSM-IV-TR criteria and diagnosed using the Structured Clinical Interview for DSM-IV (SCID).", "Subjects must have a Young Mania Rating Scale (YMRS) score < 16 and a Montgomery-Asberg Depression Rating Scale (MADRS) score < 24 at screening and baseline visits.", "Subjects must have the Scale for the Assessment of Positive Symptoms (SAPS) scores <2 on all subscales.", "Subjects must have gained > 7% of their body weight following treatment with olanzapine as either documented in their medical records or by patient report.", "Subjects must be obese, as defined by a current Body Mass Index (BMI) > 30 kg/m2.", "Subjects must sign the Informed Consent Document after the nature of the trial has been fully explained.", "If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable method(s) of contraception (e.g., hormonal methods, intrauterine device, abstinence) for at least one month prior to study entry and throughout the study.", "Subjects must be on a stable dose of olanzapine for at least 14 days and must have been on 5-30mg/day for at least 1 month. Major"], "exclusion": ["Subjects with clinically significant suicidal or homicidal ideation.", "Subjects who have a DSM-IV lifetime diagnosis of a substance dependence disorder within the past 6 months or within the past month have been diagnosed with a substance abuse disorder, (except for nicotine abuse or dependence), as determined by psychiatric history or SCID interview.", "Subjects with a clinically significant or unstable medical disease, including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions, that could interfere with diagnosis, assessment, or treatment of bipolar disorder or obesity, as well as subjects with a history of pancreatitis.", "Patients with clinically significant laboratory abnormalities (> 3 times upper limit of normal), on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, or thyroid indices or clinically abnormal ECG.", "Female patients who are either pregnant or lactating.", "Any female patient whose sexual activity is unknown or in questions.", "Any history of current or past diabetes that has been treated with pharmacological intervention. Subjects who have a diagnosis of diabetes, are currently receiving exenatide, insulin, or an oral anti-hyperglycemic medication, or who have a nonfasting blood glucose \u2265 200 mg/dl or a fasting blood glucose \u2265126 mg/dl on 2 separate tests. Subjects with pre-diabetes will not be excluded.", "Neurological disorders including epilepsy, stroke, or severe head trauma. Mental retardation (IQ <70). 10. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0. 11. Treatment with concurrent mood stabilizers (except lithium), anticonvulsants, or antipsychotics. 12. Other psychotic disorders (including delusional disorder, brief psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV. 13. Dysthymic disorder or depressive disorder not otherwise specified, bipolar disorder not otherwise specified. 14. Subjects previously enrolled in this study or have previously been treated with exenatide. 15. Subjects who have received an experimental drug within 30 days. 16. Subjects who are displaying current clinically significant depressive or manic symptoms, defined as a MADRS score >24 or a YMRS score > 16 or who currently meet DSM-IV-TR criteria for a manic, mixed, hypomanic, or depressive episode. 17. Subjects who are displaying current clinically significant psychotic symptoms, defined as any SAPS subscale score > 2 18. Subjects with a history of pancreatitis in themselves or any risk factors for developing pancreatitis (risk factors include but are not limited to: alcohol use, history of gallbladder disease or gallstones, diabetes or a family history of pancreatitis) 19. Subjects with elevated amylase or lipase levels as measured at the screening visit"], "nct_id": "NCT00845507"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["age 18-65 years", "type 1 diabetes for at least 5 years", "at least 1 of the following: a) frequent, severe hypoglycaemia b) hypoglycemic unawareness* c) glycemic lability despite an optimal insulin regimen*, and failure of intensive insulin therapy as judged by independent endocrinologist"], "exclusion": ["obesity (BMI >28", "insulin requirements > 0.7 U/kg/day", "history of cancer (except basal or squamous skin cancer)", "unstable, severe, or non-correctable cardiac disease", "previous organ transplant", "evidence of sensitization (PRA>20%)", "renal dysfunction (macroalbuminuria, renal dialysis)", "untreated proliferative retinopathy", "active infection, including hep C, hep B, HIV, TB", "current cigarette smoking (6 months abstinence required) or substance abuse", "indication for steroid medications (exception steroid inhalers, topical steroids)", "indication for anticoagulation (exception aspirin)", "pregnancy or desire for future pregnancy; breast-feeding", "major psychiatric illness"], "nct_id": "NCT00309231"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["open to Canadians only", "participant must have had Type 1 diabetes mellitus for more than 5 years", "diabetes must be complicated by at least 1 of the following situations that persist despite intensive insulin management efforts: (1) Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels < 3.0 mmol/L, indicated by, 2 or more episodes of severe hypoglycemia requiring third party assistance within 12 months; or (2) Metabolic instability, characterized by erratic blood glucose levels that interfere with daily activities and or 2 or more hospital visits for diabetic ketoacidosis over the last 12 months.", "Participants must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent."], "exclusion": ["Severe co-existing cardiac disease", "Active alcohol or substance abuse, to include cigarette smoking", "Psychiatric disorder making the subject not a suitable candidate for transplantation", "History of non-adherence to prescribed regimens", "Active infection including Hepatitis C, Hepatitis B, HIV, TB", "Any history of or current malignancies except squamous or basal skin cancer", "BMI > 28 kg/m2 at screening visit", "Creatinine clearance < 65 mL/min/1.73 m2", "Blood creatinine > 150 \u00b5mol/L (1.7 mg/dL)", "Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h)", "Baseline Hb < 105g/L (<10.5 g/dL) in women, or < 130 g/L (<13 g/dL) in men", "Baseline screening liver function tests outside of normal range", "Untreated proliferative retinopathy", "Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding", "Previous transplant, or evidence of significant sensitization on PRA", "Insulin requirement >1.0 U/kg/day", "HbA1C >12%", "Uncontrolled hyperlipidemia", "Under treatment for a medical condition requiring chronic use of steroids", "Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5", "Untreated Celiac disease", "Patients with Graves disease will be excluded unless previously adequately treated with radioiodine ablative therapy"], "nct_id": "NCT00175253"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients with histologically proven intracranial malignant glioma are eligible . -All patients must sign an informed consent", "Patients must be > 18 years old, and with a life expectancy > 8 weeks.", "Patients must have a Karnofsky performance status of > 60.", "Patients must have recovered from the toxic effects of prior therapy", "Patients must have adequate bone marrow function (WBC > 3,000/\u00b5l, ANC > 1,500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 10 gm/dl), adequate liver function (SGOT and bilirubin < 2 times ULN), and adequate renal function (creatinine < 1.5 mg/dL and/or creatinine clearance > 60 cc/min) Patients must have shown radiographic evidence for tumor progression by MRI or CT scan. A scan should be performed within 14 days prior to registration and on a steroid dose that has been stable for at least 5 days. -Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:", "They have recovered from the effects of surgery.", "Residual disease following resection of recurrent malignant glioma is not mandated for eligibility into the study.", "Patients must have failed prior radiation therapy", "Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease", "Women of childbearing potential must have a negative \u00df-HCG pregnancy test documented within 14 days prior to registration.", "Patients may have had treatment for any number of prior relapses."], "exclusion": ["Patients must not have any significant medical illnesses that in the investigator opinion cannot be adequately controlled", "Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years are ineligible.", "Patients must not have active infection or serious intercurrent medical illness.", "Patients must not be pregnant/breast feeding and must agree to practice adequate contraception.", "Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.", "Patients must not have received prior therapy with irinotecan.", "Patients with 7/7 (homozygous) UGT1A1*28 genotyping will be excluded from the study.", "Patients receiving enzyme-inducing anticonvulsants or other enzyme inducing drugs are excluded."], "nct_id": "NCT00734682"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["male or female obese or overweight type 2 diabetic subjects, between 18 and 55 years old (inclusive)", "either treatment naive or who are inadequately controlled on either metformin alone or metformin in combination with a sulfonylurea. Subjects on metformin in combination with a sulfonylurea will be allowed a 2 week period to wash out the sulfonylurea before dosing.", "have a fasting blood sugar of \u2265 100 mg/dL, hemoglobin A1C \u2265 7.5% (but \u2264 11.0%). Subjects on a combination of metformin and sulfonylurea must have a hemoglobin A1C \u2265 7.5% (but \u2264 10.0%);", "non-smoker", "body mass index (BMI) of 27-40 kg/m2"], "exclusion": ["likely allergy or sensitivity to any components of Trodusquemine (MSI-1436) for Injection based on known allergies to drugs of the same class;", "any subject with a history of allergy (rash, hives, breathing difficulty, etc.) to any medications, either prescription or nonprescription, including dietary supplements or herbal medications;", "any subject with a history of severe allergy or bronchial asthma;", "a clinically significant history of or current abnormality or disease of any organ system, including renal, hepatic, gastrointestinal, cardiovascular (except hyperlipidemia or controlled hypertension), pulmonary (including chronic asthma), endocrine (except diabetes), central nervous, or hematologic systems, or recent clinically significant surgery;"], "nct_id": "NCT00606112"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Diabetic Subjects", "12 adults (males or females) with Type 1 Diabetes, aged 18 to 55 years.", "C-peptide-negative", "Body mass index < 29.0 kg/m2", "Healthy Subjects", "12 non-smoking adults (males or females), aged 18 to 55 years", "Normal response to an oral glucose tolerance test (OGTT)", "Body mass index < 29.0 kg/m2"], "exclusion": ["Diabetic Subjects", "Hemoglobin A1c >9%", "Total daily insulin requirements >0.8 units/kg actual body weight", "History of hypoglycemia that required the subject to see medical attention (i.e., doctor's office visit, ER visit, or EMT/paramedic attention) within 6 months of the study.", "History of acute metabolic complications within 3 months of the study", "History of lipodystrophy.", "History of or suspected diabetic gastroparesis or current treatment with any drugs known to affect gastrointestinal motility.", "Inability or unwillingness to administer subcutaneous insulin injections in the abdomen.", "Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study.", "Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months years. 10. History of malignancy (except basal cell carcinoma and carcinoma in situ) within the last 5 years. 11. Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception. 12. History of alcoholism or drug abuse within 12 months of the study. 13. Is the investigator, sub-investigator, research assistant, pharmacist, study coordinator, other study staff, or relative thereof directly involved in the conduct of this protocol.", "Healthy Subjects", "Hemoglobin A1c >6.0%", "Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study.", "Historical, clinical, or laboratory evidence of liver disease including but not limited to transaminase activity concentrations >2.5 times the upper limit of the reference range.", "Current treatment with any drugs known to affect gastrointestinal motility.", "Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months.", "History of malignancy (except basal cell carcinoma and carcinoma in situ) within the last 5 years.", "Pregnant or lactating females or females of childbearing potential who are unwilling to abstain from sexual intercourse or use reliable, medically accepted methods of contraception.", "History of alcoholism or drug abuse within 12 months of the study.", "Is the investigator, sub-investigator, research assistant, pharmacist, study coordinator, other study staff, or relative thereof directly involved in the conduct of this protocol."], "nct_id": "NCT00927524"},{"minimum_age": 10.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Parents of adolescents between the ages of 10-18", "More than one year diabetes", "Adolescent's HbA1c>8"], "exclusion": ["Adolescents or parents of adolescents that are mentally retarded.", "Another chronic disease besides diabetes.", "Adolescents that are taking medications that might disturb their glycemic control."], "nct_id": "NCT00622856"},{"minimum_age": 4.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Girls/boys, 4-17 years, inclusive;", "Girls not yet of childbearing potential or, if sexually active, agree to use reliable medically accepted contraceptive measure during study;", "Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis;", "Onset of diabetes at least 1 year prior to visit 1 (V1) of study;", "Uninterrupted insulin therapy for at least 1 year before V1 of study;", "At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin;", "Glycated hemoglobin at V1 between \u2265 6.0 and \u226411.0 %;", "Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary."], "exclusion": ["Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study;", "Diabetes other than type 1 diabetes mellitus;", "Pregnancy (positive pregnancy blood test at V1) or breastfeeding;", "Pancreatectomized subjects;", "Subjects who have had pancreas and/or islet cell transplants;", "Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;", "Treatment with systemic corticosteroids in last month before V1;", "Subjects on pump therapy during last 2 months before V1;", "Subjects requiring excessively high doses of insulin (\"resistant\" patients), for example, but not limited to, subjects receiving over 150 IU per day;", "Likelihood of needing treatment during study period with drugs not permitted by protocol", "Treatment with any investigational drug in last month before V1;", "History of primary seizure disorders;", "History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1;", "History of hypoglycemia unawareness;", "History of hypersensitivity to insulin or insulin analogs or any of the excipients in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations;", "Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol;", "History of cardiac abnormalities and/or cardiovascular disorders;", "History of drug/alcohol abuse;", "Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1;", "Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1;", "Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) at V1;", "Parent/legally authorized representative unable to understand nature, scope, possible consequences of study;", "Parent/legally authorized representative unable to read/write;", "Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study;", "Children/relatives of employee of sponsor or of sponsor representatives;", "Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol;", "Subjects who have previously been treated with insulin glulisine."], "nct_id": "NCT00115570"},{"minimum_age": 10.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Male or female between the age of 12 and 35 years, inclusive (changed to between the age of 10 and 35 years, inclusive, under Amendment 2)", "If female of childbearing potential, patient must use an acceptable method of birth control prior to and for 30 days post study", "Adult (greater than or equal to 18 years) female patients who were not of childbearing potential must be 2 years postmenopausal, or have had a hysterectomy or tubal ligation", "Were newly diagnosed with type 1 diabetes mellitus", "Presence of one or more of the following:", "Anti-ICA512 antibodies", "Anti-GAD antibodies", "Anti-insulin antibodies, provided that the patient was not on insulin therapy for greater than 1 week", "Body mass index (BMI) < 28 kg/m2", "Stimulated serum C-peptide peak level between 0.4 pmol/mL and 3.0 pmol/mL, inclusive, at the time of screening", "Laboratory and 12-lead electrocardiogram (ECG) results within normal ranges or, if abnormal, considered by the investigator as non clinically significant for the safety and well being of the patient or for the purposes of the study"], "exclusion": ["Use of an excluded medication/therapy including any of the following:", "Steroids", "Oral hypoglycemic agents", "Chemotherapy and radiation", "Immunosupressants", "Nicotinamide >100 mg per day", "Any drugs containing sibutramine", "Female patients with a positive pregnancy test or who are lactating", "Adult patients with body weight <45 kg; adolescent patients with body weight <30 kg; 10- and 11-year-old patients with body weight <25 kg", "History of cancer or have existing or actively managed cancer", "History of severe or anaphylactic allergic reactions", "Patients suffering from active skin infections that would prevent subcutaneous injection", "Positive test for HIV antigens, hepatitis B surface antigen, or hepatitis C antibodies", "History of alcohol or substance abuse"], "nct_id": "NCT00873561"},{"minimum_age": 12.0, "maximum_age": 18.0, "gender": "A", "inclusion": ["Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.", "Age 12.0 years to less than 18.0 years", "HbA1c <8.0%", "Use of basal: bolus insulin therapy with either an insulin pump or glargine with MDI of a short-acting insulin for at least 6 months (approximately 5 pump and 5 MDI users will be enrolled)", "Availability of home computer to download the CGM", "For females: not currently pregnant, negative pregnancy test, and not intending to become pregnant during the next 3 months", "Parent/guardian and subject understand the study protocol and agree to comply with it", "Informed Consent Form signed by the parent/guardian and Child Assent Form signed by the subject if required by IRB"], "exclusion": ["Severe hypoglycemic event (seizure or coma) or diabetic ketoacidosis in the past 6 months", "Cardiac disease, including prolonged QT interval on EKG or pathologic arrhythmia", "An EKG will be done either prior to the CRC admission or during the CRC admission prior to the first dose of terbutaline", "Treatment for hypertension or blood pressure exceeding the 90th percentile for age and height", "Current treatment for a seizure disorder", "Asthma if treated with systemic or inhaled corticosteroids in the last 6 months or with a beta adrenergic agonist more than once a month", "Cystic fibrosis", "Use of MAO inhibitors, tricyclic antidepressants, or beta blockers", "Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.", "Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian).", "Medical condition that in the judgment of the investigator might interfere with the completion of the protocol"], "nct_id": "NCT00607503"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["type 1 diabetes mellitus for \u2265 12 months or more (including C-peptide negative secondary diabetes)", "age > 18 y.o.", "intensive insulin basal-bolus therapy for \u2265 6 months. At inclusion, patients should be treated, either with a combination of a basal, long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump", "chronically uncontrolled diabetes with HbA1c \u2265 8 % during the past 12 months and at inclusion"], "exclusion": ["patient with unstable associated evolutive pathology", "patient who need a more frequent diabetic follow up (than in the protocol)", "patient with a education teaching within the 3 months before inclusion", "patient with a hemoglobinopathy", "patient with toxicomania, alcoholism or psychological troubles", "type 2 diabetes patients", "patient who don't need strict metabolic objectives", "pregnant or parturient women", "person with no freedom (prisoner)"], "nct_id": "NCT00629304"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Individuals with a Body Mass Index (BMI) > 25. BMI defined as: Weight in kilograms divided by Height (squared) in meters.", "Residents of Mexico city", "Healthy individuals (no comorbidities or drug prescription for associated chronic diseases)"], "exclusion": ["Diabetes Mellitus Type 1 or 2", "Severe Hypertension (defined as systolic blood pressure > 160 mmHg and /or diastolic blood pressure > 100 mmHg) and/or Hypertension on pharmacological treatment.", "Chronic Kidney Disease (Glomerular Filtration Rate (GFR) < 60 ml/min)", "Hepatic Damage or Advanced Disease (clinical, biochemical or histological)", "Patient receiving any pharmacological treatments for hypercholesterolemia and/or elevated triglycerides.", "Anemia (any etiology)", "Malignancy", "Pregnancy"], "nct_id": "NCT00868673"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "M", "inclusion": ["Participant is a Caucasian (including Hispanic) male", "Participant has a maximum waist size of 40 inches", "Participant does not currently use any lipid-altering medications", "Participant is in good health other than the diagnosis of dyslipidemia"], "exclusion": ["Participant has had stomach ulcers within the last 3 months", "Participant has had a heart attack in the last 6 months or has angina", "Participant has chronic heart failure", "Participant has a history of stroke, seizures, or major neurological disorder", "Participant has a history of cancer", "Participant has a gastrointestinal condition that affects bowel movements", "Participant has type 1 or 2 diabetes"], "nct_id": "NCT00935259"},{"minimum_age": 45.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Males and females aged 45-65 years,", "non-smokers,", "HOMA index > 2.5 and", "who meet ATP III criteria for the metabolic syndrome"], "exclusion": ["History of diabetes,", "previous MI, stroke, heart failure, impaired hepatic or renal function.", "Inability to cease medications which may affect study parameters."], "nct_id": "NCT00408850"},{"minimum_age": 30.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Patients may be included in the clinical trial only if they meet all of the following criteria:", "Male or female outpatients;", "Age 30", "70 years;", "Patients have failed to achieve glycemic control with diet, exercise and max. 2 OHA; Hemoglobin A1c level between 7.0 to 11.0 % at V1 and 7-11.5 % at V4.", "Diagnosis of diabetes mellitus is over a minimum 3-month period;", "All patients give written informed consent;", "For female patients of childbearing potential, the following criteria will be applied:", "Using adequate contraception since last menses and will continue to use adequate contraception during the clinical trial.", "Not lactating.", "Negative pregnancy test (urine) within 7 days prior to the first dose of study medication. (Note: the inclusion criterion 6 does not apply to menopausal female)."], "exclusion": ["Patients will be excluded from the clinical trial for any of the following reasons:", "Patients with a serum creatinine concentration greater than 132.6 mmol/L (1.5 mg/dL) or liver function impairment (AST and ALT 2.5 times upper limit of normal range);", "Patients have laboratory test abnormality (biochemistry, hematology, or urinalysis), which in the investigator's opinion might confound the clinical trial. However, patients with hyperlipemia, elevated cholesterol or triglyceride levels, or lipid metabolism disorders are eligible;", "Use of chronic insulin therapy;", "Patients with medical conditions that could promote lactic acidosis, such as renal or hepatic disease, unstable angina, congestive heart failure (New York Heart Association Functional Classification III and IV), or chronic obstructive pulmonary disease, e.g. respiratory insufficiency, hypoxemic condition;", "Patients with a history of hypersensitivity to metformin hydrochloride, glibenclamide or acarbose;", "Patients receive an investigational drug within 30 days prior to admission to the clinical trial;", "Patients with significant alcohol, drug or medication abuse as judged by the investigator."], "nct_id": "NCT00417729"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Have diabetes mellitus (Type 1 or 2) for longer than 1 year", "Have clinical evidence of diabetic peripheral neuropathy in the lower extremities for 1 to 5 years before study entry", "Experienced lower extremity pain due to diabetic peripheral neuropathy on nearly a daily basis for the previous 3 months", "Have hemoglobin A1c levels less than or equal to 10%", "Have a stable diabetic treatment regimen, including oral medications for controlling diabetes, insulin, or diet for 3 months before screening", "Women must be postmenopausal for at least 2 years, sexually abstinent, or if sexually active, be practicing an effective method of birth control, and have a negative serum pregnancy test at screening."], "exclusion": ["History of a poor response to 3 or more medications for diabetic peripheral neuropathy (DPN), with poor response is defined as treatment with medications in the following categories of therapy for at least 1 month at therapeutic dosages without at least moderate improvement, as judged by the study doctor: antiepileptic drugs, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors (SNRIs), opioid analgesics, or lidocaine patch", "currently taking tricyclic antidepressants, Coumadin (warfarin), or continued treatment with an antiepileptic drug for any indication, Note: If taking these medications, to be eligible for the study, they must be tapered and discontinued", "Prior neurolytic treatment (destruction of nerves by the application of chemicals, heat, or cold), intrathecal pumps, or spinal cord stimulators for DPN pain", "Use of herbal creams or ointments for pain relief within 48 hours, capsaicin within 6 months, or systemic corticosteroids within 3 months before the baseline period", "Prior exposure to RWJ-333369 (carisbamate)."], "nct_id": "NCT00501202"},{"minimum_age": 30.0, "maximum_age": null, "gender": "A", "inclusion": ["Adults over 30 years of age living in Chung-ju city (who participated in 2003-2006 cohort study)"], "exclusion": ["age under 30", "subjects with known diabetes"], "nct_id": "NCT00707668"},{"minimum_age": 40.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["fasting glucose level 100-125mg/dl", "OGTT 2hr glucose level 140-199 mg/dl"], "exclusion": ["established diabetes mellitus: use of diabetic medication, fasting glucose >=126 mg/dl, OGTT 2ht glucose level >=200mg/dl"], "nct_id": "NCT00257218"},{"minimum_age": 18.0, "maximum_age": 79.0, "gender": "A", "inclusion": ["Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease (CHD) with LDL-C above 70 mg/dL or 100 mg/dL depending on their CHD risk category"], "exclusion": ["A condition which, in the opinion of the investigator, pose a risk to the patient or interfere with participating in the study", "Patient is likely to be greater than 20% noncompliant in taking study medications", "Patients with chronic medical conditions", "Patients with unstable doses of medications", "Pregnant or lactating women, women intending to become pregnant", "Patient is currently receiving prescription therapy with statins or other lipid-altering medications", "Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin)"], "nct_id": "NCT00409773"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Outpatients \u2265 18 years of age", "Patients with a diagnosis of moderate to severe hypertension, defined as msSBP \u2265 160 mmHg and < 200 mmHg at Visit 2"], "exclusion": ["Mild to moderate hypertension", "Pregnant or nursing (lactating) women", "Women of child-bearing potential", "Previous or current diagnosis of heart failure New York Heart Association(NYHA) Class II-IV.", "Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1.", "Uncontrolled Type 1 or Type 2 diabetes mellitus", "Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures", "History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention", "Patients on a combination of 3 or more antihypertensive medications Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00841672"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["Pregnant women aged 18-40 years old.", "Pregnant women at gestational age 30 to 34 weeks."], "exclusion": ["Pregnant women with known type 1 or type 2 diabetes mellitus.", "Pregnant women carrying more than one fetus.", "Pregnant women with pre-gestational hypertension.", "Pregnant women with pre-eclampsia during current pregnancy.", "Pregnant women with a history of coronary artery disease or acute ischemia.", "Pregnant women who currently smoke.", "Pregnant women without results for the 3 hour 100 gram oral glucose tolerance test.", "Pregnant women with preterm labor, cervical shortening, premature rupture of membranes or any other obstetric complications that may predispose to preterm labor.", "Pregnant women using 17-P (progesterone) to prevent recurrent pre-term labor. 10. Pregnant women with known SDB."], "nct_id": "NCT00933881"},{"minimum_age": 20.0, "maximum_age": 64.0, "gender": "A", "inclusion": ["Patients with \u226725 kg/m2 of BMI at the start of the observation period", "Patients with visceral fat area \u2267100 cm2 measured with abdominal CT scan", "Patients with the following two health impairments:", "Patients with previously diagnosed type 2 diabetes and HbA1c between \u22676.1% and <9.0% at the start of observation period", "Patients with \u2267150 mg/dL of triglyceride (TG), and/or <40 mg/dL of high-density lipoprotein cholesterol (HDL-C) for serum lipid parameters as dyslipidemic index at the start of the observation period", "Patients continuously receiving diet therapy for 8 weeks or longer before the start of the observation period", "Patients not receiving antidiabetic (12 weeks), antihyperlipidemics (4 weeks) and/or antihypertensive (4 weeks) drugs. If used, those who have received a consistent dosage and administration beginning more than 4 weeks (more than 12 weeks for antidiabetics) before the start of the observation period", "Patients with ambulatory treatment aged between \u226720 years and <65 years at the time of obtaining informed consent", "Patients who are given full explanation about the study objective and contents and can give written informed consent"], "exclusion": ["Patients with pulse rate of \u2267100/min during the observation period", "Patients with systolic blood pressure of \u2267160 mmHg and/or with diastolic blood pressure of \u2267100 mmHg during the observation period", "Patients with body weight loss of \u22673% as compared to that at the start of the observation period, or body mass index (BMI) that is reduced to <25 kg/m2 during the observation period", "Patients who have received insulin within 12 weeks before the start of the observation period", "Patients with present illness or past history of severe eating disorder (e.g., anorexia nervosa or bulimia nervosa)", "Patients with present illness or past history of drug allergy or severe allergic disease(s)", "Patients with present illness or past history of the following disorders:", "Coronary artery disease (myocardial infarction, angina), heart failure", "Serious diseases such as cardiovascular (severe tachycardiac heart failure), renal (renal failure), hepatic (severe hepatitis, cirrhosis), pancreatic (severe pancreatitis), psychotic (severe depression, schizophrenia, alcohol addict, drug addict) disorders", "Pregnant or lactating women, or women who intend to become pregnant during the study period", "Patients who previously participated in and were treated in another clinical study of KES524", "Patients who have received another study drug within 24 weeks before starting observation period of this study", "Patients who are judged to be ineligible for study entry by the investigator or subinvestigator"], "nct_id": "NCT00165685"},{"minimum_age": 0.0, "maximum_age": null, "gender": "A", "inclusion": [": Clinical diagnosis on ESRD under regular maintenance hemodialysis, no active infection, no allergy to chosen AK, informed consent acquired"], "exclusion": [": Not ESRD, temporary HD, active infection, during admission, allergy to chosen AK, without informed consent"], "nct_id": "NCT00155363"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["(for healthy people):", "Chinese male residents", "right handed", "no history of psychological/psychotic problems", "no history of important diseases"], "exclusion": ["(for healthy people):", "with factors which make subjects unsuitable to receive MR examination", "history of important diseases Inclusion Criteria (for patients):", "Chinese male patients with ischemic stroke (CT/MRI scan confirmed)", "right handed", "at least 1.5 months from onset of stroke", "ability to follow complex commands Exclusion Criteria (for patients):", "hemodynamic instability", "history of dementia", "inability to give consent because of impaired cognition or receptive aphasia", "diseases in spine/spinal cord", "with factors which make subjects unsuitable to receive MR examination"], "nct_id": "NCT00629655"},{"minimum_age": 30.0, "maximum_age": 74.0, "gender": "A", "inclusion": [": Inclusion Criteria for the screening test (within 6 months before screening):", "LDL-cholesterol 100-159 mg/dl and/or total cholesterol 180-239 mg/dl", "At least one of the following:", "Fasting plasma glucose 100-125 mg/dl, and/or casual (non-fasting) plasma glucose 120-199 mg/dl, and/or HbA1c 5.5-6.0%", "At least two of the following risk factors for impaired glucose tolerance:", "Second degree relative with diabetes", "BMI >= 24 kg/m2", "Systolic blood pressure >=130 mmHg, and/or diastolic blood pressure >= 85 mmHg, and/or receiving treatment for hypertension", "Triglyceride >= 150 mg/dl, and/or HDL < 40 mg/dl", "Written consent for participation in the study by their own volition after being provided sufficient explanation for the participation into this clinical trial Inclusion Criteria for the entry (Confirmed by screening test): -Impaired glucose tolerance by 75g oral glucose tolerance test (fasting plasma glucose <126 mg/dl and 2-h plasma glucose 140-199 mg/dl)"], "exclusion": ["History of diabetes (except gestational diabetes)", "Fasting plasma glucose >= 126 mg/dl , and/or 2-h plasma glucose >= 200 mg/dl", "HbA1c >= 6.5%", "Diabetic retinopathy", "Receiving with hormone replacement therapy", "Pancreatic diseases ( e.g. pancreatitis, pancreatectomy, pancreatic cancer), Endocrine diseases ( e.g. Cushing's syndrome, acromegaly, pheochromocytoma, aldosteronism, hyperthyroidism )", "Receiving statins, fibrates or anion exchange resins", "Cancer or suspected cancer", "History of gastrectomy", "History of myocardial infarction, angina, or heart failure (NYHA Class >= III)", "Severe hypertension (SBP >= 180 mmHg or DBP >= 110 mmHg)", "Renal disease, including serum creatinine >= 2.0 mg/dl", "Hepatic disease, including transaminase (ALT or AST) >= 2 times the upper limit of normal", "Women hoping to become pregnant during the intended study period", "Contraindication or relative contraindication of Livalo\u00ae Tab(pitavastatin calcium)", "History of hypersensitivity to any of the ingredients of the product", "Severe hepatic disorder or biliary atresia", "Receiving cyclosporine", "Pregnant women, women suspected of being pregnant, or lactating women", "Patients receiving fibrates who also have laboratory evidence of abnormal renal function", "Familial hypercholesterolemia", "Drug abuse, alcoholism", "Individuals who are ineligible in the opinion of the investigator"], "nct_id": "NCT00301392"},{"minimum_age": 18.0, "maximum_age": 70.0, "gender": "A", "inclusion": ["Patients who have received a first liver transplantation and who are 18 to 70 year old", "Patients who are treated with tacrolimus post-transplant for at least 3 months and for a maximum of 36 months", "Patients without any known diabetes before transplantation and in whom diabetes mellitus was diagnosed for the first time at least 3 months post-transplantation"], "exclusion": ["Re-transplantation or multi-organ transplantation,", "Diabetes before the transplantation,", "Type I diabetes mellitus. Other protocol-defined inclusion / exclusion criteria may apply"], "nct_id": "NCT00171717"},{"minimum_age": 19.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Signed informed consent obtained before any trial-related activities.", "Skin fold thickness of minimally 5 mm", "Age of patients in the range from 19 to 60 years.", "Type 1 diabetes"], "exclusion": ["Severe acute and/or chronic diseases", "Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.", "Taking of any vasoactive substances or anticoagulation medication.", "Diseases of the skin which could interfere with application of the catheters", "Pregnancy or breastfeeding"], "nct_id": "NCT00499954"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["18 years of age at least", "Diagnosis of diabetes mellitus (type 1 or type", "any one of the following will be considered to be sufficient evidence that diabetes is present:", "current regular use of insulin for the treatment of diabetes", "current regular use of oral hypoglycemic agents for the treatment of diabetes", "diabetes as defined by american Diabetes Association (ADA)", "symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) or eighth-hour fasting plasma glucose > 126 mg/dl", "Diabetic macular edema clinically observable associated with diabetic retinopathy:", "without prior foveal treatment with laser therapy", "if photocoagulation or peripherical or macular laser, at least 3 months", "absence of macular ischemia by fluorescein angiography on baseline visit", "BCVA score between 20 letters (20/400 ETDRS)e 70 letters (20/40 ETDRS) in the study eye measured by the ETDRS method at qualification/baseline visit", "Retinal thickness > 275um by OCT", "One eye per patient will be chosen for the study. In case of both eye eligible, it will be chosen an eye to be treated with study medication and another eye treated with laser", "Taught hyaloid syndrome"], "exclusion": ["Uncontrolled systemic disease", "Initiation of medical therapy for diabetes or a change from oral hypoglycemic agents to insulin therapy within 4 months prior to the qualification visit", "Renal failure requiring hemodialysis or peritoneal dialysis within 6 months prior to the qualification visit", "Any ocular condition in the study eye that in the opinion of the investigator would prevent a 2 lines improvement of visual acuity (e.g. severe macular ischemia)", "Presence of branch retinal vein occlusion, central retinal vein occlusion, uveitis, pseudophakic cystoid edema or any other condition in the study eye which could be contributing to macular edema", "Presence of an epiretinal membrane in the study eye", "History of IOP elevation in response to steroid treatment in either eye", "History of glaucoma or optic nerve head change consistent with glaucoma damage", "Ocular hypertension requiring more than 1 anti-glaucoma medication to maintain IOP < 11mmhg at qualification visit", "Presence of anterior chamber intraocular lens in the study eye", "Active optic disc or retinal neovascularization in the study eye at qualification visit", "Active or history of choroidal neovascularization in the study eye"], "nct_id": "NCT00737971"},{"minimum_age": 0.16666666666666666, "maximum_age": 1.6666666666666667, "gender": "A", "inclusion": ["Infants of either sex, aged 16", "20 months / 2", "4 months", "in good health as determined by: medical history physical examination clinical judgment of the investigator;", "available for all visits scheduled in the study and able to comply with all study regulations;", "written informed consent obtained, from at least one parent or legal guardian"], "exclusion": ["parent or legal guardian is unwilling or unable to give written informed consent to participate in study;", "infants who presented a previous disease potentially related to Haemophilus influenzae type b;", "infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease;", "infants who have received any other Haemophilus influenzae type b immunization dose before (for 16-20 months old children who have received a booster vaccination already);", "premature (before 37th week of gestation) or birth weight less than 2500 g;", "history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;", "fever \u226538.0 \u00b0C (axillary body temperature) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment;", "subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease;", "known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;", "subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder;", "subjects with a clinically significant genetic anomaly;", "treatment with corticosteroids or other immunosuppressive drugs;", "treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives (or: within the past 3 months", "applicable for children 16", "20 months);", "any vaccination administered within 2 weeks (14 days) before enrollment;", "participation in any other investigational trial simultaneously;", "planned surgery during the study period;", "any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective"], "nct_id": "NCT00734565"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Mild to moderate hypertension", "Age 18-75 years, inclusive"], "exclusion": ["Clinically significant illnesses or abnormalities upon evaluation", "Current treatment with 3 or more antihypertensive meds", "Presence of Type I or uncontrolled Type II diabetes", "Presence of alcohol or drug abuse"], "nct_id": "NCT00779181"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Outpatients 18 years and older.", "Male or female patients are eligible. Female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use is disallowed.", "Patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury (preferable) sphygmomanometer. Patients must have a MSDBP > 90 mmHg and < 110 mmHg at Visit 1 (week -4 to -2), and a MSDBP > 95 mmHg and < 110 mmHg at Visit 2 (week 0).", "Patients must have an absolute difference of > 10 mmHg in their average sitting diastolic blood pressure between Visits 1 and 2.", "Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent)."], "exclusion": ["Severe hypertension (MSDBP 110 mmHg and/or MSSBP 180 mmHg) at anytime.", "Inability to discontinue all prior antihypertensive medications safely for a period of 14 weeks.", "Known Keith-Wagener grade III or IV hypertensive retinopathy.", "History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 0 (week -6 to -4).", "Transient ischemic cerebral attack during the last 12 months prior to Visit 0 (week -6 to -4).", "Evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing Disease, pheochromocytoma, polycystic kidney disease etc.", "Type 1 diabetes mellitus.", "Type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (HbA1c) >8% at Visit 1 (week -4 to -2).", "Administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at Visit 0 (week -6 to -4).", "Known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers.", "Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00409643"},{"minimum_age": 1.3333333333333333, "maximum_age": 1.6666666666666667, "gender": "A", "inclusion": ["Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol", "Subjects must have completed the full three-dose primary vaccination course with one of the formulations of the DTPa-HBV-IPV/Hib vaccine in primary study 106786.", "A male or female between, and including, 16 and 20 months of age at the time of booster vaccination.", "Written informed consent obtained from the parent or guardian of the subject", "Healthy subjects as established by medical history and clinical examination before entering into the study."], "exclusion": ["Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.", "Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.", "Participation in another clinical study, between the primary study 106786 and the present booster study, or at any time during the study, in which the subject has been or will be exposed to an investigational or a non-investigational product.", "Planned administration or administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose.", "Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination or disease since the conclusion visit of study 106786.", "Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.", "History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.", "Acute disease at the time of enrolment.", "Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period."], "nct_id": "NCT00627458"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["History consistent with type 1 diabetes", "At least 18 years of age", "Available and capable of following the protocol instructions provided by the healthcare professional", "Signed and dated informed consent form"], "exclusion": ["Pregnancy", "Type 2, gestational, or secondary diabetes", "Known allergy to medical grade adhesives", "Skin abnormalities at the insertion sites that would confound the assessment of the effect of the device on the skin", "Seizure disorder", "Myocardial ischemia", "History of stroke", "Severe hypoglycemia unawareness", "Other concomitant medical conditions that in the opinion of the investigator, would affect the evaluation of device performance and/or safety"], "nct_id": "NCT00920881"},{"minimum_age": 20.0, "maximum_age": 45.0, "gender": "M", "inclusion": ["22 < BMI < 30", "fasting glucose < 5.6 mmol/L and glucose < 7.8 mmol/L 2hr after OGTT", "able and willing to sign informed consent", "history of good physical and mental health", "subject smokes less than 5 cigarettes per day", "able to keep a normal day and night rhythm"], "exclusion": ["allergy to prednisolone", "glucocorticoid use during last 3 months prior to study", "use of any drug or substance", "history of familiar diabetes type 2", "clinically relevant history or presence of any medical disorder", "clinically relevant abnormal lab or ECG", "positive drug or alcohol screen, positive hepatitis B or C surface antigen", "donation of blood (>100 mL) within 90 days prior to the first dose"], "nct_id": "NCT00971724"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Men and women of at least 18 years of age", "Established diagnosis of neuropathic pain for at least the past 3 months duration, and type 1 or type 2 diabetes, confirmed by primary care physician and/or neurologist. By signing the informed consent, participants agree to have the study coordinator contact their physician for confirmation of diagnosis.", "Pain of at least level 4 on a 0-10 scale, and not over 9, despite other treatments on intake.", "Presence of dynamic tactile allodynia or pinprick hyperalgesia", "Normal cognitive and communication skills (as judged by investigator) and ability to complete self-report questionnaires."], "exclusion": ["Pregnancy", "Previous or continuing use of Neuragen\u00ae", "Evidence of other types of pain as, or more severe, than the pain under study", "Major psychological conditions requiring treatment", "History of eczema/atopy/anaphylaxis or unusual skin reactions. This will be assessed using a subjective question (Have you ever suffered from eczema? Or experienced a skin reaction to a substance? Or experienced an anaphylactic reaction?)", "Self reported sensitivity to perfumes, essential oils, odors.", "Changes to current pain management regime within the previous month prior to start of study."], "nct_id": "NCT00861952"},{"minimum_age": 18.0, "maximum_age": 90.0, "gender": "A", "inclusion": ["Adult men and women above age 18 with a diagnosis of type 1 diabetes mellitus", "On multiple insulin injections, including a long acting or intermediate acting insulin preparation and mealtime short acting insulin preparation.", "Clinical history consistent with hypoglycemia", "Hba1c <9.0%"], "exclusion": ["Patients with type 2 diabetes mellitus", "Patients on insulin pump", "Poor control of diabetes (HbA1c > 9.0%)", "Pregnancy (women of childbearing age will undergo a pregnancy test at the start of the study and will be advised to use birth control methods during the study). Insulin glargine has been reported to have teratogenic effects in animal models, and therefore should only be used during pregnancy if clearly needed.", "Serious co-morbidities that, in clinical opinion of the investigators, could affect pharmacokinetics of glargine (e.g., CRF) or safety (e.g., recent CAD)"], "nct_id": "NCT00869414"},{"minimum_age": 18.0, "maximum_age": 60.0, "gender": "A", "inclusion": ["Type 1 diabetes mellitus (T1DM)", "Insulin pump users' \u2265 48 hours, 24 h dose < 80 U", "Insulin dose \u2265 0,4 IE/kg/24hours", "18 years < age < 50 years", "Time since diagnosis of T1DM \u2265 5 years", "HbA1c \u2264 8,5 %", "Safe anticonceptive for fertile women", "Being able to understand and read Danish"], "exclusion": ["Dysregulation of endocrine disorders other than type 1 diabetes mellitus", "Severe dysregulation of diabetes mellitus", "Other severe adverse disease", "Pregnancy, planning pregnancy, or nursing"], "nct_id": "NCT00497536"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Must have one or more of the following: Coronary artery disease (CAD); BMI 25 or higher; Type 2 diabetes", "Must be sedentary, defined by less than 150 minutes of self-reported activity per week", "Must be 18 or older", "Must have access to a computer with an Internet connection, a USB port, and Windows 2000 (latest service pack), XP or Vista", "Must be a regular email user (checking weekly)", "Must be able to communicate in English"], "exclusion": ["Pregnant", "Cannot walk a block (self-report)", "Not competent to sign consent", "Unable to obtain medical clearance from a treating physician (primary care, cardiologist, endocrinologist)", "Type 1 diabetes"], "nct_id": "NCT00729040"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Patients with T2DM and CAS as defined below:", "Clinical definitions", "T2DM: Diagnosed according to the WHO criteria [53].", "CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.", "Aged between 18 and 75", "Provided written consent for participation in the trial prior to any study-specific procedures or requirements."], "exclusion": ["Contraindication to Clopidogrel", "Smoking (current smokers and patients who quit smoking less than six months)", "Malignancy(diagnosed or under investigation)", "Haematological disorders (Anaemia, malignancy, bleeding disorders)", "Women of child-bearing potential", "Use of corticosteroids/other antithrombotic agents(warfarin)", "Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests)", "Unable to consent.", "Use of other investigational study drugs within 1 year prior to study entry", "Previous participation in this study"], "nct_id": "NCT00728156"},{"minimum_age": 18.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Acute coronary syndrome (WHO criteria) with raised cardiac troponin T", "Aged 18-80 years", "Stable Acute coronary syndrome", "On aspirin and clopidogrel", "Willing to participate in the study"], "exclusion": ["Smoking (current smokers or smokers who quit in the last 6 months preceding recruitment)", "Malignancy (any suspected or proven)", "Haematological disorders (bleeding disorders)", "Pre-menopausal women", "Use of corticosteroids/other antithrombotic agents (warfarin)", "Chronic liver disease", "Unable to consent"], "nct_id": "NCT00728286"},{"minimum_age": 18.0, "maximum_age": 45.0, "gender": "F", "inclusion": ["Regular menses, i.e. cyclus length 25-34 days", "Premenopausal", "Ferrimann-Gallway score < 2", "BMI > 27 kg/m2", "normal total testosterone value < 3.5 nmol/l"], "exclusion": ["Age <18 years", "Contraceptive pills within the past 3 months", "Postmenopausal (increased FSH)", "Diabetes mellitus", "Endocrine or other disease requiring treatment", "Eating disorder or other psychiatric history", "Drug use known to influence parameters investigated in this trial", "Pregnancy"], "nct_id": "NCT00145392"},{"minimum_age": 20.0, "maximum_age": 50.0, "gender": "A", "inclusion": ["Men and women aged 20-50", "No regular exercise for past 2 years"], "exclusion": ["Diabetes, Cardiovascular disease, Pregnant or lactating females,BMI >27", "Medications that may interfere with carbohydrate metabolism", "glucocorticoids, adrenergic agonists, ACE inhibitors, alpha blockers, diuretics, beta blockers, oral contraceptives, HMG CoA reductase inhibitors", "History of epilepsy, cancer, hepatitis, active infection, active Graves' disease, cystic fibrosis, sickle cell anemia, peripheral vascular disease, cerebrovascular disease, asthma", "Any medical condition that in the opinion of the investigator will interfere with safe completion of the trial", "Inability to give informed consent", "Prior participation in a clinical trial that could potentially alter insulin sensitivity: e.g., use of new insulin sensitizers", "HIV seropositive", "Anemia (Hgb < 12 g/dl)"], "nct_id": "NCT00970099"},{"minimum_age": 21.0, "maximum_age": 65.0, "gender": "A", "inclusion": [": HEALTHY SUBJECTS: Men and women in good general health with no significant underlying illnesses who are between the ages of 21-65 years of age with HbA(1C) less than 6.5%, fasting blood glucose less than 100 mg/dL, blood pressure less than 120/80, and BMI between 20-25 kg/m(2). Subjects should have never smoked tobacco or not smoked within the previous year. OBESE SUBJECTS: Men and women in good general health with no significant underlying illnesses except obesity who are between the ages of 21-65 years of age with HbA(1C) less than 6.5%, fasting blood glucose less than 110 mg/dl, blood pressure less than 140/90, and BMI between 30-40 kg/m(2)."], "exclusion": [": ALL SUBJECTS: Subjects will be excluded from our study if they are pregnant , breastfeeding or if they plan pregnancy prior to the end of the study. In addition, subjects will be excluded if their age is greater than 65 yrs, BMI greater than or equal to 40 kg/m(2), or have liver disease (including liver transaminase levels greater than twice the upper limit of normal), pulmonary disease, renal insufficiency (serum creatinine greater than 2.0 mg/dl), coronary heart disease, heart failure (New York Heart Association heart failure Class III or IV), peripheral vascular disease, coagulopathy, major depressive disorder, actively smoking or used tobacco within the last year, history of cancer, in treatment for any form of cancer, positive tests for HIV, hepatitis B or C, or take systemic corticosteroids, thiazolidinediones (within 3 months), insulin, or anticoagulants, use food supplements that cannot be discontinued, regular intake of 8 or more cups of tea per week within 3 months prior to study entry, regular alcoholic beverage intake of more than two drinks per day (a drink corresponds to approximately 12 ounces of beer, 4 ounces of table wine, and between 1 and 1.5 ounces of 80-proof spirits), poor compliance during run-in period or regular use of medications that affect insulin sensitivity, blood pressure or vascular function and that cannot be discontinued. In addition, history of any other medical disease, laboratory abnormalities, or psychological conditions that would make the subject (based upon the principal investigator's judgment) unsuitable for study enrollment. Subjects with known hypersensitivity to octafluoropropane, recent eye surgery, or with known cardiac shunts will also be excluded from participating because of potential adverse effects from microbubble contrast agent. Subjects will be excluded if they are unable to give informed consent for all procedures. Currently, type 2 diabetes is not rare in children, however children are excluded from this study because children do not typically take EGCG and do not typically have hypertension or type 2 diabetes mellitus."], "nct_id": "NCT00434499"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": [": For the Family protocol, proband must meet diagnostic criteria for diabetes and have nephropathy that meets one of the following:", "diabetic nephropathy diagnosed from a kidney biopsy and a history of overt proteinuria.", "ESRD considered due to diabetic nephropathy because", "diabetes is present for \u2265 5 years prior to the initiation of renal replacement therapy and diabetic retinopathy has been diagnosed at any time; or", "diabetes is present \u2265 5 years prior to the initiation of replacement therapy and either a 24 hour urine collection contains \u2265 3 gm protein/24 hours or a random urine protein (mg/dl)/ creatinine (mg/dl) ratio is \u2265 3.0; or", "diabetic retinopathy is present and either a previous 24 hour urine collection contains \u2265 3 gm protein/24 hours or a random urine protein (mg/dl)/ creatinine (mg/dl) ratio is \u2265 3.0.", "nephropathy without ESRD that is considered to be diabetic nephropathy because (a) diabetic retinopathy and a 24 hr urine collection with either \u2265 1 gram proteinuria/24 hours or a urine protein (mg/dl)/ creatinine (mg/dl) ratio \u2265 1.0; or (b) at a time when diabetes duration is \u2265 10 years, either a urine collection of \u2265 3 grams protein/24 hours or a urine protein (mg/dl) /creatinine (mg/dl) ratio \u2265 3.0. African-American patients with chronic renal failure are as MALD cases by meeting criteria for diabetic nephropathy, as described for Family probands, or having nephropathy (serum creatinine \u2265 2.0 mg/dl) not due to diabetes or known monogenic renal disease. Mexican-Americans recruited as MALD cases must meet criteria for diabetic nephropathy as defined for the Family probands. Phenotype criteria for probands entered into the Family or MALD protocols must be confirmed by medical record review. Eligibility of family members and MALD control subjects is based on laboratory tests obtained at the time of screening. Entry of a proband with diabetic nephropathy into the Family protocol also requires participation of either two living parents or at least one full sibling with diabetes. To be enrolled as having nephropathy, the diabetic sib must meet one of the following criteria:", "renal biopsy consistent with a diagnosis of diabetic nephropathy;", "urinary albumin excretion \u2265 30 mg/24hr or a urine albumin (mg/dl)/creatinine (mg/dl) ratio \u2265 0.03;", "a serum creatinine concentration \u2265 1.6 mg/dl for men or \u2265 1.4 mg/dl for women; or", "ESRD. Unaffected sibs are recruited if they have had diabetes for \u2265 10 years, have normal serum creatinine and albumin excretion (< 30 mg albumin/24 hours, or a urine albumin (mg/dl)/creatinine (mg/dl) ratio < 0.03) and no historical evidence of kidney disease. The criteria for MALD control subjects differ by ethnic group. For the African-American MALD protocol, two different control samples are recruited. First, an adult offspring with or without renal disease and the other parent of the offspring, who cannot have evidence of renal disease, are collected as controls for African-American probands with either diabetic or non-diabetic nephropathy. Together with the probands, this forms a sample of triads (offspring and other parent) or dyads (spouse only). A second group of African-American control subjects consists of unrelated individuals with diabetes duration \u2265 10 years and without nephropathy (as defined above for diabetic sibs). For Mexican Americans, a single unrelated control population is recruited with diabetes duration \u2265 10 years but without nephropathy (as defined above for diabetic sibs)."], "exclusion": [": A. Did not sign the informed consent: refusal to participate. B. Diagnosis not confirmed. C. Appropriate siblings not available. D. Judged not likely or unable to follow study protocol. E. Ethnicity of parents or grandparent not suitable. F. Spouse not available."], "nct_id": "NCT00301249"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["American Indian men and women 40 years of age or older", "Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or WHO criteria): fasting plasma glucose >= 7.0 mmol/L (126 mg/dL) or 2-hour glucose >= 11.0 mmol/L (>200 mg/dL) after a 75-gram oral glucose tolerance test.", "LDL cholesterol >= 100 mg/dL. within the previous 12 months.", "Systolic BP >= 130 mm Hg. within the previous 12 months."], "exclusion": ["New York Heart Association Stage III- IV congestive heart failure.", "SBP >180 mmHg (2% of population) or patients with known causes of hypertension.", "History of angioedema.", "Any medical condition that study physicians believe would interfere with study participation or evaluation of results.", "Mental incapacity and/or cognitive impairment on the part of the patient that would preclude adequate understanding of, or cooperation with, the study protocol.", "Serum hepatic transaminase levels 2X the upper limit of normal.", "Participation in any clinical trial of any investigational medication within 3 months prior to this trial.", "Renal insufficiency as indicated by serum creatinine >2.0 for women and >2.4 for men.", "Diagnosis of primary hyperlipidemia in medical record. 10. Secondary hypercholesterolemia due to hypothyroidism or nephrotic syndrome. Patients on stable doses of thyroid replacement therapy will be eligible. 11. Presence of malignancy or history of any cancer except skin cancer within the past 5 years. 12. Pregnancy or lactation. Premenopausal women will be requested to use birth control methods throughout the study and provided educational materials about the risks of using the study medications during pregnancy. 13. Unable to obtain quantifiable carotid measure during screening examination. 14. Concomitant long term use of cyclosporins (Sandimmune), macrolide antibiotics (erythromycin -many generic and brand name forms, clarithromycin, Biaxin, and Zithromax), azole antifungals (itraconazole-Sporanox, ritonavir, Norvir, and nelfinavir (Viracept). 15. Orthostatic hypotension as defined by the following:", "The individual has a measured fall of >20 mmHg in systolic BP upon standing associated with symptoms lasting more than one minute (or severe symptoms that would not allow further lowering of BP)", "The standing systolic blood pressure is less than 90 mm. 16. Triglyceride level >350 mg/dl. 17. Severe aortic stenosis with valve area <=1.0 square cm."], "nct_id": "NCT00147251"},{"minimum_age": 25.0, "maximum_age": 35.0, "gender": "M", "inclusion": [": T2DM group:", "Men aged 25-35", "BMI > 30 kg/m2", "Sedentary lifestyle determined by activity index questionnaire (not involved in regular exercise program) and accelerometer data.", "Are willing to eat only foods provided by Pennington for the study period", "Diagnosed with T2DM defined by one or more of the following:", "fasting plasma glucose > 126 mg/dL at entry", "a two-hour OGTT glucose > 200mg/dL", "current medication for T2DM Obese group:", "Men aged 25-35", "BMI > 30 kg/m2", "Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.", "Are willing to eat only foods provided by Pennington for the study period FH+ group:", "Men aged 25-35", "One parent diagnosed with T2DM", "fasting insulin > 10mIU/ml (> 50th %tile)", "BMI between 22 and 30 kg/m2", "Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.", "Are willing to exercise every day for the study period", "Are willing to eat only foods provided by Pennington for the study period FH- group:", "Men aged 25-35", "Parents and grandparents were not diagnosed with T2DM", "Fasting insulin < 10mIU/ml (< 50th %tile)", "BMI between 22 and 30 kg/m2", "Sedentary lifestyle activity index questionnaire (not involved in regular exercise program) and accelerometer data.", "Are willing to exercise for the study period", "Are willing to eat only foods provided by Pennington for the study period Athlete group:", "Men aged 25-35", "Maximal oxygen uptake > 60 ml/kg.min", "Are engaged in minimum of 1.5 h of aerobic exercise 3 times/ week", "Are willing to eat only foods provided by Pennington for the study period"], "exclusion": ["Abnormal resting or exercise ECG", "Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp < 140/90 on medications)", "Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc", "Alcohol or other drug abuse", "Smoking", "Gait problems", "Unwilling or unable to abstain from caffeine (48h) prior to metabolic rate measurements", "Unwilling or unable to eat all study foods", "Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)", "Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc", "NYHA class III/IV CHF is an exclusionary cardiac condition", "history of deep vein thrombosis (DVT) or pulmonary embolism (PE)", "varicose veins", "major surgery on the abdomen, pelvis, or lower extremities within previous 3 months", "cancer (active malignancy with or without concurrent chemotherapy)", "rheumatoid disease", "bypass graft in limb", "known genetic factor (Factor V Leiden, etc) or hypercoagulable state", "diagnosed peripheral arterial or vascular disease, or intermittent claudication", "family history of primary DVT or PE (pulmonary embolism)", "peripheral neuropathy"], "nct_id": "NCT00401791"},{"minimum_age": 21.0, "maximum_age": null, "gender": "A", "inclusion": ["SUBJECTS WITH DIABETIC NEUROPATHY:", "Presence of diabetic neuropathic pain with score of 3 or higher on the McGill Short Form Pain Survey", "Presence of sensory neuropathy with monofilament (Semmes-Weinstein) testing, as defined as failure to sense the filament in 2 locations (out of six total) on a least one foot.", "Previous diagnosis of diabetes (type II) as well as diabetic neuropathy by a physician", "Age greater or equal to 21"], "exclusion": ["SUBJECTS WITH DIABETIC NEUROPATHY:", "Presence of significant peripheral arterial disease in either lower extremity (abi greater than 0.9 bilaterally)", "Skin ulceration on either foot or limb threat from infection or vascular disease at study enrollment", "Inability to comply with study procedures or give informed consent", "Women of child bearing potential", "Spouse/partner is a women of child bearing potential and you share the same bed", "Non-ambulatory status", "Inability to comply with study restrictions on changing sleeping or pain medication", "Severe psychiatric or medical disorder that would affect compliance", "Known allergy to PET or Dacron Inclusion Criteria SUBJECTS WITHOUT DIABETIC NEUROPATHY:", "Chronic foot or angle pain with a score of 3 or higher on the McGill Short Form Pain Scale", "Absence of sensory neuropathy with monofilament (Semmes-Weinstein) testing, as defined as ability to sense the filament in 6 locations (out of 6 total) on both feet", "The presence of a condition that causes chronic foot pain such as arthritis, peripheral arterial disease, plantar fasciitis, or other conditions not related to diabetic neuropathy, previously diagnosed by a health care provider", "Age greater to or equal to 21 Exclusion Criteria SUBJECTS WITHOUT DIABETIC NEUROPATHY:", "Presence of significant peripheral arterial disease in either lower extremity (abi less than or equal to 0.5 in either extremity)", "Skin ulceration on either foot or limb threat from infection or vascular disease at study enrollment", "Inability to comply with study procedures or give informed consent", "Women of child bearing potential", "Spouse/partner is a women of child bearing potential and you share the same bed", "Non-ambulatory status", "Inability to comply with study restrictions on changing sleeping or pain medication", "Severe psychiatric or medical disorder that would affect compliance", "Previous diagnosis of neuropathy affecting lower extremities", "Known allergy to PET or Dacron"], "nct_id": "NCT00458497"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": [": Type 1 diabetes for > 5 years AND Hypoglycemia unawareness, not felt adequately by patient (glucose < 54mg/dL) in last 1.6 years, not otherwise explained, requiring outside help OR Metabolic lability/instability, characterized by hypoglycemia or ketoacidosis (>2 hospital < 12 mo), chaotic glucose profile (MAGE > 120mg/dL), disruption in lifestyle or danger to life, to self, to others OR Failure of intensive insulin management, as judged by an independent endocrinologist."], "exclusion": [], "nct_id": "NCT00021580"},{"minimum_age": 40.0, "maximum_age": 80.0, "gender": "A", "inclusion": ["Male or female subjects aged 40 to 80 years", "Documented stable atherosclerosis by angiography or vascular ultrasound (more that 20% luminal narrowing), previous myocardial infarction, ischemic stroke, peripheral arterial disease or type 2 diabetes mellitus (coronary heart disease (CHD) risk equivalent", "Adult Treatment Program (ATP)-III guidelines)", "LDL-cholesterol >100mg/dL (indication to treat with statin)", "Written informed consent", "Primary care physician authorization letter to participate in the study."], "exclusion": ["Inability to give consent", "Pre-menopausal women", "Current use of antibiotics, anti-inflammatory or immunosuppressant drugs", "History of LFT >2 times the upper normal limit", "History of myopathy/myositis or CPK > 10 times the upper normal limit", "CPK above normal limits at study onset", "Any evidence of inflammatory, infectious or neoplastic disease", "History of CABG, PCI or acute ischemic syndrome in the preceding 3 months"], "nct_id": "NCT00115830"},{"minimum_age": 40.0, "maximum_age": null, "gender": "A", "inclusion": ["40 years of age or older", "Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg", "Central (abdominal) obesity"], "exclusion": ["Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg", "Currently taking more then 3 medications to treat high blood pressure", "Inability to stop all current blood pressure medications if any up to 4 weeks", "History of Type 1 or Type 2 diabetes", "History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months", "History of or current diagnosis of congestive heart failure", "History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma", "Women who are pregnant or nursing", "Alcohol or drug abuse within the last 2 years Other protocol-defined inclusion/exclusion criteria may apply"], "nct_id": "NCT00439738"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["for Core Study:", "Patients with mean sitting diastolic blood pressure \u2265 100 mmHg and < 110 mmHg Inclusion criteria for the Extension:", "msSBP \u2265 140 mm Hg and/or msDBP \u2265 90 mm Hg at Visit 5 of the core study"], "exclusion": ["for Core Study:", "Patients with mean diastolic blood pressure \u2265 110 mmHg or mean systolic blood pressure \u2265 180 mmHg", "Patients with prior stroke, hypertensive encephalopathy or heart attack", "Patients with type 1 diabetes mellitus", "Patients with type 2 diabetes mellitus with poor glucose control Exclusion criteria for the Extension:", "Premature discontinuation in the core study or failure to comply with the core study protocol", "History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures, known or suspected contraindications to diuretics as described in the SmPC (particularly amlodipine 5 mg), e.g. severe hypotension, shock", "including cardiogenic shock, obstructions impairing the flow out of the left ventricle (e.g. significant aortic stenosis)", "Any patient that the investigator decides should not participate in the extension study for medical reasons Other protocol-defined inclusion/exclusion criteria applied to the study."], "nct_id": "NCT00867490"},{"minimum_age": 18.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Provide written informed consent prior to enrolment (any study-specific procedures or investigations).", "Male or female aged between 18 and 75 years.", "Patients with mild Type IIa, Type IIb or IV hyperlipidaemia (LDL-cholesterol >3.0 mmol/L< 6.0 mmol/L)", "Fasting serum TG level < 4.5 mmol/L", "Mildly elevated blood glucose defined as at least one of three of the following criteria", "HbA1c% >5.5% < 7.5%;", "Fasting glucose > 5.5 mmol/L;", "Type 2 diabetes mellitus on stable oral antihyperglycemic treatment for more than 8 weeks and HbA1c% < 7.5% at the time for inclusion.", "If female, be of non-childbearing potential, i.e., post-menopausal (defined as >12 months since last menstrual period) or surgically sterilised, or using adequate barrier contraception if of childbearing potential."], "exclusion": ["Currently taking lipid-lowering medication and are not able to complete the 4-week wash-out prior to the start of the dietary run-in period.", "History of active malignant disease the last 5 years (excluding treated basal cell carcinoma).", "History of infection with human immunodeficiency virus (HIV) or hepatitis B or C.", "History of alcohol and/or drug abuse.", "Have uncontrolled hypertension (diastolic blood pressure >100 mmHg). Patients who are taking antihypertensive medication will not be excluded provided they are maintained at a stable dose for 3 months prior to screening and the stable dose is maintained throughout the study.", "Have uncontrolled thyroid disease (thyroid dysfunction controlled for at least 6 months prior to screening is permitted).", "Known homozygous familial hypercholesterolaemia or known Type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).", "Patients with active liver disease or hepatic dysfunction as defined by elevations in liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT) and alkaline phosphatase (ALP)] or total bilirubin >2 x the upper limit of normal (ULN) at any time between Visit 1 (Week -4) and Visit 3 (Week -1).", "Patients with a serum creatinine >180 \u00b5mol/L at any time between Visit 1 (Week -4) and Visit 3 (Week -1)", "Patients who have serious or unstable medical or psychological conditions which, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study.", "Patients who started hormone replacement therapy (HRT) less than 6 months prior to screening.", "Currently taking other investigational drugs or have taken part in a clinical trial within the previous 30 days prior to screening.", "These drugs should not be given during the patient's participation in the study, and must be stopped 6 weeks before randomisation : lipid lowering drug other than study medication, Cyclosporine A, medical treatment against obesity (i.e., Orlistat, Sibutramine), oral anticoagulants. Special attention will be paid to the medications that could interfere with the lipid profile (i.e. oral corticosteroids, retinoids, thyroid hormones, thiazide derivative, diuretics, beta-blockers, and hormone replacement therapies). It is recommended not to modify these medications within 6 weeks prior to study start and during the course of the trial (unless this is medically required). All concomitant medications will be recorded."], "nct_id": "NCT00114855"},{"minimum_age": 18.0, "maximum_age": null, "gender": "M", "inclusion": ["Histologically confirmed prostate cancer", "Current Hormone therapy with GnRH agonist of 3 months or longer", "Overweight or obese (body mass index of 25kg/m2 or greater)", "No other conditions that prevent intensive lifestyle intervention"], "exclusion": ["History of diabetes mellitus requiring drug therapy", "Hemoglobin Aic of 7% or greater", "Symptomatic metastatic disease", "Myocardial infarction within 6 months", "Treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels", "Disease progression according to PSA Working Group Criteria"], "nct_id": "NCT00738140"},{"minimum_age": 30.0, "maximum_age": 75.0, "gender": "A", "inclusion": ["Ldl-C Levels >100 Mg/Dl", "Patients Who Have Signed The Consent", "Patients Of ages between 30 and 75 Years Old", "Patients Of Both Genders", "Patients With Established Cardiovascular Disease, Diabetes With Or Without Established Cardiovascular Disease", "Patients Without Previous Treatment With Ezetimibe"], "exclusion": [], "nct_id": "NCT00738296"},{"minimum_age": null, "maximum_age": null, "gender": "A", "inclusion": ["Consecutive diabetic patients entering the office (private practice)", "Subjective symptoms of numbness, burning, paresthesia, etc.", "Failed Monofilament of at least two points on each foot", "Abnormal PSSD study", "Willing to participate in protocols or study", "Taking one Metanx tablet bid for 2 weeks then one Metanx tablet daily", "Keep scheduled appointments for follow up studies", "Report any other medical interventions, studies, or medication changes", "Report any problems of medical or psycho-social matters to investigators", "HgbA1c NOT monitored or specific value required for participation"], "exclusion": ["History of back problems (Surgery or ECSI) or other large fiber neuropathies", "History of chemotherapy", "History of chemical exposure"], "nct_id": "NCT00933998"},{"minimum_age": 13.0, "maximum_age": 25.0, "gender": "A", "inclusion": ["Obesity (BMI > 97%tile for age and sex matched normative data)", "Insulin resistance: fasting insulin> 25 mIU/ml", "Good general health, taking no medication on a chronic basis", "Age 16-25 yrs, late pubertal stage (girls: breast: Tanner stage IV to V, boys: testicular volume > 15 ml) or age 13-15 yrs (with a family history of type 2 diabetes, whom have completed or reached tanner stage III and have impaired oral glucose tolerance with a 2-hour glucose of 180-199 mg/dl)", "Girls who are sexually active must use adequate birth control methods (such as barrier method or oral contraception) and must have a negative pregnancy test", "Normal liver function tests Major"], "exclusion": ["Hx of gallstones", "Elevated triglycerides >400 mg/dl", "Hx of alcohol use/ binge drinking", "Raynaud's syndrome", "Pregnancy or breastfeeding mothers", "Cigarette smokers", "Anemia (Hct < 35)", "Baseline creatinine > 1.0 mg", "Abnormal liver transaminases > 2.0 X the upper limit of normal", "Presence of endocrinopathies except for adequately treated hypothyroidism", "Presence or history of gastrointestinal disorders (inflammatory bowl disease, irritable bowl disease, hernia, ileus)", "Presence of significant chronic illness of any kind.", "Use of any drugs that might be expected to affect glucose tolerance, insulin resistance or weight gain, cardiovascular health.", "Psychiatric disorders", "History of substance abuse Lean Control Subjects (only for cardiovascular studies and CGMS): Inclusion Criteria:", "Lean (BMI < 85%tile for age and sex matched normative data)", "Fasting insulin <15 mIU/m", "Fasting glucose <100 mg/dll", "Excellent general health, having no acute or chronic health problems and taking no current medications", "Age 13-25 yrs, in puberty (age matched with obese subjects)", "Girls who are sexually active must use adequate birth control methods (such as barrier method or oral contraception) and must have a negative pregnancy test Exclusion Criteria:", "Raynaud's syndrome", "Pregnancy or breastfeeding mothers", "Cigarette smokers", "Psychiatric disorders", "History of substance abuse", "First degree relative with either T1DM or T2DM", "Presence of acanthosis nigricans"], "nct_id": "NCT00845559"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Subject has clinically diagnosed pain attributed to diabetic distal sensory motor polyneuropathy for 1-5 years and a diagnosis of diabetes mellitus (Type I or Type II).", "Subjects must have at least moderate pain (mean pain intensity \u2265 4 out of 10 during the baseline week on Likert scale).", "subjects must have good or fair diabetic control (Hgb A1c < 10%)"], "exclusion": ["Subject has other conditions that cause neuropathic pain at least as severe as the diabetic pain i.e. peripheral arterio-vascular disease.", "Subject receives treatment for seizures.", "Subject has had any amputations other than diabetically-related toe amputations.", "Subject has major skin ulcers.", "Subject has clinically significant ECG abnormalities.", "Subject is expected to take within 7 days prior to randomization and during the study: TCAs, mexiletine hydrochloride, lidoderm patch, tramadol, AEDs, dextromethorphan, opioids, capsaicin, nonsteroidal anti-inflammatory drugs, acetaminophen / paracetamol, skeletal muscle relaxants, benzodiazepines, alpha-2-agonists (e.g. clonidine), drugs indicated for sleep disturbance (e. g. zolpidem tartrate, zaleplon) and over-the-counter medications with centrally acting properties.", "Subject has laboratory values which are outside the normal range and judged by the investigator to be clinically significant.", "At study entry, subject has liver function tests values (AST, ALT,alkaline phosphatase, total bilirubin and GGT) 2 times upper limit of normal.", "subject has impaired renal function, i.e., creatinine clearance is lower than 60 mL/min."], "nct_id": "NCT00861445"},{"minimum_age": 8.0, "maximum_age": 35.0, "gender": "A", "inclusion": ["Subjects 8-35 years old", "Body weight > 36 Kg", "Diagnosis of diabetes mellitus according to the American Diabetes Association (ADA) criteria", "Randomization on Study Day 0 within 12 weeks of first visit to any physician for symptoms or signs of diabetes", "Requires insulin for T1DM or has required insulin at some time between diagnosis and administration of study drug", "Detectable fasting or stimulated C-peptide level (above the lower limit of the reportable range of the assay) at screening", "Diagnosis of T1DM as evidenced by one positive result on testing for any of the following antibodies at screening:", "Islet-cell autoantibodies 512 (ICA512)/islet antigen-2 (IA-2),", "Glutamic acid decarboxylase (GAD) autoantibodies, or", "Insulin autoantibodies (in subjects on insulin for more than 2 weeks, ICA512/IA-2 or GAD must be positive)."], "exclusion": ["Prior administration of a monoclonal antibody-within the 1 year before randomization", "Participation in any type of therapeutic drug or vaccine clinical trial within the last 12 weeks before randomization at Study Day 0", "Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial", "Pregnant females or lactating females who intend to provide their own breast milk to the baby during the study", "Current therapy with GLP-1 receptor agonists (e.g., exenatide or pramlintide), or any other agents that might stimulate pancreatic beta cell regeneration or insulin secretion", "Current treatment with oral antidiabetic agents", "Evidence of active or latent tuberculosis", "Vaccination with a live virus or organism within the 8 weeks before randomization continuing through Week 52 of the study.", "Influenza vaccination with a killed virus, including booster vaccinations, within 4 weeks before or after each dosing cycle.", "Vaccination with other antigens or killed organisms within 8 weeks before or after each dosing cycle", "Any infectious mononucleosis-like illness within the 6 months before randomization"], "nct_id": "NCT00920582"},{"minimum_age": 18.0, "maximum_age": 65.0, "gender": "A", "inclusion": ["Patients with a BMI < 35undergoing laparoscopic surgery;", "Patients undergoing bariatric surgery with a BMI >35kg/m2; and", "Those patients who have had gastric by-pass that require additional surgical procedures are eligible for this research protocol."], "exclusion": ["Unwilling to consent."], "nct_id": "NCT00495599"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the study", "Have plaque-type psoriasis covering at least 10 percentage of total body surface area", "Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater and a Physician's Global Assessment (PGA) score of 3 or greater at the time of the first administration of study drug", "Must be suitable for phototherapy or systemic treatment for psoriasis", "Have failed to respond to or have condition which prevents use of cyclosporine, methotrexate (MTX) or psoralen plus ultraviolet light A (PUVA)"], "exclusion": ["Currently have nonplaque forms of psoriasis", "Have current drug-induced psoriasis", "Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or IL-23 (Interleukins are the substance produced by body in immunological disease like psoriasis)", "Have received phototherapy or any systemic medications/treatments that could affect psoriasis or PASI evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, psoralens, sulfasalazine, hydroxyurea, or fumaric acid derivatives) within 4 weeks of the first administration of study agent", "Have used a biologic within the previous 3 months"], "nct_id": "NCT00454584"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["each patient, male or female, visiting the hospital outpatient clinic or general practice with type II diabetes mellitus during a specified period. Patients should be able to read and write the Dutch language."], "exclusion": ["pregnancy", "patients with a life expectancy < 1 year"], "nct_id": "NCT00160017"},{"minimum_age": 18.0, "maximum_age": 55.0, "gender": "A", "inclusion": ["Age 18-55 years old, men and women, otherwise in good general health, BMI >27 kg/m2"], "exclusion": ["Abnormal glucose tolerance, fasting glucose>100 mg/dl or diabetes", "History of liver condition or alanine aminotransferase (ALT) above the upper limit of the normal range", "Use of medications that cause insulin resistance or fatty liver: niacin, glucocorticoids, estrogens, tamoxifen, amiodarone, accutane, sertraline, atypical antipsychotics, anti-HIV medications", "Chronic use of anti-inflammatory medications (aspirin, ibuprofen, naprosyn, steroids, etc)", "Average alcohol intake >20 grams/day", "Tobacco use", "Creatinine >1.5 mg/dl for men and >1.4 mg/dl for women", "Hematocrit <33%", "Pregnancy or lactation", "Significant weight loss within the past 6 months (>5% body weight)", "Claustrophobia or any contraindications to being placed in the magnet for the MRS scan such as pacemakers, defibrillators, brain aneurysm clips, etc.", "Other serious medical conditions or inflammatory conditions such as cancer, inflammatory arthritis, etc.", "History of multiple food allergies or intolerances or severe food allergies", "History of coronary artery disease, history of or treatment of hyperlipidemia, LDL >200 mg/dl, fasting triglycerides >300 mg/dl", "Weight >300 pounds"], "nct_id": "NCT00930371"},{"minimum_age": 7.0, "maximum_age": 12.0, "gender": "A", "inclusion": ["African American, European American, or Hispanic American, aged 7-12, healthy, weight is equal to or greater than 25 Kg"], "exclusion": ["Type 1 or 2 diabetes, polycystic ovary disease, disturbances in glucose or lipid metabolism disturbances", "Use of medication known to affect body composition or physical activity, diagnosis of genetic disorders known to affect body composition or fat distribution", "Use of tobacco, alcohol consumption in excess of 400 g per week", "Menstruated for more than a year prior to the recruitment; OR", "A medical history that counter-indicates inclusion of the study"], "nct_id": "NCT00726778"},{"minimum_age": 10.0, "maximum_age": 17.0, "gender": "A", "inclusion": ["Age 10-17 years old", "Subject able to give assent, and parent/guardian capable of giving consent on behalf of the child", "Body mass index (BMI) \u2265 95th percentile (based on gender and age)", "Fasting insulin \u2265 15 \u00b5U/mL AND one or more of the following (cutoffs based on the International Diabetes Federation definition of pediatric metabolic syndrome)1:", "Triglycerides \u2265 150 mg/dL", "HDL cholesterol < 40 mg/dL", "Systolic blood pressure \u2265 130 mmHg"], "exclusion": ["Type 1 or 2 diabetes mellitus", "Has begun a new drug therapy within the past 30 days prior to the screening visit", "BMI \u2265 55", "History of weight loss surgery", "Obesity from a genetic cause (e.g., Prader-Willi)", "Central nervous system injury or severe neurological impairment", "Known systolic or diastolic dysfunction or heart failure", "Females who are currently pregnant or planning to become pregnant", "Liver enzymes > 2.5 times upper limit of normal"], "nct_id": "NCT00775164"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Male or females between the ages of 18 to 65 years of age.", "Documented diagnosis for the metabolic syndrome:", "Subjects with hypertension (SP>130mmHg)", "Subjects with central obesity (females waist >35\"; males waist >40\")", "Subjects with dyslipidemia (HDL <40mg/dl, triglycerides > 150 mg/dl)", "Subjects who are insulin resistance (fasting glucose >100mg/dl)"], "exclusion": ["Subjects who smoke", "Women who are pregnant (confirmed by urine beta-HCG).", "Women who are breast feeding", "Subjects with documentation of the following health risk:", "Subjects with serum creatinine >2.0 mg/dl (males), >1.8 mg/dl (females)", "Subjects whose creatinine clearance < 50 mls/min", "Subjects with serum potassium >5.5mEql", "Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration >0.2)", "Subjects who are currently taking the following medications:", "Warfarin"], "nct_id": "NCT00608465"},{"minimum_age": 18.0, "maximum_age": 40.0, "gender": "F", "inclusion": ["Pre-pregnant body mass index greater than 25", "Singleton pregnancy", "Speaks English"], "exclusion": ["High intake of DHA foods (i.e., more than 1 fish meal per week, use of DHA-fortified foods, or use of any supplements that contain DHA)", "Concurrent inflammatory, vascular, or metabolic disease, including diabetes, polycystic ovary disease, collagen vascular disease, inflammatory bowel disease, or infection", "Current or previous use of tobacco, street drugs, or medications known to affect inflammatory markers, including corticosteroids", "Excessive weight gain or loss before pregnancy (more than 20 pounds), including weight loss due to bariatric surgery", "Plans to leave the area during the study period", "Inability to travel to General Clinical Research Center"], "nct_id": "NCT00865683"},{"minimum_age": 18.0, "maximum_age": null, "gender": "A", "inclusion": ["Patients diagnosed with Type II diabetes that are on stable treatment with hypoglycemic agents", "Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mmHg but <200 mmHg and a MSDBP less than or equal to 114 mmHg following a 3 to 4-week single-blind placebo run-in period", "The difference in MSSBP between Visits 3 and 4 or between Visits 4 and 4X must be less than or equal to 10 mmHg", "Patients with a mean daytime (8AM", "4PM) SBP > 130 mmHg and less than or equal to 199 mmHg and a mean daytime DBP less than or equal to 114 as measured by an ambulatory blood pressure monitoring device (ABPM) following placebo run-in period", "If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study"], "exclusion": ["History of stroke or transient ischemic attack (TIA) within the last one year", "History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months", "Presence of overt proteinuria at screening", "Severe hypertension (DBP greater than or equal to 115 mmHg or SBP greater than or equal to 200 mmHg)", "Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome", "Type I or Type II diabetes requiring insulin", "Evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease", "Presence of heart block greater than first degree sinoatrial block, Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial fibrillation, or Atrial Flutter"], "nct_id": "NCT00403481"},{"minimum_age": 30.0, "maximum_age": 78.0, "gender": "A", "inclusion": ["Patient Has Type 2 Diabetes Mellitus", "Patient Is 30-78 Years Of Age On The Day Of Signing Informed Consent", "Patient Is Currently On Metformin Therapy (1500 Mg/Day)", "Patient Is A Male Or A Female Who Is Unlikely To Conceive, As Indicated By At Least One Yes Answer To The Following Questions: A) Patient Is A Male. B) Patient Is A Surgically Sterilized Female. C) Patient Is A Postmenopausal Female 45 Years Of Age With >2 Years Since Last Menses. D) Patient Is A Non-Sterilized Premenopausal Female And Agrees To Use An Adequate Method Of Contraception To Prevent Pregnancy Throughout The Study Starting With Visit 1 And For 14 Days After The Last Dose Of Study Medication", "Patient Understands The Study Procedures, The Alternative Treatments Available, The Risks Involved In The Study And Voluntarily Agrees To Participate By Giving Written Informed Consent", "Patient Has An A1c of 6.5 %", "11.0%"], "exclusion": ["Patient Has A History Of Type 1 Diabetes Mellitus Or History Of Ketoacidosis"], "nct_id": "NCT00875394"}]